close

Вход

Забыли?

вход по аккаунту

код для вставкиСкачать
Derwent World Patents Index:
PetDashboard20110403
Title
1
2
3
Patent Assignee
XU J
Pet snack and manufacture method thereof the chicken mud is smeared on the surface of
first mixture to manufacture pet snack.
Wherein, the first mixture is prepared by
mixing the rice crispy, glutinous rice flour and
water
Pet food tray and activity device arrangement,
has columns formed by stackable elements
and removably attached with base, and
rotating cover connected with top portion of
one of columns through hinge
ROCHON I
Manufacture of tea-leaf extract used for tea
beverage involves mixing cellulase and/or
hemicellulase, enzyme group containing
pectinase and tannase and ea leaf, and
carrying out enzymatic-decomposition
extraction process of tea leaf
MITSUBISHI KAGAKU FOODS KK
Patent Family
Patent
Kind Date
TW 2010010628
A
20100316
TW 2010010628
Y
PatentNoForDashb
oard
TW2010010628A
An INDEPENDENT CLAIM is also included for a
method of forming a pet food tray and activity
device arrangement.
WO 2011032285
Y
WO2011032285A1
The method obtains high concentration of soluble BIOLOGY - Preferred Components: The enzyme
solid content in tea-leaf extract, and performs
group contains amylase, and protease.
extraction from tea leaf in short time.
An INDEPENDENT CLAIM is included for a tealeaf extract.
JP 2011050271
N
For increasing efficacies and flavors of
formulations containing jiaogulan (Gynostemma
NOVELTY: A method of increasing efficacies and pentaphyllum and related species); and as food or
dietary supplement formulation for improving
flavors of formulations containing jiaogulan
(Gynostemma pentaphyllum and related species) general well-being by reducing fatigue, increasing
involves combining jiaogulan with various herbal metabolic rate, and by means of tonic, antioxidant
and adaptogenic effects in mammals ingesting the
and nutritional materials for the purpose of
food or dietary supplement formulation (claimed).
improving general well-being in mammals by
reducing fatigue, increasing metabolic rate, and by
means of tonic, antioxidant and adaptogenic
effects. [CONT.]
The formulation provides powerful, versatile and
easy-to-take jiaogulan preparation. The
formulation increases efficacies and flavors of
jiaogulan (Gynostemma pentaphyllum and related
species) by combining materials derived from
whole plant with other herbal and nutritional
materials for the purpose of improving general wellbeing in mammals by increasing metabolic rate
through fatigue-reducing, tonic, antioxidant and
adaptogenic effects thereby avoiding invasive and
rigorous medical intervention [CONT.]
A method of increasing efficacies and flavors of
formulations containing jiaogulan (Gynostemma
pentaphyllum and related species) involves
combining jiaogulan with various herbal and
nutritional materials for the purpose of improving
general well-being in mammals by reducing
fatigue, increasing metabolic rate, and by means
of tonic, antioxidant and adaptogenic effects;
[CONT.]
WO 2011031254
WO 2011032097 A1 UPAB: 20110331
The method is useful to: determine antibody
binding affinity to an allergen in an antibodycontaining sample from a subject; allergy
NOVELTY: Determining antibody binding affinity to treatment prognosis in a subject having an allergic
reaction to an allergen, where the allergen is a
allergen in antibody-containing sample from
subject, comprises: obtaining sample from subject food allergen and is derived from a legume, tree
nut, cereal grain, fruit, vegetable, seed, fish,
and incubating it with peptide library
crustacean, mollusk, poultry and dairy product,
corresponding to allergen immobilized on solid
and the subject is a [CONT.]
support, where library comprises at least one
allergen epitope to form incubation mixture;
[CONT.]
The method: provides greater specificity, reliability
and efficiency for predicting and characterizing
allergenic epitopes; and provides microarraybased methods of characterizing antibody
epitopes, including epitope mapping, epitope
diversity and antibody affinity, thus it is possible to
assay thousands of target peptides in parallel by
using small volumes of diluted serum, which
greatly reduces [CONT.]
BIOLOGY - Preferred Method: The competitor is
lyophilized. The competitor is provided in a
solution comprising 1% human serum albumin in
phosphate-buffered saline with Tween 20 (RTM:
Polysorbate 20). The identified epitope hotspots
are assembled as an epitope hotspot reference
profile. The control sample is derived from a
subject comprising a non-milk-allergic subject, a
subject who has outgrown an allergy to milk or a
heated-milk tolerant subject [CONT.]
WO 2011031285 A1 UPAB: 20110331
The present invention provides a method to
improve lysine and methionine content of algae
and cyanobacteria through genetic modification in
combination with modified expression of high
lysine and methionine proteins as sinks for the
amino acids. This method is specifically useful in
animal feed production.
BIOTECHNOLOGY - Preferred Method: In the
INDEPENDENT CLAIMS are:
method for producing improved animal feed,
upregulation of lysine is achieved by transforming
the alga or cyanobacterium with RNA interference
(RNAi) of algal lysineketoglutarate
reductase/saccharopine dehydrogenase.
Upregulation of methionine is achieved by
Abstract
Use
Advantages
Technology Focus
Detailed Description
TW 201010628 A UPAB: 20110331
Basic Patent Number
US Patent Number
Comments
Patent No For
Dashboard
Dashboard
Scope
NOVELTY: The present invention relates to a pet
snack and a manufacture method thereof. A first
mixture is prepared by mixing the rice crispy,
glutinous rice flour and water. Wherein, the rice
crispy is prepared by heating rice. Additionally, a
meat mud is prepared by mixing soy protein,
ground chicken breast and glycerol. The meat
mud is smeared on a surface of first mixture to
manufacture a semi-product [CONT.]
WO 2011032285
A1
20110324
WO 2011032285 A1 UPAB: 20110331
Pet food tray and activity device arrangement.
NOVELTY: The arrangement (10) has a set of
columns (12) formed by a set of stackable
elements (18) and removably attached with a base
(14), and a rotating cover connected with a top
portion of one of the columns through a hinge. A
paw-shaped aperture (16) is formed on the
column. A pin is coupled with the rotating cover. A
top opening is formed on the column. [CONT.]
JP 2011050271
A
20110317
JP 2011050271 A UPAB: 20110331
NOVELTY: A tea-leaf extract is manufactured by
mixing cellulase and/or hemicellulase, enzyme
group containing pectinase and tannase and ea
leaf, and carrying out enzymatic-decomposition
extraction process of tea leaf.
Manufacture of tea-leaf extract used for tea
beverage (claimed), foodstuff containing tea
component, or cosmetics.
DETAILED DESCRIPTION: An INDEPENDENT
CLAIM is included for a tea-leaf extract.
4
5
6
Increasing efficacies and flavors of
formulations having jiaogulan (Gynostemma
pentaphyllum and related species) involves
combining jiaogulan with herbal and
nutritional materials to improve general wellbeing in mammals by reducing fatigue
FREELIFE INT INC
Determining antibody binding affinity to
allergen in antibody-bearing sample from
subject, comprises obtaining sample,
incubating it with peptide library having
allergen epitope to form incubation mixture,
incubating, detecting and equating
MOUNT SINAI SCHOOL MEDICINE
GRESSEL J
Producing improved animal feed comprises
genetically modifying alga or cyanobacterium
methionine and/or lysine biosynthesis, and
transforming the alga or cyanobacterium with
a sequence encoding a high methionine and/or
lysine protein
WO 2011031254
A1
WO 2011032097
A1
20110317
20110317
US 20110071043
A1
20110324
WO 2011031285
A1
20110317
USE: Manufacture of tea-leaf extract used for tea
beverage (claimed), foodstuff containing tea
component, or cosmetics. [CONT.]
WO 2011031254 A1 UPAB: 20110328
The method is used for producing improved
animal feed. The animal feed composition is used
for mammals, fowl, and fish. The feed is used for
carnivorous fish (all claimed).
Y
Method for determining antibody binding affinity to WO 2011032097
an allergen in an antibody-containing sample from
a subject, comprises: obtaining the antibodycontaining sample from the subject; incubating the
sample with a peptide library corresponding to the
allergen immobilized on a solid support, where the
peptide library comprises at least one allergen
epitope to form an incubation mixture; [CONT.]
WO 2011031285
US 20110071043
N
N
WO2011031254A1
Patent No
For Snack
6
Producing improved animal feed comprises
genetically modifying alga or cyanobacterium UFAZ S
methionine and/or lysine biosynthesis, and
transforming the alga or cyanobacterium with
a sequence encoding a high methionine and/or
lysine protein
NOVELTY: Producing improved animal feed
comprises genetically modifying alga or
cyanobacterium methionine and/or lysine
biosynthesis to upregulate production of
methionine and/or lysine; transforming the alga or
cyanobacterium with a nucleotide sequence
encoding a high methionine and/or lysine protein
for a sink of the upregulated methionine and/or
lysine; [CONT.]
The method is used for producing improved
animal feed. The animal feed composition is used
for mammals, fowl, and fish. The feed is used for
carnivorous fish (all claimed).
The present invention provides a method to
improve lysine and methionine content of algae
and cyanobacteria through genetic modification in
combination with modified expression of high
lysine and methionine proteins as sinks for the
amino acids. This method is specifically useful in
animal feed production.
BIOTECHNOLOGY - Preferred Method: In the
WO 2011031285
method for producing improved animal feed,
(1) a transgenic algae or cyanobacterium having
upregulation of lysine is achieved by transforming an upregulated biosynthesis of methionine and/or
the alga or cyanobacterium with RNA interference lysine;
(RNAi) of algal lysineketoglutarate
reductase/saccharopine dehydrogenase.
Upregulation of methionine is achieved by
transforming the alga or cyanobacteria with
mutated Arabidobsis cystathionine gamma synthase. [CONT.]
(2) animal feed composition comprising transgenic
algae or cyanobacteria having a modified
biosynthesis of methionine and/or lysine and
expressing recombinant protein with high lysine
and/or methionine content; and [CONT.]
WO 2011027875
A1
20110310
WO 2011027875 A1 UPAB: 20110331
Pet water filtration system for watering device DOSKOCIL MFG CO INC
to feed dog, has bowl fluidly connected to
inner container, and bottom aperture located at
bottom of inner container, where inner
container is fluidly connected to water storage
WO 2011028931
A1
20110310
WO 2011028931 A1 UPAB: 20110323
KURMLAVAGE M M
Food separating device e.g. roller grill
separating device has several separator bars
which are located around portion of crossover
bars formed on respective opposite sides of
device
US 20110056387
7
Agent used as functional food for prevention
and/or treatment of disease associated with
decrease in intestinal tract barrier function by
improving intestinal tract barrier function,
comprises viable cells of Enterobacterium
8
9
10 Automatic water supply nozzle for animals,
has dropping cylinder that includes partition
that is provided with dropping tube
RIKEN KK
The agent is useful as functional food for
prevention and/or treatment of disease associated
NOVELTY: Agent comprises viable cells of
with decrease in intestinal tract barrier function by
Enterobacterium, where the Enterobacterium
improving intestinal tract barrier function. The
contains in the genome, at least one (preferably
disease originates in intestinal tract barrier by
both) of two gene clusters each containing a
group of genes encoding a protein constituting an transmission of pathogenic microorganism, toxin
or allergen (all claimed). [CONT.]
ATP-binding cassette (ABC) transporter and is
capable of producing an acetic acid salt from a
saccharide that is transported into cells by the
ABC transporter. [CONT.]
NOVELTY: The system (10) has an inner
container fluidly connected to a water storage and
comprising a filter such as charcoal filter and
carbon filter. A bottom aperture is located at the
bottom of the inner container. A bowl (32) is fluidly
connected to the inner container. A base (26) is
operatively attached to the bowl, the inner
container and the water storage. [CONT.]
A1
20110310
US 20110056387 A1 UPAB: 20110323
NOVELTY: The device (1400) has support
brackets and two crossover bars (1420), which are
formed on respective opposite sides. Several
separator bars (1424) are located around a
portion of crossover bars. The crossover bars and
the support brackets are configured to form a
rectangular shape.
TOBITA K
US 20110056439
A1
20110310
TOBITA T
JP 2011055711
A
20110324
11 Detecting allergen-specific activated T-cells,
by culturing T-cell containing sample and
measuring ratio of cluster of differentiation
(CD) 4-positive cells expressing CD25
RIKEN KK
WO 2011027810
A1
20110310
WO 2011027810 A1 UPAB: 20110331
N
Pet water filtration system for a watering device
(claimed) to feed an animal i.e. dog.
The interior container is fluidly connected with the
base, and the container apertures act as a screen
or filter so as to prevent large particles from
traveling between a water tank and the interior
container. The filter is attached to the bottom of
the interior container so as to allow the water
stored in the base to be easily re-circulated
through the filter, so that particles deposited by
animal can be easily removed [CONT.]
An INDEPENDENT CLAIM is also included for a
watering device comprising a core that is
connected between a water storage and a bowl.
WO 2011028931
Food separating device e.g. roller grill separating
device (claimed) for use in quick service
restaurant and convenience store for quick meal,
for use in preparation of hot dog type products
such as sausage, quarter pound hot dog, spicy
hot dog, mild hot dog, kielbasa and alternative
meat hot dogs such as turkey, beef and soy.
The food contamination in food separating device
is reduced, since the food separating device
provides separate area for uncooked and cooked
products. The food separating device is
assembled easily, and the appearance of the
roller grill is made to look neatly and orderly. The
food separating device effectively separates
cooking areas on grill without taking up much
cooking space and at the same time displays
marketing information and the types of food
products for consumers and operators [CONT.]
An INDEPENDENT CLAIM is included for roller
grill separating device.
US 20110056387
US 20110056387
N
Since water is supplied dropwise to a nozzle
cylinder, continuity of water flow is broken so that
flow of water mixed with food powders, etc., into
the water supply container is prevented. Hence
contamination of water in water supply container is
prevented so that sanitary water is supplied.
[CONT.]
An INDEPENDENT CLAIM is included for
automatic water supply cap for animals.
US 20110056439
US 20110056439
N
DETAILED DESCRIPTION: An INDEPENDENT
CLAIM is included for roller grill separating device.
[CONT.]
US 20110056439 A1 UPAB: 20110323
Automatic water supply nozzle for automatic water
NOVELTY: The nozzle has a nozzle cylinder (10) supply cap (claimed) for animals. Uses include but
are not limited to rat, mice, guinea pig, hamster,
that is equipped with an automatic water supply
and rabbit.
mechanism, and dropping cylinder (20). The
cylinder includes a partition (21) that is provided
with a dropping tube (21a). The dropping cylinder
is connected to the nozzle cylinder. A stem portion
is inserted into a water supply port of automatic
water supply mechanism when other stem portion
is protruded outside the water supply port [CONT.]
BIOLOGY - Preferred Component: The saccharide Agent for improving an intestinal tract barrier
WO 2011027875
is fructose. Preferred Bacteria: The bacteria
function, comprises viable cells of an
belong to genus Bifidobacterium or Lactobacillus. Enterobacterium, where the Enterobacterium
contains in the genome, at least one (preferably
both) of two gene clusters each containing a
group of genes encoding a protein constituting an
ATP-binding cassette (ABC) transporter and is
capable of producing an acetic acid salt from a
saccharide that is transported into cells by the
ABC transporter [CONT.]
The method (M1) is useful for detecting allergen- The method is simple and accurate.
specific activated T-cells. The method (M2) is
useful for preventing and/or treating food allergy in
animals. The allergen is food allergen (both
claimed). The animal is dog.
FOOD - Preferred Method: The method further
involves comparing the computed value with value
of normal animal and determining the possibility of
allergic reaction with respect to allergen.
An INDEPENDENT CLAIM is included for method WO 2011027810
(M2) for preventing and/or treating food allergy in
animals, which involves ingesting diet without food
allergen.
Y
N
WO2011028931A1
11 Detecting allergen-specific activated T-cells,
by culturing T-cell containing sample and
measuring ratio of cluster of differentiation
(CD) 4-positive cells expressing CD25
The method (M1) is useful for detecting allergen- The method is simple and accurate.
specific activated T-cells. The method (M2) is
NOVELTY: Method (M1) for detecting allergenspecific activated T-cells, involves (a) culturing T- useful for preventing and/or treating food allergy in
cell containing sample derived from test animal in animals. The allergen is food allergen (both
claimed). The animal is dog.
the presence of interleukin-2 (IL-2) while
ANIMAL ALLERGY CLINICAL LAB
FOOD - Preferred Method: The method further
involves comparing the computed value with value
of normal animal and determining the possibility of
allergic reaction with respect to allergen.
An INDEPENDENT CLAIM is included for method WO 2011027810
(M2) for preventing and/or treating food allergy in
animals, which involves ingesting diet without food
allergen.
BIOTECHNOLOGY - Preferred Composition: The
chunks comprise at least about 15% of the one or
more cereals and starches containing no
significant amount of amylose. The cereals or
starches contain less than about 5% amylase; the
cereals or starches contain less than about 2%
amylase; the cereals or starches contain less than
about 1% amylase; or the cereals or starches
contain less than about 0. [CONT.]
INDEPENDENT CLAIMS are:
The methods are useful for treating a patient
The method is safe and has long-lasting effects
suffering from or susceptible to cancer or
for the prevention of transplant rejection or graft
infectious disease organisms, preventing and/or
versus host disease.
treating graft versus host disease, and a patient
suffering from or susceptible to cancer or
leukemia, which is chemotherapy-refractory
lymphoid malignancy (all claimed), where the
organisms are viruses e.g. herpes simplex viruses
and Epstein-Barr virus and the cancer or leukemia
is e [CONT.]
PHARMACEUTICALS - Preferred Method: The T
cell subsets are cultured in 0.01 mu M of
rapamycin or rapamycin derivative. The allogeneic
Th2 cells are derived from allogeneic stem cells.
The allogeneic stem cells are cultured with
rapamycin or a rapamycin derivative. The
allogeneic Th2 cells are rapamycin-resistant.
[CONT.]
INDEPENDENT CLAIMS are included for:
The mAb or fragment is useful for preparing a
medicament for treating a proliferative disorder in
a human subject. The proliferative disorder is a
cancer that expresses the GnRH receptor. The
cancer is cancer of the breast, ovary,
endometrium, prostate, cervix, pancreas, colon,
lung, liver or kidney. The cell proliferative disorder
is a benign tumor selected from endometrial
hyperplasia, uterine leiomyoma, adenomyosis,
and endometriosis [CONT.]
BIOTECHNOLOGY - Preferred Antibody: An mAb INDEPENDENT CLAIMS are:
or its fragment, where: (a) the complementarity
(1) a pharmaceutical composition comprising the
determining region (CDR)1 region of the heavy
mAb or fragment and a pharmaceutical excipient;
chain has the sequence Arg-Tyr-Ser-Val-His (SEQ
ID NO: 1) or has a sequence having at least 90%
sequence identity to SEQ ID NO: 1; or (b) the
CDR2 region of the heavy chain has the a defined
sequence of 16 amino acids (SEQ ID NO: 2) or
has a sequence having at least 90% sequence
identity to SEQ ID NO: 2 [CONT.]
contacting or non-contacting with an allergen, and
(b) measuring ratio of cluster of differentiation
(CD) 4-positive cells which expresses CD25 at low
levels in all of CD4-positive [CONT.]
NESTEC SA
12 Food composition for consumption by
companion animals, where the companion
animals are dogs or cats, comprises a jelly and
one or more chunks, where the chunks
comprise one or more cereals and starches
13 Treating patient suffering from or susceptible
to cancer or infectious disease organisms,
jaundice, abdominal pain,
hepatosplenomegaly, alopecia, bullae, and
interstitial fibrosis, comprises administering
rapamycin resistant T cells
UNIV PENNSYLVANIA
WO 2011028241
US 20110052547
A2
A1
20110310
20110303
US DEPT HEALTH&HUMAN SERVICES
WO 2011028241 A2 UPAB: 20110323
The food composition is useful for consumption by
companion animals, where the companion
NOVELTY: Chunks-in-jelly food composition
comprises a jelly and one or more chunks, where animals are dogs or cats. It can also be used for
the chunks comprise from about 5% to about 95% providing complete and balanced nutrition for
animal (all claimed).
of one or more cereals and starches, where the
cereals and starches contain no significant
amount of amylose, and from about 5% to about
95% of one or more meats, animal products, or
other ingredients.
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are: [CONT.]
US 20110052547 A1 UPAB: 20110328
NOVELTY: Treating a patient suffering from or
susceptible to cancer or infectious disease
organisms, comprises administering rapamycin
resistant T cells to the patient.
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are included for:
(1) a method-1 for selecting and expanding
enriched T cell subsets, comprising: co-stimulating
isolated T lymphocytes in vitro; [CONT.]
VANCOUVER BIOTECH LTD
14 New monoclonal antibody against
gonadotropin releasing hormone (GnRH)
receptor, useful for treating a proliferative
disorder and an estrogen-dependent condition
and for controlling ovarian stimulation
WO 2011026242
A1
20110310
WO 2011026242 A1 UPAB: 20110328
NOVELTY: A monoclonal antibody (mAb) or its
fragment that reacts specifically with an epitope
present in amino acid residues 1-29 (SEQ ID NO:
7), given in the specification, of the extracellular
domain of the human gonadotropin releasing
hormone (GnRH) receptor, and that binds to the
GnRH receptor with a dissociation constant (KD)
of less than or equal to 10-7 M, and that competes
with GnRH for binding to the receptor, is new.
[CONT.]
The invention provides chunks-in-jelly food
composition that contains cereal and/or starch but
do not have a cloudy and unappealing
appearance. The non-cloudy, high-quality
appearance of the composition is achieved
through the use of a cereal or starch that contains
no significant amount of amylose.
WO 2011028241
Y
(1) a method for preparing chunks-in-jelly food
composition comprising: (a) preparing a chunks
mixture comprising one or more cereals and
starches, where the cereals and starches contain
no significant amount of amylose; (b) using the
chunks mixture to manufacture chunks; (c)
preparing a jelly; and (d) mixing the chunks with
the jelly to produce a chunks-in-jelly food
composition; [CONT.]
US 20110052547
US 20110052547
N
(1) a method-1 for selecting and expanding
enriched T cell subsets, comprising: co-stimulating
isolated T lymphocytes in vitro; adding cytokines
for selecting a T cell subset; and expanding the T
cell subset in the presence of rapamycin or a
rapamycin derivative; [CONT.]
WO 2011026242
N
JP 2011046867
N
(2) recombinant host cells or immortalized cells
that produce the mAb or fragment;
(3) a method to produce the mAb or fragment by
culturing the cells of (2) and recovering the mAb
or fragment;
(4) a transgenic non-human animal or transgenic
plant that produces the mAb or fragment; and
[CONT.]
15 Pack useful in packing material of fresh food
material, clothes, hat and helmet, obtained by
mixing alkaline water with raw egg yolk,
adding carbohydrate to stirred mixture and
filling obtained paste in bag
KOYO SANGYO CO LTD
ARON WORLD KK
JP 2011046867
A
20110310
JP 2011046867 A UPAB: 20110323
NOVELTY: Pack is obtained by mixing alkaline
water having pH of 12-13 with raw egg yolk (4.55.5 times), stirring the obtained mixture,
maintaining temperature of the mixture to 20-30
degrees C, adding carbohydrate to the stirred
mixture, again stirring the obtained mixture to
obtain paste form, filling the obtained paste in bag
having flexibility and maintaining the bag at 80-90
degrees C under atmospheric condition [CONT.]
The pack is useful in packing material of fresh
food material, clothes, hat and helmet.
The pack has excellent heat retention property
and provides cool feel to foodstuff even at warm
temperature. The pack enables cold preservation
for a long period of time.
WO2011028241A2
16 New primer pair, useful for hen, cow and pig
specific DNA detection, for detecting the
component derived from the hen, bovine, or
pig, and for identifying an animal species
DOKURITSU GYOSEI HOJIN NOGYO SEIBUTSU JP 2011045384
SH
A
20110310
DOKURITSU GYOSEI HOJIN NORIN SUISAN
SHOH
17 Primer pair useful for detecting DNA of fish
e.g. tuna, plants and animals in sample e.g.
feed additive, comprises specific base
sequence
NOVELTY: A primer pair for a hen, cow and pig
specific DNA detection, is new.
DETAILED DESCRIPTION: A primer pair for a hen
specific DNA detection, comprises
atcctcactactgtcatcttaac, ccattaagaagctatgcacc,
actagccttttaagctagagaga,
cactagccttttaagctagagag, agtatgatggagaatcatgg,
gagaaggtgaatcaagttagg, and
agaagtttgggttggataag (SEQ ID NO: 32-3); [CONT.]
DOKURITSU GYOSEI HOJIN NOGYO SEIBUTSU JP 2011045383
SH
A
20110310
DOKURITSU GYOSEI HOJIN NORIN SUISAN
SHOH
GLOBAL ONE PET PROD INC
18 Feeding a pet (e.g. dog and cat), comprises
feeding a pet a first formula during a first
period of time, and feeding a pet a second
formula during a second period of time, where
the first and second formulas comprise e.g.
proteins
JP 2011045384 A UPAB: 20110331
JP 2011045383 A UPAB: 20110331
NOVELTY: Primer pair for detecting fish DNA,
comprises base sequence chosen from SEQ ID
NOs: 7-31.
DETAILED DESCRIPTION: Primer pair for
detecting fish DNA, comprises base sequence
chosen from SEQ ID NOs: 7-31. [CONT.]
US 20110052752
A1
20110303
US 20110052752 A1 UPAB: 20110321
The primer pair and kit are useful for hen, cow and
pig specific DNA detection, for detecting the
component derived from the hen, bovine, or pig in
a sample, and for identifying an animal species
(all claimed).
BIOTECHNOLOGY - Preferred Primer Pair: The
hen becomes from a hen and a quail. Preferred
Method: In the method for detecting the
component derived from the hen in a sample, the
sample is from feed, fertilizer, and feed additive
containing a fresh meat, chicken meat processed
food, chicken meat processed goods containing
foodstuff, blood, bodily fluid, feather, meat and
bone meal, chicken meal, and their combination
[CONT.]
A primer pair for a hen specific DNA detection,
JP 2011045384
comprises atcctcactactgtcatcttaac,
ccattaagaagctatgcacc, actagccttttaagctagagaga,
cactagccttttaagctagagag, agtatgatggagaatcatgg,
gagaaggtgaatcaagttagg, and
agaagtttgggttggataag (SEQ ID NO: 32-3); for a
cow specific DNA detection, comprises
acaatgatcttatcaatattcttg, and
ccttcaaggggtgttttgttttaa (SEQ ID NO: 3 and 4); and
for a pig specific DNA detection, comprises
atctacatgattcattacaattac, and
ctatgtttttgagttttgagttca (SEQ ID N: 5 and 6). All
sequences are given in the specification.
INDEPENDENT CLAIMS are: [CONT.]
The primer pair is useful for detecting DNA of fish The primer pair detects even trace amount of
chosen from horse mackerel, sardine, anchovy,
animal origin DNA sequence with high sensitivity.
bonito, salmon, mackerel, saury, walleye pollock,
rainbow trout and tuna, animals and plants in
sample chosen from raw fish, fish processed food,
fish product containing foodstuff, blood, body fluid
and fish meal, fish soluble, feed, fertilizer, feed
additive (all claimed), fresh meat, milk or meat
[CONT.]
BIOTECHNOLOGY - Preferred Method: The
method (M2) involves using DNA sample and
primer pair, where the DNA is plant DNA and
comprises base sequence of SEQ ID NOs: 39 and
40. atgttagaaggagctaaatc (SEQ ID NO: 39) and
ccgaatgattgtttagccaa (SEQ ID NO: 40).
Primer pair for detecting fish DNA, comprises
base sequence chosen from SEQ ID NOs: 7-31.
tgatcctcactcatacttgaag (SEQ ID NO: 7),
tgatcatctctaatacttgaag (SEQ ID NO: 8),
cctcaattaaaccccgc (SEQ ID NO: 9),
ccacaacttcaacaacga (SEQ ID NO: 10),
tgatcctcactcatacttgaaga (SEQ ID NO: 11),
tgatcatctctaatacttgaaga (SEQ ID NO: 12),
ccccaactcaaccccgc (SEQ ID NO: 13),
ccactcattcccaaatga (SEQ ID NO: 14), [CONT.]
JP 2011045383
The method is useful for feeding a pet e.g. dog
and cat (all claimed).
FOOD - Preferred Method: The method further
comprises feeding a pet with a third formula
during a third period of time, where the third
formula is formulated to achieve complementary
nutritional and digestive compatibility with the first
and second formulas. In the method, the first and
second periods of time are at least partially
overlapped. [CONT.]
INDEPENDENT CLAIMS are also included for:
US 20110052752
NOVELTY: Feeding a pet comprises: feeding a
pet with a first formula during a first period of time;
and feeding a pet with a second formula during a
second period of time, where the second formula
is formulated to achieve complementary nutritional
and digestive compatibility with the first formula.
19 Forage feeding machine for feeding forage to TAN H
e.g. mink, has stander provided with hopper,
and forage transmitting device installed below
hopper, where transmitting device is in
transmission connection with power drive
device
CN 201690880
20 Automatic feeding device for feeding domestic CHENG W
animal in village, has gear and rack type
YAN C
ejecting rod that are installed in lower sides of
hollow pipe and container, where ejecting rod
is meshed with gear that is driven by motor
CN 201690883
U
20110105
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are also included for: [CONT.]
CN 201690880 U UPAB: 20110323
NOVELTY: The machine has a stander (1)
provided with a hopper (2). A forage transmitting
device is installed below the hopper, where the
transmitting device is in transmission connection
with a power drive device. The stander is provided
with a control cabinet (4) installed with an electric
control device. [CONT.]
U
20110105
CN 201690883 U UPAB: 20110323
NOVELTY: The device has a hollow pipe (1)
whose one end is connected with a container (2),
where the end of the hollow pipe is hinged with a
support (3) that is installed on one part from a
front end of the hollow pipe. Lower sides of the
hollow pipe and the container are provided with a
gear (5) and a rack type ejecting rod (4), which is
meshed with the gear driven by a motor (6)
[CONT.]
The primer pair and kit can detect trace amount
animal origin DNA sequence in a sample with high
sensitivity, thus identification of the animal species
of the meat and bone meal slightly mixed in feed,
for example is possible.
The method provides: a healthy diet to the pets by
cycling through a sequence of rotational pet-food
formulas that are digestively compatible and
developed to nutritionally complement one
another; and more-comprehensive and balanced
nutrient platform not found in any single pet food
formula.
N
N
US 20110052752
Y
US20110052752A1
(1) a method (I) of feeding a pet comprising:
feeding a pet, a first formula from a first container;
mixing a remainder of the first formula from the
first container with a second formula from a
second container, where the first container is
substantially empty and the second container is
substantially full at the time of mixing, and the
second formula is [CONT.]
Forage feeding machine for feeding forage to a
mink, a raccoon dog and a fox.
The device transmits accurate amount of forage.
The rotation speed of the drive motor is controlled
to change the forage transmitting amount to adapt
feeding amounts of different animals. The
machine has high working efficiency and low labor
intensity, and can be manufactured at low cost
CN 201690880
N
Automatic feeding device for feeding a domestic
animal in a village.
The device is convenient to operate and saves
labor for breeding a domestic animal in the village.
CN 201690883
Y
CN201690883U
21 Automatic water compensating device for
providing drinking water to pet in house, has
air pressure balance pipe whose one end is
connected to water inlet formed in water
storage barrel
QIAN H
CN 201690885
U
20110105
CN 201690885 U UPAB: 20110323
Automatic water compensating device for
NOVELTY: The device has a water storage barrel providing drinking water to a pet in house.
whose bottom part is equipped with a water outlet
that is equipped with a water valve. Top part of the
water storage barrel is equipped with a water inlet.
One end of an air pressure balance pipe is
connected to the water inlet of the water storage
barrel, where the end of the balance pipe is
pressed by a sealing plug. [CONT.]
The device is simple in structure and practical to
use. The device automatically compensates the
water into the air pressure balance pipe when
water in the pet water-drinking basin is drunken to
lower surface of the balance pipe hole by a pet,
thus solving water drinking problem of the pet
when a feeder is not in home for a short time.
CN 201690885
Y
CN201690885U
22 Protection cover for preventing pet e.g. cat,
from biting e.g. children, has rigid net cover
YUE X
CN 201690887
U
20110105
CN 201690887 U UPAB: 20110323
The cover prevents pet teeth and tongue form
contacting utensils and food bag, and enables the
CN 201690887
Y
CN201690887U
Protection cover for preventing pet such as cat
and dog, from biting children and strangers.
YUE X
22 Protection cover for preventing pet e.g. cat,
from biting e.g. children, has rigid net cover
part whose back end is connected with netted
soft fabric cover part, where back end of
netted soft fabric cover part is provided with
bag opening
PACIFIC TECHNOLOGY MFG LTD
23 Pet feeder, has rotating pipe connected with
insert pipe, control panel electrically
connected with microcomputer controller,
where microcomputer controller is electrically
connected with motor
CN 201690884
HERBAMED LTD
24 Edible composition, useful for e.g. reducing
cholesterol blood level, serum lipid
concentration, comprises malleable matrix
comprising citrus flakes and flavoring agent
comprising e.g. sesame seeds, sesame paste,
chocolate, and coconut
WO 2011024183
25 Feed additives useful for improving immunity,
comprises natural mineral and extracts of
Schisandra chinensis
KRGREEN CO LTD
20110105
CN 201690887
CN 201690884 U UPAB: 20110331
Pet feeder.
The feeder controls running times of the motor in
a certain time determined by the time of pet
master going out or in preset time by utilizing the
microcomputer. The motor drives the food pan to
rotate, so as to align any food storage
compartment to the feeding window, and the pet
can eat the food via the feeding window, thus
realizing that the pet can receive the feeding at a
fixed time and in a [CONT.]
CN 201690884
Y
(I) is useful: for reducing blood cholesterol level,
serum lipid concentration, and enhancing the
feeling of satiety in a subject, where the lipid is
cholesterol, low-density lipoprotein and triglyceride
(all claimed); for reducing the blood glucose level
and preventing hypercholesterolemia; as dietary
or nutritional composition; has antioxidative
activity. The ability of (I) (comprising 2. [CONT.]
(I) reduces serum lipid concentration by at least
5%, preferably at least 10%. (I) has palatable
taste, pleasant taste, texture and high nutritional
value. (I) maintains the body weight and prevents
obesity.
BIOLOGY - Preferred Composition: (I) comprises:
sesame seeds (3-11 wt.%) and/or sesame paste
(7-15 wt.%); date fruit and/or date fruit product at
10-40 wt.%. Preferred Method: The citrus flakes
are obtained from citrus pulp, or crushed orange
fruit. FOOD - Preferred Composition: (I) further
comprises: phytosterols at 0.5-2 wt. [CONT.]
WO 2011024183
Y
The feed additives are useful for improving
immunity.
The feed additives increase the growth rate of
domestic animal.
FOOD - Preferred Composition: The natural
mineral is chosen from barley stone, biotite,
pegmatite and sericite.
NOVELTY: The feeder has a food storage
compartment that is rotatable corresponding to a
feeding window, and a controller mounted on a
main body and comprising a power unit, a control
panel and a microcomputer controller. The power
unit comprises a gear set, a motor and a rotating
pipe, where the gear set is connected with a
spindle of the motor. [CONT.]
A1
20110303
WO 2011024183 A1 UPAB: 20110321
NOVELTY: Edible composition (I) comprises: a
malleable matrix comprising citrus flakes (5-20
wt.%), where the ratio of the soluble to insoluble
fibers is 1:1.5-1.5:1, and a flavoring agent
comprising sesame seeds, sesame paste,
chocolate, coconut, banana, and/or dates, where
(I) is in a unit dosage form.
KR 2011016576
A
20110218
ACTIVITY: Antilipemic; Antidiabetic;
Hypoglycemic; Anabolic. [CONT.]
KR 2011016576 A UPAB: 20110315
BICKERDIKE M J
N
US 20110052530
A1
20110303
The method is useful for promoting regression of a
NOVELTY: Promoting regression of a cancer in a cancer in a mammal (human), where the cancer is
mammal comprises: culturing autologous T cells; melanoma, metastatic (all claimed), acute
lymphocytic cancer, acute myeloid leukemia,
expanding the cultured T cells using ortho-antialveolar rhabdomyosarcoma, bone cancer, brain
cluster of differentiation (CD) 3 antibody,
interleukin (IL)-2 and feeder lymphocytes, where cancer, breast cancer, cancer of the anus, anal
the cultured T cells are enriched for CD8+ T cells canal or anorectum, cancer of the eye, cancer of
the intrahepatic bile duct, cancer of the joints,
prior to expansion of the T cells; administering
nonmyeloablative lymphodepleting chemotherapy cancer of the neck, [CONT.]
to the mammal [CONT.]
The method: can be used to treat the patients who
would not be eligible for treatment that involves
total body irradiation including patients who have
already undergone myeloablative therapy (e.g.
radiotherapy prior to treatment), patients with
comorbid conditions, and patients with less than
2x 106 CD34+ cells/kg; requires less time to
generate T-cell; [CONT.]
BIOTECHNOLOGY - Preferred Method: The
administered T cells have: a higher expression of
CD27 and CD28 than T cells that are 44 days old;
a mean telomere length that is longer than that of
T cells that are 44 days old; and a higher
frequency of CD4+ cells than T cells that are 44
days old. In the method: the T-cells are modified
to express a T-cell growth factor that promotes the
growth and activation of the autologous T-cells
[CONT.]
US 20110052530
US 20110052530
N
US 20110052531
A1
20110303
US 20110052531 A1 UPAB: 20110331
The method is non-toxic, and has no adverse
events.
PHARMACEUTICALS - Preferred Method: The
method further comprises administering the
compound in a composition comprising one or
more excipients, carriers, additives, adjuvants or
binders in a tablet or capsule. The method further
comprises administering another neuroprotective
agent. [CONT.]
US 20110052531
US 20110052531
N
US 20110052591
A1
20110303
US 20110052591 A1 UPAB: 20110321
BIOLOGY - Preferred Components: (I) comprises INDEPENDENT CLAIMS are also included for:
any one of a fully defined sequence of 354
nucleotide bases of SEQ ID NO: 3 (derived from
Mus musculus) or 375 nucleotide bases of SEQ ID
NO: 7 (derived fromHomo sapiens) as given in the
specification. The expression vector is a plasmid,
cosmid, bacteriophage or a viral expression
US 20110052591
US 20110052591
BRIMBLE M A
UNIV TEXAS SYSTEM
An INDEPENDENT CLAIM is included for method KR 2011016576
for preparing feed additives, which involves mixing
the above-cited composition and pulverizing the
obtained mixture using a mesh of size 50-500.
ACTIVITY: Immunostimulant. No biological data
given. [CONT.]
US 20110052530 A1 UPAB: 20110321
SIRIMANNE E S
28 New isolated nucleic acid molecule that
encodes thyroid-stimulating hormone (TSH)beta polypeptide, useful for producing the
polypeptide, which is useful for treating TSHbeta-related disorders e.g. hyperthyroidism
and Graves' disease
The cover prevents pet teeth and tongue form
contacting utensils and food bag, and enables the
pet to respire and drink water normally. The cover
can be removed while feeding the pet and can be
worn on the pet after feeding, thus preventing the
pet from biting children and stranger.
NOVELTY: Feed additives comprises (in wt.%):
natural mineral (95-99) and extracts of Schisandra
chinensis (1-5).
DETAILED DESCRIPTION: An INDEPENDENT
CLAIM is included for method for preparing feed
additives, which involves mixing the above-cited
composition and pulverizing the obtained mixture
using a mesh of size 50-500.
US DEPT HEALTH&HUMAN SERVICES
26 Promoting regression of a cancer e.g.
melanoma in a mammal (human), comprises
culturing autologous T cells, expanding the T
cells using e.g. interleukin 2, and
administering nonmyeloablative
lymphodepleting chemotherapy and expanded
T cells
27 Treating a peripheral neuropathy including
toxin-induced peripheral neuropathy and
diabetic, comprises administering a cyclic
glycyl-2-allylproline to the mammal
U
Protection cover for preventing pet such as cat
NOVELTY: The cover has a rigid net cover part (1) and dog, from biting children and strangers.
provided in front end, where the rigid net cover
part is utilized for covering mouth of a pet. Back
end of the rigid net cover part is connected with a
netted soft fabric cover part (2). Back end of the
netted soft fabric cover part is provided with a bag
opening (3) with opening and closing functions.
[CONT.]
The method is useful for treating peripheral
NOVELTY: Treating a peripheral neuropathy in a neuropathy including toxin-induced peripheral
mammal comprises administering a cyclic glycyl-2- neuropathy and diabetic, where peripheral
neuropathy is a toxic neuropathy caused by
allylproline or its salt or hydrate.
hyperglycemia, chemotherapy or pyridoxine (all
claimed). The method is useful for treating e.g.
ACTIVITY: Neuroprotective; Antidiabetic;
compromised vascular supply to the peripheral
Vasotropic; Antiinflammatory; Nephrotropic;
nerves (e.g. chronic arteriosclerotic ischemia,
Vulnerary; Muscular-Gen.; Hemostatic; Apoptotic;
vasculitis and hypercoagulable states), metabolic
Nootropic; Antiparkinsonian; Anti-HIV;
states (e [CONT.]
Anticonvulsant; Cerebroprotective;
Ophthalmological; CNS-Gen [CONT.]
(I) is useful: for producing a polypeptide, which is
useful for treating a TSH- beta -related disorder,
which is adenoma, thyroid hormone resistance,
hypopituitarism, hyperthyroidism, Graves' disease,
congenital hypothyroidism (cretinism),
hypothyroidism, Hashimoto's thyroiditis,
autoimmune thyroid diseases, Graves'
N
CN201690884U
WO 2011024183A1
encodes thyroid-stimulating hormone (TSH)beta polypeptide, useful for producing the
polypeptide, which is useful for treating TSHbeta-related disorders e.g. hyperthyroidism
and Graves' disease
NOVELTY: Isolated nucleic acid molecule (I) that
encodes any one of a fully defined sequence of 93
amino acids of SEQ ID NOs: 4 or 8 (derived from
Mus musculus and Homo sapiens respectively) as
given in the specification, is new.
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are also included for:
(1) an expression vector comprising (I);
29 Manufacture of ceramic article e.g. for tissue
engineering by forming ceramic composition
into defined shape comprising at least two
zones with different porosity or pore size,
exposing to solvent in which liquid is soluble,
and solidifying
UNIV TEXAS SYSTEM
30 New silencer cassette in a dumbbell shape,
useful for treating a mammal suffering from a
neurodegenerative disease including
Huntington's disease, Alzheimer's disease or
Spinocerebellar ataxia-1
MEDTRONIC INC
US 20110052660
US 20110052666
A1
A1
20110303
20110303
useful for treating a TSH- beta -related disorder,
which is adenoma, thyroid hormone resistance,
hypopituitarism, hyperthyroidism, Graves' disease,
congenital hypothyroidism (cretinism),
hypothyroidism, Hashimoto's thyroiditis,
autoimmune thyroid diseases, Graves'
ophthalmopathy, thyroid nodules, Pendred
syndrome, post-traumatic stress disorder, [CONT.]
(3) producing a polypeptide comprising culturing
the host cell under conditions that permit the
expression of the expression vector;
(2) a host cell comprising the expression vector;
[CONT.]
US 20110052660 A1 UPAB: 20110328
The method is for manufacturing ceramic article
for use as biodegradable scaffold useful for
repairing bone defect in an individual (claimed).
The ceramic article is useful as an implant to
repair bone defect or treat skeletal defects. It is
NOVELTY: Manufacture of ceramic article
comprises forming ceramic composition(s) into a useful as scaffolding e.g. for tissue engineering
defined shape comprising greater than or equal to and bone replacement and repair. The ceramic
2 zones with different porosity or pore size, where article is for use e.g. [CONT.]
a second zone surrounds a first zone in greater
than or equal to 2 dimensions, and each ceramic
composition contains a ceramic material and a
liquid; [CONT.]
US 20110052666 A1 UPAB: 20110328
NOVELTY: Silencer cassette (C1) in a dumbbell
shape, encoding an RNA interference (RNAi)
agent and lacking means for replication within a
host cell, inverted terminal repeats and further
lacking at least one selectable marker, is new.
any one of a fully defined sequence of 354
nucleotide bases of SEQ ID NO: 3 (derived from (1) an expression vector comprising (I);
Mus musculus) or 375 nucleotide bases of SEQ ID
NO: 7 (derived fromHomo sapiens) as given in the
specification. The expression vector is a plasmid,
cosmid, bacteriophage or a viral expression
vector, which is a baculovirus, cauliflower mosaic
virus or tobacco mosaic virus [CONT.]
(2) a host cell comprising the expression vector;
(4) a substantially isolated polypeptide comprising
SEQ ID NOs: 4 or 8; [CONT.]
The ceramic article has compressive strength that CERAMICS AND GLASS - Preferred Method: The INDEPENDENT CLAIMS are included for:
US 20110052660
is equal to or exceeding that of cortical bone. It
forming step comprises casting the ceramic
possesses unexpectedly higher strength than that composition onto a replica that is insoluble in the
possessed by similar ceramic articles that are
solvent. The replica is a negative replica
made without the solvent-based liquid removal
corresponding to the zone and comprises a
(1) ceramic article comprising greater than or
step; and has improved structural properties. The sacrificial porogen comprising a multiplicity of
equal to 2 zones comprising ceramic material(s),
scaffold has high interconnectivity and mechanical discrete components. The forming step comprises having solid struts between pores, and greater
strength, compared to scaffolds made by other
causing the multiplicity of discrete components to than or equal to 70% pore interconnectivity; and
methods. [CONT.]
coalesce to a degree that corresponds to
[CONT.]
interconnectivity of pores of greater than or equal
to 70% in the ceramic article [CONT.]
The silencer cassette is useful for treating a
mammal suffering from a neurodegenerative
disease including Huntington's disease,
Alzheimer's disease or Spinocerebellar ataxia-1
(all claimed). No biological data given.
BIOTECHNOLOGY - Preparation (Disclosed):
Preparation of the silencer cassette is by standard
molecular biology techniques including PCR
techniques, cloning, endonuclease digestion or
ligation. Preferred Composition: The silencer
cassette (C1) comprises a double-stranded
spacer region, where the region has a first spacer
strand which is contiguous, and a second spacer
strand which consists of two [CONT.]
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are also included for: [CONT.]
CHRISTENSEN N D
31 Use of an antibody to the cholecystokinin
(CCK)-C receptor for detecting and treating
HARMS J F
gastrointestinal or other tumors, e.g.
pancreatic adenocarcinoma, neuroendocrine
tumors, gastrointestinal stromal cell tumors, or
gastric cancer
US 20110052668
A1
20110303
US 20110052668 A1 UPAB: 20110328
NOVELTY: Use of an antibody to the
cholecystokinin (CCK)-C receptor, which is a
splice variant receptor of the CCK-B receptor that
retains the 4th intron (also called CCK2Ri4sv), for
detection and therapy of gastrointestinal or other
tumors which possess the receptor, including
pancreatic adenocarcinoma, neuroendocrine
tumors, insulinomas, gastrointestinal stromal cell
tumors, gastric cancer, colon cancer, and small
cell cancer of the lung. [CONT.]
The antibody to CCK-C receptor is used for
detection and therapy of gastrointestinal or other
tumors including pancreatic adenocarcinoma,
neuroendocrine tumors, insulinomas,
gastrointestinal stromal cell tumors, gastric
cancer, colon cancer, and small cell cancer of the
lung. The antibody may be used in identifying the
receptor in tissues or cells by flow cytometry,
immunohistochemistry, protein analysis (western
blots), PET, or other forms of imaging scanning
[CONT.]
INDEPENDENT CLAIMS are also included for:
US 20110052666
US 20110052660
N
US 20110052666
N
(1) a silencer cassette (C2) in a circular shape,
encoding an RNAi agent and lacking an on region
and at least one selectable marker;
(2) a composition comprising the silencer cassette
and a carrier;
(3) treating a mammal suffering from a
neurodegenerative disease comprising
administering the composition to a mammal;
[CONT.]
US 20110052668
US 20110052668
N
PHARMACEUTICALS - Preferred Tablet: The first
and second portions are present in a ratio of 1:9 to
9:1. The tablet is a multi-layer tablet. The tablet
further comprises at least one of diluent, binder,
lubricant, granulating solvent and glidants.
POLYMERS - Preferred Components: The pHindependent polymer comprises hydrophilic.
[CONT.]
US 20110052686
US 20110052686
N
INORGANIC CHEMISTRY - Preferred
Component: The teat sealant comprises 50-75
(preferably 65) wt.% heavy metal salt. The heavy
metal salt is titanium dioxide, zinc oxide, and/or
barium sulfate. ORGANIC CHEMISTRY -
US 20110052721
US 20110052721
N
MATTERS G L
SMITH J P
RANBAXY LAB LTD
32 Modified-release uncoated tablet of
lamotrigine comprises first portion containing
lamotrigine in mixture with pH-dependent
polymer; and second portion comprising
remaining amount of lamotrigine and pHindependent polymer
33 Intra-mammary teat sealant used for forming
physical barrier in teat canal for prophylactic
treatment of mammary disorders, comprises
gel base, and non-toxic heavy metal salt
RANKIN S A
US 20110052686
EP 2292217
US 20110052721
A1
20110303
US 20110052686 A1 UPAB: 20110331
A2
20110309
NOVELTY: A modified-release uncoated tablet of
lamotrigine comprises: a first portion containing
lamotrigine (20-90%) in mixture with a pHdependent polymer; and a second portion
comprising the remaining amount of lamotrigine
and a pH-independent polymer.
A1
20110303
To treat convulsions, epilepsy, bipolar I disorder,
depression, mania, and hypomania (claimed).
The tablet comprises the following in vitro
dissolution profile when measured in a USP type II
apparatus, at 50 rotation per minute, at a
temperature of 37 degrees C plus minus 0.5
degrees C in 900 mL of 0.1 N Hydrochloric acid
medium: (i) at most about 35% drug released in 2
hours; (ii) at most about 55% drug released in 4
hours; (iii) at most about 80% drug released in 8
hours; [CONT.]
ACTIVITY: Anticonvulsant; Neuroleptic; Antimania;
Antidepressant. No biological data is given.
[CONT.]
US 20110052721 A1 UPAB: 20110331
An intra-mammary teat sealant used for forming a The physical barrier does not cause black spot
physical barrier in a teat canal of a non-human
defect in dairy products, e.g. cheddar cheese,
animal for prophylactic treatment of mammary
made from the milk of the treated animal.
disorders (claimed).
33 Intra-mammary teat sealant used for forming
physical barrier in teat canal for prophylactic
treatment of mammary disorders, comprises
gel base, and non-toxic heavy metal salt
devoid of bismuth
RANKIN S A
An intra-mammary teat sealant used for forming a The physical barrier does not cause black spot
physical barrier in a teat canal of a non-human
defect in dairy products, e.g. cheddar cheese,
NOVELTY: An intra-mammary teat sealant
animal
for
prophylactic
treatment
of
mammary
made from the milk of the treated animal.
comprises a gel base; and greater than or equal to
disorders (claimed).
30 wt.% non-toxic heavy metal salt dispersed in
the gel base, where the heavy metal salt is devoid
of bismuth. The sealant is devoid of anti-infective
agents.
INORGANIC CHEMISTRY - Preferred
Component: The teat sealant comprises 50-75
(preferably 65) wt.% heavy metal salt. The heavy
metal salt is titanium dioxide, zinc oxide, and/or
barium sulfate. ORGANIC CHEMISTRY Preferred Component: The gel base comprises
aluminum stearate, or liquid paraffin.
US 20110052721
US 20110052721
BIOLOGY - Preferred Components: The host cell INDEPENDENT CLAIMS are also included for:
is a eukaryotic cell or a prokaryotic cell, where the
host cell is a bacterial cell, a fungal cell (preferably (1) a cell produced by the method;
a yeast cell), an insect cell, a plant cell or an algal
cell. The recipient cell is a bacterial cell, a yeast
cell, a fungal cell, an insect cell, a plant cell or an
algal cell. [CONT.]
US 20110053272
US 20110053272
USE: An intra-mammary teat sealant used for
forming a physical barrier in a teat canal of a nonhuman animal for prophylactic treatment of
mammary disorders (claimed). [CONT.]
ALGIRE M A
34 Cloning donor genome, useful e.g. to make a
cell that exhibits phenotype encoded by donor
genome, comprises obtaining donor genome BENDERS G A
from donor cell, and introducing donor
genome and a host vector into a heterologous
host cell e.g. yeast cell
US 20110053272
A1
20110303
US 20110053272 A1 UPAB: 20110328
NOVELTY: Cloning a donor genome, comprises:
obtaining a donor genome from a donor cell or
synthesizing a donor genome as at least one
fragment; and introducing the donor genome and
a host vector into a heterologous host cell, where
the donor genome and the host vector are
optionally joined prior to introduction into the host
cell, hence generating a host cell comprising the
donor genome containing the host vector [CONT.]
The method is useful for: cloning a donor genome;
seamlessly introducing a modification in a target
nucleic acid molecule; making a cell which
exhibits a phenotype encoded by a donor genome
(all claimed); for manipulating and engineering
donor genomes from intractable donor cells in
more tractable host cells; producing synthetic
genomes and cells; engineering and altering
genomes and organisms that [CONT.]
The method: clones large nucleic acids including
chromosomes or genomes, into alternate
heterologous hosts; minimizes incompatibility
and/or toxicity between nucleic acid sequences,
cells, and genetic systems of donors, hosts and
recipients of different species; minimizes the risk
of instability of the donor nucleic acid sequence
within the host cell during modification; [CONT.]
CHUANG R
N
(2) seamlessly introducing a modification in a
target nucleic acid molecule, comprising:
introducing a mutagenesis construct and a host
vector into a host cell, where the host vector
recombines with the mutagenesis construct in the
host cell, the mutagenesis construct comprises a
first portion of homology to a 5' portion [CONT.]
GIBSON D G
GLASS J I
HUTCHISON C A
LARTIGUE C
MERRYMAN C E
NOSKOV V N
SMITH H O
VASHEE S
VENTER J C
MATHEWS W W
35 Vented kitty litter box for venting kitty litter
odor, has Y fitting arranged along specific
degrees and including tee for installation in
clothes dryer vent flue, and blower exhaust fan
removing odor from litter enclosure
US 20110048330
A1
20110303
US 20110048330 A1 UPAB: 20110321
36 Composition useful for treatment or prevention NESTEC SA
of functional gastrointestinal disorders
comprises Bifidobacterium longum ATCC BAA999
EP 2289527
WO 2011023689
A1
20110302
EP 2289527 A1 UPAB: 20110323
A1
20110303
NOVELTY: Composition useful for the treatment
and/or prevention of functional gastrointestinal
(GI) disorders comprises Bifidobacterium longum
ATCC BAA-999.
ACTIVITY: Gastrointestinal-Gen.;
Antiinflammatory; Laxative; Antidiarrheic;
Analgesic. Test details are described, but no
results given.
MECHANISM OF ACTION: None given. [CONT.]
VLST CORP
WO 2011025962
A1
20110303
WO 2011025962 A1 UPAB: 20110323
37 New isolated antibody or its antigen binding
fragment, which binds to at least three
different specific chemokines useful for
treating a disease, disorder or condition e.g.
inflammatory disease mediated by specific
chemokines
Vented kitty litter box for venting a kitty litter odor. The inline blower exhaust fan is located away from
the litter enclosure housing to insure that the cat
NOVELTY: The box has a Y fitting arranged along
that is not disturbed by the fan noise. The box
15 to 90 degrees and including a tee for
utilizes a blower control box with a timer that can
installation in a clothes dryer vent flue (18). An
be adjusted from seconds to hours to insure that
inline blower exhaust fan (17) removes odor from
the odor is vented outside the dwelling. [CONT.]
a kitty litter enclosure. A vented kitty litter housing
with an open bottom (10) allows easy access to
change a kitty litter. [CONT.]
As a food composition, a pet food composition, a
dietary supplement, a nutraceutical, a nutritional
formula, a drink and/or a medical composition for
the treatment and/or prevention of functional
gastrointestinal (GI) disorders selected from
irritable bowel syndrome; functional dyspepsia;
functional constipation, functional diarrhea;
functional abdominal pain; and/or functional
bloating, Epigastric pain syndrome, and
postprandial distress syndrome [CONT.]
The composition in powder form has a water
activity smaller than 0.2 (e.g. 0.19-0.05, preferably
smaller than 0.15). The composition comprises an
alternative bacterial strain that is effective, readily
available, low priced and safe to administer
without unwanted side effects for treating or
preventing functional gastrointestinal disorders.
For treating a disease, disorder or condition
The isolated antibody or its antigen binding
(selected from inflammatory disease or one
fragment neutralizes the chemotactic activity of
mediated or associated with inflammation or
CC chemokine to which it binds.
autoimmune disease) mediated by at least one
CC chemokines; for preparing hybridoma cell line
(all claimed); for producing hybridomas and for
humanizing antikine antibodies; for improving
antikine antibodies by affinity maturation; [CONT.]
US 20110048330
BIOLOGY - Preferred Components: The food
grade bacteria are preferably selected from lactic
acid bacteria, bifidobacteria, and/or
propionibacteria. PHARMACEUTICALS Preferred Composition: The composition
comprises additionally at least one other kind of
other food grade bacteria; and further contains at
least one prebiotic. [CONT.]
EP 2289527
BIOTECHNOLOGY - Preferred Components: The INDEPENDENT CLAIMS are included for the
isolated antibody or its antigen binding fragment, following:
binds to at least four different CC chemokines; at
least three different CC chemokines selected from
CCL2/monocyte chemoattractant protein (MCP)-1,
CCL3/MIP-1 alpha , CCL4/MIP-1 beta ,
CCL5/RANTES, CCL14/HCC-1, CCL15/HCC-2,
CCL18/PARC, and CCL23/MPIF-1; [CONT.]
WO 2011025962
US 20110048330
N
Y
US 20110059107
N
EP2289527A1
fragment, which binds to at least three
different specific chemokines useful for
treating a disease, disorder or condition e.g.
inflammatory disease mediated by specific
chemokines
ALLISON D
US 20110059107
A1
20110310
RAPORT C
NOVELTY: An isolated antibody (a1) or its antigen
binding fragment, which binds to at least three
different CC chemokines, where at least one CC
chemokine is CCL3/macrophage inflammatory
protein-1 alpha (MIP-1 alpha ), CCL4/MIP-1 beta ,
or CCL5/RANTES is new.
(selected from inflammatory disease or one
fragment neutralizes the chemotactic activity of
mediated or associated with inflammation or
CC chemokine to which it binds.
autoimmune disease) mediated by at least one
CC chemokines; for preparing hybridoma cell line
(all claimed); for producing hybridomas and for
humanizing antikine antibodies; for improving
antikine antibodies by affinity maturation; [CONT.]
isolated antibody or its antigen binding fragment,
binds to at least four different CC chemokines; at (1) a hybridoma cell line producing the monoclonal
least three different CC chemokines selected from antibody (a1);
CCL2/monocyte chemoattractant protein (MCP)-1,
CCL3/MIP-1 alpha , CCL4/MIP-1 beta ,
CCL5/RANTES, CCL14/HCC-1, CCL15/HCC-2,
CCL18/PARC, and CCL23/MPIF-1; [CONT.]
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are included for the following:
38 Pet treating container for swimming training of JULIUS-K9 BT
dog, has protective cover comprising
intermediate substance consisting of
polyethylene-foam plates with closed cell
structure, where substance comprises specific
range of thickness
DE 202010015533
U1
20110303
39 Method for improving, enhancing or modifying INT FLAVORS&FRAGRANCES INC
a foodstuff e.g. meats, sauces, gravies and
soups, involves addition of a thiazoline
AGYEMANG D O
compound
EP 2289351
A2
20110302
US 20110052775
A1
20110303
GB 2473127
A
20110302
(2) a composition comprising the antibody (a1) or
its antigen binding fragment, in combination with a
carrier, excipient or buffer; and [CONT.]
(1) a hybridoma cell line producing the monoclonal
antibody (a1); [CONT.]
DE 202010015533 U1 UPAB: 20110323
Pet treating container for swimming training of a
NOVELTY: The container (1) has an outer textile- dog.
protective cover (6) forming a pencil-case like bag
part in the middle of the container. The protective
cover is held by a joint or by an adhesive, and a
detachable closure element (4) e.g. Velcro (RTM:
hook-and-loop fastener) or waterproof zipper
(RTM: Sliding fastener), is attached to the
protective cover. [CONT.]
BARDSLEY K A
PSOTA-KELTY L
EP 2289351 A2 UPAB: 20110321
For improving, enhancing or modifying the flavor
of a foodstuff selected from meats, sauces,
gravies, soups, convenience foods, malt
NOVELTY: A method for improving, enhancing or beverages, alcoholic beverages, soy-containing
products, milk products, dairy products, herbs,
modifying a foodstuff involves addition of a
fish, crustaceans, mollusks, candies, vegetables,
thiazoline compound.
cereals, soft drinks, snacks, dog food, soda,
DETAILED DESCRIPTION: A method for
yogurt and cat foods (claimed).
improving, enhancing or modifying a foodstuff
involves addition of a thiazoline compound of
formula (I).
R and R1=H or 1-5C alkyl. [CONT.]
The protective cover comprises the intermediate
substance consisting of the polyethylene-foam
plates with the closed cell structure, where the
substance comprises thickness of 0.4 cm to 3 cm,
thus ensuring that the dog resides and/or swims at
the water surface in a safe manner. The
detachable closure element e.g. [CONT.]
The compounds can be combined with
conventional flavoring materials or adjuvant.
DE 202010015533
FOOD - Preferred Method: The compound is used A method for improving, enhancing or modifying a EP 2289351
at a level of 0.001 to 10 (preferably 0.001-5,
foodstuff involves addition of a thiazoline
especially 0.001-1) ppm.
compound of formula (I).
R and R1=H or 1-5C alkyl.
Y
DE202010015533U1
Y
US20110052775A1
US 20110052775
TRINNAMAN L
40 New culture of Lactobacillus species or strain
having specified base pair sequence, useful
e.g. for restricting the colonization of a
vertebrate gut by pathogens, and for
prophylaxis against necrotic enteritis
PLANT BIOSCIENCE LTD
41 Automatic feeding system i.e. dry food gravity
feeder, for measuring and controlling food
intake of animals e.g. cat, has computing
device to calculate individual feeding
parameters using determined feeding amount
information
WHELAN S
GB 2473127 A UPAB: 20110310
NOVELTY: Culture of a Lactobacillus species or
strain comprising a portion of the
exopolysaccharide (EPS) gene cluster base
sequence depicted in any one of SEQ ID NOs: 1124 (comprising one of 14 fully defined 600-1422
base pair sequence as given in the specification)
or a mucin binding protein having the nucleotide
base sequence depicted in any one of SEQ ID
NOs: 1-5 (comprising one of 5 fully defined 63310208 base pair sequence as given in the
specification), is new. [CONT.]
KIKKOMAN CORP
42 Cooling device for reducing heat produced
during packing e.g. food-drink, in packing
container e.g. PET bottle, has sprinkle nozzle
formed on flow control valve, where sprinkle of
cool water is performed toward inner side of
conveyor
US 7895973
B1
20110301
US 7895973 B1 UPAB: 20110310
JP 2011038739
A
20110224
JP 2011038739 A UPAB: 20110315
The Lactobacillus johnsonii is useful: for restricting
the colonization of a vertebrate gut by one or more
pathogens; for prophylaxis against necrotic
enteritis; for improving one or more of the weight
gain, feed conversion, and the immune
competency of immature vertebrates; in food
composition; as a coccidiostat or a probiotic,
where the vertebrate is humans, bovine, ovine,
porcine, equine, avian, pets and companion
animals, and the pathogen is Clostridium
perfringens , Escherichia coli, and Campylobacter
[CONT.]
Automatic feeding system i.e. dry food gravity
feeder, for measuring and controlling food intake
NOVELTY: The system has an electronic
identification (ID) reader circuit (5) communicating of animals e.g. domestic pets such as cat and
dog. Can also be used for wild animals, livestock
with ID transponders (6) without using a wired
and zoo animals.
connection, where the ID transponders are worn
by animals. A computing device (7) and the circuit
determine feeding amount of the animal using an
algorithm by comparing feeding time of the animal
during an arbitrary interval, and feeding time
during a calibration interval [CONT.]
BIOLOGY - Preferred Components: The
Lactobacillus species is Lactobacillus johnsonii or
Lactobacillus oasseri. The Lactobacillus strain is
Lactobacillus johnsonii FI9785. The Lactobacillus
strain is deposited with NCIMB as deposit number
NCIMB 41632. The culture is a monoculture or a
mixed culture. Preferred Composition: The
composition further comprises live Bacillus
subtilis.
INDEPENDENT CLAIMS are included for: (1) an GB 2473127
isolated nucleic acid comprising a portion of the
EPS gene cluster base sequence depicted in any
one of SEQ ID NOs: 11-24; (2) an isolated nucleic
acid comprising a mucin binding protein having
the nucleotide base sequence depicted in any one
of SEQ ID NOs: 1-5; (3) an isolated nucleic acid
which encodes the protein or peptide sequence
depicted in any one [CONT.]
The system utilizes an electronic circuit to identify
authorized animals and permits regulated access
to food while restricting access by unauthorized
users or animals. The system adjusts the feed
time of each animal, so that the weight of the
animals can be managed. [CONT.]
Cooling device for reducing heat produced during The device reduces regular countermeasure
packing e.g. food-drink, liquid and paste form
against microorganisms. The device is simple in
foodstuff, in a packing container. Uses include but structure and small in size.
are not limited to a polyethylene terephthalate
(PET) bottle, retort pouch, aluminum pouch,
flexible plastic container, film-form bag container,
bottle container and tin container.
US 7895973
An INDEPENDENT CLAIM is also included for a
method for cooling packed food-drinks in a
container.
JP 2011038739
N
US 7895973
Y
N
US7895973B1
Cooling device for reducing heat produced during The device reduces regular countermeasure
against microorganisms. The device is simple in
NOVELTY: The device has a conveyor (3) moved packing e.g. food-drink, liquid and paste form
foodstuff,
in
a
packing
container.
Uses
include
but
structure and small in size.
into a duct (2) i.e. stainless steel. A sprinkle
nozzle is formed on a flow control valve (4) in an are not limited to a polyethylene terephthalate
(PET) bottle, retort pouch, aluminum pouch,
upper side direction of the conveyor. Sprinkle of
cool water is performed toward an inner side of a flexible plastic container, film-form bag container,
bottle container and tin container.
conveyor. The sprinkle particle size is about 10150 micro meters. The flow control valve
comprises a combination of a valve seat and a
valve [CONT.]
42 Cooling device for reducing heat produced
during packing e.g. food-drink, in packing
HEISEI SHOKUHIN KOGYO KK
container e.g. PET bottle, has sprinkle nozzle
formed on flow control valve, where sprinkle of
cool water is performed toward inner side of
conveyor
WADA S
43 Pet bowl for accommodating pet food has
upper cover of food dish which opens at set
arbitrary time by setting timer for arbitrary time
to provide food to pets during pet owner's
absence
CROWLEY C
44 Inhibiting growth of cell (e.g. hematopoietic
lymphoma cell) that expresses protein,
DE SAUVAGE F J
comprises contacting the cell with antibody,
oligopeptide or organic molecule that binds to
the protein, where the binding causes
inhibition of growth
JP 2011036138
A
20110224
JP 2011036138 A UPAB: 20110310
Pet bowl for accommodating pet food.
NOVELTY: The Pet bowl is arranged to provide
food to pets at predetermined arbitrary time during
the pet owner's absence. An upper cover (2) of a
food dish opens at the set arbitrary time by setting
a timer (4) for arbitrary time.
US 20110045005
A1
20110224
USE: Pet bowl for accommodating pet food.
[CONT.]
US 20110045005 A1 UPAB: 20110321
NOVELTY: Inhibiting growth of a cell that
expresses a protein having at least 80% amino
acid sequence identity to a polypeptide (A)
comprises contacting the cell with an antibody,
oligopeptide or organic molecule that binds to the
protein, where the binding of the antibody,
oligopeptide or organic molecule to the protein
causes an inhibition of growth of the cell. [CONT.]
EATON D L
An INDEPENDENT CLAIM is also included for a
method for cooling packed food-drinks in a
container.
Provides food to pets even when the pet owner or
the caretaker of the pet is not present since the
upper cover of a food dish opens at the set
arbitrary time by setting the timer for arbitrary time.
The methods are useful for: inhibiting growth and
causing death of a cell i.e. a hematopoietic cell,
which is a lymphocyte (a B cell, T cell or a cancer
cell), leukocyte, platelet, erythrocyte or natural
killer cell, where the cancer cell is further exposed
to radiation treatment or a chemotherapeutic
agent, and is a lymphoma cell, a myeloma cell or
a leukemia cell, and where the protein is more
abundantly expressed by the hematopoietic cell as
compared to a non-hematopoietic cell; and
treating or preventing a cell proliferative disorder
which is a cancer (all claimed) e [CONT.]
JP 2011038739
JP 2011036138
PHARMACEUTICALS - Preferred Components:
The antibody is a monoclonal antibody, an
antibody fragment, or a chimeric or a humanized
antibody. The antibody, oligopeptide or organic
molecule is conjugated to a growth inhibitory
agent or a cytotoxic agent, which is toxins
(preferred), antibiotics, radioactive isotopes or
nucleolytic enzymes. The toxin is a maytansinoid
(preferred) or calicheamicin. [CONT.]
Inhibiting growth of a cell that expresses a protein US 20110045005
having at least 80% amino acid sequence identity
to a polypeptide (A) comprises contacting the cell
with an antibody, oligopeptide or organic molecule
that binds to the protein, where the binding of the
antibody, oligopeptide or organic molecule to the
protein causes an inhibition of growth of the cell.
[CONT.]
BIOTECHNOLOGY - Preferred Non-Human
Mammal: The mammal is a chimeric mammal.
The mammal is a rat. One or more pain genes or
loci are misexpressed. One or more pain genes
are conditionally misexpressed. The
misexpression results in decreased expression of
one or more pain gene products. One or more
genes encoding a pain gene product is disrupted.
All alleles on the genome of the pain gene are
disrupted [CONT.]
INDEPENDENT CLAIMS are:
BIOTECHNOLOGY - Preparation: No preparation
method is given. Preferred Components: The
Apolipoprotein L-I is selected from SEQ.ID.NO: 2,
SEQ. ID.NO: 3, SEQ.ID.NO: 4, SEQ. ID.NO: 5,
SEQ. 1D.NO: 6, SEQ. ID.NO: 7, SEQ.ID.NO: 22,
SEQ.ID.NO: 23 or SEQ.ID.NO: 24. The non
human genetically modified mammal according is
genetically modified cattle (preferably cow).
A recombinant human Apolipoprotein L-I is new,
WO 2011020497
where its C-terminal portion of its wild-type
sequence (SEQ.ID.NO: 1, not given in the
specification; SEQ.ID.NO: 8, not given in the
specification; or SEQ.ID.NO: 25, not given in the
specification) comprising a replacement of its last
13 C-terminal amino acids as given in the
specification by an addition of the sequence of 13
amino acid as given in the specification (SEQ
[CONT.]
Y
US 20110045005
N
EBENS A
POLSON A
SMITH V
45 New genetically modified non-human mammal TRANSPOSAGEN BIOPHARMACEUTICALS INC
having genetic mutation in its genes, useful for
identifying useful compounds for the treatment
of abnormal condition of pain perception or
pain or sensitivity
46 New recombinant human Apolipoprotein L-I
used to treat diseases induced in human by
Trypanosoma rhodesiense or in cattle by
Trypanosoma
UNIV LIBRE BRUXELLES
47 Oxygen-scavenging composition used in e.g.
food packaging comprises oxidizable metal
component/electrolyte component/nonelectrolytic, acidifying component/nonionic
surfactant component selected from e.g. alkyl
polyethylene glycol ethers
BASF SE
WO 2011022634
A2
WO 2011020497
A1
WO 2011020777
A1
20110224
20110224
20110224
WO 2011022634 A2 UPAB: 20110310
The non-human mammal is useful for determining
whether a compound is potentially useful for
NOVELTY: A genetically modified non-human
mammal, or its progenies, at least some of whose mediating ion transport, and for screening
compounds. The method for determining whether
cells comprise a genome comprising a genetic
a compound is potentially useful for mediating ion
mutation in one or more genes that causes the
transport is used for testing for activity of a
mammal to have a greater susceptibility to
candidate pain modulating agent. [CONT.]
abnormal condition of pain perception than a
mammal not comprising the genetic mutation, is
new.
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are: [CONT.]
WO 2011020497 A1 UPAB: 20110310
For treatment and/or prevention of diseases
induced in human by Trypanosoma rhodesiense
NOVELTY: A recombinant human Apolipoprotein or in cattle by Trypanosoma (NAGANA) and
related diseases, where Trypanosoma are
L-I, is new.
DETAILED DESCRIPTION: A recombinant human selected from Trypanosoma brucei brucei,
Trypanosoma brucei rhodesiense, trypanosoma
Apolipoprotein L-I is new, where its C-terminal
portion of its wild-type sequence (SEQ.ID.NO: 1, congolense, trypanosome evansi and
not given in the specification; SEQ.ID.NO: 8, not trypanosoma vivax (claimed).
given in the specification; or SEQ.ID. [CONT.]
WO 2011020777 A1 UPAB: 20110310
As oxygen-scavenging composition in article,
which is a film, a sheet or a laminate, or is a
coextruded multilayer film or food packaging
(claimed); for packaging oxygen-sensitive
products such as pharmaceuticals, food products,
meats and beverages, which are susceptible to
degradation due to presence of oxygen; [CONT.]
The composition provides effective, lower cost
alternative that reduces level of oxygen already
present in the packaging construction. The
composition provides improved oxygenscavenging compositions and packaging with
improved efficiency. The oxygen scavenging
composition can be used effectively, even at
relatively low levels, in a wide range of activebarrier packaging films and sheets, including
laminated and coextruded multilayer films and
sheets [CONT.]
WO 2011022634
N
(1) a method for determining whether a compound
is potentially useful for mediating ion transport by
(a) providing a cell that produces a ion transporter
protein, (b) contacting the cell with the compound,
and (c) monitoring the activity of the ion transport
protein, such that a change in activity in response
to the compound indicates that the compound is
potentially useful for treating or alleviating the
symptoms of altered conditions of pain perception;
and [CONT.]
INORGANIC CHEMISTRY - Preferred
An INDEPENDENT CLAIM is included for an
Composition: The oxygen-scavenging composition article containing the composition.
comprises an oxidizable metal component; an
electrolyte component selected from NaCl, KCl
and CaCl2; a non-electrolytic, acidifying
component, preferably an alkali metal acid
pyrophosphate or alkaline earth metal acid
pyrophosphate; [CONT.]
WO 2011020777
N
N
JP2011036138A
47 Oxygen-scavenging composition used in e.g.
food packaging comprises oxidizable metal
component/electrolyte component/nonelectrolytic, acidifying component/nonionic
surfactant component selected from e.g. alkyl
polyethylene glycol ethers
BASF SE
48 New (isolated) human Apolipoprotein L-I
corresponding to a specific wild-type human
Apolipoprotein sequence modified by a
deletion of its last C-terminal amino acids,
useful for treatment of diseases induced in
human by Trypanosoma brucei
UNIV LIBRE BRUXELLES
NOVELTY: An oxygen-scavenging composition
comprises an oxidizable metal component; an
electrolyte component; a non-electrolytic,
acidifying component; and a nonionic surfactant
component, preferably selected from alkyl
polyethylene glycol ethers, polyethylene glycols,
polypropylene glycols, polypropylene glycol
polyethylene glycol block copolymers and
polyethylene polyethylene glycol block
copolymers. [CONT.]
WO 2011020865
A1
20110224
WO 2011020865 A1 UPAB: 20110310
NOVELTY: An (isolated) human Apolipoprotein L-I
corresponding to a specific wild-type human
Apolipoprotein sequence modified by a deletion of
its last C-terminal amino acids, is new.
As oxygen-scavenging composition in article,
which is a film, a sheet or a laminate, or is a
coextruded multilayer film or food packaging
(claimed); for packaging oxygen-sensitive
products such as pharmaceuticals, food products,
meats and beverages, which are susceptible to
degradation due to presence of oxygen; [CONT.]
The composition provides effective, lower cost
alternative that reduces level of oxygen already
present in the packaging construction. The
composition provides improved oxygenscavenging compositions and packaging with
improved efficiency. The oxygen scavenging
composition can be used effectively, even at
relatively low levels, in a wide range of activebarrier packaging films and sheets, including
laminated and coextruded multilayer films and
sheets [CONT.]
In blood sample (especially a serum) or blood
The pharmaceutical composition containing the
extract (especially high density lipoprotein
Apolipoprotein L-I reduces and/or suppresses the
particle); in pharmaceutical composition for
symptoms of the disease in the mammal.
treatment and/or the prevention of diseases
induced in human by Trypanosoma brucei or
Trypanosoma brucei rhodesiense; in the treatment
and/or prevention of glomerulosclerosis; and in
non-human genetically modified mammal which is
a rodent (especially cattle) (claimed) [CONT.]
INORGANIC CHEMISTRY - Preferred
An INDEPENDENT CLAIM is included for an
Composition: The oxygen-scavenging composition article containing the composition.
comprises an oxidizable metal component; an
electrolyte component selected from NaCl, KCl
and CaCl2; a non-electrolytic, acidifying
component, preferably an alkali metal acid
pyrophosphate or alkaline earth metal acid
pyrophosphate; [CONT.]
BIOTECHNOLOGY - Preparation: No general
method for the preparation of the isolated human
Apolipoprotein L-I is given. Preferred Kit: The kit
further comprises recombinant Serum ResistanceAssociated (SRA) bound on a solid support; and
ApoL1.
An (isolated) human Apolipoprotein L-I
WO 2011020865
corresponding to the wild-type human
Apolipoprotein sequence SEQ. ID. NO.1, not
given in the specification, SEQ. ID. NO.4, not
given in the specification or SEQ. ID. NO.7, not
given in the specification modified by a deletion of
1-20 (preferably 9) of its last C-terminal amino
acids, is new. INDEPENDENT CLAIMS are
included for the following: [CONT.]
49 Viscous pet food dispensing apparatus for e.g. ROCKER K S
dogs, has non-planar downwardly curved
dispensing sheet formed with multiple
apertures for extruding food, and guide rails
arranged along sidewall of container
US 20110041771
A1
20110224
DETAILED DESCRIPTION: An (isolated) human
Apolipoprotein L-I corresponding to the wild-type
human Apolipoprotein sequence SEQ. ID. NO.1,
not given in the specification, SEQ. ID. NO.
[CONT.]
US 20110041771 A1 UPAB: 20110310
HURWITZ M M
50 Therapeutic pet boot for treating injured paw
of e.g. dog, has internal therapeutic member
received within cavity of external boot member
and contacting injured paw, and outsole made
of carbon rubber or blown rubber for softer
outsole
US 20110041779
A1
20110224
US 20110041779 A1 UPAB: 20110323
Therapeutic pet boot for treating an injured paw of The boot is worn on the injured paw of the pet to
a pet animal e.g. dog and cat.
provide protection from dirt and shock absorption.
NOVELTY: The boot (10) has an external boot
The internal therapeutic member directly delivers
member (11) whose shaft (12) and paw portion
medicament to the paw and/or provides cold
(13) are constructed to form a cavity (14) and
treatment or hot treatment therapies to the paw.
receives an injured paw (15) of a pet animal e.g.
The topical delivery of the medicament or ointment
dog. An internal therapeutic member (20) is
is provided in the boot, so that the dog or cat is
received within the cavity of the boot member and
prevented from licking the medicament or
made to contact the injured paw. An outsole (16)
ointment. [CONT.]
is made of carbon rubber or blown rubber for a
softer outsole [CONT.]
An INDEPENDENT CLAIM is also included for a
method for treating an injured paw of a pet with a
therapeutic pet boot.
51 Therapeutic gel pad e.g. joint pad, for paw and HURWITZ M M
hoof of e.g. horses to treat injury and
discomfort in e.g. animal's body regions, has
base and upper gel layers to intimately contact
body region of animal, where pad is worn on
body region
US 20110041780
A1
20110224
US 20110041780 A1 UPAB: 20110323
JP 2011037753
A
52 New isolated peptide useful for treating
muscular dystrophy and myocarditis, capable
of suppressing transient receptor potential
cation channel subfamily V member 2 protein
expression in cell membrane
ZH HUMAN SCI SHINKO ZAIDAN
20110224
Viscous pet food dispensing apparatus for dogs
NOVELTY: The apparatus has a container (10) for and cats.
holding food. A non-planar downwardly curved
dispensing sheet (20) formed with multiple
apertures for extruding the food. Guide rails are
arranged along a sidewall of the container.
Recesses receive the guide rails. A collar (30)
threadably engages with a top portion of the
container. The collar retains the dispensing sheet
within the container [CONT.]
Therapeutic gel pad e.g. massaging gel insole,
joint pad, torso or back pad, head or eye
protector, heat pad, for paw and hoof of household
NOVELTY: The pad (1010) has a base gel layer
(1011), and an upper gel layer (1012) to intimately animals or farm animals (all claimed) such as
older dogs, cats and horses, to treat injury and
contact a body region of a household animal or
discomfort in animal body regions, and facilitate
farm animal, where the pad is worn on the
healing by cold treatment or hot treatment
animal's body region. An insulating cover is
therapies for elbow discomfort treatment,
provided to receive and house the gel pad. The
treatment after stomach surgery and eye
upper gel layer comprises a therapy pocket to
protection [CONT.]
house medication, which is secreted through an
aperture [CONT.]
JP 2011037753 A UPAB: 20110321
NOVELTY: An isolated peptide capable of
suppressing transient receptor potential cation
channel subfamily V member 2 (TRPV2) protein
expressions in cell membrane, is new. The
peptide comprises sequence containing N
terminal region of amino acid sequence of TRPV2
protein.
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are included for the following: [CONT.]
53 Probiotic food for cats
GRAMENZI A
IT 1385324
B
20110111
The isolated peptide is useful for treating muscular
degenerative disease, preferably myocarditis and
muscular dystrophy.
The lid is provided for sealing a set of tabs that
enable a pet owner to grip and pull the dispensing
sheet out of the container, so as to easily clean
the apparatus. The collar prevents the dispensing
sheet from being displaced from the container.
The lid is placed directly over the collar or the
container neck, so that residual pet food can be
stored within the container in an air-tight manner.
The gel pad is worn on the animal's body region to
provide comfort. The gel pad can directly deliver
the medicament to the injured region. The gel pad
can provide cold treatment or hot treatment
therapies while providing cushioning, shock
absorption and protection from dirt and debris.
The pad is constructed such that massaging effect
is created on the paw when the animal walks, and
blood circulation is promoted within the paw, thus
improving overall health and comfort of pet
[CONT.]
BIOTECHNOLOGY - Preparation (Disclosed): The
peptide is prepared by standard recombinant
method. Preferred Protein: The N terminal region
is a region at position 1-387 comprising a 764,
757 or 761 amino acid sequence (SEQ ID NO: 2,
4 or 6) fully defined in the specification. The N
terminal region of amino acid sequence comprises
TRPV2 protein containing at least seventeen
amino acid residues. [CONT.]
WO 2011020777
N
US 20110041771
US 20110041771
Y
US20110041771A1
US 20110041779
US 20110041779
Y
US20110041779A1
The base gel layer and the upper gel layer
US 20110041780
comprise polyurethane surrounding material
selected from gel, liquid silicone and polyurethane
foam. An INDEPENDENT CLAIM is also included
for a method for treating an injury of a pet with a
therapeutic gel pad.
US 20110041780
INDEPENDENT CLAIMS are included for the
following:
(1) transgenic non-human animal expressing the
above-mentioned peptide; and
N
JP 2011037753
(2) method of preparing the transgenic non-human
animal by integrating the gene encoding the
above-mentioned peptide.
IT 1385324
Y
IT1385324B
54 Probiotic food for dogs
GRAMENZI A
IT 1385325
B
20110111
55 New reporter vector useful for screening
caloric restriction mimic substance used for
preventing and/or treating life-style related
diseases e.g. cancer and aging, comprises
specific nucleotide sequence, promoter and
reporter gene
UNIV NAGASAKI
JP 2011036223
A
20110224
JP 2011036223 A UPAB: 20110315
The reporter vector is useful for screening caloric The caloric restriction mimic substance can be
restriction mimic substance and substance which screened rapidly and cost-effectively and is
NOVELTY: A reporter vector comprising (a) (i)
extends lifetime (claimed), which is used for
suitable for both in vitro and in vivo conditions.
nucleotide sequence of SEQ ID NOs: 1-4, (ii)
preventing
and/or
treating
life-style
related
nucleotide sequence of SEQ ID NOs: 1-4 in which
diseases chosen from cancer, Alzheimer's
one or more bases are deleted, substituted,
inserted or added, (iii) nucleotide sequence having disease, aging, hypertension, arteriosclerosis,
ischemic heart disease, cerebrovascular accident,
at least 70% homology to SEQ ID NOs: 1-4 and
(iv) nucleotide sequence complementary to (i)-(iii), metabolic disorder, obesity, diabetics, insulin
resistance, diabetic [CONT.]
(b) promoter and (c) reporter gene, is new.
[CONT.]
BIOTECHNOLOGY - Preparation (Disclosed): The
reporter vector is prepared by standard
recombinant methods. Preferred Vector: The
reporter vector further comprises nucleotide
sequence capable of binding with HNF-4( alpha ).
The recombinant comprises the expression vector
capable of expressing peroxisome proliferatoractivated receptor gamma coactivator (PGC)-1(
alpha ).
56 Preparing green tea beverage useful for
treating cancer, by pulverizing selected green
tea material, mixing gellan gum, honey and
kelp with obtained pulverized product,
extracting obtained mixture and filtering
obtained extract
UNIV GYEONGSANG NAT IND ACAD COOP
FOUND
KR 2011013721
A
20110210
KR 2011013721 A UPAB: 20110321
FOOD - Preferred Components: The method
involves mixing (in wt.%) gellan gum (0.05-0.1),
citric acid (0.01-0.02), honey (2), sugar (2), salt
(0.2) and kelp (1) and green tea extract (0.2-1).
The method involves packaging obtained green
tea beverage in pet bottle or aluminum can.
OMA K
57 Konjak drink useful as diet for replenishing
stomach, obtained by adding rice grain-shaped
konjak to transparent container, adding clear
liquid juice equivalent to amount of konjak to
container and sealing container with screw
cap
IT 1385325
NOVELTY: Method for preparing green tea
beverage, involves selecting green tea material,
pulverizing the obtained green tea material using
pulverizing device, mixing gellan gum, citric acid,
honey, sugar, salt and kelp with the obtained
pulverized product, extracting the obtained mixture
using water, filtering the obtained extract,
homogenizing obtained filtrate, sterilizing
homogenized product and packaging sterilized
product. [CONT.]
JP 3166010
U
20110217
The method is useful for preparing green tea
beverage useful for treating cancer, thrombosis,
cardiac disease, blood pressure, tooth decay,
diabetes, asthma and central nervous system
disease.
JP 3166010 U UPAB: 20110307
The konjak drink is useful as diet for replenishing
NOVELTY: Konjak drink is obtained by adding rice stomach.
grain-shaped konjak to transparent container,
adding clear liquid juice equivalent to amount of
konjak to the container and sealing the container
with screw cap.
The obtained green tea beverage has excellent
flavor and antioxidant property.
Y
N
A reporter vector comprising (a) (i) nucleotide
JP 2011036223
sequence of SEQ ID NOs: 1-4, (ii) nucleotide
sequence of SEQ ID NOs: 1-4 in which one or
more bases are deleted, substituted, inserted or
added, (iii) nucleotide sequence exhibiting at least
70% homology to SEQ ID NOs: 1-4 and (iv)
nucleotide sequence complementary to (i)-(iii), (b)
promoter and (c) reporter gene, where the
promoter is connected with [CONT.]
IT1385325B
KR 2011013721
N
The konjak drink has excellent taste. The drink
can be consumed easily as it is smooth and does
not block throat when consumed. The drink is
digested easily as it contains fibers. The drink is
safe and simple as it is enclosed in polyethylene
terephthalate (PET) container.
JP 3166010
N
Possibility of ear and nose touching inside the
tableware and becoming dirty during feeding can
be avoided so that hygienic supervision can be
realized. The tableware is simple in structure and
can be cleaned easily.
JP 3166066
Y
JP3166066U
BR 8901038
Y
BR8901038U2
Y
US20110038829A1
ACTIVITY: Anorectic; Gastrointestinal-Gen. No
biological data given.
MECHANISM OF ACTION: None given.
HARIO GLASS KK
58 Tableware for pets e.g. dog, has container
main portion which is elongated halving
eggshell type with opening expanded to one
end side of long axis and reduced to other end
side
JP 3166066
U
20110217
USE: The konjak drink is useful as diet for
replenishing stomach. [CONT.]
JP 3166066 U UPAB: 20110307
Tableware for pets such as dog and cat.
NOVELTY: The tableware (1) has a pair of
supporting legs (3,4) that protrudes in the lower
surface side of a glass or ceramics container main
portion (2). The supporting leg is located such that
the inclination of upper edge of one end side of
the container main portion is increased with
respect to mounting surface. [CONT.]
59 Automatic electromechanical feeding device
for feeding animals e.g. dog, has cross tube
transversely fixed to tubular structure,
discharge nozzle embedded in hole, and
hopper whose edges are adjusted to interior
part of tubular structure
PEDRA PIEROBOM P E
BR 8901038
U2
20110118
BR 8901038 U2 UPAB: 20110331
Automatic electromechanical feeding device for
feeding animals such as dog and cat.
NOVELTY: The device has an adjustable lid (2)
provided at top edge and bottom part of a tubular
structure (1), where the structure is made of PVC,
plastic material or nontoxic paint coated metal
sheet. Edges of a hopper (3) are adjusted to
interior part of the tubular structure. A discharge
nozzle (4) is embedded in a hole (5). A cross tube
(6) is transversely fixed to the structure [CONT.]
The device prevents entry of rats and insects,
avoids dampness and leakage, and is simple in
structure, inexpensive and easy to manufacture.
The device is equipped with an uninterrupted
power supply (UPS), thus avoiding lack of power
supply.
60 Treating a diarrhea condition in a mammal
involves administering a composition
comprising a bile acid sequestrant, to the
mammal
MAYO FOUND MEDICAL EDUCATION&RES
US 20110038829
A1
20110217
US 20110038829 A1 UPAB: 20110321
The method by administering the composition of
bile acid sequestrant reduces a mammal's
diarrhea without producing significant toxicity to
the mammal.
For treating a diarrhea condition (i.e. bile acid
NOVELTY: Treating (m1) a diarrhea condition in a malabsorption induced diarrhea) in a mammal (i.e.
human) (claimed).
mammal involves administering a composition
(c1) comprising a bile acid sequestrant, to the
mammal.
PHARMACEUTICALS - Preferred Method: The
composition (c1) is administered to the mammal
under conditions where the amount of the bile acid
sequestrant in the composition is 1-5 grams. The
method (m1) involves assessing the mammal
before the administering step to determine if the
mammal comprises a serum level of 7 alpha C4
greater than 25 (preferably greater than 30) ng/ml
of serum, where the presence of the serum level
indicates that the mammal is to be administered
the bile acid sequestrant, and the serum level of 7
alpha C4 is a fasting serum level of 7 alpha C4
[CONT.]
An INDEPENDENT CLAIM is included for treating US 20110038829
(m2) a diarrhea condition involving identifying a
mammal having (i) diarrhea condition, (ii) a serum
level of 7 alpha C4 greater than 20 ng/ml of
serum, and (iii) a potential bile acid malabsorption
condition based on a fecal bile acid excretion test
or 75SeHCAT retention test; [CONT.]
US 20110038829
before the administering step to determine if the
condition based on a fecal bile acid excretion test
mammal comprises a serum level of 7 alpha C4
or 75SeHCAT retention test; [CONT.]
greater than 25 (preferably greater than 30) ng/ml
of serum, where the presence of the serum level
indicates that the mammal is to be administered
the bile acid sequestrant, and the serum level of 7
alpha C4 is a fasting serum level of 7 alpha C4
[CONT.]
DETAILED DESCRIPTION: An INDEPENDENT
CLAIM is included for treating (m2) a diarrhea
condition involving identifying a mammal having (i)
diarrhea condition, (ii) a serum level of 7 alpha C4
greater than 20 ng/ml of serum, and (iii) a
potential bile acid malabsorption condition based
on a fecal bile acid excretion test or 75SeHCAT
retention test [CONT.]
BICKFORD P
61 Composition, useful to stimulate or increase
stem cell proliferation in humans for selfDAVIS S C
repairing injury, comprises blueberry extract
and carnosine, or blueberry extract, carnosine
and green tea extract
US 20110038963
A1
20110217
US 20110038963 A1 UPAB: 20110321
NOVELTY: Composition comprises: blueberry
extract and carnosine; or blueberry extract,
carnosine and green tea extract, where the
combination of at least two substances exerts a
synergistic effect on the stem cell proliferation.
SANBERG P
ACTIVITY: Vulnerary.
SHYTLE R D
MECHANISM OF ACTION: None given. [CONT.]
The composition is useful to stimulate or increase The composition exhibits a synergistic effect on
stem cell proliferation in humans (claimed) for self- the stem cell proliferation.
repairing injury. Test details are described but no
results given.
BIOLOGY - Preferred Composition: The
composition further comprises vitamin D3. The
composition comprises: at least 400 mg,
preferably 400 mg to 25 g of blueberry extract;
400 mg to 5 g of green tea extract; and 10-100 mg
carnosine.
US 20110038963
US 20110038963
Y
US 20110036299
N
US20110038963A1
TAN J
SCHEHR K B
62 Feeding device e.g. pail, for feeding food for
animals e.g. horses, has feeding compartment
comprising sigmoid-shaped lower interior
sidewall and flat smaller-diameter
compartment bottom that is enclosed within
confines of sidewall
63 Heat retention structure for pets, has water
absorbing polymer enclosed in airtight
container in predetermined ratio with respect
to specific volume of water
KUBOTA ENGINEER YG
US 20110036299
WO 2011022376
A1
20110217
US 20110036299 A1 UPAB: 20110307
A1
20110224
NOVELTY: The device e.g. pail (10), has an
upwardly open enclosure comprising a lip (19)
arranged about an open portion of the enclosure.
A sidewall (14) is positioned about the enclosure,
and a bottom surface (21) is arranged in an
interior of the enclosure within confines of the
sidewall. A set of upwardly open feeding
compartments is positioned in the bottom surface
of the enclosure [CONT.]
JP 2011033300
A
20110217
JP 2011033300 A UPAB: 20110307
NOVELTY: A thermal storage material (3) has gellike structure containing water absorbing polymer
and water, and contains polyethylene glycol. A
thermal storage structure (2) is sealed in an
airtight container (4) formed with hard synthetic
resin material having heat resistance. A cover
portion is welded and attached to an injection hole
of a container main case of the container [CONT.]
64 New transgenic non-human mammal useful for NAT CENT GLOBAL HEALTH&MEDICINE
screening substance for treating eosinophilic
leukocytosis e.g. bronchial asthma, comprises UNIV TOYAMA
fluorescent protein gene in reading frame of
exon 1 of interleukin-5 gene
JP 2011030448
A
20110217
Feeding device e.g. pail, for feeding food for
animals e.g. horses. Can also be used for cattle,
goats, cats and dogs e.g. large breed dogs.
The lower interior sidewall of the compartments
transitions from a middle interior sidewall to the
smaller-diameter compartment bottom, so as to
prevent residual food from being stuck in sharp
corners, thus preventing animals from being
frustrated, and reducing distractions of the
animals during eating to promote freedom of
movement of jaw and neck of the animals, and
avoiding economic waste.
US 20110036299
Heat retention structure for pocket warmer for
pets. Can also be used in heat retention structure
to retain heat of container with food and drink, and
to provide heat to leg portion and buttocks of
person.
The leakage of thermal storage material from the
container is prevented, by the gel-like structure.
An excellent thermal storage property is provided.
The damage to the airtight container is prevented,
since the airtight container is made of hard
synthetic resin. Hence the structure is lower in
cost, safe, and provides good heat retention
property.
JP 2011033300
JP 2011030448 A UPAB: 20110302
The transgenic non-human mammal is useful for
screening the substance capable of inhibiting the
expression of fluorescent protein gene, where the
NOVELTY: A transgenic non-human mammal
comprising fluorescent protein gene in the reading substance is useful for treating eosinophilic
leukocytosis chosen from dermal hypersensitivity,
frame of exon 1 of interleukin-5 gene, is new.
allergic inflammation, bronchial asthma,
hypereosinophilic syndrome and eosinophilic
DETAILED DESCRIPTION: INDEPENDENT
esophagitis. [CONT.]
CLAIMS are included for the following:
BIOTECHNOLOGY - Preparation (Claimed): The
transgenic non-human mammal is produced by
standard recombinant methods. Preferred Protein:
The fluorescent protein is green fluorescent
protein (GFP), venus or mCherry. The to-be-tested
substance has reduced expression of fluorescent
protein gene and suppresses and/or inhibits the
expression of interleukin-5 gene. [CONT.]
Y
JP2011033300A
Y
US20110036302A1
INDEPENDENT CLAIMS are included for the
JP 2011030448
following:
(1) embryonic stem cell of non-human mammal,
comprising reporter gene in reading frame of exon
1 of interleukin-5 gene;
(2) method (M1) for preparing the embryonic stem
cell of non-human mammal or transgenic nonhuman mammal, involves introducing vector
containing homologous region of 0.6x 103 bases
or more of fluorescent protein gene to the
embryonic stem cell (4x 106-6x 106 cells) by
electroporation method; [CONT.]
(1) embryonic stem cell of non-human mammal,
comprising reporter gene in reading frame of exon
1 of interleukin-5 gene; [CONT.]
65 Animal compartment assembly for housing
dog, has storage chamber arranged within
sidewall, where storage chamber includes
door that opens to provide access to storage
chamber from outside sidewall
HEALD J D
US 20110036302
A1
20110217
US 20110036302 A1 UPAB: 20110307
Animal compartment assembly for housing
animals i.e. dog (from drawing).
The assembly is convenient to use and arranged
with storage capacity, so that care items such as
extra food, toys, medicines, leashes, brushes,
tools and bedding, can be made readily available.
The floor is arranged with a heating element so as
to warm the assembly. The assembly enables a
user to open the door that slides upon a rail and
place the animal within the hollow chamber and
close a door behind the animal, thus allowing the
animal to access the hollow chamber and
restricting the animal to the hollow chamber
US 20110036302
US 20110036302
door that opens to provide access to storage
chamber from outside sidewall
66 Treating or alleviating allergic disease e.g.
eczema, psoriasis, conjunctivitis, urticaria,
ulcerative colitis and allergic airway disease
e.g. asthma and allergic rhinitis, comprises
administering composition comprising
phycocyanin
OEDEKOVEN J W
UNIV TAIWAN NAT
tools and bedding, can be made readily available.
The floor is arranged with a heating element so as
to warm the assembly. The assembly enables a
user to open the door that slides upon a rail and
place the animal within the hollow chamber and
close a door behind the animal, thus allowing the
animal to access the hollow chamber and
restricting the animal to the hollow chamber
[CONT.]
NOVELTY: The assembly (10) has a sidewall (14)
connected to and supporting a roof (12) including
a door (44) arranged through the roof. A floor (16)
i.e. heated floor, supports the sidewall. A storage
chamber is arranged within the sidewall, where
the storage chamber includes a door that opens to
provide access to the storage chamber from
outside the sidewall. [CONT.]
US 20110038882
A1
20110217
US 20110038882 A1 UPAB: 20110315
The method is useful for: treating or alleviating
The method is safe and less expensive.
allergic
disease
in
a
mammal,
where
the
allergic
NOVELTY: Treating or alleviating allergic disease
disease is asthma, allergic rhinitis, eczema,
in a mammal comprises administering a
psoriasis, atopic dermatitis, rheumatoid arthritis,
composition comprising a phycocyanin.
inflammatory bowel disease, Crohn's disease,
ulcerative colitis, chronic obstructive pulmonary
DETAILED DESCRIPTION: An INDEPENDENT
disease, conjunctivitis, nasal congestion, urticaria
CLAIM is included for a composition comprising a
or allergic airway disease comprising asthma,
phycocyanin and their carrier or excipient.
allergic rhinitis and allergic pneumonia [CONT.]
BIOLOGY - Preferred Components: The
phycocyanin is obtained from algae belonging to
genus of Porphyra and/or Bangia, preferably
Bangia atropurpurea.
An INDEPENDENT CLAIM is included for a
composition comprising a phycocyanin and their
carrier or excipient.
US 20110038882
US 20110038882
BIOTECHNOLOGY - Preferred Method: In the
method (A), the step of detecting the nucleotide
insertion in the ABCB4 gene comprises: isolating
DNA from the canine subject; and sequencing a
region of the DNA including the nucleotide
sequence corresponding to nucleotides 15821583 of SEQ ID NO: 1; or contacting the DNA with
a primer pair comprising a forward primer and a
reverse primer under conditions [CONT.]
INDEPENDENT CLAIMS are also included for:
US 20110038944
US 20110038944
N
ACTIVITY: Antiallergic; Antiasthmatic;
Antiinflammatory; Dermatological; Antipsoriatic;
Antiarthritic; Antirheumatic [CONT.]
67 Detecting predisposition to or presence of
hepatobiliary disease in e.g. Pomeranian,
comprises detecting a nucleotide insertion in
the ABCB4 gene in which the nucleotide
insertion results in premature termination of
gene translation
UNIV WASHINGTON STATE RES FOUND
US 20110038944
A1
20110217
US 20110038944 A1 UPAB: 20110307
NOVELTY: Method (A) for detecting predisposition
to or presence of hepatobiliary disease in a canine
subject, comprises detecting a nucleotide insertion
in the ABCB4 gene, where the nucleotide insertion
results in premature termination of ABCB4
translation.
MELALEUCA INC
68 Dietary supplement useful for improving
cardiovascular heath in a mammal comprises
phytosterols, omega-3 fatty acids, coenzyme Q10, alpha lipoic acid, and bromelain
HORPHAG RES IP PYC LTD
69 Preparation for preparing food preparation,
dietary supplement, nutraceutical, and
medicament for preventing or treating
atherosclerosis, comprises combination of
proanthocyanidins and Centella asiatica and/or
its extracts
US 20110038848
WO 2011018763
A1
A1
20110217
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are also included for: [CONT.]
US 20110038848 A1 UPAB: 20110321
20110217
ACTIVITY: Cardiovascular-Gen.; Antilipemic;
Cardiant; [CONT.]
WO 2011018763 A1 UPAB: 20110307
The method is useful for detecting predisposition
to or presence: of hepatobiliary disease
comprising gallbladder mucocele in a canine
subject (which is no older than 1-7 years)
including Shetland Sheepdog, Cairn Terrier,
Cocker Spaniel and Pomeranian (all claimed), and
related conditions (e.g. [CONT.]
For improving cardiovascular heath in a mammal
NOVELTY: A dietary supplement comprises (mg): (claimed).
phytosterols (400-3000); omega-3 fatty acids (1101000); coenzyme Q-10 (6-60); alpha lipoic acid (645); and bromelain (2.5-20); or phytosterols (10003000); omega-3 fatty acids (500-1500); coenzyme
Q-10 (15-45); alpha lipoic acid (15-45); and
bromelain (2.5-20).
NOVELTY: Preparation comprises combination of
proanthocyanidins and Centella asiatica and/or its
extracts, in a suitable excipient, where the
preparation contains from 20% to 80% w/w of
proanthocyanidins and from 20% to 80% w/w of
Centella asiatica and/or its extracts, for use in
preventing or treating atherosclerosis.
The preparation is useful for preparing food
preparation, dietary supplement, nutraceutical,
and medicament for preventing or treating
atherosclerosis, preferably atherosclerotic plaques
(all claimed).
The dietary supplement lowers blood cholesterol,
reduces the inflammation background, and
increases the antioxidant potential of the blood.
The dietary supplement slows down
atherosclerosis development and lowers the risk
of cardiac events. [CONT.]
PHARMACEUTICALS - Preferred Supplement:
The dietary supplement comprises (mg):
phytosterols (500); omega-3 fatty acids (250);
coenzyme Q-10 (7.5); and alpha lipoic acid (7.5).
The invention provides an effective and safe
composition for treating or preventing
atherosclerosis, preferably atherosclerotic
plaques.
BIOTECHNOLOGY - Preferred Preparation: In the INDEPENDENT CLAIMS are:
WO 2011018763
preparation, proanthocyanidins are procyanidins (1) a food preparation comprising the preparation;
originated from a plant extract or from a
synthesized material, where the plant extract is
selected from proanthocyanidins containing
extracts selected among extracts of pine bark,
grape seed, apples, peanut skin, walnuts,
pomegranates, tomatoes, almonds, tea, hawthorn,
cocoa or its combination. [CONT.]
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are: [CONT.]
US 20110038848
US 20110038848
(2) a dietary supplement comprising the
preparation;
(3) a nutraceutical comprising the preparation;
(4) a beverage comprising the preparation;
(5) a medicament comprising the preparation;
70 Soy protein product having protein useful e.g.
for the fortification of soft drinks and sports
drinks, and as nutritional supplements
GOSNELL B
US 20110038993
A1
20110217
US 20110038993 A1 UPAB: 20110321
The soy protein product is useful: for the
fortification of soft drinks and sports drinks without
precipitation of protein; to protein fortification of
processed foods and beverages, emulsification of
The soy protein product: is transparent,
completely soluble and heat-stable at low pH
values; does not require stabilizers or other
additives to maintain the protein product in
N
(1) method (B) for selectively breeding dogs to
decrease the frequency of hepatobiliary disease in
a dog population, comprising: identifying dogs in a
breeding population that have a predisposition to
hepatobiliary disease by the above method;
selecting dogs for breeding that do not have a
predisposition to hepatobiliary disease; and
breeding only selected dogs, thus decreasing the
frequency of hepatobiliary disease in the dog
population; [CONT.]
(6) a topical preparation comprising the
preparation; and [CONT.]
FOOD - Preferred Components: The soy protein
An INDEPENDENT CLAIM is included for
US 20110038993
product has: a protein content of at least 90
preparation of a soy protein solution, comprising:
(preferably 100) wt.% (Nx 6.25) d.b; and a phytic extracting a soy protein source with an aqueous
acid content of less than 1.5 (preferably less than calcium salt solution to cause solubilization of soy
US 20110038993
Y
US20110038848A1
70 Soy protein product having protein useful e.g.
for the fortification of soft drinks and sports
drinks, and as nutritional supplements
The soy protein product is useful: for the
fortification of soft drinks and sports drinks without
NOVELTY: Soy protein product which: has a
protein content of at least 60 wt.% (Nx 6.25) d.b; is precipitation of protein; to protein fortification of
processed foods and beverages, emulsification of
completely soluble and heat-stable in aqueous
media at acid pH values of less than 4.4; does not oils; and as a body former in baked goods and
foaming agent in products which entrap gases.
require stabilizers or other additives to maintain
The soy protein product is useful: in meat analogs;
the protein product in solution or suspension; is
low in phytic acid; and requires no enzymes in the as an egg white substitute or extender in food
products; [CONT.]
production of it, is claimed. [CONT.]
GREEN B E
The soy protein product: is transparent,
completely soluble and heat-stable at low pH
values; does not require stabilizers or other
additives to maintain the protein product in
solution or suspension; is low in phytic acid; and
requires no enzymes in the production of it; and
provides excellent nutritional properties and health
benefits. The soy protein product has no beany
flavor or off odors.
FOOD - Preferred Components: The soy protein
product has: a protein content of at least 90
(preferably 100) wt.% (Nx 6.25) d.b; and a phytic
acid content of less than 1.5 (preferably less than
0.5) wt.%. The blend is a powdered beverage. The
aqueous solution is a beverage. The aqueous soy
protein solution has a protein concentration of 550 (preferably 10-50) g/l. The aqueous calcium
salt solution contains an antioxidant [CONT.]
An INDEPENDENT CLAIM is included for
US 20110038993
preparation of a soy protein solution, comprising:
extracting a soy protein source with an aqueous
calcium salt solution to cause solubilization of soy
protein from the soy protein source and to form an
aqueous soy protein solution; at least partially
separating the aqueous soy protein solution from
residual soy protein source; and adjusting the pH
of the aqueous soy protein solution to a pH of 1
[CONT.]
US 20110038993
BIOTECHNOLOGY - Preferred Component: The
probiotic preparation comprises Pediococcus
acidilactici and Saccharomyces boulardii. The
probiotic comprises at least one billion
microorganisms. INSTRUMENTATION AND
TESTING - Preferred Method: The method further
comprises administering steroids or immune
suppressors to the mammal requiring treatment
for autoimmune anemia. [CONT.]
An INDEPENDENT CLAIM is included for
treatment of autoimmune disease including
inflammatory bowel disease, nonspecific
enteropathies or atopic dermatitis in mammals,
comprising administering a probiotic preparation
of living Pediococcus acidilactici to the mammal
requiring treatment for an autoimmune disease.
US 20110038838
BIOLOGY - Preferred Composition: The natural
extract contains neurotransmitters including
serotonin, melatonin, dopamine, norepinephrine,
epinephrine or their oxidized forms. The extract:
contains 20-80 wt.% of minerals, 0.05-30 wt.% of
carbohydrates, less than 10 wt.% of simple
sugars, and less than 20 wt.% of starch, fiber and
pectin; has a pH of 4-7; is soluble in water;
[CONT.]
An INDEPENDENT CLAIM is also included for
WO 2011018700
obtaining the extract comprising: cleaning and
disinfecting of bananas; cutting and mashing the
whole banana into paste and mixing with required
quantity of water; cooking the mixture at above 75
degrees C to breakdown fiber and starches;
treating fiber, starch and pectin with enzymes
including cellulase enzymes, amylase enzymes,
amylose, amylopectin and pectinase enzymes for
breaking down and digesting fiber, starch and
pectin [CONT.]
LOGIE J
MEDINA S
SCHWEIZER M
SEGALL K I
71 Treatment of autoimmune hemolytic anemia in IMAGILIN TECHNOLOGY LLC
mammals involves administering probiotic
preparation of living microorganisms
comprising Pediococcus acidilactici and
Saccharomyces boulardii to mammal
US 20110038838
72 Banana fruit extract from whole fruit of banana MEDASANI M
(Musa species), useful e.g. to treat e.g. obesity
and hyperlipidemia, comprises natural
melatonin, serotonin, amino acids (e.g.
tryptophan), minerals (e.g. potassium) and
antioxidants
WO 2011018700
A1
20110217
WO 2011018700 A1 UPAB: 20110307
WO 2011019641
A2
20110217
WO 2011019641 A2 UPAB: 20110310
73 Nutritional composition used for, e.g.
optimizing protein synthesis in smooth and
striated muscles in mammal, comprises
exogenous nucleotide, e.g. intact ribonucleic
acid
NESTEC SA
A1
20110217
US 20110038838 A1 UPAB: 20110315
NOVELTY: An autoimmune hemolytic anemia in
mammals is treated by administering a probiotic
preparation of living microorganisms to the
mammal requiring treatment for autoimmune
anemia.
DETAILED DESCRIPTION: An INDEPENDENT
CLAIM is included for treatment of autoimmune
disease including inflammatory bowel disease,
nonspecific enteropathies or atopic dermatitis in
mammals, comprising administering a probiotic
preparation of living Pediococcus acidilactici to the
mammal requiring treatment for an autoimmune
disease. [CONT.]
BOLSTER D R
Method of treating autoimmune hemolytic anemia The method can reduce side effects associated
in mammals including human, dog, or cat
with steroid and immune suppressor treatment
(claimed).
and reduce dosage of steroids and immune
suppressors required to treat autoimmune
hemolytic anemia in mammals.
The banana extract is useful: for mammals and
animals as food supplement, medicine, food
additive, adjuvant or adjuvant to food supplements
NOVELTY: Natural extract from whole fruit of
or foods or drinks or drink mixes or medicines; for
banana (Musa species) (including edible portion
producing juices/syrups/puree; to treat mood
and peel), whether unripe or ripe, comprises:
elevation, obesity, hyperlipidemia,
mainly natural melatonin; serotonin;
catecholamines and their precursors; tryptophan hypercholesterol, hypertension, diabetes, sleeping
disorders, neurological disorder, muscular
and tyrosine; potassium magnesium and
phosphorous; antioxidants; and very minimal or no disorder and erectile dysfunction; [CONT.]
carbohydrates. [CONT.]
The banana extract: is safe even at higher doses;
and has minimal or no simple sugars, minimal or
no fibers and high percentage of
neurotransmitters when converted into powder
form; improves cold adoption and makes the
subjects to withstand for sudden cold exposure, by
causing thermogenesis; and has higher
bioavailability of nutrients when compared to
eating whole banana.
A nutritional composition, particularly tube feed
The composition brings anabolism and catabolism
NOVELTY: A nutritional composition comprises an composition, for modifying cell energy charge for into a beneficial balance, promotes optimal level
exogenous nucleotide. The exogenous nucleotide maintaining gastrointestinal function and structure of protein synthesis, and minimizes protein
in mammal, attenuating upregulation of catabolic degradation.
is monomeric form of 5'- adenosine
monophosphate, 5'-guanosine monophosphate, 5'- processes which is result of metabolic or
nutritional stress, maintaining lean body mass in a
cytosine monophosphate, 5'-uracil
mammal, or attenuating protein breakdown;
monophosphate, 5'-inosine monophosphate
[CONT.]
and/or 5'-thymine monophosphate; and/or intact
BIOTECHNOLOGY - Preferred Component: The
prebiotic is Saccharomyces, Debaromyces,
Candida, Pichia, Torulopsis, Aspergillus,
Rhizopus, Mucor, Penicillium, Bifidobacterium,
Bacteroides, Clostridium, Fusobacterium,
Melissococcus, Propionibacterium, Streptococcus,
Enterococcus, Lactococcus, Staphylococcus,
Peptostrepococcus, Bacillus, Pediococcus,
Micrococcus, Leuconostoc, Weissella,
Aerococcus, Oenococcus, and/or Lactobacillus
[CONT.]
WO 2011019641
Dietary supplement in the form of tablet, a powder,
or liquid for reducing pain, stiffness, inflammation
in mammal (claimed), and/or discomfort
associated with inflammatory conditions such as
arthritis. The mammal is humans or domesticated
mammals (e.g., dogs, cats, and livestock such as
cows, horses, pigs, or sheep).
FOOD - Preferred Composition: The supplement
comprises (mg/serving): Devil's Claw extract (150250, preferably 200), Aronia extract (65-115,
preferably 90), Angelica gigas extract (35-65,
preferably 50), iridoid, ginger component (135225, preferably 180), anthocyanin, coumarin,
curcuminoid, green tea extract (45-75, preferably
25) and turmeric extract (15-35, preferably 25).
[CONT.]
WO 2011019867
US 20110038962
The composition/combination is useful for: treating The composition has improved solubility and
nausea and/or emesis, where hemolysis in the
bioavailability.
patient is minimized, the patient is primate,
preferably human or a companion animal, and
where the nausea and/or vomiting are induced by
PHARMACEUTICALS - Preferred Composition:
The composition further comprises a tonicity
adjuster and/or a pH adjuster. The pH of the
composition is 7-8, preferably 7.5. Preferred
Process: The process further comprises adding a
Composition comprises either (5S,8S)-8-(((1R)-1- WO 2011019911
(3,5-bis-(trifluoromethyl)phenyl)-ethoxy)-methyl)-8phenyl-1,7-diazaspiro(4.5)decan-2-one (I) or its
salt and a vehicle; or (I), macrogol 15hydroxystearate (0.50-10 wt.%), a medium chain
US 20110038925
ribonucleic acid.
GREENBERG N A
74 Dietary supplement for reducing pain, stiffness MELALEUCA INC
and inflammation and/or discomfort
associated with inflammatory conditions such
as arthritis in mammal, comprises Devil's Claw
extract, Aronia extract and Angelica gigas
extract
WO 2011019867
US 20110038962
A2
20110217
A1
20110217
ACTIVITY: Anabolic. No biological data given.
[CONT.]
WO 2011019867 A2 UPAB: 20110310
NOVELTY: A dietary supplement comprises
Devil's Claw extract, Aronia extract and Angelica
gigas extract.
ACTIVITY: Antiinflammatory; Analgesic. Test
details are described but no results given.
MECHANISM OF ACTION: None given.
USE: Dietary supplement in the form of tablet, a
powder, or liquid for reducing pain, stiffness,
inflammation in mammal (claimed), and/or
discomfort associated with inflammatory
conditions such as arthritis [CONT.]
75 Composition, useful e.g. to treat nausea,
emesis or minimizing hemolysis, comprises
(5S,8S)-8-(((1R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-methyl)-8-
OPKO HEALTH INC
WO 2011019911
A1
20110217
WO 2011019911 A1 UPAB: 20110331
US 20110038838
Y
WO2011019641A2
Y
US20110038962A1
N
(trifluoromethyl)phenyl)ethoxy)-methyl)-8phenyl-1,7-diazaspirodecan-2-one and a
vehicle e.g. human serum albumin
76 Treating cancer in a mammal, comprises
administering a composition including e.g. a
targeted vesicular exocytosis modulating
proteins comprising e.g. a Clostridial toxin
translocation domain and a Clostridial toxin
enzymatic domain
ALLERGAN INC
US 20110038925
A1
20110217
NOVELTY: Composition comprises either (5S,8S)8-(((1R)-1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy)methyl)-8- phenyl-1,7-diazaspiro(4.5)decan-2-one
(I) or its salt and a vehicle; or (I), macrogol 15hydroxystearate (0.50-10 wt.%), a medium chain
triglyceride (0.10-2.5 wt.%), a long chain
triglyceride (0.10-1.5 wt. [CONT.]
WO 2011020052
A1
20110217
WO 2011020052 A1 UPAB: 20110315
US 20110064713
A1
20110317
preferably human or a companion animal, and
where the nausea and/or vomiting are induced by
chemotherapy or post-operative nausea and/or
vomiting; minimizing hemolysis; and treating acute
and delayed nausea and vomiting associated with
initial and repeat courses of highly or moderately
emetogenic cancer chemotherapy (all claimed)
[CONT.]
composition is 7-8, preferably 7.5. Preferred
Process: The process further comprises adding a
tonicity adjuster to the microemulsion composition.
The melted macrogol 15 -hydroxystearate is
obtained by heating the macrogol 15-hydroxy
stearate at 60-65?oC. [CONT.]
The method is useful for treating cancer including The method has no adverse events.
a prostate cancer, a breast cancer, a chronic
NOVELTY: Treating cancer in a mammal,
myeloid leukemia, a promyelocytic leukemia, an
comprises administering a composition including a acute myeloblastic leukemia, a multiple myeloma,
targeted vesicular exocytosis modulating proteins a small cell lung cancer, a non-small cell lung
(TVEMP) comprising a targeting domain, a
cancer, a lung carcinomas, a neuroblastoma, a
Clostridial toxin translocation domain and a
stomach cancer, a colon cancer, a malignant
Clostridial toxin enzymatic domain, and an
melanoma, a glioblastoma, an oral squamous cell
exogenous protease cleavage site to the mammal. carcinoma, a liver cancer, a pheochromocytoma,
a teratocarcinoma, a lung adenoma, and a
testicular carcinoma (all claimed) [CONT.]
ACTIVITY: Cytostatic.
salt and a vehicle; or (I), macrogol 15hydroxystearate (0.50-10 wt.%), a medium chain
triglyceride (0.10-2.5 wt.%), a long chain
triglyceride (0.10-1.5 wt. [CONT.]
BIOLOGY - Preferred Components: The TVEMP
comprises a linear amino-to-carboxyl single
polypeptide order of (i) the Clostridial toxin
enzymatic domain, the exogenous protease
cleavage site, the Clostridial toxin translocation
domain, the targeting domain, (ii) the Clostridial
toxin enzymatic domain, the exogenous protease
cleavage site, the targeting domain, and the
Clostridial toxin translocation [CONT.]
WO 2011020052
US 20110064713
BIOLOGY - Preferred Components: The TVEMP
comprises a linear amino-to-carboxyl single
polypeptide order of (1) the clostridial toxin
enzymatic domain, the exogenous protease
cleavage site, the clostridial toxin translocation
domain, the targeting domain, (2) the clostridial
toxin enzymatic domain, the exogenous protease
cleavage site, the targeting domain, the clostridial
toxin translocation domain, [CONT.]
WO 2011020056
US 20110070211
N
N
N
MECHANISM OF ACTION: None given. [CONT.]
ALLERGAN INC
77 Treating cancer comprises administering
composition including targeted vesicular
exocytosis modulator proteins comprising e.g.
clostridial toxin translocation domain, and
exogenous protease cleavage site
WO 2011020056
US 20110070211
A2
20110217
WO 2011020056 A2 UPAB: 20110307
A1
20110324
NOVELTY: Treating cancer in a mammal,
comprises administering a composition (I)
including a targeted vesicular exocytosis
modulator proteins (TVEMP) comprising a
targeting domain, a clostridial toxin translocation
domain and a clostridial toxin enzymatic domain,
and an exogenous protease cleavage site, where
the administration of the composition reduces a
symptom associated with cancer, to the mammal.
[CONT.]
78 Treating cancer e.g. leukemia, thyroid cancer,
colon cancer, prostate cancer, ovarian cancer
and bladder cancer, involves administering
composition containing targeted vesicular
exocytosis modulating protein to mammal
ALLERGAN INC
WO 2011020115
US 20110070186
A2
20110217
WO 2011020115 A2 UPAB: 20110302
US 20110070186
20110324
BIOTECHNOLOGY - Preferred Protein: The
TVEMP comprises linear amino-to-carboxyl single
polypeptide in order of (i) clostridial toxin
enzymatic domain, exogenous protease cleavage
site, clostridial toxin translocation domain and
targeting domain, (ii) clostridial toxin enzymatic
domain, exogenous protease cleavage site,
targeting domain and clostridial toxin translocation
domain, (iii) targeting [CONT.]
WO 2011020115
A1
The method is useful for treating cancer in
The composition causes no side effects.
mammal.
The
cancer
is
acute
myeloid
leukemia,
NOVELTY: Method for treating cancer, involves
thyroid cancer, colon cancer, prostate cancer,
administering composition containing targeted
vesicular exocytosis modulating protein (TVEMP) renal cell carcinoma, ovarian cancer, bladder
cancer, colon cancer, lymphoma,
having targeting domain, clostridial toxin
rhabdomyosarcoma, breast cancer, thyroid tumor,
translocation domain, clostridial toxin enzymatic
domain and exogenous protease cleavage site to lung cancer, non-small cell lung cancer,
mammal, where the administration of composition melanoma, pancreatic cancer, ocular melanoma,
retinoblastoma, intra-ocular tumor, leukemia,
reduces symptom associated with cancer.
Kaposi's [CONT.]
[CONT.]
79 Treating cancer in mammal involves
administering targeted vesicular exocytosis
modulating proteins having targeting domain,
Clostridial toxin translocation domain and
Clostridial toxin enzymatic domain, and
exogenous protease cleavage site
ALLERGAN INC
WO 2011020117
US 20110070215
A2
20110217
WO 2011020117 A2 UPAB: 20110225
WO 2011020117
US 20110070215
A1
20110324
BIOTECHNOLOGY - Preferred Components: The
targeted vesicular exocytosis modulating proteins
(TVEMP) comprises a linear amino-to-carboxyl
single polypeptide order of 1) Clostridial toxin
enzymatic domain, the exogenous protease
cleavage site, Clostridial toxin translocation
domain, targeting domain, 2) the Clostridial toxin
enzymatic domain, exogenous protease cleavage
site, the targeting domain, [CONT.]
80 Treating cancer in mammal, by administering
composition containing targeted vesicular
exocytosis modulator proteins including
targeting domain, clostridial toxin
translocation domain and clostridial toxin
enzymatic to mammal in need
ALLERGAN INC
WO 2011020119
US 20110070212
A2
20110217
WO 2011020119 A2 UPAB: 20110302
WO 2011020119
US 20110070212
A1
20110324
NOVELTY: Method of treating cancer in mammal,
involves administering composition containing
targeted vesicular exocytosis modulator proteins
(TVEMPs) including targeting domain, clostridial
toxin translocation domain and clostridial toxin
enzymatic domain, and exogenous protease
cleavage site to the mammal in need, where
administration of the composition reduce
symptoms associated with cancer. [CONT.]
WO 2011018280
A1
20110217
WO 2011018280 A1 UPAB: 20110307
81 Flavor active composition made by multi-step NESTEC SA
reaction involving reacting amino and carbonyl
compounds, reacting second amino
compound optionally with carbonyl compound,
(I) is useful for treating cancer in a mammal,
(I) exhibits synergistic effect for treating cancer,
where the cancer is a neuroblastoma, a malignant and has no adverse events.
melanoma, an oral squamous cell carcinoma, a
head and neck squamous cell carcinoma, a
pheochromocytoma, a prostate cancer, a breast
cancer, an endometrial cancer, an ovarian cancer,
a liver cancer, a kidney cancer, a renal cancer, a
stomach cancer, a gastric cancer, a pancreatic
cancer, a head and neck [CONT.]
For treating cancer selected from breast cancer,
NOVELTY: Treating cancer in a mammal, involves neuroblastoma, melanoma, schwannoma,
insulinoma, hepatoma, medulloblastoma,
administering to the mammal a composition
prolactinoma, colon cancer, leukemia, chronic
including a targeted vesicular exocytosis
myelogenous leukemia, mast cell leukemia,
modulating Proteins (TVEMP), comprising a
targeting domain, a Clostridial toxin translocation endometrial cancer, prostate cancer, thyroid
domain and a Clostridial toxin enzymatic domain, cancer, squamous-cell lung carcinoma, lung
and an exogenous protease cleavage site, where cancer, astrocytoma, glioblastoma, fibrosarcoma,
or pheochromocytoma; [CONT.]
administration of the composition reduces a
symptom associated with cancer. [CONT.]
The method is useful for treating cancer in
mammal. The cancer is chosen from
neuroblastoma, prostate cancer, pancreatic
cancer, pancreatic adenocarcinoa, insulinoma,
cervical cancer, uterine cancer, breast cancer,
endometrial carcinoma, endometrial
adenocarcinomas, pituitary adenoma, renal cell
carcinoma, lymphoma, prostate cancer, ovarian
carcinoma, small cell lung carcinoma, gut
carcinoid, [CONT.]
The method of treating does not cause any side
effects.
BIOTECHNOLOGY - Preferred Components: The
TVEMP comprises a linear amino-to-carboxyl
single polypeptide chosen from (1) the clostridial
toxin enzymatic domain, the exogenous protease
cleavage site, the clostridial toxin translocation
domain, the targeting domain, (2) the clostridial
toxin enzymatic domain, the exogenous protease
cleavage site, the targeting domain, the clostridial
toxin translocation [CONT.]
As flavor active composition useful in food and
petfood (claimed).
The advantage of the multi step reaction process
stems from the fact that different reaction
conditions are applied for different reaction steps.
Consequently, each reaction step is optimized for
generation of a specific intermediate or group of
FOOD - Preferred Method: In the method (p1), the
last reaction is carried out directly in the food or
petfood during processing, such as extrusion,
roller drying baking, cooking, retorting, microwave
heating, toasting, roasting, or frying. INORGANIC
A flavor active composition obtainable by a multistep reaction (r1) involving reacting an amino
compound and a carbonyl compound to obtain a
first intermediate reaction mixture; reacting a
second amino compound optionally in
WO 2011018280
Y
EP2292104A1
compounds, reacting second amino
compound optionally with carbonyl compound,
then reacting optionally in combination with
amino/carbonyl compounds
MICROBIOS INC
82 Manufacturing composition comprising live
e.g. Lactobacillus acidophilus cells, useful e.g.
to treat hot dogs, comprises inoculating
bacterial fermentation medium with live cells,
harvesting, concentrating and preserving live
cells
conditions are applied for different reaction steps.
Consequently, each reaction step is optimized for
generation of a specific intermediate or group of
intermediates. This leads to improved yields of
individual intermediates as compared to reaction
in one step, namely when the different
intermediates require different reaction conditions
[CONT.]
petfood during processing, such as extrusion,
roller drying baking, cooking, retorting, microwave
heating, toasting, roasting, or frying. INORGANIC
CHEMISTRY - Preferred Components: The
catalyst is a compound comprising a phosphate or
a carboxylate group. [CONT.]
The method provides composition, which is: stable
with high yields; reduces scours events; improves
animal health and animal productivity when fed to
ruminal fermenters, cecal fermenters and
intestinal fermenters.
BIOTECHNOLOGY - Preferred Method: In the
method, the preserving step is carried out by:
lyophilization and after preservation the live cell
count of the cells is at least 1x 1010 cells/g; or
freezing and after preservation the live cell count
of the cells is at least 5x 109 cells/g.
As purified composition for transfection of
exogenous DNA into chromosomal DNA of a cell,
NOVELTY: A purified composition for transfection where the cell is selected from vertebrate cell, a
mammalian cell, a porcine cell, a human cell, a
of exogenous DNA into chromosomal DNA of a
cell, comprises a nucleoprotein filament of a probe plant cell, and a stem cell; for treating a genetic
disease in an animal (claimed); for gene
and a proteinaceous fusion molecule, where the
conversion, homology-independent gene
probe contains double-stranded denatured DNA
complementary to a chromosomal DNA site, and targeting, homologous recombination, targeted
mutagenesis, for genetic diseases and
the fusion molecule comprises a recombinase
administration into plants [CONT.]
domain and a DNA-binding domain, where the
composition is free of DNA sequences that
specifically bind to the DNA-binding domain.
[CONT.]
The efficiency of transfecting the cell is at least
about 1%, as measured by an in vitro test with
direct injection. The composition provides targeted
alteration of genomic sequences. The method is
performed without a viral vector and without a
transposon vector. The fusion protein safely and
efficiently delivers exogenous sequences to the
intended site to achieve the desired effect.
[CONT.]
BIOTECHNOLOGY - Preferred Components: The
exogenous nucleic acid is double-stranded DNA
and is free of promoter sequences. The nucleic
acid probe comprises complementary single
strand DNA (cssDNA) and the DNA-binding
domain is not specifically bound to DNA at the
time of introduction. The exogenous nucleic acid
site of insertion is in the target gene. The
recombinase comprises RecA. [CONT.]
INDEPENDENT CLAIMS are included for the
WO 2011017315
following:
(1) a method of transfecting a cell involving
introducing into the cell: an exogenous nucleic
acid and a nucleoprotein filament of a
proteinaceous fusion molecule and a nucleic acid
probe complementary to a target site of DNA of
the cell, where the fusion protein comprises a
recombinase domain that contributes to the
filament, a DNA-binding domain, and a nuclear
localization signal domain, where the exogenous
nucleic acid is incorporated into the DNA of the
cell and expressed by the cell; [CONT.]
WO 2011018547 A1 UPAB: 20110307
The probiotic preparation is useful for the
manufacture of a pharmaceutical product or a dog
food product for preventing and treating canine
gastrointestinal disorders (claimed). The probiotic
NOVELTY: Probiotic preparation comprises: at
preparation is also useful for treating e.g. smallleast two dog-specific strains of lactic acid
bacteria of Lactobacillus; 20-99 wt.% of a calcium intestine related disorders e.g. [CONT.]
source expressed as calcium carbonate of the dry
weight of the preparation; and at least one
prebiotic, and optionally additional dog-specific
strains of lactic acid bacteria, excipients and
carriers. [CONT.]
The probiotic preparation: has increased shelf life;
exhibits better stability; and can be fed for
substantially longer periods e.g. several months
without adverse effects. Test details are described
but no results given.
BIOLOGY - Preferred Components: The amount
of the prebiotic is 0.5-50 (preferably 0.5-20) wt.%.
The dog-specific strains of lactic acid bacteria of
Lactobacillus comprise at least one (preferably 25) strains of Lactobacillus fermentum,
Lactobacillus plantarum,Lactobacillus rhamnosus,
Lactobacillus salivarius or Lactobacillus mucosae,
preferably Lactobacillus fermentum (NCIMB
41636), Lactobacillus plantarum (NCIMB 41638)
and Lactobacillus rhamnosus (NCIMB 41640)
[CONT.]
INDEPENDENT CLAIMS are also included for: (1) WO 2011018547
a dog food product for preventing and treating
canine gastrointestinal disorders comprising
probiotic preparation where the probiotic
preparation is formulated into fresh food,
sausages, frozen food, dry food pellets, kibbles,
chunks, canned food, stews, premixes, savory
sauce, biscuits, chewing snacks, treats, puppy
milk replacer or fermented products; [CONT.]
US 20110034421 A1 UPAB: 20110321
As supplement for enhancing athletic performance
(claimed); as a feed additive in livestock; as a
nutritional supplement for enhancing muscle
performance and muscle mass in both humans
and livestock, including muscle quality in livestock;
and for a variety of therapeutic indications,
including muscular dystrophy, cardiovascular
diseases, neurodegenerative disorders, and
mental retardation.
The supplement comprises creatine HCl having a
shelf-life of at least 45 days in aqueous solution at
room temperature. The supplement comprises
creatine HCl that drives significant improvements
in muscle development and recovery due to its
enhanced bio-availability, has an increased
aqueous solubility of at least an order of
magnitude, a bioavailability or plasma uptake level
of at least 50% or at [CONT.]
ORGANIC CHEMISTRY - Preferred Components:
The sweetener is selected from sucralose,
aspartame, saccharin, acesulfame potassium,
neohesperidin dihydrochalcone, glycyrrhizin,
thaumatin, alitame and/or stevioside. The alcohol
is selected from ethanol, methanol, butanol, and
isopropanol. [CONT.]
INDEPENDENT CLAIMS are included for
following:
(1) a formula (F1) used to enhance athletic
performance comprising creatine HCl, where the
creatine HCl exhibits an aqueous solubility that is
at least about 15 times greater than that of
creatine monohydrate; and [CONT.]
The nutritious food is useful for pet.
The nutritious food: provides necessary nutrition
for the pet; is cost efficient and easily absorbed by
the pet; has good color, unique flavor, and
elasticity to massage the gum and clean the teeth
of the pet, and to satisfy the bite nature of pet; and
FOOD - Preferred Components: The plant starch
is at least one of rice starch, sticky rice starch,
potato starch, corn starch, wheat starch and
Manihot starch. The edible animal skin is at least
one of pig skin, cattle skin and sheep skin. The
An INDEPENDENT CLAIM is also included for
CN 101933560
preparing nutritious food for pet, comprising: (a)
weighing raw materials according to above
mentioned amount; (b) crushing the edible animal
skin into granules; (c) adding water into the plant
EP 2292104
A1
20110309
NOVELTY: A flavor active composition is formed
by a multi-step reaction (r1) involving reacting
amino compound and carbonyl compound;
reacting second amino compound optionally in
combination with carbonyl compound; optionally,
separately reacting another amino compound
optionally in combination with a carbonyl
compound; [CONT.]
US 7888062
B1
20110215
US 7888062 B1 UPAB: 20110302
The composition is useful: to treat animal waste
NOVELTY: Manufacturing composition comprising effluents including swine fecal material, chicken
fecal material, turkey fecal material, horse fecal
live Lactobacillus acidophilus, Lactobacillus
material, zoo animal fecal material, cattle fecal
animalis or Lactobacillus casei cells, comprises:
inoculating a bacterial fermentation medium with material and human fecal material; in the
the live cells; harvesting the live cells between mid- treatment of agricultural water (irrigation water),
agricultural soils and agricultural crops; to treat
log and late-log phase of growth, where the live
foods including meat and meat products including
cell count of the cells is at least 1x 109 cells/ml;
concentrating the live cells to a live cell count of at ground [CONT.]
compound and a carbonyl compound to obtain a
first intermediate reaction mixture; reacting a
second amino compound optionally in
combination with a carbonyl compound to obtain a
second intermediate reaction mixture; further
separately reacting another amino compound
optionally in combination with a carbonyl
compound to obtain further intermediate reaction
mixture [CONT.]
US 7888062
US 7888062
Y
US7888062B1
least 5x 109 cells/ml; and preserving the live cells.
[CONT.]
83 Composition to transfect exogenous DNA into RECOMBINETICS INC
chromosomal DNA of cell comprises
ESSNER J J
nucleoprotein filament of probe with doublestranded DNA complementary to chromosomal
DNA site/proteinaceous fusion molecule with
recombinase/DNA-binding domains
WO 2011017315
A2
20110210
US 20110059160
A1
20110310
VETCARE OY
84 Probiotic preparation, useful to treat e.g.
canine gastrointestinal disorders, comprises
dog-specific strains of lactic acid bacteria e.g.
Lactobacillus fermentum NCIMB 41636,
calcium source e.g. calcium oxide and
prebiotic e.g. lactose
WO 2011018547
A1
20110217
85 Supplement useful e.g. for enhancing athletic FAULKNER M C
performance, as feed additive in livestock, and
MILLER D W
for variety of therapeutic indications such as
muscular dystrophy, comprises creatine
hydrochloride having specific property
US 20110034421
WO 2011017315 A2 UPAB: 20110321
US 20110059160
N
FAHRENKRUG S C
LIAO H
A1
20110210
NOVELTY: A supplement (S1) comprises:
creatine hydrochloride, where the creatine
hydrochloride possesses a solubility of at least
600 mg/ml in water at 25 degrees C.
VENNERSTROM J L
86 Nutritious food, useful for the pet, comprises PINGYANG RONGHUA LEATHER CO LTD
plant starch, edible animal skin, bone glue,
glycerol and nutrient additive as raw materials
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are included for following:
(1) a formula (F1) used to enhance athletic
performance comprising creatine HCl, where the
creatine HCl exhibits an aqueous solubility that is
at least about 15 times greater than that of
creatine monohydrate; and [CONT.]
CN 101933560
A
20110105
CN 101933560 A UPAB: 20110331
US 20110034421
US 20110034421
Y
WO2011018547A1
Y
US20110034421A1
Y
CN101933560A
86 Nutritious food, useful for the pet, comprises PINGYANG RONGHUA LEATHER CO LTD
plant starch, edible animal skin, bone glue,
glycerol and nutrient additive as raw materials
87 New transgenic non-human animal comprising BAXTER HEALTHCARE SA
genome lacking functional, endogenous
BAXTER INT INC
Factor VIII gene and lacking functional,
endogenous von Willebrand Factor gene,
useful for treating subject having hemophilia A
The nutritious food is useful for pet.
NOVELTY: Nutritious food, comprises (in wt.%):
plant starch (50-75), edible animal skin (10-30),
bone glue (1-10), glycerol (1-10) and nutrient
additive (1-5) as raw materials.
WO 2011017414
A2
20110210
US 20110072524
A1
20110324
DETAILED DESCRIPTION: An INDEPENDENT
CLAIM is also included for preparing nutritious
food for pet, comprising: (a) weighing raw
materials according to above mentioned amount;
[CONT.]
WO 2011017414 A2 UPAB: 20110302
For treating subject having hemophilia A, and
symptom selected from bleeding disorder,
autoimmune disease, aberrant platelet
NOVELTY: A transgenic non-human animal
aggregation, aberrant platelet adhesion and
comprising a genome lacking a functional,
endogenous Factor VIII (FVIII) gene and lacking a aberrant platelet activation (claimed); and for the
study of blood coagulation disorders, such as
functional, endogenous von Willebrand Factor
hemophilia A.
(VWF) gene, is new.
The nutritious food: provides necessary nutrition
for the pet; is cost efficient and easily absorbed by
the pet; has good color, unique flavor, and
elasticity to massage the gum and clean the teeth
of the pet, and to satisfy the bite nature of pet; and
includes less amount of nutrient additive thus
making the nutrition of the food more balanced
and rich.
FOOD - Preferred Components: The plant starch
is at least one of rice starch, sticky rice starch,
potato starch, corn starch, wheat starch and
Manihot starch. The edible animal skin is at least
one of pig skin, cattle skin and sheep skin. The
nutrient additive comprises (in wt.%, based on the
total weight of the nutritious food): lecithin (0.051), linseed oil (0.05-1), vitamin (0.05-0. [CONT.]
An INDEPENDENT CLAIM is also included for
CN 101933560
preparing nutritious food for pet, comprising: (a)
weighing raw materials according to above
mentioned amount; (b) crushing the edible animal
skin into granules; (c) adding water into the plant
starch, bone glue and the edible animal skin
granules, mixing and blending them, and adding
glycerol and nutrient additive, and mixing them;
[CONT.]
The method studies the activity of human blood
coagulation factors in vivo without study on human
patients; and determines the therapeutic effects of
administration of exogenous therapeutic protein to
a patient having a blood coagulation disorder such
as hemophilia A.
BIOLOGY - Preferred Animal: The transgenic
animal further comprises a genome comprising a
human transgene polynucleotide sequence
encoding human VWF. The animal is an
experimental model of human acquired
hemophilia A, such as rodent (preferably mouse).
BIOTECHNOLOGY - Preferred Components: The
polynucleotide sequence is operably linked to a
promoter polynucleotide sequence. [CONT.]
INDEPENDENT CLAIMS are included for the
WO 2011017414
following:
(1) a method of assessing the effects of
exogenous human von Willebrand factor (VWF)
on a mammal deficient in endogenous Factor VIII
and endogenous VWF involving: administering a
human VWF to the animal, and measuring a
clinical readout of VWF activity, where an
improvement in clinical readout indicates a
therapeutic effect of exogenous VWF; and
[CONT.]
US 20110072524
ORGANIC CHEMISTRY - Preferred Materials: The
skin condition agent comprises colloidal oatmeal,
olive leaf, sulfonated shale oil, elubiol, 6-(1piperidinyl)-2,4-pyrimidinediamine-3-oxide,
finasteride, ketoconazole, zinc pyrithione, coal tar,
benzoyl peroxide, selenium sulfide,
hydrocortisone, pramoxine hydrochloride,
tricetylammonium chloride, polyquaternium 10,
panthenol, panthenol triacetate, [CONT.]
US 20110033399
US 20110033399
BIOLOGY - Preferred Method: (I) is administered
followed by transplantation of a liver into the host
or transfusion of blood into the host. Preferred
Components: The chemotherapeutic agent is e.g.
ribonucleoside analogue, N-glycosylation inhibitor,
cytidine triphosphate synthase inhibitor,
nonstructural protein 5B inhibitor,
immunomodulatory compound, thiazolidine
derivative, benzanilide, [CONT.]
Treating an infection by a virus which is a member US 20110033422
of the Flaviviridae family of viruses, in a
mammalian host, comprises administering
substituted N-(1-(5-methyl-tetrahydro-furan-2-yl)-2oxo-1,2-dihydro-pyrimidin-4-yl)- formamidine
compounds of formula (I) or their salts or
composition comprising carrier and at least one
chemotherapeutic agents, to the host. [CONT.]
US 20110033422
N
PHARMACEUTICALS - Preferred Composition:
The composition additionally comprises N-acetyl
cysteine, glycine, L-taurine, L-proline,
niacinamide, pyridoxine (preferably pyridoxine
(B6)) and methylsulfonylmethane. The weight ratio
of N-acetyl cysteine to hydroxytyrosol is 1:1-50:1
(preferably 20:1-25:1). The weight ratio of glycine
to hydroxytyrosol is 1:1-50:1 (preferably 30:140:1). [CONT.]
An INDEPENDENT CLAIM is included for a
dietary supplement in dosage unit form for oral
administration, comprising a composition
containing hydroxytyrosol or its ester or salt (0.550 mg).
US 20110034519
Y
N
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are included for the following: [CONT.]
88 Therapeutic sun-protecting composition, e.g. AVIDAS PHARM LLC
used for treating disorders and diseases
associated with low calcium uptake, includes
sun-protecting agent and vitamin D compound
to increase serum vitamin D levels
GARDNER M M
US 20110033399
A1
20110210
WO 2011017380
A1
20110210
US 20110033422
A1
20110210
PAMPLIN C L
SCHERING CORP
89 Treating infection by a virus of Flaviviridae
family i.e. hepatitis C virus, in mammalian
host, comprises administering substituted N-(1(5-methyl-tetrahydro-furan-2-yl)-2-oxo-1,2dihydro-pyrimidin-4-yl)- formamidine
compounds to host
US 20110033399 A1 UPAB: 20110321
The sun-protecting composition is used in
mammal having vitamin D deficiency or has
vitamin D insufficiency. It is used for preventing
disorders and diseases associated with vitamin D
deficiency or vitamin D insufficiency, comprising
disorders and diseases associated with low
NOVELTY: A therapeutic sun-protecting
calcium uptake, bone-related disorders and
composition comprises sun-protecting agent;
vitamin D compound to increase serum vitamin D diseases, vascular disorders and diseases,
autoimmune disorders and diseases, tuberculosis,
levels when administered to mammal; and
pharmaceutical carrier for topical administration of periodontal disease, chronic pain, seasonal
affective disorder, cognitive impairment,
the sun-protecting agent and vitamin D
depression, type I diabetes, chronic renal disease,
compound.
hypoparathyroid, Parkinson's disease, and cancer
ACTIVITY: Osteopathic; Vasotropic;
[CONT.]
Immunosuppressive; Antitubercular;
Tuberculostatic; Analgesic [CONT.]
US 20110033422 A1 UPAB: 20110323
The method is useful for treating an infection by a The method exhibits a sustained virologic
response.
NOVELTY: Treating an infection by a virus which virus i.e. hepatitis C virus (member of the
is a member of the Flaviviridae family of viruses, in Flaviviridae family of viruses) in a mammalian host
i.e. human (all claimed). The ability of (I) to inhibit
a mammalian host, comprises administering
substituted N-(1-(5-methyl-tetrahydro-furan-2-yl)-2- the ability of cells to replicate replicon was tested
in luciferase replicon cell line by using luciferase
oxo-1,2- dihydro-pyrimidin-4-yl)-formamidine
assay. [CONT.]
compounds (I) to the host or composition
comprising carrier and at least one
chemotherapeutic agents. [CONT.]
MCCORD D
90 Improving the health of a subject e.g. for
promoting quiescence in at risk cells for the
purpose of repairing aging and diseased cells,
involves orally administering specific dosage
of a composition comprising hydroxytyrosol
US 20110034519
WO 2011019735
A1
20110210
US 20110034519 A1 UPAB: 20110321
A2
20110217
NOVELTY: Improving the health of a subject,
involves orally administering a composition
comprising hydroxytyrosol to the subject to
provide the subject with a daily dose of 0.1-750
mu g hydroxytyrosol per kg of body weight.
DETAILED DESCRIPTION: An INDEPENDENT
CLAIM is included for a dietary supplement in
dosage unit form for oral administration,
comprising a composition containing
hydroxytyrosol or its ester or salt (0.5-50 mg).
[CONT.]
91 New antibody used for preventing and treating GH KITAZATO GAKUEN
digestive tract associated diseases, skin
related diseases and cancer, obtained by
immunizing female birds with mammalian
growth factor receptor and obtaining egg yolk
of immunized birds
JP 2011026252
A
20110210
JP 2011026252 A UPAB: 20110315
For improving the health of a subject (claimed)
and for treating or preventing oncosis; for
maintaining and restoring good health, for treating
an oxygen free radical-associated disease or
condition, for the inhibition and treatment of
necrosis and extended quiescence that result in
cellular necrosis instead of normal proliferation, for
reversing damage to cells and, for promoting
quiescence in at [CONT.]
The daily dose of hydroxytyrosol provides the
subject with a daily total oxygen radical
absorbance capacity of 2000-6000 (preferably
3000-5000). The dosage unit form provides 2504000 trolox equivalence (TE) of systemically
bioavailable hydroxytyrosol (preferably provides
500-3500 TE of systemically bioavailable
hydroxytyrosol per day). [CONT.]
The antibody is used in mouth wash, as foodstuff, The antibody is prepared easily by simple method.
supplement, and coating agent, and agent for
preventing and treating digestive tract associated
diseases, skin related diseases, and cancer (all
claimed). The cancer includes stomach cancer,
colorectal cancer, and skin cancer.
N
BIOTECHNOLOGY - Preparation (Claimed): The INDEPENDENT CLAIMS are included for the
antibody is prepared by immunizing female birds following:
using mammalian EGFR as antigen and obtaining
antibody from the egg yolk of immunized female
birds. Preferred Components: The mammal is
human. The birds are hens. The egg yolk is in
powder form.
US 20110034519
JP 2011026252
N
US20110034519A1
digestive tract associated diseases, skin
related diseases and cancer, obtained by
immunizing female birds with mammalian
growth factor receptor and obtaining egg yolk
of immunized birds
NOVELTY: An antibody for epidermal growth
factor receptor is obtained by immunizing female
birds using mammalian growth factor receptor
(EGFR) as antigen, and obtaining egg yolk of
immunized birds, is new.
supplement, and coating agent, and agent for
preventing and treating digestive tract associated
diseases, skin related diseases, and cancer (all
claimed). The cancer includes stomach cancer,
colorectal cancer, and skin cancer.
antibody is prepared by immunizing female birds
using mammalian EGFR as antigen and obtaining (1) preparation of the above-mentioned antibody;
antibody from the egg yolk of immunized female
birds. Preferred Components: The mammal is
human. The birds are hens. The egg yolk is in
powder form.
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are included for the following:
(1) preparation of the above-mentioned antibody;
(2) egg yolk containing the above-mentioned
antibody; and
(3) diagnostic kit comprising EGFR antigen for
immunizing female birds and antibody obtained
from the egg yolk of immunized female birds.
SILTI CO LTD
92 Mixed feed e.g. wheat bran, fermentation
storage for milking cow facility, has door
positioned at bottom of carriage, transfer
conveyor provided at bottom of additive part,
and spiral shaped screw flight parts formed in
discharge screws
KR 2011007281
A
20110124
(2) egg yolk containing the above-mentioned
antibody; and [CONT.]
KR 2011007281 A UPAB: 20110331
POWERTECH INC
93 Apparatus for removing bubbles from
aquarium in e.g. home, has screw for rotating
with power and mounted inside cylinder, and
power transmission device for setting up gear
or pulley and belt in shaft
KR 2011007896
A
20110125
KR 2011007896 A UPAB: 20110331
94 Automatic alarm system for breeding of animal UNIV KYUNGPOOK NAT IND ACAD COOP
FOUND
e.g. rabbit, at livestock shed, has
administration unit authorizing control signal
to camera and transmitting breeding action
alarm message through communication
network
KR 2011007922
A
20110125
KR 2011007922 A UPAB: 20110331
Automatic alarm system for breeding of animal
NOVELTY: The system has an administration unit e.g. pig, rabbit and poultry, at a livestock shed.
installed within a livestock shed, where the
administration unit moves a camera to an
indicated location according to a control signal. A
sensor unit is installed in a reference height at a
constant interval for sensing presence of an
animal. The camera obtains image of a location of
the livestock shed. [CONT.]
95 Remote farm management system has camera UNIV KYUNGPOOK NAT IND ACAD COOP
FOUND
part, facility part, sensor unit, facility
controller, farm management control unit,
communications network, wired terminal and
wireless terminal
KR 2011007924
A
20110125
KR 2011007924 A UPAB: 20110310
96 Prophylactic and/or therapeutic treatment for a NIKLASSON B
disease (e.g. diabetes mellitus) caused by a
Ljungan virus infection, comprises
administering ribavirin and pleconaril, and
eliminating or inhibiting proliferation of the
virus in the mammal
US 20110033418
Mixed feed fermentation storage for cattle i.e.
NOVELTY: The storage has a door (31) positioned milking cow, facility. Uses include but are not
limited to corn, rye, soybean cake, wheat bran,
at bottom of a carriage (30), and a transfer
apple pomace, citrus-peel, pineapple bran, rice
conveyor (52) provided at bottom of an additive
straw and fodder.
part (51). Spiral shaped screw flight parts are
formed in discharge screws.
USE: Mixed feed fermentation storage for cattle
i.e. milking cow, facility. Uses include but are not
limited to corn, rye, soybean cake, wheat bran,
apple pomace, citrus-peel, pineapple bran, rice
straw and fodder. [CONT.]
The storage effectively discharges the mixed feed
to the cattle facility.
KR 2011007281
N
KR 2011007896
N
The system enables automatically obtaining
breeding action image of animal, so as to
determine sexual excitement time of feeder animal
in a remote location at real-time. The system
improves economic effect, improves accuracy for
sensing of sexual excitement time, and increases
conception rate.
KR 2011007922
N
The remote farm management system has a
camera part, a facility part, a sensor unit, a facility
controller, a farm management control unit, a
communications network, a wired terminal and a
wireless terminal, and thus ensures improved
remote farm management system.
KR 2011007924
N
Apparatus for removing bubbles from an aquarium The apparatus ejects the bubbles generated
inside the aquarium to outside, effectively
NOVELTY: The apparatus has a bubble collecting in a home, office and a store.
manages the aquarium, and enhances water
device for collecting bubbles generated in an
cleaning efficiency.
aquarium. A hole is formed in an upper side of a
cylinder. A reduction device is adhered with a
motor (21) for discharging the bubbles. A screw
(12) is rotated with power and mounted inside the
cylinder. A power transmission device sets up a
gear or a pulley and a belt in a shaft [CONT.]
Remote farm management system.
NOVELTY: The remote farm management system
has a camera part (11), a facility part (12), a
sensor unit (13), a facility controller (14), a farm
management control unit (15), a communications
network (16), a wired terminal (17) and a wireless
terminal (18). A roof opening or closing device
(122) is formed for opening and closing the roof of
device for opening and closing of a curtain (121).
[CONT.]
A1
20110210
US 20110033418 A1 UPAB: 20110321
The method is useful for prophylactic and/or
therapeutic treatment for a disease caused by a
Ljungan virus infection in the mammal including
NOVELTY: Prophylactic and/or therapeutic
treatment of a mammal for a disease caused by a humans, horses, cattle, pigs, cats, dogs and
Ljungan virus infection comprises: administering rodents, where the disease is diabetes mellitus,
amyotrophic lateral sclerosis (both preferred),
ribavirin, pleconaril or their derivatives effective
myocarditis, cardiomyopathia, Guillain Barre
against the Ljungan virus, to the mammal; and
eliminating or inhibiting proliferation of the virus in syndrome, multiple sclerosis, chronic fatigue
syndrome, myasthenia gravis, [CONT.]
the mammal and at the same time preventing
and/or treating the disease in the mammal.
[CONT.]
PHARMACEUTICALS - Preferred Method: The
INDEPENDENT CLAIMS are also included for:
method of prophylactic and/or therapeutic
treatment of the mammal for the disease caused (1) a composition comprising ribavirin and
by the Ljungan virus infection further comprises
pleconaril or their derivative;
administering an anti-Ljungan virus antibody and
interferon. The method of making the medicament
further comprises the step of combining an antiLjungan virus antibody and interferon in the
medicament. [CONT.]
US 20110033418
US 20110033418
N
(2) prophylactic and/or therapeutic treatment of
the mammal for the disease caused by the
Ljungan virus infection comprising either:
administering composition comprising ribavirin or
its derivative to the mammal, where the mammal
receiving pleconaril or its derivative, and
administering step occurring simultaneously or
sequentially with the receiving pleconaril or its
derivative [CONT.]
ALLTECH INC
97 New yeast (Saccharomyces cerevisiae)
comprising yeast cell wall comprising
interlaced clay or clay component (e.g.
bentonite), useful for e.g. reducing
bioavailability of mycotoxins (e.g. ochratoxins)
to animal (e.g. camelids) or human
COMMONWEALTH SCI&IND RES ORG
98 Barley grain useful for producing a food or
beverage product, comprises a reduced level
or activity of starch synthase-IIa protein, and a AUSTRALIAN CAPITAL VENTURES LTD
specific starch content
99 Pet food comprises a chewable biscuit body
embedded with fragrant stuffing body
US 20110033576
WO 2011011833
HUZHOU JINSHENGDA PET SUPPLIES CO LTD CN 201682978
A1
A1
U
20110210
20110203
20101229
US 20110033576 A1 UPAB: 20110323
The clay or clay component interlaced yeast cell
wall extract is useful: for feeding to any member of
NOVELTY: Yeast cell comprising a yeast cell wall kingdom Animalia, preferably avian, bovine,
comprising interlaced clay or a clay component, is porcine, equine, ovine, caprine, piscine, shellfish,
camelids, feline, canine or rodent species; for
new.
reducing bioavailability of mycotoxins to an animal
DETAILED DESCRIPTION: INDEPENDENT
or human (all claimed), thus reducing incidence of
CLAIMS are also included for:
mycotoxin-associated diseases; for treating
mycotoxicosis [CONT.]
(1) a composition comprising a clay or clay
component interlaced yeast cell wall extract;
(2) an animal feedstuff comprising the clay or clay
component interlaced yeast cell wall extract, which
is present in an amount effective to sequester
mycotoxins; [CONT.]
WO 2011011833 A1 UPAB: 20110328
For producing a food or beverage product
The modified barley grain provides increased
selected from wholemeal, flour, starch, bran, beta - levels of resistant starch, dietary fiber, water
NOVELTY: Barley grain (G1) comprises a reduced glucan, fructan, a non-starch polysaccharide, and soluble carbohydrate, beta -glucan, fructan and/or
cracked, ground, polished, milled, kibbled, rolled non-starch carbohydrate in the product, and/or
level or activity of starch synthase-IIa (SS-IIa)
or pearled grain, breakfast cereal, biscuit, muffin, decreased glycemic index (GI) of the food product.
protein, and a starch content of at least 41
muesli bar, noodle, a sweetening agent, a low
wt./wt.%.
calorie additive, a bulking agent, a dietary fiber, a
DETAILED DESCRIPTION: INDEPENDENT
texturizing agent, a preservative, a probiotic agent,
CLAIMS are included for the following:
[CONT.]
(1) a barley plant (P1) capable of producing the
grain (G1);
(2) barley wholemeal or flour (W1) produced from
the grain (G1); [CONT.]
CN 201682978 U UPAB: 20110331
Used as a pet food.
NOVELTY: Pet food comprises a chewable biscuit
body (1) embedded with fragrant stuffing body (2).
DUPUIS G
US 20110028429
A1
20110203
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are included for:
BIOTECHNOLOGY - Preferred Components: The
grain (G1) comprises a mutation in an
endogenous gene encoding a polypeptide with
(SSIIa) activity, where the mutation reduces the
expression of the gene encoding (SSIIa) in a
barley plant or leads to the expression of (SSIIa)
with reduced level or activity. The grain is
homozygous for the sex6-292 allele. [CONT.]
INDEPENDENT CLAIMS are included for the
following:
(1) a barley plant (P1) capable of producing the
grain (G1);
INSTRUMENTATION AND TESTING - Preferred
Components: The chewable biscuit body is in the
shape of bone. The fragrant stuffing body is
columnar, and penetrates through the boneshaped chewable biscuit body. The chewable
biscuit body is provided with at least two fragrant
stuffing bodies. [CONT.]
The composition has a milder side effect profile
than HMG-CoA reductase inhibitor monotherapy
at increased dosage levels.
PHARMACEUTICALS - Preferred Composition:
The composition further comprises a carrier.
Preferred Components: The HMG-CoA reductase
inhibitor is Zocor (RTM: Simvastatin), atorvastatin,
mevinolin, Crestor (RTM: Rosuvastatin calcium),
nivastatin, Lipitor (RTM: Atorvastatin calcium) (all
preferred), lovastatin, pravastatin, fluvastatin or
mevastatin. The polychitosamine has a molecular
weight of 30 kDa and is deacetylated at least 93%
[CONT.]
ADVANTAGE: The chewable biscuit body can be
chewed by the pet as much as it like, and the
fragrant stuffing has a flavor of chocolate and milk
to attract the pet to take food.
AUBE A
100 Composition, useful e.g. for prophylaxis or
treatment of hyperlipidemia or its associated
BRZEZINSKI R
condition, e.g. hypercholesterolemia and
atherosclerosis, comprises 3-hydroxy-3methylglutaryl-coenzyme A reductase inhibitor
and polychitosamine
INDEPENDENT CLAIMS are also included for:
The chewable biscuit body can be chewed by the
pet as much as it like, and the fragrant stuffing has
a flavor of chocolate and milk to attract the pet to
take food.
USE: Used as a pet food.
DESCRIPTION OF DRAWINGS: The drawing
shows a schematic representation of the pet food.
[CONT.]
US 20110028429 A1 UPAB: 20110323
The composition is useful for the prophylaxis or
NOVELTY: Composition comprises a 3-hydroxy-3- treatment of hyperlipidemia or its associated
methylglutaryl-coenzyme A (HMG-CoA) reductase condition, which is hypercholesterolemia,
atherosclerosis, coronary heart disease,
inhibitor, and a polychitosamine.
cardiovascular disease or post heart attack
recovery (all claimed). The composition is useful:
for reducing serum cholesterol and/or cholesteryl
ester, triglycerides, phospholipids and fatty acids
in a mammal; [CONT.]
BIOLOGY - Preparation: No preparation method is
given. Preferred Components: The yeast is
Saccharomyces, Candida, Kluyveromyces and/or
Torulaspora, preferably Saccharomyces
cerevisiae. Preferred Method: The method of
reducing bioavailability of mycotoxins to an animal
or human further comprises incorporating an
additional agent into the clay or clay component
interlaced yeast cell wall extract incorporated
material, where the agent is an esterase,
epoxidase, yeast or bacterial strain [CONT.]
US 20110033576
US 20110033576
Y
US20110033576A1
Y
WO2011011833A1
Y
CN201682978U
(1) a composition comprising a clay or clay
component interlaced yeast cell wall extract;
(2) an animal feedstuff comprising the clay or clay
component interlaced yeast cell wall extract, which
is present in an amount effective to sequester
mycotoxins; [CONT.]
WO 2011011833
(2) barley wholemeal or flour (W1) produced from
the grain (G1);
(3) producing (M1) a food or beverage product
involving: (i) obtaining or producing barley grain
(G1), and (ii) processing the grain to produce the
product; [CONT.]
CN 201682978
INDEPENDENT CLAIMS are included for:
(1) prophylaxis or treatment of hyperlipidemia or
its associated condition, comprising administering
at least 400 mg/day of polychitosamine, and 6-80
mg/day of an HMG-CoA reductase inhibitor to the
patient, where the amounts together comprise a
therapeutically effective amount; and [CONT.]
US 20110028429
US 20110028429
N
LEHOUX J
HAWKINS INC
101 Antimicrobial composition, useful for
preserving food products comprising scrapple CAMPANO S G
or hot dogs, comprises lactic acid or its salt,
acetic acid or its salt and propionic acid or its
salt
102 Topical or aerosol composition used in
nebulizer or inhaler for treating, e.g. eczema,
comprises X-ray contrast media and topical
carrier or aerosolized carrier solution or dry
powder
(1) prophylaxis or treatment of hyperlipidemia or
its associated condition, comprising administering
at least 400 mg/day of polychitosamine, and 6-80
mg/day of an HMG-CoA reductase inhibitor to the
patient, where the amounts together comprise a
therapeutically effective amount; and [CONT.]
US 20110028550
WO 2011014669
A1
20110203
A1
20110203
US 20110028550 A1 UPAB: 20110310
(I) is useful for preserving food products (scrapple,
NOVELTY: Antimicrobial preservative composition hot dogs (all claimed), liver mush, liver pudding,
(I) comprises lactic acid (A) or its salt, acetic acid chitlin loaf, head cheese, corn meal mush,
panhaas or goetta).
(B) or its salt, and propionic acid (C) or its salt.
(I) is effective to: inhibit the growth of Listeria
monocytogenes on the food product; and limit
growth of Listeria monocytogenes to less than 2
logs over the shelf life (preferably at least 30 days)
of the food product.
HAWKINS P H
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are included for:
WALES J B
(1) a food product comprising: a meat; and 0.1-5
wt.% of (A), 0.01-0.25 wt.% of (B) and 0.01-1 wt.%
of (C); and [CONT.]
US 20110027193 A1 UPAB: 20110310
A topical or aerosol composition in the form of a
The composition is cheap, and has low molecular
gel, a cream, a lotion, a paste, an ointment, an oil weight.
NOVELTY: A topical or aerosol composition
comprises an X-ray contrast media and a topical or a foam for treating skin inflammatory condition;
or for use in a nebulizer or an inhaler for treating
carrier or an aerosolized carrier solution or dry
inflammation of the upper respiratory tract/bronchi
powder.
in a mammal, colon inflammatory condition,
ACTIVITY: Antiallergic; Antiinflammatory;
condition related to inflammation of esophagus in
Respiratory-Gen; Antipsoriatic; Dermatological;
a mammal (particularly allergic esophagitis), or a
Gastrointestinal-Gen; Vulnerary; Virucide. Test
common cold including its symptoms [CONT.]
details are described but no results given.
LASSER FAMILY PARTNERSHIP LP
US 20110027193
A1
20110203
FOOD - Preferred Composition: The food product
comprises: 0.5-4.8 wt.% of (A), 0.05-0.25
(preferably 0.1-0.25) wt.% of (B) and 0.05-0.5
(preferably 0.1-0.25) wt.% of (C). The food product
comprises an uncured food product; a ready-toeat meat product; and a food product having a
total moisture content of greater than 60 wt.%.
The food product comprises a sodium chloride
content of less than 1.9 wt. [CONT.]
INDEPENDENT CLAIMS are included for:
US 20110028550
US 20110028550
US 20110027193
US 20110027193
(1) a food product comprising: a meat; and 0.1-5
wt.% of (A), 0.01-0.25 wt.% of (B) and 0.01-1 wt.%
of (C); and
(2) the preparation of food product comprising:
adding (I) to a composition comprising a meat.
PHARMACEUTICALS - Preferred Composition:
The composition further comprises an absorption
emollient, a preservative, and
dichlorodifluoromethane, trichlorofluoromethane,
dichlorotetrafluoroethane or carbon dioxide. The
composition is formulated to be absorbed by an
epidermal layer of the skin or by a bronchus, or
formulated as retention enema. Preferred
Components: The topical carrier is an absorption
emollient [CONT.]
MECHANISM OF ACTION: None given. [CONT.]
103 Pet house i.e. wooden house, has side that is WANG J
connected with wooden door, and provided
with window, and bottom of house paved with
sleeping blanket and food case, where house
is connected with chamber pot
CN 201682863
U
20101229
CN 201682863 U UPAB: 20110331
Pet house i.e. wooden house.
NOVELTY: The house has a side that is
connected with a wooden door, and provided with
a window. Bottom of the house is paved with a
sleeping blanket and a food case, where the
house is connected with a chamber pot.
The house maintains the indoor environment to be
clean.
CN 201682863
USE: Pet house i.e. wooden house.
IAMS CO
104 Pet food kibble used for cats and dogs,
comprises core, and dusting comprising active CORRIGAN P J
component, e.g. probiotic
WO 2011014363
US 20110027419
A1
20110203
A1
20110203
GREY R M
ADVANTAGE: The house maintains the indoor
environment to be clean. [CONT.]
WO 2011014363 A1 UPAB: 20110302
NOVELTY: A pet food kibble comprises a core
having a water content of less than 12%; and a
coating or dusting on the core, comprising an
active component, preferably probiotic; where a
health benefit of the kibble is intuitively
communicated by a psychologically matched
color.
A pet food kibble used for a feed (claimed) for cats The kibble provides a health benefit including
and dogs.
digestive health, and nutritional balance.
FOOD - Preferred Component: The kibble is
colored white. The activity of the probiotic
component is greater than or equal to 1x 105
colony-forming unit/g kibble.
An INDEPENDENT CLAIM is included for a kit,
comprising a package, and kibbles.
WO 2011014363
DETAILED DESCRIPTION: An INDEPENDENT
CLAIM is included for a kit, comprising a package,
and kibbles. [CONT.]
HOUSTON M M
SUNVOLD G D
105 Manufacturing a powder, liquid or semi-liquid
food product (e.g. nutraceutical or cosmetic
product), useful to improve bone and skin
health, comprises heating flavanone in water
at specific temperature and incorporating to
food product
NESTEC SA
WO 2011012525
A1
20110203
EP 2289343
A1
20110302
WO 2011012525 A1 UPAB: 20110302
The process is useful to manufacture powder,
liquid or semi-liquid food product including a food
NOVELTY: Manufacturing a powder, liquid or semi- supplement, nutraceutical, cosmetic product, pet
food product or medicament, where the: powder
liquid food product comprising flavanones,
comprises: (a) heating the flavanone in water to at food product includes milk powder, dehydrated
least 138 degrees C, preferably 140-160 degrees soup powder, shake powder and infant formulae;
[CONT.]
C, for 1-60 seconds; and (b) incorporating the
flavanone to the food product.
The process provides food products having
improved stability.
FOOD - Preferred Process: In the process, the
INDEPENDENT CLAIMS are also included for:
flavanone (present at a concentration of 0.05-5%
in the food product) is heated to at least 138
(1) food product obtained by the above process;
degrees C, preferably 140-150 degrees C for 1-60
seconds. The process further comprises the steps
of pH adjustment, homogenization, pasteurization,
preheating, cooling, filling, drying or spray-drying.
Preferred Components: The flavanone is
hesperidin. [CONT.]
WO 2011012525
US 20110027419
N
hesperidin. [CONT.]
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are also included for:
(2) improving the stability of flavanones in the
liquid/semi-liquid food product, comprising: steps
(a) and (b) as above per se, or heating the food
product in the presence of the flavanone to at
least 138 degrees C, preferably 140-150 degrees
C for 1-60 seconds;
(1) food product obtained by the above process;
[CONT.]
(3) producing stabilized flavanones comprising
step (a) as above per se; and [CONT.]
DANISCO AS
106 Use of lactic acid bacterium and
Bifidobacterium in the manufacture of a food
product, dietary supplement or medicament for
treating metabolic endotoxemia, inhibiting
bacterial translocation, and regulating lipid
absorption
WO 2011013106
A1
20110203
WO 2011013106 A1 UPAB: 20110302
IAMS CO
107 Dusting a pet food kibble, e.g. as dog food,
comprises dusting a powder comprising active CORRIGAN P J
ingredient, e.g. probiotic microorganisms on
kibble
WO 2011014391
US 20110027417
A1
20110203
WO 2011014391 A1 UPAB: 20110302
A1
20110203
NOVELTY: Dusting a pet food kibble comprises
dusting a powder on a kibble, where the powder
comprises an active ingredient, e.g. probiotic
microorganisms. The dusting occurs free of a
binder, and the kibble comprises less than 12%
moisture during dusting.
HOUSTON M M
The bacterium is useful for manufacturing a food
product, dietary supplement or medicament for
treating metabolic endotoxemia, inhibiting
NOVELTY: Use of a bacterium selected from a
bacterial translocation, and regulating lipid
lactic acid bacterium, a Bifidobacterium or their
mixture is claimed for use in the manufacture of a absorption in a mammal. [CONT.]
food product, dietary supplement or medicament
for treating metabolic endotoxemia, inhibiting
bacterial translocation, and regulating lipid
absorption in a mammal. [CONT.]
Method for dusting a pet food kibble (claimed),
e.g. as dog and cat food.
BIOTECHNOLOGY - Preferred Bacterium: The
metabolic endotoxemia comprises an increase of
the level of lipopolysaccharides in the mammalian
body by a factor of 1.5-20, preferably 2-4,
compared with basal lipopolysaccharide levels.
The endotoxemia is diet-induced and/or dietassociated. The bacterium is a probiotic lactic acid
bacterium and/or a probiotic Bifidobacterium.
[CONT.]
The method results in a probiotic activity of greater
than about 1/asterisk105 colony forming units
(CFU)/g kibble. It provides a kibble having an
endurance factor of 0.1-0.001.
USE: Method for dusting a pet food kibble
(claimed), e.g. as dog and cat food. [CONT.]
INDEPENDENT CLAIMS are: (1) a method of
treating metabolic endotoxemia in a mammal by
administering an amount of a bacterium selected
from a lactic acid bacterium, a Bifidobacterium or
their mixture; (2) a method of inhibiting bacterial
translocation in a mammal by administering an
amount of a bacterium selected from a lactic acid
bacterium, a Bifidobacterium or their mixture;
[CONT.]
WO 2011013106
BIOTECHNOLOGY - Preferred Component: The
active ingredient comprises sources of fiber
ingredients, mineral ingredients, polyphenols
ingredients, amino acid ingredients, carotenoid
ingredients, antioxidant ingredients, fatty acid
ingredients, glucose mimetic ingredients, prebiotic
ingredients, enzymes, antibodies,
immunoglobulins, cytokines, epigenetic agents,
vitamins, and/or preferably probiotic
microorganisms [CONT.]
WO 2011014391
PHARMACEUTICALS - Preferred Components:
The product or composition is a beverage or food.
WO 2011014448
US 20110027417
SUNVOLD G D
108 Use of erythritol for manufacturing a product
or composition for stimulation of manganese
superoxide dismutase expression
109 Forming bee larvae that are greater in weight
than control larvae involves feeding histone
deacetylase inhibitors or their mixtures, to
young worker bees; and feeding bee larvae
royal jelly secreted by these young worker
bees
CARGILL INC
A1
20110203
WO 2011014448 A1 UPAB: 20110310
NOVELTY: Use of erythritol for manufacturing a
product or composition for stimulation of
manganese superoxide dismutase (SOD2)
expression.
ACTIVITY: Hypotensive.
NATUREWISE BIOTECH&MEDICALS CORP
110 Preparing a liquid pharmaceutical composition MIKA PHARMA GES
ENTWICKLUNG&VERMARKTUN
comprising a solvent, an active agent and a
SEIGFRIED B G
foaming agent, useful e.g. to treat atopic
eczema, atopic dermatitis, inflammatory or
pruritic skin disease, psoriasis, hair loss and
inflammation
111 New pyrazole derivatives are metabotropic
glutamate receptor 4 allosteric modulator
useful for treating or preventing Parkinson's
disease, depression, anxiety, agoraphobia,
WO 2011014448
ADDEX PHARMA SA
US 20110020462
A1
20110127
JP 2011024559
A
20110210
KR 2011009611
A
20110128
DE 102010027315
A1
20110127
WO 2011009436
A2
20110127
US 20110059117
WO 2011010222
A1
20110310
A1
20110127
MECHANISM OF ACTION: Manganese
superoxide dismutase stimulator. [CONT.]
US 20110020462 A1 UPAB: 20110307
The erythritol is useful for: manufacturing a
The erythritol is safe and well tolerable, and has
product or composition for stimulation of SOD2
no digestive side-effects, even after consumption
expression; preventing or treating endothelial
of large quantities.
dysfunction-induced hypertension associated with
hyperglycemia, diabetes, metabolic syndrome,
cardiovascular disease, obesity, atherosclerosis
and inflammation; and preventing or treating
hemolysis induced hypertension associated with
coronary artery disease, [CONT.]
Y
For producing bee larvae that are at least 100%
greater in weight than control larvae, and pupa or
queen bee that are at least 50% greater in weight
NOVELTY: Production of bee larvae that are at
than a control pupa or queen bee; and for
least 100% greater in weight than control larvae
producing a royal jelly comprising major royal jelly
involves feeding histone deacetylase (HDAC)
inhibitors or their mixtures, to young worker bees; protein 3 (MRJP3) having a changed ratio of 68 to
64 kDa protein relative to a control royal jelly
and feeding bee larvae royal jelly secreted by
these young worker bees, while the bee larvae of (claimed). [CONT.]
the control receive the royal jelly produced by
young worker bees not fed with HDAC inhibitors or
their mixtures. [CONT.]
The method provides bee larvae that are at least
100% greater in weight than control larvae, and
the pupas and queen bees that are at least 50%
greater in weight than control larvae. The weight
of the larvae feeding on the royal jelly after 72
hours increases higher than 1.5 (preferably by 2-5,
especially by 3-5) times. [CONT.]
BIOTECHNOLOGY - Preferred Method: The bee
larvae can be fed by worker bees on the royal jelly
secreted from it or by human with the royal jelly
collected from worker bees. Preferred
Components: The HDAC inhibitor is selected from
compounds of formula (I) or (II), their salts,
stereoisomers, enantiomers, prodrugs and
solvates; SAHA; propolis and propolins. [CONT.]
INDEPENDENT CLAIMS are included for the
following:
(1) producing a pupa that is at least 50% greater
in weight than a control pupa or a queen bee that
is at least 50% greater in weight than a control
queen bee, involving feeding young worker bees
HDAC inhibitors or their mixtures; and feeding a
bee larva royal jelly secreted by these young
worker bees and obtaining a pupa or queen bee
developed from [CONT.]
DE 102010027315 A1 UPAB: 20110225
(I) is useful for treating atopic eczema or atopic
dermatitis, inflammatory or pruritic skin diseases,
psoriasis, dermatitis, neurodermatitis, pain,
NOVELTY: Preparing a liquid pharmaceutical
inflammation, rheumatic diseases, acute trauma,
composition (I) comprising at least a solvent, at
least an active agent and at least a foaming agent, fungal infections, infections with Gram-positive
is claimed, where: (I) is applied as a foam on the bacteria, anaerobic bacteria and Mycoplasma,
preferably acne, itching of the skin, acne,
skin; the foam volume and foam stability can be
preferably acne comedonica and acne
determined according to a standardized SITA
papulopustulosa, hair loss, [CONT.]
measuring method without using a propellant;
[CONT.]
(I) has good tolerability and treats without side
effects. (I) can be homogenously applied on the
skin of warm-blooded mammal.
ORGANIC CHEMISTRY - Preferred Method: A
correlation between the foam specified by SITA
measuring method and the pharmaceutical
properties is produced. A foam applicator is used
for mechanical foaming of (I), where a foam is
produced from (I) by the foam applicator, and a
correlation between the properties, preferably
pharmaceutical properties of the resulting foam
and foam volume and/or foam stability, which is
determined according to SITA measuring method,
is produced [CONT.]
Preparing a liquid pharmaceutical composition (I) DE 102010027315
comprising at least a solvent, at least an active
agent and at least a foaming agent, is claimed,
where: (I) is applied as a foam on the skin; the
foam volume and foam stability can be determined
according to a standardized SITA measuring
method without using a propellant; the foaming
agent, the solvent and the active agent are
different from one another based on their chemical
nature and/or their concentration [CONT.]
WO 2011010222 A1 UPAB: 20110321
(I) exhibit improved potency on the target,
selectivity for the target, bioavailability, brain
penetration, and activity in behavioral models.
ORGANIC CHEMISTRY - Preparation (Disclosed): Pyrazole derivatives of formula (I) and their acid or WO 2011010222
Preparation of (I) comprises Suzuki coupling of 4- base addition salts, stereochemically isomeric
bromo-thiazole compound of formula (II) with non forms or N-oxide forms, are new.
protected boronic esters or acids of formula (III) to
obtain (Ib) (representation of (I)). Preferred
(I) are useful for treating or preventing central
nervous system disorders comprising addiction,
tolerance or dependence, Parkinson's disease
and movement disorders such as bradykinesia,
rigidity, dystonia, drug-induced parkinsonism,
US 20110020462
US 20110020462
N
US 20110059117
N
WO2011014448A1
and movement disorders such as bradykinesia,
rigidity, dystonia, drug-induced parkinsonism,
dyskinesia, tardive dyskinesia, L-3,4dihydroxyphenylalanine-induced dyskinesia,
dopamine agonist induced dyskinesia,
DETAILED DESCRIPTION: Pyrazole derivatives hyperkinetic movement disorders, Gilles de la
of formula (I) and their acid or base addition salts, [CONT.]
stereochemically isomeric forms or N-oxide forms,
are new.
X1, X2 = C, N, S or C=C representing a 5 or 6
membered heteroaryl ring which is optionally
further substituted by radicals (A)m; [CONT.]
disease, depression, anxiety, agoraphobia,
migraine, ischemia, spinal cord injury and
cerebral hypoxia
protected boronic esters or acids of formula (III) to
obtain (Ib) (representation of (I)). Preferred
X1, X2 = C, N, S or C=C representing a 5 or 6
Components: (I) can exist as optical isomers,
membered heteroaryl ring which is optionally
where (I) are either the racemic mixture or one or further substituted by radicals (A)m;
both of the individual optical isomers. [CONT.]
NOVELTY: Pyrazole derivatives (I) and their acid
or base addition salts, stereochemically isomeric
forms or N-oxide forms, are new.
m = 0-2;
A = e.g. H, halo, -CN or -OH;
n = 1 or 2;
DSM IP ASSETS BV
112 Oral dietary or nutraceutical composition,
useful to treat e.g. stress, dysphoria,
dysthymia or insomnia connected to impaired
or reduced neurotransmission in animals,
comprises a lipophilic Nigella species (Nigella
sativa) seed extract
113 Agent useful for suppressing bitterness in
drink of citrus and grape fruit, comprises
collagen peptide derived from mammal
KAO CORP
WO 2011009862
EP 2289529
A1
20110127
A1
20110302
JP 2011015632
A
20110127
WO 2011009862 A1 UPAB: 20110209
The composition is useful: in fortified food, spicy
cereal bars, bakery items, cookies, dietary
NOVELTY: Oral dietary or nutraceutical
supplements, non-alcoholic drinks, soft drinks,
composition comprises a lipophilic Nigella sp.
sport drinks, vegetable juices, teas, liquid food or
seed extract.
soups; as a mood/vitality improver, a stress
DETAILED DESCRIPTION: An INDEPENDENT
reliever, a condition improver, a reducer of
CLAIM is also included for a method of treating a
anxiety, a reducer of tension, a reducer of
condition resulting from impaired
unhappiness/discontentedness, a reducer of
neurotransmission comprising administering to an
irritability, a reducer of [CONT.]
animal, including a healthy human, a lipophilic
Nigella sativa seed extract or of at least one of its
volatile component, and observing the reduction of
impaired neurotransmission. [CONT.]
The orally administered composition prolongs the
time that serotonin is available for
neurotransmission, in the form of controlled
(delayed) release formulation.
JP 2011015632 A UPAB: 20110310
The agent has excellent solubility absorptivity and FOOD - Preferred Composition: The collagen
palatability. The agent improves storage stability peptide is derived from pig skin. The intensity of
and prevents oxidation.
the standard solution of the quinine sulfate is 7 or
less. The drink comprises bitterness suppression
agent of 0.001-0.08 %mass. The mass ratio of
bitterness suppression agent is 0.01-0.2.
The agent in the form of powder or granule is
useful for suppressing bitterness in drink of citrus
fruit, grape fruit, orange and lemon. Can also be
NOVELTY: Agent comprises collagen peptide
derived from mammal as an active ingredient. The used in pharmaceuticals.
molecular weight of the agent is 500-4500.
BIOLOGY - Preferred Components: The Nigella
sp. is Nigella sativa. The seed extract is obtained
by an extraction method consisting of liquid
carbon dioxide under supercritical conditions,
steam distillation/hydro distillation yielding
essential oils, ethanol extraction, ethyl acetate
extraction, methyl-tertiary-butyl ether, methanol,
propane, butane, acetone or nitro oxide.
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are included for the following:
114 Pet water feeding device for use in home, has HUINAN SECOND PRIMARY SCHOOL
water tank mounted on top part of lifting
frame, and water outlet rubber hose connected
with bottom part of side of water tank, where
water outlet rubber hose is provided with
block ball
115 New expression vector comprising first
nucleic acid sequence encoding inhibitor of
HIV co-receptor and second nucleic acid
sequence encoding protein that inhibits HIV
fusion to target cell/HIV replication, useful for
treating HIV infection
CALIMMUNE INC
CN 101919355
A
20101222
A2
20110120
WO 2011008348
A3
20110310
(1) method for suppressing the bitterness of drink,
involves adding the above-mentioned agent to
composition with bitterness; and
(2) drink comprising bitterness component (0
[CONT.]
CN 101919355 A UPAB: 20110321
Pet water feeding device for use in a home.
USE: Pet water feeding device for use in a home.
[CONT.]
WO 2011008348 A2 UPAB: 20110209
For treating or preventing HIV infection in a patient
(comprising patient which is naive to highly active
NOVELTY: An expression vector (V1) comprising antiretroviral therapy (HAART), patient receiving a
a first nucleic acid sequence encoding an inhibitor HAART regimen, patient failing or has failed on a
HAART regimen and patient at risk for HIV
of an HIV co-receptor and a second nucleic acid
infection) (claimed); and for treating or preventing
sequence encoding a protein that inhibits HIV
infection by simian immunodeficiency virus (SIV),
fusion to a target cell or HIV replication.
feline immunodeficiency virus (FIV) and bovine
[CONT.]
DETAILED DESCRIPTION: INDEPENDENT
116 Processing cooked food waste for producing
pet food involves processing food waste,
HY PRO PTY LTD
AU 2010101342
A4
20110113
INDEPENDENT CLAIMS are included for the
JP 2011015632
following:
(1) method for suppressing the bitterness of drink,
involves adding the above-mentioned agent to
composition with bitterness; and
The device is simple in structure and easy to use,
maintains the water for pet cleaning and sanitary
purpose, and supplies the water to pet for a long
period of time when no person in home for caring
the pet.
The patient is resistant to infection by R5 and X4
tropic strains of HIV following administration of the
composition comprising the vector (V1). The
patient is resistant to infection by highly active
antiretroviral therapy (HAART)-resistant HIV
strains following administration of the composition.
The expression vector confers resistance to
infection by X4- and R5-tropic HIV strains when
expressed in a host cell [CONT.]
CN 101919355
BIOTECHNOLOGY - Recombinant Methods
(Claimed): The method (M1) involves:
synthesizing a cDNA of a gene which expresses a
protein capable of preventing HIV fusion into a cell
or HIV replication; cloning the synthesized cDNA
into a restriction site in a viral vector; and inserting
an expression unit capable of down regulating
expression of an HIV co-receptor into a restriction
site in the vector. [CONT.]
CLAIMS are included for the following:
(1) s host cell comprising the expression vector
(V1); [CONT.]
AU 2010101342 A4 UPAB: 20110331
WO 2011009862
Y
JP2011015632A
Y
CN101919355A
(2) drink comprising bitterness component (0.050.8 %mass) and bitterness suppression agent.
NOVELTY: The device has a water tank (1)
mounted on a top part of a lifting frame (10). A
water outlet rubber hose (20) is connected with a
bottom part of a side of the water tank. The lifting
frame is provided with a rotation button (11). The
water outlet rubber hose is provided with a block
ball (21).
WO 2011008348
B1 = e.g. H, halo, -CN, -OH, -NO2, -CF3 or -SH;
[CONT.]
An INDEPENDENT CLAIM is also included for a
method of treating a condition resulting from
impaired neurotransmission comprising
administering to an animal, including a healthy
human, a lipophilic Nigella sativa seed extract or
of at least one of its volatile component, and
observing the reduction of impaired
neurotransmission.
Method for processing cooked food waste
(claimed) used in producing pet food.
The method can utilize waste materials to provide FOOD - Preferred Component: The food waste is
feed for stock and/or pets; uses low energy for
derived from grain(s). The food waste includes
INDEPENDENT CLAIMS are included for the
following:
(1) s host cell comprising the expression vector
(V1);
WO 2011008348
N
(2) treating or preventing HIV infection in a patient
involving: transducing hematopoietic cells with the
expression vector (V1) and transplanting the
transduced hematopoietic cells in the patient,
where the transduced hematopoietic cells are
resistant to HIV infection; and [CONT.]
AU 2010101342
Y
AU2010101342B4
116 Processing cooked food waste for producing
pet food involves processing food waste,
increasing moisture content of and then
pressing particulate material to provide
pressed product, and reducing moisture
content of pressed product
HY PRO PTY LTD
AU 2010101342
B4
20110113
NOVELTY: Processing cooked food waste
comprises processing the food waste to provide a
particulate material having a moisture of less than
13 wt.%; increasing the moisture content of and
then pressing the particulate material to provide a
pressed product; and reducing the moisture
content of the pressed product to be less than or
equal to 13 wt.%. [CONT.]
KOREA INST SCI&TECHNOLOGY
117 Protection color for rodent, has thin plate
formed in ring shape, and supporting member
formed at side of color member mounted on
forelegs of rodent for supporting mounted
state of color member
KR 2010137720
A
20101231
KR 2010137720 A UPAB: 20110307
TANG W
118 Tumbler-type dog-burglar-proof chicken
feeder, has cooking vessel whose top end is
formed with circular hole, where lower end of
cooking vessel is designed in tumbler-type arc
form and bottom end of vessel is provided with
plane
CN 201674871
119 Knotted pet food having knot formed in middle WENZHOU PEIDI PET PROD CO LTD
of dried meat bar layer, improves standard of
living of pet
CN 201674962
Method for processing cooked food waste
(claimed) used in producing pet food.
The method can utilize waste materials to provide
feed for stock and/or pets; uses low energy for
converting waste to a usable product; allows the
recovery of the high nutrient content that is
contained within some food waste; provides a low
moisture content stock-feed or pet food that has a
long shelf-life; has ease of processing of
packaged food through mechanized removal of
the waste material from the packaging [CONT.]
Protection color for a rodent.
The color member mounted on the color through METALLURGY - The color member is formed with
the supporting member is scattered, so that stress a transparent aluminum envelope. POLYMERS to the rodent can be reduced.
The color member is formed with a material
selected from a group consisting of
polyoxymethylene, polypropylene, undrawn
polypropylene, inflation polypropylene, biaxially
oriented polypropylene, polystyrene, acrylonitrile
butadiene styrene, polyvinylchloride,
polycarbonate, acryl, urethane, phenol resin,
epoxy, [CONT.]
KR 2010137720
Tumbler-type dog-burglar-proof chicken feeder.
The bottom end of the cooking vessel is provided
with the plane for avoiding the over-swing when
the chicken and duck eat food. The feeder
effectively prevents the dog from stealing the food,
inverts the food of chicken so to avoid wastage of
food and prevents inverting of the cooking vessel
when the chicken and duck battle for the food.
CN 201674871
Knotted pet food.
The knotted pet food has rich nutriments that can
stimulate the interest and appetite of pipe. The
standard of living level of pet is improved. The
entertainment of pet is enriched and the
development of pet food is promoted.
CN 201674962
Pet food nutrition ball.
As the gap between the jerky is filled with the
cowhide chips, the food nutrition ball is featured
with good flavor and taste for the pets. Hence the
appetite of pet is improved and entertainment is
also provided to the pet.
CN 201674958
The bone is nutritious and has excellent taste. The FOOD - Preferred Component: The bone-shaped
bone has new and unique shape and appearance. bonding buttons are formed by bonding the
extending portion of the middle portion of bone.
CN 201674959
The food is nutritious and has excellent flavor and FOOD - Preferred Components: The food is Jhard mouthfeel. The pet-food culture can be
shaped. The covering layer comprises cowhide
improved.
strip and/or chicken strip. The central layer
comprises pork skin coil.
CN 201674960
NOVELTY: The color has a supporting member
(20) formed at a side of a color member (10)
mounted at a neck part of a rodent (100). A thin
plate is formed in ring shape. The side of the color
member is mounted on forelegs of the rodent for
supporting mounted state of the color member.
The color member and the supporting member are
integrally formed. [CONT.]
U
20101222
CN 201674871 U UPAB: 20110310
NOVELTY: The feeder has a cooking vessel
whose top end is formed with a circular hole (1). A
circle of an arched hole (2) is formed at an upper
end of the cooking vessel for chicken and duck to
extend heads to get food. A lower end of the
cooking vessel is designed in a tumbler-type arc
form (3), where a bottom end of the cooking
vessel is provided with a plane (4). [CONT.]
U
20101222
CN 201674962 U UPAB: 20110328
NOVELTY: The knotted pet food comprises a knot
(2) that is formed in the middle of dried meat bar
layer (1).
USE: Knotted pet food.
FOOD - Preferred Component: The food waste is
derived from grain(s). The food waste includes
breads, biscuits, cakes, breakfast cereals, or
muesli bars. Preferred Method: The food waste is
contained within packaging, and the method
includes removing the food waste from the
packaging.
AU 2010101342
ADVANTAGE: The knotted pet food has rich
nutriments that can stimulate the interest and
appetite of pipe. The standard of living level of pet
is improved. The entertainment of pet is enriched
and the development of pet food is promoted.
[CONT.]
120 Pet food nutrition ball, has edible jerky whose
gap is filled with cowhide chips
WENZHOU PEIDI PET PROD CO LTD
CN 201674958
U
20101222
CN 201674958 U UPAB: 20110328
NOVELTY: The ball has an edible jerky (1) that is
knitted for forming a ball. The gap between the
jerky (1) is filled with the cowhide chips (2).
USE: Pet food nutrition ball.
ADVANTAGE: As the gap between the jerky is
filled with the cowhide chips, the food nutrition ball
is featured with good flavor and taste for the pets.
Hence the appetite of pet is improved and
entertainment is also provided to the pet. [CONT.]
121 Bone useful for stimulating appetite and
immunity of pet, obtained by bending and
piling cow skin and dried meat skin, and
arranging bone-shaped bonding buttons at
two ends of bone
WENZHOU PEIDI PET PROD CO LTD
CN 201674959
U
20101222
CN 201674959 U UPAB: 20110323
The bone is useful for stimulating appetite and
NOVELTY: Bone is obtained by bending and piling immunity of pet.
cow skin and dried meat skin, and arranging boneshaped bonding buttons at two ends of the bone.
The middle portion of the bone is cylinder-shaped.
ACTIVITY: Immunostimulant; Anabolic.
WENZHOU PEIDI PET PROD CO LTD
122 Food useful for stimulating appetite and
survival grade of pets, comprises edible
covering layer containing chicken strip, central
layer containing pork skin coil, and cowhide
strip
CN 201674960
U
20101222
USE: The bone is useful for stimulating appetite
and immunity of pet.
ADVANTAGE: The bone is nutritious and has
excellent taste. [CONT.]
CN 201674960 U UPAB: 20110323
The food is useful for stimulating appetite and
survival grade of pets.
N
Y
CN201674962U
WENZHOU PEIDI PET PROD CO LTD
122 Food useful for stimulating appetite and
survival grade of pets, comprises edible
covering layer containing chicken strip, central
layer containing pork skin coil, and cowhide
strip
The food is useful for stimulating appetite and
NOVELTY: Food comprises edible covering layer, survival grade of pets.
central layer and cowhide strip. The covering layer
and cowhide strip are stripped, and wound around
the central layer.
The food is nutritious and has excellent flavor and FOOD - Preferred Components: The food is Jhard mouthfeel. The pet-food culture can be
shaped. The covering layer comprises cowhide
improved.
strip and/or chicken strip. The central layer
comprises pork skin coil.
CN 201674960
The knotted food is useful for pets.
The knotted food has novel and unique shape and FOOD - Preferred Components: The two ends of
appearance, it can increase the appetite of the
two or more dried meat rods are knotted into the
pet, improves the immunity of the pet, and
knot buckles.
enriches the mouth-feel of the pet, thus it has
health benefits.
CN 201674961
Y
Single-screw, low-temperature and wet-process
bulking machine for producing bulked products.
Uses include but are not limited to bulked food,
bulked pet food, bulked aquatic product feed,
bulked livestock feed and bulked urea.
The machine is automatically controlled by the
programmable logic controller (PLC) and capable
of producing bulked products under lowtemperature condition.
CN 201674991
N
ACTIVITY: Anabolic.
123 knotted food useful for pets, comprises a dried WENZHOU PEIDI PET PROD CO LTD
meat rod, where two ends of the dried meat
rod are equipped with knot buckles formed by
knotting the tail end of the dried meat rod
CN 201674961
U
20101222
USE: The food is useful for stimulating appetite
and survival grade of pets.
ADVANTAGE: The food is nutritious and has
excellent flavor and hard mouthfeel. [CONT.]
CN 201674961 U UPAB: 20110321
NOVELTY: knotted food comprises a dried meat
rod, where two ends of the dried meat rod are
equipped with knot buckles formed by knotting the
tail end of the dried meat rod.
USE: The knotted food is useful for pets.
ADVANTAGE: The knotted food has novel and
unique shape and appearance, it can increase the
appetite of the pet, improves the immunity of the
pet, and enriches the mouth-feel of the pet, thus it
has health benefits. [CONT.]
124 Single-screw, low-temperature and wetprocess bulking machine for producing e.g.
bulked products, has moisture detecting
device connected with programmable logic
controller and equipped on double-screw
feeder and conditioner
WU Y
125 Preparing solid dosage form, useful for
treating HIV infection, comprises solidifying
melt comprising HIV protease inhibitor e.g.
ritonavir, water-soluble polymer e.g.
copovidone, and surfactant e.g. sorbitan
monolaurate
ABBOTT LAB
U
20101222
CN 201674991 U UPAB: 20110310
NOVELTY: The machine has a low-temperature
extruding bulking device (5) driven by a motor and
connected with a secondary feeder (4). A tail end
of the low-temperature extruding bulking device is
connected with an extruding mold device (6). An
outer side of the extruding mold device is
equipped with an automatic gap-regulating cutter
device (7), and an electric control system is
connected to a machine frame body (8) [CONT.]
126 Producing biological product (e.g. metabolite) ALNYLAM PHARM INC
in large scale host cell culture comprises
contacting host cell with RNA effector
molecule e.g. small interfering RNA,
modulating target gene expression in host cell,
and isolating the product
127 Isolated polynucleotide for use in vector in
recombinant cell for treating e.g.
neuropsychiatric disorder, has promoter
sequence connected to sequences that
encode light-transducing protein and lightgenerating protein
CN 201674991
UNIV DUKE
US 20110008430
A1
20110113
WO 2011005786
WO 2011005786
A2
20110113
A3
20110324
WO 2011005978
A2
20110113
US 20110008430 A1 UPAB: 20110310
(I) is useful for treating an HIV infection (claimed). (I) has improved oral bioavailability and
pharmacokinetic properties. (I) has improved
NOVELTY: Preparation of a solid dosage form (I),
stability and does not necessitate high vehicle
comprises solidifying a melt which comprises at
volumes. The pharmacokinetic property of (I)
least one HIV protease inhibitor, at least one water(comprising copovidone, Cremophor RH40 (RTM:
soluble polymer and at least one surfactant, where
Polyoxyethyleneglycerol oxystearate), ritonavir
each of the water-soluble polymer has a glass
and lopinavir) was tested in dogs. The results
transition temperature of at least 50 degrees C.
showed that the dose-adjusted area under the
curve in dogs was 0.60 mu g. [CONT.]
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are included for: [CONT.]
WO 2011005786 A2 UPAB: 20110204
The methods are useful for: producing a biological
product in a large scale host cell culture, where
NOVELTY: Producing a biological product in a
large scale host cell culture comprises: contacting the biological product is a polypeptide, metabolite
a host cell in a large scale host cell culture with at or a nutraceutical; selecting a RNA effector
molecule for modulating protein expression in a
least a first RNA effector molecule, where a
cell using the system; and improving a cell line,
portion of the RNA effector molecule is
complementary to at least one target gene of the which is a CHO cell line (all claimed).
host cell; maintaining the host cell culture for a
time sufficient to modulate expression of the target
gene, where the modulation of expression
improves production of a biological product in the
host cell; and isolating the biological product from
the host cell. [CONT.]
The RNA effector molecules are applied at low
concentrations to cells in culture to effect potent,
durable modulation of gene expression, such that
the quality and quantity of biological product that
is produced by a host cell is improved without the
need for extensive cell line engineering.
WO 2011005978 A2 UPAB: 20110127
The polynucleotide allows for tightly controlled
manipulation and monitoring of cell signaling
activity in remote and/or multiple sites
simultaneously so as to expand knowledge basis
relating to human neuropsychiatric disorders.
Isolated polynucleotide for use in vector in a
recombinant cell (claimed) for treating improper
pancreatic function such as diabetes, and
neuropsychiatric disorder. Uses include but are
not limited to treating schizophrenia, autism,
depression, anxiety-related disorders and relapse
behavior.
ORGANIC CHEMISTRY - Preferred Process: The
melt is prepared in an extruder or a twin screw
extruder. The method further comprises: milling
the solidified melt to granules, compacting the
granules, together with at least one additive, into a
tablet, and coating the tablet with a film coat to
produce the dosage form, where the additive is a
flower regulator, a disintegrant, a bulking agent, or
a lubricant [CONT.]
INDEPENDENT CLAIMS are included for:
US 20110008430
BIOLOGY - Preferred Components: The RNA
effector molecule(s) comprises a double-stranded
ribonucleic acid comprising at least two
sequences that are complementary to each other,
where a sense strand comprises a first sequence
and an antisense strand comprises a second
sequence comprising a region of complementarity
which is complementary to at least part of a target
gene, and where the region of complementarity is
10-30 nucleotides in length [CONT.]
Producing a biological product in a large scale
WO 2011005786
host cell culture comprises: contacting a host cell
in a large scale host cell culture with at least a first
RNA effector molecule, where a portion of the
RNA effector molecule is complementary to at
least one target gene of the host cell; maintaining
the host cell culture for a time sufficient to
modulate expression of the target gene, where the
modulation of expression improves production of a
biological product in the host cell; and isolating the
biological product from the host cell [CONT.]
US 20110008430
(1) treating an HIV infection comprising
administering a solid dosage form to a patient
where the dosage form comprises a solid
dispersion of at least one HIV protease inhibitor in
at least one water-soluble polymer and at least
one surfactant; and [CONT.]
INDEPENDENT CLAIMS are also included for the WO 2011005978
following:
N
N
CN201674961U
recombinant cell for treating e.g.
neuropsychiatric disorder, has promoter
sequence connected to sequences that
encode light-transducing protein and lightgenerating protein
WO 2011005978
A9
20110303
NOVELTY: The polynucleotide has a sequence for
encoding a light-generating protein and a
sequence for encoding a light-transducing protein,
where the polynucleotide is a fusion gene
encoding a fusion protein. A promoter sequence is
connected to the sequences that encode the lighttransducing protein and the light-generating
protein, where the light-transducing protein
comprises opsin and the light-generating protein
comprises luciferase [CONT.]
recombinant cell (claimed) for treating improper
pancreatic function such as diabetes, and
neuropsychiatric disorder. Uses include but are
not limited to treating schizophrenia, autism,
depression, anxiety-related disorders and relapse
behavior.
manipulation and monitoring of cell signaling
activity in remote and/or multiple sites
simultaneously so as to expand knowledge basis
relating to human neuropsychiatric disorders.
(1) a recombinant cell comprising a neuron
(2) a method for modulating cell signaling
(3) a genetically modified non-human organism
comprising an isolated polynucleotide
128 New dual functional enzyme useful in
bioengineering field and chemical industry,
obtained from rumen uncultivated
microorganism, comprises amino acid
sequence
UNIV FUDAN
CN 101906406
A
20101208
CN 101906406 A UPAB: 20110323
NOVELTY: A dual functional enzyme having
endoglucanase/xylanase, comprising amino acid
sequence chosen from (a) 1-551 or 22-551 amino
acid sequence (SEQ ID NO: 2) fully defined in the
specification and (b) protein having amino acid
sequence of SEQ ID NO: 2 in which one or more
amino residues are deleted, added, inserted or
substituted, is new. [CONT.]
129 Porcine Lactobacillus plantarum microcapsule BEIJING ACAD AGRIC&FORESTRY SCI
used as food for domestic animals i.e. pigs, is
prepared by mixing bacterium slurry of porcine
Lactobacillus plantarum with protective agent
to prepare bacterium suspension
CN 101912046
ZHANG M
130 Slaughtering waste curing machine for
processing waste of animal has sieve screen
partition board which is arranged at one end of
material tank, and is provided with check valve
at outer side
CN 201663894
131 Feed for cat includes kaoliang protein powder, GAO Y
sweet potato protein powder, fish abdominal
organ powder, freshwater shrimp powder,
duck blood powder, chicken powder, vitamins
A and B, lucid ganoderma powder, and
nutgrass powder
CN 101897389
A
20101215
CN 101912046 A UPAB: 20110315
NOVELTY: Porcine Lactobacillus plantarum
microcapsule is prepared by mixing bacterium
slurry of porcine Lactobacillus plantarum with
protective agent to prepare bacterium suspension.
Sodium alginate solution and microcapsule
substrate are mixed to prepare a precursor. The
precursor is kept in calcium chloride solution to
obtain microcapsule. [CONT.]
U
20101208
CN 201663894 U UPAB: 20110321
NOVELTY: The slaughtering waste curing
machine has main shaft which is provided with a
setting pipe on portion in the material tank. The
material tank is provided with a filling case, and is
material tank is arranged in an interlayer. The
upper side of interlayer is provided with a material
inlet, a flange and a pressure meter, while the
lower side is provided with saddle and material
outlet [CONT.]
A
20101201
CN 101897389 A UPAB: 20110321
NOVELTY: A cat feed comprises (wt.%) kaoliang
protein powder (7-10), sweet potato protein
powder (10-15), bean powder (6-10), whitefish
meal (15-25), fish abdominal organ powder (6-8),
freshwater shrimp powder (4-6), duck blood
powder (4-6), duck intestine powder (8-12),
chicken powder (2-6), vitamin B (1-3), vitamin A (13), mineral substance additive (2-4), salt (1-3),
lucid ganoderma powder (2-4), nutgrass powder
(1-3), malt powder (1-3), Salvia powder (1-3) and
mint powder (by weight). [CONT.]
The dual functional enzyme is useful in
bioengineering field, chemical, textile, food, feed
addictive and medical industries.
Porcine Lactobacillus plantarum microcapsule
used for domestic animals i.e. pigs (all claimed).
BIOTECHNOLOGY - Preparation (Claimed): The
dual functional enzyme is prepared from rumen
uncultivated microorganism. Preferred Vectors:
The recombined expression vector is Escherichia
coli expression vector, yeast expression vector,
Bacillus subtilis expression vector, Lactobacillus
expression vector, filamentous fungi expression
vector, insect expression vector or mammal cell
expression vector. [CONT.]
The porcine Lactobacillus plantarum microcapsule
has excellent acid resistant property, improves
oxidation resistance and immune power of pig,
and prevents diarrhea.
(4) an isolated fusion protein comprising two
amino acid sequences
(5) a method for identifying a neural pathway
involved in a disease state [CONT.]
INDEPENDENT CLAIMS are included for the
CN 101906406
following:
(1) gene encoding protein comprising a 1663 base
pair sequence (SEQ ID NO: 1) fully defined in the
specification, where the protein comprises a 551
amino acid sequence (SEQ ID NO: 2) fully defined
in the specification; and [CONT.]
N
CN 101912046
N
INORGANIC CHEMISTRY - Preferred
Components: Porcine Lactobacillus plantarum
microcapsule further comprises 0-10% talcum
powder and water. ORGANIC CHEMISTRY Preferred Components: Porcine Lactobacillus
plantarum microcapsule further comprises 3-10%
sucrose, 2-5% lactose, 2-5% skimmed milk, 0-2%
glucose, 0-2% glycerine and 0-10% dextrin.
Slaughtering waste curing machine for processing Provides a machine with simple process, and
waste of animal.
produces animal-source protein feed with qualified
contents of water and fat.
Feed for cat (claimed).
CN 201663894
An INDEPENDENT CLAIM is included for
CN 101897389
preparation of cat feed comprising:
(A) mixing the powder and meal, putting into a ringdie stirrer and stirring for 100 minutes;
(B) taking out, putting into a dryer and drying for 12 hours;
Y
CN101897389A
(C) taking out, cooling, putting into a ring-die
crusher and crushing into the powder completely;
132 Pet food for supplementing trace elements in
cats comprises trace elements, sucrose,
flavoring agent, taurine, additive and bread
yeast powder
133 Hair-beautifying pet food for cat comprises
vitamin, microelement, unsaturated acid,
starch, sucrose, seasoning agent, additive,
and bread yeast powder
TIANJIN JIHE SCI&TECHNOLOGY CO LTD
CN 101897393
A
20101201
CN 101897393 A UPAB: 20110321
NOVELTY: A pet food comprises (pts.wt.) trace
elements (5.45-17.9), sucrose (10-40), flavoring
agent (5-20), taurine (0.5-2), additive (5-15 ) and
bread yeast powder (10-40).
TIANJIN JIHE SCI&TECHNOLOGY CO LTD
CN 101897394
A
20101201
DETAILED DESCRIPTION: An INDEPENDENT
CLAIM is included for preparation of pet food
comprising: [CONT.]
CN 101897394 A UPAB: 20110321
(D) taking out, putting into the stirrer again and
stirring for 150 minutes; [CONT.]
Pet food for supplementing trace elements in cats The cat food is uniformly distributed in stomach
ORGANIC CHEMISTRY - Preferred Components: An INDEPENDENT CLAIM is included for
CN 101897393
(claimed).
after being chewed in oral cavity of cat. About
The trace elements comprise (pts.wt.) magnesium preparation of pet food comprising:
10% of product stops in stomach for 5.5 hours and sulfate (3-10), ferrous sulfate heptahydrate (1-2), (A) mixing each component except trace element
the product is low in residue in intestinal tract, low copper sulfate (0.1-0.5), manganese sulfate (0.05- by the method of increment by equal quantity for
in side effect, quick to absorb and high in
0.3), zinc sulfate (1-4), calcium sulfate (0.2-0.8)
110-130 seconds, sieving by 100-mesh standard
bioavailability. The food can effectively prevent
and sodium selenite (0.1-0.3). The additive is fish sieve to form base material mixture, and detecting
gastric acid from invading medicine, which is good bone powder. Preferred Method: The detecting
the uniformity of nutritious components by uniform
for increasing the stability of medicine.
standard of the gold detecting apparatus is as
point detecting method; [CONT.]
follows: stainless steel less than phi 2 [CONT.]
Pet food for beautifying hair of cat (claimed).
NOVELTY: A hair-beautifying pet food comprises
(pts.wt.) vitamin (3-8.7), microelement (0.0120.046), unsaturated acid (0.15-0.5), starch (4580), sucrose (15-40), seasoning agent (1-4),
additive (2-6), bread yeast powder (3-8).
The pet food can be widely used for different ages ORGANIC CHEMISTRY - Preferred Components:
of cat, and can be mixed with other cat foods, so The pet food comprises (pts.wt.) vitamin C (3-8),
that the cat has healthy skin and smooth hair.
vitamin B1 (0.0002-0.0008), vitamin B6 (0.00050.002), vitamin E (0.01-0.05), niacinamide (0.0060.01), calcium pantothenate (0.002-0.006), and
folic acid (0.000-10.0003). The microelement
includes (pts.wt.) zinc sulfate (0.002-0.006) and
manganese sulfate (0.01-0.04). The unsaturated
acid includes (pts.wt. [CONT.]
DETAILED DESCRIPTION: An INDEPENDENT
CLAIM is included for preparation of hairbeautifying pet food comprising: [CONT.]
134 Tooth-grinding food for pets has dry meat strip WENZHOU PEIDI PET PROD CO LTD
having both ends that are knitted and wound
outside dry meat rod
135 Bone like edible food for pet dog includes belt WENZHOU PEIDI PET PROD CO LTD
shaped wrapping layer formed to surround
surface of meat rod arranged in number eight
formation
CN 201624107
U
20101110
CN 201624107 U UPAB: 20110302
CN 201624108
U
20101110
CN101897393A
Y
CN101897394A
(B) uniformly mixing the vitamin, microelement
and unsaturated acid, and forming the outer
coating mixtures; [CONT.]
Tooth-grinding food for pets.
Provides the pet food which comprises the edible
dry meat rod and the dry meat strip, thus providing
functions to grind teeth of pet and to clean buccal
cavity and teeth.
CN 201624107
Bone like edible food for pet dog.
Provides a food made of edible meat that is tasty
and has a balanced nutrition favored by pet dogs.
CN 201624108
Ball shaped food for pets.
Raises interest in play and eating appetite of pet.
CN 201624110
Y
CN201624110U
Food with tooth cleaning property for pets.
Raises interest of pet in taking food which has an
oral cavity cleaning property to maintain teeth of
pet clean.
CN 201624109
Y
CN201624109U
NOVELTY: The tooth-grinding food has an edible
dry meat rod (1) and a dry meat strip (2). Both
ends of the dry meat strip are knitted and wound
outside the dry meat rod.
USE: Tooth-grinding food for pets.
ADVANTAGE: Provides the pet food which
comprises the edible dry meat rod and the dry
meat strip, thus providing functions to grind teeth
of pet and to clean buccal cavity and teeth.
[CONT.]
CN 201624108 U UPAB: 20110307
An INDEPENDENT CLAIM is included for
CN 101897394
preparation of hair-beautifying pet food
comprising:
(A) mixing the starch, sucrose, seasoning agent,
additive and bread yeast powder for 110-130
seconds, passing 100-mesh, forming the base
material mixtures, detecting the nutrient content
uniformity according to the uniform point detecting
method;
Y
NOVELTY: A bone like edible food includes belt
shaped wrapping layer (2) formed to surround
surface of meat rod (1) arranged in number eight
formation. The meat rod is made of visceras of
pig, beef, chicken, duck, domestic animal or
poultry with surface colored with edible coloring
matter.
USE: Bone like edible food for pet dog. [CONT.]
WENZHOU PEIDI PET PROD CO LTD
136 Ball shaped food for pets includes food
stuffing arranged inside the packing ball
comprising of dried skin and cow leather sewn
using thread like pig skin
CN 201624110
U
20101110
CN 201624110 U UPAB: 20110307
NOVELTY: A ball shaped food includes food
stuffing (2) arranged inside the packing ball (1)
comprising of dried skin and cow leather sewn
using thread like pig skin. The food stuffing is
comprised of pork, beef, chicken, duck, fowl or
fowl viscera.
USE: Ball shaped food for pets.
WENZHOU PEIDI PET PROD CO LTD
137 Food with tooth cleaning property for pets
includes dried meat pressed into rectangular,
square or circular sheet or bone-shaped figure
CN 201624109
U
20101110
ADVANTAGE: Raises interest in play and eating
appetite of pet. [CONT.]
CN 201624109 U UPAB: 20110307
NOVELTY: A food includes dried meat (1) pressed
into rectangular, square or circular sheet or boneshaped figure. An edible leather body (2) is
embedded inside the dried meat.
USE: Food with tooth cleaning property for pets.
ADVANTAGE: Raises interest of pet in taking food
which has an oral cavity cleaning property to
maintain teeth of pet clean. [CONT.]
138 Producing mung bean beverage containing
mung bean granules comprises e.g. soaking
washed mung bean and mung bean peel in
water, mixing the liquids, adding stabilizer,
sweetener, acidity regulator, and edible
essence, sterilizing and canning
UNIV CHINESE AGRIC
139 Peptide protein preparation used in fodder
includes taking micro-algae grease bacterium
dreg to perform fermentation, inoculating,
adding water and mixing, fermenting, drying,
and crushing
HU J
CN 101878940
A
20101110
CN 101878940 A UPAB: 20110307
NOVELTY: Producing a mung bean beverage
comprising mung bean granules comprises:
washing mung bean, separating mung bean peel;
soaking the mung bean and mung bean peel
separately in water; mixing the mung bean soaked
liquid and the mung bean peel soaked liquid, precooking the mung bean granules; sterilizing;
adding stabilizer to the mung bean mixed liquid
and filtering [CONT.]
CN 101880704
A
20101110
CN 101880704 A UPAB: 20110310
The method is useful for producing a mung bean
beverage.
Method for producing peptide protein used in
NOVELTY: A peptide protein is prepared by taking fodder for cultivation of special fur and animal
plant protein raw material as auxiliary material to feather (claimed).
perform fermentation, inoculating the material,
adding water and mixing, fermenting, drying, and
crushing. The material comprises micro-algae
grease bacterium dreg.
The method: sterilizes solid and liquid separately
and then carries out mixed encapsulation;
prepares beverage containing integrated mung
bean granules, with good physical and chemical
quality, and excellent mouth feel and flavor; and
exhibits quality guarantee period similar to the
conventional mung bean beverage.
FOOD - Preferred Method: The integral
sterilization is high-pressure sterilization or nonthermal sterilization. The sterilization of the mung
bean granules with bottle uses thermal
sterilization, high-pressure sterilization or nonthermal sterilization, where thermal sterilization is
carried out at 121 degrees C for 15 minutes.
[CONT.]
Producing a mung bean beverage comprising
CN 101878940
mung bean granules comprises: (i) washing mung
bean in clean water, separating mung bean peel
and removing the impurities and washing with
clean water; (ii) soaking the washed mung bean in
water, where the mass-volume ratio is 1:20 for 6
hours at room temperature to 60 degrees C, and
soaking the washed mung bean peel in water,
where the mass-volume ratio is [CONT.]
N
The method uses unsaturated fatty acid
BIOTECHNOLOGY - Preferred Materials: The
component of micro-algae grease bacterium dreg functional strain is Bacillus and Saccharomycete.
which can reduce negative effect to animal. Amino
acid structure in the product can be more
balanced and rational. The product has good
animal absorption rate and biological use rate.
Multiple anti-nutrition factors in fermentation
substrate can be reduced or eliminated. [CONT.]
CN 101880704
N
N
140 Processing and storing Trichosanthes kirilowii ZHEJIANG AGRIC SCI ACAD
maxim seed, comprises selecting raw material,
preparing flavoring liquid, boiling at high
pressure and flavoring, drying in vacuum,
packaging by composite film and marketing or
storing
CN 101878931
A
20101110
USE: Method for producing peptide protein used
in fodder for cultivation of special fur and animal
feather (claimed). [CONT.]
CN 101878931 A UPAB: 20110310
The method is useful for processing and storing
NOVELTY: Processing and storing Trichosanthes Trichosanthes kirilowii maxim seed.
kirilowii maxim seed, comprises: (i) taking
complete Trichosanthes kirilowii maxim seed as
raw material; (ii) mixing common salt, spices,
antioxidants and water to obtain flavoring liquid;
(iii) adding the raw material and the flavoring liquid
into a high pressure equipment and heating to 121
degrees C; [CONT.]
The method: improves the conventional technique
of processing the Trichosanthes kirilowii maxim
seed; avoids the processing at high temperature
and high pressure, which inhibits the hydrolytic
rancidity and the oxidizing rancidity of the grease
obtained from the Trichosanthes kirilowii maxim
seed and reduces the acid value and the peroxide
value by 39.0% and 36. [CONT.]
FOOD - Preferred Components: The spice
comprises a mixture of raw ginger, fennel, anise,
pepper and Cassia bark, which are mixed in a
weight ratio of 2:1:5:1:1. ORGANIC CHEMISTRY Preferred Components: The antioxidant comprises
a mixture of tertiary butyl hydroquinone and
butylated hydroxy toluene, which are mixed in a
weight ratio of 1:1. [CONT.]
Processing and storing Trichosanthes kirilowii
CN 101878931
maxim seed, comprises: (i) removing abortive,
small or mildewed seeds, removing worm eaten
seeds and impurities, and taking complete
Trichosanthes kirilowii maxim seed as raw
material for further use; (ii) mixing common salt,
spices, antioxidants and water in a ratio of 8-12
wt.%:0.5-1.4 wt.%:0.3-0.8 wt.%:85.8-91.2 wt.% to
obtain flavoring liquid for further use [CONT.]
141 Composition, useful as an artificial tear to treat ALLERGAN INC
keratoconjunctivitis sicca and dry eye
syndrome and improve visual acuity of a
person, who suffers from dry eye syndrome,
comprises mixture of castor oil with another
oil e.g. olive oil
WO 2010141648
A2
20101209
WO 2010141648 A2 UPAB: 20110106
WO 2010141648
20110310
NOVELTY: Composition comprises a mixture of
castor oil with another oil.
The advantages of using castor oil, alone, while
substantially reducing the viscosity is obtained by
the addition of small amounts of olive oil in the
composition. The composition has improved
spreading properties and lower viscosity, which is
favorable for use in treatment of dry eye.
BIOLOGY - Preferred Components: The other oil
is a food oil or a healthy oil including olive oil or
soybean oil (both preferred), sesame oil, maize
oil, safflower oil, cottonseed oil or peanut oil. The
mixture comprises 5-80, preferably 5-50 or 20-80
wt.% of castor oil. The mixture of castor oil and the
other oil is emulsified in an aqueous phase. The
mixture comprises 70 wt. [CONT.]
INDEPENDENT CLAIMS are also included for:
A3
The composition is useful as an artificial tear for:
treating keratoconjunctivitis sicca; improving the
visual acuity of a person, who suffers from dry eye
syndrome (all claimed); and treating dry eye
syndrome. Test details are described but no
results given.
(I) is useful as animal bedding (claimed). (I) is
useful: in power generation (preferably as a fuel
supplement or fuel replacement for coal or other
NOVELTY: Compacted body (I), comprises first
fossil fuel(s) in co-firing power plants); as waste
particles comprising a biomass material, and
absorbent (preferably as cat litter for absorbing
second particles comprising a different material,
where the compacted body resists fragmentation. liquid and/or solid waste products); as bedding for
various animals including fowl, horses, and
rabbits; and in landscaping and home heating.
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are also included for:
(I): is a mechanically stable combination of
particles; is easily separated during processing in
an intended application, or resists fragmentation
or spalling when handled by conventional feeding,
transporting, and conveying apparatus; is typically
formed under pressure (e.g. compression or
compaction) by for e.g. [CONT.]
ORGANIC CHEMISTRY - Preferred Components:
(I) is combustible. The second particles are not
combustible. (I) further comprises third particles of
composition different from that of the first particles
and the second particles. (I) has: a total moisture
content of 9 wt.% or less; and an energy density of
at least 7000 British thermal unit (BTU) per pound
when combusted. [CONT.]
INDEPENDENT CLAIMS are also included for:
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are also included for:
(1) treating keratoconjunctivitis sicca, comprising
providing the composition, and administering the
composition topically to the ocular surface or
immediate vicinity of an eye of a patient; [CONT.]
142 Compacted body, useful e.g. as waste
absorbent (as cat litter for absorbing liquid
and/or solid waste products), comprises first
particles comprising a biomass material, and
second particles comprising a different
material
AMERICAN PELLET SUPPLY LLC
WO 2010138514
A2
20101202
US 20100300368
A1
20101202
WO 2010138514
A3
20110303
WO 2010138514 A2 UPAB: 20101221
(1) a collection of compacted bodies in a
container, where each of the compacted bodies
have the composition or properties; and [CONT.]
WO 2010141648
N
(1) treating keratoconjunctivitis sicca, comprising
providing the composition, and administering the
composition topically to the ocular surface or
immediate vicinity of an eye of a patient; [CONT.]
(1) a collection of compacted bodies in a
container, where each of the compacted bodies
have the composition or properties; and
(2) a method of preparing (I), comprising:
processing a biomass feedstock (101) to convert
raw feedstock to a form comprising the first
particles; and concurrently compacting the first
particles and the second particles to produce
[CONT.]
WO 2010138514
US 20100300368
N
143 Pet food, useful as animal feeds, such as dog IAMS CO
and cat feeds, comprises an animal preference
CORRIGAN P J
enhancing amount of a fat band
WO 2010138372
A2
20101202
WO 2010138372 A2 UPAB: 20101216
US 20100303968
A1
20101202
SUNVOLD G D
WO 2010138372
A3
20110324
UNIV MARYLAND BALTIMORE
WO 2010118007
WO 2010118007
A2
20101014
A3
20110310
NOVELTY: Pet food comprises an animal
preference enhancing amount of a fat band.
DETAILED DESCRIPTION: An INDEPENDENT
CLAIM is included for a container of pet food
comprising kibbles.
USE: The pet food is useful as animal feeds, such
as dog and cat, horses, cows, ferrets, rabbits,
pigs, rats, mice, gerbils, hamsters and horses
feeds. [CONT.]
WO 2010118007 A2 UPAB: 20101101
As genetically modified host cell (claimed), for
NOVELTY: New genetically modified host cell (C1) forming biofuels such as ethanol; for making
sugar; and in food, beer, wine, animal feeds,
is modified with polynucleotide (n1) having
textile production and laundering, pulp and paper
sequence of endoglucanase (A) selected from
Cel5A, Cel5G, Cel5H, and Cel5J; polynucleotide industry, and agricultural industries.
144 New genetically modified host cell for
producing biodiesel e.g. ethanol is modified
with polynucleotide having sequence of
specific endoglucanase, or polynucleotide
encoding polypeptide having sequence of the
endoglucanase
FOOD - Preferred Components: The fat band has An INDEPENDENT CLAIM is included for a
a value of greater than or equal to 3900 or 4000. container of pet food comprising kibbles.
The pet food comprises a nutritionally balanced
kibble. The kibble comprises a first coating (102)
and a second coating (103). The first coating
comprises a solids component, and the second
coating comprises a fat component. The pet food
comprises an extruded core (101) having a water
content of less than 12% and the coating of 0
[CONT.]
The genetically modified host cell provides
improved degradative endo-1,4- beta -glucanase
enzymes (Cel5A, Cel5G, Cel5H, or Cel5J) for
plant material i.e. plant cell wall degradation,
where the endoglucanase is found in
Saccharophagus degradans and is useful for
forming biofuels such as ethanol; [CONT.]
BIOTECHNOLOGY - Preferred Cell: The host cell
is Saccharophagus degradans. Recombinant
Methods (claimed): The method for producing the
genetically modified host cell (C1) containing the
isolated nucleic acid encoding the endoglucanase
(A) polypeptide, involves: transforming a host cell
with an expression vector comprising the nucleic
acid (n1), (n2), (n3), (n4) or (n5). [CONT.]
New genetically modified host cell (C1) is
WO 2010118007
genetically modified with at least one isolated
nucleic acid selected from a polynucleotide (n1)
having a sequence of an endo-1,4- beta glucanase (A) selected from Cel5A, Cel5G,
Cel5H, and Cel5J; a polynucleotide (n2) encoding
a polypeptide having a sequence of the endo-1,4beta -glucanase (A); [CONT.]
The isolated dsRNA reduces KRAS target gene
expression of at least 10%, at least 50%, at least
80-90%, at least 95%, at least 98%, or at least
99% when the double stranded nucleic acid is
introduced into a mammalian cell; reduces KRAS
mRNA levels of at least 90% at least 8 days after
the cell is contacted with the dsRNA; or reduces
KRAS mRNA levels of at least 70% at least 10
days after the cell is [CONT.]
BIOTECHNOLOGY - Preparation (Disclosed): The
isolated double stranded ribonucleic acid (dsRNA)
is synthesized by solid phase oligonucleotide
synthesis methods as described for 19-23mer
siRNAs. Preferred Ribonucleic Acid: In the
isolated dsRNA, starting from the first nucleotide
(position 1) at the 3' terminus of the first
oligonucleotide strand, position 1, 2 and/or 3 is
substituted with a modified nucleotide [CONT.]
An isolated double stranded ribonucleic acid
WO 2010115206
(dsRNA) comprising first and second nucleic acid
strands and a duplex region of at least 25 base
pairs, is new. In the dsRNA, the second strand of
the dsRNA comprises 1-5 single-stranded
nucleotides at its 3' terminus, where the second
oligonucleotide strand is complementary to a
target V-Ki-ras2 Kirsten rat sarcoma viral
oncogene homolog (KRAS) cDNA sequence
selected from the 1452 nucleotides sequences as
given in the specification e [CONT.]
US 20110021604
WO 2010111018 A1 UPAB: 20101014
The Antibody drug conjugate is useful for: treating
tumor/cancer, or inhibiting/reducing the growth of
NOVELTY: Antibody drug conjugate comprising
cancer/tumor cells in a subject (mammal), where
an antibody or antigen binding fragment,
the cancer includes colon cancer, pancreatic
conjugated to monomethyl auristatin-E, is new.
cancer, ovarian cancer, prostate cancer or gastric
The antibody or fragment comprises: a heavy
chain variable region containing Gln-20 to Ser-143 cancer (all claimed); and prognosis, prophylaxis
and diagnosis of cancer. Test details are
of SEQ ID NO: 20 (comprising a fully defined
described but no results given.
sequence of 470 amino acid as given in the
specification), and light chain variable region
containing Asp-23 to Arg-130 of SEQ ID NO: 22
[CONT.]
The Antibody drug conjugate: exhibits synergistic
effect; enables the use of reduced dosages of
chemotherapy (or other therapies) or less frequent
administration, in the patients and particularly for
those who do not tolerate the toxicity of the
chemotherapeutic agent; and allows for a targeted
delivery of drugs without causing damage to the
normal cells.
BIOTECHNOLOGY - Preparation: No preparation
method is given. Preferred Components: The
antibody comprises the heavy chain containing
the amino acid sequence from Gln-20 to Lys-469
of SEQ ID NO: 20; and the light chain containing
the amino acid sequence from Asp-23 to Cys-236
of SEQ ID NO: 22. The antibody is: a fully human
antibody; or recombinantly produced. [CONT.]
Antibody drug conjugate comprising an antibody
or antigen binding fragment, conjugated to
monomethyl auristatin-E (MMAE), is new. The
antibody or fragment comprises: a heavy chain
variable region containing Gln-20 to Ser-143 of
SEQ ID NO: 20 (comprising a fully defined
sequence of 470 amino acid as given in the
specification), and the light chain variable region
containing Asp-23 to Arg-130 of SEQ [CONT.]
WO 2010111018
US 20100330107
DE 202010004926 U1 UPAB: 20100928
The pancreatin pellets does not comprise
auxiliaries and binding agents and thus exhibit
increased activity and avoid the deterioration of
the pharmacological effect of the pellets.
PHARMACEUTICALS - Preferred Components:
The pellet is a micropellet. The pancreatin is
obtained from the pancreas of a mammal. The
pellet exhibits a core (2) and a coating, where the
core is formed only of pancreatin. The coating
consists of pancreatin. The coating is formed of
auxiliaries and binding agents. The coating
exhibits a first inner layer which covers the core
made of pancreatin and a second outer layer (4)
[CONT.]
INDEPENDENT CLAIMS are also included for:
DE 202010004926
US 20110052706
ORGANIC CHEMISTRY - Preferred Components:
(I) is present in: a food product at a concentration
of 0.0001-5 (preferably 0.001-0.5) wt.%; a
cosmetic composition at a concentration of 0.0011 (preferably 0.01-0.5) wt.%; and indoor house, in
agriculture, in animals and in human bodies at a
concentration of 0.0001-5 (preferably 0.001-2
wt.%). (I) is present on surfaces at a concentration
Use of a cationic surfactant (I) derived from the
WO 2010084052
condensation of fatty acids and esterified dibasic
amino acids having a structure of formula (R3(CH2)n-CH(COOR2)(NHR1)+ X-) as an acaricidal
agent, is claimed.
WO 2010115206
A2
20101007
WO 2010115206 A2 UPAB: 20101027
WO 2010115206
A3
20101125
US 20110021604
A1
20110127
NOVELTY: An isolated double stranded
ribonucleic acid (dsRNA) comprising first and
second nucleic acid strands and a duplex region
of specific base pairs, is new.
DETAILED DESCRIPTION: An isolated double
stranded ribonucleic acid (dsRNA) comprising first
and second nucleic acid strands and a duplex
region of at least 25 base pairs, is new. [CONT.]
US 20110059187
WO 2010111018
US 20100330107
A1
20110310
A1
20100930
A1
20101230
SEATTLE GENETICS
WO 2010111018
A8
20110303
NORDMARK ARZNEIMITTEL GMBH&CO KG
DE 202010004926
U1
20100902
US 20110052706
A1
20110303
JP 2011046682
A
20110310
EP 2295039
A1
20110316
(1) a pharmaceutical composition comprising the
pancreatin pellets in a pharmacologically effective
amount; and [CONT.]
WO 2010084052
A2
20100729
WO 2010084052 A2 UPAB: 20100826
AGENSYS INC
146 New antibody drug conjugate comprising an
antibody or antigen binding fragment
SEATTLE GENETICS INC
conjugated to monomethyl auristatin-E, useful
for prognosis, prophylaxis, diagnosis and
treatment of cancer e.g. colon cancer, gastric
cancer or gastric cancer
148 Use of a cationic surfactant derived from the
condensation of fatty acids and esterified
dibasic amino acids, as an acaricidal agent
The pet food has enhanced vitamin delivery
stability, reduced cost savings and increased
animal preference response.
(n2) encoding polypeptide having sequence of the
endoglucanase (A); polynucleotide (n3) having
greater than or equal to 95% sequence identity to
polynucleotide having sequence encoding the
processive endoglucanase (A) [CONT.]
145 New isolated double stranded ribonucleic acid DICERNA PHARM INC
comprising first and second nucleic acid
strands and duplex region of specific base
pairs, used such as for inhibiting growth of
tumor cell, and for treating e.g. polycystic
kidney disease
147 Pancreatin pellet formed only of pancreatin
without auxiliaries and binding agents, useful
for producing medicament, as nutriment or
foodstuff, as dietary supplement and as
medicament for easier oral administration
The pet food is useful as animal feeds, such as
dog and cat, horses, cows, ferrets, rabbits, pigs,
rats, mice, gerbils, hamsters and horses feeds.
LAB MIRET SA
For reducing expression of a target KRAS gene in
a mammal of mammalian cell; for selectively
inhibiting the growth of a cell, where the cell is a
tumor cell of a subject or the cell is a tumor cell in
vitro, or the cell is a human cell; in a mammalian
cell; and for treatment of cancer (e.g. [CONT.]
The pancreatin pellet is useful: for producing a
medicament; as a nutriment or foodstuff; or as a
dietary supplement; and as a medicament for
NOVELTY: Pancreatin pellet (1) formed only of
pancreatin without auxiliaries and binding agents, easier oral administration (all claimed). The
pancreatin is also useful for treating digestive
is claimed.
disorders based on pancreatic insufficiency.
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are also included for:
(I) is useful as acaricidal agent, against acarina
(I) is highly effective against microbial
(mites, ticks and other similar pests) to prevent or proliferation. Intake of (I) is safe to humans and
inhibit their presence in foods, cosmetic products, mammals. (I) is environmental friendly.
medical applications, indoor atmosphere,
agriculture and onto animals and human bodies.
The mortality rate of (I) (lauramide of arginine
hydrochloride) (1%) was tested in adult ticks of
Hyalomma marginatum rufipes. [CONT.]
WO 2010138372
US 20100303968
N
N
US 20110059187
N
N
(1) a pharmaceutical composition comprising the
pancreatin pellets in a pharmacologically effective
amount; and
(2) a pancreatin pellet prepared by: (a)
comminuting the pork or beef derived pancreatic
tip and subjecting it to autolysis, (b) obtaining a
sieve filtrate by filtering the intermediates obtained
after (a), (c) precipitating the enzymes from the
[CONT.]
N
149 Arrangement for on-line near-infrared
measurement of ingredients of grains in e.g.
flour mill utilized in industrial bakery, has
measuring probes separated from
spectrometer and connected with
spectrometer through lines i.e. optical fibers
DUEBENDORFER U
WO 2010084052
A3
20110324
CH 700157
A2
20100630
HERSCHE M
agriculture and onto animals and human bodies.
NOVELTY: Use of a cationic surfactant (I) derived The mortality rate of (I) (lauramide of arginine
from the condensation of fatty acids and esterified hydrochloride) (1%) was tested in adult ticks of
Hyalomma marginatum rufipes. [CONT.]
dibasic amino acids, as an acaricidal agent, is
claimed.
DETAILED DESCRIPTION: Use of a cationic
surfactant (I) derived from the condensation of
fatty acids and esterified dibasic amino acids
having a structure of formula (R3-(CH2)nCH(COOR2)(NHR1)+ X-) as an acaricidal agent,
is claimed. [CONT.]
CH 700157 A2 UPAB: 20110315
NOVELTY: The arrangement has measuring
probes spatially separated from a spectrometer.
The probes are connected with the spectrometer
through lines i.e. optical fibers, for transmission of
spectra to the spectrometer. The spectrometer is
connected with a control unit. The measuring
probes are provided for measurement of raw
product, intermediate product and end product
[CONT.]
Arrangement for on-line near-infrared (NIR)
measurement of ingredients of grains in a flour
mill utilized in an industrial bakery and in a fodder
mill (all claimed) utilized to produce fodder for
domestic and pet animals, fish and shell fish. Can
also be used for oil production from oil seeds, for
treating chips and white flakes, in a high
performance plant for processing biomass to
produce energy [CONT.]
1 (preferably 0.01-0.5) wt.%; and indoor house, in
agriculture, in animals and in human bodies at a
concentration of 0.0001-5 (preferably 0.001-2
wt.%). (I) is present on surfaces at a concentration
of 0. [CONT.]
The arrangement enables on-line near-infrared
measurement of the ingredients of the grains for
process monitoring and controlling the mills in a
simple manner.
X- = counterion derived from an organic or
inorganic acid, preferably Br-, Cl-, or HSO4-, or an
anion on the basis of a phenolic compound;
[CONT.]
An INDEPENDENT CLAIM is also included for a
method for on-line near-infrared (NIR)
measurement of ingredients of grains in
production volumes in flour and fodder mills.
CH 700157
N
ZIMMERMANN R
150 Human serum albumin linker conjugate, useful MERRIMACK PHARM INC
to treat e.g. proliferative, autoimmune and
cardiovascular diseases, comprises human
FELDHAUS M
serum albumin linker, and first and second
binding moieties comprising e.g. antibodies,
hormones and ligands
WO 2010059315
A1
20100527
US 20110059076
A1
20110310
WO 2010052467
A2
WO 2010052467
A3
WO 2010059315 A1 UPAB: 20100614
The HSA linker conjugate is useful: for treating a
disease or disorder in a patient (mammal); and
treating a tumor (all claimed). The HSA linker
NOVELTY: Human serum albumin (HSA) linker
conjugate is also useful for e.g. treating:
conjugate comprises: a HSA linker comprising an proliferative diseases including e.g. cancer,
amino acid sequence of SEQ ID NO: 6-15
melanoma, clear cell sarcoma, head and neck
(Sequences not defined here may be found at
cancer, bladder cancer, breast cancer, colon
ftp://ftp.wipo.int/pub/publishedpctsequences/public cancer, ovarian cancer, endometrial cancer,
ation); and first and second binding moieties
gastric cancer and pancreatic cancer [CONT.]
comprising antibodies, single-chain variable
fragment (Fv) molecules, bispecific single chain
Fv [CONT.]
The composition, when tested in a nude mouse
human xenograft model using human breast tumor
cells at a first dosage of the agent and a second
dosage of the HSA linker conjugate, the
combination provides greater efficacy than is
provided by the first dosage of the therapeutic
agent alone or the second dosage of the HSA
linker conjugate alone in the same model. [CONT.]
BIOLOGY - Preferred Components: The HSA
linker comprises the amino acid sequence of SEQ
ID NO: 1 (Sequences not defined here may be
found at
ftp://ftp.wipo.int/pub/publishedpctsequences/public
ation). The first binding moiety specifically binds verb-b2 erythroblastic leukemia viral oncogene
homolog (ErbB)3 with a dissociation constant (Kd)
of 16 nM and the second binding moiety
specifically binds ErbB2 with Kd of 0 [CONT.]
20100514
WO 2010052467 A2 UPAB: 20100604
20110324
NOVELTY: Canine foodstuff or oral care product,
comprises canine oral cavity probiotic.
The canine foodstuff including kibble, wet food,
semi-wet food, chew or drink, oral care product
including toothpaste, gel or mouthwash, and
composition including foodstuff, oral care product
or pharmaceuticals are useful for improving or
maintaining canine oral health in canine animal
(all claimed) and preventing and/or treating oral
diseases including periodontal disease or
gingivitis.
The canine foodstuff or oral care product provides BIOLOGY - Preferred Components: The canine
permanent teeth for lifelong.
oral cavity probiotic is a Frigovirgula sp. or a
Neisseria sp.. The Frigovirgula sp. is
F.patagoniensis. The canine oral cavity probiotic
includes one or more of the strains e.g. NCTC
13429 or NCTC 13431. Preferred Antibody: The
antibody or its fragment specifically binds with the
bacterial strain or its portion. The antibody or its
fragment is monoclonal antibody [CONT.]
The method is useful for producing fermented
feed (claimed) for livestock, where the feed
provides antibacterial activity.
The method reduces processing cost of food
waste byproducts, and produces feed at high
yield. The feed is non-toxic.
Human serum albumin (HSA) linker conjugate
WO 2010059315
comprises: a HSA linker comprising an amino acid
sequence of SEQ ID NO: 6-15 (Sequences not
defined here may be found at
ftp://ftp.wipo.int/pub/publishedpctsequences/public
ation); and first and second binding moieties
comprising antibodies, single-chain variable
fragment (Fv) molecules, bispecific single chain
Fv ((scFv')2) molecules, domain antibodies,
diabodies, triabodies, hormones, antigen-binding
fragments (Fab), F(ab')2 molecules, tandem scFv
fragments, receptors, ligands and/or aptamers or
their biologically-active fragments [CONT.]
US 20110059076
N
HUHALOV A
MCDONAGH C
MARS INC
151 Canine foodstuff or oral care product useful
for improving or maintaining canine oral health
and preventing and/or treating oral diseases
e.g. gingivitis in canine animal, comprises
canine oral cavity probiotic
INDEPENDENT CLAIMS are included for the
WO 2010052467
following:
(1) bacterial strain (S1) NCTC 13431, comprising
16S ribosomal RNA (rRNA) gene comprising (a)
base sequence having a 1425 base pairs
sequence (SEQ ID NO: 1) fully defined in the
specification, or (b) base sequence exhibiting 97%
or more homology with the base sequence of SEQ
ID NO: 1, bacterial strain (S2) NCTC 13429,
comprising 16S rRNA gene [CONT.]
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are included for the following:
(1) bacterial strain (S1) NCTC 13431, comprising
16S ribosomal RNA (rRNA) gene comprising (a)
base sequence having a 1425 base pairs
sequence (SEQ ID NO: 1) fully defined in the
specification, or (b) base [CONT.]
152 Producing fermented feed for livestock, by
mixing food waste byproducts, baked shell
powder and yeast, adding yeast and onion,
fermenting obtained raw materials with waste
cooking oil and granulating raw materials
PARK B
KR 2010027280
A
20100311
KR 2010027280 A UPAB: 20100826
BIOTECHNOLOGY - Preferred Method: The
An INDEPENDENT CLAIM is included for
KR 2010027280
fermentation is performed using lactic acid
fermented feed obtained by the above-mentioned
bacteria chosen from one or more of Lactobacillus method.
reuteri, L.sakei and Pediococcus acidilactici. The
method involves mixing (in wt.%): food waste
byproducts (70-90), baked shell powder (5-15),
molasses (5-15) and yeast (0.1-1).
N
152 Producing fermented feed for livestock, by
mixing food waste byproducts, baked shell
powder and yeast, adding yeast and onion,
fermenting obtained raw materials with waste
cooking oil and granulating raw materials
153 Method of treating or preventing thrombotic
diseases e.g. arteriosclerosis, ischemic
cardiac disease, stroke and embolus,
comprises administering an extract of
processed ginseng or ginsenosides into the
mammals
PARK B K
KR 1018270
B1
20110304
NOVELTY: Producing fermented feed by
fermenting food waste byproducts, involves
collecting and selecting food waste byproducts,
mixing baked shell powder and yeast with food
waste byproducts to obtain first fermented raw
materials, mixing yeast, onion, garlic and ginger
extract with the first fermented raw materials for
40-80 hours to obtain second fermented raw
materials, fermenting second fermented raw
materials with waste cooking oil to obtain final raw
materials, and granulating the final materials at
low temperature for 30-120 minutes. [CONT.]
UNIV SEOUL NAT R & DB FOUND
US 20100028467
A1
20100204
US 20100028467 A1 UPAB: 20100222
GINSENG SCI INC
KR 2010013648
A
20100210
NOVELTY: Method for treating or preventing
thrombotic diseases in mammals, comprises
administering an extract of processed ginseng or
ginsenosides into the mammal suffering with
thrombotic diseases.
B1
20110317
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are included for:
SEOULDAEHAKGYOSANHAKHYEOPRYEOKDA KR 1021652
N
SNU R&DB FOUND
WYETH
154 Animal insecticidal device, useful for
controlling insects in a localized environment, WYETH LLC
fleas, horn flies on animal, which is cat, dog or
horse, and cattle, comprises metaflumizone
and low molecular weight amide solvent
155 Maillard flavor composition, useful for
enhancing palatability of comestible and food
compositions, comprises a structured lipid
phase comprising aqueous solvent and lipid
plus emulsifier, and at least one Maillard
reaction product
NESTEC SA
MORPHOTEK INC
156 New isolated antibody or its antigen-binding
fragment that specifically binds to human
ganglioside (GD2), useful for treating or
preventing GD2-associated disease in subject,
where the GD2-associated disease is cancer,
preferably melanoma
The method is useful for producing fermented
feed (claimed) for livestock, where the feed
provides antibacterial activity.
The method reduces processing cost of food
waste byproducts, and produces feed at high
yield. The feed is non-toxic.
The method is useful to treat or prevent thrombotic The pharmaceutical composition does not have
diseases including arteriosclerosis, embolus,
toxicity and adverse effects hence the composition
ischemic cardiac disease, stroke, angina, cerebral and method can be used with safe.
infarction, intracranial hemorrhage, aneurysm,
atherosclerosis, atheroembolus, nephrosclerosis
or cardiac infarction. [CONT.]
BIOTECHNOLOGY - Preferred Method: The
An INDEPENDENT CLAIM is included for
KR 2010027280
fermentation is performed using lactic acid
fermented feed obtained by the above-mentioned
bacteria chosen from one or more of Lactobacillus method.
reuteri, L.sakei and Pediococcus acidilactici. The
method involves mixing (in wt.%): food waste
byproducts (70-90), baked shell powder (5-15),
molasses (5-15) and yeast (0.1-1).
BIOLOGY - Preferred Method: The extract of
processed ginseng is prepared by treating Panax
plants with heat at 70-150 degrees C for 2-6
hours, as an active ingredient.
INDEPENDENT CLAIMS are included for:
US 20100028467
US 20100028467
US 20100015191
US 20100015191
(1) a pharmaceutical composition comprising an
extract of processed ginseng and ginsenosides
isolated, as an active ingredient to treat and
prevent thrombotic diseases; and
(2) a functional health food comprising an extract
of processed ginseng or ginsenosides isolated,
with an additive for the prevention and
improvement of thrombotic diseases.
(1) a pharmaceutical composition comprising an
extract of processed ginseng and ginsenosides
isolated, as an active ingredient to treat and
prevent thrombotic diseases; and [CONT.]
US 20100015191
WO 2010011596
A1
20100121
US 20100015191 A1 UPAB: 20100209
A2
20100128
WO 2010011596
A3
20101223
NOVELTY: Animal insecticidal device (I)
comprises metaflumizone and a low molecular
weight amide solvent.
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are included for:
AU 2009274220
A1
20100128
KR 2011020312
A
20110302
CA 2728357
A1
20100128
WO 2010008452
A1
20100121
AU 2009271740
A1
20100121
CA 2728087
A1
20100121
EP 2296483
WO 2010002822
US 20100008851
A1
20110323
A1
20100107
WO 2010002822 A1 UPAB: 20100122
A1
20100114
NOVELTY: An isolated antibody or its antigenbinding fragment that specifically binds to human
ganglioside (GD2), where the heavy chain
complementarity determining region (CDR)-3
comprises the amino acid sequence of SEQ ID
NO. 12, is new. Sequences not defined here may
be found at
ftp://ftp.wipo.int/pub/publishedpctsequences/public
ation.
AU 2009267113
A1
20100107
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are: [CONT.]
(I) is useful for: controlling insects in a localized
environment; controlling fleas; controlling horn
flies, on animal, which is cat, dog or horse, and
cattle (all claimed); controlling insects in a
homeothermic animal; and the prevention and
control of infestation by ectoparasites in warmblooded animals. No biological data given.
(1) a method for controlling insects in a localized
environment, comprising contacting an animal
with (I); and
(2) a composition comprising the thermoplastic
resin, metaflumizone and the low molecular weight
amide solvent. [CONT.]
(I) has prolonged protection against parasitic
infections. The device is (in the form ear tag, neck
collar or pendant) suitable for attachment to the
animal. The device is less prone to breakage, thus
allowing a greater range of compositions to be
incorporated into the tag, hence the device is
stronger.
INSTRUMENTATION AND TESTING - Preferred
Components: (I) in the form of an ear tag, neck
collar or pendant. ORGANIC CHEMISTRY Preferred Components: The low molecular weight
amide solvent is diethyltoluamide (preferred),
dimethylacetamide, 2-pyrrolidone or Nmethylpyrrolidone. (I) further comprises: one more
additional insecticidal agent; one or more
processing stabilizer, chelating agent, heat
processing stabilizer, flow agent, insecticidal
synergist, migration accelerators, or colorant;
titanium oxide; and amitraz [CONT.]
INDEPENDENT CLAIMS are included for:
(1) a method for controlling insects in a localized
environment, comprising contacting an animal
with (I); and
(2) a composition comprising the thermoplastic
resin, metaflumizone and the low molecular weight
amide solvent.
FOOD - Preferred Composition: (I) further
comprises at least one catalyst of a Maillard
reaction; and at least one additional palatability
enhancer. (I) comprises at least one Maillard
reaction product and a structured lipid phase that
comprises 0.5-25% aqueous solvent, and 7599.5% of lipid plus emulsifier. The comestible
composition comprises 0.001-50% of (I). (II)
further comprises at least one additional
palatability enhancer [CONT.]
The isolated antibody, or its antigen-binding
fragment and methods are useful for treating or
preventing GD2-associated disease in subject,
where the GD2-associated disease is cancer,
preferably melanoma; and for detecting GD2expressing cell in subject (all claimed).
BIOTECHNOLOGY - Preparation (claimed):
Making antibody or antigen-binding of fragment
comprises culturing host cell under conditions
suitable to produce the antibody or antigenbinding fragment, and recovering the antibody or
its antigen-binding fragment from the cell culture.
Preferred Antibody: In the antibody or its antigenbinding fragment, the heavy chain CDR1
comprises SEQ ID NO. [CONT.]
WO 2010008452
INDEPENDENT CLAIMS are:
(1) a polynucleotide encoding the antibody, or
antigen binding fragment;
(2) a vector comprising the polynucleotide
sequence;
WO 2010002822
US 20100008851
N
157 Nutritional composition for improving the
immune function in a mammal comprises
proteinaceous matter, leucine, lipid fraction
comprising at least omega-3 polyunsaturated
fatty acid, and immunomodulator
TW 2010004645
A
20100201
CA 2729499
A1
20100107
KR 2011025859
A
20110311
WO 2009157767
EP 2296643
A1
20091230
WO 2009157767 A1 UPAB: 20100115
A1
20110323
NOVELTY: Nutritional composition comprises: (a)
at least 18 en% of proteinaceous matter; (b) at
least 12 wt.% of leucine, based on total
proteinaceous matter; (c) a lipid fraction
comprising at least omega-3 polyunsaturated fatty
acid selected from eicosapentaenoic acid,
docosahexaenoic acid, eicosatetraenoic acid and
docosapentaenoic acid; (d) an immunomodulator,
for improving the immune function in a mammal.
[CONT.]
WO 2009154995
WO 2009154995
A2
20091223
WO 2009154995 A2 UPAB: 20100115
A3
20100715
NOVELTY: A humanized antibody or its
subsequence capable of binding with interleukin
(IL)-10 receptor alpha protein and that reduces,
inhibits or competes for binding of antibody
designated 136C5, 136C8, or 136D29, or an
antibody comprising heavy chain variable region
sequence having any one of 3 defined sequence
of 180 amino acids (SEQ ID NO: 29, 31 or 33)
given [CONT.]
EP 2293667
A2
20110316
FUNDACIO PRIVADA INST CATALA
INVESTIGACI
FUNDACIO PRIVADA INST INVESTIGACIO
BIOME
US 20090311262
A1
20091217
WO 2010000565
A1
20100107
FUNDACIO PRIVADA INST RECERCA
HOSPITAL
ICREA FUNDACIO PRIVADA INST CATALANA
REC
AU 2009265921
A1
20100107
ES 2342646
A1
20100709
ICREA INST CATALANA RECERCA I ESTUDIS
AV
EP 2293819
A1
20110316
UNIV HOSPITAL FUNDACIO PRIVADA INST
CA 2727365
A1
20100107
WO 2009152331
US 20090311199
A1
20091217
WO 2009152331 A1 UPAB: 20100112
A1
20091217
NOVELTY: Method for whitening teeth of a subject
involves: administering a composition (C1)
comprising at least one isolated, non-pathogenic,
hydrogen peroxide-producing bacterial species or
strain to an oral cavity of a subject. [CONT.]
AU 2009257440
A1
20091217
NUTRICIA NV
158 Novel humanized antibody capable of binding KYOWA HAKKO KIRIN CO LTD
with interleukin-10 receptor-alpha protein and KATO S
inhibits binding of antibody designated 136C5,
136C8, or 136D29, for treating infections, e.g.
viral, bacterial, parasitic, or fungal infection
ROGERS P
(3) a cell comprising the vector; or a cell that
expresses the antibody or its antigen-binding
fragment;
(4) a method for treating or preventing a GD2associated disease in a subject comprising
administering to the subject the antibody or its
antigen-binding fragment hat specifically binds to
GD2 in an amount effective to treat or prevent the
disease; [CONT.]
The nutritional composition is useful for improving
the immune function in mammal, where improving
the immune function comprises at least one of the
following effects: improving type 1 T helper cell
(Th1)-mediated immune response; increasing the
activity or number of natural killer (NK) cells;
increasing pathogen-specific or tumor-specific
immunoglobulin (Ig)A, IgG or IgM antibody
production; [CONT.]
BIOTECHNOLOGY - Preferred Composition: In
the composition above, the immunomodulator is
selected from immune system modulating
indigestible carbohydrates, lactoferrin, glycine,
immune system modulating drugs, and immune
system modulating bacteria or its fragments.
[CONT.]
WO 2009157767
The human or humanized antibody is useful for
The antibody or its subsequence capable of
treating a subject for a pathogen infection such as binding with greater affinity of 1-1000 fold to ILchronic or acute, for increasing numbers or
10R alpha variant R212E.
activation of immune cell in a subject with or at
risk of a pathogen infection, where the immune
cell comprises T cell, natural killer T cell (NKT)
dendritic cell (DC), macrophage, neutrophil,
eosinophil, or mast cell, and the IL- 12 is produced
by the DC or [CONT.]
BIOTECHNOLOGY - Preparation (claimed): The
humanized antibody is produced by hybridoma
cell, carbohydrate cell line or HEK293F cell.
Preferred Antibody: The heavy chain variable
region sequence with CDR1 (Ser-Tyr-Ser-MetAsn), CDR2 (Tyr-Ile-Ser-Thr-Gly-Ser-Ser-Thr-IleTyr-Tyr- Ala-Asp-Ser-Val-Lys-Gly), CDR3 (GluAsn-Tyr-Tyr-Gly-Ser-Gly-Ser-Tyr-Glu- Asp-TyrPhe-Asp-Tyr) and a light chain variable [CONT.]
A human, humanized isolated or purified single
chain antibody or its subsequence capable of
binding with interleukin (IL)-10 receptor alpha
protein, specifically binds to a chimpanzee IL-10
receptor alpha protein, and specifically binds to
macaque IL-10 receptor alpha protein, and
modulates an IL-10R/IL-10 signaling activity, and
that reduces, inhibits or competes for binding of
antibody designated [CONT.]
BIOTECHNOLOGY - Preparation (claimed): The
antibody is produced by immunizing peptide
having a defined sequence of 32 amino acids
(SEQ ID NO: 3 or 4), given in the specification,
and is optionally conjugated with an immunogen.
Preferred Antibody: The epitope is one included in
SEQ ID NO: 3. The antibody or its fragment is
suitable to distinguish the protein having SEQ ID
NO: 1, given in the specification from the HER2
receptor [CONT.]
INDEPENDENT CLAIMS are included for the
US 20090311262
following:
(1) hybridoma producing the monoclonal antibody;
WO 2009154995
N
SOLOFF NUGENT R
SONG A
TAHARA T
159 Novel antibody or its fragment that recognizes
epitope of HER2 receptor truncated form,
useful for preventing or treating, and
diagnosing cancer, preferably cancer of
breast, lung, pancreas, colon, skin, kidney and
testicle
UNIV VALL HEBRON INST RECERCA
HOSPITAL
160 Method for whitening teeth of subject involves ORAGENICS INC
administering composition comprising
isolated, non-pathogenic, hydrogen peroxideproducing bacterial species or strain to oral
cavity of subject
US 20090311262 A1 UPAB: 20100107
The antibody is useful for preventing or treating,
The antibodies provide early diagnosis and
and diagnosing cancer, preferably breast cancers treatment of cancer.
in mammals, including human beings. The cancer
NOVELTY: An antibody or its fragment that
recognizes an epitope of HER2 receptor truncated is chosen from cancer of lung, pancreas, colon,
stomach, prostate, head and neck, skin, kidney,
form, where the epitope being defined by a
sequence having a defined sequence of 42 amino testicle, thyroids, urinary bladder, uterus, vulva,
acids (SEQ ID NO: 2), given in the specification, is endometrium, ovary, oesophagus, mouth, salivary
gland, larynx, peritoneum, nose and throat region,
new.
Fallopian [CONT.]
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are included for the following:
(1) hybridoma producing the monoclonal antibody;
[CONT.]
US 20090311262
(2) method for producing the antibody;
(3) an isolated peptide comprising SEQ ID NO: 2,
3, 4 or having a defined sequence of 13 amino
acids (SEQ ID NO: 5), given in the specification;
(4) method for diagnosing cancer, involves
detecting the presence of HER2 receptor
truncated form having a defined sequence of 645
amino acids (SEQ ID NO: 1), given in the
specification in a patient sample; [CONT.]
For whitening teeth, and for treatment of stained
teeth, dental caries, periodontitis, oral bacterial
infections, oral wounds, Candida or fungal
overgrowth, halitosis, and xerostomia-induced
dental caries; of a subject (preferably a mammal)
(claimed).
The method provides method and composition for
maintenance of oral health such as tooth
whitening, by using composition comprising
isolated, non-pathogenic, hydrogen peroxideproducing species or strains of bacteria, further, in
combination with lactate dehydrogenase (LDH)deficient Streptococcus mutans, where hydrogen
peroxide produced from bacteria at level that can
whiten teeth is demonstrated for the first time
[CONT.]
BIOLOGY - Preferred Bacteria: The at least one
isolated, non-pathogenic, hydrogen peroxideproducing bacterial species or strain is selected
from Lactobacillus, Bifidobacteria, Streptococcus
viridans, Leuconostoc, Pediococcus, and/or
Lactococcus (preferably at least one isolated
strain of Streptococcus oralis, and/or at least one
isolated strain of Streptococcus uberis). [CONT.]
INDEPENDENT CLAIMS are included for the
WO 2009152331
following: (1) method for treatment of stained
teeth, dental caries, periodontitis, oral bacterial
infections, oral wounds, Candida or fungal
overgrowth, halitosis, and xerostomia-induced
dental caries, involving: administering a
composition (C2) comprising at least one isolated,
nonpathogenic, hydrogen peroxide-producing
bacterial species or strain; [CONT.]
US 20090311199
161 Detecting or quantifying target DNA in test
sample, e.g. blood, by processing DNA,
combining oligonucleotide, methylated DNA
and methylated DNA antibody, obtaining
complex, detecting methylated antibody in
complex and detecting DNA
SUMITOMO CHEM CO LTD
SUMITOMO CHEM CO LTD
162 Detecting or quantifying DNA in test sample,
e.g. blood serum, by processing DNA,
combining oligonucleotide with methylated
DNA, combining methylated DNA antibody with
DNA complex, obtaining detection complex
and detecting DNA
163 New vaccine composition comprises first
strain of species of Coccidia genus and
second strain of species, useful for
immunizing an animal subject against
coccidiosis
164 Palatability enhancer for comestible
composition which is food composition,
dietary supplement or medicament, contains
animal digest and surfactant for enhancing
palatability of comestible composition
INTERVET INT BV
INTERVET INC
NESTEC SA
CA 2727462
A1
20091217
KR 2011025798
A
20110311
WO 2009151149
A1
20091217
JP 2010017178
A
20100128
KR 2011027768
A
20110316
WO 2009151150
A1
20091217
JP 2010017179
A
20100128
KR 2011025965
A
20110314
WO 2009148895
US 20100015182
A1
20091210
A1
20100121
MX 2010012869
A1
20101231
CA 2725361
A1
20091210
whiten teeth is demonstrated for the first time
[CONT.]
bacterial species or strain; [CONT.]
WO 2009151149 A1 UPAB: 20100112
The method is useful for detecting or quantifying The target DNA can be detected or quantified
rapidly, simply and accurately with high specificity
NOVELTY: Detecting or quantifying DNA including DNA including target DNA region in test sample
and for selecting test sample derived from cancer and sensitivity.
target DNA region in test sample, involves
preparing DNA for detecting target DNA region in patient. The test sample includes (a) blood, body
fluid, excrement, body secretion, cell or tissues
sample, processing the above DNA using DNA
derived from mammal, (b) DNA extracted from
methylation enzyme, preparing single-stranded
methylated DNA from processed DNA, combining blood, body fluid, excrement, body secretion, cell
or tissues derived from mammal, (c) RNA
specific oligonucleotide with obtained singleextracted from tissues or cell derived from
stranded methylated DNA and methylated DNA
mammal as template, (d) DNA extracted from
antibody, obtaining complex, quantifying or
bacteria, fungi or virus, or (e) RNA extracted from
detecting methylated DNA antibody in complex
bacteria, fungi or virus as template [CONT.]
using identification function, and detecting DNA
containing target DNA region in single-stranded
methylated DNA. [CONT.]
BIOTECHNOLOGY - Preferred Method: The
complex is formed in the reaction system
containing divalent cation, e.g. magnesium ion.
The method involves combining methylated
antibody contained in the complex and support.
The method involves combining specific
oligonucleotide and support. The method involves
adding counter oligonucleotide when the complex
is obtained. [CONT.]
Detecting or quantifying DNA including target DNA WO 2009151149
region in test sample, involves preparing DNA for
detecting target DNA region in sample, processing
above DNA using DNA methylation enzyme,
preparing single-stranded methylated DNA from
processed DNA, combining specific
oligonucleotide, single-stranded methylated DNA
and methylated DNA antibody, obtaining complex,
quantifying or detecting methylated [CONT.]
N
WO 2009151150 A1 UPAB: 20100107
The method is useful for detecting or quantifying The target DNA can be detected or quantified
NOVELTY: Detecting or quantifying DNA including DNA including target DNA in test sample and for rapidly, simply and accurately with high specificity
selecting test sample derived from cancer patient. and sensitivity.
target DNA in test sample, involves preparing
The test sample includes (a) blood, body fluid,
DNA for detecting target DNA in sample,
processing the above DNA using DNA methylation excrement, body secretion, cell or tissues derived
from mammal, (b) DNA extracted from blood, body
enzyme, preparing single-stranded methylated
fluid, excrement, body secretion, cell or tissues
DNA from processed DNA, combining detection
derived from mammal, (c) RNA extracted from
oligonucleotide with single-stranded methylated
tissues or [CONT.]
DNA, obtaining target DNA complex, combining
immobilized methylated DNA antibody with target
DNA complex, obtaining detection complex and
quantifying or detecting DNA in single-stranded
DNA by detection complex using identification
function. [CONT.]
BIOTECHNOLOGY - Preferred Method: The
method involves adding counter oligonucleotide
when the target DNA complex is obtained. The
DNA is produced from RNA using reverse
transcriptase. The target DNA is cleaved using
restriction enzyme in specific restriction site and
not cleaved in synthetic oligonucleotide or purified
DNA. The immobilized methylated DNA antibody
is methylcytosine antibody. [CONT.]
An INDEPENDENT CLAIM is included for method WO 2009151150
of selecting test sample derived from cancer
patient, which involves quantifying or detecting
DNA using test sample derived from test subject
by the above method, quantifying or detecting
DNA using test sample derived from healthy
person by the above method, evaluating the result
and identifying the test sample derived from
cancer patient based on the [CONT.]
N
WO 2009148895 A1 UPAB: 20100119
The invention cause only minimal lesions.
BIOTECHNOLOGY - Preferred Composition: In
the vaccine composition, the genus is selected
from the group consisting of Isospora,
Cystoisospora, Cryptosporidium, and Elmeria. The
genus is Elmeria. The first strain is a nonattenuated Elmeria strain and the second strain is
a precocious Elmeria strain. The precocious
Elmeria strain is an attenuated Elmeria strain.
[CONT.]
An INDEPENDENT CLAIM is a method of
immunizing an animal subject against coccidiosis
comprising administering to the animal an
immunologically effective amount of the vaccine.
WO 2009148895
The enhancer can make foods and other
comestible compositions more palatable.
FOOD - Preferred Component: The animal digest
comprises beef, pork, poultry, lamb, and/or fish.
The enhancer comprises surfactant (0.05-10%)
and animal digest (90-99.95). The comestible
composition comprises palatability enhancer
(0.001-90%). ORGANIC CHEMISTRY - Preferred
Component: The enhancer further comprises foodcompatible acid or acidifier, sweetening agent,
edible fat, amino acid or its derivative or salt, salt,
nucleotide or ribonucleotide or its derivative or salt
[CONT.]
INDEPENDENT CLAIMS are included for:
WO 2009148521
The vaccine is useful for immunizing an animal
subject against coccidiosis (claimed).
NOVELTY: A vaccine composition comprising a
first strain of a species of a Coccidia genus and a
second strain of the species; where the first strain
and the second strain have an asynchronous
prepatent period, is new.
DETAILED DESCRIPTION: An INDEPENDENT
CLAIM is a method of immunizing an animal
subject against coccidiosis comprising
administering to the animal an immunologically
effective amount of the vaccine. [CONT.]
EP 2296698
A1
20110323
TW 2010010717
A
20100316
WO 2009148521
A1
20091210
WO 2009148521 A1 UPAB: 20100107
AU 2009255704
A1
20091210
NOVELTY: A palatability enhancer comprises
animal digest(s) and surfactant(s) for enhancing
the palatability of a comestible composition.
CA 2724904
A1
20091210
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are included for:
Palatability enhancer for comestible composition
which is a food composition, dietary supplement
or medicament (claimed).
(1) a comestible composition comprising
ingredient(s) for consumption by an animal and
palatability enhancer(s) comprising animal
digest(s) and surfactant(s) for enhancing the
palatability of the comestible composition;
(2) a method for enhancing the palatability of a
comestible composition comprising combining the
comestible composition with a palatability
enhancer comprising animal digest(s) and
surfactant(s); [CONT.]
US 20100015182
EP 2296481
A1
20110323
(1) a comestible composition comprising
ingredient(s) for consumption by an animal and
palatability enhancer(s) comprising animal
digest(s) and surfactant(s) for enhancing the
palatability of the comestible composition; [CONT.]
WO 2009148554
A1
20091210
WO 2009148554 A1 UPAB: 20100101
US 20100074910
A1
20100325
NOVELTY: A polyfunction compound, or a
pharmaceutically acceptable salt, optionally in the
form of a single stereoisomer or mixtures of
stereoisomers, is new.
EP 2288388
A1
20110302
DETAILED DESCRIPTION: A polyfunction
compound of Formula I; or a pharmaceutically
acceptable salt, optionally in the form of a single
stereoisomer or mixtures of stereoisomers, is new.
[CONT.]
CA 2726050
A1
20091210
KR 2011020874
A
20110303
WO 2009143841
WO 2009143841
A1
20091203
WO 2009143841 A1 UPAB: 20100101
A8
20101216
NOVELTY: Compressed chewing gum tablet
comprises at least one compressed chewing gum
module including a compressed particulate
chewing gum composition containing compressed
chewing gum particles containing gum base,
where the content of gum base is at least 5 wt.%
of the tablet, and the chewing gum tablet is
provided with a film coating, and the film coating
comprises liquid flavoring. [CONT.]
LORENZEN G
IN 2010KN04592
A
20110204
NIELSEN B P
EP 2296486
US 20110070287
US 20090297444
A1
20110323
A1
20110324
A1
20091203
US 20090297444 A1 UPAB: 20100101
DZURIS J L
WO 2009151708
A2
20091217
NOVELTY: Substantially pure compounds (A) or
(B) that selectively bind melanocortin 1 receptor
(MC1R) comprising a polypeptide (SEQ ID NO: 9)
or a core tetrapeptide (SEQ ID NO: 1)
respectively, are new. [CONT.]
EDLING A E
WO 2009151708
A3
20101118
PAN C Q
AU 2009258054
A1
20091217
PERRICONE M A
CA 2726076
A1
20091217
STEFANO J E
EP 2297178
A2
20110323
WO 2009145177
EP 2279739
A1
20091203
A1
20110202
SIEMENS MEDICAL SOLUTIONS USA INC
165 New polyfunction compound, or a
pharmaceutically acceptable salt, optionally in
the form of a single stereoisomer or mixtures
of stereoisomers, useful for treating cancer in
a patient in need of such treatment
166 Compressed chewing gum tablet for delivering FERTIN PHARMA AS
active pharmaceutical ingredient e.g. nicotine, DALHOFF J
cetirizine and metformin, comprises
compressed chewing gum module including
composition of chewing gum particles, and
flavored film coating
167 New compounds comprising polypeptide/core GENZYME CORP
tetrapeptide are melanocortin 1 receptor
modulators useful to treat e.g. multiple
sclerosis, aplastic anemia, rheumatoid
arthritis, allergy and psoriasis, and to
reduce/inhibit transplant rejection
The compounds and method are useful for
treating cancer in a patient in need of such
treatment (all claimed).
As chewing gum tablet for delivering active
pharmaceutical ingredient comprising nicotine,
cetirizine, levo cetirizine, metformin, metformin
hydrochloride, phenylephrine, glucagon-like
peptide-1 (GLP-1), exenatide, melanocortin 4 (MC4) receptor antagonist, pancreatic polypeptide
gene (PPY) (3-36), deca-peptide, KSL-W
(acetate), fluor, or chlorhexidine (claimed).
The compounds produce improved agents which
provide both biochemical and biophysical
feedback.
The compressed chewing gum tablet provides
moderated initial burst of taste from the chewing
gum upon chewing, can be satisfactorily used for
prolonged period of time; provides more balanced
release of sweetener from the tablet and liquid
flavor from the film coating. [CONT.]
(A) are useful for: treating an autoimmune disease (A) exhibit at least one of: ability to selectively
or condition, which is multiple sclerosis, type I
activate MC1R; stability in plasma in vitro; and
diabetes, aplastic anemia, Grave's disease, celiac resistance to protease degradation.
disease, Crohn's disease, lupus, arthritis,
osteoarthritis, autoimmune uveitis and myasthenia
gravis; treating inflammation, where the
inflammation is associated with a disease which is
inflammatory bowel disease, rheumatoid arthritis,
allergy, atherosclerosis, psoriasis, gastritis or
ischemic heart disease [CONT.]
BIOTECHNOLOGY - Preferred Compound: In the
compound, A is selected from an amino acid
residue, linear peptides, cyclic peptides, synthetic
peptides, semisynthetic peptides, peptidomimetics
and derivatives, where A is an amino acid residue
or a dipeptide, preferably a lysine residue.
Alternatively, a compound of Formula II; or a
pharmaceutically acceptable salt, optionally in the
form of a single stereoisomer or mixtures of
stereoisomers [CONT.]
A polyfunction compound of Formula I; or a
WO 2009148554
pharmaceutically acceptable salt, optionally in the
form of a single stereoisomer or mixtures of
stereoisomers, is new.
A=a low molecular weight scaffold selected from
functionalized monocyclic and polycyclic
hydrocarbons, functionalized monocyclic and
polycyclic heterocycles, an amino acid residue,
linear peptides, cyclic peptides, synthetic
peptides, semisynthetic peptides, peptidomimetics
and hyaluronic acid, and derivatives; [CONT.]
US 20100074910
FOOD - Preferred Components: The liquid
flavoring is selected from coconut, coffee,
chocolate, vanilla, grape fruit, orange, lime,
menthol, liquorice, caramel aroma, honey aroma,
peanut, walnut, cashew, hazelnut, almonds,
pineapple, strawberry, raspberry, tropical fruits,
cherries, cinnamon, peppermint, wintergreen,
spearmint, eucalyptus, mint, fruit essence such as
from apple, pear, peach, strawberry, [CONT.]
WO 2009143841
US 20110070287
BIOLOGY - Preparation: No preparation method is
given. Preferred Components: (A) comprise: a
polypeptide (SEQ ID NO: 11) having a sequence
of formula (Xaa1 Xaa2 Xaa3 Xaa4 Xaa5 Xaa6
Xaa7 Xaa8 Xaa9 Xaa10 Xaa11 Xaa12 Xaa13) (a);
a polypeptide (SEQ ID NO: 11) having a sequence
of formula (Xaa1 Xaa2 Xaa3 Xaa4 Xaa5 Xaa6
Xaa7 Xaa8 Xaa9 Xaa10 Xaa11 Xaa12 Xaa13) (b);
[CONT.]
Substantially pure compounds (A) that selectively US 20090297444
bind melanocortin 1 receptor (MC1R) comprising a
polypeptide (SEQ ID NO: 9) having a sequence of
formula (Xaa1 Xaa2 Xaa3 Xaa4 Xaa5 Xaa6 Xaa7
Xaa8 Xaa9 Xaa10 Xaa11 Xaa12 Xaa13) or a core
tetrapeptide having the sequence of formula (His
Xaa Arg Trp) (SEQ ID NO: 1) respectively, are
new.
US 20090297444
N
Xaa1 = D-Val, D-Ala or D-Lys;
Xaa2 = D-Pro, D-Ala or D-Lys; [CONT.]
WEEDEN T E
NITTO DENKO CORP
168 Donepezil containing medicated patch for
preventing or treating Alzheimer-type dementia AKEMI H
and migraine, comprises adhesive layer
containing donepezil and acrylic adhesive on
single surface of support
WO 2009145177 A1 UPAB: 20100101
The donepezil containing medicated patch is
NOVELTY: Donepezil containing medicated patch useful for preventing or treating Alzheimer-type
dementia, dementia caused by cerebrovascular
comprises adhesive layer containing donepezil
and acrylic adhesive on at least single surface of a disease, and migraine.
support. The moisture content of the adhesive
layer is 1000 part per million (ppm) or more.
The donepezil containing medicated patch has
excellent aging stability, reliability and drug
release property. The time-dependent
discoloration of adhesive layer and timedependent deterioration can be suppressed. The
utilization of drug is increased effectively, thus
quality of life (QOL) can be improved costeffectively.
ORGANIC CHEMISTRY - Preferred Components:
The moisture content of the adhesive layer is 8000
or less, preferably 7000 ppm or less. The
medicated patch and desiccant are enclosed in
the moisture-permeability prevention bag.
An INDEPENDENT CLAIM is included for a
package body, which comprises donepezil
containing medicated patch enclosed in a
moisture-permeability prevention bag.
WO 2009145177
US 20110056863
HANATANI A
KR 2011011650
A
20110208
MARUYAMA S
US 20110056863
A1
20110310
SAKAMOTO S
CA 2724502
A1
20091203
STORK TOWNSEND BV
169 Manufacture of sausage products, e.g.
Bratwurst, Weisswurst, frankfurters, hot dogs
and fresh sausage, comprises adding
structure improver to viscous paste during coextrusion
WO 2009145626
EP 2291085
A1
20091203
A1
20110309
170 Food product, e.g. cat food for maintenance or MARS INC
improvement of oral health, comprises outer
portion, and inner portion comprising myrtle
and having specified moisture content
GB 2460343
WO 2009144458
A
20091202
GB 2460343 A UPAB: 20091216
A2
20091203
NOVELTY: A food product comprises an outer
portion, and an inner portion comprising myrtle
and having a moisture content of 10-25%.
WO 2009144458
A3
20100114
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are included for:
AU 2009252998
A1
20091203
(1) a method of making a food product comprising
mixing the ingredients that form the outer portion,
mixing the ingredients that form the inner portion,
and co-extruding the outer portion and inner
portion to form a food product; and [CONT.]
CA 2724772
A1
20091203
quality of life (QOL) can be improved costeffectively.
DETAILED DESCRIPTION: An INDEPENDENT
CLAIM is included for a package body, which
comprises donepezil containing medicated patch
enclosed in a moisture-permeability prevention
bag. [CONT.]
SEKIYA J
171 Material for treating excrement of pet e.g. dog
has coloring layer changed to darkness and
lightness when moisture content of pet's
excrement contacts treating material, to
determine dried and wet conditions of pet's
excrement
WO 2009145626 A1 UPAB: 20091216
Method for manufacturing sausage products
NOVELTY: Manufacturing sausage products by co- (claimed), e.g. Bratwurst, Weisswurst,
frankfurters, hot dogs and fresh sausage.
extrusion comprises co-extruding a sausage
strand with a core of food dough enclosed by a
casing of a viscous paste (5-1250 N) comprising
polysaccharide and a protein, e.g. collagen;
subdividing the sausage strand into sausage
products; and guiding the sausage through a
fixing bath. The cohesion of the sausage
increases [CONT.]
EP 2293689
A2
20110316
ITO M
JP 2009273417
A
20091126
KOYAMA T
JP 4644269
B2
20110302
Co-extruded sausages can be manufactured more
rapidly. There is less danger of deformation of or
damage to the sausages. The addition of structure
improver to the paste during or shortly before coextrusion shortens the overall production time
required for the production of sausages and a
production device can have a more compact form.
[CONT.]
A food product (preferably pet food product) in the The product inhibits formation of biofilms and/or
form of a filled tube for maintenance or
detrimental activities of the biofilm, and reduces
improvement of oral health, prevention or
the level of pathogenic bacteria in the biofilm.
treatment of gingivitis, or reducing tartar and/or
dental plaque in an animal. The animal is cat, dog
or human. (all claimed)
WO 2009145626
BIOLOGY - Preferred Component: The myrtle is
Myrtus communis. FOOD - Preferred Component:
The outer portion is harder than inner portion
which is in the form of a paste or a gel. The inner
portion is a starch matrix. The outer portion
comprises myrtle. The myrtle is present in the
inner portion at 1-10 (preferably 4) wt.%.
INDEPENDENT CLAIMS are included for:
N
GB 2460343
(1) a method of making a food product comprising
mixing the ingredients that form the outer portion,
mixing the ingredients that form the inner portion,
and co-extruding the outer portion and inner
portion to form a food product; and
(2) a method of maintaining or improving oral
health in an animal comprising administering a
food product to the animal.
JP 2009273417 A UPAB: 20091209
Material for treating excrement of pet such as dog The color of the coloring layer on the surface of
the excrement treating material can be determined
NOVELTY: The treating material (30) has coloring and cat.
easily when moisture content in pet's excrement
layer (35) that is formed by mixing granule (31)
contacts the excrement treating material.
consisting of 65-80%weight of paper manufacture
Therefore, the pet's excrement can be wastesludge and 20-35%weight of used tea leaves,
processed easily while removing the portion of
calcium carbonate (32), starch (33) and dye (34).
treating material which changed dark. [CONT.]
The coloring layer is made dark when moisture
JP 2009273417
N
Material for treating excrement of pet such as dog The color of the coloring layer on the surface of
the excrement treating material can be determined
NOVELTY: The treating material (30) has coloring and cat.
easily when surface layer is made semilayer (35) is formed by mixing granule (31)
transparent. Therefore, the pet's excrement can
consisting of 65-80%weight of paper manufacture
be waste-processed easily while removing the
sludge and 20-35%weight of used tea leaves,
portion of treating material which changed dark.
calcium carbonate (32), starch (33) and dye (34).
Since the used tea leaves contain green tea
A surface layer (36) is formed around a coloring
flavonoids, the deodorizing effect of the pet
layer and is made semi-transparent when
excrement can be increased.
moisture content of pet's excrement contacts the
surface of treating material, to determine dried
condition and wet condition of the pet's
excrement. [CONT.]
JP 2009273418
N
WO 2009141294
Y
content of pet's excrement contacts surface of the
treating material. [CONT.]
172 Material for treating excrement of pet e.g. dog
has surface layer that is made semitransparent when moisture content of pet's
excrement contacts surface of treating
material, to determine dried and wet
conditions of pet's excrement
ITO M
JP 2009273418
A
20091126
KOYAMA T
JP 4644270
B2
20110302
WO 2009141294
EP 2140770
A1
20091126
WO 2009141294 A1 UPAB: 20091216
A1
20100106
NOVELTY: Food preparation comprises
acylamino acid compound (I) or its salt in an
amount to generate mainly tingling and not
burning sensations in the oral cavity.
173 Food preparation useful as a spice, flavor and NESTEC SA
seasoning comprises acylamino acid
compound to generate mainly tingling and not
burning sensations in the oral cavity
JP 2009273418 A UPAB: 20091209
As a food preparation to generate mainly tingling
and not burning sensations in the oral cavity; and
as a spice, flavor and seasoning (claimed). The
food preparation comprises food additives, food
products such as beverages, soups, ice-cream,
confectionary, dairy, petfood and neutraceuticals.
The food preparation provides spicy food product ORGANIC CHEMISTRY - Preferred Compounds:
which is consumed without any side-effect such as The acylamino acid compound (I) is a compound
burning sensations in the oral cavity.
of formula R2-C(O)-NH-C(O)-OH. The acylamino
acid compound (I) is formed in situ by
condensation from fatty acids and amino acids
available in the food preparation. R1=H, 1-10C
(preferably 1-5C) alkyl, 1-10C (preferably 1-5C)
hydroxyalkyl or 2-10C (preferably 1-5C)
carboxyalkyl (preferably H, methyl, hydroxyethyl or
EP2296492A1
174 New phenyl or pyridinyl substituted indazolyl
derivative useful for treating e.g.
glucocorticoid receptor mediated disease
state, inflammatory conditions or respiratory
disorder, asthma, and chronic obstructive
pulmonary disease
CA 2725155
A1
20091126
USE: As a food preparation to generate mainly
tingling and not burning sensations in the oral
cavity; and as a spice, flavor and seasoning
(claimed). The food preparation comprises food
additives, food products such as beverages,
soups, ice-cream, confectionary, dairy, petfood
and neutraceuticals. [CONT.]
A1
20110323
ASTRAZENECA AB
EP 2296492
WO 2009142569
A1
20091126
WO 2009142569 A1 UPAB: 20100107
BAYER SCHERING PHARMA AG
US 20100080786
A1
20100401
NOVELTY: Phenyl or pyridinyl substituted
indazolyl derivative, or its salt is new.
BERGER M
US 20100087489
A1
20100408
DAHMEN J
AU 2009249872
A1
20091126
DETAILED DESCRIPTION: Phenyl or pyridinyl
substituted indazolyl derivative of formula (I), or its
salt is new.
A'=1-6C alkyl, 1-6C alkoxy, 3-7C cycloalkyl, 1-6C
haloalkyl, 1-6C alkylthio, 1-6C alkyl C(O)-, 1-6C
alkyloxy C(O)-, NR5R6, NR5R6 C(O)- or 5-10C
heteroaryl (all optionally substituted by halo,
cyano, hydroxyl, 1-4C alkyl, 1-4C alkoxy or 1-4C
haloalkyl); [CONT.]
EDMAN K
KR 2011007208
A
20110121
ERIKSSON A
EP 2291359
A1
20110309
HANSSON T
CA 2724584
A1
20091126
WO 2009143472
WO 2009143472
A2
20091126
A3
20100311
AU 2009248834
A1
20091126
EP 2288623
A2
20110302
CA 2725169
A1
20091126
KR 2011020860
A
20110303
EP 2123620
A1
20091125
products such as beverages, soups, ice-cream,
confectionary, dairy, petfood and neutraceuticals.
condensation from fatty acids and amino acids
available in the food preparation. R1=H, 1-10C
(preferably 1-5C) alkyl, 1-10C (preferably 1-5C)
hydroxyalkyl or 2-10C (preferably 1-5C)
carboxyalkyl (preferably H, methyl, hydroxyethyl or
carboxyethyl) [CONT.]
In a pharmaceutical composition; in a therapy; and
in the manufacture of a medicament for treatment
of inflammatory conditions or respiratory disorder,
asthma, chronic obstructive pulmonary disease in
a mammal (claimed). [CONT.]
ORGANIC CHEMISTRY - Preparation (Claimed):
Preparation of the compound (I) involves coupling
indazole compound of formula (II) with acylation
reagents of formula A'-C(O)-L', A'-N=C=Z', or A'S(=O)2-L'. L1= OH or leaving group;
Z'(disclosed)=A'-C(O) or A'-S(O)2. Provided that,
when L1 is OH, then leaving group is generated
by reaction of a coupling reagent.
Phenyl or pyridinyl substituted indazolyl derivative WO 2009142569
of formula (I), or its salt is new.
A'=1-6C alkyl, 1-6C alkoxy, 3-7C cycloalkyl, 1-6C
haloalkyl, 1-6C alkylthio, 1-6C alkyl C(O)-, 1-6C
alkyloxy C(O)-, NR5R6, NR5R6 C(O)- or 5-10C
heteroaryl (all optionally substituted by halo,
cyano, hydroxyl, 1-4C alkyl, 1-4C alkoxy or 1-4C
haloalkyl);
US 20100080786
US 20100087489
R5 and R6=H, 1-6C alkyl, 3-7C cycloalkyl, 1-6C
alkyl C(O)- or 3-7C cycloalkyl C(O)-;or [CONT.]
HEMMERLING M
HOSSAIN N
JOHANSSSON H
KLINGSTEDT P T
LEPISTOE M
NILSSON S
REHWINKEL H
175 New chimeric single variable light (VL) domain ALIVA BIOPHARMACEUTICALS INC
antibody comprises a human VL domain
segment and a human J domain segment,
useful for treating or preventing a disease or
disorder, e.g. cancer, graft versus host
disease, or allergies
BAYER SCHERING PHARMA AG
176 New fluorinated glutamate and glutamine
derivatives used in the manufacturing of
pharmaceutical formulation or medicament for
preventing or treating proliferative diseases
e.g. malignant lymphoma, pharyngeal cancer, BERNDT M
malignant melanoma
WO 2009141090
A1
20091126
WO 2009143472 A2 UPAB: 20091216
The VL domain antibody, composition, and
The antibodies have high-affinity binding and good
methods
are
useful
for
producing
a
homologous
solubility, which are desired for therapeutic drug
NOVELTY: A chimeric single variable light (VL)
recombination
competent
non-human
mammalian
discovery and development.
domain antibody comprising a human VL domain
segment and a human J domain segment, where cell and a knock-in non-human mammal (all
the antibody specifically binds to a target antigen, claimed). The VL domain antibody is useful for the
treatment or prevention of a disease or disorder,
and where the antibody is generated by
immunizing a knock-in non-human mammal with such as various types of cancer, graft versus host
disease, cardiovascular disease and associated
the target antigen and recovering the chimeric
single VL domain antibody that specifically binds disorders, neurological diseases [CONT.]
to the target antigen, is new. [CONT.]
BIOTECHNOLOGY - Preferred Antibody: The
chimeric single VL domain antibody further
comprises a DH domain segment. It further
comprises a non-human heavy chain C region,
where the non-human heavy chain C region
comprises a hinge, a CH2, and a CH3 domain
segment and is substantially or completely devoid
of a CH1 domain segment. The human VL domain
segment is a Vkappa domain segment or a
Vlambda domain segment [CONT.]
EP 2123620 A1 UPAB: 20091216
ORGANIC CHEMISTRY - Preparation (claimed): Fluorinated glutamate and glutamine derivative of EP 2123620
Preparation of the compound (I) involves reacting formula A-C(=O)-C(R1)-C(R2)-C(NH2)-C(=O)-G'(I)
a non-fluorinated compound (I) with a fluorine
or its salt, diastereomer or enantiomer, is new.
atom or derivative to obtain (I).
A=OH, 1-5C alkoxy, hydroxy-1-5C alkoxy, O-1-5C
alkyl-(O-1-4C alkyl)n-O-1-4C alkyl, N(1-5C alkyl)2,
NH2, N(H)-L', O-L'or O-Z';
NOVELTY: Fluorinated glutamate and glutamine
derivative (I) or its salt, is new.
In pharmaceutical composition; for the
manufacturing of imaging agent (i.e. magnetic
resonance imaging (MRI) agent) for imaging
proliferative diseases in a patient; in the
manufacture of a medicament for use as inhibitor
for treating, preventing or alleviating proliferative
diseases (all claimed) such as malignant
lymphoma, pharyngeal cancer, lung cancer, liver
cancer, bladder tumor, rectal cancer, [CONT.]
INDEPENDENT CLAIMS are:
WO 2009143472
N
(1) a homologous recombination competent nonhuman mammalian cell having a genome
comprising human VL and J gene segments
operably linked to a non-human heavy chain C
region, where the human VL, diversity heavy chain
(DH), and joining (J) gene segments replace an
endogenous VH domain, and where the nonhuman heavy chain C region comprises a hinge, a
CH2, and a CH3 gene segment and is
substantially or completely devoid of a heavy
chain 1 (CH1) gene segment, so that the cell
comprises a genome encoding a chimeric single
VL domain antibody; [CONT.]
US 20110064673
N
177 Preparing non cellular pet chew involves
preparing mixture of cereal flour having
specific protein content, plasticizer and
fibrous material, converting mixture into
thermoplastic mass, and molding
thermoplastic mass into desired pet chew
178 New isolated antibody or its antigen-binding
fragment that induces or enhances cell killing
of cancer cells in vivo or in vitro, useful for
inducing death of a tumor cell, preventing or
reducing tumor cell growth, and treating a
cancer
DINKELBORG L
WO 2009141090
A8
20101028
FRIEBE M
WO 2009141090
A9
20100325
GRAHAM K
EP 2282981
A1
20110216
KOGLIN N
KR 2011013411
A
20110209
MUELLER A
CA 2723594
A1
20091126
SCHMITT-WILLICH H
US 20110064673
A1
20110317
TW 2010010733
A
20100316
EP 2123169
WO 2009142493
A1
20091125
EP 2123169 A1 UPAB: 20091209
A1
20091126
CA 2724985
A1
20091126
EP 2293686
A1
20110316
WO 2009140177
US 20090324602
A2
20091119
NOVELTY: Process for preparing a non cellular
pet chew involves:
(A) preparing a mixture of at least a cereal flour
having protein content (below 10 wt.%), a
plasticizer and a fibrous material;
(B) converting the mixture into a thermoplastic
mass; and
(C) molding the thermoplastic mass into the
desired pet chew. [CONT.]
WO 2009140177 A2 UPAB: 20091214
A1
20091231
WO 2009140177
A3
20100826
AU 2009246640
A1
20091119
CA 2723973
A1
20091119
PARAGON PROD BV
BIOGEN IDEC MA INC
HSU Y
ARRAY BIOPHARMA INC
179 New pyrrolopyridine compound useful for
treating hyperproliferative disease e.g.
sarcoma, lymphoma, fibrosarcoma, carcinoma,
leukemia
180 Use of Lactobacillus paracasei for the
preparation of a composition to e.g. treat or
prevent overweightness, obesity and/or
associated metabolic disorders comprising
hypertension, liver cirrhosis and metabolic
syndrome
diseases (all claimed) such as malignant
DETAILED DESCRIPTION: Fluorinated glutamate lymphoma, pharyngeal cancer, lung cancer, liver
cancer, bladder tumor, rectal cancer, [CONT.]
and glutamine derivative of formula A-C(=O)C(R1)-C(R2)-C(NH2)-C(=O)-G'(I) or its salt,
diastereomer or enantiomer, is new.
NESTEC SA
G'=OH, O-Z', O-1-5C alkyl, O-2-5C alkenyl, O-15C alkyl-(O-1-4C alkyl)n-O-1-4C alkyl or O-2-5C
alkinyl; [CONT.]
A=OH, 1-5C alkoxy, hydroxy-1-5C alkoxy, O-1-5C
alkyl-(O-1-4C alkyl)n-O-1-4C alkyl, N(1-5C alkyl)2,
NH2, N(H)-L', O-L'or O-Z'; [CONT.]
NOVELTY: An isolated antibody or its antigenbinding fragment that: (a) selectively binds to the
polypeptide comprising fully defined 129 amino
acids (SEQ ID NO. 1) given in the specification,
when expressed on the surface of a cell, (i) at an
epitope that includes the amino acid residue
tryptophan at position 42 of SEQ ID NO. [CONT.]
For preparing non cellular pet chew (claimed).
The process provides pet chew from thermoplastic
starch i.e. cereal flour with specific protein
content, fibrous material and plasticizer, which is
prepared from natural materials of renewable
sources, making the chew both edible and
biodegradable; where as compared to a proteinbased product, starch based product requires
specific production steps, in which starch is
gelatinized or destructurized, [CONT.]
The antibody and its antigen-binding fragment is The antibodies are effective in animal models of
useful for inducing death of a tumor cell,
cancer at low doses and with a prolonged effect in
preventing or reducing tumor cell growth, and
preventing tumor growth.
treating a cancer. The cancer is a colon cancer or
a breast cancer (all claimed).
FOOD - Preferred Components: The cereal flour is
rye flour, which is native cereal flour or chemically
or physically modified cereal flour; or a cereal flour
hydrolyzate (preferably rye floor). The plasticizer is
selected from polyols, esters of citric acid and
urea (preferably glycerol). The fibrous material is
selected from cellulose, hennep, coconut, grass,
flax, potato, and other natural fibers [CONT.]
An INDEPENDENT CLAIM is included for a pet
EP 2123169
chew comprising: thermoplastic cereal flour (51-80
wt.%), where the cereal flour has a protein content
(below 10 wt.%); plasticizer (5-30, preferably 1830) wt.%, based on the dry solid weight of the pet
chew, and fibrous material (1-35, preferably 1-25,
especially 5-20) wt.%, based on the dry solid
weight of the pet chew.
BIOTECHNOLOGY - Preferred Antibody: The
isolated antibody or its antigen-binding fragment:
(a) selectively binds to the polypeptide of SEQ ID
NO. 1, when expressed on the surface of a cell;
(b) comprises a variable heavy (VH) domain that
is at least 80% identical to the amino acid
sequence of any one of fully defined 121 or 118
amino acid sequences (SEQ ID NO. 11 or 12)
given in the specification; [CONT.]
INDEPENDENT CLAIMS are:
WO 2009140177
US 20090324602
WO 2009140320
US 20110070317
(1) an isolated cell that produces the antibody or
its antigen-binding fragment;
(2) a method of inducing death of a tumor cell
comprising contacting a tumor cell that expresses
Fn14 with an amount of the antibody or its antigenbinding fragment to induce death of the tumor cell;
[CONT.]
EP 2294089
A2
20110316
TW 2010008579
A
20100301
WO 2009140320
A1
20091119
AU 2009246402
A1
20091119
KR 2011008102
A
20110125
NOVELTY: Pyrrolopyridine compound and its
stereoisomer, tautomer or salt is new.
DETAILED DESCRIPTION: Pyrrolopyridine
compound of formula (I) and its stereoisomer,
tautomer or salt is new.
IN 2010KN04478
A
20110128
A1=direct bond or CRa1Rb1; [CONT.]
CA 2724262
A1
20091119
TW 2010002707
A
20100116
US 20110070317
WO 2009138448
A1
20110324
A1
20091119
EP 2123168
A1
20091125
WO 2009140320 A1 UPAB: 20091216
WO 2009138448 A1 UPAB: 20091209
In a pharmaceutical composition; in therapy; and
for treating hyperproliferative disease (i.e. cancer)
(all claimed) selected from e.g. sarcoma,
lymphoma, fibrosarcoma, carcinoma, leukemia.
(I) is useful for treating or preventing
overweightness, obesity and/or associated
NOVELTY: Use of Lactobacillus paracasei for the metabolic disorders comprising diabetes,
preparation of a composition (I) to treat or prevent hypertension, liver cirrhosis, metabolic syndrome
and/or cardiovascular diseases, where (I) is
overweightness, obesity and/or associated
intended for treating humans (infants, children
metabolic disorders, is claimed.
and/or adults) or animals, preferably pets,
livestock and/or companion animals comprising
dogs or cats. [CONT.]
ORGANIC CHEMISTRY - Preparation (claimed): 4
methods for the preparation of the compound (I) is
given i.e. (1) Process A: reacting pyrrolopyridine
compound of formula (II) with substituted amine
compound of formula (III) under SNAr reaction
condition to obtain the compound (I); (2) Process
B: alkylating pyrrolopyridine compound of formula
(IV) to obtain the compound (I); [CONT.]
(I) is pleasant to consume.
BIOLOGY - Preferred Components: The
Lactobacillus paracasei is Lactobacillus paracasei
strain ST11. (I) comprises at least one other kind
of other food grade microorganisms comprising
bacteria and/or yeasts, where the food grade
microorganisms are probiotics. Preferred
Composition: (I) further contains at least one
prebiotic comprising oligosaccharides and
optionally contain fructose, galactose, mannose,
soy and/or inulin and/or dietary fibers [CONT.]
Pyrrolopyridine compound of formula (I) and its
stereoisomer, tautomer or salt is new.
A1=direct bond or CRa1Rb1;
R1=H, halogen, CN, 1-6C alkyl, 1-6C alkenyl, -O-16C alkyl, -S-1-6C alkyl, 3-6C cycloalkyl, 4 to 6
membered heterocyclic, phenyl, and 5 or 6
membered heteroaryl (where the alkyl, alkenyl,
cycloalkyl, heterocyclic, phenyl or heteroaryl are
optionally substituted with halogen, CN, CF, 1-3C
alkyl, -O-1-3C alkyl and NRc1Rd1; [CONT.]
WO 2009138448
N
EP 2296489
A1
20110323
and/or adults) or animals, preferably pets,
livestock and/or companion animals comprising
dogs or cats. [CONT.]
Composition: (I) further contains at least one
prebiotic comprising oligosaccharides and
optionally contain fructose, galactose, mannose,
soy and/or inulin and/or dietary fibers [CONT.]
The beta -amylase is useful in food processing for The produced enzyme is inexpensive, highly
preparing foodstuffs including bread and rice cake purified, and improves the quality and anti-aging
of foodstuffs.
NOVELTY: A beta -amylase derived from Bacillus and in saccharification for producing maltose
containing syrup or maltose starch syrup.
flexus, is new.
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are included for the following:
BIOTECHNOLOGY - Preparation (claimed): The
beta -amylase is prepared by culturing B.flexus
which has beta -amylase production ability and
recovering beta -amylase from culture solution
and/or microbial cell, where the transformant is
cultured on conditions such that protein encoded
by the gene is produced. [CONT.]
ACTIVITY: Anorectic; Metabolic; Antidiabetic;
Hypotensive; Hepatotropic; Cardiovascular-Gen.
MECHANISM OF ACTION: None given. [CONT.]
181 Novel beta-amylase derived from Bacillus
flexus, useful for processing foodstuffs, e.g.
bread and saccharification for producing
maltose containing syrup or maltose starch
syrup
AMANO ENZYME INC
WO 2009136471
A1
20091112
US 20110059491
A1
20110310
EP 2295563
A1
20110316
WO 2009136471 A1 UPAB: 20091209
INDEPENDENT CLAIMS are included for the
WO 2009136471
following:
(1) agent, comprising beta -amylase as an active
ingredient;
(2) beta -amylase gene comprising (i) DNA which
codes amino acid sequence of SEQ ID NO: 7, (ii)
DNA which contains base sequence of SEQ ID
NO: 6, or (iii) DNA having base sequence
equivalent to the base sequence of SEQ ID NO: 6,
and has beta -amylase activity; [CONT.]
US 20110059491
(1) agent, comprising beta -amylase as an active
ingredient;
(2) beta -amylase gene comprising (i) DNA which
codes amino acid sequence of SEQ ID NO: 7, (ii)
DNA which contains base sequence of SEQ ID
NO: 6, or (iii) DNA having base sequence
equivalent to the base sequence of SEQ ID NO: 6,
and has beta -amylase activity; [CONT.]
GENENTECH INC
182 New affinity matured immunoglobulin
superfamily (CRIg) variant, useful for
LI B
preventing or treating complement-associated
disease or condition, e.g. autoimmune
disease, and for selective inhibiting alternative
complement pathway in mammal
WO 2009137605
WO 2009137605
A2
20091112
WO 2009137605 A2 UPAB: 20091209
A3
20100121
NOVELTY: An immunoglobulin superfamily (CRIg)
variant comprising an amino acid substitution in a
region selected from Glu8-Lys15, Arg41-Thr47,
Ser54-Gln64, Glu85-Gln99, and Gln105-Lys111 of
SEQ ID NO. 2, is new. Sequences not defined
here may be found at
ftp://ftp.wipo.int/pub/publishedpctsequences/public
ation.
SIDHU S S
TW 2009048377
A
20091201
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are: [CONT.]
VAN LOOKEREN CAMPAGNE M
US 20100150908
A1
20100617
WIESMANN C
AU 2009244300
A1
20091112
MX 2010011372
A1
20101130
EP 2280996
A2
20110209
CA 2720685
A1
20091112
KR 2011020798
A
20110303
WO 2009137838
A1
20091112
WO 2009137838 A1 UPAB: 20091209
AU 2009244077
A1
20091112
NOVELTY: A sweetener comprises high intensity
sweetener (HIS) and taste modifying composition
comprising non-congruent flavor volatile(s).
MX 2010012248
A1
20101130
DETAILED DESCRIPTION: An INDEPENDENT
CLAIM is included for manufacture of tabletop
sweetener comprising depositing HIS and taste
modifying composition onto bulking material
having particle size distribution of 0.125-1.0 mm.
[CONT.]
CARGILL INC
183 Sweetener for manufacturing tabletop
sweetener and preparing food product,
beverage, or pharmaceutical or over the
counter drug product, comprises high intensity
sweetener and taste modifying composition
with non-congruent flavor volatile
CARGILL INC
184 Syrup having specific viscosity and dextrose
equivalence, useful as bulking, coating, or
water-retention ingredient in food e.g. cereals,
beverage e.g. dairy-based beverage and
pharmaceutical products, comprises monoand di-saccharides
US 20110059218
A1
20110310
CA 2723814
A1
20091112
WO 2009137839
A1
20091112
WO 2009137839 A1 UPAB: 20091204
The variant and methods are useful for preventing The invention provides CRIg variant with improved
or treating complement-associated disease or
therapeutic efficacy.
condition; inhibiting production of C3b
complement fragment in mammal; and for
selective inhibiting alternative complement
pathway in mammal, where the complementassociated disease is an inflammatory disease, an
autoimmune disease, rheumatoid arthritis (RA),
adult respiratory distress syndrome (ARDS),
[CONT.]
BIOTECHNOLOGY - Preferred Variant: The
INDEPENDENT CLAIMS are:
variant selectively binds to C3b over C3, or its
(1) a chimeric molecule comprising the variant;
fragment. It has increased binding affinity to C3b
over native sequence human CRIg of SEQ ID NO.
2, where the binding affinity is increased by at
least 2-fold. The variant is a more potent inhibitor
of the alternative complement pathway than native
sequence human CRIg of SEQ ID NO. 2. [CONT.]
WO 2009137605
US 20100150908
(2) a pharmaceutical composition comprising the
CRIg variant in admixture with a pharmaceutically
acceptable excipient; or a pharmaceutical
composition comprising an immunoadhesin in
admixture with a pharmaceutically acceptable
excipient; [CONT.]
A sweetener for manufacturing tabletop sweetener
and preparing food product, beverage, or
pharmaceutical or over the counter drug product
(claimed). The foods and beverages include
baked goods, chocolate, candy and confections,
chewing gum, ice cream, yogurt, breakfast cereal,
oatmeal, pudding, fruit preserves and
preparations, breakfast bars, protein bars, granola
bars, cereal coatings, syrups, [CONT.]
Even if HIS has the same number of calories as
sucrose, the usage amount of HIS is less than the
sucrose, thus reducing total calorie amount.
Because HIS is compound having sweetness that
is many times that of sucrose, much less HIS is
required to obtain similar effect as sucrose and its
energy contribution is negligible. [CONT.]
ORGANIC CHEMISTRY - Preferred Components:
The taste modifying composition further comprises
congruent flavor volatile(s). The HIS has sweet
quality that is slower in onset and longer in
duration than that of sugar. The congruent and
non-congruent flavor volatiles modify the sweet
quality of HIS such that the sweet quality intensity
occurs earlier and the sweet quality diminishes
earlier compared to composition of HIS alone
[CONT.]
An INDEPENDENT CLAIM is included for
WO 2009137838
manufacture of tabletop sweetener comprising
depositing HIS and taste modifying composition
onto bulking material having particle size
distribution of 0.125-1.0 mm. The bulking material
is introduced into vessel; the HIS composition is
deposited onto bulking material; and the taste
modifying composition is deposited onto the
bulking material.
US 20110059218
(I) is useful: as bulking, binding, bodying, coating,
or water-retention ingredient in food, beverage,
and pharmaceutical or over-the-counter drug
products; in enhancing flavors or non-masking
flavors of food, beverage, and pharmaceutical or
over-the-counter drug products, where the food is
baked goods, cereals, condiments, confectionery
(I): exhibits a higher rate of flow, improved
microbial stability, a bland taste and minimal or no
sweetness, when compared to a starch derived
product having a similar total mono- and disaccharides. (I) exhibits: a lower adhesiveness to
food processing equipment and a shorter texture.
(I): readily loses more water during food drying;
ORGANIC CHEMISTRY - Preferred Composition:
(I) further comprises: oligosaccharides (greater
than 60 wt.%) with a degree of polymerization of 314 (preferably 3-10) and polysaccharides (less
than 15 or 20 wt.%) with a degree of
polymerization of at least 15 (preferably 11); and a
dry substance (DS) (75-85%). (I) comprises: the
An INDEPENDENT CLAIM is included for a
WO 2009137839
method of making a low-viscosity reduced-sugar
syrup comprising (a) liquefying a starch slurry
having dry solids 10-70% with an acid or an
enzyme to obtain a DE of 1-65, (b) contacting the
liquefied starch slurry from step (a) with an
enzyme, which is pullulanase, isoamylase, and/or
US 20110061645
N
CARGILL INC
184 Syrup having specific viscosity and dextrose
equivalence, useful as bulking, coating, or
water-retention ingredient in food e.g. cereals,
beverage e.g. dairy-based beverage and
pharmaceutical products, comprises monoand di-saccharides
AFEXA LIFE SCI INC
185 Synergistic blood lipid lowering composition
for the preparation of a pharmaceutical
composition for lowering blood lipid levels, for
treating e.g. angina, stroke comprises
combination of huanglian and Ku Ding Cha
extract
MIVAC DEV AB
186 New stable amyloid beta peptide, useful for
preparing pharmaceutical compositions or
vaccine for immunization of mammals, e.g.
humans, for preventing or treating Alzheimer's
disease and other conditions, e.g. amyloidosis
187 Edible composition, useful e.g. to treat anxiety NESTEC SA
e.g. alcohol abuse and cocaine abuse, and
neurodegenerative diseases e.g. Alzheimer's
and Huntington's disease, comprises
Bifidobacterium longum and/or its fermented
growth medium
MALAYSIAN PALM OIL BOARD
188 Treatment of metabolic imbalance, e.g.
diabetes mellitus or gestational diabetes, in
UNIV BRANDEIS
mammal for enhancing insulin secretion or
sensitivity or reducing blood glucose level, by
administering extract from fruit of genus Elaeis
to mammal
MX 2010012252
A1
20101231
EP 2288714
A1
20110302
CA 2723900
A1
20091112
US 20110061645
WO 2009133458
A1
20110317
A1
20091105
US 20090285915
A1
20091119
WO 2009133458
A4
20091230
AU 2009241274
A1
20091105
CA 2723132
A1
20091105
KR 2011021828
A
20110304
(I) is useful: as bulking, binding, bodying, coating,
or water-retention ingredient in food, beverage,
NOVELTY: Syrup (I) comprises mono- and diand pharmaceutical or over-the-counter drug
saccharides (less than 25 wt.% or 0.5-25 wt.%),
products; in enhancing flavors or non-masking
having a lower viscosity compared to a starchderived product having a similar dry wt.% of mono- flavors of food, beverage, and pharmaceutical or
over-the-counter drug products, where the food is
and di-saccharides, and a dextrose equivalence
baked goods, cereals, condiments, confectionery
(DE) of 20-52 or 26-52. [CONT.]
including chocolate, hard and soft candies, mints,
gum and [CONT.]
(I): exhibits a higher rate of flow, improved
microbial stability, a bland taste and minimal or no
sweetness, when compared to a starch derived
product having a similar total mono- and disaccharides. (I) exhibits: a lower adhesiveness to
food processing equipment and a shorter texture.
(I): readily loses more water during food drying;
can easily pumped particularly at low
temperatures; [CONT.]
ORGANIC CHEMISTRY - Preferred Composition:
(I) further comprises: oligosaccharides (greater
than 60 wt.%) with a degree of polymerization of 314 (preferably 3-10) and polysaccharides (less
than 15 or 20 wt.%) with a degree of
polymerization of at least 15 (preferably 11); and a
dry substance (DS) (75-85%). (I) comprises: the
mono- and di-saccharides (less than 25 wt.
[CONT.]
An INDEPENDENT CLAIM is included for a
WO 2009137839
method of making a low-viscosity reduced-sugar
syrup comprising (a) liquefying a starch slurry
having dry solids 10-70% with an acid or an
enzyme to obtain a DE of 1-65, (b) contacting the
liquefied starch slurry from step (a) with an
enzyme, which is pullulanase, isoamylase, and/or
amylase, where the total enzyme relative to the
dry weight of the starch is 0. [CONT.]
US 20110061645
WO 2009133458 A1 UPAB: 20091204
The synergistic combination of HL and KDC
promotes cardiovascular health by reducing
triglyceride levels, low-density-lipoprotein
cholesterol levels and total cholesterol levels.
ORGANIC CHEMISTRY - Preferred Solvent: The
solvent is water, acid water, aqueous alcohol,
acidic aqueous alcohol, ethyl acetate and ethyl
acetate-based solvent mixture (preferably
aqueous alcohol extraction, ethyl acetate or an
ethyl acetate-based solvent mixture).
PHARMACEUTICALS - Preferred Components:
The huanglian is berberine containing plant
extract. [CONT.]
INDEPENDENT CLAIMS are included for the
following:
(1) method (m1) of lowering the blood lipid levels
in a patient involving administering to the patient
HL and KDC;
WO 2009133458
US 20090285915
BIOTECHNOLOGY - Preferred Peptide: The
peptide further comprises fully defined 20 amino
acids (SEQ ID NO: not defined) given in the
specification corresponding to amino acids 17 to
36 of SEQ ID NO. 4, or a variant of the peptide
where 1-5 amino acids have been replaced by
conservative substitution, 1-5 amino acids have
been deleted, or 1-5 amino acids have been
inserted; or an amino acid sequence
corresponding to amino acids 1 to 40 of SEQ ID
NO [CONT.]
A peptide comprising Leu-Val-Phe-Phe-Cys (SEQ WO 2009128772
ID NO: not defined) corresponding to amino acids
17-21 of SEQ ID NO. 4 and Cys-Ile-Ile-Gly-LeuMet-Val (SEQ ID NO: not defined) corresponding
to amino acids 30-36 of SEQ ID NO. 4, where the
peptide further comprises a disulfide bond
between the cysteine residues corresponding to
amino acids 21 and 30 of SEQ ID NO. [CONT.]
US 20110064741
As blood lipid lowering composition for the
preparation of a pharmaceutical composition, as
food or a beverage for the lowering of blood lipid
NOVELTY: A synergistic blood lipid lowering
composition comprises synergistic combination of levels, for treating or preventing cardiovascular
disease, hyperlipidemia, cardiomyopathy,
huanglian (HL) and Ku Ding Cha (KDC) extract.
hyperlipoproteinemia, high levels of lipoprotein,
ischemia, coronary heart disease, atherosclerosis,
DETAILED DESCRIPTION: INDEPENDENT
angina, cerebrovascular disease, stroke,
CLAIMS are included for the following:
overweight or obesity, [CONT.]
(2) producing (m2) a blood lipid level lowering
composition involving obtaining KDC extract using
liquid extraction in 1-1000 ml solvent per gram of
KDC in a solvent, recovering the KDC product,
obtaining a berberine product from a [CONT.]
(1) method (m1) of lowering the blood lipid levels
in a patient involving administering to the patient
HL and KDC; [CONT.]
WO 2009128772
A1
20091022
WO 2009128772 A1 UPAB: 20091112
AU 2009236699
A1
20091022
NOVELTY: A peptide comprising fully defined 5
amino acids (SEQ ID NO: not defined) given in the
specification corresponding to amino acids 17-21
of SEQ ID NO. 4 and fully defined 7 amino acids
(SEQ ID NO: not defined) given in the
specification corresponding to amino acids 30-36
of SEQ ID NO. 4, where the peptide further
comprises a disulfide bond between the cysteine
residues corresponding to amino acids 21 and 30
of SEQ ID NO [CONT.]
EP 2262526
A1
20101222
CA 2721156
A1
20091022
US 20110064741
EP 2110028
WO 2009127566
A1
20110317
A1
20091021
A1
20091022
TW 2009048372
A
20091201
EP 2291089
US 20090252817
WO 2009146102
A1
20110309
A1
20091008
A1
20091203
The peptide is useful for preparing pharmaceutical
compositions or vaccine for immunization of
mammals, including humans, for preventing or
treating Alzheimer's disease. The peptide and
methods are useful for identifying compound
suitable for treating Alzheimer's disease; selecting
binding proteins; and for preventing or treating
mammal, including human being, suffering from
Alzheimer's disease or facing the risk of
developing Alzheimer's disease (all claimed)
[CONT.]
EP 2110028 A1 UPAB: 20091106
(I) is useful as a food composition, a pet food
composition, a dietary supplement, a drink and/or
NOVELTY: Edible composition (I) comprises
medical composition. (I) is useful: for the
Bifidobacterium longum, preferably B. longum
preparation of a formulation to increase
ATCC BAA-999 and/or its fermented growth
hippocampal brain-derived neurotrophic factor
medium.
expression; to treat or prevent anxiety, anxiety
ACTIVITY: Anabolic; Tranquilizer; Antidepressant;
related disorders including depression, abuse of
Antiaddictive; Antialcoholic; Eating-Disorderssubstances, such as alcohol abuse, cocaine
Gen.; Hypnotic; Nootropic; Neuroprotective;
abuse, opiate abuse, compulsive [CONT.]
Antiparkinsonian; Anticonvulsant;
Antiinflammatory; Cerebroprotective; Antidiabetic.
[CONT.]
(I) is easily available to everybody. The pleasant
taste of food compositions will further contribute to
the acceptance of the product, in particular small
children or pets are much more likely to readily
consume (I) with a taste that is generally liked.
BIOLOGY - Preferred Composition: (I) comprises
additionally at least one other kind of other food
grade bacteria, preferably lactic acid bacteria,
bifidobacteria and/or propionibacteria. (I) further
contains at least one prebiotic, which is:
oligosaccharides and optionally contain fructose,
galactose, mannose, soy and/or inulin; and/or
dietary fibers. In (I), at least a part of B. longum,
preferably B [CONT.]
US 20090252817 A1 UPAB: 20091028
The method prevents a secondary medical
complication of diabetes mellitus like heart
disease, stroke, hypertension, retinopathy,
cataract, nephropathy, neuropathy, peripheral
vascular disease, dental disease, gastroparesis,
sexual dysfunction, or complications during
pregnancy.
PHARMACEUTICALS - Preferred Components:
The extract is in a nutraceutical or pharmaceutical
composition, and is a water-soluble component
having phenolic including cinnamate or benzoate
derivatives. The extract is from the vegetation
liquor of the palm oil milling process and is palm
fruit juice. [CONT.]
Method of treating a metabolic imbalance in a
NOVELTY: A metabolic imbalance in a mammal is mammal for enhancing an insulin secretion or
treated by administering to the mammal an extract sensitivity, or reducing a blood glucose level. The
metabolic imbalance is diabetes mellitus,
from a fruit of genus Elaeis.
gestational diabetes, genetic defects of beta -cell
function, genetic defects in insulin action,
diseases of the exocrine pancreas,
endocrinopathies, drug or chemical-induced
infections, other genetic syndromes associated
with diabetes, a pre-diabetic state, or metabolic
syndrome, preferably diabetes mellitus or
metabolic syndrome [CONT.]
EP 2110028
An INDEPENDENT CLAIM is included for a kit
US 20090252817
comprising a package comprising a composition
of an extract of the vegetation liquor from the
milling process of the fruit of genus Elaeis; and
instructions for use of the extract of the vegetation
liquor from the milling process of the fruit of genus
Elaeis for a treatment of a metabolic imbalance.
US 20090252817
administering extract from fruit of genus Elaeis
to mammal
vascular disease, dental disease, gastroparesis,
sexual dysfunction, or complications during
pregnancy.
derivatives. The extract is from the vegetation
liquor of the palm oil milling process and is palm
fruit juice. [CONT.]
instructions for use of the extract of the vegetation
liquor from the milling process of the fruit of genus
Elaeis for a treatment of a metabolic imbalance.
The synthetic analogs of human growth hormone
releasing hormone hGH-RH(1 -29)NH2 comprise
specific mutations or amino acid replacements at
specific positions; and result in inhibition of
release of growth hormone from pituitary in
mammals as well as inhibition of proliferation of
human cancers through direct effect on cancer
cells, where a stronger inhibitory potencies is
achieved as compared to the prior art hGH-RH
antagonists, GH antagonists and somatostatin
analogs [CONT.]
BIOTECHNOLOGY - Preparation (disclosed): The
synthetic hGHRH(1-29)NH2 polypeptides are
synthesized by standard solid phase techniques
e.g. as described in Solid Phase Peptide
Synthesis, J. M. Stewart and J. D. Young, Pierce
Chem. Company, Rockford, Illinois, 1984 (2nd.
ed.) and Merrifield, J. Am. Chem. Soc, 85 p.
[CONT.]
New synthetic analogs of human growth hormone WO 2009120831
releasing hormone (hGHRH)(1-29)NH2 comprise:
polypeptides having sequences containing 29-31
amino acids with specific mutations at specific
positions as given in the specification, selected
from sequences of (SEQ ID NO:99), (SEQ ID
NO:100) and (SEQ ID NO: 101) as given in the
specification, and their salts.
AU 2009251568
A1
20091203
EP 2288364
WO 2009120831
WO 2009120831
A1
20110302
A2
20091001
WO 2009120831 A2 UPAB: 20091015
A3
20091223
NOVELTY: Synthetic analogs of human growth
hormone releasing hormone (hGHRH)(1-29)
comprising: polypeptides having specific
sequences with specific mutations at specific
positions as given in the specification and their
salts; are new. [CONT.]
A1
20100415
CAI R Z
US 20100092539
WO 2009120831
A8
20100506
SCHALLY A
US DEPT VETERANS AFFAIRS
189 New synthetic human growth hormone
releasing hormone analogs for treating e.g.
UNIV MIAMI
cancer comprise polypeptides having
sequences with specific mutations at specified
positions
BLOCK N L
190 New composition comprises human
mesenchymal stem cells as the active
principle, useful for treating atopic dermatitis
in humans
gestational diabetes, genetic defects of beta -cell
function, genetic defects in insulin action,
DETAILED DESCRIPTION: An INDEPENDENT
diseases of the exocrine pancreas,
CLAIM is included for a kit comprising a package
endocrinopathies, drug or chemical-induced
comprising a composition of an extract of the
infections, other genetic syndromes associated
vegetation liquor from the milling process of the
with diabetes, a pre-diabetic state, or metabolic
fruit of genus Elaeis; and instructions for use of
syndrome, preferably diabetes mellitus or
the extract of the vegetation liquor from the milling
metabolic syndrome [CONT.]
process of the fruit of genus Elaeis for a treatment
of a metabolic imbalance. [CONT.]
AU 2009228244
A1
20091001
VARGA J
EP 2288374
A2
20110302
ZARANDI M
CA 2718146
A1
20091001
JCR PHARM CO LTD
EP 2105498
US 20090246181
A1
20090930
MIRACURE INC
A1
20091001
JAPAN CHEM RES CO LTD
JP 2009242265
A
20091022
DETAILED DESCRIPTION: An INDEPENDENT
CLAIM is a human mesenchymal stem cell for use
as a medicament for the treatment of atopic
dermatitis.
MIRACURE KK
US 20110070207
A1
20110324
ACTIVITY: Dermatological. Test details are
described but no results given.
MECHANISM OF ACTION: Cell Therapy. [CONT.]
WO 2009117566
A1
20090924
WO 2009117566 A1 UPAB: 20091012
US 20110059137
A1
KURODA M
For the production of a pharmaceutical
composition for suppressing levels of growth
hormone (GH) in a patient; suppressing insulinlike growth factor (IGF)-I (preferably serum IGF-I
levels) or IGF-II levels in the tumor tissue of a
patient having a cancer carrying receptors for IGFI; suppressing vascular endothelial growth factor
(VEGF) or fibroblast growth factor (FGF) levels in
the tumor tissue of a patient having a cancer
[CONT.]
EP 2105498 A1 UPAB: 20091012
The mesenchymal stem cell and composition are
useful for the treatment of atopic dermatitis (all
NOVELTY: A composition for the treatment of
atopic dermatitis comprising human mesenchymal claimed).
stem cells as the active principle, is new.
The composition is a non-steroidal composition for BIOTECHNOLOGY - Preferred Composition: The An INDEPENDENT CLAIM is a human
the treatment of atopic dermatitis.
composition is an injection. The atopic dermatitis mesenchymal stem cell for use as a medicament
is in a mammal, where the mammal is selected
for the treatment of atopic dermatitis.
from human, dog, cat, rabbit, or rodent. The
human mesenchymal stem cells are of humanbone marrow origin. The mammal is a human and
is not the same as the human from whom the
human mesenchymal stem cells originate.
US 20100092539
EP 2105498
US 20090246181
US 20110070207
WO 2009117566
US 20110059137
N
SUDO K
TAKANASHI M
YAMAUCHI S
MOFFITT CANCER CENT&RES INST INC H LEE
191 New population of chemokine gene-modified
cells, useful for inducing an immune response
UNIV SOUTH FLORIDA
to a cancer and for treating cancer
20110310
The population of cells and therapeutic
The present invention provides CCL21
composition are useful for inducing an immune
augmenting anti-tumor immune responses, and
response to a cancer and for treating cancer. The thus improves efficacy of cancer immunotherapy.
NOVELTY: A population of cells that have been
population of cells is useful for manufacturing a
genetically-modified to express exogenous
macrophage colony stimulating factor (GM-CSF), medicament for the treatment of cancer. The
exogenous CD40 ligand (CD40L), and exogenous population of cells is used as a medicament.
[CONT.]
chemokine C-C motif ligand 21 (CCL21), where
the population of cells comprises bystander cells
and target cancer cells, is new.
BIOTECHNOLOGY - Preferred Population: The
INDEPENDENT CLAIMS are:
bystander cells express GM-CSF and CD40L,
where the bystander cells also express CCL21.
(1) a method of preparing a population of cells
The target cancer cells express CCL21. The
above; and
bystander cells are major histocompatibility
complex (MHC) negative. The bystander cells are
from the cell line K562. The target cancer cells
comprise cells from a solid or hematopoieticderived tumor. [CONT.]
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are: [CONT.]
192 New gene construct comprises linked
nucleotide sequence with a region that
recognizes the beta chain of class II DR
antigen, and nucleotide sequence encoding a
vaccine antigen of interest, useful for treating
or preventing disease
ALGENEX ALTERNATIVE GENE EXPRESSION
SL
INST NACIONAL
INVESTIGACION&TECNOLOGIA
WO 2009112603
A1
20090917
WO 2009112603 A1 UPAB: 20091001
CA 2717997
A1
20090917
NOVELTY: A gene construct comprising
operatively linked: (a) a nucleotide sequence (A)
that encodes a polypeptide of SEQ ID NO: 1
which has a region that recognizes the beta chain
of class II DR antigen on the surface of antigen
presenting cells; and (b) a nucleotide sequence
(B) encoding a vaccine antigen of interest,
capable of inducing an immune response in the
host where it is introduced, is new. [CONT.]
The gene construct is useful for transforming plant
cells or animal cells in general and in particular
human; and for treating or preventing disease (all
claimed).
BIOTECHNOLOGY - Preferred Construct: In the
gene construct, the vaccine antigen of interest is
2L21 canine parvovirus peptide, VP60 protein of
rabbit hemorrhagic disease, rotavirus VP6 protein,
E2 protein or E2T Bovine viral diarrhea virus, or
influenza virus hemagglutinin protein. [CONT.]
(2) a method of treating a cancer in a subject by
administering to the subject a therapeutic amount
of a composition comprising a population of cells
above.
INDEPENDENT CLAIMS are:
WO 2009112603
(1) a recombinant expression vector useful for
transforming plant cells or animal cells in general
and in particular human comprising the gene
constructs above;
US 20110061136
N
N
NIPPON SUISAN KAISHA LTD
193 Agent useful in food/beverage products, e.g.
canned foods used as dietary supplement for
enhancing saltiness with reduced salt content,
comprises dipeptide having glutamic acid as
constituent amino acid as active ingredient
BIOLAB SANUS FARM LTDA
194 Composition, useful to treat mitochondrial
disturbance e.g. Alzheimer's disease or
Parkinson's disease and to treat mitochondrial
disturbance related side effect induced by a
drug, comprises a racetam, carnitine and
vehicle
US 20110061136
A1
20110310
EP 2298910
A1
20110323
WO 2009113563
A1
20090917
WO 2009113563 A1 UPAB: 20091006
AU 2009224376
A1
20090917
NOVELTY: Saltiness enhancing agent comprises
dipeptide having at least one glutamic acid as
constituent amino acid, as an active ingredient.
EP 2253227
A1
20101124
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are included for the following:
US 20110064861
A1
20110317
(1) salty augmentation method, involves adding
saltiness enhancing agent to foodstuff containing
salt; and [CONT.]
WO 2009105853 A2 UPAB: 20090915
WO 2009105853
A2
20090903
BR 2008000432
A2
20091103
WO 2009105853
A3
20091126
WO 2009105853
A8
20100218
AU 2009219050
A1
20090903
MX 2010009290
A1
20100930
KR 2010126454
A
20101201
BR 2009001321
A2
20101116
(2) a cell transformed or transfected with the
vector of (1) comprising in its genome any of the
gene constructs above;
(3) a transgenic plant transformed or transfected
with the vector of (1) comprising in its genome any
of the gene constructs above; [CONT.]
NOVELTY: Pharmaceutical composition (I)
comprises: a racetam or its salt or isomer; a
carnitine or its salt or isomer; and a vehicle.
DETAILED DESCRIPTION: An INDEPENDENT
CLAIM is included for a process for the
preparation of (I) comprising mixing the racetam
and carnitine, or their salts or isomers, with a
vehicle.
ACTIVITY: Muscular-Gen.; Neuroprotective;
Nootropic [CONT.]
EP 2262495
A2
20101222
CA 2716020
A1
20090903
US 20110052556
WO 2009106368
EP 2252324
A1
20110303
A1
20090903
WO 2009106368 A1 UPAB: 20090923
A1
20101124
NOVELTY: An ectophosphatase is used for
preparing a medicament for the prophylaxis of a
mammal at risk of inflammatory diseases.
US 20110052560
A1
20110303
DETAILED DESCRIPTION: An INDEPENDENT
CLAIM is included for a pharmaceutical
composition comprising an ectophosphatase and
carriers and/or diluents.
CA 2716400
A1
20090903
WO 2009100871
WO 2009100871
A2
20090820
ACTIVITY: Immunostimulant. Test details are
described but no results given. [CONT.]
WO 2009100871 A2 UPAB: 20090907
A3
20091223
GENERAL S
TW 2009040069
A
20091001
TEREBESI I
AU 2009214307
A1
20090820
KR 2010117603
A
20101103
GELATO CORP NV
195 Use of ectophosphatase for preparing
medicament or pharmaceutical composition
ALLOKSYS LIFE SCI BV
for prophylaxis of mammal (preferably human)
at risk of inflammatory diseases (preferably
conditions resulting in decreased activity of
immune system)
196 Unit dosage form for treating e.g. osteoporosis BAYER SCHERING PHARMA AG
comprises thin water-soluble film matrix
FUNKE A
having polyvinyl alcohol-polyethylene glycol
graft copolymer as water-soluble matrix
polymer, and six, seven-unsubstituted steroid
as active ingredient
The agent is useful in food/beverage products for
enhancing salty taste with reduced salt content (all
claimed). The food/beverage products include fish
processing foodstuffs, e.g. salmon flakes, grilled
fish, fish meat sausage or canned foods, snacks,
e.g. [CONT.]
BIOTECHNOLOGY - Preferred Peptide: The
dipeptide which contains at least one glutamic
acid as constituent amino acid is a dipeptide
chosen from the Glu-Ala, Glu-Arg, Glu-Asn, GluAsp, Glu-Gln, Glu-Glu, Glu-Gly, Glu-His, Glu-Ile,
Glu-Leu, Glu-Lys, Glu-Pro, Glu-Ser, Glu-Thr, GluTrp, Glu-Tyr, Glu-Val, Arg-Glu, Asn-Glu, Asp-Glu,
Gln-Glu, His-Glu, Pro-Gly, Ser-Glu, Thr-Glu and
Trp-Glu. [CONT.]
INDEPENDENT CLAIMS are included for the
following:
(1) salty augmentation method, involves adding
saltiness enhancing agent to foodstuff containing
salt; and
(I) is useful in the manufacture of a medicament: (I) exhibits synergistic effect to treat mitochondrial
for the treatment and/or prevention of a
disturbance.
mitochondrial disturbance and mitochondrial
disturbance related side effect induced by a drug
in a mammal, where the mitochondrial disturbance
is myopathy or a neurodegenerative dysfunction,
which is Alzheimer's disease or Parkinson's
disease (all claimed); and for the treatment and/or
prevention of toxicity induced by a drug, or
conditions associated with oxidative stress, such
as hypoxia, hypoglycemia and aging [CONT.]
PHARMACEUTICALS - Preferred Composition: (I)
further comprises: a coenzyme Q10
(2,3,dimethoxyl-5-methyl-6-decaprenil-1,4benzoquinone); and at least one therapeutic agent
associated with mitochondrial and/or metabolic
disturbance. Preferred Components: The
therapeutic agent associated with mitochondrial
and/or metabolic disturbance is a
hypocholesterolemic agent (preferred), a pyridinic
nucleotide oxidant, a thyroid hormone, an
antiepileptic agent or a hypoglycemic agent
[CONT.]
An ectophosphatase for preparing a medicament
or pharmaceutical composition for the prophylaxis
of a mammal at risk of inflammatory diseases. The
prophylaxis is an increased in activity of the
immune system, or induction of endogenous
ectophosphatase levels. The risk of inflammatory
disease is conditions resulting in a decreased
activity of the immune system. [CONT.]
The ectophosphatase is capable of
dephosphorylating an extra-cellular substrate in
the extra-cellular space, and modulating the
activity of the immune system.
BIOTECHNOLOGY - Preferred Component: The
ectophosphatase is alkaline phosphatase, CD39
or CD73 nucleotidase, or apyrase (preferably
CD39 like ATP/Adenosine diphosphatase).
The unit dosage form has a weight of 5-200
(preferably 10-100, especially 10-50) mg; has a
modulus of elasticity of less than 200 (preferably
less than 150, especially less than 100) MPas or
20-200 MPas; and a % elongation of greater than
15 (preferably greater than 20)% or 15-100%.
With a thickness normalized to about 50 mu m the
disintegration time of the unit dosage form is 1525 seconds. [CONT.]
PHARMACEUTICALS - Preferred Components:
The active ingredient is a steroidal estrogen in
which the positions 6 and 7 of the steroidal
skeleton are both a -CH2- residue; or is a steroidal
estrogen in which the positions 6 and 7 of the
steroidal skeleton are both a -CH2- residue and
with an OH group, an ester or an ether group in
position 3 of the steroidal skeleton. [CONT.]
As unit dosage form; as a medicament (claimed).
For the formulation of steroidal hormones such as
NOVELTY: A unit dosage form comprises a thin
steroidal sex hormones like estrogens and/or
water-soluble film matrix, where the film matrix
progestins; in hormone replacement therapy; for
contains a polyvinyl alcohol-polyethylene glycol
graft copolymer (PVA-PEG graft copolymer) as a treating physical conditions in female mammal
caused by insufficient endogenous levels of
water-soluble matrix polymer; and active
ingredient, which is steroid in which the positions estrogen such as osteoporosis, headache,
nausea, depression, vasomotor symptoms,
6 and 7 of the steroidal skeleton are both -CH2residues, where the film matrix has a thickness of symptoms of urogenital atrophy, decrease in bone
mineral density and increased risk or incidence of
less than 300 (preferably less than 100) mu m.
bone fracture [CONT.]
[CONT.]
The saltiness enhancing agent compensates
insufficient saltiness in case of intending salt
reduction, and thus prevents disease caused by
excessive intake of salt. The saltiness enhancing
agent does not impair salt taste and flavor of
food/beverage products. The saltiness enhancing
agent is cost-effective.
WO 2009113563
US 20110064861
An INDEPENDENT CLAIM is included for a
process for the preparation of (I) comprising
mixing the racetam and carnitine, or their salts or
isomers, with a vehicle.
WO 2009105853
US 20110052556
N
An INDEPENDENT CLAIM is included for a
pharmaceutical composition comprising an
ectophosphatase and carriers and/or diluents.
WO 2009106368
US 20110052560
N
WO 2009100871
US 20110052699
(2) method for enhancing saltiness enhancing
effect of enzymatic decomposition product of
protein, involves concentrating the dipeptide
having at least one glutamic acid of enzymatic
decomposition product of protein.
197 Composition, useful to influence recovery from NESTEC SA
strenuous physical activity and reduce
MIDDLETON R P
symptom of damage from strenuous physical
activity e.g. muscle fiber damage, comprises
carbohydrate, maltodextrins and starch, and
protein
REYNOLDS A J
ZANGHI B M
198 New bi-cyclic substituted pyrazolone azo
compound or its salt, hydrate, solvent
compound, or ester, useful for preparing
thyroid peroxidase (TPO) regulator and for
preparing medicine for treating platelet
decrease in mammals
199 Treating or preventing dyslipidemia and
steatosis disorders, e.g. atherosclerosis, by
administering nucleic acid molecule that
downmodulates activity of X box binding
protein-1 (XBP-1) or interferon response
element (IRE)-1 to a subject
200 Evaluating excrement from group-housed
animals in an excrement elimination event by
providing primary enclosure, at least two
animals, and automated collection system,
detecting identifiers, and collecting the
detected animal's excrement
EP 2252261
A2
20101124
MX 2010008945
A1
20100930
US 20110052699
A1
20110303
CA 2714598
A1
20090820
WO 2009099628
WO 2009099628
A2
20090813
WO 2009099628 A2 UPAB: 20090902
A3
20091029
NOVELTY: Composition comprises readilyabsorbable carbohydrate (4-6%), maltodextrins
(10-30%) and starch (20-50%) for a total of 4080% of carbohydrate, and protein (20-40%).
AU 2009210728
A1
20090813
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are included for: [CONT.]
EP 2240185
A2
20101020
MX 2010008726
A1
20100831
CA 2712987
A1
20090813
CN 101939011
A
20110105
US 20110052753
A1
20110303
JIANGSU HENGRUI MEDICINE CO LTD
CN 101481352
A
20090715
SHANGHAI HENGRUI MEDICAL CO LTD
WO 2009092276
A1
20090730
SHANGHAI HENGRUI PHARM CO LTD
CN 101679286
A
20100324
CHEN Y
AU 2009207966
A1
20090730
FEL H
EP 2236500
A1
20101006
LUE H
KR 2010120141
A
20101112
TANG P C
MX 2010007553
A1
20101031
WANG L
US 20100316601
A1
20101216
WANG S
CA 2711535
A1
20090730
ZHENG H
JP 2011509263
T
20110324
20090723
LEE A
WO 2009091815
WO 2009091815
A2
A3
20090911
A1
20090917
A1
20110303
IAMS CO
US 20090232738
US 20110052669
WO 2009091886
A2
20090723
HARVARD COLLEGE
The composition is useful for influencing recovery
from strenuous physical activity in an animal within
a time period of 90 minutes before the start of the
physical activity to 90 minutes after the completion
of the physical activity, and to reduce at least one
symptom of damage from strenuous physical
activity so as to hasten recovery from the
strenuous physical activity, relative to a control
[CONT.]
The composition influences faster or more
complete recovery for the next strenuous activity,
and has improved performance during the activity
because of reduced damage from preceding
exercise or activity session.
CN 101481352 A UPAB: 20090819
The compound is useful for preparing thyroid
peroxidase (TPO) regulator; for preparing
medicine for treating platelet decrease in
NOVELTY: A bi-cyclic substituted pyrazolone azo mammals, where the mammal is human; as a
compound or its salt, hydrate, solvent compound, colony stimulating factor, cellular factor,
chemotactic factor, interleukin or cellular factor
or ester, is new.
DETAILED DESCRIPTION: A bi-cyclic substituted receptor stimulant or antagonist, soluble receptor,
receptor stimulant or antagonist antibody or
pyrazolone azo compound or its salt, hydrate,
solvent compound, or ester of formula (I), is new. peptide or small molecule substance with same
action mechanism with one or more medicines
[CONT.]
INSTRUMENTATION AND TESTING - Preferred
Components: The means is a displayed web site,
visual display kiosk, brochure, product label,
package insert, advertisement, handout, public
announcement, audiotape, videotape, DVD,
compact disc read-only memory, computer
readable chip, computer readable card, computer
readable disk, universal serial bus device, firewire
device and/or computer memory. [CONT.]
INDEPENDENT CLAIMS are included for:
ORGANIC CHEMISTRY - Preferred Component:
The salt includes ethanolamine salt and choline
quaternary ammonium salt. Preparation (claimed):
Preparation of the compound of formula (I)
comprises: diazotizing the substituted aniline
compound and sodium nitrate in acid and
performing coupling reaction with the compound in
the formula (IA) in the alkaline solution to obtain
the compound in the formula (I) [CONT.]
A bi-cyclic substituted pyrazolone azo compound
or its salt, hydrate, solvent compound, or ester of
formula (I), is new.
R=OH or carboxylic ester;
R=OH or carboxylic ester; [CONT.]
WO 2009099628
US 20110052753
CN 101481352
US 20100316601
(1) a kit (a) for influencing recovery of an animal
from strenuous physical activity, comprising the
composition in separate containers in a single
package or in separate containers in a virtual
package, and instructions for using the
composition for influencing recovery from
strenuous physical activity in an animal that has or
is undergone such physical activity; [CONT.]
R1, R2, R3, and R4=H, alkyl, alkoxy, halogen, aryl
or heteroaryl; aryl or heteroaryl is further
substituted by alkyl, halogen, hydroxyl, tetrazolyl,
carboxylic acid or carboxylic ester;
R5, R6, and R7=H, alkyl, alkoxy, halogen,
hydroxyl, amino, nitro, cyano, carboxylic acid or
carboxylic ester; [CONT.]
WO 2009091815 A2 UPAB: 20090811
The methods are useful for treating and/or
preventing dyslipidemia, atherosclerosis, hepatic
NOVELTY: Treating and/or preventing
steatosis, steatohepatitis, or non-alcoholic hepatic
dyslipidemia, atherosclerosis, hepatic steatosis,
steatohepatitis; and for identifying compound that
steatohepatitis, or non-alcoholic hepatic
steatohepatitis comprises administering a nucleic is useful in treating and/or preventing dyslipidemia
acid molecule that downmodulates the activity of X (all claimed).
box binding protein-1 (XBP-1) or interferon
response element (IRE)-1 to a subject having
dyslipidemia, atherosclerosis, hepatic steatosis,
steatohepatitis, non-alcoholic hepatic
steatohepatitis in an amount sufficient to
downmodulate de novo hepatic lipogenesis,
hepatic steatosis, or non-alcoholic hepatic
steatohepatitis. [CONT.]
BIOTECHNOLOGY - Preferred Method:
Alternatively, treating and/or preventing
dyslipidemia comprises administering an agent
that upmodulates the activity of XBP-1 or IRE-1 to
a subject that would benefit from increased de
novo hepatic lipogenesis in an amount sufficient to
upmodulate de novo hepatic lipogenesis, to thus
treat and/or prevent dyslipidemia in the subject.
[CONT.]
Treating and/or preventing dyslipidemia,
WO 2009091815
atherosclerosis, hepatic steatosis, steatohepatitis,
or non-alcoholic hepatic steatohepatitis comprises
administering a nucleic acid molecule that
downmodulates the activity of X box binding
protein-1 (XBP-1) or interferon response element
(IRE)-1 to a subject having dyslipidemia,
atherosclerosis, hepatic steatosis, steatohepatitis,
non-alcoholic hepatic [CONT.]
US 20090232738
US 20110052669
WO 2009091886 A2 UPAB: 20100712
BIOTECHNOLOGY - Preferred Method: The
method further comprises placing the collected
excrement into one of the storage containers;
identifying the excrement containing storage
container; and correlating the identified excrement
containing storage container with the identifier of
the detected animal. The automated collection
system is selected from a urine collection system,
a fecal collection system, and a combination
Evaluating excrement from group-housed animals WO 2009091886
in an excrement elimination event comprises: (a)
providing a primary enclosure (10); (b) providing at
least two animals within the primary enclosure; (c)
providing at least one automated collection
system within the primary enclosure, the
automated collection system (20) comprises a
collection system detection means for detecting
an animal; [CONT.]
US 20090250012
The methods are useful for evaluating excrement The invention provides an improved method for
from group-housed animals in an excrement
feeding animals and subsequently collecting the
elimination event; and for evaluating the impact of animal's excrement.
a diet composition on an animal's urinary tract
health or gastrointestinal tract health (all claimed).
N
200 Evaluating excrement from group-housed
animals in an excrement elimination event by
providing primary enclosure, at least two
animals, and automated collection system,
detecting identifiers, and collecting the
detected animal's excrement
201 New cadherin-11 antagonist that specifically
binds an extracellular domain of a mammalian
cadherin-11 protein useful to manufacture of a
medicament for treating an inflammatory joint
disorder e.g. rheumatoid arthritis and
osteoarthritis
PROCTER&GAMBLE CO
US 20090250012
A1
20091008
ADAMS K M
WO 2009091886
A3
20091029
GOUBEAUX C T
AU 2009206149
A1
20090723
GREENE J H
CA 2712784
A1
20090723
MANOS S C
US 7905201
WO 2009089062
WO 2009089062
B2
20110315
A2
20090716
A3
20090924
US 20090253200
A1
20091008
AU 2009204467
A1
20090716
WO 2009089062
EP 2242769
US 20110008323
A8
20100902
A2
20101027
A1
20110113
MX 2010007551
A1
20101130
CA 2711394
A1
20090716
US 20110045003
A1
20110224
CN 101952316
A
20110119
JP 2011509094
T
20110324
WO 2009086591
A1
20090716
CA 2711497
A1
20090716
JP 2011509080
T
20110324
WO 2009087467
A2
20090716
CA 2619381
A1
20090630
SYNOVEX CORP
The methods are useful for evaluating excrement The invention provides an improved method for
from group-housed animals in an excrement
feeding animals and subsequently collecting the
NOVELTY: Evaluating excrement from groupelimination
event;
and
for
evaluating
the
impact
of
animal's excrement.
housed animals in an excrement elimination event
comprises: (a) providing a primary enclosure (10); a diet composition on an animal's urinary tract
health or gastrointestinal tract health (all claimed).
(b) providing at least two animals within the
primary enclosure; (c) providing at least one
automated collection system within the primary
enclosure; (d) associating an identifier with each
of the animals; [CONT.]
BIOTECHNOLOGY - Preferred Method: The
method further comprises placing the collected
excrement into one of the storage containers;
identifying the excrement containing storage
container; and correlating the identified excrement
containing storage container with the identifier of
the detected animal. The automated collection
system is selected from a urine collection system,
a fecal collection system, and a combination
urine/fecal collection system [CONT.]
Evaluating excrement from group-housed animals WO 2009091886
in an excrement elimination event comprises: (a)
providing a primary enclosure (10); (b) providing at
least two animals within the primary enclosure; (c)
providing at least one automated collection
system within the primary enclosure, the
automated collection system (20) comprises a
collection system detection means for detecting
an animal; [CONT.]
WO 2009089062 A2 UPAB: 20090806
BIOLOGY - Preparation: No preparation method is
given. Preferred Components: (I) binds to a
sequence of human cadherin-11, which comprises
a fully defined 34 amino acid (SEQ ID No. 3)
sequences given in the specification. (I) is an
isolated antibody, an antibody, a fusion protein, a
peptide, a peptidomimetic, a nucleic acid or a
small molecule. The antibody binds: an epitope
that is present in SEQ ID NO [CONT.]
INDEPENDENT CLAIMS are included for:
(I) is useful in the manufacture of a medicament
for treating an inflammatory joint disorder in a
NOVELTY: Cadherin-11 antagonist (I) that
specifically binds an extracellular 1 (EC1) domain mammalian subject (preferably human), where the
inflammatory joint disorder is rheumatoid arthritis,
of a mammalian cadherin-11 protein, is new,
where (I) inhibits aggregation of cells that express osteoarthritis, psoriatic arthritis, Reiter's syndrome
or ankylosing spondylitis (all claimed). Tests
the mammalian cadherin-11 protein.
details are described but no results given.
WO 2009089062
(1) a fusion protein comprising at least a portion of
a mammalian immunoglobulin protein and a
portion of a human cadherin-11 extracellular
region that includes 54-90 amino acids of SEQ ID
NO. 2, which comprises a fully defined 796 amino
acid sequences given in the specification, where
the portion of the human cadherin-11 extracellular
region does not include the entire human cadherin11 extracellular region consisting of 1-609 amino
acids of SEQ ID NO. 2; [CONT.]
US 7905201
US 20090253200
US 20110008323
N
202 Diagnosing illness associated with functional MEDVET SCI PTY LTD
protocadherin 19 (PCDH19) protein deficiency,
such as epilepsy and/or mental retardation, by
detecting loss of PCDH19 protein function or
altered PCDH19 protein function in test sample
203 New monoclonal antibody directed to
melanocortin-4 receptor (MC4-R), useful for
increasing appetite and for treating cachexia
and related conditions
UNIV BASEL
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are included for: [CONT.]
US 20110045003
WO 2009086591 A1 UPAB: 20090803
The method is useful for diagnosing, preventing or
treating illness associated with functional
protocadherin 19(PCDH19) protein deficiency or
NOVELTY: Method of diagnosing an illness
related to functional protocadherin 19 (PCDH19) altered PCDH19 protein function, or assessing a
predisposition to an illness related to functional
protein deficiency or altered PCDH19 protein
PCDH19 protein deficiency or altered PCDH19
function, or assessing a predisposition to an
protein function, or screening for identifying
illness related to functional PCDH19 protein
deficiency or altered PCDH19 protein function, or carriers of illness associated with functional
screening to identify carriers of illnesses related to PCDH19 protein deficiency [CONT.]
functional PCDH19 protein deficiency or altered
PCDH19 protein function, involves detecting in a
biological sample isolated from a subject, a loss of
PCDH19 protein function or altered PCDH19
protein function. [CONT.]
WO 2009087467 A2 UPAB: 20090803
The monoclonal antibody or its binding fragment is
NOVELTY: An isolated monoclonal antibody or its useful for preparing a medicament to increase the
appetite in a mammal or a medicament for the
binding fragment that binds to the MC4-R or a
treatment of cachexia and related conditions. The
portion of the MC4-R, or an isolated monoclonal
composition is also useful for stimulating the
antibody or its binding fragment, comprising one
appetite and for treating the symptoms of cachexia
or more of the defined sequences of 116, 107,
(all claimed).
and 117 amino acids (SEQ ID NO: 5, 7, and 9),
given in the specification, is new.
The present invention provides new and improved
therapeutic agents for the treatment of cachexia
and related conditions, including the development
of therapeutic agents, and in particular
monoclonal antibodies, that modulate MC4-R
activity.
BIOTECHNOLOGY - Preferred Method: The
PCDH19 protein is coded by a nucleotide
sequence exhibiting at least 70% sequence
identity to a complete PCDH19 open reading
frame (ORF) nucleotide sequence of SEQ ID NO:
1. The method involves detecting a mutant
sequence in a region of PCDH19 encoding an
extracellular (EC) domain of PCDH19 protein.
[CONT.]
INDEPENDENT CLAIMS are included for the
WO 2009086591
following:
(1) kit for diagnosing an illness related to
functional PCDH19 protein deficiency or altered
PCDH19 protein function, or assessing a
predisposition to an illness related to functional
PCDH19 protein deficiency or altered PCDH19
protein function, or screening to identify carriers of
illnesses related to functional PCDH19 protein
deficiency or altered [CONT.]
BIOTECHNOLOGY - Preferred Antibody: The
antibody or its binding fragment binds to a portion
of the MC4-R comprising the defined sequence of
15 amino acids (SEQ ID NO: 2), given in the
specification. The binding fragment comprises the
variable domain of the heavy chain of the isolated
monoclonal antibody. The binding fragment
comprises the variable domain of the light chain of
the isolated monoclonal antibody [CONT.]
INDEPENDENT CLAIMS are:
(1) a pharmaceutical composition comprising a
therapeutic amount of the isolated monoclonal
antibody or its binding fragment above, and which
is present in the composition in an amount that is
therapeutically effective to increase the appetite of
a mammal;
WO 2009087467
N
US 20110044987
204 Composition useful in pharmaceuticals or
nutraceuticals for e.g. enhancing cognitive
functions and treating Alzheimer's disease,
strokes and dementia, comprises unsaturated
fatty acids and nitric oxide releasing
compounds
205 Multilayer dressing used to reduce pain after
surgical procedures proximate to mucous
membrane comprises tissue adhesive layer to
contact mucous membrane, and abrasionresistant layer covering a side of tissue
adhesive layer
AU 2008200795
A1
20090716
WO 2009087467
EP 2227490
US 20110044987
A3
20091217
A2
20100915
A1
20110224
JP 2011508739
T
20110317
NESTEC SA
WO 2009088433
A1
20090716
PAN Y
AU 2008347177
A1
20090716
EP 2224930
A1
20100908
US 20100233304
A1
20100916
CA 2709660
A1
20090716
MX 2010007438
A1
20100731
CN 101909632
A
20101208
JP 2011508773
T
20110317
ACCLARENT INC
WO 2009088726
A2
20090716
CARLYLE W
US 20090181074
A1
20090716
CHANG J Y
WO 2009088726
A3
20100422
FACTEAU W M
US 20100152730
A1
20100617
LEVINE H
AU 2008346830
A1
20090716
MAKOWER J
EP 2234652
A2
20101006
MUNI K P
MX 2010007282
A1
20101130
CA 2711174
A1
20090716
JP 2011507665
T
20110310
WO 2009088753
EP 2238261
A1
20090716
A1
20101013
CA 2710922
A1
20090716
US 20110053245
A1
20110303
VERENIUM CORP
206 New nucleic acid (polynucleotide) comprises
isomerase, used in making commercial
products, e.g. baked products, beverage, food
or feed additive, cleaning composition, or
wood
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are: [CONT.]
(2) a method for stimulating the appetite of a
mammal by administering to a mammal having a
reduced appetite an isolated monoclonal antibody
or its binding fragment above; and [CONT.]
WO 2009088433 A1 UPAB: 20090803
The composition is useful in pharmaceutical or
The composition effectively promotes health and
nutraceutical composition for enhancing cognitive wellness and extends the prime for an animal.
and related functions in an animal, for preventing
NOVELTY: Composition comprises (a)
or treating Alzheimer's disease, for reducing or
unsaturated fatty acids (UFA) and nitric oxide
releasing compounds (NORC) or (b) fish oil (1-50) preventing a decline of social interaction and agerelated behavioral changes, for increasing
and arginine (0.1-20).
trainability, for maintaining optimal brain function,
for facilitating learning and memory, for reducing
memory loss, for retarding brain aging, for
preventing or treating strokes and dementia, for
maintaining mental clarity and alertness in an
animal such as human or companion animal
DETAILED DESCRIPTION: INDEPENDENT
[CONT.]
CLAIMS are included for the following: [CONT.]
ORGANIC CHEMISTRY - Preferred Composition:
The unsaturated fatty acids (UFA) (0.1-50%)
comprises natural fish oil, alpha -linolenic acid
(ALA), eicosapentaenoic acid (EPA),
docosapentaenoic acid (DPA), docosahexaenoic
acid (DHA), or another n-3 fatty acid from any
source. The nitric oxide releasing compound
(NORC) (0.1-20) is arginine or its nitric oxidereleasing derivative, citrulline and ornithine
[CONT.]
INDEPENDENT CLAIMS are included for the
WO 2009088433
following:
(1) kit, which comprises unsaturated fatty acids
(UFA) and nitric oxide releasing compounds
(NORC) in separate containers in a single
package or in separate containers in a virtual
package, as appropriate for the kit component, (a)
UFA, and (b) NORC, other ingredients suitable for
consumption by an animal, B vitamins,
antioxidants, cognitive drugs, [CONT.]
US 20100233304
WO 2009088726 A2 UPAB: 20090803
ORGANIC CHEMISTRY - Preferred Components:
The energy is ultraviolet light, visible light, infrared
light, radiofrequency energy, ultrasound and/or
heat. The curing agent is water.
PHARMACEUTICALS - Preferred Dressing: The
multilayer dressing further comprises a
therapeutic agent (a1). The total thickness of the
dressing is 0.1-0.7 (preferably 0.3) mm. In the
dressing, the thickness of the tissue adhesive
layer is 0 [CONT.]
INDEPENDENT CLAIMS are included for the
WO 2009088726
following:
(1) assembling an apparatus for post-surgical
protection of mucosal tissue involving: providing a
barrier material and an adhesive material; and
applying the barrier material to the adhesive
material, where the barrier material and the
adhesive material are adapted to remain intact for
48 hours to 14 days after the apparatus is placed
proximate to mucosal tissue; and [CONT.]
US 20090181074
BIOTECHNOLOGY - Preferred Sequences: An
isolated, synthetic or recombinant polypeptide or
peptide has an isomerase activity, (a) comprising
an amino acid sequence having at least 50-99%,
or more, or has 100% (complete) sequence
identity to the amino acid sequence of EVEN SEQ
ID NOS: 2-498, or their enzymatically active
fragments, where the polypeptide or peptide of (i)
or (ii) has an isomerase [CONT.]
INDEPENDENT CLAIMS are:
US 20110053245
As a multilayer dressing for reducing pain after
surgical procedures proximate to a mucous
membrane; in assembling an apparatus for
NOVELTY: A multilayer dressing comprises: a
protecting mucosal membranes associated with
tissue adhesive layer to contact the mucous
an adenoid, tonsil, sinus, turbinate, gum, cheek,
membrane; and an abrasion-resistant layer
pharynx, esophagus, stomach, gut, or anus; and
covering at least one side of the tissue adhesive
layer, where the multilayer dressing remains intact in preformed film for post-surgical protection of
mucosal tissue (claimed). [CONT.]
for 48 hours to 14 days after applying the
apparatus to mucosal tissue.
The dressing remains intact for 48 hours to 14
days after applying the apparatus to mucosal
tissue; contains abrasion-resistant layer to provide
shock absorbing properties; is applied
intraoperatively, quickly and easily, immediately
after completion of surgery at the site; forms a
mechanical barrier that protects the healing tissue
from abrasion such as that due to swallowing of
solid food; [CONT.]
US 20100152730
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are included for the following: [CONT.]
WO 2009088753 A1 UPAB: 20090817
The nucleic acid and polypeptide are used in a
The present invention provides isomerase having
dough,
bread
or
baked
products
and/or
dough,
a new and enhanced specificity.
NOVELTY: An isolated, synthetic or recombinant
nucleic acid (polynucleotide) comprising any of the bread or baked product precursors, or a beverage
nucleic acids of described in (a) to (l) is new. Full or beverage precursor, or a feed, food, food or
feed additive, food or feed supplement, or dietary
definitions of the isolated, synthetic or
recombinant nucleic acid (polynucleotide) given in aid, or a granule, pellet or particle, or a cleaning
composition, or a pharmaceutical composition, or
the DEFINITIONS section.
a biomass, wood, wood pulp, wood product, paper
pulp, paper [CONT.]
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are: [CONT.]
(1) a nucleic acid probe for identifying a nucleic
acid encoding a polypeptide with an isomerase
activity;
(2) an amplification primer pair for amplifying a
nucleic acid encoding a polypeptide having an
isomerase activity;
(3) an isomerase-, e.g., a racemase-, e.g., an
amino acid racemase-, an alanine racemase-,
and/or an epimerase-encoding nucleic acid
generated by amplification of a polynucleotide
using the amplification primer pair, where
optionally the amplification is by PCR; [CONT.]
WO 2009088753
207 New plasminogen activator inhibitor (PAI)-1
ligand or polyligand, useful for treating,
preventing, or ameliorating a cardiovascular
disease, a fibrotic condition, or
atherosclerosis
208 New compound comprising anti-cell
proliferative activity comprises a conserved
motif, useful for treating a cell proliferative
disorder and identifying a compound having
anti cell proliferative activity
INTREXON CORP
KALOS THERAPEUTICS INC
KALOS THERAPEUTICS
209 New sulfonamide containing metal complexes MOLECULAR INSIGHT PHARM INC
and compounds are carbonic anhydrase IX
inhibitors useful for imaging tissue of
mammal, and imaging and treating mammal
suspected of harboring tumor
210 New modified small interfering RNA (siRNA)
molecule capable of silencing polo-like kinase
1 (PLK-1) expression, useful for treating
cancer, e.g. hepatocellular carcinoma
PROTIVA BIOTHERAPEUTICS INC
WO 2009089059
WO 2009089059
A2
20090716
WO 2009089059 A2 UPAB: 20090803
A3
20090924
AU 2009204464
A1
20090716
EP 2242501
A2
20101027
NOVELTY: A plasminogen activator inhibitor (PAI)- useful for transferring a polynucleotide encoding a
ligand or polyligand to cardiovascular tissue;
1 ligand or polyligand that has been modified to
assessing the function of PAI-1 in the formation of
comprise one or more amino acid deletions,
unstable plaques; achieving spatial or temporal
substitutions, insertions, truncations, or
control of a ligand or polyligand; treating,
combinations, is new.
preventing, or ameliorating a cardiovascular
DETAILED DESCRIPTION: INDEPENDENT
disease; treating, preventing, or ameliorating a
CLAIMS are:
fibrotic condition [CONT.]
(1) a protein A mimetic (PAM) ligand or polyligand
that is at least 60-99% identical to PAI-1 ligand or
polyligand; [CONT.]
IN 2010KN02849
A
20101015
KR 2010129271
A
20101208
CA 2711878
A1
20090716
US 20110055940
A1
20110303
JP 2011509093
T
20110324
WO 2009086516
US 20090238817
A1
20090709
WO 2009086516 A1 UPAB: 20090728
A1
20090924
EP 2224946
A1
20100908
NOVELTY: A compound having anti-cell
proliferative activity comprising a conserved motif,
is new.
DETAILED DESCRIPTION: A compound having
anti-cell proliferative activity comprising a
conserved motif: residue compound ((Res) 1)(Res 2)-(Res 3)-(Res 4)-(Res 5)-(Res 6)-(Res 7)(Res 8), where Res 1- is an amino acid or
mimetic, where the backbone is selected from an
[CONT.]
CA 2710920
A1
20090709
JP 2011509248
T
20110324
US 20090175794
A1
20090709
US 20090175794 A1 UPAB: 20090803
WO 2009089383
A2
20090716
WO 2009089383
A3
20090903
NOVELTY: Sulfonamide containing metal
complexes (I), and substituted sulfonamide
compounds (A) and their stereoisomers or salts
are new.
DETAILED DESCRIPTION: Sulfonamide
containing metal complexes of formula (MetalChelate-(CH2)m-V1-(CH2)n-W1-Z-S(=O)2-NH2)
(I), and substituted sulfonamide compounds (A) of
formulae (II)-(V) and their stereoisomers or salts
are new [CONT.]
AU 2009204133
A1
20090716
A2
20101020
A1
20090716
JP 2011509304
T
20110324
WO 2009082817
US 20090291131
A1
20090709
WO 2009082817 A1 UPAB: 20090728
A1
20091126
NOVELTY: A modified siRNA molecule
comprising a double-stranded region of 15-60
nucleotides in length, where one or more of the
nucleotides in the double-stranded region
comprise modified nucleotides, and where the
modified siRNA molecule is capable of silencing
PLK-1 expression, is new.
20100527
AU 2008342535
A1
20090709
INDEPENDENT CLAIMS are:
WO 2009089059
US 20110055940
(1) a protein A mimetic (PAM) ligand or polyligand
that is at least 60-99% identical to PAI-1 ligand or
polyligand;
(2) a polypeptide at least 60-99% identical to any
of SEQ ID NO. 1- 30, odd numbers only;
(3) an inhibitor of PAI-1;
The composition and methods are useful for
The invention is safe and effective.
treating a cell proliferative disorder in a subject,
diagnosing a subject having increased probability
of responding to treatment with a compound, and
identifying a compound having anti cell
proliferative activity, where the cell proliferative
disorder comprises a metastatic or non-metastatic
neoplasia, tumor, cancer, the neoplasia, tumor, or
cancer, or [CONT.]
BIOTECHNOLOGY - Preferred Method: In treating
a cell, the neoplasia, tumor, or cancer, or
metastasis, is progressively worsening. The
neoplasia, tumor, or cancer, or metastasis, is in
remission. The neoplasia, tumor, or cancer, or
metastasis, is solid or liquid. The treatment
reduces or decreases cell numbers, proliferation,
volume or size; inhibits or prevents an increase in
cell numbers, proliferation, volume or size [CONT.]
A compound having anti-cell proliferative activity WO 2009086516
comprising a conserved motif: residue compound
((Res) 1)-(Res 2)-(Res 3)-(Res 4)-(Res 5)-(Res 6)(Res 7)-(Res 8), where Res 1- is an amino acid or
mimetic, where the backbone is selected from an
ether, ester, ketone, alkyl, alkylene or amide linker
of 5 or less atoms, having a side chain selected
from hydrophobic, non-polar, and non-ionizable
side [CONT.]
US 20090238817
(I), (A) and their radiolabeled derivatives are
useful for imaging tissue of a mammal; and
imaging and treating a mammal suspected of
harboring a tumor (all claimed). Tests details are
described but no results given.
INORGANIC CHEMISTRY - Preparation
(Disclosed): Preparation of (I) comprises: reaction
of 6-(bis-pyridin-2-ylmethyl-amino)-hexanoic acid
with an amine compound of formula (H2N-R) in
the presence of 1-ethyl-3-(3dimethylaminopropyl)carbodiimide and
triethylamine to give amide compounds of formula
(1a); and reaction of (1a) with a metal carbonyl
complex of formula (M(CO)3(H2O)3) in the
presence of triethylamine to give metal complexes
of formula (Ib) (representative of (I)) [CONT.]
Sulfonamide containing metal complexes of
US 20090175794
formula (Metal-Chelate-(CH2)m-V1-(CH2)n-W1-ZS(=O)2-NH2) (I), and substituted sulfonamide
compounds (A) of formulae (II)-(V) and their
stereoisomers or salts are new. In formula (I),
US 20090175794
(I)/(A) reduces side effect and are selective to
inhibit CA IX.
N
N
V1 = bond, O, C=O, C(=X)-NH, an amide group of
formula (W1-C(=O)-(CH2)2-C(=O)-NH-) or an
amino group of formula (U1-NH-C(=X)-NH-);
X = O or S;
U1 = bond or (O-CH2-CH2-O)-CH2-CH2-; [CONT.]
EP 2240171
A1
BIOTECHNOLOGY - Preparation (claimed):
Producing PAI-1 ligand or polyligand polypeptide
comprises transfecting the vector into the host cell
and culturing the transfected host cell under
conditions suitable to produce at least one copy of
a PAI-1 ligand or polyligand polypeptide. Preferred
Ligand: The PAI-1 ligand or polyligand comprises
at least one peptide at least 60-99% identical any
of SEQ ID NO [CONT.]
(4) a polynucleotide encoding the polypeptide; or
a polynucleotide at least 60% identical to the
polynucleotide comprising SEQ ID NO. [CONT.]
CA 2711678
US 20100130588
The PAI-1 ligand or polyligand and methods are
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are: [CONT.]
The siRNA and composition are useful for treating
cancer, where the cancer is liver cancer,
specifically hepatocellular carcinoma (all claimed).
Other cancer includes, but is not limited to,
hepatocellular carcinoma, papilloma,
blastoglioma, Kaposi's sarcoma, melanoma, lung
cancer, ovarian cancer, prostate cancer,
squamous cell carcinoma, astrocytoma, head
cancer, neck cancer, bladder cancer, breast
[CONT.]
The present invention provides new therapeutic
agents that will restore the processes of
checkpoint control and programmed cell death to
cancerous cells.
BIOTECHNOLOGY - Preferred siRNA Molecule: INDEPENDENT CLAIMS are:
WO 2009082817
The modified siRNA molecule comprises modified (1) a nucleic acid-lipid particle comprising (i) a
nucleotides selected from 2'-O-methyl (2'OMe)
modified siRNA molecule above, (ii) a cationic
nucleotides, 2'-deoxy-2'-fluoro (2'F) nucleotides, 2'- lipid comprising 50-85 mol % of the total lipid
deoxy nucleotides, 2'-O-(2-methoxyethyl) (MOE)
present in the particle, (iii) a non-cationic lipid
nucleotides, locked nucleic acid (LNA)
comprising 13-49.5 mol % of the total lipid present
nucleotides, and their mixtures. [CONT.]
in the particle, and (iv) a conjugated lipid that
inhibits aggregation of particles comprising 0.5-2
mol % of the total lipid present in the particle;
[CONT.]
US 20090291131
US 20100130588
N
211 New pharmaceutical composition comprising SOLVAY PHARM GMBH
granules containing a pharmaceutical core
ABBOTT PROD GMBH
particle and a coating layer coated on the core
particle, useful for preventing or treating, e.g.
digestive disorders or diabetes
212 High melting point fats containing
composition, e.g. for use as pet (e.g. cat)
composition (e.g. feline treat) for kit,
comprises high melting point fat, humectant,
and gelling agent
213 Treatment of disorder of nail/nail bed such as
onychomycosis involves topically applying
composition comprising volatile vehicle, nonvolatile solvent, active pharmaceutical
ingredient and wetting agent
A1
20101013
A1
20090709
JP 2011507534
T
20110310
WO 2009083607
A1
20090709
WO 2009083607 A1 UPAB: 20090725
AU 2009203123
A1
20090709
NOVELTY: A pharmaceutical composition
comprising granules containing: (a) a
pharmaceutical core particle; and (b) at least one
coating layer coated on the core particle, the
coating layer comprising at least one
recombinantly produced purified microbial lipase,
where the recombinantly produced purified
microbial lipase has a protein purity of at least 90
area-% (w/w) and a protein content of at least
60% (w/w), is new. [CONT.]
KR 2010101106
A
20100916
EP 2237771
A1
20101013
MX 2010007242
A1
20100930
US 20110008423
A1
20110113
CA 2711187
A1
20090709
CN 101951893
A
20110119
JP 2011508755
T
20110317
NESTEC SA
WO 2009085192
A1
20090709
WO 2009085192 A1 UPAB: 20090728
DIXON D K
AU 2008343847
A1
20090709
NOVELTY: A high melting point fats containing
composition comprises high melting point (HMP)
fat(s), humectant(s), and gelling agent(s). The
composition has a water content of not greater
than 16% and a water activity of not greater than
0.65.
PARTHASARATHY M
CA 2708892
A1
20090709
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are included for: [CONT.]
SHE M J
EP 2230930
A1
20100929
MX 2010007338
A1
20100831
US 20100310750
A1
20101209
IN 2010DN04770
A
20101210
JP 2011509082
T
20110324
20090709
DOW PHARM SCI INC
WO 2009085314
US 20090175810
A1
A1
20090709
FIELDSON G T
AU 2008343795
A1
20090709
WO 2009085314
A8
20100826
CA 2706114
A1
20090709
DOW PHARM SCI
WINCKLE G
214 Pet food formulation for cats comprises
specific amount of amino acids and
phosphorus
EP 2238251
CA 2710713
HILL'S PET NUTRITION INC
EP 2234621
A1
20101006
KR 2010108555
A
20101007
IN 2010KN01876
A
20100910
CN 101909634
A
20101208
MX 2010007230
A1
20101231
JP 2011508774
T
20110317
WO 2009086275
A1
20090709
The pharmaceutical composition is useful for the
prevention or treatment of digestive disorders,
pancreatic exocrine insufficiency, pancreatitis,
cystic fibrosis, diabetes type I, and/or diabetes
type II. It can also be used for the manufacture of
a medicament for the prevention or treatment of
digestive disorders, pancreatic exocrine
insufficiency, pancreatitis, cystic fibrosis, diabetes
type I, [CONT.]
BIOTECHNOLOGY - Preparation (claimed):
Manufacture of a pharmaceutical composition
comprises: (a) providing pharmaceutical particles;
(b) providing a coating solution comprising at least
one recombinantly produced purified microbial
lipase which has a purity of at least 90 area-% and
a protein content of at least 60% (w/w); (c) coating
one or more times the core particles of (a) with the
coating solution of (b) to obtain granules
containing at least one recombinantly produced
purified microbial lipase; and (d) optionally
incorporating the granules of (c) into a
pharmaceutical composition [CONT.]
INDEPENDENT CLAIMS are:
WO 2009083607
US 20110008423
(1) a method of preventing or treating digestive
disorders, pancreatic exocrine insufficiency,
pancreatitis, cystic fibrosis, diabetes type I, and/or
diabetes type II by administering to a mammal an
amount of a recombinantly produced purified
microbial lipase which has a protein purity of at
least 90 area-% and a protein content of at least
60% (w/w); [CONT.]
A high melting point fats containing composition
for use as human food composition, pet
composition (preferably) or dietary supplement for
a kit. The pet composition is feline food
composition, a feline treat or snack food. The pet
is a mammal, preferably companion animal which
is a dog or a cat. (all claimed)
The composition has a water content of not
greater than 16 (preferably not greater than 10)%
and a water activity of not greater than 0.65 (0.40.6); is free of added preservatives and
antimicrobial additives; has (wt.%) propionic acid
(less than 0.12, preferably less than 0.7), calcium
silicate (0.12, preferably 0.7), or sorbic acid (0.5,
preferably 0. [CONT.]
ORGANIC CHEMISTRY - Preferred Composition:
The high melting point fats containing composition
comprises (wt.%) HMP fat(s) ( not greater than 18,
preferably greater than or equal to 5),
humectant(s) (10-35, preferably 15-25), and
gelling agent(s) (5-20, preferably greater than or
equal to 8). Preferred Components: The HMP has
an average m. pt. of greater than 40 (preferably
greater than 50) degrees C [CONT.]
INDEPENDENT CLAIMS are included for:
WO 2009085192
US 20100310750
For treatment of disorder of nail or nail bed such
as onychomycosis (claimed), psoriasis, onychia,
NOVELTY: Treatment of disorder of nail or nail
bed involves topically applying a pharmaceutical onychocryptosis, onychodystrophy,
composition (C1) comprising a volatile vehicle that onychogryposis, onycholysis, onychomadesis,
rapidly penetrates a nail following the application onychophosis, onychoptosis, paronychia,
koilonychia, subungual hematoma and laminitis, in
onto the nail, non-volatile solvent that dissolved,
humans, cats, dogs, horses, cattle, sheep, goats,
suspended, dispersed or emulsified within the
pigs and birds.
vehicle, active pharmaceutical ingredient (API)
soluble in the solvent or in mixture of the solvent
and the vehicle, and wetting agent, where the
application of the composition is in an amount and
for a time to ameliorate the symptoms of the
disorder. [CONT.]
The pharmaceutical composition is free of
polymeric film forming compounds; does not form
a film when topically applied to the surface of a
nail; and provides enhanced penetration of
pharmaceutical agent into and through an intact
nail.
ORGANIC CHEMISTRY - Preferred Components:
The wetting agent and the vehicle are the same
compound. The wetting agent is a volatile silicone.
The vehicle is an alcohol. The non-volatile solvent
is non-polar such as at least one ester of formula
RCO-OR', (preferably combination of diisopropyl
adipate and 12-15C alkyl lactate, or diisopropyl
adipate and myristyl lactate). [CONT.]
An INDEPENDENT CLAIM is included for a
WO 2009085314
pharmaceutical composition (C2) for the topical
treatment of disorder of nail or nail bed comprising
alcohol, volatile silicone, anti-oxidant, at least one
ester of formula RCO-OR', and a triazole
antifungal agent, where the ratio of alcohol to
volatile silicone wt./wt.% is at least 2:3, the volatile
silicone is present in the composition at a
concentration less than 25 wt [CONT.]
US 20090175810
WO 2009086275 A1 UPAB: 20090728
The food formulation increases serum vitamine E
level. The formulation provides the highest
percentage of lean tissue and the highest lean to
FOOD - Preferred Composition: The pet food
formulation comprises ash (less than 6 wt.%); at
least one of n-3 fatty acid and at least one of n-6
WO 2009086275
US 20100304003
WO 2009085314 A1 UPAB: 20090728
As pet food formulation (claimed) for cats useful
for reducing oxidative stress.
(1) a method of manufacturing a soft-textured food
compositions comprising mixing HMP fat(s),
humectant(s), and gelling agent(s) with additional
ingredient(s) to provide a mixture; heating the
mixture to provide a soft-textured food
composition; and forming the food composition to
a desired shape and size; [CONT.]
N
214 Pet food formulation for cats comprises
specific amount of amino acids and
phosphorus
215 Composition, useful to treat/prevent parasitic
disease, comprises a combination of e.g.
eugenol, camphor, chrysene, geraniol,
camphene, piperonal, thymol or blend
comprising licorice flavonoid oil and
buthionine sulfoximine
HILLS PET NUTRITION INC
AU 2008345571
A1
20090709
FRIESEN K
EP 2197292
A1
20100623
PAETAU-ROBINSON I
CA 2710211
A1
20090709
YAMKA R
US 20100304003
A1
20101202
JP 2011505876
T
20110303
CN 101951786
A
20110119
WO 2009086471
WO 2009086471
A2
20090709
A3
20090911
EP 2242498
US 20110008471
A2
20101027
A1
20110113
JP 2011507969
T
20110310
WO 2009085659
US 20090202476
A1
20090709
A1
20090813
TW 2009032214
A
20090801
AU 2008343423
A1
20090709
TYRATECH INC
216 New crystalline polymorphic forms of N-(tert- BRISTOL-MYERS SQUIBB CO
butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7chloro-4-methoxy-1- isoquinolinyl)oxy)-N((1R,2S)-1-((cyclopropylsu1fonyl)carbamoyl)-2vinylcyclopropyl)-L-prolinamide for treating
vial infection
217 New amide substituted heterocyclic
compounds useful for treating disorder e.g.
neurodegenerative disorder, inflammation,
anxiety, Alzheimer's disease, Parkinson's
disease, Huntington's disease, multiple
sclerosis, multiple system atrophy
UNIV SYDNEY
218 Iron composition used as dietary supplement GREEN EARTH IND INC
or feed additive to ameliorate e.g. iron deficient HOFSETH BIOCARE AS
anemia, comprises iron and peptides (at
greater than specified percentage), which are
obtained from enzymatically hydrolyzed fish
protein
The food formulation increases serum vitamine E
level. The formulation provides the highest
percentage of lean tissue and the highest lean to
fat ratio in cats.
FOOD - Preferred Composition: The pet food
formulation comprises ash (less than 6 wt.%); at
least one of n-3 fatty acid and at least one of n-6
fatty acid. The pet food formulation contains n-6
and n-3 fatty acids in a ratio of less than 7:1. The
long-chain fatty acids are present in an amount of
0.2-0.6 (preferably 0.3-0.4)%. The pet food
formulation comprises leucine (at least 3.5 wt.
[CONT.]
WO 2009086275
US 20100304003
WO 2009086471 A2 UPAB: 20090728
(I) is useful as medicament for treating or
NOVELTY: Antiparasitic composition (I) comprises preventing parasitic disease or infestation, where:
the parasite has a host comprising canola, cat,
a synergistic combination of: 183 components A
dog, goat, horse, man, maize, mouse, ox, pig,
e.g. benzyl alcohol, eugenol, camphor and
poultry, rabbit, rice, sheep, soybean, tobacco, or
davanone; 265 components B e.g.
wheat; the parasite is endoparasites,
dibenzannulene, pyrimidine, imidazole and
ectoparasites, human parasites, animal parasites,
chrysene; compound C e.g. borneol, geraniol,
or agricultural parasites, preferably protozoan
camphene and cineol; 181 components D e.g.
allyl sulfide, piperonal, thymol and cis-verbenol; or parasite, a helminthic [CONT.]
185 blends (in wt [CONT.]
(I) exhibits synergistic effects on the parasite. The
synergistic effect of (I) (comprising (in wt.%) pcymene (30), thymol (35), alpha -pinene (4),
linalool (7) and soybean oil (24)) to treat parasitic
infection was tested against Hymenolepis nana in
vivo. The result showed that the percentage of
cure rate exhibited by (I) was 100%.
PHARMACEUTICALS - Preferred Composition: (I)
additionally comprises an ingredient comprising a
surfactant or a fixed oil. Preferred Components:
The amount of each compound in the blends is
within a range obtained by multiplying the amount
of compound by plus minus 200%, plus minus
100%, plus minus 40% or plus minus 10%. The
coefficient of synergy relative to a component of
the composition is greater than 5, 10, 25, 50, 75 or
100 [CONT.]
Antiparasitic composition (I) comprises a
WO 2009086471
synergistic combination of: 183 components A e.g.
benzyl alcohol, benzaldehyde, allyl sulfide,
benzoic acid, bergamotene, bisabolene oxide,
camphor, chamazulene, citronellyl acetate,
davanone, diallyl tetrasulfide, estragole, eugenol,
fenchone, garlic oil, grapefruit oil, isoborneol,
jasmone, lecithin, linalyl acetate, menthone,
nerolidol, peppermint oil, [CONT.]
US 20110008471
N
WO 2009085659 A1 UPAB: 20090826
In a pharmaceutical composition useful for treating
Hepatitis C virus (HCV) infection in a mammal
NOVELTY: Crystalline polymorphic Forms H-1
and T1F-1/2 of N-(tert-butoxycarbonyl)-3-methyl-L- (preferably human) (claimed).
valyl-(4R)-4-((7-chloro-4-methoxy-1isoquinolinyl)oxy)-N-((1R,2S)-1((cyclopropylsu1fonyl)carbamoyl)-2vinylcyclopropyl)-L-prolinamide (I), having an XRay powder diffraction pattern as given in the
specification are new. [CONT.]
The crystalline polymorphic Forms H-1 and T1F1/2 of compound (I) in combination with other
medication shows synergistic effect. The
crystalline polymorphic Forms H-1 and T1F-1/2 of
compound (I) can be repeatedly crystallized on
large scale and each polymorph possesses
characteristics that are acceptable for commercial
use.
PHARMACEUTICALS - Preferred Components:
The additional compound (a1) is an interferon
(preferably interferon a-2B, pegylated interferon- a
, consensus interferon, interferon a-2A, and
lymphoblastiod interferon- t), ribavirin, interleukin2, interleukin-6, interleukin-12, a compound that
enhances the development of a type-1 helper T
cell response, interfering RNA, anti-sense RNA,
imiqimod, ribavirin, [CONT.]
An INDEPENDENT CLAIM is included for a
WO 2009085659
pharmaceutical composition comprising Form H-1
and/or Form T1F-1/2 of compound (I) in
combination with at least one additional
compound (a1) having anti-Hepatitis C virus
(HCV) activity.
US 20090202476
N
WO 2009079683 A1 UPAB: 20090811
In the manufacture of a medicament for the
treatment of a disorder in a subject i.e.
neurodegenerative disorder, inflammation,
anxiety, Alzheimer's disease, Parkinson's disease,
NOVELTY: Amide substituted heterocyclic
compounds, and their salts and solvates are new. Huntington's disease, multiple sclerosis, multiple
system atrophy, epilepsy, encephalopathy, stroke,
brain tumor, stress, emotional disturbances or
cognitive impairment, glioblastoma, ischemic
DETAILED DESCRIPTION: Amide substituted
heterocyclic compounds of formulae (III) and (IV), stroke, herpes encephalitis, HIV, amyotrophic
lateral sclerosis, corticobasal degeneration,
and their salts and solvates are new.
cancer, depression, autoimmune disease and
infectious disease in a subject e [CONT.]
R12 and R13=H, benzyl, 1-10C alkyl, 2-10C
alkenyl, 2-10C alkynyl, or (hetero)aryl (all
optionally substituted with at least one halo or 16C alkyl);or [CONT.]
The compounds are effective translocator protein
(18 kDa) (TSPO) ligand with improved brain
kinetics, has high binding affinity to TSPO, and
elicits a response when bound to a TSPO
receptor. The compounds radiolabeled with
radioisotope are selective ligands for TSPO and
have high affinity for TSPO. The activation of
TSPO ligand increases the concentration of
neurosteroids in the brain. [CONT.]
ORGANIC CHEMISTRY - Preparation (Claimed):
Preparation of (III) involves reacting substituted
pyridazin-3-ylamine compound of formula (VII)
with substituted phenyl compound of formula
(VIII). Preparation of (IV) involves reacting (V) with
amine compound of formula NH(R23)(R24). Y1=a
leaving group that reacts with (VII) (preferably
halo). Preferred Components: The compound (IV)
is the (R)-enantiomer [CONT.]
Amide substituted heterocyclic compounds of
WO 2009079683
formulae (III) and (IV), and their salts and solvates
are new.
R12 and R13=H, benzyl, 1-10C alkyl, 2-10C
alkenyl, 2-10C alkynyl, or (hetero)aryl (all
optionally substituted with at least one halo or 16C alkyl);or
NR12R13=optionally substituted heterocyclic ring
having 3-7 ring members;
US 20110044898
The peptides increase absorption of the iron when
ingested by an animal or human. The iron
composition can be palatable to animals even
when fish is not part of their natural diet. Iron
absorption is increased by 50 up to greater than
100%. In vitro assay was conducted to investigate
potential presence of bioactive peptides of feeds
that impact storage iron concentration in the feed
subjects. [CONT.]
NOVELTY: A pet food formulation comprises
amino acids (at least 7 wt.%) and phosphorus
(less than 1 wt.%).
ACTIVITY: Tranquilizer. No biological data is
given.
MECHANISM OF ACTION: None given.
As pet food formulation (claimed) for cats useful
for reducing oxidative stress.
USE: As pet food formulation (claimed) for cats
useful for reducing oxidative stress.
ADVANTAGE: The food formulation increases
serum vitamine E level. [CONT.]
EP 2231639
A1
20100929
KR 2010099703
A
20100913
MX 2010006489
A1
20100630
IN 2010DN04151
A
20101112
CN 101903371
A
20101201
JP 2011507869
T
20110310
WO 2009079683
A1
20090702
AU 2008340182
A1
20090702
EP 2231659
A1
20100929
CA 2710016
A1
20090702
US 20110044898
A1
20110224
JP 2011506487
T
20110303
WO 2009079401
WO 2009079401
A2
20090625
WO 2009079401 A2 UPAB: 20090723
A3
20091001
EP 2231171
A2
20100929
NOVELTY: An iron composition comprises iron
and peptides (greater than 50%), which are
obtained from enzymatically hydrolyzed fish
protein.
ACTIVITY: Anabolic; Antianemic.
CA 2709159
A1
20090625
MECHANISM OF ACTION: None given.
The iron composition is used as dietary
supplement or feed additive useful for human or
animal i.e. mammal or bird ingestion, where
animal or human has iron deficient anemia or is at
risk for having iron deficient anemia or on a
normal protein diet (claimed). It is used to
ameliorate diseases and disorders resulting from
inadequate iron in human or animal, such as iron
deficient anemia. [CONT.]
R14-R18=H or T1; [CONT.]
BIOTECHNOLOGY - Preferred Parameter: The
peptides have molecular weights of less than or
equal to 3500 daltons. Less than 50% of the
peptides are chelated to the iron. The dry weight
of the peptides is greater than 800 g/dry weight kg
of the iron composition. The peptides are greater
than 50% of the iron composition on a caloric
basis or on a dry weight basis.
PHARMACEUTICALS - Preferred Composition:
WO 2009079401
N
KR 2010112133
A
20101018
JP 2011506479
T
20110303
EP 2072525
WO 2009080810
A1
20090624
A1
20090702
FELDWISCH J
AU 2008339976
A1
20090702
HERNE N
EP 2235044
A1
20101006
LENDEL C
CA 2709915
A1
20090702
TOLMACHEW V
IN 2010KN02137
A
20101022
US 20110020223
A1
20110127
JP 2011507497
T
20110310
CN 101952302
A
20110119
US 20090162407
WO 2009085952
A1
20090625
US 20090162407 A1 UPAB: 20090806
A1
20090709
NOVELTY: Preparing low residual solvent level
microparticles involves providing a dispersed
phase comprising a polymer excipient in a weight
amount of dispersed phase solvent; combining the
dispersed phase with a continuous phase
processing medium to form an emulsion where
the dispersed phase is a discontinuous phase in
the continuous phase; combining the emulsion
with an extraction phase solvent, to forming
microparticles; and isolating the microparticles.
[CONT.]
BIGGS D
EP 2222281
A1
20100901
NETTLES H
CA 2709712
A1
20090709
JP 2011508733
T
20110317
PGX HEALTH LLC
221 New ((amino-(dihydroxy-tetrahydro-furan-yl)purin-2-yl)-prop-2-ynyl)- piperidine-1-carboxylic
acid esters are adenosine 2A receptor agonists
useful e.g. to treat pathological condition or
symptom which is caused by e.g. skin
PGXHEALTH LLC
diseases
US 20090162292
A1
20090625
WO 2009082720
A2
20090702
BEAUGLEHOLE A
WO 2009082720
A3
20090827
RIEGER J
AU 2008340186
A1
20090702
SCHMIDTMANN F
EP 2234490
A2
20101006
THOMPSON R
KR 2010103631
A
20100927
CA 2710151
A1
20090702
MX 2010006645
A1
20100930
US 20110003765
A1
20110106
IN 2010CN04246
A
20110107
CN 101938906
A
20110105
JP 2011507907
T
20110310
WO 2009079335
A1
20090625
219 New human epidermal growth factor receptor 2 AFFIBODY AB
(HER2) binding polypeptide, useful for treating ABRAHMSEN L
a mammalian, including human subject having
a cancer having overexpression of HER2
220 Preparing microparticles involves combining BROOKWOOD PHARM INC
dispersed phase comprising polymer excipient SURMODICS PHARM INC
with continuous phase processing medium to
form emulsion, followed by combining with
extraction phase solvent to form
microparticles
222 New isolated binding molecule that competes
for binding to human OX40 receptor with an
BRISTOL-MYERS SQUIBB CO
USE: The iron composition is used as dietary
supplement or feed additive useful for human or
animal i.e. [CONT.]
inadequate iron in human or animal, such as iron
deficient anemia. [CONT.]
that impact storage iron concentration in the feed
subjects. [CONT.]
EP 2072525 A1 UPAB: 20090720
The HER2 binding polypeptide and methods are
useful for in vivo imaging of the body of a
NOVELTY: A human epidermal growth factor
receptor 2 (HER2) binding polypeptide comprising mammalian subject having or suspected of having
a cancer having overexpression of HER2; and
a fully defined 48 amino acid sequence (SEQ ID
treating a mammalian, including human, subject
NO. 1), is new.
having a cancer having overexpression of HER2.
DETAILED DESCRIPTION: A human epidermal
The radionuclide is suitable for imaging for use
growth factor receptor 2 (HER2) binding
diagnosis or for therapy. It can be used for the
polypeptide comprising the amino acid sequence
diagnosis or treatment of cancers having
Glu-X1-Arg-Asn-Ala-Tyr-Trp-Glu-Ile-Ala-Leu-Leuoverexpression of HER2 [CONT.]
Pro-Asn-Leu-Thr-Asn-Gln-Gln- Lys-Arg-Ala-PheIle-Arg-Lys-Leu-Tyr-Asp-Asp-Pro-Ser-Gln-Ser-SerGlu-Leu- Leu-X2-Glu-Ala-Lys-Lys-Leu-Asn-AspSer-Gln (SEQ ID NO [CONT.]
basis or on a dry weight basis.
PHARMACEUTICALS - Preferred Composition:
The iron is greater than 0 [CONT.]
BIOTECHNOLOGY - Preferred Polypeptide: The
HER2 binding polypeptide comprises: (a) a fully
defined 51 amino acid sequence (SEQ ID NO. 2)
given in the specification, where X1 in position 5 is
Met, Ile, or Leu; and X2 in position 42 is Ser or
Cys; (b) a fully defined 55 amino acid sequence
(SEQ ID NO. 3) given in the specification, where
X1 in position 9 is Met, Ile, or Leu; and X2 in
position 46 is Ser or Cys [CONT.]
A human epidermal growth factor receptor 2
EP 2072525
(HER2) binding polypeptide comprising the amino
acid sequence Glu-X1-Arg-Asn-Ala-Tyr-Trp-Glu-IleAla-Leu-Leu-Pro-Asn-Leu-Thr-Asn-Gln-Gln- LysArg-Ala-Phe-Ile-Arg-Lys-Leu-Tyr-Asp-Asp-Pro-SerGln-Ser-Ser-Glu-Leu- Leu-X2-Glu-Ala-Lys-LysLeu-Asn-Asp-Ser-Gln (SEQ ID NO. 1), where X1
in position 2 is Met, Ile, or Leu; and X2 in position
39 is Ser or Cys, is new. [CONT.]
US 20110020223
BIOLOGY - Preferred Components: The dispersed
phase further comprises an agent, the agent
comprises at least one member of antigens to
cush bacterial organisms selected from
Streptococcus pneumoniae, Haemophilus
influenzae, Staphylococcus aureus, Streptococcus
pyrogenes, Corynebacterium diphteriae, Listeria
monocytogenes, Bacillus anthracis, Clostridium
tetani, Clostridium botulinum, Clostridium
perfringens [CONT.]
Preparing low residual solvent level microparticles US 20090162407
involves: (a) providing a dispersed phase
comprising a polymer excipient in a weight amount
of dispersed phase solvent, W1; (b) combining the
dispersed phase with a continuous phase
processing medium to form an emulsion where
the dispersed phase is a discontinuous phase in
the continuous phase; (c) combining the emulsion
with an extraction phase solvent, to forming
microparticles [CONT.]
US 20090162407
(I) is useful to treat a pathological condition or
symptom, which is caused by autoimmune
stimulation (autoimmune diseases), inflammation,
allergic diseases, skin diseases, infectious
diseases, wasting diseases, organ transplantation,
tissue or cell transplantation, open wounds,
NOVELTY: 4-(3-(6-Amino-9-(3,4-dihydroxytetrahydro-furan-2-yl)-9H-purin- 2-yl)-prop-2-ynyl)- adverse effects from drug therapy, a
cardiovascular condition, ischemia-reperfusion
piperidine-1-carboxylic acid esters (I) and their
injury, dialysis, gout, chemical trauma, thermal
stereoisomers or salts, are new.
DETAILED DESCRIPTION: 4-(3-(6-Amino-9-(3,4- trauma, diabetic nephropathy, sickle cell disease,
laminitis, and founder's disease in a subject
dihydroxy-tetrahydro- furan-2-yl)-9H-purin-2-yl)prop-2-ynyl)-piperidine-1-carboxylic acid esters (I) [CONT.]
of formula ((IA), (IB) or (IC)) and their
stereoisomers or salts, are new. [CONT.]
ORGANIC CHEMISTRY - Preparation: No
preparation method is given.
4-(3-(6-Amino-9-(3,4-dihydroxy-tetrahydro- furan-2- US 20090162292
yl)-9H-purin-2-yl)-prop-2-ynyl)-piperidine-1carboxylic acid esters (I) of formula ((IA), (IB) or
(IC)) and their stereoisomers or salts, are new.
US 20090162292
WO 2009079335 A1 UPAB: 20090710
BIOTECHNOLOGY - Preferred Molecule: The
isolated binding molecule (a) binds to human
For peparing low residual solvent level
microparticles (claimed)
US 20090162292 A1 UPAB: 20090710
The isolated binding molecule is useful for treating
and preventing cancer in a mammal; enhancing
The method utilizes low volumes of processing
water while still providing microparticles having
low residual solvent levels.
N
N
R1, R2 = H or 1-3C alkyl;
US 20110003765
Z = cyclopropyl, cyclobutyl, cyclopentyl,
tetrahydrofuranyl, azetidin-2-onyl, pyrrolidinyl or
pyrrolidin-2-onyl (substituted with 0-2 of Z2);
[CONT.]
An isolated binding molecule that: (a) competes
WO 2009079335
for binding to human OX40R with an antibody that
US 20090214560
222 New isolated binding molecule that competes
for binding to human OX40 receptor with an
antibody, useful for treating and preventing
cancer, e.g. breast cancer, prostate cancer,
colorectal cancer, lung cancer, or
hematological cancer
MEDAREX INC
US 20090214560
A1
20090827
PFIZER INC
AU 2008338591
A1
20090625
AGOURON PHARMA
CA 2707773
A1
20090625
BRAMS P
KR 2010102657
A
20100924
DEVAUX B
EP 2242771
A1
20101027
FINN R F
MX 2010006466
A1
20100930
GLADUE R P
CN 101918447
A
20101215
HUANG H
JP 2011505836
T
20110303
LEBLANC H N
TW 2009032268
A
20090801
NOVELTY: An isolated binding molecule that
competes for binding to human OX40 receptor
(OX40R) with an antibody that comprises: (a) a
heavy chain variable region comprising SEQ ID
NO: 7; and (b) a light chain variable region
comprising SEQ ID NO: 8, is new. [CONT.]
The isolated binding molecule is useful for treating
and preventing cancer in a mammal; enhancing
an immune response in a mammal; and inhibiting
growth of tumor cells, where the cancer is breast
cancer, prostate cancer, colorectal cancer, lung
cancer, or hematological cancer (all claimed).
BIOTECHNOLOGY - Preferred Molecule: The
isolated binding molecule (a) binds to human
OX40R with a KD of 1x10-6 M or less; and (b) has
agonist activity on human OX40R. The molecule is
a human antibody, preferably a chimeric or
humanized antibody. The antibody binds to human
OX40R with a KD of 100 nM or less. The nucleic
acid molecule also comprises SEQ ID NO: 11, 12,
23, or 24. [CONT.]
An isolated binding molecule that: (a) competes
WO 2009079335
for binding to human OX40R with an antibody that
comprises: (i) a heavy chain variable region
comprising SEQ ID NO: 7; and (ii) a light chain
variable region comprising SEQ ID NO: 8; and (b)
comprises: (i) a heavy chain complementarity
determining region (CDR) 1 comprising SEQ ID
NO: 1; (ii) a heavy chain CDR2 comprising SEQ
ID NO: 2; [CONT.]
US 20090214560
The composition are useful for preparing a
vaccine protecting against S. equi infection
inclusive of strangles caused by subspecies equi
infection in horses, producing an antigen of an
immunogen of an antigenic composition,
preparing a vaccine composition, producing an
antiserum, and prophylactic or therapeutic
treatment of S. equi infection in non-human
mammals (all claimed).
BIOTECHNOLOGY - Preparation (claimed):
Producing an antigen or an immunogen of an
antigenic composition comprises: (a) providing a
DNA fragment encoding the antigen and
introducing the fragment into an expression
vector; (b) introducing the vector, which contains
the DNA fragment, into a compatible host cell; (c)
culturing the host cell provided in (b) under
conditions required for expression of the product
encoded by the DNA fragment [CONT.]
An antigenic composition comprising antigen,
WO 2009075646
where the antigen comprises at least part of a
protein or polypeptide of Streptococcus equi
subspecies zooepidemicus and the at least part of
the protein or polypeptide comprises antigenic
epitope or antigenic determinant of S. equi, and
where the protein or polypeptide is selected from a
protein or polypeptide which is designated EAG
and has an amino acid sequence comprising fully
defined 121 amino acids (SEQ ID NO [CONT.]
US 20110020403
A homogeneous dispersion of micronized opioid
particles may provide for a greater uniformity
and/or greater stability of micronized opioid in a
formulation or dosage form. Micronization of
opioid particles aids in the suspension (including
dispersion) of opioid particles (i.e. to create a
uniform suspension) during processing in
manufacturing process. [CONT.]
PHARMACEUTICALS - Preferred Component:
The particles are uniformly dispersed within a fluid
medium. The opioid is oxycodone or
hydromorphone, and is in a freebase form or salt
form. The oxycodone is oxycodone freebase or
oxycodone hydrochloride. The hydromorphone is
hydromorphone hydrochloride. The formulation
further comprises an excipient which is a
hydrophilic or hydrophobic solvent, or an antioxidant [CONT.]
INDEPENDENT CLAIMS are included for:
WO 2009076236
US 20090169631
(I) has: increased biological half-life; reduced
potential for adverse immune reactions; and
improved stability and/or therapeutic efficacy.
BIOLOGY - Preparation (Disclosed): Preparation
of the isolated antibody or antibody fragment
comprises culturing a recombinant host cell under
conditions allowing the expression of the nucleic
acid molecule and recovering the polypeptide,
where the polypeptide may be glycosylated or not
or may contain other post-translational
WO 2009071696
US 20090208494
LIAO W
MIN J
PARADIS T J
RAJPAL A
THIELE B R
TOY K
WU Y
223 New antigenic composition comprises antigen, INTERVACC AB
useful for prophylactic or therapeutic
FLOCK J
treatment of Streptococcus equi infection in
non-human mammals, e.g. horses
FLOCK M
FRYKBERG L
GUSS B
224 Non-aerosol pharmaceutical formulation e.g.
for treatment of pain, comprises stabilized
micronized opioid particles having particle
size distribution at certain value
PAIN THERAPEUTICS INC
ZYMOGENETICS INC
225 New isolated antibody or antibody fragment,
comprising humanized heavy and light chain
variable domains, is interleukin-31 antagonist
useful for treating inflammation e.g. ulcerative
colitis, splenomegaly, tuberculosis and pruritis
WO 2009075646
A1
20090618
WO 2009075646 A1 UPAB: 20090707
AU 2008336295
A1
20090618
EP 2227249
A1
20100915
NOVELTY: An antigenic composition comprising
antigen, is new.
DETAILED DESCRIPTION: An antigenic
composition comprising antigen, where the
antigen comprises at least part of a protein or
polypeptide of Streptococcus equi subspecies
zooepidemicus and the at least part of the protein
or polypeptide comprises antigenic epitope or
antigenic determinant of S. [CONT.]
CA 2708260
A1
20090618
US 20110020403
A1
20110127
JP 2011506433
T
20110303
WO 2009076236
US 20090169631
A2
20090618
A1
20090702
WO 2009076236
A3
20091126
AU 2008335360
A1
20090618
CA 2707969
A1
20090618
EP 2247283
A2
20101110
IN 2010DN04154
A
20101112
JP 2011506342
T
20110303
WO 2009071696
A2
20090611
WO 2009076236 A2 UPAB: 20090710
A non-aerosol pharmaceutical formulation for
manufacture of stable pharmaceutical products for
NOVELTY: A non-aerosol pharmaceutical
formulation comprises stabilized micronized opioid treatment of pain including chronic pain, for
particles having Dv90 particle size distribution of providing pain relief, and for treatment of
moderate to severe pain. The drug delivery form is
less than or equal to 10 mu m or less than or
a transdermal patch, suppository, lotion, cream,
equal to 20 mu m.
ointment, gel, implant or pump (claimed). A
DETAILED DESCRIPTION: INDEPENDENT
subject includes human, canine, feline, equine,
CLAIMS are included for:
bovine or any other mammal [CONT.]
N
(1) a drug delivery form comprising stabilized
micronized opioid particles in liquid, semi-liquid or
waxy medium; and
(2) preparation of micronized opioid particles
comprising colliding particles of non-micronized
opioid injected with an injector gas into an air jet
mill in the presence of grinding gas for a period of
time and under gas pressure levels sufficient to
micronize the opioid, where injector gas pressure
is greater than the grinding gas pressure [CONT.]
(1) a drug delivery form comprising stabilized
micronized opioid particles in liquid, semi-liquid or
waxy medium; and [CONT.]
WO 2009071696 A2 UPAB: 20090629
The isolated antibody or antibody fragment is
useful for manufacturing medicaments to treat
inflammation, and pruritis in a mammal (all
claimed), where the inflammation is IL-31
mediated and includes acute inflammation,
inflammation as a result of trauma, tissue injury,
surgery, sepsis or infection, and chronic
N
225 New isolated antibody or antibody fragment,
comprising humanized heavy and light chain
BECKMANN R
variable domains, is interleukin-31 antagonist
useful for treating inflammation e.g. ulcerative
colitis, splenomegaly, tuberculosis and pruritis
BONDENSGAARD K
226 New composition comprising a compound or
agent for inhibiting the activity of the human
neuronal pentraxin 1 (NP1) protein, useful for
treatment or prevention of neurological
diseases in humans, preferably
neurodegenerative disease
227 Pharmaceutical composition for treating
cancer, comprises 4,7-dioxy-quinoline
derivative, its salt or solvate, optionally in
combination with an anti-tumor platinum
complex
228 New antibody specific of the beta-amyloid
peptides useful for preparing a drug or a
vaccine intended for the prevention or the
treatment of Alzheimer disease
US 20090208494
A1
20090820
WO 2009071696
A3
20090903
AU 2008333131
A1
20090611
EP 2215120
A2
20100811
CA 2708251
A1
20090611
KR 2010100860
A
20100915
IN 2010CN03408
A
20101126
JP 2011506302
T
20110303
WO 2009071732
A1
20090611
ES 2325779
A1
20090916
ES 2325779
B1
20100706
A1
20100901
A1
20110324
EISAI R & D MANAGEMENT CO LTD
EP 2224002
US 20110070234
WO 2009060945
A1
20090514
EISAI R&D MANAGEMENT CO LTD
AU 2008325608
A1
20090514
YAMAMOTO Y
CA 2704000
A1
20090514
EP 2218712
A1
20100818
KR 2010090690
A
20100816
US 20100239688
A1
20100923
CN 101848895
A
20100929
IN 2010CN03334
A
20101126
CONSEJO SUPERIOR INVESTIGACIONES
CIENTIF
JP 2009540099
X
20110324
INNOGENETICS NV
WO 2009056490
A1
20090507
INSERM INST NAT SANTE & RECH MEDICALE
AU 2008317705
A1
20090507
SANOFI-AVENTIS
EP 2205633
A1
20100714
NOVELTY: Isolated antibody or antibody
fragment, which binds to human interleukin-31, is
new, where the antibody comprises (a) a
humanized heavy chain variable domain
comprising complementarity determining region
(CDR)-1, CDR-2 and CDR-3 consisting of amino
acid sequence SEQ ID NO: 1, 2, and 3, or 1, 4
and 3, respectively, and (b) a humanized light
chain variable [CONT.]
The isolated antibody or antibody fragment is
useful for manufacturing medicaments to treat
inflammation, and pruritis in a mammal (all
claimed), where the inflammation is IL-31
mediated and includes acute inflammation,
inflammation as a result of trauma, tissue injury,
surgery, sepsis or infection, and chronic
inflammatory diseases such as asthma,
inflammatory bowel disease including ulcerative
colitis, chronic colitis, splenomegaly, recurrent
acute inflammatory episodes (e [CONT.]
(I) has: increased biological half-life; reduced
potential for adverse immune reactions; and
improved stability and/or therapeutic efficacy.
WO 2009071732 A1 UPAB: 20090619
The composition is useful for developing drugs or
pharmaceutical compositions for the treatment or
NOVELTY: A composition useful for developing
prevention of neurological diseases in humans,
drugs or pharmaceutical compositions for the
treatment or prevention of neurological diseases preferably neurodegenerative disease, e.g.
in humans, preferably neurodegenerative disease Alzheimer's disease; for passive or active
comprising a compound or agent for inhibiting the immunization (all claimed).
activity of the human neuronal pentraxin 1 (NP1)
protein, is new.
BIOLOGY - Preparation (Disclosed): Preparation
of the isolated antibody or antibody fragment
comprises culturing a recombinant host cell under
conditions allowing the expression of the nucleic
acid molecule and recovering the polypeptide,
where the polypeptide may be glycosylated or not
or may contain other post-translational
modifications depending on the used host cell
type. [CONT.]
PHARMACEUTICALS - Preferred Composition: In
the composition, the human NP1 protein
sequence shows the NPTX1HUMAN, SwissProt
primary accession number Q15818 or its variant.
The inhibitor compound is a nucleic acid or
polynucleotide that prevents or reduces the
expression of the gene coding for human NP1
protein and comprises: (a) an antisense sequence
of nucleotides specifies the sequence of the gene
or mRNA of the NP1 protein [CONT.]
INDEPENDENT CLAIMS are:
PHARMACEUTICALS - Preferred Component:
The anti-tumor platinum complex is chosen from
cisplatin, carboplatin, nedaplatin, zeniplatin,
enloplatin, lobaplatin, ormaplatin, loboplatin,
sebriplatin, oxaliplatin, miboplatin and spiroplatin,
preferably cisplatin or carboplatin.
A pharmaceutical composition, comprises 4,7dioxy-quinoline derivative of formula (I), its salt or
solvate, optionally in combination with an antitumor platinum complex.
R1=-V1-V2-V3;
WO 2009071696
US 20090208494
WO 2009071732
US 20110070234
WO 2009060945
US 20100239688
N
(1) a peptide or epitope useful for developing
drugs or pharmaceutical compositions for the
treatment of human neurological disease that is
characterized by an amino acid fragment of the
area between amino acids 24-229 of human NP1
protein (NPTX1HUMAN, SwissProt primary
accession number Q15818), preferably with a size
of 15 amino acids; [CONT.]
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are: [CONT.]
WO 2009060945 A1 UPAB: 20090602
The pharmaceutical composition is useful for
treating cancer (claimed) in mammals preferably
human. Uses include but are not limited to cancer
such as brain tumor, head and neck cancer,
cervical cancer, maxillary cancer, submandibular
NOVELTY: A pharmaceutical composition
comprises 4,7-dioxy-quinoline derivative (I), its salt gland cancer, cancer of mouth, salivary gland
or solvate, optionally in combination with an anti- cancer, sublingual gland cancer, parotid gland
cancer, nasal cavity cancer, laryngeal cancer,
tumor platinum complex.
esophageal cancer, lung [CONT.]
DETAILED DESCRIPTION: A pharmaceutical
composition, comprises 4,7-dioxy-quinoline
derivative of formula (I), its salt or solvate,
optionally in combination with an anti-tumor
platinum complex. [CONT.]
N
V1=optionally substituted 1-6C alkylene;
V2=single bond, oxygen, sulfur, carbonyl, sulfinyl,
sulfonyl, group of formula: -CONR6, group of
formula: -SO2NR6-, group of formula: -NR6SO2-,
group of formula: -NR6CO- or group of formula: NR6; [CONT.]
WO 2009056490 A1 UPAB: 20090602
The antibody, vaccine, and methods are useful for The invention can be polyclonal with a high
specificity and a high affinity, or monoclonal with a
NOVELTY: An antibody which specifically binds to preparing a drug or a vaccine intended for the
prevention
or
the
treatment
of
Alzheimer
disease;
high specificity and a high affinity.
the N-terminal region of Abeta8-x peptide, x being
preparing
a
drug
or
a
vaccine
intended
for
the
comprised from 11 to 42, and recognizes neither
clearance of beta amyloid burden, inducing an
Abeta1-40 nor Abeta1-42, is new.
immune response in a mammal being affected by
or susceptible to develop an Alzheimer disease,
DETAILED DESCRIPTION: INDEPENDENT
determining in vitro amyloid burden in a mammal,
CLAIMS are:
determining, in a [CONT.]
BIOTECHNOLOGY - Preferred Antibody: In the
antibody, the antibody presents a high specificity
for the free N-terminal end of Abeta8-x peptide.
The antibody presents a high affinity with respect
to Abeta8-x peptide. The antibody specifically
target parenchymal amyloid deposits of Abeta8-x
peptide in the brain and does not interact with
vascular amyloid deposits. The x is comprised
from 15 to 42, in particular a monoclonal antibody
[CONT.]
INDEPENDENT CLAIMS are:
(1) a hybridoma producing an antibody;
(2) a peptide preparation to generate an immune
response giving rise to antibody production which
is efficient to reduce the amyloid deposits and to
isolate an antibody and consisting of: Abeta 8-x
mimicking peptide: comprising 13 amino acids
(SEQ ID NO. not defined); [CONT.]
WO 2009056490
US 20110059092
INSERM INST NAT SANTE&RECH MEDICALE
229 Kit for producing molecular probe for positron HAMAMATSU PHOTONICS KK
emission tomography drug screening,
contains furan-containing compound,
formamide compound, isoquinoline compound
and their salt
RIKEN KK
CA 2703825
A1
20090507
KR 2010097651
A
20100903
IN 2010DN02884
A
20101001
MX 2010004660
A1
20100731
CN 101883792
A
20101110
JP 2011502139
T
20110120
(1) a hybridoma producing an antibody; [CONT.]
US 20110059092
A1
20110310
TW 2009036605
A
20090901
WO 2009057528
A1
20090507
WO 2009057528 A1 UPAB: 20090602
EP 2228363
A1
20100915
JP 2009539040
X
20110310
NOVELTY: A molecular probe production kit
contains a furan-containing compound (I), a
formamide compound (II), an isoquinoline
compound (III) and their salt.
DETAILED DESCRIPTION: A molecular probe
production kit contains a furan-containing
compound of formula (I), a formamide compound
of formula (II), an isoquinoline compound of
formula (III) and their salt. [CONT.]
US 20110064662
A1
20110317
The kit is useful for producing molecular probe for
positron emission tomography (PET) drug
screening (claimed) for producing a compound
containing a short-lived radionuclide for PET
applications, where the molecular probe includes
10-O-p-methyl benzyl ginkgolide B, 10-O-p-bromo
benzyl ginkgolide B, 10-O-p-iodobenzyl ginkgolide
B, and 10-O-p-(tri-n-butyl stannyl)benzyl
ginkgolide B.
The kit enables producing molecular probe for
positron emission tomography (PET) drug
screening, in short time by a simple method, and
the compound has excellent blood brain barrier
passage ability, and short lifetime emission
nuclide.
A molecular probe production kit contains a furan- WO 2009057528
containing compound of formula (I), a formamide
compound of formula (II), an isoquinoline
compound of formula (III) and their salt.
US 20110064662
X1=-SnR13 or group of formula (a);
n=1-8;
R1=1-6C alkyl;
A=groups of formula (b);and
X2-X6=H or X1.
INDEPENDENT CLAIMS are included for the
following: (i) furan compound of formula (I); (ii)
formamide compound of formula (II) [CONT.]
230 Treating/inhibiting pathological condition e.g.
cancer or asthma involving inhibiting activity
of cyclooxygenase-2 and 5-lipoxygenase
involves administering composition
comprising alpha acid derivatives e.g. tetrahydroisoalpha acids
METAPROTEOMICS LLC
For treating or inhibiting a pathological condition in
a mammal. The pathologic condition is allergic
NOVELTY: Treating or inhibiting a pathological
disorder, cancer selected from breast cancer,
condition in a mammal involving inhibiting
prostate cancer, colon cancer or pancreatic
inducibility or activity of either cyclooxygenase-2
(COX-2) and 5-lipoxygenase (5-LOX), or (5-LOX), cancer, inflammatory disease selected from
involves administering a composition comprising asthma, Alzheimer's disease, arthritis, Crohn's
disease, eczema, inflammatory bowel disease,
alpha acid derivatives selected from reduced
osteoarthritis or psoriasis (claimed). [CONT.]
isoalpha acids, tetra-hydroisoalpha acids, and
hexa-hydroisoalpha acids. [CONT.]
The fractions derived or isolated from hops have
utility in treating the myriad of diseases associated
with hyperactivity of COX-2 and/or 5-LOX. Due to
low toxicity, high dosages of hops derivatives can
be employed to produce useful results, depending
upon the particular effect that is desired.
ORGANIC CHEMISTRY - Preferred Compound:
The compound selected from reduced isoalpha
acids, tetra-hydroisoalpha acids, and hexahydroisoalpha acids is derived from hops. The
compound selected from reduced isoalpha acids,
tetra-hydroisoalpha acids, and hexa-hydroisoalpha
acids comprises a member of a supragenus of
formula (I) (preferably a member of Genus A of
formula (II) or a member of Genus B of [CONT.]
20090507
WO 2009057763 A1 UPAB: 20090615
EP 2221062
A1
20100825
PHARMACEUTICALS - Preferred Vaccine: The
vaccine adjuvant composition comprises
haemozoin (5 mu mol-2 mM) or beta -hematin.
The adjuvant composition is a mucosal vaccine
adjuvant. Preferred Allergen: The allergen is
pollen allergen or mite allergen.
US 20100247568
A1
20100930
JP 2009539133
X
20110310
NOVELTY: Adjuvant composition comprises
haemozoin or beta -hematin, and/or alum
adjuvant, which is used in combination with
allergen vaccine, infectious disease vaccine or
tumor vaccine.
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are included for the following:
(1) vaccine composition containing the above
adjuvant composition and allergen vaccine,
infectious vaccine or tumor vaccine; and [CONT.]
The vaccine administered in combination with the
adjuvant composition effectively induces T-helper
cell (Th1) immunoreaction, and antibody titer with
respect to in vivo pathogen.
CHUGAI SEIYAKU KK
WO 2009051201
A1
20090423
WO 2009051201 A1 UPAB: 20090527
SBI BIOTECH CO LTD
AU 2008312858
A1
20090423
NOVELTY: An anti-human bone marrow stromal
cell antigen 2 (BST2) antibody capable of binding
with a human BST2D antigen, and not binding
with human BST2H antigen substantially, or a
fragment including the antigen binding region, is
new.
BABISH J G
US 20090118373
US 7901713
A1
20090507
B2
20110308
WO 2009057763
A1
US 20090118373 A1 UPAB: 20090527
US 20090118373
US 20090118373
US 7901713
WO 2009057763
US 20100247568
N
BLAND J S
DARLAND G K
FULLER M
TRIPP M L
231 Adjuvant composition useful in vaccine for
preventing and/or treating infectious disease
caused by bacteria and virus, allergy and
tumor, comprises haemozoin or beta-hematin
232 Novel anti-human bone marrow stromal cell
antigen 2 (BST2) antibody capable of binding
with human BST2D antigen, and not binding
with human BST2H antigen substantially, for
treating tumor capable of expressing human
BST2D antigen
NIPPON ZENYAKU KOGYO KK
UNIV OSAKA
The adjuvant composition is useful in vaccine
composition for preventing and treating infectious
disease caused by bacteria or virus, allergy and
tumor (all claimed) in mammals such as human,
monkey, cow, horse, sheep and guinea pig, thus
useful in veterinary medicine. Can also be used
for preventing and treating parasitic infection.
INDEPENDENT CLAIMS are included for the
following:
(1) vaccine composition containing the above
adjuvant composition and allergen vaccine,
infectious vaccine or tumor vaccine; and
N
(2) dendritic cell activator comprising haemozoin
or beta -hematin.
The anti-human bone marrow stromal cell antigen
2 (BST2) specific antibody e.g. monoclonal
antibody or a fragment including the antigen
binding region, is useful in therapeutic agent for
treating disease resulting from the proliferation of
tissue or with respect to tumor capable of
expressing the human BST2D antigen, and as
diagnostic for detecting the tissue or tumor
capable of expressing the human BST2D antigen,
The anti-human BST2 antibody has excellent
specificity with respect to BST2D antigen. The
therapeutic agent has excellent anti-cancer effect
even at reduced dosage. The blood level of the
antibody can be maintained over a long period of
time.
BIOTECHNOLOGY - Preparation (Claimed): The
antibody is produced by culturing the above
hybridoma or transformant, and then collecting the
accumulated antibody from the culture. Preferred
Antibody: The antibody or a fragment including the
antigen binding region is capable of recognizing
polypeptide having an amino acid sequence of
SEQ ID No. 3. [CONT.]
INDEPENDENT CLAIMS are included for the
WO 2009051201
following:
(1) polynucleotide encoding the above antibody or
a fragment including the antigen binding region;
US 20100278832
N
233 Novel polyketide synthase-nonribosomal
peptide synthetase useful for discriminating
and identifying cyclopiazonic acid nonproducing strain e.g. Aspergillus oryzae used
for obtaining mycotoxin-free foodstuffs e.g.
bean paste
diagnostic for detecting the tissue or tumor
capable of expressing the human BST2D antigen,
DETAILED DESCRIPTION: INDEPENDENT
where the tumor is derived from myeloid cells,
CLAIMS are included for the following:
(1) polynucleotide encoding the above antibody or such as myeloma, preferably multiple myeloma
(all claimed) [CONT.]
a fragment including the antigen binding region;
[CONT.]
SEQ ID No. 3. [CONT.]
CHO M
CA 2702939
A1
20090423
ISHIDA K
EP 2210939
A1
20100728
KAMOGAWA Y
KR 2010090258
A
20100813
(4) method of producing the above antibody; and
NAMIKI S
US 20100278832
A1
20101104
(5) hybridoma BST2 [CONT.]
MX 2010004251
A1
20100831
IN 2010DN03243
A
20101105
JP 2009538149
X
20110303
CN 101952426
A
20110119
NODA INST SCI RES
WO 2009051152
A1
20090423
FUJII I
JP 2009538119
X
20110303
KOYAMA Y
US 20110070579
A1
20110324
WO 2009047356
US 20090130113
A1
20090416
A1
20090521
HALLEUX C
TW 2009022621
A
20090601
HU S
AU 2008309514
A1
20090416
KNEISSEL M
MX 2010003915
A1
20100430
WO 2009051152 A1 UPAB: 20090514
The polyketide synthase-nonribosomal peptide
synthetase is useful for discriminating and
NOVELTY: A polyketide synthase-nonribosomal
identifying cyclopiazonic acid non-producing
peptide synthetase, comprising a polypeptide
strain. The transformant e.g. Penicillium and
chosen from polypeptide having an amino acid
sequence of SEQ ID No. 2, polypeptide having an Aspergillus oryzae incapable of producing
cyclopiazonic acid, preferably cyclo-acetoacetyl Lamino acid sequence of SEQ ID No. 2 in which
one or more amino acids are deleted, substituted tryptophan (all claimed), is used in preparation of
soy sauce, bean paste, and sake.
or added, and polypeptide having an amino acid
sequence exhibiting 90% or more homology to an
amino acid sequence of SEQ ID No [CONT.]
(2) vector containing the above polynucleotide;
(3) transformant obtained by introducing the above
vector;
The cyclopiazonic acid producing strain can be
discriminated accurately and rapidly, in a simple
manner. The mycotoxin-free brewing foodstuffs
can be obtained industrially, as the cyclopiazonic
acid which is type of mycotoxin producing ability is
destroyed in the transformant.
BIOTECHNOLOGY - Preparation (Disclosed): The
polyketide synthase-nonribosomal peptide
synthetase is prepared by standard recombinant
methods. Preferred Polynucleotide: The genomic
DNA is contained in the genome of Aspergillus
oryzae. The polynucleotide is cDNA. Preferred
Method: The cyclopiazonic acid non-production
trait transformant is a cyclo-acetoacetyl Ltryptophan non-producing microorganism.
[CONT.]
INDEPENDENT CLAIMS are included for the
WO 2009051152
following: (1) polynucleotide encoding the above
polypeptide, comprising a base sequence of SEQ
ID No. 1 or base sequence hybridizing under
stringent conditions with polynucleotide having a
base sequence of SEQ ID No. [CONT.]
US 20110070579
N
BIOTECHNOLOGY - Preparation (claimed):
Producing the antibody or functional protein
comprises culturing the host cell and isolating the
antibody or functional protein. Preferred Antibody:
The antibody or functional protein binds to the
sclerostin polypeptide with a dissociation constant
(Kd) of less than 10 nM, preferably less than 100
pM. It can block the inhibitory effect of sclerostin in
a cell based Wnt signaling assay [CONT.]
INDEPENDENT CLAIMS are:
US 20090130113
US 7879322
N
SESHIME Y
TAKAHASHI T
TOKUOKA M
NOVARTIS AG
234 New isolated antibody or functional protein
comprises an antigen-binding portion of
DIEFENBACH-STREIBER B
antibody for a target in sclerostin polypeptide,
useful for manufacturing medicament for
treating or preventing pathological disorder,
e.g. osteoporosis
PRASSLER J
DSM IP ASSETS BV
235 New animal feed composition comprises a
mixture of triglyceride oils having a solid fat
KARUTZ M
content at ambient to body temperature and an
emulsifier, useful for reducing calorie uptake,
and for reducing the fat mass in an animal, e.g.
dog
KRAMMER-LUKAS S J M
EP 2203478
A1
20100707
KR 2010074271
A
20100701
CA 2702005
A1
20090416
CN 101821291
A
20100901
IN 2010DN02067
A
20100820
JP 2011502470
T
20110127
US 7879322
US 20110052592
WO 2009046964
EP 2197294
B2
20110201
A1
20110303
A1
20090416
A1
20100623
US 20110052751
A1
20110303
WO 2009047356 A1 UPAB: 20090509
The antibody or functional protein and methods
are useful for treating a bone-related disorder in a
NOVELTY: An isolated antibody or a functional
mammalian subject; and for identifying a cell or
protein comprising an antigen-binding portion of
the antibody for a target in sclerostin polypeptide tissue expressing sclerostin. Additionally, the
comprising SEQ ID NO. 155, where the antibody antibody or functional protein and zoledronic acid,
or functional protein specifically binds to sclerostin DKK1 antibody, alendronate, anti-LRP4 antibody,
hPTH and/or calcilytics are useful for
polypeptide and can increase bone formation,
bone mineral density and bone mineral content in manufacturing a medicament for treating or
preventing a pathological disorder that is mediated
a mammal, is new. [CONT.]
by sclerostin or that is associated with an
increased level of sclerostin, e [CONT.]
WO 2009047356
(1) an antibody comprising either: (a) heavy chain
sequence of SEQ ID NO. 113 and light chain
sequence of SEQ ID NO. 124; (b) heavy chain
sequence of SEQ ID NO. 114 and light chain
sequence of SEQ ID NO. 125; (c) heavy chain
sequence of SEQ ID NO. 115 and light chain
sequence of SEQ ID NO. 126; (d) heavy chain
sequence of SEQ ID NO. 116 and light chain
sequence of SEQ ID NO. [CONT.]
US 20110052592
WO 2009046964 A1 UPAB: 20090514
The animal feed composition, product, and
NOVELTY: Animal feed composition for reducing methods are useful for reducing calorie uptake;
calorie uptake comprising a mixture of triglyceride balancing and maintaining body weight and/or for
oils having a solid fat content at ambient to body reducing the fat mass in an animal; reducing the
weight of companion animals and for reducing the
temperature and an emulsifier, is new.
risk for regaining weight; and for treating obesity
and/or overweight, for controlling calorie or fat
DETAILED DESCRIPTION: INDEPENDENT
intake and for preventing and treating
CLAIMS are:
cardiovascular diseases and diabetes in pets
[CONT.]
(1) product for companion animals comprising 130% by weight, preferably 2-15 % by weight of oilin-water emulsion; [CONT.]
BIOTECHNOLOGY - Preferred Composition: In
the animal feed composition above, the
triglyceride oils are combined with other lipids
containing essential fatty acids. The mixture is an
oil-in-water emulsion of the triglyceride oils and
where the triglyceride oils are selected from palm
oil, cocoa butter and other fats having a solid fat
content at ambient to body temperature. The
triglyceride oils are a fraction of palm oil [CONT.]
INDEPENDENT CLAIMS are:
(1) product for companion animals comprising 130% by weight, preferably 2-15 % by weight of oilin-water emulsion;
(2) a method for balancing and maintaining body
weight and/or for reducing the fat mass in an
animal comprising administering an effective dose
of the composition or animal feed product to the
animal; [CONT.]
WO 2009046964
US 20110052751
MARS INC
236 Gas-solids contact apparatus for processing
e.g. cooking and roasting edibles e.g.
confectionery, comprises drum having interior
wall concentric with inner tube to define
annular space between the drum and the tube,
and gas supply source
237 New pharmaceutical composition comprises a
vaccinia virus (VV) based vector construct,
useful for manufacturing a medicament for
treating, e.g. infectious diseases, chronic
inflammatory or degenerative diseases, or
autoimmunity diseases
238 New uracil or thymine derivatives useful for
inhibiting replication of a ribonucleic acid
virus, and for treating hepatitis C
239 Antimicrobial formulation for reducing or
controlling formation of microbial colonies on
or at surface, comprises surfactant, and
antimicrobial composition including
antimicrobial agent with surfactant properties
and hydrophobic material
240 Use of octreotide peptide having a specific
amino acid sequence in medicine for treating
e.g. cancer, autoimmune diseases, fibrotic
US 20090092752
WO 2009048744
A1
20090409
US 20090092752 A1 UPAB: 20090430
A2
20090416
NOVELTY: The gas-solids contact apparatus for
processing e.g. cooking and roasting edibles e.g.
confectionery, comprises a drum (10) having an
interior wall concentric with an inner tube (20) for
defining an annular space (30) between the drum
and the inner tube, a source for supplying gas to
the annular space at a gas entry zone, a solid
entry point for introducing [CONT.]
EP 2211633
WO 2009048744
EP 2042604
A2
20100804
A3
20110310
A1
20090401
WO 2009040131
A1
20090402
EP 2198031
A1
20100623
US 20110064769
WO 2009039127
A1
20110317
ABBOTT LAB
A1
20090326
WO 2009039127 A1 UPAB: 20090527
ABBOTT GMBH&CO KG
TW 2009018066
A
20090501
AU 2008302448
A1
20090326
NOVELTY: Uracil or thymine derivatives or their
salts, are new.
DETAILED DESCRIPTION: Uracil or thymine
derivatives of formula (I) or their salts, are new.
CA 2699981
A1
20090326
a=single or double carbon-carbon bond;
KR 2010068289
A
20100622
R1=e.g. H or methyl;
CN 101801935
A
20100811
R2 and R3=e.g. H or halo;
EP 2222646
A1
20100901
IN 2010DN02632
A
20101001
R4=e.g. alkyl or alkenyl (both optionally
substituted), nitro or halo;
R5=e.g. H, hydroxy or alkyl;
MX 2010002905
A1
20100731
L1=e.g. bond or C?=C; [CONT.]
JP 2010539186
T
20101216
VN 24379
A
20101125
US 20110070193
GB 2453038
WO 2009037445
A1
20110324
A
20090325
GB 2453038 A UPAB: 20090720
A1
20090326
AU 2008300404
A1
20090326
NOVELTY: An antimicrobial formulation comprises
surfactant(s), and antimicrobial composition
including an antimicrobial agent with surfactant
properties, hydrophobic material and polar
solvent.
DETAILED DESCRIPTION: An INDEPENDENT
CLAIM is included for preparation of antimicrobial
formulation comprising mixing an antimicrobial
composition with other components of formulation
[CONT.]
EP 2190962
A1
20100602
CA 2699696
A1
20090326
IN 2010MN00511
A
20100806
MX 2010002930
A1
20100731
HELMHOLTZ ZENT MUENCHEN DEUT
FORSCHUNGSZ
HELMHOLTZ-ZENT INFEKTIONSFORSCHUNG
GMBH
BYOTROL PLC
SCHWARZ U W
MONDOBIOTECH LAB AG
US 20100279906
A1
20101104
CN 101861379
A
20101013
JP 2010539276
T
20101216
GB 2453038
WO 2009033722
B
20110309
A2
20090319
The gas-solids contact apparatus is useful for
processing such as heating e.g. cooking and
roasting and cooling edibles, which include
confectionery including chocolate, caramel,
nougat, gummies, pressed candies and hard
candies, wafers, crackers, biscuits, cookies,
granola, rice, grains, legumes, cocoa beans,
coffee beans, nuts, fresh and dried fruits, fresh
and dried vegetables, dairy snacks, [CONT.]
EP 2042604 A1 UPAB: 20090430
The pharmaceutical composition is useful for the
manufacture of a medicament for the treatment of
infectious diseases, chronic inflammatory or
NOVELTY: A pharmaceutical composition
comprising: (a) a vaccinia virus (VV) based vector degenerative diseases, autoimmunity diseases,
fungal diseases, cancer, and allergies. It is also
construct, where the vector construct encodes a
heterologous antigen under the control of a strong useful in evoking an immune response against
subdominant and/or cryptic epitopes (all claimed).
VV specific promoter; and (b) a carrier, is new.
The apparatus enables an effective gas-solids
contact in the manufacture of edibles in a
controlled and continuous manner, and removes
the dust formed by the tumbling action of the
solids without an expensive dust filtration
equipment in an eco-friendly manner thus
simplifying manufacturing process of the edible
product and reducing the maintenance cost of the
apparatus.
WO 2009033722 A2 UPAB: 20090423
US 20090092752
US 20110064769
The pharmaceutical composition uses a strong
promoter, which makes it possible to expand the
strength and broadness of cellular immune
responses. The overall number of viruses to be
administered to a patient can also be reduced
considerably, thus, leading to a reduced risk of
unwanted side effects which are due to the viruses
themselves.
BIOTECHNOLOGY - Preferred Method: In evoking
an immune response in a patient against an
antigen, the immune response is a cellular
immune response. The patient is a mammalian,
preferably a human patient. The method further
comprises: (a) priming of a mammal with an
amount of the pharmaceutical composition; (b)
optionally repeating (a) between one and three
times after one week to eight months; [CONT.]
INDEPENDENT CLAIMS are:
The compounds are advantageous due to at least
one of the salt's properties such as, enhanced
pharmaceutical stability in differing temperatures
and humidities, or a desirable solubility in water or
other solvents; and inhibit RNA virus replication by
at least 20%, at least 30%, at least 40%, at least
50%, at least 60%, at least 70%, at least 80%, at
least 90%, or at least 95%.
INORGANIC CHEMISTRY - Preferred
Components: The base is selected from
potassium salt, sodium salt, and cesium salt. The
nitrogenous heteroaryl ligand comprises a
picolinamide compound of formula (V); and is
selected from 8-hydroxyquinoline, 2-(2-pyridyl)benzimidazole, N-(4-cyano- phenyl)picolinamide,
and N-(2-cyanophenyl)picolinamide. R11-R17=H,
1-4C perfluoroalkyl, 1-4C alkyloxy, 1-4C haloalkyl,
chloro or cyano [CONT.]
Uracil or thymine derivatives of formula (I) or their WO 2009039127
salts, are new.
a=single or double carbon-carbon bond;
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are: [CONT.]
In the preparation of a pharmaceutical
composition for treating hepatitis C in a mammal
(claimed).
The gas-solids contact apparatus for processing
US 20090092752
e.g. cooking and roasting edibles e.g.
confectionery, comprises a drum (10) having an
interior wall concentric with an inner tube (20) for
defining an annular space (30) between the drum
and the inner tube, a source for supplying gas to
the annular space at a gas entry zone, a solid
entry point for introducing particulate solids to the
drum, a rotatable [CONT.]
EP 2042604
N
(1) a combined composition comprising the
following ingredients: (a) a first composition
above, provided for priming; and (b) a second
composition above, provided for boosting; and
[CONT.]
US 20110070193
N
R1=e.g. H or methyl;
R2 and R3=e.g. H or halo;
R4=e.g. alkyl or alkenyl (both optionally
substituted), nitro or halo;
R5=e.g. H, hydroxy or alkyl;
L1=e.g. bond or C?=C;
R6=fused 2-ring carbocyclyl or fused 2-ring
heterocyclyl (both optionally substituted with e.g.
R'e or R'f);
R'e=e.g. [CONT.]
An antimicrobial formulation is used for application
to a surface to reduce or control a formation of
microbial colonies on or at the surface. The
formulation is in the form of a surface cleaner,
toilet care product, dishwashing product, laundry
product, outdoor cleaning product, food spray,
personal care product, baby product, first aid
product, foot hygiene product or car cleaning
product. [CONT.]
The colloidal structure of antimicrobial
composition is maintained in the formulation. The
colloids present in antimicrobial composition
remain on the surface even after the rest of
formulation has been removed and that the
presence of colloids on surface prevents biofilm
formation/growth of colonies of microorganisms.
[CONT.]
In medicine; for the preparation of a lyophilized
The peptide is less toxic in comparison to
formulation or a buffered liquid formulation; and in commonly used drugs used for the treatment of
the manufacture of a pharmaceutical composition diseases and have less side effects; can be used
INORGANIC CHEMISTRY - Preferred
Component: The surfactant comprises an amine
oxide. ORGANIC CHEMISTRY - Preferred
Component: The polar solvent is water, ethanol, npropanol, isopropanol, diethylene glycol and/or
dipropylene glycol. The surfactant comprises
amphoteric surfactant(s) ( less than or equal to 5
wt.%), or preferably non-ionic surfactant(s). The
formulation does not comprise an anionic
surfactant [CONT.]
An INDEPENDENT CLAIM is included for
GB 2453038
preparation of antimicrobial formulation
comprising mixing an antimicrobial composition
with other components of formulation. The
antimicrobial composition is prepared by mixing
together an antimicrobial agent with surfactant
properties and hydrophobic material, adding polar
solvent, and agitating resulting mixture until a
clear solution is formed.
US 20100279906
In medicine, octreotide peptide having sequence
of formula D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Lthreoninol (SEQ ID NO.: not defined) or its salts
US 20110065630
WO 2009033722
N
240 Use of octreotide peptide having a specific
amino acid sequence in medicine for treating
e.g. cancer, autoimmune diseases, fibrotic
diseases, inflammatory diseases,
neurodegenerative diseases, infectious
diseases
BACHER G
WO 2009033722
A3
20090611
BEVEC D
WO 2009033722
A8
20090730
CAVALLI F
AU 2008297896
A1
20090319
CAVALLI V
243 Bird toy for exciting foraging instinct in pet
bird, has treat placed on platform that is
accessed by pet bird through side openings
upon successfully aligning holding feature
with release feature
The peptide is less toxic in comparison to
commonly used drugs used for the treatment of
diseases and have less side effects; can be used
for long term treatment of diseases and can be
easily administered. The peptides are selective
targets and under physiological conditions no toxic
or noxious degradation products are formed.
[CONT.]
For treatment or prophylaxis of viral infection
selected from arenavirus infection (where the
arenavirus is selected from Lassa, Junin,
Machupo, Guanarito, Sabia, Whitewater Arroyo,
Chapare, LCMV (Lymphocytic choriomeningitis),
LCMV-like viruses (preferably Dandenong,
Tacaribe, and Pichinde)) or disease associated
with the infection in a mammal e.g. [CONT.]
The compound (I) is safe, hydrophobic, are welltolerated and exhibits improved solubility. The
compound (I) shows increased potency against
viral entry mediated by the Lassa envelope
glycoprotein i.e. the compound (3-(4-ethoxyphenyl)-3H-imidazo (4, 5-b) pyridin-6-yl)-(4-ethylbenzyl)-amine shows very potent with EC50 value
of 0. [CONT.]
Polygonal sheet for constructing a structure
(claimed) i.e. three dimensional (3D) structure, in
outdoor and indoor. Uses include but are not
limited to a pot holder for a plant, pet
feeding/water bowl for a pet, cake mold, lining for
a mold, portable toilet and a chamber pot.
The sheet provides increased rigidity and stability
to the structure. The sheet can be folded into
compact mountain valley mountain bellows-like
configuration in order to provide easy storage and
transfer.
In medicine, octreotide peptide having sequence WO 2009033722
of formula D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Lthreoninol (SEQ ID NO.: not defined) or its salts
and hydrates, is used. An INDEPENDENT CLAIM
is included for pharmaceutical composition
comprising the octreotide peptide together with at
least one carrier, cryoprotectant, lyoprotectant,
excipient and/or diluent.
US 20110065630
Fused imidazol and thiazole compounds of
formula (I), and their salts are new.
B1, D1, E1 and G1=N or C-R';
US 20110064693
EP 2188016
A2
20100526
KR 2010057051
A
20100528
JP 2010539012
T
20101216
US 20110065630
WO 2009029622
A1
20110317
A2
20090305
WO 2009029622 A2 UPAB: 20090602
WO 2009029622
A3
20090423
AU 2008293532
A1
20090305
NOVELTY: Fused imidazol and thiazole
compounds, and their salts are new.
DETAILED DESCRIPTION: Fused imidazol and
thiazole compounds of formula (I), and their salts
are new.
DAI D
EP 2182805
A2
20100512
B1, D1, E1 and G1=N or C-R'; [CONT.]
HRUBY D E
MX 2010002278
A1
20100331
LARSON R A
CA 2698075
A1
20090305
CN 101801189
A
20100811
IN 2010DN01508
A
20100806
JP 2010538000
T
20101209
VN 24355
A
20101125
20110317
TEA&LEMON LTD
US 20110064693
WO 2009027982
A1
A2
20090305
WO 2009027982 A2 UPAB: 20090407
LEVKOVITCH M
WO 2009027982
A3
20090514
NOVELTY: The sheet (10) has two rows (I, II)
provided with panels (12, 14) and made of semirigid material and a rigid though pliable material
e.g. plastic material and paper material such as
cardboard, laminated paper and cloth. The panels
are hinged to one another through a living hinge
(16), where the sheet is folded along tapering
edges (T) of the panels. [CONT.]
EP 2192849
US 20110052838
A2
20100609
(2) a kit comprising a lining element
A1
20110303
(3) a system comprising an annular polygonal
ring.
US 20090050073
US 7900583
A1
20090226
US 20090050073 A1 UPAB: 20090327
B2
20110308
NOVELTY: The bird toy (10) has platforms (24,27)
that are accessible through side openings
provided in housing (12). A support feature on the
housing is located to engage rings (28,30) to
expose treat (T) on the platform. A holding feature
is normally aligned in the housing to hold ring in
raised vertical portion. The holding feature is
aligned with release feature to allow the ring to
expose treat on platform [CONT.]
WO 2009023704
A1
20090219
WO 2009023704 A1 UPAB: 20090313
SIGA TECHNOLOGIES INC
241 New fused imidazole or thiazole compounds
useful for treating viral infection and disease
associated with infection selected from Lassa AMBERG S M
fever, Argentine hemorrhagic fever or Bolivian
BOLKEN T C
or Venezuelan hemorrhagic fever in mammal
242 Polygonal sheet for constructing e.g. pot
holder, has panels hingedly articulated
through edges of rows, and additional
intermediate panel including shape of
isosceles such that neighboring intermediate
panels form shape of rhombus
In medicine; for the preparation of a lyophilized
formulation or a buffered liquid formulation; and in
NOVELTY: In medicine, a octreotide peptide
the manufacture of a pharmaceutical composition
having a sequence of 8 amino acids as given in
in the form of an artificial mother milk formulation
the specification, is used.
or mother milk substitute for oral delivery to
DETAILED DESCRIPTION: In medicine,
newborns, toddlers and infants, for treatment
octreotide peptide having sequence of formula Dand/or prophylaxis of cancer, autoimmune
Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-L-threoninol
diseases, fibrotic diseases, inflammatory
(SEQ ID NO.: not defined) or its salts and
diseases, neurodegenerative [CONT.]
hydrates, is used. [CONT.]
CAITEC CORP
SIMON D F
UNIV SLIPPERY ROCK
244 Treating mammal for parasitic infection,
bacterial infection, fungal infection or infection
caused by parasitic nematode, comprises
administering of alpha, beta-unsaturated
aliphatic aldehyde to the mammal
Bird toy for exciting foraging instinct in pet bird.
ORGANIC CHEMISTRY - Preparation (disclosed):
Preparation of (I) (R is H, and R1 and R2 are H)
involves reacting a solution of crude fused
imidazol or thiazole compound of formula (II) in
DCM (dichloromethane) (3 ml) with aldehyde of
formula Ar2-CHO (2 mmol) and Na(OAc)3BH
(sodium triacetate borohydride) (630 mg); followed
by stirring the reaction at room temperature for 1.5
hours. [CONT.]
BIOLOGY - Preferred Components: The trans-2dodecenal is isolated from plant source
comprising Eryngium foetidum and Coriandrum
sativum. ORGANIC CHEMISTRY - Preferred
Components: (I) is 10-14 carbon- alpha , beta unsaturated aliphatic aldehyde, or trans-2dodecenal.
N
R'=alkyl, carbamoyl or aminosulfonyl (all optionally
substituted), alkenyl, alkynyl, cycloalkyl,
heterocycloalkyl, arylalkyl, (hetero)aryl, hydroxy,
alkyloxy, aryloxy, heteroaryloxy, acyloxy,
arylacyloxy, heteroarylacyloxy, alkylsulfonyloxy,
arylsulfonyloxy, thio, alkylthio, arylthio, amino,
[CONT.]
INDEPENDENT CLAIMS are also included for the WO 2009027982
following:
(1) a structure comprising a fastening
arrangement
The bird can manipulate the toy to gain access to
the treat placed in the toy in simple and
inexpensive manner.
The method is useful for treating infectious
The method provides safe treatment without side
diseases in mammal (preferably human), which is effect.
infected or to be infected with: parasite of
Trypanosoma comprising T. rangeli, T. mega, T.
avium, T. conorhini, T. brucei gambiense, T.
brucei rhodesiense and T. cruzi; Enterococcus
faecalis and Streptococcus pyrogen bacteria;
fungus comprising Cryptococcus neoformans,
Microsporum gypseum and Penicillium marneffei
[CONT.]
WO 2009029622
US 20110052838
US 20090050073
US 20090050073
US 7900583
Method for treating mammal for parasitic infection, WO 2009023704
bacterial infection, fungal infection or infection
caused by parasitic nematode, comprises
administering 8-16 carbon alpha , beta unsaturated aliphatic aldehyde (I) to mammal,
where the parasite is Trypanosoma genus, the
bacteria is Enterococcus faecalis and
Streptococcus pyrogen, the fungus is
Cryptococcus neoformans, Microsporum gypseum
and [CONT.]
US 20090047342
N
244 Treating mammal for parasitic infection,
bacterial infection, fungal infection or infection UNIV SLIPPERY ROCK FOUND
caused by parasitic nematode, comprises
administering of alpha, beta-unsaturated
aliphatic aldehyde to the mammal
245 Use of an amidohydrolase for conditioning
foodstuff or a semi-luxury food e.g. crisp
bread, rusk, cookies, pretzels, toast, wafers,
muffins, beagles, croissant, brownies, potato
chips tortilla chips, corn chip and bread
mixtures
246 New isolated and purified peptide that is
capable of blocking with high affinity and
specificity a potassium channel Kv1.3, useful
for preventing or treating an autoimmune
disease, e.g. multiple sclerosis or rheumatoid
arthritis
247 Anatomical parameter measuring device for
e.g. dog, transmits laser beam through sheet
of treated glass and direction of beam is
changed by refraction so that beam aligned
with position such as tail of animal, to
measure tail length
US 20090047342
A1
20090219
The method is useful for treating infectious
The method provides safe treatment without side
diseases
in
mammal
(preferably
human),
which
is
effect.
NOVELTY: Treating mammal for parasitic
infected
or
to
be
infected
with:
parasite
of
infection, bacterial infection, fungal infection or
Trypanosoma comprising T. rangeli, T. mega, T.
infection caused by parasitic nematode,
comprises administering alpha , beta -unsaturated avium, T. conorhini, T. brucei gambiense, T.
brucei rhodesiense and T. cruzi; Enterococcus
aliphatic aldehyde (I), where the parasite is
faecalis and Streptococcus pyrogen bacteria;
Trypanosoma, the bacteria is Enterococcus
faecalis and Streptococcus pyrogen, the fungus is fungus comprising Cryptococcus neoformans,
Cryptococcus neoformans, Microsporum gypseum Microsporum gypseum and Penicillium marneffei
[CONT.]
and Penicillium marneffei, and the parasitic
nematode is Parastrongyloides trichosuri,
Haemonchus contortus and Ancylostoma
caninum. [CONT.]
BIOLOGY - Preferred Components: The trans-2dodecenal is isolated from plant source
comprising Eryngium foetidum and Coriandrum
sativum. ORGANIC CHEMISTRY - Preferred
Components: (I) is 10-14 carbon- alpha , beta unsaturated aliphatic aldehyde, or trans-2dodecenal.
Method for treating mammal for parasitic infection, WO 2009023704
bacterial infection, fungal infection or infection
caused by parasitic nematode, comprises
administering 8-16 carbon alpha , beta unsaturated aliphatic aldehyde (I) to mammal,
where the parasite is Trypanosoma genus, the
bacteria is Enterococcus faecalis and
Streptococcus pyrogen, the fungus is
Cryptococcus neoformans, Microsporum gypseum
and [CONT.]
DE 102007027825 A1 UPAB: 20090311
BIOLOGY - Preferred Components: The
amidohydrolase exhibits: a specific activity of at
least 200 units/mg at 60-120 degrees C; an
optimum pH of 1-14; and a residual activity of at
least 80% after storage in 4 degrees C over a
period of 1 month. The amidohydrolase is an
asparaginase, where the asparaginase
(asparaginase I) is from Pyrococcus furiosus.
[CONT.]
INDEPENDENT CLAIMS are included for:
BIOTECHNOLOGY - Preferred Peptide: The
peptide comprises SEQ ID NO. 1 or 2. In the
labeled peptide, the labeling moiety is selected
from a radioactive isotope, a fluorescent moiety,
chemiluminescent moiety, a chromophore, or a
protein. Preferably, the labeling protein is an
antibody, biotin, green fluorescent protein, or
green fluorescent protein with distinct emission
spectra. Preferred Method: In inhibiting Kv1
[CONT.]
INDEPENDENT CLAIMS are:
US 7910114
B2
20110322
DE 102007027825
A1
20081218
WO 2008151807
A2
20081218
WO 2008151807
A3
20090312
AU 2008261251
A1
20081218
CA 2689935
A1
20081218
EP 2193198
A2
20100609
CN 101778939
A
20100714
IN 2009DN08335
A
20100723
A1
20110303
UNIV MEXICO NACIONAL AUTONOMA
US 20110052758
WO 2008139243
A1
20081120
WO 2008139243 A1 UPAB: 20090205
FERREIRA B C V
AU 2007353147
A1
20081120
NOVELTY: An isolated and purified peptide that
shares at least 83% pairwise sequence identity
over the 36 aligned positions of SEQ ID NO. 3 not
defined in the specification, where the peptide is
capable of blocking with high affinity and
specificity a potassium channel Kv1.3, is new.
GASPAR R
CA 2686216
A1
20081120
GURROLA-BRIONES G
KR 2010023867
A
20100304
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are:
(1) a method of inhibiting Kv1. [CONT.]
PANYI G
EP 2158213
A1
20100303
POSSANI-POSTAY L D
MX 2009012092
A1
20100228
SALAS-CASTILLO S P
IN 2009DN07396
A
20100702
VARGA Z S
ZA 2009007909
A
20100728
JP 2010528988
T
20100826
CN 101796069
A
20100804
US 20110059064
EP 2014230
EP 2014230
A1
20110310
A1
20090114
B1
20110309
C-LECTA GMBH
VEREZ FRAGUELA J L
The amidohydrolase is useful for the conditioning
NOVELTY: Use of an amidohydrolase exhibiting a of the foodstuff or the semi-luxury food, which is
residual activity of at least 75% after an incubation crisp bread, rusk, cookies, pretzels, toast, wafers,
of 5 minutes at 50 degrees C, for the conditioning muffins, beagles, croissant, brownies, break fast
cereals, potato chips tortilla chips, corn chip,
of a foodstuff or a semi-luxury food, is claimed.
cracker, french fries, rice cake, polenta, couscous,
pancake, nuts, finished cake mixtures, biscuit
mixtures, bread mixtures, croutons, dog food,
[CONT.]
The conditioning process provides less time
consuming and economically improved process by
reducing the concentration of asparagine in the
foodstuff or the semi-luxury food. The
amidohydrolase is highly stable and exhibits a
residual activity of at least 80% after storage in 4
degrees C over a period of 1 month.
US 7910114
DE 102007027825
US 20110052758
WO 2008139243
US 20110059064
(1) conditioning of the foodstuff or the semi-luxury
food, comprising: (i) incubating the foodstuff or the
semi-luxury food with an amidohydrolase with an
incubation temperature of at least 50 degrees C;
and (iii) optionally, heating the foodstuff or the
semi-luxury food on at least 10 degrees C above
the incubation temperature; [CONT.]
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are included for: [CONT.]
EP 2014230 A1 UPAB: 20090205
The peptide is useful for inhibiting Kv1.3
potassium channel activity in a mammalian cell;
attenuating calcium signaling pathway in a Tlymphocyte cell; suppressing T-cell activation
process in the immune system of a mammal;
suppressing an immune response in mammals;
prophylactic or therapeutic treatment of
heterologous organ rejection in a subject;
prophylactic or therapeutic treatment of an
autoimmune disease associated to lymphocyte
TEM in a subject; identification of cells expressing
Kv1 [CONT.]
Anatomical parameter measuring device for pet
NOVELTY: The device has an electronic weighing animal e.g. dog.
platform on which the animal whose parameter is
to be measured is situated. A laser measuring
instrument (5) transmits the laser beam (8)
through a sheet of treated glass (4). The direction
of the laser beam is changed by the refraction so
that the laser beam aligned with the positions
such as head, tail and leg of the animal, to
measure the height, weight and length of the
animal [CONT.]
The weight, height and length of the animal are
simultaneously measured so that the animal
overweight and the growth of the young animal
are easily diagnosed and the chronic disease of
the animal is monitored by the single clinical
action.
N
(1) a method of inhibiting Kv1.3 potassium
channel activity in a mammalian cell comprising
contacting the mammalian cell with an amount of
a peptide to block the channel activity in the cell,
where the peptide has an amino acidic sequence
selected from SEQ ID NO. 1-3 not defined in the
specification, or its functional equivalent analog
with at least 83% pairwise sequence identity over
the 36 aligned positions of SEQ ID NO. 3, or its
salt; [CONT.]
EP 2014230
Y
EP2014230B1
248 Pharmaceutical composition useful for
treatment of e.g. amyloidosis comprises a
compound which depletes serum amyloid P
component from circulation, in combination
with an antibody specific for serum amyloid P
component
PENTRAXIN THERAPEUTICS LTD
WO 2009000926
A1
20081231
WO 2009000926 A1 UPAB: 20090307
PEPYS M B
US 20090191196
A1
20090730
NOVELTY: A pharmaceutical composition (C1)
comprises a compound (A1) which depletes
serum amyloid P component from the circulation,
in combination with an antibody specific for serum
amyloid P component.
AU 2008267148
A1
20081231
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are included for the following: [CONT.]
CA 2691054
A1
20081231
EP 2173341
A1
20100414
IN 2009KN04264
A
20100409
KR 2010050495
A
20100513
CN 101801372
A
20100811
JP 2010531338
T
20100924
AU 2008358292
A1
20091230
CA 2729034
A1
20091230
US 7910106
WO 2008150841
US 20090136483
B2
20110322
A1
20081211
A1
20090528
HANSEN G
AU 2008260135
A1
20081211
SABBADINI R A
US 20100034814
EP 2164992
A1
20100211
SWANEY J S
A1
20100324
MATTEO R
JP 2010530218
T
20100909
MILLS G
CA 2724432
A1
20081211
WOJCIAK J M
US 20110064744
WO 2008132601
A1
20110317
A1
20081106
WO 2008132601 A1 UPAB: 20081222
INSERM INST NAT SANTE & RECH MEDICALE
EP 1987839
A1
20081105
NOVELTY: A molecule binding to Lymphocyte
activation gene (LAG)-3 protein and causing
depletion of LAG-3' activated T cells, is new.
IMMUTEP
EP 2142210
A1
20100113
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are:
IMMUTEP PARC CLUB ORSAY
CA 2685584
A1
20081106
(1) a cytotoxic anti-LAG-3 monoclonal antibody or
fragment, where the monoclonal antibody causes
depletion of more than 30% preferably more than
50% of LAG-3 activated T cells; [CONT.]
HAUDEBOURG T
CN 101720227
A
20100602
TRIEBEL F
JP 2010526052
T
20100729
US 20100233183
US 20110070238
WO 2008122817
A1
20100916
A1
20110324
A2
20081016
249 New isolated anti-LPA (LPA) agent for treating LPATH INC
or preventing a disease or disorder associated GARLAND W A
with aberrant levels of LPA, e.g. cancer
comprises complementary determining region
(CDR) peptide
250 New molecule binding to Lymphocyte
activation gene (LAG)-3 protein and causing
depletion of LAG-3' activated T cells for
treating or preventing organ transplant
rejection or autoimmune diseases
INSERM INST NAT SANTE&RECH MEDICALE
VANHOVE B
251 New immunogenic composition, comprises a
viral vector, where the vector comprises a
nucleic acid sequence encoding a C4bp
domain, useful for treating or preventing
malaria
ISIS INNOVATION LTD
For the treatment or prophylaxis of amyloid
disease selected from systemic amyloidosis, local
amyloidosis, diseases associated with amyloid
deposition, Alzheimer's disease and type 2
diabetes (claimed).
WO 2008150841 A1 UPAB: 20090629
The methods, agent, and reagent are useful for
treating or preventing a disease or disorder
NOVELTY: An isolated anti-LPA (LPA) agent,
associated with aberrant levels of LPA, decreasing
which agent binds LPA under physiological
aberrant hyperproliferation, immune response,
conditions and comprises complementary
neurodegeneration, angiogenesis,
determining region (CDR) peptide having an
amino acid sequence that has a sequence identity neovascularization, apoptosis, fibrogenesis or
fibrosis, detecting an anti-LPA agent, and
of at least 65% with an amino acid sequence
detecting in a sample an anti-LPA agent, where
selected from SEQ ID NO. 56-62, 69-74, 81-86,
the disease or disorder is a hyperproliferative
93-98, and 105-111, is new. Sequences not
disease, including cancer [CONT.]
defined here may be found at ftp://ftp [CONT.]
PHARMACEUTICALS - Preferred Composition:
The composition (C1) does not comprise
ethanolamines; phosphoethanolamines; 4,6pyruvate acetyl of beta -D-galactopyranose;
calcium and/or interleukin (IL-4 and/or IL-3). The
antibody specific for serum amyloid P component
does not target the portion of SAP which is
functional in inhibiting fibrocyte formation from
monocytes. [CONT.]
INDEPENDENT CLAIMS are included for the
following:
(1) a kit (K1) for the treatment of amyloidosis
comprising a compound (A1) which depletes
serum amyloid P component (SAP) from the
circulation and an antibody specific for serum
amyloid P component; and [CONT.]
WO 2009000926
BIOTECHNOLOGY - Preferred Nucleic Acid
Molecule: In the nucleic acid molecule, the
immunoglobulin heavy chain is derived from a
fish, bird or mammal, optionally a primate,
optionally a human. Preferred Method: In
decreasing aberrant hyperproliferation, immune
response, neurodegeneration, angiogenesis,
neovascularization, apoptosis, fibrogenesis or
fibrosis, the subject is human. [CONT.]
INDEPENDENT CLAIMS are:
WO 2008150841
US 7910106
(1) a composition comprising an anti-LPA agent
and a carrier;
(2) an anti-LPA agent combined with a second
agent which is optionally selected from an
antibody, an antibody fragment, an antibody
derivative, and an antibody variant; [CONT.]
WO 2008122817 A2 UPAB: 20091012
The antibody, molecule, and method are useful for
manufacturing a medicament for treating or
preventing organ transplant rejection or for
treating autoimmune diseases (claimed).
The immunogenic composition, product,
combination or kit, viral vector, and method are
useful for immunizing an individual; for generating
a protective T cell response in a subject against at
least one target antigen of a pathogen or tumor;
BIOTECHNOLOGY - Preferred Molecule: In the
molecule binding to LAG-3 protein, the molecule is
a cytotoxic anti-LAG-3 monoclonal antibody or
fragment causing depletion of LAG-V activated T
cells measured by changes in peripheral blood
lymphocyte numbers, the antibody comprising the
human immunoglobulin (Ig)G1 or IgM or murine
IgG2a subclass Fc fragment and an Fab fragment
which binds LAG-3 protein, where the antibody
exhibits a complement-dependent cytotoxicity
(CDC) and/or an antibody-dependent cell
cytotoxicity activity (ADCC) [CONT.]
INDEPENDENT CLAIMS are:
BIOTECHNOLOGY - Preferred Composition: In
the immunogenic composition, the nucleic acid
encoding the C4bp domain is in frame with the
nucleic acid encoding the antigen. The encoded
C4bp domain is selected from the amino acid
INDEPENDENT CLAIMS are:
US 20090191196
US 20090136483
US 20100034814
N
US 20110064744
WO 2008132601
(1) a cytotoxic anti-LAG-3 monoclonal antibody or
fragment, where the monoclonal antibody causes
depletion of more than 30% preferably more than
50% of LAG-3 activated T cells;
US 20100233183
N
US 20110070238
(2) a method of treating or preventing organ
transplant rejection or autoimmune diseases in a
mammal comprises administering to the mammal
an antibody; [CONT.]
WO 2008122817
US 20110064768
N
251 New immunogenic composition, comprises a
viral vector, where the vector comprises a
nucleic acid sequence encoding a C4bp
domain, useful for treating or preventing
malaria
252 Oral transmucosal composition, useful for
treating diabetes, cancer, viral or bacterial
infection, and psychiatric diseases e.g. mood
disorder, comprises a polypeptide, an
effervescent excipient component and a bile
salt
IMAXIO SA
WO 2008122817
A3
20081211
NOVELTY: An immunogenic composition,
comprising a viral vector, the vector comprising a
nucleic acid sequence encoding a C4bp domain
or variant or fragment and a nucleic acid
sequence encoding an antigen, is new.
DRAPER S
AU 2008235315
A1
20081016
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are:
HILL A
CA 2683117
A1
20081016
HILL F
EP 2155242
A2
20100224
(1) a vaccine comprising the immunogenic
composition;
(2) a product, combination or kit comprising;
[CONT.]
IN 2009MN01945
A
20100528
JP 2010523138
T
20100715
US 20110064768
WO 2008137054
WO 2008137054
A1
20110317
A2
20081113
WO 2008137054 A2 UPAB: 20081128
A3
20090604
NOVELTY: Oral transmucosal composition (I)
comprises: a polypeptide (A); an effervescent
excipient component (B); and a bile salt (C).
AU 2008248228
A1
20081113
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are included for:
CA 2685853
A1
20081113
(1) a method of enhancing transmucosal
absorption of (A), comprising administering (A) to
a recipient as a dosage form, which comprises (I);
[CONT.]
MX 2009011784
A1
20091130
CEPHALON INC
OCEAN NUTRITION CANADA LTD
253 Preparing lipid composition, useful for e.g.
lowering cholesterol levels and/or triglyceride RADIANINGTYAS H
levels, and reducing hyperglycemia, comprises
culturing oil producing microbe in
heterotrophic medium having fatty acid
production antagonist
VECTA LTD
254 Multiple unit pharmaceutical composition
useful for reducing gastric acid secretion and
treating gastritis, gastric ulcer or duodenal
ulcer in human subject, comprises succinic
acid particles and enteric-coated proton pump
inhibitor
EP 2155229
A2
20100224
CN 101674843
A
20100317
IN 2009CN07048
A
20100312
US 20100111902
A1
20100506
JP 2010526071
T
20100729
EP 2155229
B1
20110119
DE 602008004656
E
20110303
WO 2008129358
EP 2082053
A2
20081030
WO 2008129358 A2 UPAB: 20090806
A2
20090729
NOVELTY: Method of preparing a lipid
composition (I), comprises (a) culturing an oil
producing microbe in a heterotrophic medium
comprising a fatty acid production antagonist.
AU 2007351658
A1
20081030
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are included for: [CONT.]
CA 2659603
A1
20081030
WO 2008129358
A8
20090903
MX 2009001346
A1
20090331
JP 2010511377
T
20100415
US 20100285105
WO 2008129358
US 20080248109
A1
20101111
A3
20110303
A1
20081009
US 20080248109 A1 UPAB: 20091126
The immunogenic composition, product,
combination or kit, viral vector, and method are
useful for immunizing an individual; for generating
a protective T cell response in a subject against at
least one target antigen of a pathogen or tumor;
for treating or preventing malaria; and for
manufacturing the immunogenic composition or
vaccine for preventing or treating malaria (all
claimed). [CONT.]
BIOTECHNOLOGY - Preferred Composition: In
the immunogenic composition, the nucleic acid
encoding the C4bp domain is in frame with the
nucleic acid encoding the antigen. The encoded
C4bp domain is selected from the amino acid
sequences shown in the specification. The C4bp
domain and antigen are expressed as a fusion
protein. [CONT.]
WO 2008122817
US 20110064768
WO 2008137054
US 20100111902
WO 2008129358
US 20100285105
US 20080248109
US 20080248109
(1) a vaccine comprising the immunogenic
composition;
(2) a product, combination or kit comprising; (i) a
priming composition comprising the first viral
vector, the viral vector further comprising the
nucleic acid encoding the C4bp domain or variant
of fragment, and at least one pathogen or tumor
antigen; and (ii) a boosting composition
comprising a second viral vector, the [CONT.]
(I) is useful for treating diabetes. (I) having
interferon- gamma , is useful for treating cancer
and a viral or bacterial infection. (I) having amylin,
is useful for treating a psychiatric disease or
disorder (including a mood disorder, an anxiety
disorder or schizophrenia) (all claimed). (I) is
useful for: treating obesity; and controlling blood
glucose.
(I) enhances transmucosal permeation of the
polypeptide across oral mucosal tissue and
provides relatively rapid efficacious therapeutics.
(I) enhances transmucosal absorption of
polypeptides in therapeutic serum concentrations
of the recipient. (I) improves the delivery of large
molecules including polypeptides, across the oral
mucosal tissue. [CONT.]
PHARMACEUTICALS - Preferred Components:
(A) has a molecular weight of 500 Daltons to 200
kilo Daltons (preferably 1000-20000 Daltons). (B)
comprises a food grade acid and a base. (B)
comprises citric acid and sodium bicarbonate. (C)
is sodium taurocholate (preferred), sodium
glycocholate, sodium glycodeoxycholate, sodium
taurodeoxycholate, sodium cholate, sodium
taurochenodeoxycholate, and/or sodium
tauroursodeoxycholate [CONT.]
INDEPENDENT CLAIMS are included for:
(I) is useful in: microcapsule, which is useful to
prepare medicament for delivering a loading
substance to a subject; a delivery device, which
comprises microcapsule, microsphere,
nanosphere or nanoparticle, liposome, noisome,
nanoerythrosome, solid-liquid nanoparticle,
leuprolide, gel, gel capsule, tablet, lotion, cream,
spray, emulsion, or powder, where the delivery
device is useful to deliver (I) to the subject
[CONT.]
(I) is easy to separate and purify.
BIOLOGY - Preferred Method: The method of
preparing (I) further comprises isolating (I). The
ratio of omega-3 and omega-6 fatty acids to
omega-9 fatty acids is increased. The overall fatty
acid content is unaltered. The method of preparing
carotenoid composition or antioxidant composition
further comprises isolating the carotenoid
composition or antioxidant composition. [CONT.]
INDEPENDENT CLAIMS are included for:
The multiple unit pharmaceutical composition is
useful for reducing gastric acid secretion in a
human subject and treating nocturnal gastroesophageal reflux disease (GERD) symptoms,
reflux esophagitis, gastritis, duodenitis, gastric
ulcer, duodenal ulcer, pathologies associated with
The composition provides a unique combination of
active agents that increase the efficacy of PPI in
inhibiting gastric acid secretion without the
requirement of timed food injection. The carboxylic
acid or its analog releases therapeutic effect in
stomach in conjunction with PPI without undue
N
(1) a method of enhancing transmucosal
absorption of (A), comprising administering (A) to
a recipient as a dosage form, which comprises (I);
(2) a method of administering (A) to a recipient
comprising contacting (I) with mucosal tissue in an
oral cavity of the recipient for a period of time
sufficient for dissolution of (I) and transmucosal
delivery of (A) across the mucosa; and [CONT.]
(1) a microcapsule, comprising an agglomeration
of primary microcapsules and a loading
substance, each individual primary microcapsule
having a primary shell, where the loading
substance having (I) and is encapsulated by the
primary shell, and where the agglomeration is
encapsulated by an outer shell; and [CONT.]
PHARMACEUTICALS - Preferred Composition:
INDEPENDENT CLAIMS are included for the
The succinic acid particles are encapsulated in an following:
internal capsule, the internal capsule is
encapsulated within an external capsule which
contains the enteric-coated PPI. The entericcoated PPI is encapsulated in an internal capsule,
N
useful for reducing gastric acid secretion and
treating gastritis, gastric ulcer or duodenal
ulcer in human subject, comprises succinic
acid particles and enteric-coated proton pump
inhibitor
A2
20091119
WO 2009138884
A3
20100128
AU 2009247712
A1
20091119
CA 2725437
A1
20091119
EP 2296470
US 20080265056
WO 2008132696
A2
20110323
A1
20081030
A1
20081106
AU 2008243785
A1
20081106
GLASSMEYER S R
EP 2139610
A1
20100106
MORRISON L R
CA 2683234
A1
20081106
PEGOLI R E
MX 2009011280
A1
20091031
QUAN K
CN 101674891
A
20100317
WEN L
JP 2010524492
T
20100722
AU 2008243785
B2
20110303
PHARMACURE HEALTH CARE AB
WO 2008102150
A2
TOWLER P D
GB 2447012
PROCTER & GAMBLE CO
255 Ultrasonic spray apparatus for substrate e.g.
pasta, has control unit for controlling power
PROCTER&GAMBLE CO
supply applied to transducer, where fluid is
ejected from surface, when high power level is
applied to transducer
DECHERT G J
256 Gel composition useful for preventing or
treating epistaxis, comprises carboxy
polymethylene polymer, glycine, source of
calcium ions, and water
WO 2009138884
HONEYWELL INT INC
257 Blowing agent for producing foam useful for
article, e.g. refrigerator, comprises
trifluoromonochloropropene(s) and adjuvant(s)
NOVELTY: A multiple unit pharmaceutical
composition comprises succinic acid particles or
its salts and an enteric-coated proton pump
inhibitor (PPI), where the succinic acid particles
are released in the stomach in an amount
sufficient to reduce gastric acid secretion in
conjunction with the PPI, and where the entericcoated PPI and the succinic acid particles are
physically separated within the multiple unit
composition. [CONT.]
useful for reducing gastric acid secretion in a
active agents that increase the efficacy of PPI in
human subject and treating nocturnal gastroinhibiting gastric acid secretion without the
esophageal reflux disease (GERD) symptoms,
requirement of timed food injection. The carboxylic
reflux esophagitis, gastritis, duodenitis, gastric
acid or its analog releases therapeutic effect in
ulcer, duodenal ulcer, pathologies associated with stomach in conjunction with PPI without undue
nonsteroidal anti-inflammatory drugs (NSAID), non- adverse side effects.
ulcer dyspepsia, gastro-esophageal reflux
disease, gastrinomas, [CONT.]
US 20080265056 A1 UPAB: 20081118
The succinic acid particles are encapsulated in an
internal capsule, the internal capsule is
encapsulated within an external capsule which
contains the enteric-coated PPI. The entericcoated PPI is encapsulated in an internal capsule,
the internal capsule is encapsulated within an
external capsule which contains the succinic acid
particles. [CONT.]
Ultrasonic spray apparatus for ejecting a snack
NOVELTY: The apparatus (10) has an ultrasonic food-flavoring fluid such as oil, propylene glycol,
and water, from an atomizing surface i.e. vibrating
power supply (12) operating at a frequency. A
transducer vibrates with amplitude, when a power nozzle tip, to apply the fluid to a substrate. Uses
is applied to the transducer. A vibrating nozzle is include but are not limited to a snack chip e.g.
acoustically coupled to the transducer to transmit sliced potato chip, fabricated snack e.g. [CONT.]
the transducer vibration to a surface i.e. vibrating
nozzle tip. [CONT.]
The apparatus avoids the utilization of expensive
additive materials outside of the substrate, thus
reducing the cost of the apparatus, and
eliminating the need to create a recycle stream of
the materials. The apparatus provides quick
changeovers from a flavor/strength to another
flavor/strength in the same production line, thus
reducing manufacturing down time. [CONT.]
20080828
WO 2008102150 A2 UPAB: 20081112
A
20080903
NOVELTY: A gel composition, comprises carboxy
polymethylene polymer, glycine, source of calcium
ions, and water.
WO 2008102150
A3
20090430
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are included for the following:
The gel composition is easily administered to the POLYMERS - Preferred Composition: The carboxy
nasal cavity and do not require removal after use. polymethylene polymer is carbopol 974P NF
and/or carbopol 971P NF. The concentration of
carboxy polymethylene polymer is 10-100, 20-50,
30-40 or 35 g dry weight/l of gel. The
concentration of glycine is 50-200, 80-150, 110120 or 117 g dry weight/l of gel. The concentration
of calcium ions is 10-200, 20-100, 40-70 or 58
mg/l of gel.
AU 2008217608
A1
20080828
(1) making the composition, involves mixing water
with the dry components such as carboxy
polymethylene polymer, glycine and source of
calcium ions; [CONT.]
EP 2117502
A2
20091118
CA 2678706
A1
20080828
KR 2009130001
A
20091217
CN 101677940
A
20100324
IN 2009DN05206
A
20100319
US 20100119472
A1
20100513
JP 2010519285
T
20100603
ZA 2009005519
A
20101027
GB 2447012
US 20080207788
B
20110316
A1
20080828
US 20080207788 A1 UPAB: 20090811
The composition is useful for preventing or
treating epistaxis (claimed).
(1) pharmaceutical composition comprising (a)
first and second unit, the first unit comprising one
or more small carboxylic acid molecules, or its
salts and the second unit comprising an enteric
coated proton pump inhibitor (PPI), where the
small carboxylic acid molecules and entericcoated PPI are physically separated, the first unit
releasing at [CONT.]
US 20080265056
US 20080265056
INDEPENDENT CLAIMS are included for the
WO 2008102150
following:
(1) making the composition, involves mixing water
with the dry components such as carboxy
polymethylene polymer, glycine and source of
calcium ions;
(2) treating epistaxis by prophylaxis or therapy,
involves inserting gel composition into a nasal
cavity of a human or non-human animal;
US 20100119472
N
(3) dry composition comprising carboxy
polymethylene polymer, glycine and source of
calcium ions; and [CONT.]
Blowing agent for producing foam useful for
manufacturing article, e.g. refrigerator, freezer
(claimed), or panel.
The blowing agent has low toxicity level. It is
compatible with existing foaming methods and
systems. The resulting foam made of blowing
agent has exceptional thermal performance, good
thermal insulation efficiency, dimensional stability,
compressive strength, aging of thermal insulation
properties, and low global warming potential.
ORGANIC CHEMISTRY - Preferred Compound:
INDEPENDENT CLAIMS are included for:
The trifluoromonochloropropene compound
comprises a compound of formula XCFzR3-z. It
comprises CF3CCl=CH2 (HFCO-1233xf), or
preferably CF3CH=CHCl (HFCO-1233zd). X=2-5C
unsaturated, optionally, radical; R=Cl, F, Br, I or
H;and z=1-3. Preferred Property: The blowing
agent has a Global Warming Potential (GWP) of
not greater than 150, and an Ozone Depleting
Potential (ODP) of not greater than 0 [CONT.]
US 20080207788
US 20080207788
N
HONEYWELL INT INC
257 Blowing agent for producing foam useful for
article, e.g. refrigerator, comprises
trifluoromonochloropropene(s) and adjuvant(s)
258 New anti-roundabout 4 (Robo4) antibody,
useful for modulating angiogenesis and for in
vivo imaging
GENENTECH INC
BIOGAIA AB
259 Improving fur and claw quality in companion
animal, e.g. dog or cat, includes providing
product containing biologically pure culture of
selected nonpathogenic, lysine-uptake
stimulating lactic acid bacterial strain of
Lactobacillus reuteri
TW 2006015370
A
20060516
EP 2085422
A2
20090805
EP 2098581
A2
20090909
EP 2098581
A3
20091104
ZA 2006007176
A
20090930
EP 2154223
EP 2163591
EP 2163592
A1
20100217
A2
20100317
A2
20100317
ES 2338519
T1
20100510
EP 2228421
A2
20100915
JP 2010265471
A
20101125
JP 2010265472
A
20101125
EP 2258404
EP 2258755
EP 2258784
EP 2258802
EP 2258819
EP 2277969
EP 2277974
EP 2277975
EP 2277977
EP 2277984
EP 2279670
EP 2228421
WO 2008100805
US 20080247951
A2
20101208
A2
20101208
A2
20101208
A2
20101208
A2
20101208
A2
20110126
A2
20110126
A2
20110126
A2
20110126
A2
20110126
A2
20110202
A3
20110302
A2
20080821
A1
20081009
AU 2008216495
A1
20080821
EP 2125896
A2
20091202
CA 2676766
A1
20080821
CN 101652389
A
20100217
JP 2010518115
T
20100527
KR 2009114443
A
20091103
US 7834154
B2
20101116
VN 21850
A
20100125
US 20110059013
US 20110059112
US 20080213431
A1
20110310
A1
20110310
A1
20080904
NOVELTY: Blowing agent comprises
trifluoromonochloropropene(s); and adjuvant(s)
containing greater than or equal to 2 of co-blowing
agent(s), surfactant(s), polymer modifier (s),
toughening agent(s), colorant(s), dye(s), solubility
enhancer(s), rheology modifier(s), plasticizing
agent(s), flammability suppressant(s), antibacterial
agent(s), viscosity reduction modifier(s), filler(s),
vapor pressure modifier(s), nucleating agent(s),
and catalyst(s). [CONT.]
Blowing agent for producing foam useful for
manufacturing article, e.g. refrigerator, freezer
(claimed), or panel.
The blowing agent has low toxicity level. It is
compatible with existing foaming methods and
systems. The resulting foam made of blowing
agent has exceptional thermal performance, good
thermal insulation efficiency, dimensional stability,
compressive strength, aging of thermal insulation
properties, and low global warming potential.
ORGANIC CHEMISTRY - Preferred Compound:
US 20080207788
The trifluoromonochloropropene compound
(1) foamable composition comprising a foam
comprises a compound of formula XCFzR3-z. It
forming agent and trifluoromonochloropropene(s);
comprises CF3CCl=CH2 (HFCO-1233xf), or
preferably CF3CH=CHCl (HFCO-1233zd). X=2-5C
unsaturated, optionally, radical; R=Cl, F, Br, I or
H;and z=1-3. Preferred Property: The blowing
agent has a Global Warming Potential (GWP) of
not greater than 150, and an Ozone Depleting
Potential (ODP) of not greater than 0 [CONT.]
US 20080207788
(2) foam premix composition comprising polyol
and trifluoromonochloropropene(s);
(3) method of forming a foam comprising adding
to a foamable and/or foaming composition and the
blowing agent;and [CONT.]
WO 2008100805 A2 UPAB: 20090907
The antibody is useful for modulating
NOVELTY: An anti-Robo4 antibody comprising at angiogenesis and for in vivo imaging.
least 1-6 hypervariable region (HVR) sequence(s), Angiogenesis is associated with a disorder
selected from cancer, atherosclerosis, retrolental
is new.
fibroplasia, hemangiomas, chronic inflammation,
DETAILED DESCRIPTION: An anti-Robo4
intraocular neovascular diseases, proliferative
antibody comprising at least 1-6 HVR sequence(s)
retinopathies, diabetic retinopathy, age-related
selected from (i) HVR-L 1 comprising sequence Almacular degeneration (AMD), neovascular
A11, where A1-A11 is Arg-Ala-Ser-Gln-Asp-Valglaucoma, immune rejection of transplanted
Ser-Thr-Ala-Val-Ala (SEQ ID NO: 1), (ii) HVR-L2
corneal tissue and other tissues, rheumatoid
comprising sequence B1-B7, where [CONT.]
arthritis, psoriasis, or their combinations [CONT.]
The present invention provides additional drugs to
treat diseases and disorders associated
angiogenesis including, e.g. aberrant
angiogenesis associated with cancers dependent
on the growth and proliferation of vasculature of
endothelial origin. It also provides additional
endothelial cell-targeted anti-Rono4 antibody drug
conjugates for the detection and visualization of
blood vessel growth and proliferation in, e [CONT.]
BIOTECHNOLOGY - Preferred Antibody: The
antibody comprises a light chain variable domain
comprising an amino acid sequence selected from
SEQ ID NOS: 72-97 shown in the specification.
The antibody comprises a heavy chain variable
domain comprising an amino acid sequence
selected from SEQ ID NOS: 140-165 shown in the
specification. The antibody is humanized. The
antibody is a Fab, a Fab', or a (Fab')2 [CONT.]
An anti-Robo4 antibody comprising at least 1-6
WO 2008100805
HVR sequence(s) selected from (i) HVR-L 1
comprising sequence Al-A11, where A1-A11 is
Arg-Ala-Ser-Gln-Asp-Val-Ser-Thr-Ala-Val-Ala
(SEQ ID NO: 1), (ii) HVR-L2 comprising sequence
B1-B7, where B1-B7 is Ser-Ala-Ser-Phe-Leu-TyrSer (SEQ ID NO: 2), (iii) HVR-L3 comprising
sequence C1-C9, where C1-C9 is Gln-Gln-Ser-TyrThr-Thr-Pro-Pro-Thr (SEQ ID NO: 3), (iv) [CONT.]
US 20080247951
US 7834154
N
US 20110059013
US 20110059112
US 20080213431 A1 UPAB: 20091012
For improving fur and claw quality in companion
animal (claimed), e.g. dog or cat.
The Lactobacillus reuteri strain (ATCC PTA-6127) BIOLOGY - Preferred Method: The selecting step
stimulates lysine-uptake in fur animals. This
includes analyzing the ability of lactic acid
results in improved fur and claw quality.
bacterial strains to directly facilitate or improve
absorption of lysine in animal, using Caco-2 cell
system for intestinal epithelial permeability
studies, or using radiolabeled fluxes for lysine.
INDEPENDENT CLAIMS are included for: (1) a
biologically pure culture of lactic acid bacteria
strain; and (2) a product, e.g. feed, tablet, or
capsule, for improving fur and claw quality in pet
animals, comprising biologically pure culture of
Lactobacillus reuteri strain, and feed mixture
US 20080213431
US 20080213431
259 Improving fur and claw quality in companion
animal, e.g. dog or cat, includes providing
CONNOLLY E
product containing biologically pure culture of
selected nonpathogenic, lysine-uptake
stimulating lactic acid bacterial strain of
Lactobacillus reuteri
WO 2008108722
A1
20080912
NOVELTY: Improving fur and claw quality in
companion animal includes selecting
nonpathogenic, lysine-uptake stimulating lactic
acid bacterial strain of Lactobacillus reuteri and
providing a product containing biologically pure
culture of selected strain to animal.
AU 2008221660
A1
20080912
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are included for: (1) a biologically pure
culture of lactic acid bacteria strain; and (2) a
product, e [CONT.]
AU 2008221660
A2
20080912
EP 2117341
A1
20091118
AU 2008221660
A9
20091105
CN 101641020
A
20100203
JP 2010519900
T
20100610
AU 2008221660
B2
20101118
AU 2008221660
B8
20101223
B2
20110322
HILLS PET NUTRITION INC
US 7910127
WO 2008103950
A1
20080828
WO 2008103950 A1 UPAB: 20081023
HILL'S PET NUTRITION INC
AU 2008218187
A1
20080828
NOVELTY: Pet food composition (I) comprises:
vitamin E (200-1200 IU/kg); vitamin C (50-500
ppm); eicosapentaenoic acid (EPA) (0.1-0.9%);
and docosahexaenoic acid (DHA) (0.1-0.7%).
FRIESEN K G
EP 2124612
A1
20091202
DETAILED DESCRIPTION: An INDEPENDENT
CLAIM is included for a method to enhance the
immune response of a feline to an antigen
comprising administering (I) to the feline.
YAMKA R M
CA 2678938
A1
20080828
ACTIVITY: Immunostimulant. [CONT.]
ZICKER S C
CN 101686711
A
20100331
MOELLSTAM B
260 Pet food composition, useful to enhance the
immune response of a feline to an antigen,
comprises vitamin E, vitamin C,
eicosapentaenoic acid and docosahexaenoic
acid
261 New pyridine N-oxide compounds useful for
treating, inhibiting or ameliorating a bacterial
infection e.g. acne, bacterial endocarditis or
bacterial sepsis, in a subject
US 20100104599
A1
20100429
JP 2010519315
T
20100603
US 20110059138
WO 2008082562
A1
20110310
A2
20080710
KRASTEL P
WO 2008082562
A3
20081113
LAMARCHE M J
KR 2009082504
A
20090730
DETAILED DESCRIPTION: Pyridine N-oxide
compounds (I) selected from 11 compounds as
given in the specification or their salts are new
e.g. compounds of formulae (I)-(V).
INDEPENDENT CLAIMS are included for the
following:
LEEDS J A
AU 2007339279
A1
20080710
(1) preparation of (I); [CONT.]
NOVARTIS AG
NAEGELI H
262 New alkyl carbonyl amino aryl compounds are ORCHID RES LAB LTD
histone deacytlase inhibitors, useful e.g. to
treat autoimmune diseases, skin diseases,
infections, cancer and psoriasis
EP 2097423
A2
20090909
CN 101563353
A
20091021
CA 2673506
A1
20080710
MX 2009006745
A1
20090731
IN 2009DN04594
A
20100212
US 20100093615
A1
20100415
JP 2010513512
T
20100430
EP 2097423
WO 2007054776
B1
20110302
A2
20070518
For improving fur and claw quality in companion
animal (claimed), e.g. dog or cat.
(I) is useful to enhance the immune response of a (I) increases the efficacy of vaccine.
feline to an antigen, where the feline is a kitten
(claimed). (I) were tested for the ability to
improved immune response as measured by
increased antibody titer to the rabies vaccination.
The results showed that (I) exhibited the mean
antibody titer value of 37.2, when compared to
control (25), after 16 weeks.
WO 2008082562 A2 UPAB: 20090817
For treating, inhibiting or ameliorating a bacterial
infection i.e. acne, bacterial endocarditis or
bacterial sepsis and an EF-Tu associated-state in
a subject (claimed). Also useful for treating
rosacea, skin infection, pneumonia, otitis media,
sinusitus, bronchitis, tonsillitis, mastoiditis,
NOVELTY: Pyridine N-oxide compounds selected pharynigitis, rheumatic fever, glomerulonephritis,
from 11 compounds as given in the specification respiratory tract infections, uncomplicated skin
and [CONT.]
or their salts are new.
WO 2007054776 A2 UPAB: 20090604
The Lactobacillus reuteri strain (ATCC PTA-6127) BIOLOGY - Preferred Method: The selecting step
stimulates lysine-uptake in fur animals. This
includes analyzing the ability of lactic acid
results in improved fur and claw quality.
bacterial strains to directly facilitate or improve
absorption of lysine in animal, using Caco-2 cell
system for intestinal epithelial permeability
studies, or using radiolabeled fluxes for lysine.
The biologically pure culture is applied by dry
spraying at 1x 107 CFU/g product, before the
tallow sets to adhere to or be partially penetrated
in the fat layer [CONT.]
The compound inhibits a bacterial target
(preferably EF-Tu) affecting the life cycle of
bacteria and protein synthesis in bacteria. The
compounds can produce in a cost-effective
manner while producing high yield and have
valuable pharmacological properties.
INDEPENDENT CLAIMS are included for: (1) a
biologically pure culture of lactic acid bacteria
strain; and (2) a product, e.g. feed, tablet, or
capsule, for improving fur and claw quality in pet
animals, comprising biologically pure culture of
Lactobacillus reuteri strain, and feed mixture
coated with coating substrate and with dry spray
of biologically pure culture of selected strain.
US 20080213431
US 7910127
PHARMACEUTICALS - Preferred Composition: (I)
comprises: DHA (0.2-0.5%); vitamin E (200-1200
IU/kg); vitamin C (50-500 ppm); carnitine (100-500
ppm); choline (2400-7500 ppm); EPA (0.1-0.6%);
manganese (50-200 ppm); and methionine (0.51.6%). (I) further comprises: carbohydrates (0-90
wt.%); protein (5-70 wt.%); fat (2-50 wt.%); total
dietary fiber (0.1-20 wt.%); and vitamins, minerals,
and other nutrients (0-15 wt [CONT.]
An INDEPENDENT CLAIM is included for a
WO 2008103950
method to enhance the immune response of a
feline to an antigen comprising administering (I) to
the feline.
US 20100104599
US 20110059138
ORGANIC CHEMISTRY - Preparation (claimed):
Preparation of (I) involves cultivation of a strain of
Nonomuraea Streptosporangiaceae Bp3714-39,
its variant or mutant in a suitable medium
containing at least one source of carbon atoms
and nitrogen atom. Preferred Process: The
cultivation occurs under aerobic conditions at 1840 (preferably 28-32) degrees C at pH 6-9.
[CONT.]
Pyridine N-oxide compounds (I) selected from 11
compounds as given in the specification or their
salts are new e.g. compounds of formulae (I)-(V).
INDEPENDENT CLAIMS are included for the
following:
US 20100093615
WO 2008082562
N
(1) preparation of (I);
(2) an isolated microorganism, Nonomurea
Streptosporangiaceae Bp3714-39 strain or its
antibiotic producing mutant; and [CONT.]
(I) is useful for: modulating the number of
biological processes (including transcription, cell
cycle, and regulating nucleosomal integrity);
treating diseases involved in cellular growth such
as malignant tumors, autoimmune diseases, skin
diseases and infections; inhibiting histone
deacytelase in a cell; the treatment of a condition
ORGANIC CHEMISTRY - Preparation (Disclosed):
Preparation of (I) comprises condensing the
aldehyde compounds (1a) of formula (R-C(=O)H)
and alkyl carboxylic acid compound (1b) of
formula (HO-C(=O)R1) with acetic anhydride to
give a alkylene acid compound of formula (1c);
[CONT.]
Alkyl carbonyl amino aryl compounds of formula
WO 2007054776
(I), their derivatives, analogs, tautomeric forms,
stereioisomers, polymorphs, solvates, salts,
compositions, metabolites and prodrugs, are new.
US 20090136431
N
ORCHID CHEM&PHARM LTD
formula (HO-C(=O)R1) with acetic anhydride to
give a alkylene acid compound of formula (1c);
[CONT.]
IN 2005CH01644
A
20070921
WO 2007054776
A3
20080904
US 20090136431
WO 2007054776
WO 2008103939
A1
20090528
A9
20110303
A1
20080828
AU 2008218176
A1
20080828
YAMKA R M
EP 2112889
A1
20091104
ZICKER S C
CA 2679682
A1
20080828
CN 101686712
A
20100331
JP 2010518865
T
20100603
US 20110059202
WO 2008086573
A1
20110310
A1
20080724
WO 2008086573 A1 UPAB: 20080918
AU 2008207287
A1
20080724
NOVELTY: Treatment or prophylaxis of a
neurodegenerative disease or condition comprises
administering galanin or its homolog, derivative,
analog or mimetic and/or an agent which upregulates the level or activity of a galanin receptor
to promote survival and/or maintenance of
oligodendrocytes, inhibit demyelination and/or
promote axonal and/or neuronal repair and
function. [CONT.]
A1
20110317
PROCTER&GAMBLE CO
US 20110064669
US 20070299086
A1
20071227
US 20070299086 A1 UPAB: 20090430
PROCTER & GAMBLE CO
WO 2008002576
A2
20080103
WARNER CHILCOTT CO LLC
WO 2008002576
A3
20080703
NOVELTY: Pyridine or phenyl compounds (I) are
new.
DETAILED DESCRIPTION: Pyridine or phenyl
compounds of formula (I) are new.
EP 2044005
A2
20090408
X = N or CH;
R4 = 1-4C alkyl; either
KR 2009060264
A
20090611
R, R1 = H, phenyl or heteroaryl, both optionally
substituted with 1-4C alkyl, 1-4C alkoxy, 1-4C
haloalkyl, halo, CN, -NHC(O)R4, -C(O)NR5aR5b,
heteroaryl, two substitutions can be taken together
to form a fused ring having 5-7 atoms; [CONT.]
R5a, R5b = H or 1-4C alkyl; or
AU 2007265460
A1
20080103
R5aR5b = a ring having 3-7 atoms;
CA 2659682
A1
20080103
R2 = -OR6, or -NR7aR7b; [CONT.]
MX 2009000286
A1
20090331
CN 101506149
A
20090812
JP 2009541486
T
20091126
ZA 2009000560
A
20100224
HILLS PET NUTRITION INC
263 Pet food composition, useful to e.g. promote
bone development, enhance neurologic
FRIESEN K G
development and reduce fat in canine,
comprises methionine, manganese,
docosahexaenoic acid, eicosapentaenoic acid,
choline, methionine, carnitine and lysine
264 Treatment or prophylaxis of neurodegenerative FLOREY INST EXPERIMENTAL PHYSIOLOGY
disease or condition, e.g. multiple sclerosis,
comprises administering galanin or its
homolog, derivative, analog or mimetic and/or
agent which up-regulates level or activity of
galanin receptor
265 New pyridine or phenyl compounds are prolyl
hydroxylase inhibitors useful to treat e.g.
carotid obstructive disease, mycobacterial
infections, Lyme's disease, systemic lupus
erythematosis and retinopathy of prematurity
as malignant tumors, autoimmune diseases, skin
NOVELTY: Alkyl carbonyl amino aryl compounds diseases and infections; inhibiting histone
deacytelase in a cell; the treatment of a condition
(I), their derivatives, analogs, tautomeric forms,
mediated by histone deacytelase; the treatment of
stereioisomers, polymorphs, solvates, salts,
compositions, metabolites and prodrugs, are new. proliferative condition [CONT.]
A = -(CH2)n (optionally substituted by aryl,
arylalkyl or heteroaryl, which may be substituted
by OH or halo); [CONT.]
DETAILED DESCRIPTION: Alkyl carbonyl amino
aryl compounds of formula (I), their derivatives,
analogs, tautomeric forms, stereioisomers,
polymorphs, solvates, salts, compositions,
metabolites and prodrugs, are new. [CONT.]
WO 2008103939 A1 UPAB: 20081002
(I) is useful to promote bone development,
enhance neurologic development, cognitive and
NOVELTY: Pet food composition (I) comprises
methionine (0.8-1.6%), manganese (50-200 ppm), motor skills, promote a healthy body composition
and/or reduce fat in a canine (claimed). (I) is
docosahexaenoic acid (0.1-0.5%),
useful as a veterinary therapeutic product. Tests
eicosapentaenoic acid (0.1-0.7%) and choline
details are described but no results given.
(2500-7500 ppm).
DETAILED DESCRIPTION: An INDEPENDENT
CLAIM is included for a method to promote bone
development, enhance neurologic development,
cognitive and motor skills, promote a healthy body
composition and/or reduce fat in a canine
comprising administering (I) to the canine.
[CONT.]
(I) improves the general fitness of animals and
increases lean muscle. (I) is cost effective as it
uses readily available ingredients.
FOOD - Preferred Composition: (I) comprises
An INDEPENDENT CLAIM is included for a
WO 2008103939
methionine (0.5-1.6%), docosahexaenoic acid
method to promote bone development, enhance
(0.10-0.5%), carnitine (100-500 ppm), lysine (2.5-7 neurologic development, cognitive and motor
(preferably 2.2-7) g/1000 kcal), taurine (1000-2000 skills, promote a healthy body composition and/or
ppm), linoleic acid (2.5-6%), total n-3 fatty acids (1- reduce fat in a canine comprising administering (I)
3%), vitamin E (50-1200 IU/kg), vitamin C (50-500 to the canine.
ppm), carbohydrates (0-90 wt.%), protein (5-70
wt.%), fat (2-50 wt.%) and total dietary fiber (0.120 wt [CONT.]
Treatment or prophylaxis of a neurodegenerative
condition, preferably multiple sclerosis (MS), acute
disseminated encephalomyelitis, optic neuropathy
(including neuromyelitis optic with transient
autonomic disturbances), Devic's neuromyelitis
optica, tropical spastic paraparesis, noncompressive myelopathies, concentric sclerosis,
diffuse sclerosis, acute hemorrhagic
leukoencephalopathy, metabolic [CONT.]
Elevating levels of galanin or its homologs,
PHARMACEUTICALS - Preferred Materials: The
derivatives, analogs or mimetics or of a galanin
galanin receptor is galanin receptor 1, galanin
receptor potentiates oligodendrocyte survival and receptor 2 or other galanin receptor.
inhibits demyelination and/or promotes axonal and
neuronal repair and function. This in turn is useful
in ameliorating or reducing the effects of
inflammatory neurodegeneration. Galanin was
tested for its effect for oligodendrocyte survival in
vitro in rats [CONT.]
INDEPENDENT CLAIMS are included for:
(I) are useful for treating a disease such as
diabetic retinopathy, macular degeneration,
cancer, sickle cell anemia, sarcoid, syphilis,
pseudoxanthoma elasticum, Paget's disease, vein
occlusion, artery occlusion, carotid obstructive
disease, chronic uveitis/vitritis, mycobacterial
infections, Lyme's disease, systemic lupus
erythematosis, retinopathy of prematurity, Eales'
disease, Behcet's disease, [CONT.]
(I) are effective human protein prolyl hydroxylase ORGANIC CHEMISTRY - Preparation: No
inhibitors for increasing blood flow, oxygen
preparation method is given.
delivery and energy utilization in ischemic tissues;
for increasing the concentration of HIF-1 alpha
leading to greater activation and sustaining the
various biological pathways that are the normal
response to cellular hypoxia; and for upregulating
the production of erthropoietin. [CONT.]
Pyridine or phenyl compounds of formula (I) are
new.
X = N or CH;
US 20110059202
WO 2008086573
US 20110064669
US 20070299086
US 20070299086
N
(1) a neuroprotective formulation comprising
galanin or its homolog, derivative, analog or
mimetic and/or a galanin receptor agonist and
leukemia inhibitory factor (LIF) and/or ciliary
neurotrophic factor (CNTF) and carriers and/or
diluents; [CONT.]
R, R1 = H, phenyl or heteroaryl, both optionally
substituted with 1-4C alkyl, 1-4C alkoxy, 1-4C
haloalkyl, halo, CN, -NHC(O)R4, -C(O)NR5aR5b,
heteroaryl, two substitutions can be taken together
to form a fused ring having 5-7 atoms;
US 7811595
N
IN 2009DN00509
A
20100820
US 7811595
EP 2044005
B2
20101012
B1
20101020
DE 602007009992
E
20101202
AU 2007265460
B2
20110303
CA 2659682
C
20101221
WO 2008032153
WO 2008032153
A2
20080320
WO 2008032153 A2 UPAB: 20080903
A3
20081127
NOVELTY: Treating a health condition in a
mammal comprises inducing a translocation of a
calreticulin (CRT) protein, an ERP57, or their
combination, to a cellular membrane in order to
provoke an immunogenic apoptosis.
US 20090004134
A1
20090101
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are:
US 20090004172
A1
20090101
(1) a method of using a kit for treating a health
condition in a mammal; [CONT.]
A1
20090101
A1
20090101
A1
20090101
A1
20090101
A1
20090219
A1
20090108
A1
20110310
A1
20080710
OSPREY PHARM INC
US 20090004178
US 20090004211
US 20090004678
US 20090005305
US 20090048159
US 20090010952
US 20110060120
WO 2008080218
WO 2008080218
A9
20080828
COGGINS P J
266 Treating health condition comprises inducing OBEID M S
a translocation of a calreticulin or an ERP57 to
a cellular membrane to provoke an
immunogenic apoptosis
267 Selecting a modified ribosome inactivation
protein (RIP) for treating or inhibiting a
disease, e.g. CNS inflammatory diseases by
isolating a cell that expresses a RIP or its
active fragment
OSPREY PHARM LTD
TW 2008033843
A
20080816
MCDONALD J R
US 20090092578
A1
20090409
MCINTOSH L M
AU 2007339753
A1
20080710
SU H
268 Inhibiting growth of a mammalian cell, useful COLD SPRING HARBOR LAB
for screening cancer therapeutics, and
diagnosing and treating cancer such as human
breast cancer and human lymphoma cell
comprises increasing the level of a Chd5
protein within the cell
The methods, compositions, and kits are useful for
treating a health condition, e.g. cancer,
autoimmune disease, sterility, allergy, transplant
rejection, and an infection, where the cancer
includes any one or more of: breast cancer,
prostate cancer, melanoma, colon cancer, lung
cancer, kidney cancer, osteosarcoma, and a
tumor sensitive to VP16/etoposide, radiotherapy,
or immunotherapy, and where [CONT.]
BIOTECHNOLOGY - Preferred Method: In the
INDEPENDENT CLAIMS are:
method for treating a health condition in a
(1) a method of using a kit for treating a health
mammal, the CRT protein includes any one or
condition in a mammal;
more of: endogenous CRT, recombinant CRT, and
CRT in mimetic form; and where the endogenous
form of CRT includes any one of: a plasma
membrane CRT and an intracellular CRT. [CONT.]
WO 2008032153
(2) a pharmaceutical composition, for treating a
health condition in a mammal, by inducing a
translocation of any one or more of: a CRT protein
and an ERP57 protein, to a cellular membrane in
order to provoke an immunogenic apoptosis;
[CONT.]
US 20090004134
US 20090004172
N
US 20090004178
US 20090004211
US 20090004678
US 20090005305
US 20090048159
US 20090010952
US 20110060120
WO 2008080218 A1 UPAB: 20090428
The methods, polypeptide, and conjugate are
useful for targeting a toxin to a cell; for formulating
NOVELTY: Selecting a modified ribosome
a medicament for targeting a toxin to a cell and
inactivation protein (RIP) or its active fragment
comprises: (a) introducing a nucleic acid molecule treating or inhibiting immune of inflammatory
encoding a RIP, or its active fragment into a host disease; for treating an immune or inflammatory
cell(s); (b) growing the cells; (c) isolating cells that disease or disorder; for inhibiting a disease or
disorder, e.g. [CONT.]
grow; and (d) from among the cells that grow,
isolating a cell that expresses a RIP or its active
fragment, where the RIP or fragment contains a
modification compared to that encoded by the
nucleic acid molecule that is introduced in (a).
[CONT.]
EP 2097529
A1
20090909
IN 2009CN04335
A
20090814
CA 2673668
A1
20080710
KR 2009130849
A
20091224
MX 2009007021
A1
20090831
CN 101622352
A
20100106
JP 2010514425
T
20100506
JP 2011050388
A
20110317
WO 2008082438
WO 2008082438
A2
20080710
WO 2008082438 A2 UPAB: 20080724
A3
20081113
CA 2660448
A1
20080710
NOVELTY: Inhibiting growth of a mammalian cell
comprises increasing the level of a Chd5 protein
within the cell.
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are:
US 20110055941
A1
20110303
(1) a method of inducing apoptosis of a
mammalian cell comprises increasing the level of
a Chd5 protein within the cell;
The methods are useful for inhibiting growth of a
mammalian cell, inducing apoptosis of a
mammalian cell, inducing expression of p16lnk4a,
p19Arf, or p53 in a mammalian cell, increasing
growth of a mammalian cell, diagnosing cancer in
a human subject, and identifying an anti-cancer
compound. [CONT.]
The invention can be administered in a high
concentration without risk of the complications that
can accompany systemic administration of a
therapeutic agent.
BIOTECHNOLOGY - Preferred Method: Selecting
a modified RIP further comprises identifying or
isolating or purifying the modified RIP or its active
fragment that is expressed in the isolated cell. The
cells are grown in medium that does not contain a
selective modulator. The medium in which the
cells are grown does not contain an adenine
analog. The adenine analog is 4-aminopyrazolo(3,4-d)pyrimidine (4-APP) [CONT.]
INDEPENDENT CLAIMS are: (1) a method for
WO 2008080218
increasing production of a RIP, or its active
fragment comprises: (a) introducing a nucleic acid
comprising a sequence of nucleotides encoding a
RIP, or its active fragment into a host cell(s); (b)
incubating the cells in the presence of a RIP
inhibitor, where the amount of RIP inhibitor is
selected to decrease the toxicity of the RIP;
[CONT.]
US 20090092578
N
BIOTECHNOLOGY - Preferred Method: In
inhibiting growth and inducing apoptosis of a
mammalian cell or inducing expression of
p16lnk4a, p19Arf, or p53, increasing comprises
introducing to the cell a Chd5 protein, where
introducing comprises contacting the cell with the
Chd5 protein or an expression vector encoding the
Chd5 protein. The expression vector is preferably
a viral vector. [CONT.]
INDEPENDENT CLAIMS are:
US 20110055941
N
(1) a method of inducing apoptosis of a
mammalian cell comprises increasing the level of
a Chd5 protein within the cell;
(2) a method of inducing expression of p16lnk4a,
p19Arf, or p53 in a mammalian cell comprises
increasing the level of a Chd5 protein within the
cell;
(3) a method of increasing growth of a mammalian
cell comprises reducing the Chd5 level in the cell;
[CONT.]
WO 2008082438
269 Use of alpha-ketoglutarate for manufacturing
medical preparation for prophylaxis or
treatment of undesired medical conditions
related with presence and/or activity of
ureolytic bacteria in vertebrate, including e.g.
human being and bird
KRUSZEWSKA D
272 Preventing or treating in a subject obesity or
obesity-related disorder, e.g., type II diabetes,
by inducing Prdm16 expression sufficient to
activate brown fat cell differentiation which
increases energy expenditure
A1
20080507
A1
20090108
US 20100124537
A1
20100520
KR 2010053546
A
20100520
IN 2010MN00202
A
20100625
JP 2010532347
T
20101007
The alpha-ketoglutarate is useful for
manufacturing medical preparation, dietary
NOVELTY: Use of alpha-ketoglutarate for
manufacturing medical preparation for prophylaxis supplement and medicated food product for
prophylaxis or treatment of undesired medical
or treatment of undesired medical conditions
conditions related with the presence and/or activity
related with the presence and/or activity of
ureolytic bacteria in vertebrate, including a human of ureolytic bacteria in vertebrate, including a
human being, mammal, bird, amphibian and fish,
being, mammal, bird, amphibian and fish, is
where: the undesired medical conditions is related
claimed.
with the presence and/or activity [CONT.]
EP 1917959
B1
20110119
E
20110303
WO 2008072361
US 20090191319
A1
20080619
WO 2008072361 A1 UPAB: 20080707
A1
20090730
NOVELTY: Method of preparing tea drink, involves
extracting tea leaves and adjusting pH of obtained
extract to 5.0-6.0, mixing nitrogen with tea extract
and applying negative pressure of 0.01 Mpa or
more, subsequently to the step of applying
negative pressure, stabilizing tea extract by
maintaining the atmospheric pressure for 30
seconds to 20 minutes, and during or after
stabilization step, adjusting tea extract to a pH of
5.5-6.5. [CONT.]
AU 2006351677
A1
20080619
AU 2006351677
A8
20090514
EP 2092833
A1
20090826
CN 101522039
A
20090902
CA 2664952
A1
20080619
AU 2006351677
B2
20110310
WO 2008066734
A2
20080605
WO 2008066734 A2 UPAB: 20080703
UNIV YESHIVA EINSTEIN COLLEGE MEDICINE
WO 2008066734
A3
20081106
NOVELTY: A non-human mammal comprising
transgenic nucleic acid sequence capable of
causing an alteration of Bri2 or Bri3 expression in
mammal, where the mammal is a model for
Alzheimer's disease, is new.
DADAMIO L
EP 2096910
A2
20090909
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are included for the following:
GILIBERTO L
CA 2706535
A1
20080605
(1) non-human mammal comprising Bri2 or Bri3
gene under the control of the native Bri2 or Bri3
promoter, where the Bri2 or Bri3 gene does not
naturally occur in the mammal; [CONT.]
US 20110055936
WO 2008063330
WO 2008063330
A1
20110303
DANA FARBER CANCER INST INC
A2
20080529
WO 2008063330 A2 UPAB: 20080703
A3
20081231
NOVELTY: Preventing or treating obesity or
obesity-related disorder in a subject comprises
inducing Prdm16 expression sufficient to activate
brown fat cell differentiation, where the
differentiated brown fat cells increase energy
expenditure to thereby prevent or treat obesity or
an obesity-related disorder in the subject.
US 20110059051
A1
20110310
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are: [CONT.]
UNIV YESHIVA EINSTEIN COLLEGE
The alpha-ketoglutarate removes the free radicals,
very toxic compounds, not completely metabolized
products, from the organism, and improves the
quality of life. The alpha-ketoglutarate enhances
secretion of growth hormone and optimizes
muscle metabolism, increases the activity of
insulin and polyamines in a safe way, enhances
neurotransmission thus helping to maintain a good
mental status of the [CONT.]
EP 1917959
US 20100124537
WO 2008072361
US 20090191319
WO 2008066734
US 20110055936
ACTIVITY: Antibacterial; Antipyretic; Antimicrobial;
Uropathic; Antiulcer; Gastrointestinal-Gen [CONT.]
DE 602007012036
ITO EN LTD
270 Preparing tea drink, involves extracting tea
leaves, mixing nitrogen and applying negative
pressure, stabilizing tea extract by maintaining
atmospheric pressure, and adjusting pH of tea
extract
271 Novel non-human mammal e.g. mouse
comprising transgenic nucleic acid sequence
capable of altering expression of Bri2 or Bri3
in mammal, useful as Alzheimer's disease
model for screening compound useful for
treating dementia
EP 1917959
WO 2009005379
(2) a method of inducing expression of p16lnk4a,
p19Arf, or p53 in a mammalian cell comprises
increasing the level of a Chd5 protein within the
cell; [CONT.]
EP 1917959 A1 UPAB: 20090130
As packed beverage.
The non-human mammal such as a mouse,
TgCRN D8 mouse is useful as model for
Alzheimer's disease, familial British dementia
and/or familial Danish dementia useful for
screening a compound for treatment of disease
such as cerebral amyloidosis, dementia and/or
cognitive impairment such as recognition,
reference memory, special working memory, fear
conditioning or learning and memory (all claimed).
The tea drink has excellent flavor, aroma, and
color tone, and has a stable quality. The loss of
aroma during the preparation process is
suppressed.
FOOD - Preferred Method: The stabilization
process is performed under atmospheric pressure.
The method further involves disinfecting the tea
drink and filling in a sealed container, where the
sealed container is a high barrier PET.
BIOTECHNOLOGY - Preferred Mammal: The
sequence comprises a segment encoding a
portion of the Bri2 or Bri3 protein at least 80%
homologous to SEQ ID No. 1 or 2. The Bri2 or
Bri3 protein is at least 90%, preferably 99%
homologous to SEQ ID No. 1 or 2. The Bri2 or
Bri3 protein is a wild-type Bri2 or Bri3 protein. The
Bri2 or Bri3 protein is a human protein. [CONT.]
INDEPENDENT CLAIMS are included for the
following:
(1) non-human mammal comprising Bri2 or Bri3
gene under the control of the native Bri2 or Bri3
promoter, where the Bri2 or Bri3 gene does not
naturally occur in the mammal;
N
N
(2) non-human mammal genetically engineered to
lack expression of a Bri2 or Bri3 gene;
(3) non-human mammal comprising a transgene
encoding a Bri2 or Bri3 protein under the control
of the alpha CaMKII promoter; [CONT.]
The method is useful for preventing or treating
obesity or obesity-related disorder, comprising
insulin resistant obesity, type II diabetes,
hyperphagia, endocrine abnormalities, triglyceride
storage disease, Bardet-Biedl syndrome,
Lawrence-Moon syndrome, Prader-Labhart-Willi
syndrome, anorexia or cachexia (claimed).
BIOTECHNOLOGY - Preferred Method: In the
INDEPENDENT CLAIMS are:
WO 2008063330
method of preventing or treating obesity or obesity- (1) an isolated nucleic acid comprising SEQ ID
related disorder in a subject, the obesity-related
NO: 7;
disorder is insulin resistant obesity, type II
diabetes, hyperphagia, endocrine abnormalities,
triglyceride storage disease, Bardet-Biedl
syndrome, Lawrence-Moon syndrome, PraderLabhart-Willi syndrome, anorexia or cachexia. The
obesity-related disorder is Type II diabetes
[CONT.]
(2) a method for increasing energy expenditure in
a mammal;
US 20110059051
N
(3) a method for treating obesity or an obesityrelated disorder in a subject;
(4) a method for identifying a compound capable
of inducing expression of Prdm16 in a cell;
(5) a method for identifying a compound capable
of inducing the activity of Prdm16; [CONT.]
273 New resistin antagonist that is capable of
binding human resistin and modulating NFkappaB mediated signaling, useful for
preparing a composition for treating diseases
with aberrant fibroblast activity, e.g., liver
fibrosis
CENTOCOR INC
A2
20080502
CENTOCOR ORTHO BIOTECH INC
WO 2008052111
WO 2008052111
A3
20081113
BLAKE S
US 20090162375
A1
20090625
CARTON J
EP 2097446
A2
20090909
FARRELL F
JP 2010508027
T
20100318
LEE J H
US 20110071277
A1
20110324
A2
20080327
PIRAMAL LIFE SCI LTD
WO 2008035309
WO 2008035309
A3
20080814
ADITYA K
EP 2064545
A2
20090603
ANTHONY J
IN 2009MN00765
A
20090703
BHUMRA S K
US 20090318465
EP 2256496
EP 2256496
A1
20091224
A2
20101201
A3
20110316
WO 2007133665
A2
20071122
WO 2008052111 A2 UPAB: 20080627
The resistin antagonist that is capable of binding
NOVELTY: A new resistin antagonist is capable of human resistin and modulating nuclear factor (NF)kappaB mediated signaling is useful for preparing
binding human resistin and modulating nuclear
a pharmaceutical composition for treating or
factor (NF)-kappaB mediated signaling.
alleviating the symptoms of the diseases with
aberrant fibroblast activity, including interstitial
DETAILED DESCRIPTION: INDEPENDENT
lung diseases, hypertrophic scarring, keloid
CLAIMS are:
scarring, scleroderma, liver fibrosis, renal fibrosis
or [CONT.]
(1) an isolated antibody reactive with an epitope
located at residues 50 to 65 (SEQ ID NO: 3) or
residues 78 to 93 (SEQ ID NO: 4) of human
resistin; [CONT.]
BIOTECHNOLOGY - Preferred Resistin
Antagonist: The resistin antagonist capable of
binding human resistin and inhibiting resistinmediated release of at least one inflammatory
cytokine comprises MCP1, IL-8, IL-6 or TNFalpha. The resistin antagonist is capable of
binding human resistin and inhibiting resistinmediated induction of at least one pro- fibrotic
gene expression consisting of collagen I, alpha
smooth muscle actin, TGFbeta1, CTGF, TGFR,
PDGFR, CD44, fibrillin, fibronectin or IL-6 [CONT.]
INDEPENDENT CLAIMS are:
WO 2008052111
US 20090162375
US 20110071277
(1) an isolated antibody reactive with an epitope
located at residues 50 to 65 (SEQ ID NO: 3) or
residues 78 to 93 (SEQ ID NO: 4) of human
resistin;
(2) a pharmaceutical composition comprising the
resistin antagonist and a pharmaceutically
acceptable carrier or diluent;
(3) a method of modifying the biological activity of
resistin in a mammal by administering the
pharmaceutical composition to the mammal;
[CONT.]
MA K
MARSTERS P
MURRAY L
ORT T
PICHA K
SONG X R
TEPLYAKOV A
274 Identifying lead compounds used for treating
e.g. obesity, which act as insulin-sensitizers
involves screening test compounds in
phenotype-based assay and screening
compounds identified as actives in an insulin
resistance assay
PIRAMAL INDIA LTD NICHOLAS
DEKA N
GANGOPADHYAY A K
WO 2008035309 A2 UPAB: 20080627
For identifying lead compounds e.g. 2,4-dichloroN-(5-chloro-6-(isoquinolin-3-yloxy)pyridin-3-yl)NOVELTY: Identifying (M1) lead compounds
which act as insulin-sensitizers involves screening benzenesulfonamide, useful for treating type 2
test compounds in a phenotype-based assay; and diabetes, obesity, glucose intolerance,
screening compounds identified as actives in the dyslipidemia, hyperinsulinemia, atherosclerotic
disease, polycystic ovary syndrome, coronary
phenotype-based assay in an insulin resistance
artery disease, hypertension, aging, non alcoholic
assay.
fatty liver disease, infections, cancer and stroke
DETAILED DESCRIPTION: An INDEPENDENT
(claimed).
CLAIM is included for treating disorders caused by
insulin resistance to glucose uptake and disorders
related to it involving administering to a mammal a
compound identified by (M1). [CONT.]
The method identifies compounds that effectively
treats diseases or disorders caused by insulin
resistance. The compounds also demonstrate
greater than 5 fold adipogenesis than vehicle and
greater than 1.5 fold increase in glucose uptake.
PHARMACEUTICALS - Preferred Method: The
method (M1) further involves screening the lead
compounds for activity in an animal model of
insulin resistance involving measuring plasma
glucose levels in genetically diabetic db/db BL/6J
mice; and measuring food intake and body weight
gain in diet-induced obese C57BI6/J mice. In
(M1), screening in the adipogenesis assay
involves screening against 3T3-L1 adipocytes
[CONT.]
An INDEPENDENT CLAIM is included for treating WO 2008035309
disorders caused by insulin resistance to glucose
uptake and disorders related to it involving
administering to a mammal a compound identified
by (M1).
US 20090318465
WO 2007133665 A2 UPAB: 20090307
The method does not require administration or
injection of an anticoagulant into the placenta prior
to perfusing. The cell count is increased
significantly compared to venipuncture alone.
BIOTECHNOLOGY - Preferred Method: The
isolated mammalian placenta is nonexsanguinated. The method optionally involves
providing an isolated non-exsanguinated
mammalian placenta comprising cord blood
comprising cord blood stem cells, partially
exsanguinating the isolated non-exsanguinated
mammalian placenta to produce a partially
exsanguinated placenta and a volume of cord
blood comprising cord [CONT.]
INDEPENDENT CLAIMS are included for the
following:
US 20090123437
GHATE A
MARITA R A
NEMMANI K V S
SHARMA S
TAKEBE N
275 Collecting cord blood stem cells used for
treating e.g. aplastic anemia or tumor, involves
perfusing isolated non- or partiallyexsanguinated mammalian placenta with
pressure mediated flow of perfusion solution,
and isolating cells
The method is useful for collecting cord blood
stem cells used for treating a mammal in need of
hematopoietic reconstitution, such as mammal
having aplastic anemia, hematopoietic malignancy
chosen from leukemia, lymphoma, multiple
myeloma and myelodysplasia syndrome,
autoimmune disease, genetic disorder,
immunodeficiency resulting from irradiation,
chemotherapy, infection by a pathogenic
microorganism, [CONT.]
WO 2007133665
N
treating e.g. aplastic anemia or tumor, involves
NAOKO T
perfusing isolated non- or partiallyexsanguinated mammalian placenta with
pressure mediated flow of perfusion solution,
and isolating cells
WO 2007133665
A3
20081218
EP 2023717
A2
20090218
KR 2009026158
A
20090311
NOVELTY: Method of collecting cord blood stem
cells, involves providing an isolated nonexsanguinated or partially exsanguinated
mammalian placenta comprising cord blood
comprising cord blood stem cells, perfusing the
isolated non-exsanguinated or partially
exsanguinated mammalian placenta with a
pressure mediated flow of a perfusion solution to
produce a perfusate comprising cord blood
comprising cord blood stem cells, collecting the
perfusate, and isolating the cord blood stem cells
from the perfusate to produce isolated cord blood
stem cells. [CONT.]
stem cells used for treating a mammal in need of injection of an anticoagulant into the placenta prior
hematopoietic reconstitution, such as mammal
to perfusing. The cell count is increased
having aplastic anemia, hematopoietic malignancy significantly compared to venipuncture alone.
chosen from leukemia, lymphoma, multiple
myeloma and myelodysplasia syndrome,
autoimmune disease, genetic disorder,
immunodeficiency resulting from irradiation,
chemotherapy, infection by a pathogenic
microorganism, [CONT.]
isolated mammalian placenta is nonexsanguinated. The method optionally involves
providing an isolated non-exsanguinated
mammalian placenta comprising cord blood
comprising cord blood stem cells, partially
exsanguinating the isolated non-exsanguinated
mammalian placenta to produce a partially
exsanguinated placenta and a volume of cord
blood comprising cord [CONT.]
As an dermatological or cosmetic composition in
The polyol system increases the stability of the
composition and controls unpleasant odors such
as sulfur odor, thus obtaining odor improved
composition.
ORGANIC CHEMISTRY - Preferred Components:
The polyol system is a polyol or a mixture of
polyols selected from glycerol, glyceryl fatty acid
esters, polyglyceryl fatty acid esters, sugar
polyalcohols or saccharides. The glyceryl fatty
acid esters comprise glycerol partially esterified
with fatty acids selected from 8-22C fatty acid
including octanoic (caprylic) acid, pelargonic acid,
decanoic (capric) acid, dodecanoic (lauric) acid,
myristic) acid, palmitic acid, stearic acid, isostearic
acid, oleic acid or linoleic acid [CONT.]
An INDEPENDENT CLAIM is included for
WO 2008012220
preparing a topical application medicament and/or
a cosmetic preparation for the treatment of the
surface of the skin of a mammal, involving
blending NAC with a carrier.
US 20100021399
The compound allows imaging of amyloid deposits
in brain in vivo to allow antemortem diagnosis of
Alzheimer's disease as well as measuring clinical
efficacy of Alzheimer's disease therapeutic
agents. The compound effectively determines the
presence, location and/or amount of amyloid
deposit in an organ or body area, including the
brain of an animal.
BIOLOGY - Preferred Method: The detection is
carried out by gamma imaging, magnetic
resonance imaging or magnetic resonance
spectroscopy. ORGANIC CHEMISTRY Preparation (disclosed): 5 Methods for the
preparation of (I) are given e.g. preparation of (I)
involves palladium catalyzed Suzuki coupling of
aryl halides, or pseudo halides of intermediates of
formulas (II) and (III) (where Y1 and Y2 is chloride,
bromide, iodide or triflates) with boronic acids
[CONT.]
Heteroaryl substituted benzothiazoles of formula
(I), or their salts, solvates or solvates of salt are
new. At least one atom of (I) is optionally a
detectable isotope.
R1=T1, 1-5C alkyl or SO2NH2;
US 20090028787
US 20090123437
A1
20090514
IN 2008MN02405
A
20090227
CA 2652051
A1
20071122
CN 101483998
A
20090715
MX 2008014426
A1
20090228
JP 2009536824
T
20091022
ZA 2008009770
A
20100331
IN 246517
B
20110304
WO 2008012220
EP 2046277
A1
20080131
WO 2008012220 A1 UPAB: 20080606
A1
20090415
CN 101489523
A
20090722
the manufacture of a medicament for the
NOVELTY: An odor-improved dermatological or
cosmetic composition for topical use, comprises N- treatment of dermatological disorders e.g.
hypercheratosis, xerosis, diseases mediated by
acetyl cysteine (NAC); a carrier; and a polyol
proteases, ichtyosis, psoriasis, acne vulgaris and
system as odor controlling agent.
dermal inflammations propagated by leukotriens;
treating cosmetic conditions e.g. [CONT.]
DETAILED DESCRIPTION: An INDEPENDENT
CLAIM is included for preparing a topical
application medicament and/or a cosmetic
preparation for the treatment of the surface of the
skin of a mammal, involving blending NAC with a
carrier. [CONT.]
IN 2009CN00993
A
20090529
US 20100021399
EP 2046277
A1
20100128
B1
20110119
DE 602007012107
E
20110303
WO 2007086800
A1
20070802
EP 1981883
A1
20081022
JONASSON C
NO 2008003394
A
20081002
MAELMSTROM J
IN 2008DN06133
A
20080926
NORDVALL G
KR 2008090542
A
20081008
PYRING D
US 20090028787
A1
20090129
SLIVO C
AU 2007207904
A1
20070802
SOHN D
CN 101410393
A
20090415
STROEM P
TW 2007036252
A
20071001
WENSBO D
CA 2640213
A1
20070802
MX 2008009396
A1
20080731
JP 2009528271
T
20090806
ZAMBON SPA
276 Odor-improved dermatological or cosmetic
composition useful for treating psoriasis, acne
vulgaris, xerosis, comprises N-acetyl cysteine,
a carrier, and a polyol system as odor
controlling agent
ASTRAZENECA AB
277 New heteroaryl substituted benzothiazoles
useful for measuring amyloid deposits and for
treating e.g. Alzheimer's Diseases, multiple
sclerosis, Parkinson's Disease, Huntington's
GRAVENFORS Y
Disease, motor neuron diseases in a patient
WO 2007086800 A1 UPAB: 20090307
For in vivo imaging of amyloid deposits; for
measuring amyloid deposits in a subject
suspected of having a disease or syndromes e.g.
Alzheimer's Diseases, familial Alzheimer's
NOVELTY: Heteroaryl substituted benzothiazoles, Diseases, Down's Syndrome and homozygotes for
or their salts, solvates or solvates of salt are new. the apolipoprotein E4 allele; for manufacture of
medicament for preventing and/or treating
At least one atom of the heteroaryl substituted
benzothiazoles is optionally a detectable isotope. Alzheimer's Diseases, familial Alzheimer's
Diseases, Cognitive deficit in schizophrenia
DETAILED DESCRIPTION: Heteroaryl substituted (CDS), Down's Syndrome and homozygotes for
the apolipoprotein E4 allele in a mammal (e
benzothiazoles of formula (I), or their salts,
solvates or solvates of salt are new. At least one [CONT.]
atom of (I) is optionally a detectable isotope.
[CONT.]
(1) method for treating a mammal in need of
hematopoietic reconstitution, involves (a) culturing
in vitro the hematopoietic stem cells isolated by
the above mentioned method, thus expanding
hematopoietic stem cells, and introducing into the
mammal a composition comprising the expanded
hematopoietic stem cells, thus effecting
hematopoietic reconstitution, or (b) introducing
into the mammal intravenously or intraosseously a
composition comprising the isolated hematopoietic
stem cells; and [CONT.]
T1=H, halo, 1-6C fluoroalkyl, 1-3C alkylene-O-13C alkyl, 1-3C alkylene-O-1-3C fluoroalkyl, 1-3C
alkylene-NH2, 1-3C alkylene-NH-1-3C alkyl, 1-3C
alkylene-N(1-3C alkyl)2, 1-3C alkylene-NH-1-3C
fluoroalkyl, [CONT.]
WO 2007086800
N
N
RU 2008130965
A
20100310
AU 2007207904
B2
20110310
US 20080085327
WO 2008045920
A1
20080410
US 20080085327 A1 UPAB: 20080604
A2
20080417
NOVELTY: Forming a physical barrier in the teat
canal of a non-human animal for prophylactic
treatment of mammary disorders during the
animal's dry period and simultaneously preventing
black spot defect in dairy products made with milk
from the animal, comprises: infusing a teat seal
formulation (I) into the teat canal of the animal,
where (I) is bismuth-free, non-toxic heavy metal
salt, form a physical barrier to entry of
microorganisms into the teat canal, and does not
cause black spot defect in diary products made
with milk from the animal. [CONT.]
WO 2008045920
WO 2008045920
EP 2079477
A9
20080612
A3
20080918
A2
20090722
AU 2007307778
A1
20080417
KR 2009088876
A
20090820
CN 101547698
A
20090930
MX 2009003924
A1
20091031
JP 2010505595
T
20100225
IN 2009CN02513
A
20100625
ZA 2009002544
A
20100825
US 7906138
US 20080070997
B2
20110315
A1
20080320
DOKURITSU GYOSEI HOJIN NIPPON
GAKUJUTSU
JP 2008069315
A
20080327
GUNMA IND SUPPORT ORG
CN 101157760
A
20080409
INDEPENDENT ADMIN LEGAL PERSON JAPAN GB 2445818
ATOMIC ENERGY AGENCY
ZH GUNMAKEN SANGYO SHIEN KIKO
JP 2008230996
A
20080723
A
20081002
DOKURITSU NIPPON GENSHIRYOKU KENKYU JP 2009024089
KAIHATSU KIKO
AMADA H
JP 2009102655
A
20090205
A
20090514
HIROKI A
JP 4288618
B2
20090701
GB 2445818
B
20110309
WO 2008031133
A2
20080320
WO 2008031133 A2 UPAB: 20090527
WO 2008031133
A3
20080529
NOVELTY: An isolated nucleic acid molecule
encoding a protein, preferably a hyperimmune
serum reactive antigen, or its fragment,
comprising a nucleic acid sequence having at
least 70% sequence identity to a nucleic acid
molecule selected from SEQ ID NO. 1-134, 269387, and 507-628, is new. [CONT.]
278 Forming physical barrier in teat canal of non- WISCONSIN ALUMNI RES FOUND
human animal for prophylactic treatment of
RANKIN S A
mammary disorders and preventing black spot
defect in dairy products, comprises infusing
teat seal formulation into teat canal of animal
279 Preparation of gel, e.g. for catalyst carriers,
energy-absorption materials, and medical
applications for sticking materials, comprises
mixing carboxymethyl cellulose alkali metal
salt with acid or acid solution
JAPAN ATOMIC ENERGY AGENCY
KASAI N
(I) is useful for forming a physical barrier in the
teat canal of a non-human animal for prophylactic
treatment of mammary disorders during the
animal's dry period (claimed).
US 20080070997 A1 UPAB: 20090222
Preparation of carboxymethyl cellulose gel for use
in agriculture, industry, medical treatment, and
NOVELTY: Preparing a gel comprises mixing
carboxymethyl cellulose alkali metal salt with acid foods, preferably for domestic animal waste
treatment agents, waste water treatment agents,
or acid solution.
deodorization materials, catalyst carriers, energyDETAILED DESCRIPTION: An INDEPENDENT
absorption materials, and medical applications for
CLAIM is included for a gel containing
sticking materials and patty materials.
carboxymethyl cellulose alkali metal salt as a
principal ingredient, acid or acid solution and
water-insoluble metal compound or organic
reinforcement. [CONT.]
(I) is bismuth-free, non-toxic heavy metal salt. (I)
provides physical barrier to entry of
microorganisms into the teat canal. (I) prevents
the formation of black spot defect in diary products
made with milk from the animal (all claimed),
where the diary product is cheddar cheese. (I)
reduces or eliminates visual defects in aged
cheeses.
INORGANIC CHEMISTRY - Preferred
Components: (I) is devoid of anti-infective agents.
(I) comprises at least 30 wt.% (preferably 65 wt.%)
of the bismuth-free, non-toxic heavy metal salt in a
gel base. The non-toxic heavy metal salt is
titanium dioxide, zinc oxide and/or barium sulfate.
The gel base comprises aluminum stearate and
liquid paraffin.
An INDEPENDENT CLAIM is included for an intra- US 20080085327
mammary teat sealant comprising, in combination
a gel base and a non-toxic heavy metal salt
dispersed in the gel base, where the heavy metal
salt is devoid of bismuth.
US 20080085327
US 7906138
N
The method prepares a gel derived from
carboxymethyl cellulose without using polyvalent
metal ions or cross-linking agents. The gel is
environmentally friendly and safe to human. It has
high elasticity, excellent compression modulus
and high heat resistance and acid resistance.
INORGANIC CHEMISTRY - Preferred Materials:
The acid or acid solution is a hydrochloric acid or
hydrochloric acid solution. The water-insoluble
metal compound is aluminum oxide. POLYMERS Preferred Method: The gel is subjected to ionizing
radiation. Preferred Composition: The weight of
carboxymethyl cellulose is less than 65 wt.% of
the total weight of initial materials. [CONT.]
An INDEPENDENT CLAIM is included for a gel
US 20080070997
containing carboxymethyl cellulose alkali metal
salt as a principal ingredient, acid or acid solution
and water-insoluble metal compound or organic
reinforcement.
US 20080070997
N
BIOTECHNOLOGY - Preferred Molecule: The
nucleic acid is DNA or RNA. The sequence
identity is at least 70-100%. The nucleic acid
molecule is isolated from a genomic DNA,
preferably from a species selected from B.
burgdorferi, B. garinii, B. afzelii, B. andersonii, B.
bissettii, B. valaisiana, B. lusitaniae, B. spielmani,
B. japonica, B. tanukii, B. turdae, and B. sinica.
[CONT.]
A new isolated nucleic acid molecule encodes a
WO 2008031133
protein, preferably a hyperimmune serum reactive
antigen, or its fragment, comprising a nucleic acid
sequence, which is selected from:
US 20100136039
NAGASAWA N
TAKIGAMI M
TAMADA M
YAGI T
YOSHII F
280 New isolated nucleic acid molecule encodes a INTERCELL AG
protein, hyperimmune serum reactive antigen,
or antigen from Borrelia, useful for diagnosing
or treating an infection with a Borrelia
organism
The protein, hyperimmune serum reactive antigen,
antigen, probe, primer, antibody, nucleic acid,
vector, or pharmaceutical composition, is useful
for diagnosing or treating an infection with a
Borrelia organism; immunizing an animal or man
against infection with a Borrelia organism; and
stimulating an immune response in an animal or
man against a Borrelia organism. [CONT.]
N
(A) a nucleic acid molecule having at least 70%
sequence identity to a nucleic acid molecule
selected from SEQ ID NO. 1-134, 269-387, and
507-628;
281 Multi-layered, flat or tube-like plastic food
casing or covering, useful as a food
packaging, comprises nine different layers
from polyethylene terephthalate, adhesion
promoter, polyethylene, polyamide and ethyl
vinyl alcohol
EP 2059526
A2
20090520
AU 2007295927
A1
20080320
CN 101516905
A
20090826
JP 2010503384
T
20100204
CA 2661224
A1
20080320
US 20100136039
EP 2275434
EP 2287176
EP 2289906
A1
20100603
A1
20110119
A1
20110223
A1
20110302
DE 102006036844
B3
20080103
WO 2008017453
A1
20080214
KR 2009029825
A
20090323
EP 2051854
A1
20090429
IN 2009MN00261
A
20090515
AU 2007283094
A1
20080214
CN 101516619
A
20090826
MX 2009001393
A1
20090430
CA 2660139
A1
20080214
JP 2010500187
T
20100107
US 20100003432
A1
20100107
ZA 2009000763
A
20100127
NZ 574319
A
20100930
AU 2007283094
B2
20110203
EP 2298549
WO 2008040550
WO 2008040550
A1
20110323
A2
HAENEN G R M M
KUHNE ANLAGENBAU GMBH
(A) is used as a food packaging in the form of a
shrink bag, sealing film or a wrapping film
NOVELTY: Multi-layered, flat or tube-like plastic
food casing or covering (A), which is obtained by (claimed).
bell-type nozzle blow-molding process and
biaxially-stretched by triple-bubble blow molding
process, preferably for food packaging, comprises
at least nine layers such as a first layer from the
outside containing polyethylene terephthalate
(PET)-; [CONT.]
(A) exhibits excellent optical properties, good
workability, high temperature resistance and
shrinking characteristics.
20080410
WO 2008040550 A2 UPAB: 20080501
A3
20080626
NOVELTY: Nutraceutical composition (I)
comprises olive extract (II), which is effective in
promoting muscle health in an animal, including
humans that are subject: to post-exercise muscle
soreness, muscle pain or muscle injury due to
lactic acid accumulation; or to a decrease in
glutathione levels in muscle during exercise.
(I) is suitable for human and animal consumption
(claimed). (I) protects muscles by methods, which
are not directly associated with its anti-oxidant
properties. (I) allows the participant to exercise or
train for a longer period of time, and to exercise
more strenuously while minimizing post-exercise
soreness, by decreasing the amount of lactic acid
which can accumulate in blood plasma, body and
muscle cells during exercise [CONT.]
EP 2068901
A2
20090617
ACTIVITY: Muscular-Gen.; Anabolic; Analgesic.
[CONT.]
HEYDEN V D L C G
KR 2009064398
A
20090618
RIETJENS J S
CN 101522182
A
20090902
IN 2009DN02946
A
20091225
JP 2010505784
T
20100225
A1
20110303
A2
20070907
ALTMANN S W
US 20110052750
WO 2007100807
WO 2007100807
A3
20071227
HAWES B E
EP 1986489
A2
20081105
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are:
ONEILL K A
US 20090098128
A1
20090416
(1) an isolated fusion polypeptide comprising the
polypeptide which is radiolabeled or fused to a
heterologous polypeptide; [CONT.]
SCHIFFMAN J
DSM IP ASSETS BV
282 Nutraceutical composition comprises olive
extract, which is effective in promoting muscle BAST A
health in an animal, including humans that are
subject e.g. to post-exercise muscle soreness
and muscle pain due to lactic acid
accumulation
283 New polypeptide, useful in preparing a
composition for treating atherosclerosis,
hyperlipidemia, hypertriglyceridemia or
hypercholesterolemia
(B) a nucleic acid molecule, which is
complementary to the nucleic acid molecule of (a);
[CONT.]
SCHERING CORP
DE 102006036844 B3 UPAB: 20080504
WO 2007100807 A2 UPAB: 20090430
(I) is useful for: decreasing lactic acid and
glutathione accumulation in muscles resulting
from exercise; and for promoting muscle health in
an animal, including humans that are subject: to
post-exercise muscle soreness, muscle pain or
muscle injury due to lactic acid accumulation; or to
a decrease in glutathione levels in muscle during
exercise (claimed). [CONT.]
The polypeptide is useful in preparing a
NOVELTY: A new isolated polypeptide comprises composition for treating atherosclerosis,
527, 42, 70, 84 or 104 or more contiguous amino hyperlipidemia, hypertriglyceridemia or
acids of SEQ ID NO: 2, 4, 6, 8 or 10, respectively. hypercholesterolemia.
POLYMERS - Preferred Components: The layers
containing polyethylene as the layered
component, alternatively contains further
polyolefins such as polypropylene, ethylene vinyl
acetate, ethyl methyl methacrylate and/or
ionomers. The layer containing an adhesion
promoter, exhibits an adhesion promoter that is
based on polyethylene, polypropylene, ethylene
vinyl acetate (EVA), ethyl methyl methacrylate
(EM(M)A) or an ionomer as the base substance
[CONT.]
BIOTECHNOLOGY - Preferred Polypeptide: The
polypeptide comprises SEQ ID NO: 2, 4, 6, 8 or
10. The polypeptide is antigenic. The polypeptide
complexed with a compound comprising the
structural formula 1, 2, 3, 4, 5, 6, 7, 8, 9, a sterol
or a 5alpha-stanol. The sterol is cholesterol. The
structural formula is detectably labeled. The
isolated fusion polypeptide comprises the
polypeptide which is radiolabeled or fused to a
heterologous polypeptide [CONT.]
INDEPENDENT CLAIMS are:
(1) an isolated fusion polypeptide comprising the
polypeptide which is radiolabeled or fused to a
heterologous polypeptide;
(2) an isolated polynucleotide which hybridizes to
a polynucleotide encoding the polypeptide under
high stringency hybridization conditions;
(3) a recombinant vector comprising the
polynucleotide;
DE 102006036844
US 20100003432
WO 2008040550
US 20110052750
WO 2007100807
US 20090098128
US 7910698
N
YAO X
WO 2007100807
A8
20090723
20110322
METAPROTEOMICS LLC
A1
20070719
US 20070166418 A1 UPAB: 20100729
METAPROTEOMICS LLP
US 7910698
US 20070166418
US 7901714
B2
284 Composition, useful to treat autoimmune
disease e.g. Crohn's disease, Raynaud's
phenomenon, rheumatoid arthritis and
psoriasis, comprises reduced isoalpha acid
compound, a mineral and a vitamin
B2
20110308
NOVELTY: Composition (I) comprises at least one
reduced isoalpha acid compound, a mineral and a
vitamin.
ACTIVITY: Immunosuppressive; Antiinflammatory;
Gastrointestinal-Gen; Vasotropic; Antiarthritic;
Antirheumatic; Dermatological; Endocrine-Gen;
Antianemic; Auditory; Hemostatic; Hepatotropic;
Antidiabetic; Nephrotropic; Antithyroid ; CNS-Gen;
Neuroprotective; [CONT.]
285 Preparing fermented lactic acid composition
useful as feed, by obtaining koji malt by
fermenting rice with Aspergillus, fermenting
organic waste with rice bran fermented using
bio-liquid produced by fermenting koji malt
with yeast
BIO GIKEN YG
JP 2008023523
A
20080207
JP 2008023523 A UPAB: 20110315
JP 4646952
B2
20110309
286 Assessing risk, diagnosing, or prognosing
type 2 diabetes (T2D) or T2D related condition
by detecting T2D and/or obesity or related
phenotype associated biomarkers in patient
sample, and comparing to healthy and
diseased people
JURILAB LTD OY
WO 2007128884
A1
20071115
WO 2007128884 A1 UPAB: 20080318
US 20070292412
A1
20071220
NOVELTY: Risk assessment, diagnosis, or
prognosis of T2D or a T2D related condition in a
mammalian subject comprises detecting T2D
and/or obesity or related phenotype associated
biomarkers in a sample, and comparing the
biomarker data from the subject to biomarker data
from healthy and diseased people to make risk
assessment, diagnosis, or prognosis of T2D or a
T2D related condition. [CONT.]
EP 2021502
A1
20090211
US 7901885
WO 2008012696
US 20080026101
B2
20110308
A2
20080131
A1
20080131
CA 2691044
A1
20080131
20110317
JW PET CO INC
WO 2008012696
US 20080029045
A3
A1
20080207
US 20080029045 A1 UPAB: 20080221
PET CO INC J W
CN 101120657
A
20080213
NOVELTY: The chain has a biodegradable
material ring interconnected with another
biodegradable material ring in a looped fashion,
such that the biodegradable material rings are
independently movable and inseparable relative to
each other. [CONT.]
DSM IP ASSETS BV
COSTELLO P
287 Evaluating efficacy of compounds against
cells in abnormal, cancerous or pre-cancerous MCDONALD W
tissue, involves implanting tissue comprising
cell types within three dimensional matrix,
providing nutrients, incubating or culturing
cells
NICKEL G
ROY A
288 Interconnected biodegradable material ring
chain for forming pet chew toy e.g. dog bone,
has one biodegradable material ring attached
around other biodegradable material ring,
where latter ring is molded in mold
(4) an isolated host cell comprising the vector;
[CONT.]
(I) is useful to treat autoimmune disease, which is (I) has synergistic effect. (I) is non-toxic.
Crohn's disease, Raynaud's phenomenon,
rheumatoid arthritis, systemic lupus
erythematosus (all preferred), alopecia areata,
ankylosing spondylitis, arthritis, antiphospholipid
syndrome, autoimmune Addison's disease,
autoimmune hemolytic anemia, autoimmune inner
ear disease (Menier's disease), autoimmune
lymphoproliferative syndrome, autoimmune
[CONT.]
The method is useful for preparing lactic acid
NOVELTY: Preparation of lactic acid fermentation fermentation composition (claimed), which is
composition, involves fermenting steamed boiled useful as organic fertilizer and feed for livestock,
pet or fish.
rice with Aspergillus, to obtain koji malt, diluting
the koji malt with hot water to obtain
saccharogenic amylase liquid, fermenting
saccharogenic amylase liquid using yeast, to
obtain yeast bio-liquid, fermenting steamed rice
bran and sake strained lees with yeast [CONT.]
The lactic acid fermentation composition enables
preparing non-toxic and odorless organic fertilizer
from organic waste material, foodstuffs waste
material and/or livestock excrement, within a short
period of time and at low cost. Hence, the
resources such as organic waste material,
foodstuffs waste material and/or livestock
excrement can be recycled and prevents
environmental pollution. [CONT.]
The methods are useful for the risk assessment,
diagnosis, or prognosis of T2D or a T2D related
condition in a mammalian subject; and for
preventing, treating or reducing the risk of T2D or
a T2D related condition in a mammalian subject.
[CONT.]
ORGANIC CHEMISTRY - Preferred Components:
The reduced isoalpha acid compound is dihydroisohumulone, dihydro-isocohumulone, dihydroadhumulone, tetrahydro-isohumulone, tetrahydroisocohumulone, tetrahydro-adhumulone,
hexahydroisohumulone, hexahydroisocohumulone or hexahydroadhumulone.
[CONT.]
BIOLOGY - Preferred Method: The yeast (0.025%)
is mixed with saccharogenic amylase liquid at
30degreesC, and fermented for 24 hours in an
anaerobic condition, to obtain yeast bio-liquid. The
steamed boiled rice is left to stand such that
temperature is 30-35degreesC, and then the
Aspergillus is sprinkled on the steamed boiled
rice. [CONT.]
US 20070166418
US 20070166418
US 7901714
Preparation of lactic acid fermentation
JP 2008023523
composition, involves milling and washing old rice,
imported rice and crushed rice, steaming the
washed rice, mixing and stirring Aspergillus to the
steamed rice after certain period of time, placing
the obtained mixture in a wooden box of
fermentation chamber, where the wooden box is
covered with wet cloth, stirring the mixture after 1820 hours at predetermined temperature to obtain
koji malt after 40-45 hours, adding 3 [CONT.]
BIOTECHNOLOGY - Preferred Method: In the risk Risk assessment, diagnosis, or prognosis of T2D WO 2007128884
assessment, diagnosis, or prognosis of T2D or a or a T2D related condition in a mammalian subject
T2D related condition in a mammalian subject, at comprises:
least one biomarker is a T2D and/or obesity
(A) providing a biological sample taken from the
and/or related phenotype associated polymorphic subject;
site residing in a genomic region containing the
gene given in the specification. The biomarker is
selected from the single nucleotide polymorphism
(SNP) markers given in the specification (Tables 343) [CONT.]
US 20070292412
N
US 7901885
(B) detecting one or more T2D and/or obesity or
related phenotype associated biomarkers in the
sample, where the biomarkers are related to one
or more genes given in the specification (Tables 1
and 2) or the biomarkers are related to one or
more polypeptides encoded by the genes; and
[CONT.]
WO 2008012696 A2 UPAB: 20080306
The method is useful for evaluating the efficacy of
NOVELTY: A method of evaluating the efficacy of compounds with respect to tissue from mammal,
compounds with respect to tissue from mammal, for activity against cells in abnormal, cancerous or
for activity against cells in abnormal, cancerous or pre-cancerous tissue (claimed).
pre-cancerous tissue, involves obtaining a tissue
sample comprising one or more types of cells,
implanting the tissue sample within a 3dimensional physiological matrix, providing
nutrients to the cells and incubating or culturing
the cells in the presence of a candidate
therapeutic compound. [CONT.]
The invention provides a rapid method to test one
or more therapeutic substances to determine their
efficacy against a particular tumor or type of
tumor.
Interconnected biodegradable material ring chain The interconnected biodegradable material ring
for forming a pet chew toy e.g. dog bone, ball and chain can produce a more versatile pet toy,
chicken leg (all claimed), that is utilized for
without utilizing an adhesive for locking the rings.
providing tug-of-war amusement for a pet i.e. dog.
BIOTECHNOLOGY - Preferred Method: The
method further involves (vii) determining the
efficacy of one or more therapeutic compounds
with respect to the tissue and the cells, (viii)
recording the data in some form, and (ix)
transmitting the data to at least one evaluator,
where the at least one evaluator is chosen from
technicians, physicians, physician's staff
members, physician's assistants, hospital [CONT.]
N
A method for evaluating the efficacy of one or
WO 2008012696
more therapeutic compounds with respect to at
least one tissue from a mammal, where the tissue
comprising cells, and the tissue being suspected
of being abnormal, cancerous or pre-cancerous,
involves (i) obtaining a sample of the suspected
tissue from the mammal, where the tissue
comprises one or more types of cells, (ii)
implanting the sample quantity [CONT.]
US 20080026101
US 20080029045
US 20080029045
US 7909003
WILLINGER J
289 Dietary supplement for supporting blood lipid
health useful for treating hypercholesterolemy
comprises fatty alcohols/policosanols of
specific particle size, dispersed in a foodgrade fats or oils
290 Preparing chitosan/RNA nanoparticle, for
treating, e.g. cancer or viral infection, by
mixing a chitosan solution and an RNA
solution, and incubating the solution for the
formation of chitosan/RNA nanoparticle
complex
291 New isoxazoline compound useful for
controlling invertebrate pests; for protecting
seed from an animal from an invertebrate
parasitic pest; and for protecting an animal
from an invertebrate parasitic pest
US NUTRACEUTICALS DBA VALENSA INT LLC
US 7909003
WO 2007092509
US 20070213395
B2
20110322
A2
20070816
A1
20070913
EP 1981361
A2
20081022
NO 2008003735
A
20081023
IN 2008DN06669
A
20081024
AU 2007212412
A1
20070816
KR 2008098630
A
20081111
WO 2007092509 A2 UPAB: 20090205
As a dietary supplement composition e.g. food,
NOVELTY: A dietary supplement composition (C1) feed or beverage for supporting the maintenance
comprises at least one 24-36C long chain primary of healthy blood lipid levels, reducing blood serum
cholesterol levels and treating
alcohols (i.e. policosanols) dispersed in at least
hypercholesterolemy in human and animal
one food-grade fats or oils, in which the particle
subjects (claimed). Also useful for treating
sizes of the alcohols are less than 10 microns.
atherosclerosis and coronary heart disease.
[CONT.]
US 20090123557
A1
20090514
JP 2009525755
T
20090716
MX 2008010150
A1
20090331
US 20090285902
A1
20091119
AU 2010201897
A1
20100603
AU 2007212412
B2
20100708
DE 202007019139
U1
20101118
AU 2010201897
B2
20110317
WO 2008003329
WO 2008003329
A2
20080110
WO 2008003329 A2 UPAB: 20080205
A3
20080221
NOVELTY: Preparing a chitosan/RNA
nanoparticle comprises: (a) providing a chitosan
solution; (b) providing an RNA solution; (c) mixing
the solution of (a) with the solution of (b); and (d)
incubating the solution of (c) under conditions of
complex formation so that chitosan/RNA
nanoparticles form.
EP 2037899
A2
20090325
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are: [CONT.]
US 20100015232
A1
20100121
CA 2706124
A1
20080110
EP 2295045
WO 2007079162
A1
20110316
DU PONT DE NEMOURS&CO E I
A1
20070712
WO 2007079162 A1 UPAB: 20090222
DU PONT DE NEMOURS & CO E I
AU 2006332749
A1
20070712
NOVELTY: An isoxazoline compound, is new.
LAHM G P
EP 1973888
A1
20081001
SHOOP W L
IN 2008DN04364
A
20080815
DETAILED DESCRIPTION: An isoxazoline
compound of formula (I), or its N-oxide or salt, is
new.
A1-A6=CR3 or N;
XU M
CN 101351456
A
20090121
B1-B3=CR2 or N;
KR 2008094015
A
20081022
W1=O or S;
CA 2632694
A1
20070712
R1=1-6C alkyl, 2-6C alkenyl, 2-6C alkynyl, 3-6C
cycloalkyl, 4-7C alkylcycloalkyl or 4-7C
cycloalkylalkyl (all optionally substituted with at
least one R6); [CONT.]
TW 2007038696
A
20071016
JP 2009522282
T
20090611
MX 2008008414
A1
20080731
ZA 2008004384
A
20090826
US 20100234219
A1
20100916
NZ 568026
A
20101029
UNIV AARHUS
The body's absorption and utilization of the
policosanols from the composition is substantially
enhanced as compared with the absorption and
utilization of policosanols administered in solid or
tablet form. The policosanol dispersion of the
composition is stable on storage and does not
separate from the lipid carrier. The composition
includes food-grade emulsifiers, for example,
polysorbates, lecithin [CONT.]
The method is useful for preparing a
chitosan/RNA nanoparticle. The nanoparticle is
useful as a medicament. It can be used for the
preparation of a medicament for treatment of
cancer, viral infection such as influenza,
respiratory synthetic virus, and tuberculosis, and
inflammatory conditions such as arthritis, Crohn's
disease, and hay fever (all claimed).
FOOD - Preferred Composition: The composition
(C1) further comprises biologically active extracts
and compounds, including vitamins, minerals,
antioxidants, carotenoids, tocopherols,
tocotrienols, phytosterols, polyphenols,
polysaccharides or bioflavonoids. It further
comprises a delivery vehicle as an emulsion,
solution, dispersion, cream, tablet, capsules and
powder and further a delivery vehicle for carrying
the composition comprising food, feed or
beverage [CONT.]
WO 2007092509
US 20070213395
US 20090123557
US 20090285902
BIOTECHNOLOGY - Preferred Method: In
INDEPENDENT CLAIMS are:
WO 2008003329
preparing a chitosan/RNA nanoparticle, the
(1) a nanoparticle prepared by the method above;
chitosan/RNA nanoparticle does not comprise an
initial cross-linker. The nanoparticle is formed at a
N:P ratio greater than 50 and lower than 70. The
formed nanoparticle comprises loosely bound
chitosan. The formed particles are discrete in form
and have a polydispersity index lower than 0.4.
Preferably, the size of the particle is 10-500 nm
[CONT.]
(2) a method of treatment comprising: (a)
providing a nanoparticle prepared above, and (b)
administrating the nanoparticle to a subject;
US 20100015232
N
(3) a method of delivering siRNA into a mammal
or cell;
(4) a method of increasing the stability of a siRNA
in a cell or in an organism; and [CONT.]
For controlling an invertebrate pests; for protecting
a seed from an animal from an invertebrate
parasitic pest; for controlling a mosquito, black fly,
stable, fly, deer fly, horse fly, wasp, yellow jacket,
hornet, tick, spider, ant or gnat; and for protecting
an animal from an invertebrate parasitic pest
(claimed).
The compounds exhibit activity, controlling a
spectrum of agronomic and nonagronomic
invertebrate pests; are more effective, less costly,
less toxic, and environmentally safer.
AGRICULTURE - Preferred Composition: The
composition (C1) is in the form of a soil drench
liquid formulation. The seed is protected by
coating it with the compound (I), formulated as a
composition comprising a film former or adhesive
agent. [CONT.]
An isoxazoline compound of formula (I), or its Noxide or salt, is new.
A1-A6=CR3 or N;
B1-B3=CR2 or N;
W1=O or S;
R1=1-6C alkyl, 2-6C alkenyl, 2-6C alkynyl, 3-6C
cycloalkyl, 4-7C alkylcycloalkyl or 4-7C
cycloalkylalkyl (all optionally substituted with at
least one R6); [CONT.]
WO 2007079162
US 20100234219
N
292 Ruminant feed supplement useful for treating
e.g. milk fever comprises rice bran, which is
subjected to ruminal bypass treatment
293 Screening for therapeutic agents for treating
telomerase positive cancers in a mammal
comprises contacting a test compound with a
MKRN polypeptide, and detecting binding of
the test compound to the MKRN polypeptide
NUTRECO NEDERLAND BV
UNIV CENT FLORIDA RES FOUND INC
CHUNG I K
RU 2008131307
A
20100210
EP 1973888
B1
20110126
DE 602006019915
E
20110310
WO 2007145519
EP 2040566
A1
20071221
A1
20090401
AU 2007259468
A1
20071221
ACTIVITY: Hypotensive; Antilipemic; Antidiabetic;
Antipyretic. No biological data given.
WO 2007145519 A1 UPAB: 20080123
As ruminant feed supplement/composition for
NOVELTY: Ruminant feed supplement comprises prophylactic treatment of milk fever (parturient
rice bran, where the rice bran has been subjected paresis) in ruminants (claimed), for prevention of
hypertension, hyperlipidemia and/or
to a ruminal bypass treatment.
hyperglycemia.
US 20090202671
A1
20090813
MECHANISM OF ACTION: None given.
CA 2655317
A1
20071221
USE: As ruminant feed supplement/composition
for prophylactic treatment of milk fever (parturient
paresis) in ruminants (claimed), for prevention of
hypertension, hyperlipidemia and/or
hyperglycemia. [CONT.]
EP 2040566
US 20070224199
US 7901906
B1
20110309
A1
20070927
US 20070224199 A1 UPAB: 20080118
B2
20110308
NOVELTY: Screening for therapeutic agents
useful in the treatment of telomerase positive
cancers in a mammal comprises contacting a test
compound with a MKRN polypeptide, and
detecting binding of the test compound to the
MKRN polypeptide, where a test compound, which
binds to the MKRN polypeptide is identified as a
potential cancer therapeutic agent. [CONT.]
WO 2007123777
US 20070297984
A2
20071101
WO 2007123777 A2 UPAB: 20100107
A1
20071227
NOVELTY: Increasing a sensitivity of a tumor in a
subject to a treatment comprises administering to
the tumor a composition comprising an amount of
an inhibitor of nitric oxide synthase, a nitric oxide
scavenger, and/or an inhibitor of HIF-1
nitrosylation, where (a) the tumor is resistant to
radiation therapy, chemotherapy, or both radiation
therapy and chemotherapy [CONT.]
WO 2007123777
A3
20081016
US 20110054023
A1
20110303
The rice bran has beneficial dietary when applied
in mammals, such as general improvement of lipid
metabolism, improvement of oxidative status and
positive effects on prevention of hypertension,
hyperlipidemia, and/or hyperglycemia. By treating
the rice bran with a ruminal bypass treatment,
calcium absorption in the duodenum is effectively
reduced and negative calcium balance is obtained
which is [CONT.]
FOOD - Preferred Components: The ruminal
bypass treatment is selected from chemical crosslinking (preferably cross-linking with an aldehyde,
tannin and/or any other protein binding product),
physical cross-linking (preferably cross-linking by
a heat treatment) and/or coating. The ruminant
feed supplement further comprises clay-mineral.
The ruminal bypass treated rice bran comprises
phytic acid (at least 3 wt [CONT.]
The methods are useful for screening for
therapeutic agents useful in the treatment of
telomerase positive cancers in a mammal.
BIOTECHNOLOGY - Preferred Method: Screening
for therapeutic agents useful in the treatment of
telomerase positive cancers in a mammal also
comprises determining the activity of a MKRN
polypeptide at a certain concentration of a test
compound or in the absence of the test
compound, and determining the activity of the
polypeptide at a different concentration of the test
compound. [CONT.]
INDEPENDENT CLAIMS are:
The methods are useful for increasing a sensitivity
of a tumor in a subject to a treatment; delaying
tumor growth; inhibiting tumor blood vessel
growth; inhibiting HIF-1 activity in a cell; and
inhibiting an inflammatory response in a cell. The
inhibitors of nitric oxide synthases and nitric oxide
scavengers can be used to prevent activation of
H1F-1 activity in tumors by cancer therapy that
includes radiation and chemotherapy [CONT.]
BIOTECHNOLOGY - Preferred Method: In
INDEPENDENT CLAIMS are:
increasing a sensitivity of a tumor in a subject to a (1) a method for delaying tumor growth in a
treatment, the inhibitor of nitric oxide synthase is subject;
selected from L-N(6)-(1-iminoethyl)lysine tetrazoleamide (SC-51); aminoguanidine (AG);
guanidinoethyldisulfide; L-NG-nitroarginine methyl
ester; mercaptoethylguanidine (MEG); Nomeganitro-L-arginine methyl ester (L-NAME); N-(3(aminomethyl)benzyl)acetamidine (1400W)
[CONT.]
WO 2007145519
US 20090202671
N
US 20070224199
US 20070224199
US 7901906
N
WO 2007123777
US 20070297984
US 20110054023
N
US 20070261126
US 20100325746
N
(1) a pharmaceutical composition for the treatment
of treatment of a telomerase positive cancer
comprising: (a) a therapeutic agent, which binds to
a MKRN polypeptide; or (b) a therapeutic agent,
which regulates the activity of a MKRN
polypeptide, and where the therapeutic agent is a
small molecule, an RNA molecule, an antisense
oligonucleotide, a polypeptide, an antibody, or a
ribozyme; [CONT.]
MULLER M T
UNIV DUKE
294 Increasing sensitivity of tumor to a treatment
by administering a composition comprising an
inhibitor of nitric oxide synthase, a nitric oxide
scavenger, and/or an inhibitor of hypoxia
inducible factor (HIF)-1 nitrosylation
295 Nucleic acid duplex useful for the treatment of MEDTRONIC INC
e.g. Huntington's disease, comprises two
KAEMMERER W F
strands of nucleic acid containing specific
nucleotides
KAYTOR M D
US 20070261126
WO 2008021136
A1
20071108
A2
20080221
WO 2008021136
WO 2008021136
EP 2056881
A3
20080703
B1
20080807
A2
20090513
CN 101557831
A
20091014
(2) a method for inhibiting tumor blood vessel
growth in a subject;
(3) a method for inhibiting HIF-1 activity in a cell;
(4) a method for inhibiting an inflammatory
response in a cell;
(5) a method for identifying an inhibitor of
nitrosylation of an HIF-1 polypeptide;
(6) an expression construct comprising one or
more of SEQ ID NO [CONT.]
US 20070261126 A1 UPAB: 20090521
For preventing cytotoxic effects of Huntington's
The nucleic acid duplex reduces Huntington's
BIOLOGY - Preferred Components: The duplex is INDEPENDENT CLAIMS are included for the
US 20070261126
disease
(HD)
or
inhibiting
expression
of
huntingtin
disease
(HD)
messenger
RNA
(mRNA)
without
19-30
base
pairs
in
length.
The
first
and/or
the
following:
(1)
an
expression
cassette
comprising
a
NOVELTY: An isolated nucleic acid duplex
in Macaca mulatta or Homo sapiens (claimed).
causing death, anatomical aberrations, alterations second strand further comprises an overhang
nucleic acid encoding at least one strand of the
comprises a first strand of nucleic acid and a
in
endoplasmic
reticulum
of
the
transduced
cells,
region.
The
overhang
region
comprises
a
3'
nucleic acid duplex; (2) a vector comprising the
second strand of nucleic acid, where the first
locomotor impairment or cellular alterations of
overhang region, a 5' overhang region, or both 3' expression cassette; (3) a vector (Ve1) comprising
strand comprises at least 19 contiguous
Macaca mulatta or Homo sapiens.
and 5' overhang regions. The overhang region is 1- two expression cassettes, a first expression
nucleotides encoded by the group consisting of
10 nucleotides in length. The first strand and the cassette comprising a nucleotide sequence
SEQ ID NO:1 and SEQ ID NO:4, each containing
second strand are operably linked by means of a encoding the first strand of the nucleic acid duplex
19 nucleotides as given in specification and where
nucleic acid loop strand to form a hairpin structure and a second expression cassette comprising a
the second strand is complementary to at least 15
comprising a duplex structure and a loop structure nucleotide sequence encoding the second strand
contiguous nucleotides of the first strand. [CONT.]
[CONT.]
of the nucleic acid duplex [CONT.]
US 7902352
296 Oral delivery system for remineralizing enamel CADBURY ADAMS USA LLC
subsurface lesions in tooth of mammal,
contains phosphopeptide or phosphoprotein
stabilized calcium phosphate or calcium
fluoride phosphate complex, and salt from
calcium and/or phosphate salts
297 New antibody or its fragment having high
affinity for wild type human Abeta protofibrils,
useful in preparing a medicament for treating
e.g., Alzheimer's disease, Down's syndrome,
Lewybody dementia or vascular dementia
BIOARCTIC NEUROSCIENCE AB
JP 2010500025
T
20100107
US 20100325746
US 7902352
US 20070237725
WO 2007117536
A9
20101223
B2
20110308
A1
20071011
US 20070237725 A1 UPAB: 20071219
A2
20071018
NOVELTY: An oral delivery system comprises a
phosphopeptide or phosphoprotein stabilized
calcium phosphate or calcium fluoride phosphate
complex; and a salt from calcium and/or
phosphate salts.
WO 2007117537
A2
20071018
DETAILED DESCRIPTION: An INDEPENDENT
CLAIM is included for a kit for remineralizing
enamel subsurface lesions in the tooth of a
mammal comprising the oral delivery system, a
set of instructions for using the system, and a
package for housing the system and the set of
instructions. [CONT.]
WO 2007117627
WO 2007117627
WO 2007117536
WO 2007117537
EP 2001436
EP 2001452
EP 2026745
A2
20071018
A3
20080110
A3
20080724
A3
20081106
A2
20081217
A2
20081217
A2
20090225
AU 2007235359
A1
20071018
AU 2007235444
A1
20071018
CN 101415393
A
20090422
AU 2007235445
A1
20071018
CN 101415398
A
20090422
CN 101415406
A
20090422
CA 2645763
A1
20071018
CA 2648313
A1
20071018
CA 2648460
A1
20071018
IN 2008KN04014
A
20090227
IN 2008KN04044
A
20090227
IN 2008KN04045
A
20090227
MX 2008012522
A1
20081031
MX 2008012523
A1
20081031
MX 2008012524
A1
20081031
JP 2009532065
T
20090910
JP 2009532478
T
20090910
JP 2009534313
T
20090924
AU 2007235359
B2
20110310
WO 2007108756
A1
20070927
WO 2007108756 A1 UPAB: 20071026
IN 2008DN03968
A
20080815
NOVELTY: A new antibody or its fragment is
selective and has high affinity for wild type human
Abeta protofibrils. The antibody or fragment may
exhibit amino acid deletions, substitutions and
insertions within the CDR regions.
EP 2004688
A1
20081224
DETAILED DESCRIPTION: The new antibody or
its fragment is selective and has high affinity for
wild type human Abeta protofibrils. [CONT.]
NO 2008004445
A
20081022
The oral delivery system, e.g. confectioneries,
The system promotes remineralization of tooth
chewing gum, gels, dentifrices, toothpaste,
enamel of consumers.
mouthwash, mouth rinse, mouth spray, edible film,
beverages or food, is used for remineralizing
enamel subsurface lesions in the tooth of a
mammal. The confectionery product is hard
candy, soft candy, center-fill candy (preferred),
cotton candy, pressed tablets, lozenges, edible
films, nougats, caramels, frappes or taffies
[CONT.]
INORGANIC CHEMISTRY - Preferred
Component: The phosphopeptide comprises
casein phosphopeptide. The calcium salt is
calcium chloride, calcium lactate, calcium sulfate,
calcium carbonates, calcium phosphates, calcium
glutareate, calcium malate, calcium citrate,
calcium gluconate, calcium glycerophosphate,
calcium fumarate, calcium hydroxide, and/or
calcium oxide. The phosphate salt is neutral,
monobasic or dibasic phosphate salts [CONT.]
An INDEPENDENT CLAIM is included for a kit for US 20070237725
remineralizing enamel subsurface lesions in the
tooth of a mammal comprising the oral delivery
system, a set of instructions for using the system,
and a package for housing the system and the set
of instructions.
US 20070237725
The antibody or composition is useful in preparing
a medicament for treating Alzheimer's disease,
Down's syndrome, Lewybody dementia, vascular
dementia and other neurodegenerative disorders.
BIOTECHNOLOGY - Preferred Antibody: The
antibody exhibits 1-10 amino acid deletions,
substitutions and insertions within the CDR
regions. The antibody exhibits 1-5 amino acid
deletions, substitutions and insertions within the
CDR regions. The antibody exhibits 1-3 amino
acid deletions within the CDR regions. The
antibody is monoclonal. The antibody has reduced
complement activation activity. [CONT.]
The new antibody or its fragment is selective and WO 2007108756
has high affinity for wild type human Abeta
protofibrils. The antibody or fragment may exhibit
amino acid deletions, substitutions and insertions
within the CDR regions. The antibody or fragment
in its six CDR regions has the following consensus
sequences:
US 20090258009
N
(1) Ser-Phe-Gly-Met-His (VH-CDR1);
(2) Tyr-Ile-Ser-Ser-Gly-Ser-Ser-Thr-Ile-Tyr-Tyr-GlyAsp-Thr-Val-Lys- Gly (VH-CDR2); [CONT.]
A1
20070927
KR 2008106288
A
20081204
CA 2630344
A1
20070927
CN 101421303
A
20090429
MX 2008012223
A1
20081231
JP 2009530374
T
20090827
US 20090258009
A1
20091015
ZA 2008005805
A
20100224
NZ 567888
A
20100827
EP 2004688
B1
20101222
DE 602007011415
E
20110203
EP 2004688
WO 2007106769
US 20070218065
B8
20110302
A2
20070920
WO 2007106769 A2 UPAB: 20071026
A1
20070920
JASPERS S R
WO 2007106769
A3
20080313
NOVELTY: A new isolated antibody that binds to
both interleukin (IL)-17A (SEQ ID NO: 2) and IL17F (SEQ ID NO: 4).
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are:
PRESNELL S R
EP 1996622
A2
20081203
(1) an isolated antisera containing the antibody;
HUBER M J
US 20080299129
A1
20081204
(2) a diagnostic kit comprising the antibody and
means for detecting binding by that antibody;
[CONT.]
LEVIN S D
US 20090004199
A1
20090101
LEWIS K E
AU 2007226627
A1
20070920
MABRY G R
CA 2646478
A1
20070920
IN 2008CN05376
A
20090320
JP 2009534297
T
20090924
B2
20100907
A1
20101209
B2
20110322
A2
20070802
WO 2007085923 A2 UPAB: 20090806
EVROGEN AYPI STOCK CO
US 7790163
US 20100310565
US 7910703
WO 2007085923
WO 2007085923
A3
20071018
NOVELTY: An isolated nucleic acid comprising a
nucleic acid sequence encoding an EqFP578related functional fluorescent protein, where the
protein is substantially the same as or identical to
the wild type fluorescent protein EqFP578 of fully
defined 231 amino acids (SEQ ID NO. 2) given in
the specification, is new.
EVROGEN IP JOINT STOCK CO
EP 1994149
A2
20081126
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are: [CONT.]
EVROGEN IP STOCK CO
WO 2007085923
A8
20090730
EVROGEN STOCK CO
US 7638615
US 20100015701
B1
20091229
A1
20100121
RU 2395581
C2
20100727
EP 1994149
B1
20100929
DE 602007009498
E
20101111
RU 2008134484
A
20100227
US 20110070625
A1
20110324
298 New antibody that binds to both interleukin (IL)- ZYMOGENETICS INC
17A and IL-17F, useful in treating a mammal
HUBER M
afflicted with an inflammatory disease, e.g.,
asthma
299 New isolated nucleic acid encoding red
fluorescent protein from Entacmaea
quadricolor (EqFP578), useful for labeling
biological molecules, cells, or cell organelles;
or for analyzing gene expression, e.g.
promoter activity
AU 2007227813
EVROGEN IP
The isolated antibody that binds to both interleukin
(IL)-17A (SEQ ID NO: 2) and IL-17F (SEQ ID NO:
4) is useful in treating a mammal afflicted with an
inflammatory disease, e.g., asthma, inflammatory
bowel disease, irritable bowel syndrome,
ulcerative colitis, Crohn's disease, arthritis, atopic
dermatitis or psoriasis.
BIOTECHNOLOGY - Preferred Antibody: The
isolated antibody that binds to both interleukin (IL)17A (SEQ ID NO: 2) and IL-17F (SEQ ID NO: 4).
The antibody binds an IL-17F epitope comprising
amino acid residues 23, 25, 27, 29 and 34 of SEQ
ID NO: 4. The antibody binds an IL-17A epitope
comprising amino acid residues 20, 22, 24, 26 and
31 of SEQ ID NO: 2. [CONT.]
INDEPENDENT CLAIMS are:
WO 2007106769
(1) an isolated antisera containing the antibody;
US 20070218065
US 20080299129
(2) a diagnostic kit comprising the antibody and
means for detecting binding by that antibody;
US 20090004199
(3) a pharmaceutical composition for treating or
preventing inflammation comprising the antibody
and a pharmaceutically acceptable vehicle, carrier
or excipient;
US 7790163
(4) a method of treating or preventing
inflammation by administering to a human or
animal patient the antibody; [CONT.]
US 20100310565
N
US 7910703
The nucleic acids and its encoded proteins can be
used for labeling a biological molecule, cell, or cell
organelle; for analyzing gene expression (e.g.,
promoter activity); for identifying and/or measuring
the expression and/or localization of protein or
polypeptide of interest in biological material; in
fluorescence resonance energy transfer (FRET)
methods; [CONT.]
BIOTECHNOLOGY - Preferred Nucleic Acid: The INDEPENDENT CLAIMS are:
WO 2007085923
EqFP578-related functional fluorescent protein is (1) a vector comprising the nucleic acid;
a genetically engineered functional fluorescent
protein whose amino acid sequence differs from
the wild type fluorescent protein EqFP578 of SEQ
ID NO. 2 by at least one amino acid substitution
selected from R320 and S131P, where the
genetically engineered functional fluorescent
protein has an increased maturation speed at a
temperature of 37degreesC as compared to
(2) an expression cassette comprising (a) a
EqFP578 [CONT.]
transcriptional initiation region functional in an
expression host; (b) the nucleic acid; and (c) and
a transcriptional termination region functional in
the expression host;
(3) a host cell or its progeny comprising the
expression cassette as part of an
extrachromosomal element or integrated into the
genome of a host cell as a result of introduction of
the expression cassette into the host cell; [CONT.]
US 7638615
US 20100015701
US 20110070625
N
VERTEX PHARM INC
300 New solid amorphous N-(2,4-bis(1,1dimethylethyl)-5-hydroxyphenyl)-1,4- dihydro-4oxoquinoline-3-carboxamide useful for treating CONNELLY P R
e.g. diabetes mellitus, Alzheimer's disease,
Parkinson's disease, and Pick's disease
WO 2007079139
A2
20070712
WO 2007079139 A2 UPAB: 20071026
WO 2007079139
A9
20071129
NOVELTY: Solid amorphous N-(2,4-bis(1,1dimethylethyl)-5-hydroxyphenyl)- 1,4-dihydro-4oxoquinoline-3-carboxamide (a1) is new.
COSTACHE A
WO 2007079139
A3
20080117
FENG Y
AU 2006332726
A1
20070712
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are included for the following:
(1) a preparation (p1) comprising the carboxamide
(a1) and is free of crystalline N-(2,4-bis(1,1dimethylethyl)-5-hydroxyphenyl)-1,4-dihydro- 4oxoquinoline-3-carboxamide; [CONT.]
GONG Y
EP 1993360
A2
20081126
HURTER P
CN 101384172
A
20090311
KRAWIEC M
CA 2635581
A1
20070712
ROWE W
JP 2009522278
T
20090611
TRUDEAU M
US 20110064811
A1
20110317
EP 1832295
WO 2007104646
A1
20070912
A2
20070920
WO 2007104646
A3
20071115
For treating cystic fibrosis transmembrane
conductance Regulator (CFTR) mediated disease
involves cystic fibrosis, hereditary emphysema,
hereditary hemochromatosis, coagulationfibrinolysis deficiencies (e.g. protein C deficiency),
Type 1 hereditary angioedema, lipid processing
deficiencies (e.g. [CONT.]
The solid dispersion (d1) has a higher glass
transition temperature than the glass transition
temperature of neat amorphous N-(2,4-bis(1,1dimethylethyl)-5-hydroxyphenyl)-1,4-dihydro-4oxoquinoline- 3-carboxamide; and provides high
bioavailability.
ORGANIC CHEMISTRY - Preferred Components:
The solid amorphous carboxamide (a1) has
crystalline N-(2,4-bis(1,1-dimethylethyl)-5hydroxyphenyl)-1,4- dihydro-4-oxoquinoline-3carboxamide (less than 15%). The surfactant is
sodium lauryl sulfate. The solvent is acetone or
methyl ethyl ketone (MEK), acetone and water, or
MEK and water, where water is present in 10 wt.%
(preferably acetone, or acetone (70-100) and
water (0-20)) [CONT.]
In the preparation of a medicament for the
The long pentraxin-3 inhibits the virus activation
prevention
and/or
treatment
of
virus
diseases
in
a
and prevents viral diseases effectively.
NOVELTY: In the preparation of a medicament for
mammal
subject;
for
the
inhibition
of
the
virus
the prevention and/or treatment of virus diseases
activation; for treating influenza induced syndrome
in a mammal subject, long pentraxin-3 (PTX3) is
and for treating cytomegalovirus induced
used.
syndrome e.g. CMV mononucleosis, the syndrome
ACTIVITY: Virucide. Mice infected with herpes
associated with an immunocompromised host in
virus such as cytomegalovirus (CMV) were treated
the immunocompromised host having AIDS, and
dosage of long pentraxin-3 (PTX-3)
an organ transplant recipient.
intraperitoneally. The result showed that the PTX3 significantly decreased the viral load and
prevented the CMV infection. [CONT.]
BIOLOGY - Preferred Components: The virus is
selected from herpes virus (preferably
cytomegalovirus (CMV)), influenza virus
(preferably H1N1, H3N2 or H5N7), paramyxovirus
(preferably measles), respiratory syncytial virus,
coronavirus (preferably SARS), HIV Virus,
hepatitis virus, or rotavirus.
BIOTECHNOLOGY - Preferred Sequences: The
isolated polypeptide comprises amino acids 16-25
of SEQ ID NO: 1. Amino acid 1 (X1) is a glutamine
and amino acid 2 (X2) is a glutamic acid, (PI6 and
16-I). Amino acid 1 (X1) is a glutamine and amino
acid 2 (X2) is a leucine, (P16-1). Amino acid 1
(X1) is a tyrosine and amino acid 2 (X2) is a
leucine, (P16-2). [CONT.]
INDEPENDENT CLAIMS are included for the
WO 2007079139
following:
(1) a preparation (p1) comprising the carboxamide
(a1) and is free of crystalline N-(2,4-bis(1,1dimethylethyl)-5-hydroxyphenyl)-1,4-dihydro- 4oxoquinoline-3-carboxamide;
(2) a solid dispersion (d1) comprising the
carboxamide (a1);
(3) a pharmaceutical composition (c1) comprising
the amorphous carboxamide as a solid dispersion
and at least one surfactant, polymer, inert
pharmaceutically acceptable substance, or a
carrier; [CONT.]
US 20110064811
N
YOUNG C R
301 Use of long pentraxin-3 in the preparation of a TECNOGEN SPA
medicament for the prevention and/or
treatment of virus diseases in a mammal and
for inhibiting virus activation
EP 1832295 A1 UPAB: 20071026
EP 1832295
EP 1993585
A2
20081126
KR 2008104059
A
20081128
AU 2007224564
A1
20070920
CN 101426516
A
20090506
CA 2646419
A1
20070920
IN 2008KN03884
A
20090227
JP 2009529563
T
20090820
MX 2008011413
A1
20081231
US 20090286726
US 7910092
WO 2007100607
A1
20091119
B2
20110322
A2
20070907
WO 2007100607 A2 UPAB: 20090222
US DEPT HEALTH & HUMAN SERVICES
WO 2007100607
A3
20080306
US DEPT OF HEALTH&HUMAN SERVICES
EP 1989224
A2
20081112
PASTAN I H
US 20090035266
A1
20090205
X3 = V or Y;
SCHLOM J
AU 2007221255
A1
20070907
X4 = E or L;
TSANG K
CA 2642994
A1
20070907
X5 = V or L;
302 New immunogenic peptide, useful for eliciting US DEPT HEALTH&HUMAN SERVICES
an immune response and for treating cancer,
e.g. uterine, cervical, prostate or testicular
cancer
The peptide, composition, and methods are useful
for eliciting an immune response and for treating
cancer, e.g. uterine, cervical, prostate or testicular
cancer.
US 20090286726
US 7910092
An isolated polypeptide comprises at most ten
WO 2007100607
consecutive amino acids of the amino acid
sequence:
MSARVRSRSRGRGDGX1X2APDVVAFVAPGES
QQEEPPTDNQDIEPGQEREG
TPPIEERKX3X4GDCQEMDX5EKTRSERGDGSD
VKEX6X7TPPNPKHX8KTKEA GDGQP (SEQ ID
NO: 1), where:
US 20090035266
NOVELTY: An isolated polypeptide comprising at
most ten consecutive amino acids of the amino
acid sequence of SEQ ID NO: 1 is new.
X1 = Q or Y;
US 7910692
DETAILED DESCRIPTION: An isolated
polypeptide comprises at most ten consecutive
amino acids of the amino acid sequence:
MSARVRSRSRGRGDGX1X2APDVVAFVAPGES
QQEEPPTDNQDIEPGQEREG
TPPIEERKX3X4GDCQEMDX5EKTRSERGDGSD
VKEX6X7TPPNPKHX8KTKEA GDGQP (SEQ ID
NO: 1), where: [CONT.]
X2 = E or L;
N
N
GATTO H
303 Non-therapeutic treatment of mammalian
superficial surface of human body part,
THOREL J N
comprises disposing liquid blood fraction and
complex nutritional base, mixing the mixture
to obtain active liquid phase and contacting
the body part
304 New isolated progenitor or stem cell originated UNIV CATHOLIQUE LOUVAIN
from adult liver co-expressing mesenchymal
markers, useful for manufacturing medicament
for treating liver disease, e.g. phenylketonuria,
galactosemia, fatty liver, or liver cancer
305 Full duplex radio frequency identification tag
reader, for e.g. controlling e.g. cat flap, has
negative feedback circuit to provide control
signal for electromagnetic field generator for
controlling generator
HILL N P R
HILLS PET NUTRITION INC
306 Preparing food composition, useful for
nutritional and/or organoleptical consumption
by animal, comprises contacting hydrocolloids
with water to form solution, contacting
solution with food ingredients and allowing to
form solid mass
EP 1989224
B1
20101020
X6 = K or Y;
DE 602007009941
E
20101202
X7 = T or L, and
US 7910692
FR 2895680
FR 2895680
B2
20110322
X8 = A or V [CONT.]
A1
20070706
FR 2895680 A1 UPAB: 20071024
B1
20110318
NOVELTY: Method of non-therapeutic treatment
of a superficial surface of body part of a
mammalian, particularly human being, comprises:
disposing a liquid blood fraction of the same
species of the mammal to be treated; disposing a
complex nutritional base (CNB) in aqueous
medium; mixing the liquid blood fraction with the
CNB to obtain active liquid phase of local and
surface treatment; and contacting the body part to
be treated with the active liquid phase. [CONT.]
WO 2007071339
EP 1969118
A1
20070628
WO 2007071339 A1 UPAB: 20090222
A1
20080917
AU 2006328988
A1
20070628
US 20080311094
A1
20081218
IN 2008DN06264
A
20081024
CN 101356264
A
20090128
CA 2634510
A1
20070628
JP 2009520474
T
20090528
EP 2281875
EP 1969118
A1
20110209
B1
20110209
DE 602006020071
E
20110324
WO 2007068975
A1
20070621
EP 1969522
A1
20080917
US 20100289617
A1
20101118
EP 1969522
B1
20110126
DE 602006019914
E
20110310
EP 2296100
EP 2296101
WO 2007048106
A1
20110316
A1
20110316
A1
20070426
The composition is useful for the preparation of
the medicament to treat a mammal e.g. human,
and for teeth or mouth care, dental or periodontal
surgery, and to prepare a surface care device,
particularly bandage for medical, therapeutic or
cosmetic purpose (claimed).
The composition improves the maintenance or the BIOLOGY - Preferred Components: The liquid
survival of the scalp graft.
blood fraction is an autologous and obtained only
from a blood sample of the mammal to be treated,
by fractionation. The liquid blood fraction is a
decomplemented serum obtained by successive
fractionations from a blood sample, by coagulation
without anticoagulant and heating at 56degreesC
for 30 minutes. [CONT.]
The liver progenitor or stem cells, or the cell line
or cell population or progeny including
NOVELTY: An isolated progenitor or stem cell
differentiated progeny, preferably hepatocytes or
originated from adult liver, which co-expresses
hepatocyte like cells, is useful in therapy. It can be
one or more of mesenchymal markers CD90,
CD73, CD44, vimentin, and alpha-smooth muscle used for the manufacture of a medicament for the
actin (ASMA), with the hepatocyte marker albumin treatment of liver disease selected from
phenylketonuria and other aminoacidopathies,
(ALB), is new.
hemophilia and other clotting factor deficiencies,
DETAILED DESCRIPTION: INDEPENDENT
familial [CONT.]
CLAIMS are included for:
BIOTECHNOLOGY - Preparation (claimed):
Obtaining an isolated progenitor or stem cell or a
cell population comprising the progenitor or stem
cell comprises: (A) disassociating adult liver or a
part to form a population of primary cells from the
adult liver or part; (B) plating the primary cell
population onto a substrate, which allows
adherence of cells; and (C) culturing cells from the
primary cell population, which have adhered to the
substrate, for at least 7-15 days [CONT.]
Method of non-therapeutic treatment of a
FR 2895680
superficial surface of body part of a mammalian,
particularly human being, comprises disposing a
liquid blood fraction of the same species of the
mammal to be treated, disposing a complex
nutritional base (CNB) in aqueous medium, which
is distinguished from a cellular culture medium,
excludes all cellular growth factor and/or any
biological extract of animal [CONT.]
INDEPENDENT CLAIMS are included for:
N
WO 2007071339
US 20080311094
INDEPENDENT CLAIMS are also included for the WO 2007068975
following:
(1) a method of remotely interrogating a
transponder
US 20100289617
N
(1) a cell line of or a cell population comprising the
isolated liver progenitor or stem cell, or its
progeny;
(2) an isolated human adult liver progenitor or
stem cell, and cell line, as deposited on February
20, 2006 under the Budapest Treaty with the
Belgian Coordinated Collections of
Microorganisms (BCCM) under accession number
LMBP 6452CB, sub-lines including clonal sublines, and progeny; [CONT.]
(1) a cell line of or a cell population comprising the
isolated liver progenitor or stem cell, or its
progeny; [CONT.]
WO 2007068975 A1 UPAB: 20071002
Used in a radio frequency identification (RFID)
system e.g. asset tracking RFID system,
identification RFID system of people or animal
NOVELTY: The reader has an electromagnetic
field generator for generating an electromagnetic such as cat in a pet entry control system
(claimed), animal feeding control RFID system,
field for pulse width modulation (PWM) by a tag
automatic vehicle identification RFID system for
e.g. radio frequency identification (RFID) tag,
where the modulation has modulated load of the labeling of products in a retail environment and for
theft protection or bill totaling, and RFID system
electromagnetic field by the tag. A detector
system is responsive to fluctuations in strength of for storing information on a credit card and a
passport, and for controlling an animal flap e
the field at the reader. [CONT.]
[CONT.]
The full duplex radio frequency identification tag
reader utilizes the negative feedback circuit to
provide a control signal for the field generator for
controlling the field generator, thus quickly
compensating a transponder by a change in the
reader to keep the antenna amplitude constant,
and hence providing the single antenna full duplex
reader with the properties of high Q for efficient
power [CONT.]
(2) an apparatus for remotely interrogating a
transponder
(3) an animal flap incorporating a tag reader
(4) a radio frequency identification (RFID) system
including a transponder and a reader for the
transponder.
WO 2007048106 A1 UPAB: 20070927
The process is useful for the preparation of (I),
which is useful for nutritional and/or organoleptical
consumption by an animal of the order carnivora
such as feline, canine (claimed), a fish, a bird,
parrots, ducks, geese, chickens, turkeys,
ostriches, a reptile or a mammal (non-human
mammals such as monkeys, chimpanzees),
companion and working animals (e.g. horses),
The process provides (I), which is nutritionally
and/or organoleptically adapted for consumption
by an animal of the order carnivora such as feline
and canine. (I) has a gelatinous texture (all
claimed) that is less sticky and more easily
removed from the container. (I) allows for easy
mixing with other dry food products.
FOOD - Preferred Process: The process further
An INDEPENDENT CLAIM is included for: the
WO 2007048106
comprises: contacting the hydrocolloids with a fat; food composition comprising food ingredients, the
retorting the solid mass; and contacting the
hydrocolloid and water (50-90 wt.%).
mixture of food ingredients and colloidal solution
with enzyme. The food ingredients are mixed
before contacting the food ingredients with the
colloidal solution. The mixture formed by
contacting the food ingredients with the colloidal
US 20080299251
N
306 Preparing food composition, useful for
nutritional and/or organoleptical consumption HILL'S PET NUTRITION INC
by animal, comprises contacting hydrocolloids
with water to form solution, contacting
solution with food ingredients and allowing to
form solid mass
DEVRO PLC
307 Production of defatted collagen paste for
producing collagen products, such as sausage NORWOOD D S D
casings, involves cutting natural collagen into
pieces, squeezing collagen pieces under
pressure and disintegrating defatted pieces
PAUL R G
HILLS PET NUTRITION INC
308 Enhancing balance of beneficial and
deleterious bacteria in gastrointestinal tract of
animal having or at risk of inflammatory bowel HILL'S PET NUTRITION INC
disease, involves administering composition
comprising antioxidant
KHOO C
309 New fully human specific binding protein that
preferentially binds to insulin-like growth
factor-II (IGF-II) with cross-reactivity to IGF-I,
useful in preparing a medicament for treating
e.g., malignant tumor
ASTRAZENECA AB
ASTRAZENECA GLOBAL INTELLECTUAL
PROPERTY
AMGEN FREMONT INC
The process is useful for the preparation of (I),
NOVELTY: Preparation of a food composition (I) which is useful for nutritional and/or organoleptical
comprises: contacting hydrocolloids with water to consumption by an animal of the order carnivora
prepare a colloidal solution; contacting the colloid such as feline, canine (claimed), a fish, a bird,
parrots, ducks, geese, chickens, turkeys,
solution with food ingredients; and allowing the
ostriches, a reptile or a mammal (non-human
resulting mixture to form a solid mass having a
mammals such as monkeys, chimpanzees),
gelatinous texture.
companion and working animals (e.g. horses),
farm animals (e.g. [CONT.]
DETAILED DESCRIPTION: An INDEPENDENT
CLAIM is included for: the food composition
comprising food ingredients, the hydrocolloid and
water (50-90 wt.%). [CONT.]
EP 1947959
A1
20080730
AU 2006304915
A1
20070426
CN 101291591
A
20081022
US 20080299251
A1
20081204
JP 2009512442
T
20090326
CA 2625147
A1
20070426
RU 2390257
C2
20100527
AU 2006304915
B2
20110324
WO 2007072064
WO 2007072064
A2
20070628
WO 2007072064 A2 UPAB: 20070914
A3
20080124
NOVELTY: The production of defatted collagen
paste involves cutting natural collagen derived
from animal, mammal, avian and/or fish skin into
pieces, squeezing the collagen pieces under
pressure to remove fat and to produce defatted
pieces, and finally disintegrating defatted pieces
into fibrous paste.
EP 1962607
A2
20080903
DETAILED DESCRIPTION: An INDEPENDENT
CLAIM is included for process for the production
of an extrudable collagen gel. [CONT.]
US 20090023899
A1
20090122
JP 2009520799
T
20090528
US 7906623
WO 2007076534
B2
20110315
A1
20070705
WO 2007076534 A1 UPAB: 20090222
US 20070178078
A1
20070802
NOVELTY: Balance of beneficial and deleterious
bacteria in gastrointestinal tract of animal having
or at risk of inflammatory bowel disease (IBD) is
enhanced by administering a composition
comprising antioxidant(s).
AU 2006330421
A1
20070705
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are included for the following: [CONT.]
EP 1978821
A1
20081015
CN 101351124
A
20090121
CA 2635038
A1
20070705
JP 2009522311
T
20090611
RU 2008131072
A
20100210
AU 2006330421
B2
20110324
WO 2007070432
US 20070196376
A2
20070621
WO 2007070432 A2 UPAB: 20090205
A1
20070823
NOVELTY: A new isolated fully human specific
binding protein preferentially binds to insulin-like
growth factor-II (IGF-II) with cross-reactivity to
insulin-like growth factor I (IGF-I) and neutralizes
IGF-I and IGF-II activity.
WO 2007070432
A3
20071129
AU 2006326649
A1
20070621
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are included for:
(1) a nucleic acid molecule encoding the specific
binding protein; [CONT.]
The process provides (I), which is nutritionally
and/or organoleptically adapted for consumption
by an animal of the order carnivora such as feline
and canine. (I) has a gelatinous texture (all
claimed) that is less sticky and more easily
removed from the container. (I) allows for easy
mixing with other dry food products.
FOOD - Preferred Process: The process further
An INDEPENDENT CLAIM is included for: the
WO 2007048106
comprises: contacting the hydrocolloids with a fat; food composition comprising food ingredients, the
retorting the solid mass; and contacting the
hydrocolloid and water (50-90 wt.%).
mixture of food ingredients and colloidal solution
with enzyme. The food ingredients are mixed
before contacting the food ingredients with the
colloidal solution. The mixture formed by
contacting the food ingredients with the colloidal
solution is further contacted with a source of
calcium, preferably calcium chloride [CONT.]
US 20080299251
For producing extrudable collagen gel used in
The method enables production of defatted
production of collagen products (claimed), such as collagen with reduced fat content, and enables
sausage casings and films.
production of collagen gel and collagen products
with improved mechanical properties.
FOOD - Preferred Source: The collagen source
comprises pig skin or pig rind. The natural
collagen is porcine collagen derived from sheep,
poultry, birds or fish. Preferred Method: The
production of extrudable collagen gel involves
swelling defatted collagen paste, followed by
adding alginate glycol, humectant, cellulose or
coagulating agent.
An INDEPENDENT CLAIM is included for process WO 2007072064
for the production of an extrudable collagen gel.
US 20090023899
US 7906623
In pharmaceuticals and foodstuffs (claimed) for
increasing level of beneficial bacteria such as
Lactobacillus sp. and Bifidobacterium sp., and
decreases level of deleterious bacteria such as
Clostridium sp., Desulfovibrio sp., Helicobacter sp.
and pathogenic forms of Escherichia coli. Cats
diagnosed with inflammatory bowel disease were
fed with feed containing tocopherol (221
micrograms/g), vitamin C (87 micrograms/g) and
beta-carotene (0 [CONT.]
PHARMACEUTICALS - Preferred Component:
The antioxidant comprises vitamin E, vitamin C
and carotenoid. Preferred Amounts: The
composition such as food, supplement, snack,
treat, or partially edible toy contains (in
micrograms) vitamin E (50-1000, preferably 100800), vitamin C (30-400, preferably 50-200) and
beta-carotene (0.1-5, preferably 0.2-2) per gram of
food on a dry matter basis consumed by animal
[CONT.]
INDEPENDENT CLAIMS are included for the
WO 2007076534
following:
(1) use of antioxidant in preparation of a
composition for enhancing the balance of
beneficial and deleterious bacteria in the
gastrointestinal tract of an animal having or at risk
for IBD;
US 20070178078
The method effectively enhances balance of
beneficial and deleterious bacteria in
gastrointestinal tract of animal having or at risk of
inflammatory bowel disease.
N
(2) food composition comprising above-mentioned
composition;
(3) kit comprising the above-mentioned
composition, prebiotic, base food, an anti-IBD
agent and instructions for administering the
antioxidant-containing composition; and [CONT.]
The specific binding protein is useful in preparing
a medicament for treating a growth factordependent disease comprising osteoporosis,
diabetes or cardiovascular diseases or a
malignant tumor consisting of melanoma, nonsmall cell lung cancer, glioma, hepatocellular
(liver) carcinoma, thyroid tumor, gastric (stomach)
cancer, prostrate cancer, breast cancer, ovarian
cancer, bladder cancer, lung [CONT.]
BIOTECHNOLOGY - Preferred Protein: The
specific binding protein binds to IGF-II with at least
2.5 times greater affinity than to IGF-I. The binding
protein has an EC50 of no more than 15 nM for
inhibiting IGF-I-dependent IGF-I receptor
phosphorylation in NIH3T3 cells expressing IGF1R ectopically. The binding protein has an EC50
of no more than 5 nM for inhibiting IGF-IIdependent IGF-I receptor phosphorylation in
NIH3T3 cells expressing IGF-1R ectopically
[CONT.]
INDEPENDENT CLAIMS are included for:
(1) a nucleic acid molecule encoding the specific
binding protein;
(2) a vector comprising the nucleic acid molecule;
(3) a host cell comprising the vector;
WO 2007070432
US 20070196376
N
310 New monoclonal antibody that inhibits
aggregation of the A-beta monomers to high
molecular polymeric fibrils, useful for
preventing, treating, or ameliorating diseases
such as neurological disorders, e.g.
Alzheimer's Disease
EP 1979001
A2
20081015
(4) a method of determining the level of insulin-like
growth factor-II (IGF-II) and insulin-like growth
factor I (IGF-I) in a patient sample;
IN 2008MN01367
A
20081017
(5) a method of treating a malignant tumor or a
growth factor-dependent disease in a mammal;
and [CONT.]
TW 2008001040
A
20080101
KR 2008089592
A
20081007
CA 2633956
A1
20070621
JP 2009519711
T
20090521
MX 2008007688
A1
20080930
CN 101495141
A
20090729
ZA 2008004925
A
20091125
RU 2008128355
A
20100120
SG 167857
A1
20110128
AU 2006326649
B2
20110324
20070621
GREFERATH R
WO 2007068412
US 20070166311
A2
A1
20070719
HICKMAN D
EP 1959996
A2
20080827
MUHS A
AU 2006326284
A1
20070621
NICOLAU C
CN 101325972
A
20081217
PFEIFER A
KR 2008089596
A
20081007
NO 2008002134
A
20080710
JP 2009519708
T
20090521
CA 2632822
A1
20070621
TW 2007032348
A
20070901
MX 2008007477
A1
20080930
IN 2008CN02922
A
20090306
US 20100098707
US 7772375
A2
20100422
B2
20100810
JP 2010187674
A
20100902
US 20100297132
A1
20101125
RU 2008128139
A
20100120
VN 22402
A
20100426
US 20110070613
WO 2007053574
WO 2007053574
A1
20110324
A2
20070510
A3
20080313
EP 1968589
US 20090068146
A2
20080917
A1
20090312
JP 2009513707
T
20090402
CA 2627875
A1
20070510
EP 2289515
WO 2007053943
A2
20110302
A1
20070518
AC IMMUNE SA
311 Treatment of cancer in mammalian subject or BAYER PHARM CORP
derived cell, by administering interferon and 4- BAYER HEALTHCARE LLC
(4-((((4-Chloro-3-(trifluoromethyl)
phenyl)amino)carbonyl)amino)phenoxy)- Nmethylpyridine-2- carboxamide tosylate in the
polymorph II (Sorafenib)
WILHELM S
312 Supplemental dietary composition for
increasing muscle mass and muscle
MULTI FORMULATIONS LTD
WO 2007068412 A2 UPAB: 20090212
The composition is useful in the treatment of
diseases and disorders, which are caused by or
NOVELTY: A monoclonal antibody comprising
associated with amyloid or amyloid-like proteins.
functionally equivalent antibody or functional
parts, where the antibody, upon co-incubation with The monoclonal antibody and/or a functional part
and/or pharmaceutical composition or mixture is
amyloid monomeric peptides, particularly betauseful for the preparation of a medicament for
amyloid monomeric peptides inhibits the
treating or alleviating the effects of diseases and
aggregation of the Abeta monomers to high
disorders which are caused by or associated with
molecular polymeric fibrils, is new. [CONT.]
amyloid or [CONT.]
WO 2007053574 A2 UPAB: 20070727
BIOTECHNOLOGY - Preparation (claimed):
Producing an antibody comprising functionally
equivalent antibody or functional parts comprises
raising in a host organism antibodies, particularly
monoclonal antibodies against a supramolecular
antigenic construct comprising an antigenic
peptide corresponding to the amino acid
sequence of the beta-amyloid peptide, particularly
of beta-amyloid peptide modified [CONT.]
The method is used for treating cancer (e.g.
cancers of breast, respiratory tract, brain,
NOVELTY: Cancer in a mammalian subject or a
reproductive organs, digestive tract, urinary tract,
derived cell is treated by administering an
eye, liver, skin, head and neck, thyroid,
interferon alpha-2a and 4-(4-((((4-Chloro-3(trifluoromethyl)phenyl)amino)carbonyl)amino)phe parathyroid, and their distant metastases) in a
noxy)- N-methylpyridine-2-carboxamide tosylate in mammalian subject or a derived cell. It may be
the polymorph II (Sorafenib) or 4-(4-((((4-chloro-3- used in modulating angiogenesis and/or
lymphangiogenesis in cells.
(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)- N-methylpyridine-2carboxamide tosylate in the polymorph I
(Sorafenib). [CONT.]
The method ameliorates, prevents, or modulates
cancer in humans and other mammals. The
compound inhibits angiogenesis and/or
lymphangiogenesis, e.g. the formation of new
blood vessels.
WO 2007053943 A1 UPAB: 20070719
The supplemental dietary composition regulates
molecular signals to control anabolic and anti-
For increasing muscle mass and muscle
performance.
A monoclonal antibody comprising functionally
WO 2007068412
equivalent antibody or functional parts, where the
antibody, upon co-incubation with amyloid
monomeric peptides, particularly beta-amyloid
monomeric peptides such as Abeta monomeric
peptides 1-39, 1-40, 1-41, 1-42, or 1-43, but
especially Abeta-1-42 monomeric peptides inhibits
the aggregation of the Abeta monomers to high
molecular polymeric fibrils by at least 50-90%, or
more as compared to the respective amyloid
peptide monomers incubated in buffer (control), is
new. [CONT.]
US 20070166311
US 20100098707
WO 2007053574
US 20090068146
N
WO 2007053943
US 20070117867
N
INSTRUMENTATION AND TESTING - Preferred INDEPENDENT CLAIMS are included for:
Method: The method of forming the kit, comprises
N
US 7772375
US 20100297132
US 20110070613
312 Supplemental dietary composition for
increasing muscle mass and muscle
IOMEDIX SLEEP INT SRL
performance, contains monobasic amino acid,
and ketoacid(s) or its salt
US 20070117867
A1
20070524
NOVELTY: A supplemental dietary composition
comprises a monobasic amino acid; and
ketoacid(s) or its salt.
CHAUDHURI S
US 20070196348
A1
20070823
CLEMENT K
US 20070202165
A1
20070830
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are included for:
(1) a method of regulating molecular signals to
control anabolic activity in skeletal muscles or to
control anti-catabolic activity in skeletal muscle,
comprising the use of a combination of a
monobasic amino acid and a ketoacid to regulate
the molecular signals to control the anabolic
activity or anti-catabolic activity in the skeletal
muscles; [CONT.]
GARDINER P T
US 20070264337
US 7476405
A1
20071115
HEUER M
B2
20090113
HEUER M A
CA 2628265
A1
20070518
RAMSBOTTOM J
US 7906154
WO 2007047459
EP 1945780
B2
20110315
A1
20070426
A1
20080723
US DEPT HEALTH&HUMAN SERVICES
313 New vector system comprises a first vector
comprising a full-length rabies virus
US DEPT HEALTH & HUMAN SERVICES
antigenomic DNA, and helper vectors, useful
for producing recombinant rabies virus useful
as vaccines against rabies infection
For increasing muscle mass and muscle
performance.
The supplemental dietary composition regulates
molecular signals to control anabolic and anticatabolic activity in skeletal muscle. The
composition stimulates muscle growth, increases
muscle mass, decreases muscle catabolism and
associated muscle and weight loss, increases
performance, decreases recovery time, improves
body composition, treats muscle wasting and/or
degeneration, and/or provides a beneficial effect
by influencing the genetic control system for
global protein synthesis [CONT.]
INSTRUMENTATION AND TESTING - Preferred
Method: The method of forming the kit, comprises
administering the kit for stimulating muscle
growth, for increasing muscle mass, for increasing
muscular performance, for decreasing recovery
time, for regulating molecular signals to control
anabolic activity in skeletal muscles or to control
anti-catabolic activity in skeletal muscles, and for
regulating the genetic control system for somatic
protein synthesis [CONT.]
WO 2007053943
(1) a method of regulating molecular signals to
control anabolic activity in skeletal muscles or to
control anti-catabolic activity in skeletal muscle,
comprising the use of a combination of a
monobasic amino acid and a ketoacid to regulate
the molecular signals to control the anabolic
activity or anti-catabolic activity in the skeletal
muscles; [CONT.]
US 20070202165
US 20070264337
US 7476405
US 7906154
WO 2007047459 A1 UPAB: 20070719
The vector system is useful for producing
NOVELTY: A vector system comprising: (a) a first recombinant rabies virus useful as vaccines
against rabies infection.
vector comprising a full-length rabies virus
antigenomic DNA, where the full-length
antigenomic DNA is selected from a full-length
rabies virus antigenomic DNA or a derivative; and
(b) helper vectors comprising nucleic acids that
encode at least one rabies virus strain EvelynRokitnicki-Abelseth (ERA) protein, where
expression of the vectors in a transfected host cell
results in production of a recombinant rabies virus,
is new. [CONT.]
BIOTECHNOLOGY - Preferred Vector System: In
the vector system above, the full-length
antigenomic DNA comprises an ERA strain
antigenomic DNA or a derivative. The full-length
antigenomic DNA is selected from fully defined
10288-13556 bp (SEQ ID NO. 8-18) given in the
specification. Preferably, the vectors are plasmids.
The first vector comprises in a 5' to 3' direction: a
hammerhead ribozyme; [CONT.]
INDEPENDENT CLAIMS are:
IN 2008DN03390
A
20080815
(2) a recombinant virus comprising the genome;
US CENTERS DISEASE&PREVENTION
US 20080274130
A1
20081106
(3) a live rabies vaccine comprising at least one
recombinant rabies virus genome, where the
recombinant rabies genome comprising 1193013150 bp (SEQ ID NO. 8, 10, or 13) given in the
specification; [CONT.]
AU 2006304268
A2
20070426
AU 2006304268
A1
20070426
CN 101287838
A
20081015
CA 2624768
A1
20070426
MX 2008004860
A1
20080831
US 7863041
US 20110070264
WO 2007046441
B2
20110104
A1
20110324
A1
20070426
WO 2007046441 A1 UPAB: 20090619
JP 2007110914
A
20070510
NOVELTY: Pet food (C1) comprises fats and oils
containing diacyl glycerol (at least 20 wt.%), and
carbohydrate source of modified starch, barley,
sorghum, corn or high amylase starch.
JP 2007110915
A
20070510
ACTIVITY: Anorectic.
JP 2007110916
A
20070510
The anorectic effect of the pet food comprising
fats and oils (20 wt.% or more of diacyl glycerol
and modified starch) was evaluated using obese
male beagle dogs. [CONT.]
JP 2007135586
A
20070607
EP 1946651
US 20090148560
A1
20080723
A1
20090611
(C1) Is useful for preventing or suppressing
obesity.
(C1) Is excellent in obesity preventive or reducing FOOD - Preferred Components: (C1) Further
effect without reducing the food intake and has
comprises maltooligosaccharide and lactic acid
less influence on the conditions of feces.
bacteria. The maltooligosaccharide is a substance
of glucose having a degree of polymerization of 47. The amount of maltooligosaccharide is 20 wt.%
in the whole amount of sugar. The lactic acid
bacteria are Enterococcus. The fats and oils
contain omega-3 unsaturated fatty acid (at least
2.5 wt. [CONT.]
WO 2007047459
(1) a recombinant virus genome comprising fully
defined 11931 or 12266 bp (SEQ ID NO. 1, 7)
given in the specification, or its derivative;
US GOVERNMENT
KAO CORP
314 Pet food, useful for treating obesity in pet
animals, comprises preset amounts of fats and
oils containing diacyl glycerol, and
carbohydrate source of modified starch,
barley, sorghum, corn or high amylase starch
US 20070196348
US 20080274130
US 7863041
US 20110070264
WO 2007046441
US 20090148560
N
NESTEC SA
315 Pet food composition or dietary supplement
for improving cognitive function in animal, e.g. REYNOLDS A J
dog or cat, comprises long chain
polyunsaturated fatty acids
WALDRON M K
316 Treating pancreatic disease comprises
administering to a mammal an amount of an
agent, e.g. antibody or an antibody fragment
that selectively binds a synaptic adhesion
molecule, e.g. neuroligin 1
UNIV CALIFORNIA
317 Preparation of 4-hydroxy-5,6-dihydro-pyran-2- PFIZER INC
one derivatives used to treat hepatitis-C virus
infection involves treating pyran-2,4-dione
derivatives with (1,2,4)triazolo(1,5-a)pyrimidine2-carbaldehyde
EP 1946651
WO 2007041418
EP 1928552
B1
20110323
A2
20070412
WO 2007041418 A2 UPAB: 20070604
A2
20080611
IN 2008DN02318
A
20080523
NOVELTY: A pet food composition or dietary
supplement comprises long chain polyunsaturated
fatty acids (LCPUFA).
ACTIVITY: Nootropic.
AU 2006299665
A1
20070412
CN 101277739
A
20081001
MX 2008004210
A1
20080430
JP 2009510117
T
20090312
For improving cognitive function in an animal, e.g. The composition improves problem solving,
dog or cat (claimed).
memory retention, and mental stability.
ORGANIC CHEMISTRY - Preferred Material: The
LCPUFA includes n-6 LCPUFA such as
arachidonic acid (AA) or linoleic acid; and n-3
LCPUFA such as eicosapentaenoic acid (EPA),
docosapentaenoic acid (DPA), or preferably
docosahexaenoic acid (DHA). Preferred
Composition: The LCPUFAs are present in an
amount of 0.1-10 (preferably 0.4-5) wt.% of the
composition.
The methods are useful for treating a pancreatic
disease selected from diabetes (e.g. autoimmune
diabetes mellitus) or pancreatic cancer (claimed).
BIOTECHNOLOGY - Preferred Method: In treating
a pancreatic disease, the synaptic adhesion
molecule is selected from neuroligin 1, neuroligin
2, neuroligin 3, neuroligin 4X, neuroligin 4Y,
neurexin 1alpha, neurexin 2alpha, neurexin
3alpha, neurexin 1beta, neurexin 2beta, neurexin
3beta, SynCam, Thy-l, or neuronal pentrexin. It is
also a fragment, analog, or derivative of a synaptic
adhesion molecule [CONT.]
Puppies received daily supplements of DHA and
AA at 1% and 2% of total fatty acid content of their
basal diet. Puppies were weighed weekly, the
weights recorded, and the dosage of supplements
adjusted accordingly. [CONT.]
US 20090203786
A1
20090813
ZA 2008003712
A
20090930
RU 2413427
C2
20110310
WO 2007019406
A2
20070215
WO 2007019406 A2 UPAB: 20090213
EP 1909836
A2
20080416
AU 2006278386
A1
20070215
JP 2009503116
T
20090129
US 20090068199
A1
20090312
NOVELTY: Treating a pancreatic disease
comprises administering to a mammal an amount
of an agent that selectively binds a synaptic
adhesion molecule.
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are also included for:
(1) a method for detecting a cell expressing a
synaptic adhesion molecule;
(2) a method for treating autoimmune diabetes
mellitus; [CONT.]
CA 2617807
A1
20070215
WO 2007019406
US 7906104
WO 2007023381
A3
20090430
B2
20110315
A1
20070301
WO 2007023381 A1 UPAB: 20090212
JP 2007056022
A
20070308
NOVELTY: Preparation of substituted 4-hydroxy5,6-dihydro-pyran-2-one derivatives involves
treating pyridine derivative with an anion to form
substituted pyridine derivative; hydrolyzing the
substituted pyridine derivative; treating the formed
compound with a combination of reagents to form
corresponding protected pyridine derivative;
treating the protected pyridine derivative with an
acid or base to form corresponding substituted
pyridine derivative; and treating the derivative with
(1,2,4)triazolo(1,5-a)pyrimidine-2-carbaldehyde.
[CONT.]
AU 2006283297
A1
20070301
EP 1928878
A1
20080611
IN 2008DN01288
A
20080620
KR 2008038354
A
20080506
US 20090023921
A1
20090122
CA 2619077
A1
20070301
CN 101426793
A
20090506
TW 2007040817
A
20071101
ZA 2008000821
A
20090729
TW 2009042546
A
20091016
TW 316516
B1
20091101
SG 163629
A1
20100830
US 7807838
B2
20101005
RU 2401268
C2
20101010
INDEPENDENT CLAIMS are also included for:
WO 2007041418
US 20090203786
WO 2007019406
US 20090068199
(1) a method for detecting a cell expressing a
synaptic adhesion molecule;
N
US 7906104
(2) a method for treating autoimmune diabetes
mellitus;
(3) a method for identifying an agent that binds a
synaptic adhesion molecule;
(4) a method for isolating a beta islet cell;
(5) a kit for detecting a synaptic adhesion
molecule, the kit comprising an agent that binds
the synaptic adhesion molecule; and [CONT.]
In the preparation of substituted 4-hydroxy-5,6dihydro-pyran-2-one derivatives (claimed) useful
as hepatitis-C virus polymerase inhibitors in the
treatment of mammal suffering from infection with
hepatitis C virus.
The compounds prepared by the method are
potent HCV RdRp inhibitors having desirable or
improved physical and chemical properties
appropriate for pharmaceutical application. The
compounds prepared by the method exhibits
improved efficacy and reduced side-effect profile.
The method provides the compound in higher
yield.
INORGANIC CHEMISTRY - Preferred
Components: The chiral, non-racemic base is a
chiral, non-racemic amine. The non-racemic
amine is cis-1-amino-2-indanol, cinchonidine, 1aminoindane, tert-leucinol, 2-amino-1,2diphenylethanol, alpha-methylbenzylamine, or 2amino-1-(4-nitrophenyl)-1,3-propanediol. [CONT.]
Preparation of substituted 4-hydroxy-5,6-dihydro- WO 2007023381
pyran-2-one derivatives of formula (Ia) involves
treating pyridine derivative of formula (V) with an
anion of formula H3C-C(=O)-OR13 (X) to form
substituted pyridine derivative of formula (IV);
hydrolyzing the substituted pyridine derivative (IV)
to form (IV) (in which R13 is H); treating the
formed compound with a combination of reagents
to form corresponding protected pyridine
derivative of formula (III) [CONT.]
US 20090023921
US 7807838
US 20110070187
N
318 Novel chimeric protein comprising a portion of CHILDRENS HOSPITAL INC
non-typeable Haemophilus influenzae (NTHi)
NATIONWIDE CHILDREN'S HOSPITAL INC
twitching plus major subunit protein and a
portion of the LB1 peptide, useful as vaccine
for treating or preventing NTHi bacterial
infection
JIATEFU BIOLOGY SCITECH CO LTD
319 Composition, useful for preventing and
treating cardiovascular disorders, comprises a
lactoferrin; and a trivalent chromium
compound, where trivalent chromium
compound is e.g. chromium (III) chloride
hexahydrate and chromium (III) chloride
MAXLUCK BIOTECHNOLOGY CORP
320 Food composition useful for the prevention
and treatment of kidney disease comprises at
least one food ingredient containing relatively
low amounts of protein, sodium, and
potassium
HILLS PET NUTRITION INC
NZ 565496
A
20101029
US 20110070187
WO 2007008527
A1
20110324
A2
20070118
WO 2007008527 A2 UPAB: 20070417
EP 1904519
A2
20080402
NOVELTY: A chimeric protein comprising a
portion of non-typeable Haemophilus influenzae
(NTHi) twitching plus major subunit protein (PilA)
and a portion of the LB1 peptide, is new.
CA 2613970
A1
20070118
US 20080311110
A1
20081218
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are included for the following:
(1) a polynucleotide encoding the chimeric protein;
JP 2009500037
T
20090108
JP 2010172332
A
20100812
US 7811591
EP 1904519
B2
20101012
B1
20101117
DE 602006018308
E
20101230
EP 2298794
US 20070010426
A2
20110323
A1
20070111
US 20070010426 A1 UPAB: 20070402
BR 2006001290
A
20070306
NOVELTY: A composition (I), useful for preventing The ability of (I) to prevent and treat
and treating cardiovascular disorders, comprising cardiovascular disorder was tested in mouse.
a lactoferrin, and a trivalent chromium compound, [CONT.]
where the trivalent chromium compound is
chromium (III) chloride hexahydrate, chromium
(III) chloride, chromium (III) acetate, chromium (III)
sulfate, chromium picolinate, chromium nicotinate,
inorganic salts of trivalent chromium and/or
organic salts of trivalent chromium, is new.
[CONT.]
DE 102006012263
A1
20070118
FR 2888750
GB 2428007
A1
20070126
A
20070117
JP 2007016012
A
20070125
AU 2006201157
A1
20070125
NL 1032065
C2
20070309
KR 2007005494
A
20070110
IN 2006KO00230
A
20070803
AU 2006201157
B2
20071213
TW 276442
B1
20070321
TW 2007001987
A
20070116
CH 698459
B1
20090814
GB 2428007
B
20100602
IT 1374695
B
20100517
FR 2888750
WO 2007002836
B1
20110304
A2
20070104
The chimeric protein is useful for eliciting an
immune response to NTHi bacteria. The antibody
is useful for treating or preventing NTHi bacterial
infection. The NTHi infection occurs in the middle
ear (both claimed). The chimeric protein is useful
as vaccine for treating or preventing NTHi
bacterial infection.
BIOTECHNOLOGY - Preparation: The chimeric
protein is prepared by standard recombinant
methods (disclosed). Preferred Protein: The LB1
peptide portion comprises B-cell epitope of the
LB1 peptide. The portion of the LB1 peptide
comprises SEQ ID No. 4-8. The chimeric protein
comprises one of 24 fully defined 130-156 amino
acid sequences (SEQ ID No. 9-32) given in the
specification, and a fully defined 129, 126, 138 or
144 amino acid sequence (SEQ ID No [CONT.]
(2) a vector comprising the polynucleotide;
[CONT.]
WO 2007002836 A2 UPAB: 20070329
(I) is useful to prevent and treat cardiovascular
(I) is effective to treat and prevent cardiovascular
disorders of an acceptor (claimed). (I) is useful to: disorders.
enhance the normal metabolism of fat,
carbohydrates and protein; and reduce level of
blood lipids and inflammation factors.
For preventing or treating kidney disease in a
patient (e.g. canine or a feline) (claimed).
The composition do not cause undesirable weight
loss and muscle wasting for preventing and
treating kidney disease; decreases the morbidity
and mortality for patients susceptible to or
suffering from kidney diseases.
INDEPENDENT CLAIMS are included for the
WO 2007008527
following:
(1) a polynucleotide encoding the chimeric protein;
US 20080311110
N
US 7811591
(2) a vector comprising the polynucleotide;
(3) an antibody that specifically binds to the
chimeric protein;
(4) a composition comprising the chimeric protein
or antibody and a carrier;
(5) eliciting an immune response to NTHi bacteria,
involves administering an immunogenic dose of
the chimeric protein to a patient at risk of NTHi
bacterial infection; and [CONT.]
FOOD - Preferred Components: The lactoferrin
comes from unpurified milk or whey protein,
preferably cow milk lactoferrin, goat milk
lactoferrin, unpurified cow milk and/or unpurified
goat milk. (I) serves as an additive of a dairy
product, which is fresh milk of mammals, long-life
milk, concentrated milk, fermented milk, cheese or
milk powder. [CONT.]
US 20070010426
FOOD - Preferred Components: The food is a
INDEPENDENT CLAIMS are included for the
canned moist food or a dry food.
following:
INSTRUMENTATION AND TESTING - Preferred
Device: The device for communicating comprises
a displayed web site or a brochure, product label,
package insert, advertisement, or visual display
containing such information or instructions.
ORGANIC CHEMISTRY - Preferred Composition:
The composition (c1) comprises (wt. [CONT.]
WO 2007002836
US 20070010426
N
US 20090197804
and treatment of kidney disease comprises at
least one food ingredient containing relatively
low amounts of protein, sodium, and
potassium
patient (e.g. canine or a feline) (claimed).
HILL'S PET NUTRITION INC
EP 1896070
A2
20080312
NOVELTY: A food composition (c1) comprises at
least one food ingredient containing relatively low
amounts of protein, sodium, and potassium.
FRIESEN K G
AU 2006263651
A1
20070104
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are included for the following: [CONT.]
YAMKA R M
WO 2007002836
A3
20080912
CA 2613788
A1
20070104
JP 2009500017
T
20090108
CN 101365351
A
20090211
BOSTON SCI SCIMED INC
321 Device for controlling release of therapeutic
agent in systemic/localized treatment of
mammals, has implantable/insertable medical SCHWARZ M C
device, release layer containing non-graft, nonblock styrene copolymer, and therapeutic
agent
US 20090197804
A1
20090806
AU 2006263651
B2
20100909
RU 2412608
C2
20110227
JP 2011051988
A
20110317
US 20070003599
A1
20070104
US 20070003599 A1 UPAB: 20070329
US 7901702
B2
20110308
NOVELTY: The therapeutic agent releasing
medical device has an implantable or insertable
medical device, a release layer containing nongraft, non-block styrene copolymer selected from
an alternating styrene copolymer and a random
styrene copolymer and an additional polymer
disposed over the device, and a therapeutic
agent.
loss and muscle wasting for preventing and
treating kidney disease; decreases the morbidity
and mortality for patients susceptible to or
suffering from kidney diseases.
For releasing therapeutic agent in patients
The novel implantable or insertable medical
(claimed) useful in systemic treatment or localized device provides control release of therapeutic
treatment of mammalian tissue or organ.
agent.
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are also included for the following:
[CONT.]
SEKISUI CHEM CO LTD
322 Inducing humoral immune response with
respect to antigenic protein e.g. cancer
SEKISUI PLASTICS CO LTD
antigen in an animal, comprises administering
fused gene of gene encoding antigen protein
attached to another gene encoding chaperonin
subunit to animal
WO 2006041157
EP 1811026
A1
20060420
WO 2006041157 A1 UPAB: 20090222
A1
20070725
NOVELTY: A method (M1) of inducing a humoral
immune response with respect to an antigenic
protein in an animal, comprises administering to
the animal, a fused gene composed of a gene
encoding all or a part of the antigen protein
attached to another gene encoding a chaperonin
subunit or a chaperonin subunit ligation.
SEKISUI CHEM IND CO LTD
AU 2005292852
A1
20060420
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are included for: [CONT.]
CHIBA J
KR 2007073908
A
20070710
FURUTANI M
JP 2006540983
X
20080522
HATA J
US 20090041761
A1
20090212
NISHIGUCHI N
AU 2005292852
B2
20110203
CHIBA T
JP 2011032276
A
20110217
JP 4644680
B2
20110302
WO 2006132752
A1
20061214
ELAN PHARMA INT LTD
323 Nanoparticulate vitamin K2 composition for
treating osteoporosis comprises particles of a
vitamin K2 having a specified average particle
size and surface stabilizer (b)
WO 2006132752 A1 UPAB: 20090619
canned moist food or a dry food.
INSTRUMENTATION AND TESTING - Preferred
Device: The device for communicating comprises
a displayed web site or a brochure, product label,
package insert, advertisement, or visual display
containing such information or instructions.
ORGANIC CHEMISTRY - Preferred Composition:
The composition (c1) comprises (wt. [CONT.]
MECHANICAL ENGINEERING - Preferred Device:
The implantable or insertable medical device is
catheter, guide wire, balloon, filter, stent, stent
graft, vascular graft, vascular patch, shunt and/or
intraluminal paving system, for implantation or
insertion into the coronary vasculature, peripheral
vascular system, esophagus, trachea, colon,
biliary tract, urinary tract, prostate or brain.
[CONT.]
(1) preparation of the food composition (c1)
suitable for preventing or treating renal disease
involving: mixing the food composition (c1) and at
least one supplements containing sufficient
protein, sodium, or potassium to produce the food
composition containing relatively low amounts of
protein, sodium, and potassium when the
supplement(s) are mixed with the food
composition containing extremely low amounts of
one or more of protein, sodium, and potassium;
[CONT.]
INDEPENDENT CLAIMS are also included for the US 20070003599
following:
(1) formation of therapeutic agent releasing
medical device;
US 20070003599
N
US 7901702
(2) method of releasing therapeutic agent in a
patient; and
(3) method of modulating a rate of release of
therapeutic agent by release layer.
BIOTECHNOLOGY - Preferred Method: In method INDEPENDENT CLAIMS are included for:
WO 2006041157
(M1), the chaperonin subunit or chaperonin
(1) a composition for immunizing an animal,
subunit ligation is derived from Escherichia coli.
comprising the fused gene as a main component;
The fused gene is integrated in expression vector
and the expression is controlled by the promoter
of the expression vector. The promoter is a
cytomegalovirus (CMV) promoter, adenovirus
major late (AML) promoter, Simian virus 40
(SV40) promoter, SRalpha promoter and
elongation factor-1 (EF-1)alpha promoter [CONT.]
(2) producing an antibody, comprising immunizing
the animal and inducing humoral immune
response in the animal by method (M1) and
extracting the antibody from the animal; [CONT.]
For inducing humoral immune response with
respect to antigenic peptides in an animal such as
mammals e.g. mouse, rat, rabbit, cow, horse, dog,
cat, goat, sheep or pig, or birds e.g. hen, duck or
turkey. The antigenic peptide is G-protein coupled
receptor (GPCR), tyrosine kinase receptor, CD
antigen, cell adhesion molecule, cancer antigen,
cytokine, growth factor, proliferation factor,
nutritive factor, viral antigen, bacterial antigen or
toxic antigen (all claimed) [CONT.]
For preventing and/or treating osteoporosis
(claimed).
The nanoparticulate vitamin K2 particles have
improved bioavailability as compared to
conventional vitamin K2 tablets. The composition
does not produce significantly different absorption
levels when administered under fed as compared
to fasting conditions. The pharmacokinetic profile
of the composition is not significantly affected by
the fed or fasted state of a patient ingesting the
composition. [CONT.]
PHARMACEUTICALS - Preferred Composition:
INDEPENDENT CLAIMS are included for the
The composition (C1) is formulated into a dosage following:
form selected from tablets, capsules, sachets,
solutions, gels, aerosols, ointments, creams
and/or dispersions and/or into a dosage form
selected from controlled release formulations, fast
melt formulations, lyophilized formulations,
delayed release formulations, extended release
formulations, pulsatile release formulations, or
WO 2006132752
US 20090041761
N
US 20110064803
N
size and surface stabilizer (b)
JP 2008540550
T
20081120
NOVELTY: A stable nanoparticulate vitamin K2
composition comprises: particles (a) of a vitamin
K2 having an effective average particle size of
less than 2000 nm; and at least one surface
stabilizer (b).
US 20110064803
A1
20110317
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are included for the following: [CONT.]
EP 1745703
A1
20070124
EP 1745703 A1 UPAB: 20100202
DE 102005034568
A1
20070201
BRAUSS M
US 20070020355
A1
20070125
SCHLEBUSCH J P
AU 2006203071
A1
20070208
WASSERFUHR U
EP 1745703
B1
20080402
DE 502006000558
G
20080515
US 7651708
B2
20100126
AU 2006203071
B2
20110317
JP 2006345830
A
20061228
JP 4640799
B2
20110302
324 Production of animal feed with core and shell, MARS INC
e.g. for cats and dogs, involves mixing,
BEZENAC E D
optionally baking and chopping core materials
including meat and humectant, applying shell
by dusting coating, cooking and conditioning
KAO CORP
325 Pet e.g. dog, excrement treatment material
contains mass percentages of ground plantderived raw material, synthetic resin, and tecto
silicate e.g. zeolite
The product is animal feed (claimed), which can
be used for various animals, preferably cats and
NOVELTY: In producing animal feed with core
(partly) covered by shell, starting materials include dogs.
(parts weight, pw) core 20-100 pw meat and/or
similar and 1-20 pw humectant; shell 20-90 pw
vegetable/animal protein and 10-80 pw cereal
derivative and/or sugar (derivative). [CONT.]
JP 2006345830 A UPAB: 20070212
For treating pet e.g. dog, cat, excrement such as
NOVELTY: The pet excrement treatment material urine, and is preferably placed on top of drain
board in toilet main body.
(1) consists of 70 to 98.99 percent by mass of
ground material obtained from plant-derived raw
material e.g. woody plant or conifer bark, 1 to 20
percent by mass of synthetic resin, and 0.01 to 5
percent by mass of tecto silicate such as zeolite.
does not produce significantly different absorption
levels when administered under fed as compared
to fasting conditions. The pharmacokinetic profile
of the composition is not significantly affected by
the fed or fasted state of a patient ingesting the
composition. [CONT.]
solutions, gels, aerosols, ointments, creams
and/or dispersions and/or into a dosage form
selected from controlled release formulations, fast
melt formulations, lyophilized formulations,
delayed release formulations, extended release
formulations, pulsatile release formulations, or
mixed immediate release and controlled release
formulations [CONT.]
(1) a method of preparing the nanoparticulate
vitamin K2 composition involving contacting the
particles of the vitamin K2 with the surface
stabilizer to provide the composition having
average particle size of less than 2000 nm;
(2) a controlled-release composition (C2)
comprising a population of vitamin K2-containing
particles. [CONT.]
This method of producing animal feed with a core FOOD - Preferred Process: The baking
In the production of animal feed with a core
and (partial) shell is very simple and avoids the
temperature in stages (a1) and/or (b) is about 150- (partly) covered by a shell, the starting materials
need for extrusion of the components. The feed
250degreesC and baking time 1-20 (preferably 2- for the core are (in parts weight, pw) 20-100 pw
maintains a considerable difference in texture
15) minutes. Cold forming is carried out at room
meat and/or meat-like components, 0-30 pw
between the core and shell for long periods (over temperature. Preferred Composition: The core
added water, 0-25 pw oil and/or fat, 0-15 pw
10 months), even if the package is open. It
contains 50-75 pw meat and/or meat-like
vitamins, minerals, salts, antioxidant, colorant
ensures microbiological safety, even if the core
components, 5-10 pw added water, 5-10 pw oil
and/or preservative, 0-15 pw vegetable fibers, 1has a high moisture content, and good oxidation
and/or fat, 5-10 pw vitamins, minerals, salts,
20 pw humectant and 0-8 pw dried animal blood
stability for core material with a high fat content
antioxidant, colorant and/or preservative, 5-10 pw plasma and for the shell [CONT.]
[CONT.]
vegetable fibers, 5-15 pw humectant and 2-7 pw
dried animal blood plasma [CONT.]
Provides excellent water repellent property,
swelling prevention property, and shape retaining
property. Maintains high deodorizing capability.
POLYMERS - The synthetic resin used for the
treatment material is selected from polyolefin,
polyester, polyethylene, polypropylene,
polyethylene terephthalate, polyamide, vinyl tape
resin.
EP 1745703
US 20070020355
US 7651708
JP 2006345830
N
USE: For treating pet e.g. dog, cat, excrement
such as urine, and is preferably placed on top of
drain board in toilet main body. [CONT.]
HOLLIS-EDEN PHARM INC
326 Characterizing steroid compound ability to
increase survival to radiation exposed
HARBOR BIOSCIENCES INC
nonhuman primate, by administering the
compound to subject, comparing effect of
compound on survival rate of exposed treated
subjects with control
WO 2006110172
US 20070014719
A2
20061019
A1
20070118
US 20070077201
EP 1807118
A1
20070405
FRINCKE J M
A2
20070718
READING C L
AU 2005330504
A1
20061019
IN 2007KN01349
A
20070720
AU 2005330504
A2
20061019
AU 2005330504
B2
20101028
AU 2011200199
A1
20110217
B2
20110322
CJ CHEILJEDANG CORP
US 7910755
WO 2006129954
A1
20061207
CJ CORP
KR 2006125971
A
20061207
CHEIL JEDANG CORP
EP 1885850
A1
20080213
KR 744479
B1
20070801
DOWDING C
327 New psicose 3-epimerase, useful for
producing D-psicose used as a dietary or
pharmaceutical addictive
WO 2006110172 A2 UPAB: 20101109
For characterizing the ability of F1C to increase
survival of nonhuman primate that has been
NOVELTY: Characterizing the ability of steroid
exposed to radiation (claimed). For treating or
compound (F1C) to increase survival of
preventing hypercalcemia, Cushing's syndrome,
nonhuman primate that has been exposed to
radiation, involves exposing a group of nonhuman acromegaly, non-islet cell tumor hypoglycemia,
cancer or related hyperproliferation, lung fibrosis,
primates to a radiation dose to obtain exposed
hypertension, emphysema, asthma, sepsis,
subjects and administering F1C to exposed
shock, inflammation, viral infection, endometriosis,
subjects to obtain exposed treated subjects,
congenital heart [CONT.]
determining survival rate of the exposed treated
subjects, and comparing the effect of the F1C on
the survival rate of the exposed treated subjects
with the survival rate of control subjects. [CONT.]
BIOTECHNOLOGY - Preferred Method: The F1C
is not 3beta,17beta-dihydroxyandrost-5-ene, the
comparison compound is 3beta,17betadihydroxyandrost 5-ene and the comparison
treatment protocol is administering once per day
to the nonhuman primates 8-50 mg/kg/day of the
3beta,17beta-dihydroxyandrost-5-ene for 1-10
consecutive days, where the administration of the
3beta,17beta-dihydroxyandrost-5-ene begins
immediately after the radiation exposure or within
15 minutes to 6 hours after the radiation exposure
[CONT.]
Characterizing the ability of formula (1) steroid
WO 2006110172
compound (F1C) to increase survival of
nonhuman primate that has been exposed to
radiation, involves (a) exposing a group of
nonhuman primates to a radiation dose of
LD50/30 or LD60/30 to obtain exposed subjects
and administering F1C to the exposed subjects to
obtain exposed treated subjects, where the
exposed treated subjects are not provided with
[CONT.]
US 20070014719
US 20070077201
US 7910755
WO 2006129954 A1 UPAB: 20071219
The protein and method are useful for producing D- The method of producing D-psicose of the present
psicose (claimed). The D-psicose is used as a
invention is environmental-friendly because an
NOVELTY: A protein having an amino acid
dietary
or
pharmaceutical
addictive.
enzyme derived from a microorganism is used,
sequence of SEQ ID NO: 1, and having an activity
requires a simple process for enzyme
of psicose 3-epimerase, is new.
immobilization, uses a substrate which is cheaper
DETAILED DESCRIPTION: INDEPENDENT
than that used in a conventional method, and is
CLAIMS are included for:
significantly increases the production yield of D(1) a gene encoding a protein which has an amino
psicose thus reducing production costs, while
acid sequence of SEQ ID NO: 1, and has an
maximizing the effect of [CONT.]
activity of psicose 3-epimerase;
BIOTECHNOLOGY - Preferred Method: Producing
D-psicose by reacting the protein above with Dfructose. The protein is a protein product obtained
by culturing a microorganism transformed with the
recombinant expression vector of (2), and isolating
the protein from the culture solution of the
microorganism. The reaction is performed in the
presence of a metal ion selected from
manganese, magnesium, iron, cobalt, or
aluminum [CONT.]
INDEPENDENT CLAIMS are included for:
(1) a gene encoding a protein which has an amino
acid sequence of SEQ ID NO: 1, and has an
activity of psicose 3-epimerase;
(2) a recombinant expression vector containing
the gene; and
(3) producing D-psicose.
WO 2006129954
US 20100190225
N
328 New antibody to myostatin, useful for treating
or preventing disorders, e.g. muscle loss in
wasting diseases, metabolic diseases, or
disorders associated with bone loss
329 New composition comprises sclerostin
polypeptides, useful as vaccines or for
treating, e.g. fibrous dysplasia,
neurofibromatosis, osteogenesis imperfecta,
sclerotic lesions, periodontal disease, or
osteoarthritis
CN 101189332
A
20080528
IN 2008DN00007
A
20080711
JP 2008541753
T
20081127
EP 1885850
B1
20100310
DE 602006012827
E
20100422
US 20100190225
A1
20100729
JP 4648975
B2
20110309
20061102
PFIZER INC
WO 2006116269
US 20060263354
A2
A1
20061123
AGOURON PHARM INC
NL 1031674
C2
20070426
EP 1877075
A2
20080116
NO 2007006061
A
20071126
AU 2006239860
A1
20061102
IN 2007KN04198
A
20080215
CA 2605723
A1
20061102
KR 2008011403
A
20080204
CN 101272802
A
20080924
JP 2008539241
T
20081113
ZA 2007009291
A
20090128
MX 2007013217
A1
20080301
TW 2007024548
A
20070701
NL 2002255
C2
20090924
BR 2006010248
A2
20100608
US 7807159
EP 2295466
WO 2006119062
B2
20101005
A2
20110316
A2
20061109
WO 2006119062 A2 UPAB: 20070109
UCB SA
US 20070072797
A1
20070329
NOVELTY: A composition comprising a
polypeptide comprising any of fully defined 7-26
amino acid sequences (SEQ ID NO. 2-6, 63-73)
given in the specification, is new.
AMGEN INC
AU 2006242476
A1
20061109
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are also included for:
EP 1891100
A2
20080227
(1) a polypeptide comprising truncated human
sclerostin protein of fully defined 190 amino acid
sequence (SEQ ID NO. [CONT.]
CA 2607276
A1
20061109
JP 2009500296
T
20090108
ZA 2007009480
A
20081029
MX 2007013756
A1
20080831
US 20090304713
EP 2251351
A1
20091210
A1
20101117
AMGEN FREMONT INC
UCB PHARMA SA
aluminum [CONT.]
(2) a recombinant expression vector containing
the gene; and [CONT.]
WO 2006116269 A2 UPAB: 20090307
The antibodies, compositions, and methods are
useful for (i) treating or preventing conditions and
NOVELTY: A human, chimeric or humanized
monoclonal antibody or its antigen-binding portion disorders, age-related loss of muscle mass and
strength including muscle atrophy, muscle loss in
that specifically binds to myostatin, where the
wasting diseases, metabolic diseases (e.g.
antibody or portion selectively binds myostatin
diabetes or obesity), or diseases associated with
over GDF11 by at least 50-fold, and where the
antibody or portion inhibits myostatin binding to an bone loss (e.g. [CONT.]
activin type I or type Il receptor, is new.
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are included for: [CONT.]
The compositions and methods are useful for
increasing bone formation, bone mineral density,
bone mineral content, bone quality, or bone
strength. It can also be used for treating
conditions in which an increase in bone formation,
bone mineral density, bone mineral content, bone
quality, or bone strength is desirable. The
composition can also be used as a vaccine.
[CONT.]
BIOTECHNOLOGY - Preferred Monoclonal
INDEPENDENT CLAIMS are included for:
WO 2006116269
Antibody: A monoclonal antibody or its antigen(1) a pharmaceutical composition comprising an
binding portion having at least one property
antibody or its antigen-binding portion above and
selected from (i) competes for binding to
a pharmaceutical carrier;
myostatin with an antibody selected from
1_161_1; 1_136_3; 1_257_1; 1_46_1; 2_112_1;
1_314_1; 1_66_1; 2_43_1; 2_177_1; 1_132_1;
1_268_1; 2_112_K; 1_116_1L-Q45K; 1_257_1LL21I; 1_314_1H-T92A; 1_46_1H-L81M; 2_112_1HI12V; 2_112_1L-F58I [CONT.]
(2) a method which comprises administering to a
subject an antibody or its antigen-binding portion
or the pharmaceutical composition above, where
the antibody, antigen-binding portion or
pharmaceutical composition inhibits myostatin
activity, where the subject is in need of increasing
muscle mass, promoting skeletal muscle
development, treating a muscle wasting disorder
or enhancing skeletal muscle growth; [CONT.]
US 20060263354
US 7807159
BIOTECHNOLOGY - Preferred Composition: The
composition comprises at least 2, 3, or 4 of SEQ
ID NO. 2-5. The composition comprises a
polypeptide having the amino acid sequences of
SEQ ID NO. 2-5, where SEQ ID NO. 2 and 4 are
joined by a disulfide bond at amino acid positions
57 and 111 with reference to SEQ ID NO. 1; and
SEQ ID NO. 3 and 5 are joined by at least one of
(a) a disulfide bond at amino acid positions 82 and
142 with reference to SEQ ID NO [CONT.]
US 20070072797
INDEPENDENT CLAIMS are also included for:
WO 2006119062
(1) a polypeptide comprising truncated human
sclerostin protein of fully defined 190 amino acid
sequence (SEQ ID NO. 1) given in the
specification, where amino acids 1-50, 65-72, 91100, 118-137, and 150-190 of SEQ ID NO. 1 are
absent from the polypeptide;
US 20090304713
(2) a polypeptide comprising truncated human
sclerostin protein of SEQ ID NO. [CONT.]
US 7872106
N
N
330 Cell composition for diagnosing Clostridia
infection e.g. Clostridium botulinum infection,
comprises a membrane-associated Clostridial
toxin substrate, and a membrane-associated
member of a fluorescence resonance energy
transfer pair
ALLERGAN INC
331 Peptide for treatment of cancer, e.g. malignant NOVO NORDISK AS
melanoma, comprises first sequence, i.e.
interleukin-21 variant obtained by deleting
and/or substituting amino acid(s) in specified
region of amino acid sequence
US 7872106
EP 2295448
EP 2298800
WO 2006107921
EP 1869459
B2
20110118
A1
20110316
A1
20110323
A2
20061012
WO 2006107921 A2 UPAB: 20100617
A2
20071226
NOVELTY: A cell composition comprising:
AU 2006231470
A1
20061012
US 20080160561
A1
20080703
CA 2604039
A1
20061012
(a) a membrane-associated Clostridial toxin
substrate having:
(i) a first member of a fluorescence resonance
energy transfer (FRET) pair; and
(ii) a Clostridial toxin recognition sequence
including a cleavage site; and [CONT.]
EP 1869459
B1
20100609
DE 602006014812
E
20100722
EP 2293064
WO 2006111524
A1
20110309
A2
20061026
NO 2007005927
A
20071207
AU 2006237329
A1
20061026
EP 1877439
A2
20080116
(3) a nucleic acid construct encoding the peptide;
IN 2007DN07529
A
20071109
(4) a vector comprising the nucleic acid construct;
CN 101180315
A
20080514
(5) a host comprising the nucleic acid construct or
the vector; and [CONT.]
CA 2604222
A1
20061026
KR 2008013878
A
20080213
JP 2008538290
T
20081023
MX 2007012887
A1
20071201
ZA 2007008407
A
20081029
US 20090035254
A1
20090205
BR 2006009079
A2
20101116
WO 2006111524 A2 UPAB: 20090222
The peptide is for use in therapy. It is used in the
manufacture of a medicament for the treatment of
NOVELTY: A peptide comprising a first sequence cancer from non-metastatic and metastatic
neoplastic disorders such as non-melanoma skin
obtained by deleting and/or substituting amino
acid(s) in the region consisting amino acids 65-96 cancers, renal cell carcinoma, cancer of the head
and neck, cancer of the endocrine system, ovarian
of SEQ ID No. 2, or a sequence obtained by
conservatively substituting up to 10 amino acids in cancer, small-cell lung cancer, non small-cell lung
cancer, breast cancer, esophageal cancer, upper
the first sequence, is new.
gastro-intestinal [CONT.]
The composition enables determination of
Clostridial toxin activity, which can be used to
analyze crude and bulk samples as well as highly
purified dichain, and are amenable to automated
high-throughput formats.
BIOTECHNOLOGY - Preferred Composition: The
cell transiently or stably contains the Clostridial
toxin substrate, being expressed from a nucleic
acid. The substrate comprises a viral expression
construct encoding a Clostridial toxin substrate.
The cell is a neuronal cell or non-neuronal cell.
The neuronal cell is chosen from a primary
neuronal cell, an immortalized neuronal cell and a
transformed neuronal cell [CONT.]
The potency of peptide is greater than or equal
to80% of, or preferably 10 fold higher than the
potency of wildtype IL-21 in the assay(s). The
pharmaceutical formulation comprising the peptide
is stable for more than 6, preferably more than 2
weeks of usage and for more than 3, preferably
more than 2 years of storage.
BIOTECHNOLOGY - Preferred Component: The INDEPENDENT CLAIMS are also included for:
peptide comprises the sequence obtained by
deleting and/or substituting amino acid(s) in the
(1) a pharmaceutical composition comprising a
region consisting amino acids 83-86, 83-88, 83peptide and a cancer agent;
90, 82-88, 77-92, 71-92, 65-92, or 77-96 of SEQ
ID No. 2 (The sequences are published separately
in electronic form and available upon request from
the International Bureau). It is (A) SEQ ID No. 3,
SEQ ID No. 4, SEQ ID No [CONT.]
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are also included for: [CONT.]
EP 1877439
B1
20110209
RU 2412199
C2
20110220
DE 602006020032
E
20110324
WO 2006094269
A2
20060908
US 20060205670
A1
20060914
NOVELTY: A compound (C1) having
antiangiogenic targeting agent and linker
molecule, is new.
DOPPALAPUDI V R
EP 1853294
A2
20071114
LAI J
AU 2006218437
A1
20060908
DETAILED DESCRIPTION: A compound having LAA targeting agent, is new.
AA targeting agent=a peptide chosen from R1-SarGly-Val-(D-alloIle)-Thr-Nva-Ile-Arg-Pro-R3 (SEQ
ID No. 1), R2-Pro-Phe-Val-(D-alloIle)-Thr-Nva-IleArg-Pro-R3 (SEQ ID No. 2), R1-Sar-Gly-Val-(DalloIle)-Thr-Nva-Lys-Arg-Pro-R3 (SEQ ID No
[CONT.]
RIZZO J
KR 2007108958
A
20071114
IN 2007KN03415
A
20080321
US 20080152660
A1
20080626
COVX TECHNOLOGIES IRELAND LTD
332 Novel compound having antiangiogenic
targeting agent and linker molecule, useful for
BRADSHAW C W
treating disease or symptom associated with
angiogenic disorder and angiogenesisdependent condition in mammal e.g. cancer,
arthritis, hypertension
The composition is useful for determining
Clostridial toxin activity, preferably BoNT/A or
BoNT/E activity in a sample. The sample is
chosen from a purified Clostridial toxin, partially
purified Clostridial toxin or unpurified Clostridial
toxin. The sample is chosen from purified
Clostridial toxin light chain, partially purified
Clostridial toxin light chain or unpurified Clostridial
toxin light chain [CONT.]
WO 2006094269 A2 UPAB: 20090509
A cell composition comprises:
WO 2006107921
US 20080160561
WO 2006111524
US 20090035254
N
(a) a membrane-associated Clostridial toxin
substrate having:
(i) a first member of a fluorescence resonance
energy transfer (FRET) pair; and
(ii) a Clostridial toxin recognition sequence
including a cleavage site; and [CONT.]
N
(2) treatment of cancer comprising the
administration of a peptide, optionally in
combination with a cancer agent, to a patient;
For treating or preventing a disease or symptom
associated with an angiogenic disorder, and
angiogenesis-dependent condition in a mammal
(both claimed). The disease is cancer, arthritis,
hypertension, kidney disease, psoriasis,
angiogenesis of the eye associated with ocular
disorder, infection or surgical intervention, macular
degeneration, diabetic retinopathy.
BIOTECHNOLOGY - Preparation (disclosed): No
preparation method is given. Preferred
Compound: The antiangiogenic compound has
any one of 9 compounds, e.g. formula (F11) and
(F12). In (C2), the backbone length of X is 1-50,
preferably 1-10 atoms. The variable Z' has the
structure (II) or (III). The antibody is a full-length
antibody, Fab, Fab', F(ab')2, Fv, dsFv, scFv, VH,
diabody, or minibody having VH and VL domains
from h38c2, preferably h38c2 IgGl [CONT.]
A compound having L-AA targeting agent, is new. WO 2006094269
AA targeting agent=a peptide chosen from R1-SarGly-Val-(D-alloIle)-Thr-Nva-Ile-Arg-Pro-R3 (SEQ
ID No. 1), R2-Pro-Phe-Val-(D-alloIle)-Thr-Nva-IleArg-Pro-R3 (SEQ ID No. 2), R1-Sar-Gly-Val-(DalloIle)-Thr-Nva-Lys-Arg-Pro-R3 (SEQ ID No. 3),
R1-Sar-Gly-Val-(D-alloIle)-Thr-Lys-Ile-Arg-Pro-R3
(SEQ ID No. 4), R1-Sar-Gly-Val-(D-alloIle)-Thr-GlnIle-Arg-Pro-R3 (SEQ ID No [CONT.]
US 20060205670
US 20080152660
US 7521425
N
333 New monoclonal antibody that binds
specifically to a 161P2F10B protein, useful for
treating prostate, pancreas, bladder, kidney,
colon, lung, ovary, or breast cancer
334 Preparing pluripotent stem cell derived from
cardiac tissue of mammal, by treating cardiac
tissue with enzyme, isolating and culturing
cardiac tissue origin cell group in growth
medium, and selecting cells forming floating
spheres
JP 2008531734
T
20080814
CN 101287485
A
20081015
US 7521425
B2
20090421
AU 2006218437
B2
20110217
20110309
A2
20061005
CHALLITA-EID P M
EP 2292248
WO 2006105488
US 20060275211
A2
A1
20061207
GUDAS J
EP 1863848
A2
20071212
JAKOBOVITS A
AU 2006230563
A1
20061005
JIA X
IN 2007KN03814
A
20080404
KANNER S B
KR 2008003390
A
20080107
MORRISON K J M
US 7427399
B2
20080923
MORRISON R K
JP 2008538182
T
20081016
PEREZ-VILLAR J J
US 20090022663
WO 2006105488
A1
20090122
RAITANO A B
A3
20090416
SATPAEV D
NO 2007005103
A
20071228
MX 2007012133
A1
20080531
JP 2009171982
A
20090806
CN 101500590
A
20090805
AGENSYS INC
UNIV KYOTO
US 20090214556
A1
20090827
JP 4324636
B2
20090902
MX 270335
B
20090923
AU 2006230563
A2
20061005
BR 2006009655
A2
20100316
ZA 2007009303
A
20100331
AU 2006230563
B2
20100603
US 20100260756
US 7811565
US 20110020353
A1
20101014
B2
20101012
A1
20110127
RU 2413735
C2
20110310
WO 2006093276
A1
20060908
EP 1857544
A1
20071121
JP 2007506027
X
20080807
WO 2006105488 A2 UPAB: 20090212
The monoclonal antibody or its fragment is useful
for preparing a medicament for the treatment of
NOVELTY: A monoclonal antibody or its antigen
prostate, pancreas, bladder, kidney, colon, lung,
binding fragment comprising an antigen binding
site that binds specifically to a 161P2F10B protein ovary, or breast cancer, where the monoclonal
antibody or its fragment is administered in
comprising 871 amino acids (SEQ ID NO: 4),
where the monoclonal antibody is H16-7.213, H16- combination with radiation or a chemotherapeutic
agent (claimed).
9.69, H16-l.52, Ha16-1(1)23, Ha16- 9.44, H161.67. Ha16-l(3,5)36,H16-l.86,Hal6- 9.10, H169.33, H16-1. [CONT.]
BIOTECHNOLOGY - Preferred Antibody: The
INDEPENDENT CLAIMS are included for:
antibody is a fully human antibody. The fragment (1) a hybridoma that produces the monoclonal
is an Fab, F(ab')2, Fv or Sfv fragment. The
antibody above;
antibody or fragment is coupled to a detectable
marker, a toxin, a therapeutic agent, or a
chemotherapeutic agent, where the detectable
marker is a radioisotope, a metal chelator, an
enzyme, a fluorescent compound, a
bioluminescent compound or a chemiluminescent
compound [CONT.]
WO 2006105488
(2) a vector comprising a polynucleotide encoding
an antibody above;
(3) a pharmaceutical composition that comprises
the antibody or its fragment above in a human unit
dose form;
(4) an assay for detecting the presence of a
161P2F10B protein in a biological sample;
[CONT.]
US 20060275211
US 7427399
N
US 20090022663
US 20090214556
US 20100260756
US 7811565
US 20110020353
WO 2006093276 A1 UPAB: 20110323
For preparing pluripotent stem cell derived from
The method enables to prepare pluripotent stem
cardiac tissue of a mammal, preferably human.
cells having excellent differentiation potency to a
NOVELTY: Preparing pluripotent stem cell derived The stem cells and the composition are useful for cardiac myocyte.
treating a disease of a tissue or organ, preferably
from cardiac tissue of a mammal, involves
cardiac disease. The stem cells are also useful for
producing a cell suspension by treating the
cardiac tissue piece obtained from mammal with preparing the composition for treating a disease of
a tissue or organ, preferably cardiac disease (all
an enzyme, isolating cardiac tissue origin cell
group from the cell suspension by density gradient claimed) such as myocardial infarction, dilated
[CONT.]
method, carrying out suspension culture of the
isolated cell group in a culture medium containing
fibroblast growth factor and epidermal growth
factor, and selecting and isolating cells forming
floating spheres. [CONT.]
BIOTECHNOLOGY - Preferred Method: The
prepared pluripotent stem cells are c-kit, CD31
and CD34 negative, and are CD105 positive. The
stem cells are of human origin, and have
capability to differentiate into cardiac myocyte.
[CONT.]
INDEPENDENT CLAIMS are included for the
following:
(1) pluripotent stem cell obtained by the above
method;
(2) treating disease of a tissue or a organ,
involves transplanting therapeutically effective
amount of the above mentioned pluripotent stem
cells to the patients tissue or organ;
WO 2006093276
US 20080241111
N
335 Composition for manufacturing medicament
for treating cat allergy comprises virus-like or
virus core particle, with first attachment site,
and specific feline protein antigen, with
second attachment site, covalently linked via
the sites
CYTOS BIOTECHNOLOGY AG
SLOVAK ACAD SCI INST VIROLOGY
336 Diagnosing/prognosing
preneoplastic/neoplastic disease comprises
detecting hypoxia in a sample by detecting
MN/carbonic anhydrase (CA)9 gene expression
product in the vertebrate tissue
HARRIS A L
US 20080241111
A1
20081002
(3) composition for treating a disease of tissue or
organ, e.g. cardiac disease, comprising the
pluripotent stem cell and a carrier; and [CONT.]
EP 2295541
WO 2006097530
EP 1868642
A1
20110316
A2
20060921
WO 2006097530 A2 UPAB: 20090307
A2
20071226
NOVELTY: A composition (C1) comprises:
IN 2007DN06597
A
20070921
(i) a core particle that comprises a virus-like
particle (VLP) or a virus particle, with at least one
first attachment site; and
AU 2006224529
A1
20060921
(ii) at least one antigen that comprises a feline Fel
d1 (Felis domesticus allergen 1) protein (P1) or its
fragment, with at least one second attachment
site, covalently linked through the first and second
attachment site(s). [CONT.]
KR 2007112225
A
20071122
CN 101141979
A
20080312
JP 2008535800
T
20080904
MX 2007011160
A1
20071101
ZA 2007007413
A
20090128
NZ 561040
A
20090430
US 20090175896
A1
20090709
BR 2006008455
A2
20100105
US 7767212
US 20110045013
B2
20100803
A1
20110224
RU 2414239
C2
20110320
US 20060188981
A1
20060824
US 20060188981 A1 UPAB: 20060919
US 7910549
B2
20110322
NOVELTY: A method which is
diagnostic/prognostic for a
preneoplastic/neoplastic disease afflicting a
subject vertebrate comprises detecting hypoxia in
a sample comprising preneoplastic/neoplastic
tissue taken from the vertebrate by detecting
MN/carbonic anhydrase (CA)9 gene expression
product in the vertebrate tissue. [CONT.]
WO 2006081425
A1
20060803
WO 2006081425 A1 UPAB: 20060914
US 20060194271
A1
20060831
NOVELTY: An isolated or recombinant complex
comprising an mTOR polypeptide, a rictor
polypeptide, and an Akt polypeptide, is new.
In the manufacture of a medicament and vaccine
for the treatment of cat allergy, in a human and to
a non-human mammals (preferably a dog or cat)
(claimed).
The feline antigen composition or vaccine
composition containing Fel d1 antigen protein
(allergic glycoprotein present in pelt, saliva and
lachrymal glands of the cat) or its fragment are not
only capable of inducing potent immune
responses i.e. antibody response against Fel d1,
but are also capable of desensitizing a patient
suffering from cat allergy, within a short period of
time; [CONT.]
The methods are useful or diagnosing/prognosing
a preneoplastic/neoplastic disease and in making
a decision in the treatment of the
preneoplastic/neoplastic disease (claimed).
BIOTECHNOLOGY - Preferred Antigen: The Fel
d1 protein (P1) is a fusion protein that comprises
chain 1 of Fel d1, associated with chain 2 of Fel
d1 by at least one covalent bond (preferably a
peptide bond) or via a spacer, which links the Nterminus of one chain with the C-terminus of
another chain. [CONT.]
INDEPENDENT CLAIMS are included for:
WO 2006097530
BIOTECHNOLOGY - Preferred Method: The
hypoxia is chronic hypoxia. The hypoxia
represents a tissue oxygen tension of 1% or less.
The presence or level of hypoxia in the tissue is
considered indicative of a poorer prognosis, where
a poorer prognosis is measured in terms of
shortened survival or increased risk of recurrence
of the preneoplastic/neoplastic disease. [CONT.]
A method which is diagnostic/prognostic for a
US 20060188981
preneoplastic/neoplastic disease afflicting a
subject vertebrate comprises detecting hypoxia in
a sample comprising preneoplastic/neoplastic
tissue taken from the vertebrate, where the tissue
normally expresses no or low MN/CA IX protein,
the detection comprises:
(1) a vaccine (V1) comprising the composition
(C1);
(2) a Fel d1 fusion protein (P1a) comprising:
chains 1 and 2 of Fel d1 fused via an amino acid
spacer that consists of an amino acid sequence
containing 10 - 30 amino acid residues, and links
the N-terminus of one chain with the C-terminus of
another chain, provided that the fusion protein is
other than a fusion [CONT.]
US 20090175896
US 7767212
N
US 20110045013
US 20060188981
N
(a) detecting MN/CA9 gene expression product in
the vertebrate tissue; [CONT.]
US 7910549
INDEPENDENT CLAIMS are included for the
WO 2006081425
following:
(1) identifying an antagonist of Akt kinase
involving: a) contacting a test agent with an Akt
polypeptide and a rictor-mTOR complex for
phosphorylation of Akt by the rictor-mTOR
complex; and b) assaying for phosphorylation of
Akt by the rictor-mTOR complex in the presence
of the test agent, as compared to phosphorylation
of Akt by the rictor-mTOR complex in the absence
of test agent, where the test agent is an
antagonist of Akt kinase if the test agent
decreases phosphorylation of Akt by the rictormTOR complex; [CONT.]
US 20060194271
RATCLIFFE P J
337 Isolated or recombinant complex comprising a WHITEHEAD INST BIOMEDICAL RES
mammalian target of rapamycin complex
(mTOR), rictor and protein kinase polypeptide,
useful in identifying compounds that inhibit
function of a rictor-m(TOR) complex to treat
e.g., cancer
For inhibiting Akt activity in a cell e.g. human cell,
cancer cell that has no expression or reduced
expression of phosphatase and Tensin homolog
(PTEN); for treating or preventing a disorder that
is associated with aberrant Akt activity e.g. cancer
that has no expression or reduced expression of
PTEN in a subject such as human, and diabetes;
for identifying antagonist of Akt kinase e.g.
[CONT.]
The compound inhibits activity or expression of
rictor, activity or expression of mTOR, interaction
between rictor and mTOR, assembly of the rictormTOR complex, and phosphorylation of Akt on
S473 by the rictor-mTOR complex.
PHARMACEUTICALS - Preferred Method: The
Akt activity is measured by Akt phosphorylation, or
by Akt kinase activity, or by Akt-mediated
signaling. Preferred Complex: The complex further
comprises a GbetaL polypeptide. Preferred
Components: The Akt kinase antagonist is an
antitumor agent. The agent (A1) increases the
amount of rictor-mTOR complex in the presence
of rapamycin.
US 7906308
N
ANGIOCHEM INC
338 New aprotinin polypeptide having specific
amino acid sequence useful in the treatment of
e.g. neurological diseases such as brain
tumor, a brain metastasis, schizophrenia, and
epilepsy
339 Topical treatment composition for alleviating
or inhibiting joint pain, muscle pain and
musculoskeletal pain e.g. arthritis pain
comprises a nettle extract
340 New isolated antigen binding protein
comprising a light chain CDR3 and/or a heavy
chain CDR3 region, and the antigen binding
protein binds specifically to human IGF-IR,
useful for treating cancer, and autoimmune
disorders
US 7906308
B2
20110315
WO 2006086870
A1
20060824
US 20060189515
A1
20060824
AU 2005327497
A1
20060824
EP 1859041
A1
20071128
IN 2007KN03255
A
20080104
CN 101160403
A
20080409
JP 2008529539
T
20080807
MX 2007010113
A1
20071201
ZA 2007006917
A
20081029
US 20080299039
A1
20081204
BR 2005020032
A
20090414
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are included for the following:
(1) identifying an antagonist of Akt kinase
involving: a) contacting a test agent with an Akt
polypeptide and a rictor-mTOR complex for
phosphorylation of Akt by the rictor-mTOR
complex [CONT.]
WO 2006086870 A1 UPAB: 20060911
NOVELTY: Aprotinin polypeptide (C1) selected
from aprotinin fragments which either have a fully
defined sequence of 19 amino acids (SEQ ID
No.:1), as given in the specification, or which
contain the amino acid sequence as a part; or
their biological active fragments or analogs, is
new. [CONT.]
The polypeptide can efficiently cross a cell layer
mimicking a mammalian blood brain barrier in an
in vitro assay. The polypeptide can effectively act
as a carrier for transporting a compound or drug
across blood brain barrier of an individual.
BIOTECHNOLOGY - Preparation: No general
preparation of the polypeptide is given in the
specification. The modification of the polypeptide
may occur by chemical modification of genetic
engineering. Preferred Polypeptide: The aprotinin
polypeptide is selected from a aprotinin fragment
having length of 19 - 50 amino acids including the
amino acid sequence of SEQ ID No. 1, or
consisting of SEQ ID No. [CONT.]
Aprotinin polypeptide (C1) selected from aprotinin WO 2006086870
fragments which either have the sequence ThrPhe-Val-Tyr-Gly-Gly-Cys-Arg-Ala-Lys-Arg-AsnAsn-Phe-Lys-Ser-Ala-Glu- Asp (SEQ. ID No. 1), or
which contain the amino acid sequence as a part;
or their biological active fragments or analogs.
US 20060189515
N
INDEPENDENT CLAIMS are also included for:
US 20080299039
(1) a conjugate comprising: a carrier selected from
the polypeptide (C1) [CONT.]
US 7557182
US 7902156
US 7557182
B2
20090707
MX 277774
B
20100802
US 7902156
WO 2006086648
B2
20110308
SCOTT D E
A2
20060817
WO 2006086648 A2 UPAB: 20090817
SCOTT D
EP 1848271
A2
20071031
NOVELTY: A topical treatment composition (C1)
comprising an extract of nettle, is new.
AU 2006213760
A1
20060817
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are also included for:
KR 2007108173
A
20071108
(1) a topical treatment fabric comprising a textile
fabric and the treatment composition (C1); and
JP 2008530116
T
20080807
(2) making the topical treatment fabric involving:
contacting a liquid containing an extract of nettle
with a textile fabric [CONT.]
US 20080248074
A1
20081009
MX 2007009696
A1
20071101
BR 2006007046
A2
20090804
AU 2006213760
B2
20110317
WO 2006069202
A2
20060629
EP 1828248
A2
20070905
AU 2005319176
A1
20060629
NO 2007003475
A
20070921
AMGEN INC
In the preparation of pharmaceutical composition
and a conjugate for transporting an agent across a
blood brain barrier of a mammal; in the
manufacture of a medicament for the diagnostic of
brain or neurological disease and for treating brain
or neurological diseases e.g. brain tumor, a brain
metastasis, schizophrenia, epilepsy, Alzheimer's
disease, Parkinson's disease, Huntington's
disease, stroke and blood-brain barrier related
malfunctions [CONT.]
WO 2006069202 A2 UPAB: 20090307
For alleviating or inhibiting joint pain, muscle pain
and musculoskeletal pain, in a mammal (claimed)
in e.g. pain associated with arthritis, osteoarthritis
and prostate, headache and hemorrhoids and
other inflammatory conditions caused by including
physical injuries, swelling and elevated
temperature. [CONT.]
The protein, polypeptide and composition are
useful for treating multiple myeloma, a liquid
tumor, liver cancer, a thymus disorder, a T-cell
NOVELTY: An isolated antigen binding protein
mediated autoimmune disease, an
comprising a light chain CDR3 and/or a heavy
endocrinological disorder, ischemia, or a
chain CDR3 region, and the antigen binding
protein binds specifically to human IGF-IR, is new. neurodegenerative disorder. The liquid tumor is
selected from acute lymphocytic leukemia (ALL)
and chronic myelogenous leukemia (CML); where
the liver cancer is selected from hepatoma,
[CONT.]
DETAILED DESCRIPTION: The isolated antigen
binding protein comprises: [CONT.]
The topical composition containing the nettle
extract provides pain alleviation without the need
for further medication, and for a longer period of
time as compared to the prior art analgesic agents
such as, aspirin, non-steroidal anti-inflammatory
drugs (NSAIDs), steroid injections and other
medications and treatments. The nettles act as
painkillers and diuretics, and attract the
components and effects of the immune system
[CONT.]
ORGANIC CHEMISTRY - Preferred Method: The
making of the fabric further involves: making an
extract of the nettle (preferably Urtica dioica) by
alcohol extraction (preferably alcohol/water
mixture containing the alcohol (50 - 90, preferably
51) wt.%)). PHARMACEUTICALS - Preferred
Composition: The treatment composition (C1)
contains an extract of Urtica dioica, in dried form
or a liquid containing the extract [CONT.]
INDEPENDENT CLAIMS are also included for:
BIOTECHNOLOGY - Preferred Protein: The
isolated antigen binding protein comprises a light
chain CDR3 comprising a sequence of:
MX1X2X3X4X5PX6X7; or
QSYX13X14X15NX16X17X18. The heavy chain
CDR3 comprises a sequence of:
X19X20X21X22X23X24X25X26X27FDI; or
X28X29X30X31X32X33X34X35X36X37X38MDV,
X1 = glutamine residue or a glutamate residue; X2
= an alanine residue, a glycine residue, a
threonine residue, or a serine residue [CONT.]
The isolated antigen binding protein comprises:
WO 2006086648
US 20080248074
WO 2006069202
US 20090285824
(1) a topical treatment fabric comprising a textile
fabric and the treatment composition (C1); and
(2) making the topical treatment fabric involving:
contacting a liquid containing an extract of nettle
with a textile fabric; and removing at least a
portion of the liquid.
(A) a light chain CDR3 comprising a sequence
selected a light chain CDR3 sequence that differs
by no more than a total of two amino acid
additions, substitutions, and/or deletions from a
CDR3 sequence selected from the light chain
CDR3 sequences of L1-L52 as shown in Figure 6;
[CONT.]
US 7871611
US 20110070615
N
IN 2007CN03203
A
20071012
KR 2007100317
A
20071010
CN 101128484
A
20080220
ZA 2007005732
A
20080625
JP 2008525034
T
20080717
MX 2007006921
A1
20070701
BR 2005019775
A
20090210
JP 2009142293
A
20090702
TW 2006035944
A
20061016
JP 4372825
B2
20091125
US 20090285824
A1
20091119
NZ 555964
A
20100430
AU 2005319176
B2
20101111
US 7871611
B2
20110118
AU 2010257339
A1
20110120
US 20110070615
WO 2006074071
A1
20110324
A1
20060713
WO 2006074071 A1 UPAB: 20060822
EP 1833850
A1
20070919
NOVELTY: A new humanized COL-1 monoclonal
antibody comprises a heavy chain of a sequence
of 124 amino acids (SEQ ID NO: 8) and a light
chain, where several framework residues in SEQ
ID NO: 8 are substituted with an amino acid from a
corresponding position in a MO30 human
antibody, and where the humanized COL-1
antibody retains binding affinity for
carcinoembryonic antigen (CEA) and has reduced
immunogenicity, as compared to HuCOL-1AbrDR.
[CONT.]
US DEPT OF HEALTH
AU 2005322869
A1
US SEC OF NAVY
US 20080274055
US DEPT OF HEALTH&HUMAN SERVICES
341 New framework residue substituted humanized US DEPT HEALTH&HUMAN SERVICES
antibody, useful for diagnosing and treating
US DEPT HEALTH & HUMAN SERVICES
tumor, e.g. colorectal, breast, ovarian, or
prostate cancer
The antibody, composition, and methods are
useful for diagnosing and treating tumor, e.g.
colorectal, breast, ovarian, or prostate cancer.
BIOTECHNOLOGY - Preferred Antibody: At least
1 or 5 additional framework residue in SEQ ID NO:
8 is substituted with an amino acid from a
corresponding position in a MO30 human
antibody. At least five additional framework
residues comprises framework residues at
positions 20, 38, 48, 67, and 81 of the amino acid
sequence of SEQ ID NO: 8. [CONT.]
INDEPENDENT CLAIMS are also included for:
WO 2006074071
US 20080274055
(1) a composition comprising a functional
fragment of the humanized antibody above, where
the functional fragment specifically binds CEA;
US 7855276
20060713
(2) a pharmaceutical composition comprising a
therapeutic amount of the humanized antibody
above, in a pharmaceutical carrier, where the
humanized antibody inhibits tumor growth;
US 20110053264
A1
20081106
(3) treating a subject with a tumor that expresses
CEA; [CONT.]
US 7855276
EP 1833850
US 20110053264
B2
20101221
B1
20110302
A1
20110303
WO 2006051805
A1
20060518
EP 1842857
A1
20071010
MAYUMI T
JP 2006544910
X
20080529
NAKAGAWA S
US 20090311218
US 7666403
EP 1842857
WO 2006063128
A1
20091217
B2
20100223
B1
20110309
A2
20060615
KASHMIRI R M
KASHMIRI S
N
PADLAN E A
SCHLOM J
HAYASHIBARA SEIBUTSU KAGAKU KK
342 Novel mutant human interferon alpha-8
protein, useful as antitumor agent, antiviral
agent or as antiallergic agent for treating colon HAYASHIBARA SEIBUTSU KAGAKU
KENKYUSHO KK
cancer, rectal cancer, AIDS, hepatitis B
TSUTSUMI Y
SIRION THERAPEUTICS INC
343 Treating retinol-related diseases e.g.
hyperostosis, comprises administering retinol
binding protein or transthyretin sequences to
the mammal
WO 2006051805 A1 UPAB: 20060814
(I) and (III) are useful as an anti-tumor agent,
(I) has excellent kinetics in the living body, and
antiviral agent or as an anti-allergic agent
remains in the blood for longer time.
(claimed). (I) is useful for treating colon cancer,
NOVELTY: A mutant human interferon alpha8
protein (I), comprising SEQ ID No. 1-3 (sequences rectal cancer, stomach cancer or renal carcinoma,
not defined in the specification), with substitution AIDS, severe acute respiratory syndrome,
hepatitis B, rheumatism, etc.
of the arginine residue at the 145-position by a
leucine residue, isoleucine residue or valine
residue, substitution of the alanine residue at the
146-position by an asparagine residue or a serine
residue and substitution of the methionine residue
at 149-position by a tyrosine residue, is new.
[CONT.]
BIOTECHNOLOGY - Preparation: No general
preparation is given. Preferred Protein: (I) has
SEQ ID No. 4-7 (sequences not defined in the
specification). The lysine residues other than at
position 31-134 are substituted by other amino
acids. (I) comprises SEQ ID No. 8 or 9
(sequences not defined in the specification).
INDEPENDENT CLAIMS are also included for the WO 2006051805
following:
(1) a bioactive conjugate (II) comprising (I) bound
with a water soluble polymer; and
US 20090311218
N
US 7666403
(2) therapeutic agent (III) for sensitive diseases,
comprising (I) or (II).
WO 2006063128 A2 UPAB: 20090130
The methods are useful for treating retinol-related
disease, e.g. hyperostosis, idiopathic intracranial
hypertension, amyloidosis, Alzheimer's disease, or
Alstrom-Hallgren syndrome, for treating agerelated macular degeneration or dystrophy, and
for treating type I or type II diabetes (claimed).
BIOTECHNOLOGY - Preferred Method: The RBP
transcription inhibitor is chosen from RXR/RAR
agonists, RXR/RAR antagonists, estrogen
agonists, estrogen antagonists, testosterone
agonists, testosterone antagonists, progesterone
agonists, progesterone antagonists,
Treating retinol-related diseases in a mammal
WO 2006063128
comprising administering to the mammal at least
once an amount of at least one of the compounds,
e.g. an retinol binding protein (RBP) transcription
inhibitor, a transthyretin (TTR) transcription
inhibitor, an RBP translation inhibitor, a TTR
US 20060135460
N
343 Treating retinol-related diseases e.g.
hyperostosis, comprises administering retinol SYTERA INC
binding protein or transthyretin sequences to
the mammal
REVISION THERAPEUTICS INC
344 Diagnosing Crohn's disease in a mammal,
comprises determining the presence of antiCbir1 expression in the sample, where
presence of anti-Cbir1 expression indicates
that the mammal has Crohn's disease
CEDARS SINAI MEDICAL CENT
GB 2421433
A
20060628
US 20060135460
A1
20060622
US 20070015827
WO 2007008821
GB 2428975
EP 1827407
A1
20070118
A2
20070118
A
20070214
A2
20070905
AU 2005314039
A1
20060615
NO 2007003510
A
20070906
NO 2007005018
A
20070906
GB 2421433
B
20080102
BR 2005018616
A
20080115
AU 2007229394
A1
20071108
JP 2008007518
A
20080117
KR 2007102591
A
20071018
CN 101072555
A
20071114
EP 1904043
A2
20080402
AU 2005314039
B2
20080131
NO 2008000718
A
20080402
CN 101129344
A
20080227
EP 1930046
A1
20080611
JP 2008523080
T
20080703
AU 2006268374
A1
20070118
KR 2007086074
A
20070827
JP 2008179648
A
20080807
SG 144145
A1
20080729
GB 2428975
B
20080813
AU 2006268374
A8
20080320
AU 2006268374
A2
20070118
MX 2007006245
A1
20070801
CN 101252924
A
20080827
KR 2008055790
A
20080619
JP 4178281
B2
20081112
JP 2009500455
T
20090108
CA 2614627
A1
20070118
MX 2008000064
A1
20080430
KR 890410
B1
20090326
ZA 2008000844
A
20090429
ZA 2007008091
A
20090826
AU 2007229394
B2
20091210
AU 2007229394
B9
20100218
AU 2010200842
A1
20100401
KR 971695
B1
20100723
EP 2289500
WO 2006063093
A1
20110302
A2
20060615
The methods are useful for treating retinol-related
NOVELTY: Treating retinol-related diseases in a disease, e.g. hyperostosis, idiopathic intracranial
mammal comprising administering to the mammal hypertension, amyloidosis, Alzheimer's disease, or
Alstrom-Hallgren syndrome, for treating ageat least once an amount of at least one of the
related macular degeneration or dystrophy, and
compounds, e.g. retinol binding protein or
for treating type I or type II diabetes (claimed).
transthyretin sequences, is new.
DETAILED DESCRIPTION: Treating retinolrelated diseases in a mammal comprising
administering to the mammal at least once an
amount of at least one of the compounds, e
[CONT.]
WO 2006063093 A2 UPAB: 20060714
The methods and kit are useful for diagnosing and
treating Crohn's disease in a mammal.
BIOTECHNOLOGY - Preferred Method: The RBP
transcription inhibitor is chosen from RXR/RAR
agonists, RXR/RAR antagonists, estrogen
agonists, estrogen antagonists, testosterone
agonists, testosterone antagonists, progesterone
agonists, progesterone antagonists,
dexamethasone agonists, dexamethasone
antagonists, antisense oligonucleotides, siRNA,
fatty acid binding protein antagonists, C/EBP
agonists, [CONT.]
Treating retinol-related diseases in a mammal
WO 2006063128
comprising administering to the mammal at least
once an amount of at least one of the compounds,
e.g. an retinol binding protein (RBP) transcription
inhibitor, a transthyretin (TTR) transcription
inhibitor, an RBP translation inhibitor, a TTR
translation inhibitor, an RBP clearance agent, a
TTR clearance agent, an RBP antagonist, an RBP
agonist, a TTR antagonist, a TTR agonist, or a
retinol binding receptor antagonist. [CONT.]
BIOTECHNOLOGY - Preferred Method: In
INDEPENDENT CLAIMS are also included for:
diagnosing Crohn's disease in a mammal, the
Crohn's disease is Crohn's disease with small
bowel disease, internal perforating disease, and/or
fibrostenosing disease. Determining the presence
of anti-Cbir1 expression comprises determining
the presence of an RNA sequence or a fragment
of an RNA sequence that encodes an anti-Cbir1
antibody in the sample obtained from the mammal
[CONT.]
WO 2006063093
US 20070015827
US 20100021455
N
treating Crohn's disease in a mammal.
comprises determining the presence of antiCbir1 expression in the sample, where
presence of anti-Cbir1 expression indicates
that the mammal has Crohn's disease
A2
20070822
NOVELTY: Diagnosing Crohn's disease in a
mammal comprising obtaining a sample from the
mammal, and determining the presence of antiCbir1 expression in the sample, where the
presence of anti-Cbir1 expression indicates that
the mammal has Crohn's disease, is new.
AU 2005314089
A1
20060615
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are also included for:
US 20100021455
A1
20100128
(1) treating Crohn's disease in a mammal [CONT.]
EP 1819827
B1
20100811
DE 602005022924
E
20100923
EP 2270512
A1
20110105
AU 2005314089
B2
20110303
WO 2006061723
A2
20060615
EP 1819732
A2
20070822
AU 2005313026
A1
20060615
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are also included for:
(2) a subsequence of the antibody above, where
the subsequence is selected from a heavy chain
variable region, (VH), a light chain variable region
(VL), Fab, Fab', F(ab')2, Fv, Fd, scFv, sdFv, or a
combination of the subsequences;
IN 2007CN01956
A
20070831
(1) an amino acid subsequence of the antibody
above; [CONT.]
(3) a host cell that expresses the antibody;
[CONT.]
KR 2007085439
A
20070827
CN 101072795
A
20071114
JP 2008522610
T
20080703
TW 2006026614
A
20060801
US 20090196872
EP 2295465
WO 2006051172
A1
20090806
A2
20110316
A1
20060518
EP 1812586
A1
20070801
A1
20071220
B1
20110323
NOVAGALI PHARMA SA
US 20070292350
EP 1812586
WO 2006056823
A1
20060601
OCTOPLUS BV
EP 1827602
A1
20070905
345 New isolated antibody that specifically binds to KIRIN BEER KK
an epitope in influenza A virus protein M2
KIRIN BREWERY KK
extracellular domain, useful for treating,
diagnosing, and preventing influenza virus
infections
KYOWA HAKKO KIRIN CO LTD
346 Method, useful for testing and screening a
compound for a therapeutic effect, comprises
administering the compound and determining
its ability to restore the unbalanced
phosphatidyl inositol phosphate cascade
and/or signaling pathway
347 Use of agonist or antagonist of vascular
endothelial growth factor receptor 1 for
manufacture of medicament for preventing or
treating subject suffering from ocular disease
such as macular edema and central serous
chorioretinopathy
diagnosing Crohn's disease in a mammal, the
Crohn's disease is Crohn's disease with small
(1) treating Crohn's disease in a mammal; and
bowel disease, internal perforating disease, and/or
fibrostenosing disease. Determining the presence
of anti-Cbir1 expression comprises determining
the presence of an RNA sequence or a fragment
of an RNA sequence that encodes an anti-Cbir1
antibody in the sample obtained from the mammal
[CONT.]
(2) a kit for diagnosing Crohn's disease or a
subtype of Crohn's disease in a mammal
comprising a quantity of Cbir1 flagellin antigen or
its immunoreactive fragment, and instructions for
diagnosing Crohn's disease or a subtype of
Crohn's disease in a mammal.
EP 1819827
CHEMPATH OY
WO 2006061723 A2 UPAB: 20090728
The antibodies, compositions, and methods are
useful for treating, diagnosing, and preventing
influenza virus infections (claimed), and for
NOVELTY: An isolated antibody that specifically
binds to an epitope in influenza A virus protein M2 identifying the presence of M2 or influenza virus in
a sample or a subject.
extracellular domain, where the antibody
comprises a human, humanized, or chimeric
monoclonal antibody, is new.
WO 2006051172 A1 UPAB: 20110328
BIOTECHNOLOGY - Preferred Antibody: The
INDEPENDENT CLAIMS are also included for:
antibody binds to an epitope to which the antibody
produced by the CHO cell deposited as ATCC
(1) an amino acid subsequence of the antibody
PTA-5967 specifically binds, or the hybridoma
above;
deposited as ATCC PTA-5968 specifically binds.
Preferably, the antibody binds to an epitope within
the amino acid sequence Leu-Leu-Thr-Glu-ValGlu-Thr-Pro-Ile-Arg (SEQ ID NO. 1). [CONT.]
WO 2006061723
The method is useful for treating disorders related
to unbalanced phosphatidyl inositol phosphate
cascade and/or signaling pathway, where disorder
NOVELTY: A method for testing and screening a is prostatic atypical hyperplasia, prostatic
compound (A) for a therapeutic effect, comprises intraepithelial neoplasia or carcinoma (preferably
administering (A) to a cell or a non-human animal bladder cancer or pancreatic cancer). The method
is also useful to treat myopathy
having disruption in the prostatic acid
(myodegeneration) or neuropathy
phosphatase (PAP) gene or its regulation, and
(neurodegeneration). [CONT.]
determining the ability of (A) to substantially
restore the unbalanced phosphatidyl inositol
phosphate cascade and/or signaling pathway
related to PAP expression or activity, is new.
[CONT.]
BIOLOGY - Preferred Method: The restoring is the
decrease in PI(4,5)P2 accumulation or decrease
in the level of phosphatidyl inositol 3-phosphate
(PI(3)P). A response of (A) on a control, (cell or
animal not exposed to (A)) is determined and is
compared with other responses to determine the
effect of (A). The disruption is introduced in the
exon 3 of the PAP gene. [CONT.]
Method for testing and screening a compound (A) WO 2006051172
for a therapeutic effect, comprises:
WO 2006056823 A1 UPAB: 20060623
BIOTECHNOLOGY - Preferred Modulator: In (I),
the agonist of VEGFR-1 is chosen from vascular
endothelial growth factor (selected from the group
VEGF) and agonists comprising those originating
from Timeresurus flavoridis venom, preferably
placenta growth factor (PlGF). [CONT.]
INDEPENDENT CLAIMS are also included for:
(I) is useful for the manufacture of a medicament
for preventing or treating a subject suffering from
an ocular disease, where the subject is a
NOVELTY: Using an agonist or antagonist of
mammal, preferably a human being. The ocular
vascular endothelial growth factor receptor-1
disease is chosen from macular edema, central
(VEGFR-1) (I) for the manufacture of a
serous chorioretinopathy, epitheliopathy and age
medicament for preventing or treating a subject
suffering from an ocular disease, where disorders related macular degeneration (ARMD). (II) is
useful for preventing or treating a subject suffering
of the retinal pigment epithelium (RPE)
from an ocular disease [CONT.]
permeation are involved, is new.
US 20090196872
N
US 20070292350
N
(a) administering (A) to a cell or a non-human
animal having disruption in the prostatic acid
phosphatase (PAP) gene or its regulation
(resulting in the absence or decrease in the
activity of PAP level); and [CONT.]
(1) a pharmaceutical composition (C1) comprising
an antisense oligonucleotide of the mRNA
encoding VEGFR-1, where the antisense
oligonucleotide has:
WO 2006056823
US 20090087424
N
INSERM INST NAT SANTE&RECH MEDICALE
US 20090087424
A1
20090402
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are also included for: [CONT.]
BEHAR-COHEN F
EP 1827602
B1
20110309
WO 2006053110
A2
20060518
EP 1817055
A2
20070815
AU 2005304462
A1
20060518
JP 2008519841
T
20080612
US 20090136490
A1
20090528
(2) a method of producing the antibody;
AU 2005304462
B2
20110310
(3) a composition comprising the antibody and a
carrier; [CONT.]
MONSANTO TECHNOLOGY LLC
WO 2006052662
A2
20060518
WO 2006052662 A2 UPAB: 20090327
ARHANCET J P
US 20060110521
A1
20060525
HEISE J D
EP 1827123
A2
20070905
MAKADIA V
AU 2005304994
A1
20060518
MORGENSTERN D A
IN 2007DN03450
A
20070831
CN 101098629
A
20080102
KR 2007107664
A
20071107
JP 2008519129
T
20080605
MX 2007005486
A1
20070601
BR 2005017776
A
20081021
TW 2006028076
A
20060816
TW 2006028077
A
20060816
TW 2006030478
A
20060901
US 20100255157
A1
20101007
CN 101098629
B
20101013
US 7902388
WO 2006037328
B2
20110308
A1
20060413
(a) SEQ ID No. 1;
(b) a sequence having at least 70 % of identify
with SEQ ID No. 1;
(c) a sequence comprising the sequence in (a) or
(b); or
(d) a sequence complementary to the sequence in
(a), (b) or (c), together with a carrier; [CONT.]
MIYAMOTO N
NORMAND N
PLOUET J
348 New isolated Ovr110 antibody that binds to an DIADEXUS INC
Ovr110 on a mammalian cell, for treating
ovarian, pancreatic, lung, or breast cancer, or
an autoimmune disease, e.g. multiple sclerosis
349 Oil composition useful as e.g. food
composition, beverage comprises
polyunsaturated fatty acid having at least four
carbon-carbon double bonds or its derivative
based upon total weight of fatty acid or its
derivative
NOVOZYMES AS
350 Novel isolated polypeptide having phytase
activity, useful in animal feed, in preparation of
composition for use in animal feed, and for
improving nutritional value of animal feed
WO 2006053110 A2 UPAB: 20090604
The Ovr110 antibody is useful for treating an
autoimmune disease selected from Multiple
NOVELTY: An isolated Ovr110 antibody that binds sclerosis, Myasthenia gravis, Autoimmune
neuropathies such as Guillain-Barre, Autoimmune
to an ovarian, pancreatic, lung or breast cancer
uveitis, Crohn's Disease, Ulcerative colitis,
antigen (Ovr110) on a mammalian cell, is new.
Primary biliary cirrhosis, Autoimmune hepatitis,
Autoimmune hemolytic anemia, Pernicious
DETAILED DESCRIPTION: INDEPENDENT
anemia, Autoimmune thrombocytopenia,
CLAIMS are also included for:
Temporal arteritis, Antiphospholipid syndrome,
(1) a cell that produces the antibody;
[CONT.]
As a food composition comprising food product or
food analog containing spray-dried or freeze-dried
NOVELTY: An oil composition comprises at least food particle, extruded food, meat product, meat
analog, cereal product, snack food, baked good,
one polyunsaturated fatty acid (preferably
dough product, health food, fried food, dairy
stearidonic acid) (at least 0.4, preferably 3 - 30
product (e.g. cheese and milk analog), dairy
wt.%) having at least four carbon-carbon double
bonds or its derivative based upon the total weight product analog, pet food, animal feed and
aquiculture feed; a beverage such as adult
of fatty acids or its derivatives. The compound
nutritional formula, infant formula, soy milk, yogurt
additionally comprises tocopherols (at least of
drink, juice, milk drink and reconstitutable dry400, preferably 5000 parts per million (ppm))
powder; nutritional supplement; and cooking oil (e
[CONT.]
[CONT.]
The composition has a peroxide value of less than
about 1 or 10 (preferably 5) meq/kg and is derived
from a source other than marine oil. The
composition exhibits less than 1 wt.% of fatty acid;
trans-fatty acid (not more than 10, preferably not
more than 5 wt.%); anisidine value of 20
(preferably 10); and has totox value of 26
(preferably 10). The composition has an aroma
total impact score of 2. [CONT.]
BIOTECHNOLOGY - Preferred Antibody: The
antibody internalizes upon binding to Ovr110 on a
mammalian cell. Preferably, the antibody is a
monoclonal antibody, an antibody fragment, or a
chimeric or a humanized antibody. It binds to an
Ovr110 peptide selected from one of four
sequences of 15 amino acids (SEQ ID NO. 27, 32,
34, or 35), given in the specification, where the
Ovr110 peptide contains a post-translational
modification, which is a phosphorylation [CONT.]
INDEPENDENT CLAIMS are also included for:
WO 2006053110
FOOD - Preferred Composition: The composition
is derived from a genetically-modified seed
selected from Arabidopsis, canola, carrot,
coconut, corn, cotton, flax, linseed, maize, palm
kernel, peanut, potato, rapeseed, safflower,
soybean, sunflower, and/or tobacco. ORGANIC
CHEMISTRY - Preferred Components: The
polyunsaturated fatty acid or its derivative
comprises stearidonic acid (SDA; [CONT.]
INDEPENDENT CLAIMS are included for the
WO 2006052662
following:
(1) a method of determining oxidative stability of
oil involving placing a layer of the oil composition
on an infrared card to form a treated infrared card,
placing the treated infrared card in an inert
atmosphere for the layer to have a substantially
uniform thickness, exposing the infrared card with
the layer of substantially uniform thickness to air,
and periodically collecting the infrared spectrum of
the oil composition; and [CONT.]
US 20090136490
N
(1) a cell that produces the antibody;
(2) a method of producing the antibody;
(3) a composition comprising the antibody and a
carrier;
(4) a method of killing an Ovr110-expressing
cancer cell;
(5) a method of alleviating an Ovr110-expressing
cancer in a mammal;
(6) an article of manufacture comprising a
container and a composition contained in it, where
the composition comprises the antibody; [CONT.]
US 20060110521
US 20100255157
US 7902388
WO 2006037328 A1 UPAB: 20060523
(I) is useful in animal feed, in the preparation of a
composition for use in animal feed, and for
improving the nutritional value of an animal feed,
where one or more of (I) is added to the feed.
(claimed) and the improvement of nutritional value
include promotion of growth of animal,
improvement in feed utilization, improvement in
bio-availability of proteins, increase of level of
digestible phosphate, improvement of release
and/or degradation of phytate, and improvement
of bio-availability of trace minerals and macro
minerals [CONT.]
(I) belonging to acid histidine phosphatase family,
has high specificity towards the substrate phytate.
(I) exhibits improved properties such as increased
stability (acid-stability, heat-stability, protease
stability and/or pepsin stability) at optimum pH,
and improved performance in animal feed (such
as improved release of phosphate and/or
degradation of phytate).
BIOTECHNOLOGY - Preparation: (I) is produced INDEPENDENT CLAIMS are also included for:
by: (a) cultivating a cell, which in its wild-type form
is capable of producing (I), under conditions
conducive for production of (I), and recovering (I);
or (b) cultivating a recombinant host cell
comprising (III) having a nucleotide sequence
encoding (I) under conditions conducive for
production of (I), and recovering (I) (claimed).
[CONT.]
WO 2006037328
US 20080292753
N
activity, useful in animal feed, in preparation of
composition for use in animal feed, and for
improving nutritional value of animal feed
WYETH
351 Composition, to treat/control parasiticidal
infection in homeothermic animal, comprises
amitraz and additional parasiticidal compound WYETH CORP
in non-hydroxyl-group containing solvent
mixture comprising N,N-diethyl-m-toluamide
and gamma-hexalactone
WYETH LLC
EP 1799818
A1
20070627
NOVELTY: An isolated polypeptide (I) having
phytase activity, chosen from polypeptide (P1)
comprising an amino acid sequence having at
least 98.6% identity with amino acids 1-411 of fully
defined 433 amino acid (SEQ ID No. 2) sequence
given in specification and/or mature polypeptide
portion of SEQ ID No. 2, a variant of P1
comprising a deletion, insertion and/or
conservative substitution of one or more amino
acids, and a fragment of P1, is new. [CONT.]
AU 2005291728
A1
20060413
IN 2007CN01366
A
20070831
CN 101035892
A
20070912
JP 2008515397
T
20080515
CA 2610106
A1
20060413
MX 2007003564
A1
20070601
BR 2005017540
A
20081014
US 20080292753
US 7867743
A1
20081127
B2
20110111
AU 2005291728
B2
20110317
US 20060078585
A1
20060413
US 20060078585 A1 UPAB: 20090811
WO 2006042099
A1
20060420
NOVELTY: Composition (I), comprises a nonhydroxyl-group containing solvent mixture
comprising N,N-diethyl-m-toluamide and gammahexalactone, optionally with dimethyl sulfoxide,
eucalyptol and 1-methoxy-2-propyl acetate; and
each of amitraz and at least one additional
parasiticidal compound.
NO 2007001614
A
20070328
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are also included for: [CONT.]
EP 1799037
A1
20070627
AU 2005294257
A1
20060420
IN 2007DN02548
A
20070803
CN 101035431
A
20070912
KR 2007101214
A
20071016
JP 2008515912
T
20080515
MX 2007004003
A1
20070601
BR 2005016540
A
20080909
TW 2006016542
A
20060601
SG 156001
A1
20091029
CN 100566566
C
20091209
ZA 2007002874
A
20100929
US 7906130
WO 2006031901
B2
20110315
A2
20060323
WO 2006031901 A2 UPAB: 20060413
EP 1793835
A2
20070613
NOVELTY: Composition comprises:
US 20070149470
A1
20070628
KASPAR R L
JP 2008512500
T
20080424
(a) a shRNA comprising a sequence of SEQ ID
NOS: 12, 17-25, 27, 32 and 33; or
(b) a siRNA comprising a sequence of SED ID
NOS: 19-25, 27, 32 and 33.
SEYHAN A A
US 20090170794
A1
20090702
VLASSOV A V
US 7902351
B2
20110308
SOMAGENICS INC
352 Composition comprising shRNA or siRNA
useful for inhibiting gene expression in a virus
or treating a viral infection, especially hepatitis ILVES H
C
JOHNSTON B H
353 New trifluoromethanesulfonanilide oxime ether SCHERING-PLOUGH ANIMAL HEALTH CORP
compounds useful for treating or protecting
animal or plant from parasite e.g. arthropod,
infestation
US 20060063841
A1
20060323
composition for use in animal feed, and for
improving the nutritional value of an animal feed,
where one or more of (I) is added to the feed.
(claimed) and the improvement of nutritional value
include promotion of growth of animal,
improvement in feed utilization, improvement in
bio-availability of proteins, increase of level of
digestible phosphate, improvement of release
and/or degradation of phytate, and improvement
of bio-availability of trace minerals and macro
minerals [CONT.]
has high specificity towards the substrate phytate.
(I) exhibits improved properties such as increased
stability (acid-stability, heat-stability, protease
stability and/or pepsin stability) at optimum pH,
and improved performance in animal feed (such
as improved release of phosphate and/or
degradation of phytate).
by: (a) cultivating a cell, which in its wild-type form
is capable of producing (I), under conditions
conducive for production of (I), and recovering (I);
or (b) cultivating a recombinant host cell
comprising (III) having a nucleotide sequence
encoding (I) under conditions conducive for
production of (I), and recovering (I) (claimed).
[CONT.]
(I) is useful for the treatment and control of
ectoparasiticidal infection/infestation in a
homeothermic animal (swine, cattle, horses,
sheep, dogs or cats); where the ectoparasiticidal
infection/infestation is caused by lice, mites, flies
or especially fleas or ticks (claimed). The
antiparasitic efficacy of (I) was tested in dogs that
were infested with adult fleas (Ctenocephalides
felis). [CONT.]
(I) is stable and allows for high concentrations of a
mixture of parasiticidal agents in a single
application. (I) contains sufficiently high
concentrations of each of the active ingredients;
and provides at least a one-month interval
between applications. (I) provides improved
efficacy over a broad spectrum of parasites for an
extended period of time; [CONT.]
ORGANIC CHEMISTRY - Preparation (Claimed):
Preparation of (I) comprises admixing N,N-diethylm-toluamide and dimethyl sulfoxide, optionally
with eucalyptol, gamma-hexalactone and 1methoxy-2-propyl acetate to form a solvent
mixture; treating the solvent mixture with amitraz
and an additional parasiticidal compound to form a
homogeneous solution; and optionally passing the
solution through a solid dehydrating agent
[CONT.]
INDEPENDENT CLAIMS are also included for:
BIOTECHNOLOGY - Preferred Method: (M1)
comprises introducing a small interfering RNA into
a virus-containing cell, where the small interfering
RNA comprises a sequence that is at least
partially complementary to a polynucleotide
sequence of the virus, where interaction of this
partially complementary sequence of the small
interfering RNA with the polynucleotide sequence
of the virus leads to inhibition of gene expression
in the virus [CONT.]
INDEPENDENT CLAIMS are also included for:
ORGANIC CHEMISTRY - Preparation of (I)
involves: (A) reacting benzene (substituted on 2 6 positions with -C(R5)=O, R4, R3, R2 and R1
respectively) with a mixture o fuming nitric and
concentrated sulfuric acid to give nitrobenzene
Trifluoromethanesulfonanilide oxime ether
US 20060063841
compounds of formulae (I) and (II) and their salt or
solvate are new.
For inhibiting gene expression in a virus and for
treating a viral infection in a mammal, where the
virus is hepatitis C virus.
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are also included for:
(1) inhibiting (M1) gene expression in a virus;
(2) treating (M2) a viral infection in a mammal; and
[CONT.]
US 20060063841 A1 UPAB: 20090327
For treating or protecting an animal or plant from a The compound effectively controls endo and/or
parasite (such as an arthropod or helminth)
ectoparasites in the environment.
infestation by killing or inhibiting the growth of an
arthropod or helminth (claimed). Also useful for
protecting the animals or plants from insects,
(1) an isolated polynucleotide (II) comprising a
nucleotide sequence encoding (I) having phytase
activity, chosen from a polynucleotide encoding
P1, and a polynucleotide having at least 98.3%
identity with nucleotides 67-1299 of a fully defined
1302 nucleotide (SEQ ID No. 1) sequence given in
the specification; [CONT.]
US 7867743
US 20060078585
(1) a method for the treatment and control of
ectoparasiticidal infection/infestation in a
homeothermic animal comprises the topical
administration of (I); and
US 20060078585
N
US 7906130
(2) the preparation of (I).
WO 2006031901
US 20070149470
(1) inhibiting (M1) gene expression in a virus;
US 20090170794
(2) treating (M2) a viral infection in a mammal; and
US 7902351
N
(3) a kit comprising a siRNA and instructions for
use in any of the above methods.
US 20060063841
N
animal or plant from parasite e.g. arthropod,
infestation
SCHERING-PLOUGH LTD
WO 2006034333
A2
20060330
SCHERING-PLOUGH PTY LTD
EP 1799636
A2
20070627
LIEPA A J
AU 2005286723
A1
20060330
MEYER A G
IN 2007CN01202
A
20070831
SAWUTZ D G
US 7312248
B2
20071225
WINZENBERG K N
KR 2007054691
A
20070529
CN 101065352
A
20071031
JP 2008514610
T
20080508
MX 2007003378
A1
20070601
BR 2005015917
A
20080812
EP 1799636
B1
20080827
E
20081009
ZA 2007002389
A
20081029
ES 2314724
T3
20090316
TW 2006024414
A
20060716
MX 266855
B
20090520
IN 239098
B
20100312
AU 2010201450
A1
20100513
JP 2010209083
A
20100924
JP 4644254
B2
20110302
WO 2006021001
A2
20060223
WO 2006021001 A2 UPAB: 20090806
US 20060115448
A1
20060601
EP 1793838
A2
20070613
AU 2005272585
A1
20060223
NOVELTY: Amphiphilic polynorbornene
monomers are new.
DETAILED DESCRIPTION: Amphiphilic
polynorbornene monomers of formula (I) and (II)
are new.
R1=polar or non-polar group;
IN 2007MN00237
A
20070713
CN 101027066
A
20070829
KR 2007089120
A
20070830
JP 2008510850
T
20080410
AU 2005272585
B2
20110303
20060309
LEXICON GENETICS INC
WO 2006026222
EP 1781824
A2
A2
20070509
LEXICON PHARM INC
AU 2005280266
A1
20060309
EDWARDS J A
JP 2008510488
T
20080410
MONTGOMERY C
US 20080160034
A1
20080703
SHI Z
ZA 2008002559
A
20090527
SPARKS M J
ZA 2008002560
A
20090527
TEW G N
GENENTECH INC
6 positions with -C(R5)=O, R4, R3, R2 and R1
respectively) with a mixture o fuming nitric and
concentrated sulfuric acid to give nitrobenzene
(substituted on 2 - 6 positions with -C(R5)=O, R4,
R3, R2 and R1 respectively) (Ia); (B) reduction of
nitro group in (Ia) in presence of an acid e.g.
[CONT.]
R1 - R4=T;
US 7312248
T=cycloalkyl, cycloalkenyl, heterocyclyl,
(hetero)aryl, alkanoyl, heterocycloyl, (hetero)aroyl,
alkoxycarbonyl, heterocyclyloxycarbonyl,
(hetero)aryloxycarbonyl, alkylaminocarbonyl,
heterocyclylaminocarbonyl,
(hetero)arylaminocarbonyl, cycloalkoxy,
cycloalkenyloxy, alkoxyalkoxy, [CONT.]
R1 - R4=T; [CONT.]
DE 602005009381
POLYMEDIX INC
354 New amphiphilic polynorbornene monomers
useful for preparing polymer/copolymer useful
COUGHLIN E B
in pharmaceutical composition for treating
microbial infection e.g. HIV-1
ILKER M F
355 Identifying a phenotype associated with a
disruption of a gene encoding for a PRO
polypeptide for treating a disorder, comprises
comparing a measured characteristic of
transgenic and wild-type animals
infestation by killing or inhibiting the growth of an
arthropod or helminth (claimed). Also useful for
NOVELTY: Trifluoromethanesulfonanilide oxime
protecting the animals or plants from insects,
ether compounds and their salt or solvate are
mites and pests.
new.
DETAILED DESCRIPTION:
Trifluoromethanesulfonanilide oxime ether
compounds of formulae (I) and (II) and their salt or
solvate are new.
For preparing polymer/copolymer useful in
pharmaceutical composition for treating microbial
infection e.g. bacterial, fungal and viral infection;
for inhibiting microbial growth on or in a material
e.g. paint, lacquer, coating, varnish, caulk, grout,
adhesive, resin, film, cleanser, polish, cosmetic,
soap, lotion, hand wash and detergent (claimed).
[CONT.]
R2=absent or group with opposite polarity of that
of R1.
INDEPENDENT CLAIMS are included for the
following:
(P1)/(P2) exhibits potent antibacterial activity and
low hemolytic activity; are non-toxic to mammals;
has a broad range of antimicrobial activity and are
effective against a variety of microorganisms.
ORGANIC CHEMISTRY - Preparation: No general
preparation given. POLYMERS - Preferred
Polymer: (P1) further comprises a second
polynorbornene. (P1)/(P2) is block, random or
alternating. The first amphiphilic monomer is 2-(2amino-ethyl)-5-isopropylidene-4,6-divinyltetrahydro-cyclopenta(c)pyrrole-1,3-dione (poly2)
and the second amphiphilic monomer is 2-(2amino-ethyl)-5-isobutylidene-4,6-divinyltetrahydro-cyclopenta(c)pyrrole-1,3-dione (poly3)
[CONT.]
Amphiphilic polynorbornene monomers of formula WO 2006021001
(I) and (II) are new.
R1=polar or non-polar group;
BIOTECHNOLOGY - Preferred Method: The nonhuman transgenic animal is heterozygous for the
disruption of a gene which encodes the PRO
polypeptide. The phenotype exhibited by the nonhuman transgenic animal as compared with
gender matched wild-type littermates is at least
one of the following a neurological disorder, a
cardiovascular, endothelial or angiogenic disorder,
an eye abnormality, an immunological disorder, an
oncological disorder, a bone metabolic
abnormality or disorder, a lipid metabolic disorder,
or a developmental abnormality [CONT.]
Identifying a phenotype associated with a
WO 2006026222
disruption of a gene which encodes for a PRO196,
PRO217, PRO231, PRO236, PRO245, PRO246,
PRO258, PRO287, PRO328, PRO344, PRO357,
PRO526, PRO724, PRO731, PRO732, PRO1003,
PRO1104, PRO1151, PRO1244, PRO1298,
PRO1313, PRO1570, PRO1886, PRO1891,
PRO4409, PRO5725, PRO5994, PRO6097,
PRO7425, PRO10102, PRO10282, PRO61709 or
PRO779 polypeptide by: [CONT.]
US 20060115448
N
R2=absent or group with opposite polarity of that
of R1.
INDEPENDENT CLAIMS are included for the
following:
(1) a polymer (P1) formed from the amphiphilic
polynorbornene monomer;
(2) an amphiphilic copolymer (P2) comprising a
polar polynorbornene monomeric unit and non
polar polynorbornene monomeric unit of formula
(I) and (II); [CONT.]
(1) a polymer (P1) formed from the amphiphilic
polynorbornene monomer; [CONT.]
WO 2006026222 A2 UPAB: 20060328
The method is useful in identifying a phenotype
associated with a disruption of a gene which
NOVELTY: Identifying a phenotype associated
encodes for a PRO196, PRO217, PRO231,
with a disruption of a gene which encodes for a
PRO236, PRO245, PRO246, PRO258, PRO287,
PRO polypeptide comprises:
PRO328, PRO344, PRO357, PRO526, PRO724,
(1) providing a non-human transgenic animal
PRO731, PRO732, PRO1003, PRO1104,
whose genome comprises a disruption of the gene
PRO1151, PRO1244, PRO1298, PRO1313,
which encodes for a PRO polypeptide; and
PRO1570, PRO1886, PRO1891, PRO4409,
PRO5725, PRO5994, PRO6097, PRO7425,
(2) comparing the measured physiological
PRO10102, PRO10282, PRO61709 or PRO779
characteristic of the non-human transgenic animal
polypeptide [CONT.]
with that of a gender matched wild-type animal.
[CONT.]
US 20080160034
US 20110061114
N
ZA 2007002321
A
20090930
ZA 2008002557
A
20100127
ZA 2008002558
A
20100127
ZA 2008002556
A
20100224
ZA 2008002561
A
20100224
ZA 2008002562
A
20100224
ZA 2008002563
A
20100224
US 20110061114
WO 2006025990
A1
20110310
A2
20060309
EP 1784487
A2
20070516
CHANG G J
AU 2007200847
A1
20070322
CRILL W D
IN 2007DN01310
A
20070803
US 20080248064
A1
20081009
AU 2007200847
B2
20100617
A1
20110310
B2
20110315
TAKEDA PHARM CO LTD
US 20110059131
US 7906292
WO 2006022420
A1
20060302
WO 2006022420 A1 UPAB: 20101112
HASHIMOTO T
EP 1792629
A1
20070606
KAMO I
US 20070274913
A1
20071129
NOVELTY: A therapeutic and prophylactic agent
of stress-induced urinary incontinence (I)
comprises a substance activating serotonin 5HT2c receptor.
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are also included for the following:
JP 2006532742
X
20080508
EP 2248524
EP 2248524
A2
20101110
A3
20110309
358 Oral care product for preventing dental plaque, LION SHOJI KK
dental caries and periodontal disease in pet
animals such as dog and cat, contains
dextranas and oolong tea extract as main
ingredients
JP 2006055050
A
20060302
JP 4656288
B2
20110323
NUTRICIA NV
359 Use of indigestible oligosaccharides and
digestible galactose saccharide for
manufacture of composition for use in
treatment and/or prevention of respiratory tract
infection and/or respiratory tract infection
disease
EP 1629850
A1
20060301
US DEPT HEALTH & HUMAN SERVICES
356 New isolated mutant flavivirus polypeptide,
which exhibits measurably reduced antibody
US DEPT HEALTH&HUMAN SERVICES
cross-reactivity, for treating or preventing
flavivirus infection, e.g. dengue virus infection
357 Agent for preventing and treating stressinduced urinary incontinence, caused by
disconnecting nerve concerned with
contraction of urethral muscle during
childbirth, comprises substance activating
serotonin receptor
WO 2006025990 A2 UPAB: 20100729
The mutant flavivirus polypeptides and nucleic
acids are useful for eliciting an immune response
against a flavivirus and for detecting flaviviral
NOVELTY: An isolated mutant flavivirus
polypeptide comprising any of 3 fully defined 495- infection in humans. They can also be used for
inhibition or treatment of flaviviral infection, e.g.
501 amino acid sequences (SEQ ID NO: 14, 81,
dengue virus infection, yellow fever virus infection,
or 85), given in the specification, where at least
one of the amino acids at position 104, 106, 107, Japanese encephalitis virus infection, St. [CONT.]
126, 226, or 231 is substituted compared to a wildtype flavivirus polypeptide, and where the
polypeptide exhibits measurably reduced antibody
cross-reactivity, is new. [CONT.]
(I) Is useful for preventing and treating stressinduced urinary incontinence, caused by
disconnecting the nerve concerned with
contraction of pelvic muscle or outer sphincter
muscle of urethra during childbirth, ovariectomy,
mechanical vagina enlargement treatment,
diabetes and/or drug administration (claimed).
BIOTECHNOLOGY - Preferred Polypeptide: The INDEPENDENT CLAIMS are also included for:
WO 2006025990
amino acid substitution is selected from Gly104His
(SEQ ID NO: 16), Gly106Gln (SEQ ID NO: 18),
(1) an isolated nucleic acid molecule encoding the
Leu107Lys (SEQ ID NO: 20), Glu126Ala (SEQ ID polypeptide;
NO: 22), Thr226Asn (SEQ ID NO: 24), Trp231Phe
(SEQ ID NO: 26), Trp231Leu (SEQ ID NO: 28),
Glu126Ala or Thr226Asn (SEQ ID NO: 30), or its
combinations. Preferably, the amino acid
substitution comprises Gly106Gln (SEQ ID NO:
83) or Gly106Val (SEQ ID NO: 87) [CONT.]
(I) Effectively prevents and treats stress-induced
urinary incontinence. The novel screening method
enables effective measurement of urethral
resistance during rapid and transient abdominal
pressure raise.
PHARMACEUTICALS - Preferred Compound: The
substance activating serotonin 5-HT2c receptor is
preferably serotonin 5-HT2c receptor agonist or a
substance which stimulates androgen coupling.
US 20080248064
N
US 20110059131
(2) a recombinant nucleic acid molecule
comprising a regulatory sequence operably linked
to the nucleic acid molecule;
(3) a cell comprising the recombinant nucleic acid
molecule;
(4) a virus-like particle comprising the new
polypeptide;
(5) a method for identifying a flavivirus crossreactive epitope; [CONT.]
US 7906292
INDEPENDENT CLAIMS are also included for the WO 2006022420
following:
(1) prevention and treatment of stress-induced
urinary incontinence in mammals, which
comprises administering (I);
US 20070274913
N
(2) use of substance activating serotonin 5-HT2c
receptor for manufacturing (I); and [CONT.]
(1) prevention and treatment of stress-induced
urinary incontinence in mammals, which
comprises administering (I); [CONT.]
JP 2006055050 A UPAB: 20060320
For preventing dental plaque, dental caries and
periodontal disease in pet animals such as dog
NOVELTY: An oral care product contains
dextranas (0.2-200 U/g) and oolong tea extract as and cat.
main ingredients.
DETAILED DESCRIPTION: An INDEPENDENT
CLAIM is also included for preparation of oral care
product, which involves spraying aqueous oolong
tea extract solution on foodstuffs, drying, followed
by spraying aqueous dextranas solution and
drying obtained product. [CONT.]
The oral care product has excellent therapeutic
effect with respect to dental plaque, dental caries
and periodontal disease.
FOOD - Preferred Ingredients: The dextranas and An INDEPENDENT CLAIM is also included for
oolong tea extract are adhered to the surface of
preparation of oral care product, which involves
foodstuffs.
spraying aqueous oolong tea extract solution on
foodstuffs, drying, followed by spraying aqueous
dextranas solution and drying obtained product.
EP 1629850 A1 UPAB: 20060320
The invention reduces occurrence of respiratory
tract infections. It is safe and can be mixed to
nutrition. This leads to reduced stress, particularly
in infants.
ORGANIC CHEMISTRY - Preferred Compositions:
The composition comprises (a) 10-60 en% lipid; 550 en% protein; and 15-90 en% carbohydrate; (b)
40-60 wt.% lactose; (c) 0.1-12 g
transgalactvoligosaccharides with a degree of
polymerization (DP) of 2-10/100 g dry wt. of the
composition; and (d) long chain polyunsaturated
fatty acid (LC-PUFA) consisting of
eicosapentaenoic acid (EPA, n-3),
docosahexaenoic acid (DHA, n-3), or arachidonic
acid (AA, n-6) [CONT.]
The invention is used for manufacture of
composition for use in treatment and/or prevention
of respiratory tract infection and/or respiratory tract
infection disease, preferably respiratory syncytial
virus infection, childhood bronchiolitis, and/or
pediatric pneumonia. The composition is
administered to a patient suffering from acquired
immune deficiency syndrome (AIDS), chronic
obstructive pulmonary disease (COPD), or
diabetes (all claimed) [CONT.]
JP 2006055050
The indigestible oligosaccharides and digestible
EP 1629850
galactose saccharide are used for the
manufacture of composition for use in the
treatment and/or prevention of respiratory tract
infection and/or respiratory tract infection disease
by orally administering the composition to
mammal. [CONT.]
Y
US 20070274983
N
JP4656288B2
NUTRICIA NV
359 Use of indigestible oligosaccharides and
digestible galactose saccharide for
manufacture of composition for use in
treatment and/or prevention of respiratory tract
infection and/or respiratory tract infection
disease
360 Pharmaceutical composition useful for treating MEDICAL RES FUND TEL AVIV SOURASKY
MED
e.g. infections, inflammatory disease and
neurodegenerative diseases comprises one of FROKLIS I
venom obtained from venomous insect, snake,
scorpion and spider
LOCKER C
WO 2006022542
A1
20060302
WO 2006022543
EP 1629850
EP 1784218
EP 1784222
A1
20060302
B1
20070502
A1
20070516
A1
20070516
DE 602004006258
E
20070614
AU 2005275576
A1
20060302
AU 2005275577
A1
20060302
AU 2005275576
A2
20060302
IN 2007DN01243
A
20070803
US 20070274983
A1
20071129
ES 2286558
T3
20071201
DE 602004006258
T2
20080110
CN 101043904
A
20070926
JP 2008510803
T
20080410
CN 101094687
A
20071226
US 20080124323
A1
20080529
BR 2005014536
A
20080617
NZ 553390
A
20091127
RU 2385714
C2
20100410
RU 2385725
C2
20100410
AU 2005275577
B2
20110310
WO 2006018844
A1
20060223
EP 1784200
A1
20070516
AU 2005273487
A1
20060223
NOVELTY: Indigestible oligosaccharides and
digestible galactose saccharide are used for
manufacture of composition for use in treatment
and/or prevention of respiratory tract infection
and/or respiratory tract infection disease by orally
administering the composition to a mammal. The
composition comprises galactose containing
indigestible oligosaccharide, and digestible
galactose saccharide. [CONT.]
The invention is used for manufacture of
composition for use in treatment and/or prevention
of respiratory tract infection and/or respiratory tract
infection disease, preferably respiratory syncytial
virus infection, childhood bronchiolitis, and/or
pediatric pneumonia. The composition is
administered to a patient suffering from acquired
immune deficiency syndrome (AIDS), chronic
obstructive pulmonary disease (COPD), or
diabetes (all claimed) [CONT.]
WO 2006018844 A1 UPAB: 20110315
For modulating or managing and treating patient
suffering from non-specific systemic inflammatory
response syndrome (SIRS) that an infectious or
NOVELTY: A pharmaceutical composition
non-infectious origin or symptoms associated with
comprises at least one venom and carrier,
excipient or diluent. The venom is obtained from at it; immunizing a mammal against SIRS or
pathologies associated with it; and treating tumor
least one venomous insect, snake, scorpion
necrosis factor (TNF)-alpha-mediated diseases
and/or spider.
(e.g. bacterial, viral or parasitic infections (e.g.
ACTIVITY: Antiinflammatory; Antibacterial;
[CONT.]
Virucide; Antiparasitic; Immunosuppressive;
The invention reduces occurrence of respiratory
tract infections. It is safe and can be mixed to
nutrition. This leads to reduced stress, particularly
in infants.
ORGANIC CHEMISTRY - Preferred Compositions:
The composition comprises (a) 10-60 en% lipid; 550 en% protein; and 15-90 en% carbohydrate; (b)
40-60 wt.% lactose; (c) 0.1-12 g
transgalactvoligosaccharides with a degree of
polymerization (DP) of 2-10/100 g dry wt. of the
composition; and (d) long chain polyunsaturated
fatty acid (LC-PUFA) consisting of
eicosapentaenoic acid (EPA, n-3),
docosahexaenoic acid (DHA, n-3), or arachidonic
acid (AA, n-6) [CONT.]
The indigestible oligosaccharides and digestible
EP 1629850
galactose saccharide are used for the
manufacture of composition for use in the
treatment and/or prevention of respiratory tract
infection and/or respiratory tract infection disease
by orally administering the composition to
mammal. [CONT.]
The composition inhibits TNF-alpha synthesis or
release and neutralizes TNF-alpha activity; hence
lowers TNF-alpha serum concentrations or
blocking the activity of TNF-a in patient suffering
from disease associated with increased TNFalpha concentrations.
BIOLOGY - Preferred Components: At least one of
the venom is obtained from a venomous snake
selected from Viperidae, Elapidae, Crotolidae,
Hydrophidue and Atraetaspidae (preferably Vipera
aspis). PHARMACEUTICALS - Preferred
Composition: The composition comprises at least
two venoms from two different groups of snakes.
[CONT.]
WO 2006018844
(I) reduces the risks attached to feeding whey
dominant infant formula. (I) stimulates: the
development of a optimal intestinal flora; the
maturation of the gastrointestinal tract; and the
maturation of the immune system, resulting in a
better defense in case an allergen, pathogen or
toxin crosses the intestinal barrier and/or enters
the systemic circulation. (I): is synergistic and
provides an improved resistance to infant [CONT.]
FOOD - Preferred Components: (I) comprises
transgalactooligosaccharide, pectin hydrolyzate
and fructooligosaccharides and/or inulin. (I)
contains docosahexaenoic acid, arachidonic acid
or eicosapentaenoic acid. (I) comprises zinc (2100 mg) per 100 g dry weight of (I). The protein
component (5-15 en.%), the fat component (30-60
en.%) and the carbohydrate component (25-75
en.%). [CONT.]
Nutritional or pharmaceutical composition (I)
WO 2006018314
(containing fat, protein and carbohydrate
components) comprises whey (A1) and casein
(A2), where the weight ratio of A2 to A1 is 1:11:2.4 and (I) contains arginine (3 g); linoleic acid
(10 wt.%); alpha linolenic acid (1 wt.%); long chainpolyunsaturated fatty acid (0.1 wt.%)
(docosahexaenoic acid, arachidonic acid or
eicosapentaenoic acid); polyunsaturated fatty acid
(5-25 wt [CONT.]
US 20080124323
US 20070248687
N
Immunomodulator; Fungicide; Anti-HIV; Nootropic;
Dermatological; Antirheumatic; Antiarthritic
[CONT.]
SORKINE P
NUTRICIA NV
361 Nutritional or pharmaceutical composition,
useful for treating/preventing e.g. inflammatory
diseases, diarrhea, eczema and/or atopic
dermatitis, comprises whey and casein
US 20070248687
A1
20071025
JP 2008509990
T
20080403
AU 2005273487
B2
20110303
WO 2006018314
EP 1634599
A2
20060223
WO 2006018314 A2 UPAB: 20060315
A1
20060315
NOVELTY: Nutritional or pharmaceutical
composition (I) (containing fat, protein and
carbohydrate components) comprises whey (A1)
and casein (A2), where (I) contains arginine (3 g);
linoleic acid (10 wt.%); alpha linolenic acid (1
wt.%); long chain-polyunsaturated fatty acid (0.1
wt.%) (docosahexaenoic acid, arachidonic acid or
eicosapentaenoic acid); polyunsaturated fatty acid
(5-25 wt [CONT.]
EP 1781307
A2
20070509
AU 2005274266
A1
20060223
IN 2007KN00691
A
20070706
CN 101048167
A
20071003
JP 2008510689
T
20080410
BR 2005014526
A
20080610
Composition (I) is useful for the preparation of an
infant formula food or a medicament for the
treatment and/or prevention of inflammatory
diseases (allergy), diarrhea, eczema and/or atopic
dermatitis in a mammal (preferably a human
infant) (claimed). (I) is useful for the treatment
and/or prevention of allergic rhinitis, allergic
conjunctivitis, allergic dermatitis, atopic dermatitis
and/or food allergy [CONT.]
US 20100136134
N
362 New short interfering RNA, useful for
diagnosing and treating angiogenesis-related
disorder is cancer, arthritis, macular
degeneration, diabetic retinopathy, psoriasis,
or cardiovascular diseases
EP 1781307
B1
20090401
DE 602005013679
E
20090514
ES 2322380
T3
20090619
NZ 553248
A
20091224
US 20100136134
A1
20100603
CN 101766228
A
20100707
VN 10008242
B
20100325
AU 2005274266
B2
20110310
WO 2006015426
A1
20060216
EP 1784488
A1
20070516
AU 2005270734
A1
20060216
JP 2008508889
T
20080327
US 20080119430
US 7667028
A1
20080522
B2
20100223
NZ 553126
A
20101126
AU 2005270734
B2
20110324
WO 2006012644
US 20060024269
A2
20060202
WO 2006012644 A2 UPAB: 20060224
A1
20060202
AU 2005266892
A1
20060202
NOVELTY: Treating cancer comprising
administering to a patient a polypeptide selected
from 61 fully defined sequences comprising 175200 amino acids (I), as given in the specification,
is new.
DETAILED DESCRIPTION: Treating cancer
comprises administering a polypeptide selected
from 61 fully defined sequences comprising 175200 amino acids (I) (SEQ ID NO. [CONT.]
CHAN C
EP 1793845
A2
20070613
DOYLE S
IN 2007CN00847
A
20070824
KINDSVOGEL W R
CN 101031316
A
20070905
KLUCHER K M
JP 2008508310
T
20080321
SIVAKUMAR P V
US 7351689
B2
20080401
BR 2005013865
A
20080520
US 20080167244
A1
20080710
RU 2389502
C2
20100520
BIONOMICS LTD
363 Treating cancer by administering to a patient a ZYMOGENETICS INC
first polypeptide and a second polypeptide
ZYMOGENETICS LLC
selected from interferon-alpha, interferon-beta,
or interferon-gamma
BRISTOL-MYERS SQUIBB CO
364 Oral composition, useful to treat e.g.
cutaneous signs of aging and unhealthy skin
comprises, Vitamin E, vitamin C and white tea
extract
FERROSAN AS
US 7786075
B2
20100831
CN 101829318
A
20100915
WO 2006015426 A1 UPAB: 20060310
The siRNA, shRNA, nucleic acid molecule, vector,
modulator of expression or activity of a
polypeptide encoded by a nucleic acid molecule,
NOVELTY: A short interfering RNA (siRNA)
molecule comprising a complement of a segment or polypeptide, or its active fragment is useful in
manufacturing a medicament for the treatment of
of an mRNA transcribed from the BN069 gene,
an angiogenesis-related disorder. The nucleic acid
where the siRNA molecule modulates the
expression of BNO69 by RNA interference, is new. molecule, polypeptide or its active fragment, cell,
or genetically modified non-human animal is
useful for the screening of candidate
DETAILED DESCRIPTION: INDEPENDENT
pharmaceutical compounds for the treatment of
CLAIMS are also included for:
angiogenesis-related disorders [CONT.]
BIOTECHNOLOGY - Preferred Sequences: The
BN069 gene is encoded by an isolated nucleic
acid molecule comprising the sequence of 2936,
4593, 2417, 1856, or 531 bp (EVEN SEQ ID NOS:
8-16). The siRNA molecule comprises a sequence
of 19 bp each (SEQ ID NOS: 3 or 4). The shRNA
molecule further comprises a linker sequence and
a sequence, which is the reverse complement of
the siRNA molecule, where the linker sequence is
a nucleotide sequence comprising 5 bp (SEQ ID
NO: 5) [CONT.]
INDEPENDENT CLAIMS are also included for:
BIOTECHNOLOGY - Preferred Method: In treating
cancer, the polypeptide further comprises
polyethylene glycol, where the polyethylene glycol
is covalently linked N-terminally to the polypeptide.
The polyethylene glycol is 20kD, 30kD, or 40kD.
The polyethylene glycol is also linear or branched.
Preferably, the polyethylene glycol is
monomethoxy-PEG propionaldehyde. In the
method, the patient is a mammal, preferably a
human [CONT.]
Treating cancer comprises administering a
WO 2006012644
polypeptide selected from 61 fully defined
sequences comprising 175-200 amino acids (I)
(SEQ ID NO. 2, 4, 6, 13, 15, 17, 19, 21, 23, 25,
27, 29, 36, 37, 38, 39, 40, 41, 75, 77, 79, 81, 83,
85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107,
109, 111, 113, 115, 117, 119, 121, 123, 125, 127,
129, 131, 133, 135, 137, 139, 141, 143, 145, 147,
149, 151, 153, 155, [CONT.]
(1) a short hairpin RNA (shRNA) molecule which
comprises the siRNA molecule above; [CONT.]
The methods are useful for treating cancer,
inhibiting the progression of cancer, delaying the
onset of cancer, reducing the severity of cancer,
and inhibiting a condition or symptom of cancer.
Cancer is selected from B-cell lymphomas,
chronic lymphocytic leukemia, acute lymphocytic
leukemia, Non-Hodgkin's lymphomas, multiple
myeloma, acute myelocytic leukemia, chronic
myelocytic leukemia, renal [CONT.]
WO 2006015426
(1) a short hairpin RNA (shRNA) molecule which
comprises the siRNA molecule above;
US 20080119430
N
US 7667028
(2) a nucleic acid molecule comprising the
sequence of 19 bp each (SEQ ID NOS: 1 or 2), or
2936, 2417, 1856, or 531 bp (SEQ ID NOS: 8, 12,
14, or 16);
(3) a vector comprising one or more of an siRNA
molecule, a shRNA molecule, or a nucleic acid
molecule above; [CONT.]
US 20060024269
US 7351689
N
US 20080167244
US 7786075
US 20100291030
US 20100291030
A1
20101118
AU 2005266892
B2
20110303
WO 2006000226
A1
20060105
EP 1768500
A1
20070404
BR 2005011322
A
20071204
CN 101026965
A
20070829
JP 2008503505
T
20080207
(1) a pharmaceutical composition obtained by (I);
and
(2) a tablet comprising (I) along with excipients.
MX 2006014963
A1
20070601
ACTIVITY: Dermatological.
WO 2006000226 A1 UPAB: 20060206
(I) is useful to treat skin conditions and cutaneous (I) reduces: signs of wrinkles; and improves skin
signs of aging. (I) is useful to obtain a
conditions such as increases skin elasticity and
skin softness.
NOVELTY: Oral composition (I) for the prevention pharmaceutical composition (all claimed). (I) is
also useful to treat unhealthy skin and the skin
and treatment of skin conditions in a mammal
overexposed to sunlight. The ability of (I) to treat
comprises Vitamin E, vitamin C and white tea
aging of skin was tested using biological assays.
extract.
The results showed that (I) significantly reduces
DETAILED DESCRIPTION: INDEPENDENT
the aging of skin.
CLAIMS are also included for:
ORGANIC CHEMISTRY - Preferred Components:
(I) further comprises: naturally occuring
antioxidants (5-95 wt.%) extracted from grape
seed, tomato, soy (5-95 wt.%) and/or chamomille;
an extract comprising glycosaminoglycans
(preferably cartilage extract); and at least one
transition metal component. The cartilage extract
comprises chondroitin sulfate, keratan sulfate,
hyaluronic acid and/or dermatan sulfate [CONT.]
INDEPENDENT CLAIMS are also included for:
WO 2006000226
Y
(1) a pharmaceutical composition obtained by (I);
and
(2) a tablet comprising (I) along with excipients.
EP1768500B1
365 Nucleic acid-lipid particle useful for treating
diseases e.g. viral infection, liver diseases or
tumors, comprises interfering RNA, cationic
lipid, non-cationic lipid and conjugated lipid
for inhibiting aggregation of particles
MX 274812
B
20100326
RU 2409290
C2
20110120
EP 1768500
WO 2005121348
B1
20110302
A1
20051222
WO 2005121348 A1 UPAB: 20091012
US 20060008910
A1
20060112
EP 1766035
A1
20070328
NOVELTY: A nucleic acid-lipid particle (NP)
comprises an interfering RNA, a cationic lipid, a
non-cationic lipid, and a conjugated lipid that
inhibits aggregation of particles.
DETAILED DESCRIPTION: A nucleic acid-lipid
particle (NP) comprises an interfering RNA, a
cationic lipid of formula (I), a non-cationic lipid and
a conjugated lipid that inhibits aggregation of
particles. [CONT.]
AU 2005252273
A1
20051222
CN 1981044
A
20070613
JP 2008501730
T
20080124
CN 1981044
B
20100505
US 7799565
US 20110060032
WO 2005123778
B2
20100921
A1
20110310
A2
20051229
WO 2005123778 A2 UPAB: 20060130
US 20060002925
A1
20060105
NOVELTY: An isolated soluble receptor comprises
at least one ZcytoR14 subunit, where the
ZcytoR14 subunit comprises a polypeptide
comprising fully defined 432 amino acids (SEQ ID
NO. 3) or comprises amino acid residues 1-427 of
a fully defined 667 amino acid sequence (SEQ ID
NO. 24) given in the specification, is new.
BURKHEAD S K
US 20070048257
A1
20070301
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are also included for: [CONT.]
GAO Z
US 20070048826
A1
20070301
JASPERS S R
NO 2007000153
A
20070309
KUESTNER R E
EP 1765865
A2
20070328
LEVIN S D
AU 2005254998
A1
20051229
PRESNELL S R
IN 2007CN00093
A
20070824
CN 101001871
A
20070718
BR 2005011952
A
20080129
JP 2008509227
T
20080327
MX 2006014465
A1
20070601
B2
20110322
A1
20051222
WO 2005121316 A1 UPAB: 20060120
OBRIEN INST MICROSURGERY BERNARD
US 7910540
WO 2005121316
US 20060153797
A1
20060713
NOVELTY: A composition (C1) useful in
promoting cell effects, comprises either a cellbased or cell-free extract of a muscle tissue
preparation, which preparation provides a source
of laminin, collagen I, collagen IV,
entactin/nidogen, heparan sulfate proteoglycan
and other components including cytokines and
growth factors such as epidermal growth factor
(EGF) and tumor necrosis factor-alpha (TNFalpha) or their homologs, is new. [CONT.]
VICTORIAN TISSUE ENG CENT PTY LTD
EP 1765981
A1
20070328
ABBERTON K M
AU 2005252267
A1
20051222
BORTOLOTTO S K
CN 1969039
A
20070523
MESSINA A
JP 2008501724
T
20080124
AU 2005252267
B2
20110303
WO 2005118864
A2
20051215
PROTIVA BIOTHERAPEUTICS INC
PROTIVA BIOTHERAPEUTIES INC
ZYMOGENETICS INC
366 New isolated soluble receptor comprises at
least one ZcytoR14 subunit, useful for treating
BILSBOROUGH J
an inflammatory disease, e.g. asthma,
inflammatory bowel disease, ulcerative colitis,
arthritis, atopic dermatitis, or psoriasis
367 Composition for promoting cell effects and
generating donor vascularized tissue for
transplantation, has cell-based or cell-free
extract of muscle tissue preparation that
provides source of laminin, cytokines and
growth factors
O'BRIEN INST MICROSURGERY BERNARD
AGENSYS INC
368 New antibody that binds to PSCA protein,
useful for diagnosing, prognosing, preventing,
MECHANISM OF ACTION: None give. [CONT.]
NP is useful for introducing an interfering RNA into The interfering RNA of NP is resistant in aqueous
a cell of a mammal e.g. human. NP is useful for
solution to degradation by a nuclease (claimed).
delivering interfering RNA to a human having a
disease or disorder associated with expression of
a gene, where the expression of the gene is
reduced by the interfering RNA. The disease or
disorder is associated with overexpression of the
gene (claimed). [CONT.]
The soluble receptor comprising at least one
ZcytoR14 subunit is useful for treating an
inflammatory disease, e.g. asthma; chronic
inflammatory disease selected from inflammatory
bowel disease, ulcerative colitis, Crohn's disease,
arthritis, atopic dermatitis, or psoriasis; or acute
inflammatory disease selected from endotoxemia,
septicemia, toxic shock syndrome, or infectious
disease (claimed).
BIOTECHNOLOGY - Preferred Particle: In NP, the
cationic lipid is chosen from 1,2-DiLinoleyloxy-N,Ndimethylaminopropane (DLinDMA) and 1,2Dilinolenyloxy-N,N-dimethylaminopropane
(DLenDMA). NP has a median diameter of less
than 150 nm. The interfering RNA comprises
siRNA having 15-60 (duplex) nucleotides. The
interfering RNA is transcribed from a plasmid. The
interfering RNA comprises double-stranded RNA
[CONT.]
A nucleic acid-lipid particle (NP) comprises an
interfering RNA, a cationic lipid of formula (I), a
non-cationic lipid and a conjugated lipid that
inhibits aggregation of particles.
R1,R2=H and 1-3C alkyls;and
BIOTECHNOLOGY - Preferred Soluble Receptor:
The soluble receptor comprises two ZcytoR14
subunits, where the subunits are linked together
by a polypeptide linker. The polypeptide linker has
100-240 amino acid residues. The soluble
receptor reduces the pro-inflammatory activity of
both IL-17A (SEQ ID NO. 14) and IL-17F (SEQ E)
NO: 16). Preferred Antibody: The antibody or
antibody fragment reduces the pro-inflammatory
activity of both IL-17A (SEQ ID NO [CONT.]
INDEPENDENT CLAIMS are also included for:
WO 2005121348
US 20060008910
N
US 7799565
R3,R4=alkyl groups having 10-20C, where one or
more of R3 and R4 comprises two or more sites of
unsaturation.
US 20110060032
WO 2005123778
(1) an isolated soluble receptor comprising
ZcytoR14, where ZcytoR14 comprises a
polypeptide having SEQ ID NO. 3; and where the
soluble receptor reduces the pro-inflammatory
activity of either IL-17A comprising fully defined
155 amino acids (SEQ ID NO. 14) or IL-17F
comprising fully defined 153 amino acids (SEQ ID
NO. 16); [CONT.]
US 20060002925
N
US 20070048257
US 20070048826
US 7910540
WO 2005118864 A2 UPAB: 20090609
(C1) is useful in a bioassay for adipogenic
(C1) induces a wider range of cellular activities
potential of some material, and in an in vitro assay and can be applied in a species-conserved way.
for adipogenesis modulating components,
extracts, or cell systems, which involves screening
a muscle preparation to identify a group of cells
having a propensity for adipocytic differentiation,
generating or obtaining a potential adipogenesis
modulating component or extract or cell system,
seeding onto [CONT.]
BIOTECHNOLOGY - Preferred Composition: In
(C1), the preparation is a source of laminin,
entactin/nidogen, heparan sulfate proteoglycan,
collagen IV, bFGF, PDGF, TGF-beta, VEGF and
TNF-alpha. The cells are from muscle tissue from
a human, non-human, primate, livestock animal,
laboratory test animal, companion animal, avian
species, reptile or amphibian, preferably from a
human, pig or rat. [CONT.]
A composition (C1) useful in promoting cell
WO 2005121316
effects, comprises either a cell-based or cell-free
extract of a muscle tissue preparation, which
preparation provides a source of laminin, collagen
I, collagen IV, entactin/nidogen, heparan sulfate
proteoglycan as well as other components
including cytokines and growth factors such as
epidermal growth factor (EGF), basic fibroblast
growth factor (bFGF), [CONT.]
US 20060153797
The antibody, protein, composition, vaccines, and
method are useful for diagnosing, prognosing,
preventing, and/or treating cancer, e.g. prostate,
BIOTECHNOLOGY - Preferred Antibody: The
antibody is a monoclonal antibody, which is
assigned A.T.C.C. (Accession Number not
INDEPENDENT CLAIMS are also included for:
US 20060029940
WO 2005118864
N
N
useful for diagnosing, prognosing, preventing,
and/or treating cancer, e.g. prostate, pancreas, CHALLITA-EID P M
bladder, kidney, colon, lung, ovary, or breast
cancer
GE W
369 New composition comprising modified
nuclease, useful for treating or preventing a
viral disease or a non-viral disease, e.g.
Alzheimer disease, Parkinson disease,
multiple sclerosis or age-related dementia
method are useful for diagnosing, prognosing,
NOVELTY: An antibody or fragment comprising an preventing, and/or treating cancer, e.g. prostate,
pancreas, bladder, kidney, colon, lung, ovary, or
antigen-binding site that binds specifically to
breast cancer.
PSCA protein, is new.
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are also included for:
(1) a transgenic animal that produces the
monoclonal antibody above;
(2) a hybridoma that produces the monoclonal
antibody above;
US 20060029940
A1
20060209
US 20060147375
A1
20060706
JAKOBOVITS A
NO 2006005874
A
20061219
RAITANO A B
EP 1753871
A2
20070221
AU 2005250370
A1
20051215
MX 2006013834
A1
20070301
IN 2006DN06928
A
20070803
CN 1997751
A
20070711
KR 2007047251
A
20070504
JP 2008500833
T
20080117
BR 2005011624
A
20080102
ZA 2006009894
A
20080130
US 7541442
US 20090202548
US 7622564
B2
20090602
A1
20090813
B2
20091124
RU 2381234
C2
20100210
NZ 551627
A
20100226
AU 2005250370
B2
20100401
MX 276788
B
20100621
JP 4651663
B2
20110316
AVIRID BIOTECHNOLOGY LLC
WO 2005115444
A2
20051208
AVIRID INC
EP 1734991
A2
20061227
APPELBAUM J G
AU 2005247298
A1
20051208
SALGANIK R I
JP 2007532666
T
20071115
IN 2006DN06353
A
20070831
CA 2604243
A1
20051208
US 20090047272
A1
20090219
AU 2005247298
B2
20101111
AU 2011200602
A1
20110303
AU 2005247298
B8
20110310
WO 2005105115
A1
20051110
WO 2005105115 A1 UPAB: 20091006
EP 1742646
A1
20070117
NOVELTY: A skin condition treating composition
for use in treating a wound, bum or other skin
condition, comprises a functionalized siloxane
compound present at greater than or equal to1%
of the composition.
370 Skin condition treating composition, in form of UNIV QUEENSLAND
e.g. gel or gel sheeting, for use in manufacture
of medicament for treatment of wound (i.e.
scar), bum or other skin condition, comprises
functionalized siloxane compound
UNIV QUEENSLAND TECHNOLOGY
antibody is a monoclonal antibody, which is
assigned A.T.C.C. (Accession Number not
defined), and where the monoclonal antibody is a
humanized antibody. The fragment is a Fab,
F(ab')2, Fv, or SfV fragment. The antibody is a
fully human antibody. The antigen-binding site is a
murine antigen-binding domain. [CONT.]
(3) a vector comprising a polynucleotide encoding
an antibody above; [CONT.]
WO 2005115444 A2 UPAB: 20090401
The composition and methods are useful for
treating or preventing a viral disease or a non-viral
NOVELTY: An antiviral composition comprising a disease, e.g. neurodegenerative disease selected
modified nuclease, where at least one amino acid from Alzheimer disease, Parkinson's disease,
multiple sclerosis (MS), or age-related dementia.
in the amino acid sequence of the modified
nuclease is a non-natural amino acid residue that
is substituted for a naturally-occurring amino acid
in the amino acid sequence of a parent nuclease,
where the modified nuclease has greater
hydrolytic activity than the parent nuclease, is
new. [CONT.]
The modified nucleases are less prone to
degradation and show improved cellular uptake
and half-life and are less likely to cause drug
resistance.
BIOTECHNOLOGY - Preferred Antiviral
Composition: The substituted non-natural amino
acid comprises a keto or a thiol side chain group.
The non-natural amino acid is located at the N- or
C-terminus of the amino acid sequence of the
nuclease. The non-natural amino acid is located in
position of the sequence comprising a substrate
nucleic acid binding domain of the nuclease,
where the substituted non-natural amino-acid
residue comprises a multiply-charged side chain
group [CONT.]
(1) a transgenic animal that produces the
monoclonal antibody above;
US 20060147375
(2) a hybridoma that produces the monoclonal
antibody above;
(3) a vector comprising a polynucleotide encoding
an antibody above;
(4) a pharmaceutical composition that comprises
the antibody or fragment above in a human unit
dose form;
(5) an assay or a method for detecting the
presence of a PSCA protein in a biological
sample; [CONT.]
US 7541442
INDEPENDENT CLAIMS are also included for:
US 20090202548
US 7622564
WO 2005115444
US 20090047272
N
(1) a method for preventing and treating a viral
disease in a subject caused by infection with at
least one viral agent selected from emerging wildtype viruses, naturally occurring mutant viruses, or
mutant viruses occurring in the course of an
antiviral therapy;
(2) a method for preventing development of viral
resistance to nucleases administered for treating a
viral disease; [CONT.]
The composition, in the form of gel, gel sheeting
or low molecular weight poly alcohol that acts as
an artificial skin upon drying, is used in the
manufacture of medicament for treatment of
wound (i.e. scar), bum or other skin condition e.g.
keloid scarring, hypertrophic scarring, acne
scarring, and erythematous skin and stretch mark
scarring (claimed), in mammals such as humans,
domestic animals, [CONT.]
The composition is effective in modifying one or
more clinical marker consisting of scar color, scar
profile, amount of hair, size of wound and/or
amount of infection, or one or more marker
consisting of number of fibroblasts, alteration of
interstitial tissue, epidermal thickness, number of
hair follicles and alteration in papillary and/or
reticular dermis. [CONT.]
INORGANIC CHEMISTRY - Preferred
Component: The composition further comprises
an additive consisting of a carrier, a diluent or an
excipient, from oil in water emulsion, water in oil
emulsion, particulate carrier, clay, silicate,
clathrate or other inorganic material. The
particulate carrier is talcum powder. The
composition further comprises an additive
consisting of colorant and a second
pharmaceutically active material which is not the
compound (I) [CONT.]
A skin condition treating composition for use in
treating a wound, bum or other skin condition,
comprises a functionalized siloxane compound of
formula R-(-Si(CH3)2-O-)n-(-Si(CH3)(Q)-O-)mSi(CH3)3-R' (I).
m= 0-6;
WO 2005105115
US 20080299067
N
compound (I) [CONT.]
371 Compressed composition for preparing a
medicament in treating constipation
comprises polyethylene glycol and electrolyte
NORGINE EURO BV
NORGINE BV
372 Reducing symptom of psoriasis, e.g. scaling, GANEDEN BIOTECH INC
blistering, skin lesions, itchiness, or join pain,
involves administering composition containing FARMER S
Bacillus coagulants bacteria to patient
LEFKOWITZ A R
AU 2005237185
A1
20051110
KR 2007007201
A
20070112
CN 1980680
A
20070613
IN 2006DN06364
A
20070831
JP 2007536281
T
20071213
ZA 2006009085
A
20080430
US 20080299067
A1
20081204
NZ 550876
A
20100827
AU 2005237185
B2
20110317
WO 2005102364
EP 1742645
A1
20051103
A1
20070117
NO 2006004780
A
20070118
AU 2005235345
A1
20051103
MX 2006011906
A1
20070101
KR 2007001280
A
20070103
CN 1950097
A
20070418
BR 2005010175
A
20071002
IN 2006DN05707
A
20070622
JP 2007533719
T
20071122
DETAILED DESCRIPTION: A skin condition
treating composition for use in treating a wound,
bum or other skin condition, comprises a
functionalized siloxane compound of formula R-(Si(CH3)2-O-)n-(-Si(CH3)(Q)-O-)m-Si(CH3)3-R' (I).
[CONT.]
n=6-100;
Q,R,R'=1-5C alkyl, OU, UOCH2CH3, CH2CH3,
UOCH3, OH, O(CH2)y(OU)yCH3,
(OCH2CH2)yOU, (OCH2CH2)yOH, UOH, UCO2H,
COX, UCOX, UOU', UCO2U', CO2U, UCO2COU',
CO2H, UCO2R', CO2COU, aryl, ArylU, ArylUU',
ArylUU'U', NH2, UNH2, NHU, NUU', NO2, UNO2,
UCONH2, CONH2, UCONHU', CONHU,
UCONU'U'', CONU'U'', halo, PO4H3, PO4H3-z,
PO4H3-zU, PU3, PU'U'U''SH, SO2 or SO3H;
[CONT.]
WO 2005102364 A1 UPAB: 20060112
For preparing a medicament in treating
NOVELTY: A compressed composition comprises constipation, feacal impaction, intestinal gas and
cramping or in a mammal, cleansing the colon
polyethylene glycol (PEG) having molecular
weight 2000 - 4500 (80 - 99.5 wt.%); and at least (claimed).
one electrolyte.
DETAILED DESCRIPTION: An INDEPENDENT
CLAIM is included for preparing composition
involving mixing PEG, sweeteners, flavouring
agent, excipient, ascorbic acid and/or an
ascorbate salt, sodium sulfate and optional
components; and compressing the mixture.
[CONT.]
The composition has more agreeable taste and
INORGANIC CHEMISTRY - Preferred
more agreeable mouthfeel than previously
Components: The electrolyte is sodium chloride,
proposed liquid powder or granular compositions. sodium bicarbonate or potassium chloride.
ORGANIC CHEMISTRY - Preferred Components:
The electrolyte is sodium chloride, sodium
bicarbonate or potassium chloride.
PHARMACEUTICALS - Preferred Composition:
The composition is further comprises at least one
sweetener; at least one flavoring agent. The
composition comprises (g): PEG (1 [CONT.]
An INDEPENDENT CLAIM is included for
WO 2005102364
preparing composition involving mixing PEG,
sweeteners, flavouring agent, excipient, ascorbic
acid and/or an ascorbate salt, sodium sulfate and
optional components; and compressing the
mixture.
US 20070298100
The invention provides greater than 10 %
INSTRUMENTATION AND TESTING - Preferred
reduction. It can be used for short periods of time. Components: The bacteria is Bacillus coagulans
hammer. The bacteria is derived from Bacillus
coagulans hammer strain Accession No. ATCC
31284. The composition includes non-microbially
derived antifungal agent, or retinoid. The
antifungal agent is clotrimazole, fluconazole,
itraconazole, ketoconazole, miconazole, mystatin,
terbinafine, terconazole, or tiocanazole [CONT.]
INDEPENDENT CLAIMS are also included for:
US 20060073130
US 20070298100
A1
20071227
ZA 2006008496
A
20080730
EP 2263680
EP 1742645
A1
20101222
B1
20110126
DE 602005026117
E
20110310
WO 2005110445
A2
20051124
WO 2005110445 A2 UPAB: 20101216
US 20060073130
A1
20060406
NOVELTY: Reducing symptom of psoriasis
comprising identifying patient suffering from or at
risk of developing psoriasis, and administering
composition containing Bacillus coagulans
bacteria to the patient, is new.
EP 1751271
A2
20070214
AU 2005244083
A1
20051124
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are also included for:
(1) reducing symptom of autoimmune disorder
comprising: [CONT.]
JP 2007537270
T
20071220
AU 2005244083
B2
20101125
US 7854927
B2
20101221
For reducing symptom of psoriasis, e.g. scaling,
blistering, skin lesions, itchiness, or joint pain. It
can also be used in reducing symptom of other
autoimmune disorder, e.g. Crohn's Disease,
colitis, lupus, or arthritis; Rheumatoid Arthritis;
Scleroderma; Sjogren's syndrome; Multiple
Sclerosis; Myasthenia Gravis; Guillain-Barre
syndrome; Hashimoto's Thyroiditis; Grave's
Disease; Insulin-dependent diabetes [CONT.]
WO 2005110445
(1) reducing symptom of autoimmune disorder
comprising:
US 7854927
(a) identifying patient suffering from or at risk of
developing an autoimmune disorder; and
(b) administering to the patient the above
mentioned composition; and
(2) decreasing serum tumor necrosis factor (TNF)alpha-levels in mammal comprising:
(a) identifying mammal containing elevated level
of TNF-a [CONT.]
US 20110064708
N
N
373 Delivery composition for therapeutic or
diagnostic entities, useful in preventing
disease in e.g. living human, comprises
liposome having interior space separated from
medium by membrane comprising lipid
374 Nutraceutical for maintaining urinary tract
health, preventing cardiovascular disease, or
for protecting skin from damage, includes
cranberry seed oil, cranberry flour, and freeze
dried whole cranberries
HERMES BIOSCIENCES INC
US 20110064708
WO 2005107712
A1
20110317
A1
20051117
WO 2005107712 A1 UPAB: 20090817
NO 2006005532
A
20061213
NOVELTY: A delivery composition (I) comprises a
liposome in a medium. The liposome has an
interior space separated from the medium by a
membrane comprising at least one lipid; and the
interior space of the liposome contains a
substituted ammonium (II) and an anion (III).
EP 1746976
A1
20070131
DETAILED DESCRIPTION: A delivery
composition (I) comprises a liposome in a
medium. [CONT.]
AU 2005240131
A1
20051117
US 20070110798
US 20070116753
A1
20070517
A1
20070524
IN 2006DN07275
A
20070427
KR 2007036055
A
20070402
CN 1980637
A
20070613
JP 2007536247
T
20071213
TW 2006005908
A
20060216
AU 2005240131
B2
20110303
NORTHERN LIGHTS FOOD PROCESSING LLC
WO 2005107476
A2
20051117
WO 2005107476 A2 UPAB: 20060203
HEEG T
JP 2008500027
T
20080110
LAGER B G
US 20080199547
A1
20080821
HIEG T
JP 2011045372
A
20110310
NOVELTY: A nutraceutical comprises cranberry
seed oil, cranberry flour, and freeze dried whole
cranberries.
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are also included for:
(1) a food comprising the nutraceutical;
LEGER B
(I) Is useful for delivery of therapeutic or
diagnostic entities used in the diagnosis, testing,
screening, treatment or prevention of an
undesirable conditions, e.g. a disease in living
organism, e.g. human, plant or animal.
The invention is used for maintaining urinary tract
health, preventing cardiovascular disease, or for
protecting skin from damage. It is used for, e.g.
food such as bread or chocolate bar, nutrition bar,
powder, dietary supplement, pet food, dietary or
topical formulation (all claimed).
(I) Is capable of breaking down to non-toxic units
within the living organisms. (I) Effectively delivers
composition for therapeutic or diagnostic entities
to prevent disease in living human.
The invention treats symptoms associated with
urinary tract health, without requiring the use to
ingest additional calories associated with
cranberry juice.
BIOLOGY - Preferred Component: The mammal is
a rat. BIOTECHNOLOGY - Preferred Component:
The therapeutic entity is an antimicrobial, antiviral
or anti-neoplastic therapeutic. The therapeutic
entity is an aminoglycoside antibiotic or
fluoroquinolone derivative (topoisomerase
inhibitor, farnesyltransferase inhibitor, tyrosine
kinase inhibitor, cyclin dependent kinase inhibitor,
phosphatase inhibitor, [CONT.]
A delivery composition (I) comprises a liposome in WO 2005107712
a medium. The liposome has an interior space
separated from the medium by a membrane
comprising at least one lipid; and the interior
space of the liposome contains a substituted
ammonium of formula R1-(R2-)N+(-R3)-R4 (II)
and an anion (III).
US 20070110798
N = ammonium nitrogen atom; and [CONT.]
US 20070116753
PHARMACEUTICALS - Preferred Component:
The nutraceutical is packaged as a soft gel. The
nutraceutical comprises 35.1 wt.% omega-3
linolenic acid, 34.2 wt.% omega-6 linoleic acid,
28.1 wt.% omega-9 oleic acid, tocopherols,
tocotrienols, and beta-sitosterol. Preferred
Concentration: The ratio of cranberry flour to
cranberry seed oil is 85:15.
INDEPENDENT CLAIMS are also included for:
(2) a topical formulation comprising the
nutraceutical;
(3) a capsule comprising cranberry flour;
LIFELINE NUTRACEUTICALS CORP
US 20050226942
WO 2005094862
A1
20051013
US 20050226942 A1 UPAB: 20091006
DRISCOLL W J
A1
20051013
NOVELTY: Antioxidant-promoting composition (A)
comprising active ingredients comprising Bacopa
monniera extract; milk thistle extract,
ashwagandha powder, green tea extract, and
turmeric extract, where (A) increases the enzyme
activity of at least one antioxidant enzyme
(superoxide dismutase; catalase; or glutathione
peroxidase) and decreases the plasma
concentration of thiobarbituric acid reactive
chemical species in mammals, is new. [CONT.]
MYHILL P R
EP 1740196
A1
20070110
AU 2005229008
A1
20051013
US 7241461
B2
20070710
IN 2006KN03016
A
20070608
KR 2007007837
A
20070116
CN 1956726
A
20070502
JP 2007530574
T
20071101
EP 2266586
A1
20101229
AU 2005229008
B2
20110324
WO 2005107476
US 20080199547
Y
US20080199547A1
Y
EP2266586A1
(1) a food comprising the nutraceutical;
(2) a topical formulation comprising the
nutraceutical;
(3) a capsule comprising cranberry flour;
(4) a capsule comprising ellagic acid;
(5) scrub cleanser, soap, or spa product
comprising a topical formulation comprising red
raspberry oil and/or flour;
(6) a dietary fiber comprising black raspberry
seeds; [CONT.]
(4) a capsule comprising ellagic acid; [CONT.]
375 Antioxidant-promoting composition, useful
e.g. to treat/prevent memory loss, comprises
active ingredients comprising Bacopa
monniera extract; milk thistle extract,
ashwagandha powder, green tea extract, and
turmeric extract
N
(A) is useful to promote antioxidant acitivity and to
increase the enzyme activity of at least one
antioxidant enzyme (superoxide dismutase;
catalase; or glutathione peroxidase); to decrease
the plasma concentration of thiobarbituric acid
reactive chemical species in mammals (claimed);
to alleviate inflammation and oxidative stress in
mammals. (A) is also useful to treat or prevent
e.g. memory loss [CONT.]
(A) safely induces cellular antioxidant potential to
achieve an overall net decrease in oxidative stress
without the undesirable side effects associated
with the individual components of (A).
PHARMACEUTICALS - Preferred Components:
The Bacopa monniera extract is standardized
extract prepared from the leaves of the Bacopa
monniera plant. The standardized extract contains
at least 20% of bacosides. The Bacopa monniera
extract is about 5-50 (preferably 12) wt.%; the milk
thistle extract is 5-60 (preferably 22) wt.%; the
turmeric extract is 2.5-25 (preferably 6) wt.
[CONT.]
US 20050226942
US 20050226942
US 7241461
SNOW BRAND MILK PROD CO LTD
376 Bacterial-flora improving agent useful in
food/beverage products and feed for
promoting growth of useful bacterial flora and SNOW BRAND MILK PROD CO
suppressing growth of harmful microbes,
comprises a ganglioside
HANADA N
377 Use of an isolated monoclonal antibody or
antigen binding fragment which binds to an
epitope of the extracellular region of prostate
specific membrane antigen (PSMA) for
designing a mimetope binding to PSMA for
treating prostate cancer
378 Preparation of a plant extract, useful in pet
food composition, comprises combining the
plant extract with an aqueous solution and
optionally with an enzyme to give a digested
plant mixture; and concentrating
JP 2005320275
A
20051117
JP 2005320275 A UPAB: 20091012
WO 2005107769
A1
20051117
NOVELTY: A bacterial-flora improving agent
comprises ganglioside as an active ingredient.
EP 1747783
A1
20070131
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are included for the following:
IMAI S
AU 2005239926
A1
20051117
(1) food/beverage products or feed for improving
bacterial flora, which contain the ganglioside;
KAWAKAMI H
CN 1950093
A
20070418
(2) an antimicrobial agent of Streptococcus
sobrinus, S. anginosus and Staphylococcus
aureus, which contains ganglioside as an active
ingredient; and [CONT.]
IN 2006KN03230
A
20070608
US 20070270377
US 20100048493
A1
20071122
A1
20100225
NZ 551555
A
20101029
AU 2005239926
B2
20110317
WO 2005100404
EP 1756166
A1
20051027
WO 2005100404 A1 UPAB: 20090602
A1
20070228
NOVELTY: An isolated monoclonal antibody or
antigen binding fragment which binds to an
epitope of the extracellular region of prostate
specific membrane antigen (PSMA) is useful for
designing a mimetope binding to PSMA. [CONT.]
CA 2606138
A1
20051027
A1
20090521
B2
20110322
A1
20051110
US 20050249837 A1 UPAB: 20100712
IAMS CO G
US 20090131277
US 7910693
US 20050249837
WO 2005110036
A2
20051124
NOVELTY: Preparation of a plant matter extract
(A) comprises: providing plant matter (avocado,
alfalfa, fig and/or primrose); combining the plant
matter with an aqueous solution and an enzyme
(optional) and optionally heating, to give a
digested plant mixture (I); and concentrating (I) to
enhance the concentration of carbohydrate.
[CONT.]
PROCTER & GAMBLE CO
CA 2569249
A1
20051124
GEROTECH INC
AU 2005244119
A1
20051124
EP 1773133
A2
20070418
AU 2006246538
A1
20070111
JP 2007181473
A
20070719
CN 1949985
A
20070418
CN 1981599
A
20070620
BR 2005011047
A
20071127
IN 2006DN06269
A
20070831
JP 2007536384
T
20071213
IN 2008DN00366
A
20080208
EP 1773133
B1
20081029
DE 602005010709
E
20081211
ES 2317243
T3
20090416
MX 2006012851
A1
20080630
AU 2005244119
B2
20090326
TW 2006005796
A
20060216
MX 275941
B
20100517
JP 2011041581
A
20110303
WO 2005103253
A1
20051103
PROSCAN RX PHARMA
PROSCAN RX PHARMA INC
IAMS CO
GEROSCIENCE INC
379 Novel recombinant cell having polynucleotides COMMONWEALTH SCI & IND RES ORG
encoding enzymes such as Delta 5/6
desaturase and Delta 5/6 bifunctional
elongase, useful for synthesizing long chain
polyunsaturated fatty acids
WO 2005103253 A1 UPAB: 20090819
For use in food/beverage products and feed such The ganglioside effectively suppresses growth of
as candy, chewing gum, soft drink, milk beverage, harmful microbe and promotes growth of useful
fermented milk, ice cream, pet food, for promoting microbe.
growth of useful bacterial flora e.g. S. mitis and
suppressing growth of harmful microbes e.g. S.
sobrinus, S. anginosus and Staphylococcus
aureus.
ORGANIC CHEMISTRY - Preferred Components: INDEPENDENT CLAIMS are included for the
The ganglioside is ganglioside GD3 and/or
following:
ganglioside GM3.
(1) food/beverage products or feed for improving
bacterial flora, which contain the ganglioside;
The isolated monoclonal antibody or antigenbinding fragment which binds to an epitope of the
extracellular region of prostate specific membrane
antigen (PSMA) is useful for designing a
mimetope binding to PSMA for preparing a
composition for treating prostate cancer or its
metastasis. [CONT.]
BIOTECHNOLOGY - Preferred Method: Designing
a mimetope which binds to an epitope of PSMA
comprises determining a region of an antibody
which binds to the epitope responsible for the
binding and designing the mimetope based on the
region. The antibody is a monoclonal antibody.
Treating prostate cancer or its metastasis
comprises administering to an individual the
pharmaceutical composition. [CONT.]
The isolated monoclonal antibody or antigen
WO 2005100404
binding fragment which binds to an epitope of the
extracellular region of prostate specific membrane
antigen (PSMA) is useful for designing a
mimetope binding to PSMA, where the epitope
comprises 51-67, 85-102, 104-118, 161-173, 236245, 278-288, 345-354, 490-500, 531-545, 551567, 608-619, 649-660, 716-724 or 738-750 of the
fully defined sequence comprising 10-19 amino
acids (SEQ ID NO [CONT.]
US 20090131277
US 7910693
BIOLOGY - Preferred Process: The plant matter
comprises fruit of avocado and is combined with
the aqueous solution and the enzyme (cellulase
enzyme), with heating at 120 (preferably 60100)degreesC to give (I). The process further
comprises separating fractions present in (I), if
any, to give the carbohydrate extract. The
fractions present in (I) are separated by filtration to
give carbohydrate extract as the resulting filtrate
[CONT.]
An INDEPENDENT CLAIM is also included for the US 20050249837
process of preparing a food composition
comprising: preparing (I) and combining (I) with
one or more food composition components.
US 20050249837
BIOTECHNOLOGY - Preferred Enzyme: In (I), one
of the enzymes is a Delta5 elongase, Delta9
elongase, Delta5/Delta6 bifunctional desaturase
or Delta5/Delta6 bifunctional elongase, Delta5
desaturase, or Delta8 desaturase, where the
A recombinant cell (I) capable of synthesizing long WO 2005103253
chain polyunsaturated fatty acid(s) (LC-PUFA) or
having an enhanced capacity to synthesize LCPUFA relative to an isogenic non-recombinant
cell, comprises one or more polynucleotides (PN)
US 20050273885
(A) is useful in pet food composition (preferably
dog/cat food composition) (claimed).
(I) is useful for producing a LC-PUFA, comprising
culturing (I) under suitable conditions, and in a
fermentation process. (I) or recombinant plant cell
(III) is useful for producing oilseed transgenic plant
capable of synthesizing LC-PUFA. A transgenic
The yield of mannoheptulose present in (A) is less
than 20 (preferably 1-7)% and the yield of (A) is
less than 30 (preferably 8-20)%, based on the
starting mass of the plant matter (claimed).
JP 2005320275
US 20070270377
US 20100048493
(2) an antimicrobial agent of Streptococcus
sobrinus, S. anginosus and Staphylococcus
aureus, which contains ganglioside as an active
ingredient; and
(3) a growth promoter of Streptococcus mitis,
which contains ganglioside as an active
ingredient.
N
N
379 Novel recombinant cell having polynucleotides
encoding enzymes such as Delta 5/6
COMMONWEALTH SCI&IND RES ORG
desaturase and Delta 5/6 bifunctional
elongase, useful for synthesizing long chain
polyunsaturated fatty acids
US 20050273885
A1
20051208
ELLIS B S I
EP 1756280
A1
20070228
GREEN A G
AU 2005235627
A1
20051103
NICHOLS P D
BR 2005010132
A
20071002
PETRIE J R
CN 101018862
A
20070815
US 20080268539
US 7807849
US 7834250
US 20110015415
US 20110054198
WO 2005100563
A1
20081030
B2
20101005
B2
20101116
A1
20110120
A1
20110303
A1
20051027
WO 2005100563 A1 UPAB: 20091006
JP 2005323584
A
20051124
NOVELTY: A follistatin mutant polypeptide (P1)
containing (a) follistatin domain I, (b) not
containing an amino acid sequence having 50% or
higher homology to a fully defined 72 amino acid
(SEQ ID No. 2) or 73 amino acid (SEQ ID No. 29)
sequence given in the specification, and (c) an
activity of inhibiting growth/differentiation factor-8
(GDF-8) more selectively than activin, is new.
[CONT.]
EP 1748069
A1
20070131
AU 2005233474
A1
20051027
KR 2007039483
A
20070412
CN 1993463
A
20070704
ROBERT S S
SINGH S P
ZHOU X
380 Novel follistatin mutant polypeptide capable of KYOWA HAKKO KOGYO KK
selectively inhibiting growth/differentiation
TECHNO NETWORK SHIKOKU CO LTD
factor-8, useful for treating cachexia, muscular
dystrophy, diabetes type II, obesity and
acquired immune deficiency syndrome
TECHNO NETWORK SHIKOKU KK
BIOTECHNOLOGY - Preferred Enzyme: In (I), one
of the enzymes is a Delta5 elongase, Delta9
elongase, Delta5/Delta6 bifunctional desaturase
or Delta5/Delta6 bifunctional elongase, Delta5
desaturase, or Delta8 desaturase, where the
Delta5 elongase also has Delta6 elongase activity,
and the elongase is more efficient at synthesizing
DPA from EPA than it is at synthesizing ETA from
SDA. [CONT.]
A recombinant cell (I) capable of synthesizing long WO 2005103253
chain polyunsaturated fatty acid(s) (LC-PUFA) or
having an enhanced capacity to synthesize LCPUFA relative to an isogenic non-recombinant
cell, comprises one or more polynucleotides (PN)
encoding two enzymes each of which is a
Delta5/Delta6 bifunctional desaturase, Delta5
desaturase, Delta6 desaturase, Delta5/Delta6
bifunctional elongase, Delta5 [CONT.]
US 20080268539
US 7807849
US 7834250
US 20110015415
US 20110054198
(P1), (P2) or (V1) is useful for increasing the
(P1) selectively inhibits GDF-8, and effectively
muscles and reducing the fat of a non-human
increases skeletal muscle and reduces fat.
animal, which involves administering (P1), (P2) or
(V1) to the non-human animal. (A1) is useful for
preventing or treating cachexia, muscular
dystrophy, diabetes Type II, obesity, acquired
immune deficiency syndrome or diseases
associated with muscular dystrophy e.g. [CONT.]
BIOTECHNOLOGY - Preparation: Culturing (C1)
in culture medium and collecting (P1) expressed
and stored in the culture medium (claimed).
Preferred Polypeptide: (P1) contains FS domain I
and deleted FS domain III. (P1) further does not
contain FS domain III. (P1) contains two or more
FS domain I and further contains N-terminal
domain. [CONT.]
Follistatin (FS) mutant polypeptide (P1) contains WO 2005100563
(a) FS domain I, (b) an amino acid sequence of
Cys-(X1)a-Cys-(X2)b-Cys-(X3)c-Cys-(X4)d-Cys(X5)e- Cys-(X6)f-Cys-(X7)g-Cys-(X8)h-Cys-(X9)iCys, where X1-X9 are same or different and
represents any naturally occurring amino acid
residue except cysteine, a is 2-6, b is 3-7, c is 711, d is 0-4, e is 1-6, f and g are 8-12, h is 4-8 and
i is 11-15, (c) not containing an amino acid
sequence having 50% or higher homology to a
fully defined 72 amino acid (SEQ ID No [CONT.]
US 20080090755
US 7867973
(I), (III) or (IV) is useful for producing albumin and (I) is safe when administered to animal, and
bioactive substance such as blood coagulation
effective in the production of albumin and
factor, or treating liver disease e.g. liver failure.
bioactive substance.
BIOTECHNOLOGY - Preferred Cell Line: (I) is
CYNK-1 (FERM BP-08657). The mammal is
human. (I) does not comprise promoter derived
from virus.
INDEPENDENT CLAIMS are also included for:
US 20090148424
US 20080090755
A1
20080417
AU 2005233474
B2
20101209
US 7867973
EP 1748069
WO 2005100546
B2
20110111
B1
20110309
A1
20051027
WO 2005100546 A1 UPAB: 20060125
CN 1926233
A
20070307
NOVELTY: A reversibly immortalized mammalian
liver cell line (I) or subcultured strain, comprising
an immortalizing gene located between a pair of
site-specific recombination sequences and a
suicide gene at a site excluding the pair of sitespecific recombination sequences, where the
suicide gene exhibits its function after ligating off
the pair of site-specific recombination sequences,
is new. [CONT.]
KOBAYASHI N
JP 2006512172
X
20080306
(2) a bio-artificial liver (III) comprising (I) or (II);
KOHARA M
US 20090148424
A1
20090611
(3) a cell formulation (IV) comprising (I) or (II); and
TANAKA N
JP 2010187702
A
20100902
(4) a non-virus vector comprising suicide gene,
non-viral vector and immortalized gene.
TANAKA T
JP 4647597
B2
20110309
NSGENE AS
WO 2005095450
A2
20051013
EP 1745069
A2
20070124
381 Novel reversibly immortalized mammalian liver TOKYO METROPOLITAN ORG MEDICAL RES
cell line or its subcultures strain, comprising
ZH TOKYOTO RINSHO IGAKU SOGO
immortalizing gene located between pair of
KENKYUSHO
site-specific recombination sequences and
suicide gene, useful for treating liver disease
382 New isolated polypeptide, designated as
NsG33, which is a secreted therapeutic
protein, useful for treating immunological, or
neurological disorders, e.g. Parkinson's
disease, Huntington's disease
NOVELTY: A recombinant cell (I) capable of
synthesizing long chain polyunsaturated fatty
acid(s) (LC-PUFA) or having an enhanced
capacity to synthesize LC-PUFA relative to
isogenic non-recombinant cell, comprising one or
more polynucleotides (PN) encoding at least two
enzymes such as Delta5/Delta6 bifunctional
desaturase, Delta5 desaturase and Delta6
desaturase, is new. [CONT.]
(I) is useful for producing a LC-PUFA, comprising
culturing (I) under suitable conditions, and in a
fermentation process. (I) or recombinant plant cell
(III) is useful for producing oilseed transgenic plant
capable of synthesizing LC-PUFA. A transgenic
plant (IV) is useful for producing an oilseed, which
involves growing (IV) and harvesting the seed of
the plant. (IV) is useful for producing LC-PUFA
[CONT.]
WO 2005095450 A2 UPAB: 20090509
The polypeptide, polynucleotide, vector, host cell,
packaging cell line, device, composition and
methods are useful for treating an immunological
NOVELTY: An isolated polypeptide, designated as disorder, e.g. infectious diseases, immune
NsG33, which is a secreted therapeutic protein, is deficiencies, cancer, autoimmune disorders
including multiple sclerosis, allergic reactions and
new.
conditions, and graft-versus-host disease; a
disease, disorder, or damage associated with the
nervous system; [CONT.]
BIOTECHNOLOGY - Preferred Polypeptide: The
polypeptide is a naturally occurring variant of SEQ
ID No. 3, 4, 5, 8, 9, 10, 13, 14, 15, 19, 20, 21, 22,
23 or 24. The allelic variant comprises an amino
acid sequence that is the translation of a nucleic
acid sequence differing by a single nucleotide
from a nucleic acid sequence selected from SEQ
ID No. 1, 2, 6, 7, 11, 12, 16, 17, and 18. [CONT.]
WO 2005100546
N
N
(1) a mammalian liver cell (II) obtained by
removing immortalizing gene from (I);
An isolated polypeptide, designated as NsG33,
WO 2005095450
which is a secreted therapeutic protein comprises:
US 20070275026
N
(a) a sequence 293, 270, 166, 294, 270, 166, 291,
275, 166, 104, 104, 109, 97, 97, or 102 amino
acids (SEQ ID No. 3, 4, 5, 8, 9, 10, 13, 14, 15, 19,
20, 21, 22, 23 or 24, respectively), given in the
specification;
383 Promoting angiogenesis in an organ or tissue
of an animal other than heart for treating
coronary artery disease, comprises
administering mesenchymal stem cells
384 Drug delivery composition, useful to control
release of therapeutical active agent and to
treat cancer, comprises a phospholipid, a
chitosan based material and an active agent
385 Preparation of liposomal formulation for
delivering active agent e.g. drugs involves
hydration of phospholipid film containing
surface active agent with aqueous mixture of
AU 2005229434
A1
20051013
MX 2006011339
A1
20070101
CN 1950397
A
20070418
BR 2005009278
A
20070918
IN 2006CN03985
A
20070727
JP 2007530064
T
20071101
US 20070275026
A1
20071129
KR 2007012664
A
20070126
NZ 550542
A
20090327
EP 1745069
B1
20090506
DE 602005014354
E
20090618
EP 2075254
A1
20090701
ES 2326670
T3
20091016
MX 268814
B
20090730
AU 2005229434
B2
20100930
IN 244678
B
20101217
EP 2289911
WO 2005093044
A2
20110302
A1
20051006
AGGARWAL S
US 20050239897
A1
20051027
PITTENGER M F
EP 1727892
A1
20061206
DANILKOVITCH A
AU 2005227295
A1
20051006
VARNEY T
JP 2007530543
T
20071101
US 20080095749
US 20090180997
A1
20080424
A1
20090716
AU 2009200019
A1
20090205
AU 2010200916
A1
20100401
US 20100172885
US 20100330048
EP 2298861
EP 2298862
EP 2298863
EP 2298864
WO 2005087221
US 20050208122
A1
20100708
A1
20101230
A2
20110323
A2
20110323
A2
20110323
A2
20110323
A1
20050922
A1
20050922
PIQUETTE-MILLER M
US 7901707
B2
20110308
UNIV DUKE
US 20050191345
A1
20050901
OSIRIS THERAPEUTICS INC
ALLEN C
GRANT J
DETAILED DESCRIPTION: An isolated
polypeptide, designated as NsG33, which is a
secreted therapeutic protein comprises:
(a) a sequence 293, 270, 166, 294, 270, 166, 291,
275, 166, 104, 104, 109, 97, 97, or 102 amino
acids (SEQ ID No. [CONT.]
disease, disorder, or damage associated with the
nervous system; [CONT.]
ID No. 1, 2, 6, 7, 11, 12, 16, 17, and 18. [CONT.]
(b) a sequence variant of the above sequences,
which is at least 70% identical to any of them; or
[CONT.]
WO 2005093044 A1 UPAB: 20090725
(M1) Is useful for promoting angiogenesis in an
organ or tissue of an animal other than the heart,
where the animal is a mammal, preferably
NOVELTY: Promoting (M1) angiogenesis in an
organ or tissue of an animal other than the heart, primate, most preferably human. (M2) Is useful for
comprises administering mesenchymal stem cells treating an autoimmune disease (preferably
multiple sclerosis), inflammatory response, cancer
(I) to the animal, to promote angiogenesis in an
organ or tissue other than the heart of the animal. or allergic disease or disorder (preferably arthritis)
in an animal. The inflammatory response is
associated with psoriasis [CONT.]
BIOTECHNOLOGY - Preferred Method: In (M1),
the mesenchymal stem cells are administered by
direct injection to the organ or tissue other than
the heart of the animal.
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are also included for the following:
[CONT.]
INDEPENDENT CLAIMS are also included for the WO 2005093044
following:
(1) treating (M2) an autoimmune disease,
inflammatory response, cancer or allergic disease
or disorder in an animal, comprising administering
(I) to the animal, to treat autoimmune disease,
inflammatory response, cancer or allergic disease
or disorder in the animal;
US 20050239897
(2) promoting (M3) wound healing in an animal,
comprising administering (I) to the animal, to
promote wound healing in the animal; and
[CONT.]
US 20090180997
N
US 20080095749
US 20100172885
US 20100330048
WO 2005087221 A1 UPAB: 20051223
(I) is useful for controlled release of therapeutical
active agent and for the treatment, prevention or
NOVELTY: Drug delivery composition (I)
inhibition of various cancer e.g. ovarian cancer
comprises a phospholipid (a), a chitosan based
material (b) and an active agent (c) (where (a) and (claimed), prostate, breast, bladder, brain, liver,
gastric, head and neck.
(b) form a physical cross-linked matrix for
controlled release of (c)).
DETAILED DESCRIPTION: An INDEPENDENT
CLAIM is also included for a method of
manufacturing a drug delivery composition for
controlled release in a mammal comprising
complexing (b) with (a) and physical cross-linking
(b) with (a) to provide controllable release of at
least one (c). [CONT.]
US 20050191345 A1 UPAB: 20051223
For preparation of liposomes containing active
agents, e.g. pharmacological agent, flavor agent,
diagnostic agent or nutritional agent (claimed).
(I) provides high drug concentrations at the site of
action while reducing systemic exposure for a
sustained period of time. (I) improves compatible
blends of pharmaceutical active agents within an
implantable delivery vehicle. (I) is biodegradable
and biocompatible. The bioavailability of the
implant was examined in vivo in healthy Balb/c
mice. [CONT.]
PHARMACEUTICALS - Preferred Composition:
The chitosan based material comprises 85%
chitosan and 15% chitin. The chitosan to
phospholipid ratio is 0.03:1-2.5:1 w/w. (I) further
comprises additive such as polymeric
nanoparticles (poly (dl-lactide) nanoparticle),
liposomes or hydrophilic polymers or second
pharmaceutical agent. (I) is formulated for
injection through a syringe needle. [CONT.]
An INDEPENDENT CLAIM is also included for a
method of manufacturing a drug delivery
composition for controlled release in a mammal
comprising complexing (b) with (a) and physical
cross-linking (b) with (a) to provide controllable
release of at least one (c).
WO 2005087221
US 20050208122
US 7901707
N
The process enables synthesis of liposomes
having improved stability and increased load of
the active agent. The liposomes are sensitive to
alterations in the temperature of the surrounding
environment; exhibit excellent stability at normal
ORGANIC CHEMISTRY - Preferred Components:
The surface active agent is lysolipid, bile acid,
myristoyl surfactant, palmitoyl surfactant, stearoyl
surfactant, glyceryl monooleate, glyceryl
monopalmitate, ceramide, polyethylene glycol-
Preparation (M1) of liposomes containing an
active agent entrapped within their interior space,
involves preparing a phospholipid film that
contains a surface active agent; hydrating the
phospholipid film with an aqueous preparation to
US 20050191345
US 20050191345
N
385 Preparation of liposomal formulation for
delivering active agent e.g. drugs involves
NEEDHAM D
hydration of phospholipid film containing
surface active agent with aqueous mixture of
surface active agent and drug; and cooling the
liposomes
US 7901709
B2
20110308
NOVELTY: Preparation (M1) of liposomes
containing an active agent entrapped within their
interior space, involves preparing a phospholipid
film that contains a surface active agent; hydrating
the phospholipid film with an aqueous preparation
of the active agent and the surface active agent at
a temperature above the phase transition
temperature of the phospholipid film; and cooling
the liposomes. [CONT.]
WO 2005085288
A2
20050915
WO 2005085288 A2 UPAB: 20060203
US 20050276811
A1
20051215
HARVARD COLLEGE
EP 1725659
A2
20061129
CBR INST BIOMEDICAL RES
AU 2005219839
A1
20050915
CBR INST BIOMEDICAL RES INC
CN 1977043
A
20070606
BRIGHAM&WOMENS HOSPITAL INC
JP 2008504807
T
20080221
US 7442783
US 20090176966
US 20100136684
EP 1725659
EP 2290077
B2
20081028
A1
20090709
A1
20100603
B1
20110209
A2
20110302
DE 602005026260
E
20110324
EP 1570855
WO 2005087258
A1
20050907
A1
20050922
BRIGHAM & WOMENS HOSPITAL
386 New isolated nucleic acid inhibiting natural
IgM, useful for treating inflammatory diseases,
BRIGHAM & WOMENS HOSPITAL INC
such as stroke, arthritis, arteriosclerosis,
coronary artery disease, sepsis, osteoporosis,
diabetes, dermatitis, lupus and psoriasis
IMMUNE DISEASE INST INC
CARROLL M C
HECHTMAN H B
MOORE F D
387 Using botulinum toxin for preventing growth of SCRAS SOC CONSEILS RECH & APPL SCI
hair, useful in treatment of hypertrichosis and IPSEN PHARMA SAS
hirsutism, also for treating domestic animals
For preparation of liposomes containing active
agents, e.g. pharmacological agent, flavor agent,
diagnostic agent or nutritional agent (claimed).
The methods and compositions of the present
invention are useful for treating inflammatory
NOVELTY: An isolated nucleic acid (I) encoding a diseases, such as reperfusion injury, stroke,
peptide comprising a fully defined sequence of 12 rheumatoid arthritis, arteriosclerosis, coronary
artery disease, sepsis, osteoporosis, diabetes,
amino acids (SEQ ID NO: 14, 36 or 38), or a
natural IgM antibody-binding portion of any 7 fully gout, dermatitis, lupus, psoriasis, ulcerative colitis
and liver fibrosis.
defined sequences of 1960-2000 amino acids
(SEQ ID NO: 48, 50, 52, 54, 56, 58 and 60), is
new.
EP 1570855 A1 UPAB: 20100729
(A) is used for pharmaceutical or cosmetic
NOVELTY: Use of botulinum toxin (A) to prepare a treatment of hypertrichosis or hirsutism, in both
humans and domestic animals.
composition for preventing growth of hair in
IPSEN PHARMA
NO 2006004064
A
20060925
ACTIVITY: Depilatory.
LE LOUARN C
EP 1722813
A1
20061122
A 39 year old woman received an injection of 3
units Botox (RTM) into the epidermis of the upper
lip, at several sites just above the red border of
the lip. When examined 4 months later, the growth
of hair on the lip was significantly reduced.
[CONT.]
JP 2007526286
T
20070913
US 20070292546
US 7754253
EP 1722813
A1
20071220
B2
20100713
B1
20110209
DE 602005026259
E
20110324
WO 2005080586
US 20060014245
A1
20050901
WO 2005080586 A1 UPAB: 20090619
A1
20060119
NOVELTY: Preparing an immunotoxin comprising
culturing a mammalian host cell transformed with
nucleic acid sequences encoding fusion proteins
containing recombinant cytotoxic RNAses, is new.
[CONT.]
EP 1720996
A1
20061115
AU 2005214361
A1
20050901
JP 2007524686
T
20070830
US 7544487
US 20090246214
B2
20090609
A1
20091001
ORGANIC CHEMISTRY - Preferred Components:
The surface active agent is lysolipid, bile acid,
myristoyl surfactant, palmitoyl surfactant, stearoyl
surfactant, glyceryl monooleate, glyceryl
monopalmitate, ceramide, polyethylene glycolderivatized surfactants, PEG-ceramide, 18C-ether
linked lysophosphatidyl choline, and/or fatty acid.
[CONT.]
The methods and composition are useful for
diagnosing, preventing or treating diseases or
syndromes associated with unwanted or
inappropriate cell proliferation or activation, such
as cancer, infection or autoimmune disorders.
Preparation (M1) of liposomes containing an
active agent entrapped within their interior space,
involves preparing a phospholipid film that
contains a surface active agent; hydrating the
phospholipid film with an aqueous preparation to
produce liposomes at a temperature above the
phase transition temperature of the phospholipid
film; and cooling the liposomes having a gelphase lipid bilayer. [CONT.]
BIOTECHNOLOGY - Preferred Nucleic Acid: The INDEPENDENT CLAIMS are also included for:
isolated nucleic acid molecule further comprises a
fully defined sequence of or a sequence 96%
(1) a vector (II) comprising (I);
identical to 405, 15, 51, 309, 45 or 21 base pairs
(bp) (SEQ ID NO: 1, 3, 5, 7, 9 and 11), or a
molecule hybridizing to SEQ ID NO: 1 or 7 under
stringent conditions, and encoding a polypeptide
comprising SEQ ID NO: 2, 4, 6, 8, 10 or 12.
[CONT.]
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are also included for: [CONT.]
subjects with hypertrichosis or hirsutism.
IMMUNOMEDICS INC
388 Preparing an immunotoxin for diagnosing or
treating, for e.g. cancer or infection, comprises
culturing a mammalian host cell transformed
with nucleic acid sequences encoding fusion
proteins containing recombinant cytotoxic
RNAses
The process enables synthesis of liposomes
having improved stability and increased load of
the active agent. The liposomes are sensitive to
alterations in the temperature of the surrounding
environment; exhibit excellent stability at normal
body temperature in mammals; and facilitates
release of the entrapped active agents at
selectively temperatures to target sites e.g.
diseased sites. [CONT.]
US 7901709
WO 2005085288
US 20050276811
US 20090176966
(3) a composition (IV) comprising a peptide having
the amino acid sequence of SEQ ID NO: 14, 36 or
38, or any of 9 fully defined sequences of 12
amino acids (SEQ ID NO: 16, 18, 20, 22, 24, 26,
28, 30 and 32), or (VII) and a pharmaceutical
carrier; [CONT.]
US 20100136684
Preparing an immunotoxin comprising culturing a
mammalian host cell, where the host cell is
transformed with a first nucleic acid sequence
encoding a fusion polypeptide, where the fusion
polypeptide comprises a non-mammalian
ribonuclease fused to a first immunoglobulin
variable domain, and a second nucleic acid
sequence encoding a second polypeptide
comprising a second immunoglobulin variable
domain, where the first and second
immunoglobulin variable domains together form
an antigen binding site. [CONT.]
N
US 7442783
(2) a host cell (III) comprising (II);
Treatment with (A) effectively inhibits growth of
PHARMACEUTICALS - Preferred Materials: (A) is
hair without side effects. The effect of (A) lasts for botulinum toxin types A, B or F, most preferably
3-4 months.
A1, and it may be used as a complex. Preferred
Process: Compositions containing (A) are applied
topically to the area requiring treatment, e.g. torso,
legs, arms, axillae or face. The composition may
be a lyophilized powder (reconstituted before use)
or a solution for injection.
BIOTECHNOLOGY - Preferred Method: In
preparing an immunotoxin, the non-mammalian
ribonuclease is fused to the N-terminus of the first
immunoglobulin variable domain. It bears an Nterminal pyroglutamate residue. The first
immunoglobulin variable domain is a light chain
variable domain. The fusion polypeptide and the
second immunoglobulin variable domain are
produced as separate molecules in the host cell
[CONT.]
US 20050191345
EP 1570855
US 20070292546
US 7754253
WO 2005080586
US 20060014245
US 7544487
US 20090246214
N
389 Novel anti-dendritic cell-specific
transmembrane protein (DC-STAMP) antibody
suppressing formation of osteoclast and
capable of specifically binding DC-STAMP,
useful for treating bone metabolic disorder,
e.g. osteoporosis
AU 2005214361
B2
20110324
DAIICHI SANKYO CO LTD
WO 2005078087
A1
20050825
SANKYO CO LTD
JP 2005255674
A
20050922
DAIICHI SANKYO KK
A1
20061025
A1
20070208
KUKITA T
EP 1715038
US 20070031421
US 20070081974
A1
20070412
NOMIYAMA H
KR 2006111691
A
20061027
BR 2005007645
A
20070710
CN 1942581
A
20070404
TW 2005029872
A
20050916
CN 1942581
B
20100908
JP 4633491
B2
20110216
JP 2011057682
A
20110324
WO 2005067620
US 20050232917
A2
20050728
A1
20051020
NL 1027975
C2
20051223
NO 2006003601
A
20060808
GREEN L L
EP 1709080
A2
20061011
HAAK-FRENDSCHO M
AU 2005204678
A1
20050728
KELLERMANN S
BR 2005006768
A
20070522
MOLLOY E
KR 2006129006
A
20061214
PULLEN N
IN 2006KN02237
A
20070525
HIRUMA Y
PFIZER INC
390 New antibody to Mucosal Adressin Cell
Adhesion Molecule, useful for diagnosing and PFIZER LTD
treating an inflammatory disease, e.g.
inflammatory bowel disease, ulcerative colitis,
gastritis, insulin-dependent diabetes or graft
versus host disease
ABGENIX INC
AMGEN FREMONT INC
391 Continuous process for multimicroencapsulationof biologically active
materials, useful for preparing e.g. food
supplements or medicines, comprises in situ
interfacial polymerization
GAT FORMULATION
US 20070166308
A1
20070719
CN 1956738
A
20070502
ZA 2006005825
A
20071128
JP 2008505606
T
20080228
US 20080124339
A1
20080529
JP 2009005695
A
20090115
AU 2005204678
B2
20080925
NZ 548702
A
20090626
JP 4315982
B2
20090819
WO 2005067620
A9
20091001
TW 2005035144
A
20051101
JP 2010042025
A
20100225
EP 2177537
EP 2177537
A2
20100421
A3
20100505
PH 12006501310
B1
20100629
MY 140862
A
20100129
EP 1709080
WO 2005058476
B1
20110309
A1
20050630
WO 2005078087 A1 UPAB: 20090902
(I) or pharmaceutical composition (PC) comprising (I) suppresses formation of an osteoclast and
(I) is useful for treating bone metabolic disorders, specifically binds to DC-STAMP (claimed).
NOVELTY: An anti-dendritic cell-specific
where the bone metabolic disorder is
transmembrane protein (anti-DC-STAMP)
osteoporosis, rheumatoid arthritis or cancerous
antibody (I) suppressing formation of an
osteoclast, and capable of specifically binding DC- hypercalcemia. (I) is useful for detecting subject
STAMP chosen from a protein (P1) having a fully suffering bone metabolic disorder. (All claimed).
defined 470 amino acid (SEQ ID No. 2) sequence [CONT.]
given in the specification, and protein (P2) having
a fully defined 470 amino acid (SEQ ID No.
[CONT.]
BIOTECHNOLOGY - Preferred Antibody: (I) is a
monoclonal antibody, and is humanized. (I) is a
perfect human antibody. (I) is an IgG antibody.
Preferred Method: In (M1), the bone metabolic
disorder is osteoporosis, rheumatoid arthritis
and/or cancerous hypercalcemia. The
measurement of expression level of PN1 or PN2 is
carried out by Northern blotting method, dot
plotting method, slot plotting method, reverse
transcriptase-PCR, or RNase protection assay
[CONT.]
An anti-dendritic cell-specific transmembrane
WO 2005078087
protein (anti-DC-STAMP) antibody (I) suppressing
formation of an osteoclast, binds specifically to DCSTAMP chosen from a protein (P1) having a fully
defined 470 amino acid (SEQ ID No. 2) sequence
given in the specification, protein (P2) having a
fully defined 470 amino acid (SEQ ID No. 4)
sequence given in the specification, and a protein
(P3) having a fully defined 414 amino acid (SEQ
ID No [CONT.]
US 20070031421
US 20070081974
N
WO 2005067620 A2 UPAB: 20090220
The antibody, composition, and method are useful
for diagnosing and treating an inflammatory
NOVELTY: A human monoclonal antibody or its
disease, e.g. inflammatory disease of the
antigen-binding portion that specifically binds to
gastrointestinal tract selected from inflammatory
Mucosal Adressin Cell Adhesion Molecule
bowel disease, Crohn's disease, ulcerative colitis,
(MAdCAM), is new.
diverticulas disease, gastritis, liver disease,
DETAILED DESCRIPTION: A human monoclonal
primary biliary sclerosis and sclerosing
antibody or its antigen-binding portion, produced
cholangitis, insulin-dependent diabetes and graft
by a hybridoma cell line, that specifically binds to
versus host disease.
Mucosal Adressin Cell Adhesion Molecule
(MAdCAM), where the antibody [CONT.]
BIOTECHNOLOGY - Preferred Monoclonal
Antibody: The antibody or portion possesses at
least one of the following properties: binds to
human cells, has a selectivity for MAdCAM over
VCAM or fibronectin of at least 100 fold, binds to
human MAdCAM with a Kd of 3 x 10-10 M or less,
inhibits the binding of alpha4beta7 expressing
cells to human MAdCAM, or inhibits the
recruitment of lymphocytes to gastrointestinal
lymphoid tissue, where the antibody or portion
binds human MAdCAM with a Kd of 3 x 10-10 M or
less and inhibits alpha4beta7 binding to human
MAdCAM [CONT.]
A human monoclonal antibody or its antigenWO 2005067620
binding portion, produced by a hybridoma cell line,
that specifically binds to Mucosal Adressin Cell
Adhesion Molecule (MAdCAM), where the
antibody is selected from an antibody comprising
any of the 17 sequences of 233-241 amino acids
(SEQ ID NOS: 4, 8, 12, 16, 20, 24, 28, 32, 36, 40,
44, 48, 54, 58, 62, 66 or 68), without the signal
sequences, where the [CONT.]
US 20050232917
US 20070166308
N
WO 2005058476 A1 UPAB: 20091006
BIOLOGY - Preferred Process; The method of (1) Continuous process for multi-microencapsulation, WO 2005058476
comprises: (A) mixing aqueous and oil solutions
by in situ interfacial polymerization, of biologically
containing (A) and optionally cations, either free or active materials (A) comprises:
sequestered for subsequent release; (B) forming
an emulsion of water droplets (a food-grade
emulsifier is present in one of the starting
solutions) and the solubility of (A) in the different
US 20070077308
The compositions are used in preparation of a
Incorporation into microcapsules stabilizes (A),
wide range of foods, beverages (specifically fruit particularly those that are sensitive to light or
juices) and animal feeds; to provide (quasioxidation.
)continuous release of anabolites and/or nutrients
to microbial cells; as condiments; as stabilizers or
UV absorbers; in human or veterinary medicine
(especially to promote neuronal development or
US 20080124339
supplements or medicines, comprises in situ
interfacial polymerization
392 Culturing mammalian pluripotent stem cells,
involves culturing cells in unfertilized
telolecithal or eutelolecithal egg, or culturing
cells in juxtaposition to vitelline membrane of
embryonated telolecithal or eutelolecithal egg
GAT FORMULATION GMBH
ES 2235642
A1
20050701
GINER V C
ES 2235642
B2
20060301
CASANA G V
EP 1702675
A1
20060920
GIMENO S B
AU 2004298792
A1
20050630
GIMENO S M
US 20070077308
A1
20070405
MOSER M
BR 2004017767
A
20070417
CN 1917946
A
20070221
JP 2007521135
T
20070802
MX 2006006735
A1
20070301
ZA 2006004896
A
20071031
CN 100566812
C
20091209
AU 2004298792
B2
20100715
US 20110064778
US 20110064817
WO 2005068610
A1
20110317
A1
20110317
A1
20050728
CHAPMAN K B
US 20060031955
A1
20060209
KLIMANSKAYA I V
US 20060112438
A1
20060525
WEST M D
EP 1711594
A1
20061018
AU 2005205516
A1
20050728
US 20070067860
A1
20070322
NZ 548623
A
20100430
AU 2005205516
B2
20101216
IL 176641
A
20110228
US 7910369
WO 2005062967
B2
20110322
A2
20050714
EP 1703893
A2
20060927
FUNG S C
AU 2004308494
A1
20050714
HUANG D
MX 2006007181
A1
20061001
LU M
CN 1898264
A
20070117
MOYLE M
JP 2007161724
A
20070628
ADVANCED CELL TECHNOLOGY INC
393 New antibody or its antigen-binding fragment GENENTECH INC
that binds specifically and with high affinity to
TANOX INC
glycosylated and non-glycosylated human
interleukin-13 (IL-13), useful for treating IL-13mediated disorders, such as asthma and
eczema
)continuous release of anabolites and/or nutrients
to microbial cells; as condiments; as stabilizers or
NOVELTY: Continuous process for multiUV absorbers; in human or veterinary medicine
microencapsulation, by in situ interfacial
polymerization, of biologically active materials (A). (especially to promote neuronal development or
intellectual capacity in the fetus or in new born
babies), and [CONT.]
sequestered for subsequent release; (B) forming
an emulsion of water droplets (a food-grade
emulsifier is present in one of the starting
solutions) and the solubility of (A) in the different
solutions may be modified by derivatization;
[CONT.]
(A) adding an aqueous phase, containing at least
one polymerization initiator (I), to an oil phase,
provided that the starting phases include at least
one (A) and at least one emulsifier (II); [CONT.]
US 20110064778
DETAILED DESCRIPTION: Continuous process
for multi-microencapsulation, by in situ interfacial
polymerization, of biologically active materials (A)
comprises: [CONT.]
WO 2005068610 A1 UPAB: 20100527
(M1) is useful for culturing mammalian pluripotent
stem cells, where the mammalian pluripotent stem
NOVELTY: Culturing (M1) mammalian pluripotent cells are obtained from human, canine or feline
(claimed). (M1) is useful for culturing human
stem cells comprising:
embryonic stem cells, human neural cells and
human embryo-derived cells that are useful in cell
transplantation, veterinary practice to treat canine
(a) culturing the cells in an unfertilized telolecithal or feline diseases, for treating diseases such as
Parkinson's [CONT.]
or eutelolecithal egg;
US 20110064817
(M1) provides an efficient and cost-effective
process for producing many kinds of differentiated
cells under specific pathogen-free conditions. The
cultivation enables high yield of human embryonic
stem cells. (M1) enables differentiation of cells in
the context of a specific pathogen-free culture
system capable of generating complex tissues.
[CONT.]
BIOTECHNOLOGY - Preferred Method: In (M3),
the mammalian chromatin is human. The oocyte is
activated by the introduction and removal of a
sperm or sperm head. In (M4), the specific
pathogen-free species is avian. The human
embryo-derived cells are maintained as embryonic
stem cell lines by co-culture with chick embryonic
fibroblasts feeder cells. [CONT.]
INDEPENDENT CLAIMS are also included for:
WO 2005068610
(1) culturing (M2) a nonhuman mammalian
embryo or fetus comprising culturing the
nonhuman mammalian embryo or fetus in an
unfertilized telolecithal or eutelolecithal egg;
US 20060112438
(2) reconstituting (M3) mammalian cells from
chromatin comprising injecting the chromatin into
the oocyte of a telolecithal or eutelolecithal egg,
activating the egg, and allowing karyokinesis and
cytokinesis to occur; and [CONT.]
US 20070067860
(b) culturing the cells in a fertilized telolecithal or
eutelolecithal egg external to the developing nonhuman animal until the time of the involution of the
yolk sac; or [CONT.]
WO 2005062967 A2 UPAB: 20090907
The antibody and methods are useful for treating
IL-13-mediated disorders, such as allergic
asthma, non-allergic (intrinsic) asthma, allergic
NOVELTY: An antibody or its antigen-binding
rhinitis, atopic dermatitis, allergic conjunctivitis,
fragment that binds specifically and with high
eczema, urticaria, food allergies, chronic
affinity to glycosylated and non-glycosylated
obstructive pulmonary disease, ulcerative colitis,
human interleukin-13 (IL-13), does not bind
mouse IL-13, and neutralizes human IL-13 activity RSV infection, uveitis, scleroderma, or
at an approximate molar ratio of 1:2 (MAb:IL13), is osteoporosis (claimed).
new.
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are also included for: [CONT.]
US 20060031955
N
US 7910369
BIOTECHNOLOGY - Preferred Antibody: The
antibody or its antigen-binding fragment is 228B/C
and produced by the hybridoma designated PTA5657. The antibody is 228A-4 and produced by
the hybridoma designated PTA-5656; 227-26 and
produced by the hybridoma designated PTA-5654;
or 227-43 and produced by the hybridoma
designated PTA-5655. The antibody has a VL
sequence at least 95% homologous to that set
forth in SEQ ID No [CONT.]
INDEPENDENT CLAIMS are also included for:
(1) an antibody that binds to the same epitope as
the antibody cited above;
(2) an antibody comprising antigen binding
regions derived from the light and heavy chain
variable regions of the novel antibody;
(3) a hybridoma cell line that produces a
monoclonal antibody selected from 228B/C-1,
228A-4, 227-26, and 227-43 and designated with
the ATCC deposit number PTA-5657, PTA-5656,
PTA-5654, and PTA-5655, respectively; [CONT.]
WO 2005062967
US 20090214523
US 20110014199
N
394 Use of Tumor Antigens of Hematopoietic
Origin polypeptides for inhibiting, treating, or
preventing cell proliferative disorders of
hematopoietic origin
395 Novel high affinity anti-human IP-10 antibody
or its fragment, useful for treating, preventing
and diagnosing inflammatory bowel disease
such as Crohns disease and ulcerative colitis
SINGH S
KR 2006130625
A
20061219
YAN C
CN 1973053
A
20070530
JP 2008500024
T
20080110
GENENTECH INC
US 20090214523
A1
20090827
SG 151296
A1
20090430
AU 2004308494
B2
20100318
US 20110014199
A1
20110120
JP 2011042669
A
20110303
WO 2005063299
A2
20050714
WO 2005063299 A2 UPAB: 20051223
EP 1696963
A2
20060906
NOVELTY: Use of Tumor Antigens of
Hematopoietic Origin (TAHO) polypeptides for
inhibiting, treating, or preventing a cell proliferative
disorder of hematopoietic origin, is new.
US 20060216232
A1
20060928
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are included for the following:
US 20060251662
A1
20061109
(1) a method of inhibiting the growth of a cell that
expresses a protein having at least 80% amino
acid sequence identity to: [CONT.]
AU 2004308972
A1
20050714
JP 2007519632
T
20070719
NZ 548096
A
20090626
AU 2004308972
B2
20090528
AU 2009202783
A1
20090730
US 7858330
B2
20101228
JP 2011019523
A
20110203
US 7888478
B2
20110215
JP 4658967
B2
20110323
WO 2005060457
EP 1708961
A2
20050707
A2
20061011
US 20080063646
EP 1708961
A1
20080313
B1
20110309
A2
20050707
IAMS CO G
WO 2005060708
US 20050158293
A1
20050721
PROCTER & GAMBLE CO
EP 1718154
A2
20061108
ALIMENTARY HEALTH LTD
AU 2004305121
A1
20050707
PROCTER&GAMBLE CO
BR 2004017805
A
20070410
BOILEAU T W
JP 2007513639
T
20070531
CEDDIA M A
US 20080292604
A1
20081127
COLLINS J K
AU 2004305121
B2
20090122
PDL BIOPHARMA INC
PROTEIN DESIGN LABS INC
ABBOTT BIOTHERAPEUTICS CORP
BALASA B
The polypeptides, nucleic acids, antibodies, and
methods are useful for treating or preventing a cell
proliferative disorder, preferably hematopoietic
tumors in mammals.
BIOTECHNOLOGY - Preferred Method: Inhibiting
the growth of a cell that expresses a protein
having at least 80% amino acid sequence identity
to the polypeptides given above, comprises
contacting the cell with an antibody, oligopeptide,
or organic molecule that binds to the protein, the
binding of the antibody, oligopeptide, or organic
molecule to the protein causes an inhibition of
growth of the cell [CONT.]
WO 2005060457 A2 UPAB: 20110315
(I) is useful for preventing or reducing severity of
NOVELTY: An HuAIP12 or HuAIP12 T55I antibody at least one symptom of an inflammatory bowel
disease (IBD) in a subject in need, which involves
or its fragment (I) comprising a variable heavy
(VH) chain amino acid sequence of a fully defined administering (I) to the subject, where the IBD is
138 or 119 amino acid (SEQ ID No. 50 or 78, VH Crohn's disease (CD) or ulcerative colitis (UC), (I)
inhibits at least one biological activity of IP-10, and
sequence of HuAIP12 and HuAIP12 T55I,
respectively) sequence given in the specification the method further involves administering an
and a variable light chain amino acid sequence of immunosuppressive agent to the subject (claimed)
[CONT.]
a fully defined 127 amino acid (SEQ ID No
[CONT.]
BIOTECHNOLOGY - Preferred Antibody: (I) is a
monoclonal antibody chosen from chimeric
antibody, humanized antibody and fully human
antibody. The antibody fragment is a Fab
fragment, (Fab')2 fragment or Fv fragment. (I) is
conjugated to a cytotoxic agent.
INDEPENDENT CLAIMS are included for the
following:
(1) a method of inhibiting the growth of a cell that
expresses a protein having at least 80% amino
acid sequence identity to:
WO 2005063299
US 20060216232
(a) the polypeptide having the amino acid
sequence selected from fully defined 124-515
amino acid sequences (SEQ ID NO. 2-12, even
numbers only) given in the specification;
US 7858330
(b) the polypeptide selected from SEQ ID NO.
[CONT.]
US 7888478
An INDEPENDENT CLAIM is also included for a
pharmaceutical composition (II), comprising (I)
and a carrier.
WO 2005060457
US 20080063646
WO 2005060708
US 20050158293
US 20080292604
LANDOLFI N F
TSURUSHITA N
396 Specific strain of lactobacillus isolated from
canine gastrointestinal tract useful for
maintaining or improving health of a
companion animal e.g. dog has probiotic
activity
IAMS CO
WO 2005060708 A2 UPAB: 20100712
For maintaining or improving health of a
companion animal (e.g. a dog or cat); such as for
NOVELTY: A strain of lactic acid bacteria
treatment of conditions such as, regulation of the
belonging to genus Lactobacillus; and isolated
from resected and washed canine gastrointestinal immune system (e.g. treating or preventing
autoimmune disease and inflammation);
tract, exhibits probiotic activity.
maintaining or improving the health of the skin
and/or coat system (e.g. treating or preventing
DETAILED DESCRIPTION: An INDEPENDENT
atopic disease of the skin); treating or preventing
CLAIM is included for a composition comprising
gastrointestinal infection (e. [CONT.]
the lactic acid bacteria strain.
ACTIVITY: Antimicrobial; Antibacterial; Virucide;
Antifungal; Immunomodulator [CONT.]
The lactic acid bacteria are isolated from the
canine gastrointestinal tract; thus comprise natural
intestinal microflora from the canine
gastrointestinal tract (preferably upper portion of
the gastrointestinal tract) and adapted to the
companion animals, rather than organisms
isolated from human, hence exhibit improved
probiotic activity in the companion animals such
as, dogs and cats. [CONT.]
BIOTECHNOLOGY - Preferred Bacteria: The
An INDEPENDENT CLAIM is included for a
lactic acid bacteria comprises a 16s - 23s
composition comprising the lactic acid bacteria
intergenic polynucleotide sequence having at least strain.
88% homology with a sequence selected from 4
polynucleotide sequences containing 231, 234,
243 and 235 nucleotides, respectively; as given in
the specification. FOOD - Preferred Composition:
The composition contains viable or non-viable
cells of the lactic acid bacteria, or its constituent
fractions [CONT.]
N
US 20060251662
US 7906112
N
DAVENPORT G M
JP 4503614
B2
20100714
EP 2261319
EP 2261320
EP 2261321
US 7906112
A1
20101215
A1
20101215
A1
20101215
B2
20110315
US 20050142102
A1
20050630
US 20050142102 A1 UPAB: 20051223
SYGNIS BIOSCIENCE GMBH & CO KG
WO 2006008582
A1
20060126
NOVELTY: Treating a neurological condition in a
mammal comprising administering a
hematopoietic factor selected from granulocyecolony stimulating factor (G-CSF), granulocytemonocyte (GM)-CSF, interleukin (IL)-3, IL-5, their
derivatives or mimetics, or their combination or
contacting a neural stem cell composition with any
of the stated hematopoietic factors, and
subsequently administering the neural stem cells
to the mammal, is new. [CONT.]
SYGNIS BIOSCIENCE GMBH&CO KG
EP 1765381
A1
20070328
AU 2004321585
A1
20060126
JP 2008504358
T
20080214
IN 2006CN04825
A
20071005
US 7695723
EP 1765381
B2
20100413
B1
20101013
DE 602004029616
E
20101125
AU 2004321585
B2
20110203
EP 2295069
WO 2005049075
A1
20110316
A2
20050602
WO 2005049075 A2 UPAB: 20051222
EP 1689432
A2
20060816
NOVELTY: Inhibiting the growth of a cell that
expresses a protein comprises contacting the cell
with an antibody, oligopeptide or organic molecule
that binds to the protein, the binding of the
antibody, oligopeptide or organic molecule to the
protein and causing an inhibition of growth of the
cell. [CONT.]
AU 2004291141
A1
20050602
JP 2007516242
T
20070621
US 20070207142
A1
20070906
AU 2004291141
B2
20090611
AU 2009213070
A1
20091008
EP 1689432
B1
20091230
DE 602004024921
E
20100211
KIELY B P
OMAHONY L D
SUNVOLD G D
TETRICK M A
VICKERS R J
397 Treating a neurological condition, e.g. stroke
or amyotrophic lateral sclerosis, comprises
administering to the mammal a hematopoietic
factor
AXARON BIOSCIENCE AG
398 Inhibiting the growth of a cell that expresses a GENENTECH INC
protein by contacting the cell with anti-tumor
antigens of hematopoietic origin (TAHO)
polypeptide, antibody or organic molecule,
useful for treating hematopoietic and
malignant tumors
CHILDREN'S HOSPITAL MEDICAL CENT
399 New self-cleaving ribozyme that cleaves an
RNA molecule comprising the self-cleaving
CHILDRENS MEDICAL CENT
ribozyme in a mammalian cell, useful for
treating cancer or infections, or for generating
systems for gene regulation
The method and hematopoietic factor are useful
for treating a neurological condition, e.g. a
neurological disease with pathophysiological
mechanisms involving ischemia or hypoxia (i.e.
stroke), a neurodegenerative disease, a disease
of the nervous system accompanied by neural cell
death, psychiatric condition (i.e. [CONT.]
BIOTECHNOLOGY - Preferred Method: The
method further comprises administering one or
more additional hematopoietic factors. The
hematopoietic factors are selected from G-CSF,
GM-CSF, their derivatives or mimetics, or their
combinations and where the additional
hematopoietic factor is erythropoietin. A
combination comprising at least two hematopoietic
factors selected from GCSF, GMCSF, IL-3, IL-5,
their derivatives or mimetics and where the
additional hematopoietic factor is erythropoietin
[CONT.]
INDEPENDENT CLAIMS are also included for:
US 20050142102
(1) enhancing the survival of a cell transplanted
into a mammal, of enhancing the viability of a
neural cell culture; and
US 20050142102
N
US 7695723
(2) enhancing the cognitive ability of a mammal.
The methods and compositions of the present
invention are useful for treating hematopoietic and
malignant tumors in mammals.
BIOTECHNOLOGY - Preferred Method: The
antibody in inhibiting the growth of a cell that
expresses a protein is a monoclonal antibody, an
antibody fragment, a chimeric or a humanized
antibody. The antibody, oligopeptide or organic
molecule is conjugated to a growth inhibitory
agent or cytotoxic agent that is selected from
toxins, antibiotics, radioactive isotopes and
nucleolytic enzymes, preferably a toxin from
maytansinoid and calicheamicin [CONT.]
The protein in the method of inhibiting the growth WO 2005049075
of a cell cited above has at least 80 % amino acid
sequence identity to:
(a) a polypeptide having any of 9 fully defined
sequences of 226-661 amino acids (SEQ ID NO:
2, 8, 10, 12, 16, 20, 22, 49 and 51);
US 20070207142
N
(b) a polypeptide having the amino acid sequence
of (a), lacking its associated signal peptide;
[CONT.]
EP 2161283
A1
20100310
JP 2010154864
A
20100715
EP 2295073
WO 2005049817
A1
20110316
A2
20050602
WO 2005049817 A2 UPAB: 20100514
US 20050158741
A1
20050721
NOVELTY: A self-cleaving ribozyme (I), which
efficiently cleaves an RNA molecule which
comprises the self-cleaving ribozyme in a
mammalian cell, is new.
EP 1689784
A2
20060816
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are also included for:
The composition and methods are useful for
treating cancer or for inhibiting infection by a virus
(e.g. HIV) or a pathogenic microorganism
(claimed). These may also be used for generating
systems for gene regulation.
BIOTECHNOLOGY - Preferred Ribozyme: The
schistosome ribozyme mutant (I) comprises a loop
on stem III. The loop comprises at least 3
nucleotides. The loop is selected from 5'-UUCG3', 5'-CUUCGG-3', and 5'-GCUUCGGU-3'. The
ribozyme mutant further comprises at least one
nucleotide substitution in the ribozyme core
sequence. The nucleotide C at position 7 is
substituted with a nucleotide selected from U, A
and G [CONT.]
INDEPENDENT CLAIMS are also included for:
(1) a nucleic acid (II) encoding a schistosome
ribozyme mutant, where the schistosome
ribozyme mutant comprises a loop on stem III,
and optionally, an aptamer in a position such that
the cleaving activity of the schistosome ribozyme
mutant can be modulated by binding of an effector
to the aptamer; [CONT.]
WO 2005049817
US 20050158741
US 20110061120
N
AU 2004291911
A1
20050602
AU 2010201034
A1
20100408
US 20110061120
WO 2005049789
A1
20110310
A2
20050602
EP 1636343
A2
20060322
AU 2004291828
A1
20050602
US 20070098700
A1
20070503
JP 2007515941
T
20070621
AU 2004291828
B2
20100923
JP 4653751
B2
20110316
WO 2005047456
A2
20050526
WO 2005047456 A2 UPAB: 20051222
DE 10352977
A1
20050609
MUELLER-HERMELINK H K
EP 1694708
A2
20060830
VOLLMERS H
AU 2004288870
A1
20050526
NOVELTY: An isolated anti-idiotype antibody,
which specifically binds a polypeptide comprising
the SC-1 human monoclonal antibody heavy chain
sequence (SEQ ID NO: 1), fully defined in the
specification, is new.
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are also included for:
(1) a hybridoma cell line with DSMZ accession
number DSM ACC2625; [CONT.]
VOLLMERS H P
US 20070269425
A1
20071122
JP 2008500957
T
20080117
US 7611894
US 20100316630
EP 2270054
B2
20091103
A1
20101216
A2
20110105
AU 2004288870
B2
20110310
EP 1533369
A1
20050525
EP 1533369 A1 UPAB: 20091001
WO 2005049813
A1
20050602
NOVELTY: Phage isolate (I) with substantial lytic
potential towards Enterobacter sakazakii is new.
BR 2004016768
A
20070227
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are also included for:
CN 1890366
A
20070103
MX 2006005557
A1
20061201
(a) a food product containing at least one (I) or
cocktail with substantial lytic potential towards
Enterobacter sakazakii;
(b) a phage cocktail containing at least one (I),
which infects at least 80% of E. [CONT.]
EP 1533369
WO 2005040428
B1
20110323
A2
20050506
UNIV JOHNS HOPKINS
400 New synthetic mammalian (retro)transposon
open reading frame 2 (ORF2) or ORF1 gene
exhibiting a higher level of expression relative
to a natural L1 (retro)transposon ORF2 or
ORF1 gene, useful for treating e.g., metabolic
diseases
DEBIOVISION INC
401 New anti-idiotype antibody of the human
monoclonal antibody SC-1, useful for
diagnosing, detecting, monitoring, and treating H3 PHARMA INC
neoplasms
402 New phage isolates with substantial lytic
potential towards Enterobacter sakazakii
useful as e.g. disinfectant in food or for
sanitation of factory environment
403 Identifying an oligoadenylate synthetase 1
gene mutation, useful for treating, e.g. viral
infection, cancer or diabetes, comprises
detecting in a nucleic acid sample, the
presence of an oligoadenylate synthetase 1
NESTEC SA
ILLUMIGEN BIOSCIENCES INC
(1) a nucleic acid (II) encoding a schistosome
ribozyme mutant, where the schistosome
ribozyme mutant comprises a loop on stem III,
and optionally, an aptamer in a position such that
the cleaving activity of the schistosome ribozyme
mutant can be modulated by binding of an effector
to the aptamer; [CONT.]
WO 2005049789 A2 UPAB: 20051222
The composition is useful for treating a genetic
disorder in a mammal such as hemophilia,
Parkinson's disease, Fabry's disease, familial
NOVELTY: A synthetic mammalian
(retro)transposon ORF2 or ORF1 gene exhibiting hypercholesterolemia, Gaucher's disease, cystic
a higher level of expression relative to a natural L1 fibrosis, adrenoleukodystrophy cystic fibrosis,
disorders associated with mutations in the
(retro)transposon ORF2 or ORF1 gene, is new.
dystrophin gene, adenosine deaminase
deficiency, alpha-antitrypsin deficiency, Duchenne
DETAILED DESCRIPTION: INDEPENDENT
muscular dystrophy, phenylketonuria, sickle cell
CLAIMS are also included for:
anemia, Tay-Sachs disease, the thalassemias,
(1) a (retro)transposon comprising the synthetic
lysosomal storage disorders, and metabolic
gene above;
disorders (claimed) [CONT.]
(2) a mammalian L1 retrotransposon comprising
the synthetic gene; [CONT.]
BIOTECHNOLOGY - Preferred Method: Delivering INDEPENDENT CLAIMS are also included for:
a desired gene, or its biologically active fragment,
to the cells of a mammal, comprises the
(1) a (retro)transposon comprising the synthetic
administration of the gene above and the desired gene above;
gene to the mammal. The synthetic gene
comprises human-associated codons. [CONT.]
WO 2005049789
US 20070098700
N
(2) a mammalian L1 retrotransposon comprising
the synthetic gene;
(3) a recombinant vector construct comprising the
synthetic gene;
(4) a eukaryotic cell transfected, transformed, or
infected with the recombinant vector construct;
(5) delivering a desired gene, or its biologically
active fragment, to the cells of a mammal;
[CONT.]
WO 2005040428 A2 UPAB: 20051222
The antibody, composition and method are useful
for diagnosing, detecting, monitoring, and treating
neoplasms.
(I) is useful as disinfectant in food or for sanitation
of factory environment. (I) or cocktail is useful for
decontamination of food products and sanitation
of factory environment. (I) is useful in the
preparation of a composition intended to prevent
or treat infections caused by E. sakazakii in
humans or animals (all claimed). (I) is useful as
anti-microbial agents in food products (particularly
in infant formula) and for sanitation of factory
environments [CONT.]
M1 is useful for identifying an oligoadenylate
synthetase gene (OAS1) mutation. It is also useful
for identifying susceptibility to viral infection,
hepatitis C infection, predisposition to diabetes
mellitus or schizophrenia in humans, susceptibility
to cancer such as prostate cancer, or for
(I) has a strong lytic activity against Enterobacter
sakazakii. (I) provides an agent to disinfect, clean
and decontaminate working surfaces or
processing equipment in factories, as well as
floors and walls and is environmentally safe and
nontoxic for humans.
BIOTECHNOLOGY - Preferred Antibody: The antiidiotype antibody specifically binds CD 5 positive
B lymphocytes. The anti-idiotype antibody further
comprises a detectable agent. Preferred Method:
Generating an immune response in a mammal
against the anti-idiotype antibody comprises
immunizing a mammal with the purified antibody in
a pharmaceutical carrier. The anti-idiotype
antibody is humanized prior to immunizing the
mammal [CONT.]
INDEPENDENT CLAIMS are also included for:
WO 2005047456
FOOD - Preparation: The sewage water sample
(50 ml; whose pH was adjusted to 7) was
centrifuged for 10 minutes at 2500 g, the
supernatant was filtered, the sample was
maintained at 4degreesC for 1-2 days, the
bacteriophages were isolated using biological
tests, amplified and stored. Preferred
Components: The food product is in the form of a
milk based product, a nutritional composition, a
pet food, a dietary supplement or any food at risk
of contamination by Enterobacter sakazakii
[CONT.]
INDEPENDENT CLAIMS are also included for:
BIOTECHNOLOGY - Preparation (claimed): (I) is
produced by expressing the polypeptide in a cell,
and recovering the polypeptide. Preferred
Polypeptide: The polypeptide is covalently
attached to a polypeptide comprising a protein
transduction domain. The protein transduction
A human genetic screening method (M1) for
WO 2005040428
identifying an oligoadenylate synthetase gene
(OAS1) mutation comprising detecting in a nucleic
acid sample the presence of an OAS1 point
mutation selected from substitution of a nonreference nucleotide for a reference nucleotide at
US 20070269425
(1) a hybridoma cell line with DSMZ accession
number DSM ACC2625;
US 7611894
(2) an anti-idiotype antibody expressed by the
hybridoma cell line;
(3) a humanized antibody having the binding
specificity of the anti-idiotype antibody of (2);
(4) generating an immune response in a mammal
against the anti-idiotype antibody; and [CONT.]
US 20100316630
N
EP 1533369
(a) a food product containing at least one (I) or
cocktail with substantial lytic potential towards
Enterobacter sakazakii;
(b) a phage cocktail containing at least one (I),
which infects at least 80% of E. sakazakii strains
(FSM-16; FSM-33; FSM-261; FSM-265; FSM-266,
FSM-269; FSM-270; FSM-271; FSM-272; FSM273; FSM-274; FSM-280; FSM-281; FSM-284;
FSM-286; [CONT.]
US 20050191649
N
403 Identifying an oligoadenylate synthetase 1
gene mutation, useful for treating, e.g. viral
infection, cancer or diabetes, comprises
detecting in a nucleic acid sample, the
presence of an oligoadenylate synthetase 1
point mutation
404 Novel linear, non-crosslinked,
immunomodulatory polymeric synthetic
polysaccharide antigenic compounds, useful
for modulating immune response and treating
disease or disorder susceptible to treatment
with immunomodulator
ILLUMIGEN BIOSCIENCES INC
M1 is useful for identifying an oligoadenylate
synthetase gene (OAS1) mutation. It is also useful
NOVELTY: Identifying (M1) an oligoadenylate
for identifying susceptibility to viral infection,
synthetase gene (OAS1) mutation comprising
detecting in a nucleic acid sample the presence of hepatitis C infection, predisposition to diabetes
mellitus or schizophrenia in humans, susceptibility
an OAS1 point mutation, is new. [CONT.]
to cancer such as prostate cancer, or for
identifying a patient responsiveness to therapeutic
treatments for viral infection, where the
therapeutic treatment is interferon-based and the
patient response is measured by sustained viral
clearance [CONT.]
BIOTECHNOLOGY - Preparation (claimed): (I) is
produced by expressing the polypeptide in a cell,
and recovering the polypeptide. Preferred
Polypeptide: The polypeptide is covalently
attached to a polypeptide comprising a protein
transduction domain. The protein transduction
domain is comprised of a polypeptide selected
from 10 fully defined 7-621 amino acid (SEQ ID
NO:85-94) sequences given in the specification or
having at least 80% sequence similarity to a
polypeptide selected from SEQ ID NO:85-94
[CONT.]
A human genetic screening method (M1) for
WO 2005040428
identifying an oligoadenylate synthetase gene
(OAS1) mutation comprising detecting in a nucleic
acid sample the presence of an OAS1 point
mutation selected from substitution of a nonreference nucleotide for a reference nucleotide at
nucleotide position 2135728, 2135749, 2135978,
2144072, 2144088, 2144116, 2144321, 2131025,
2133961, 2139587, 2144294, 2144985, 2156523,
and 2156638 of reference sequence comprising a
27160 base pair (bp) (SEQ ID NO: 19) sequence
fully defined in the specification [CONT.]
C1 is useful for the preparation of a medicament
for the prevention or treatment of a disease or
disorder susceptible to treatment with an
immunomodulator, for the preparation of a vaccine
adjuvant and for preventing or treating a disease
or disorder susceptible to treatment with an
immunomodulator. C1 is useful for inducing an
immune response (inflammatory or antiinflammatory) in a mammal. [CONT.]
BIOTECHNOLOGY - Preferred Compound: C1 is
in substantially pure form. One or more of,
preferably each of R12, R22,... Rn-12 and Rn2
has a net charge. The net charge is negative,
preferably has a net neutral charge. The linear
polymer is a homopolymer. The linear polymer is a
random copolymer, alternating copolymer or block
copolymer. The linear polymer is preferably a
random copolymer. [CONT.]
A linear, non-crosslinked, immunomodulatory
WO 2005035588
polymeric compound (C1) of formula (I) or its salt,
where the linear polymer is not a homopolymer of
the formula called IV, where n is 75 to 375 or a
homopolymer comprising a monomeric unit of the
following formula V.
The composition is useful for treating or
preventing infection, preferably a recurrent
infection by HSV-1 or HSV-2 (claimed).
BIOTECHNOLOGY - Preferred Composition: The
composition prepared by a method comprising
complexing in vitro a stress protein comprises the
stress protein that is a member of hsp60, hsp70,
or hsp90 family of stress proteins. The stress
protein is hsc70, hsp70, or hsp90, hsp110,
grp170, gp96, calreticulin, or their combinations.
The stress protein is a human stress protein.
[CONT.]
A composition comprising different antigenic
WO 2005028496
peptides, each comprising one or more HLAbinding epitopes of a different herpesvirus peptide
selected from among herpesvirus peptides
differing in amino acid sequence, the amino acid
sequence of each herpesvirus peptide selected
from any of the 49 sequences of 35 amino acids
(SEQ ID Nos. 1-49), given in the specification, is
new. [CONT.]
US 20050191649
A1
20050901
EP 1689888
A2
20060816
AU 2004283294
A1
20050506
BR 2004015771
A
20061226
KR 2006116825
A
20061115
CN 1910293
A
20070207
MX 2006004493
A1
20061201
US 20070154467
A1
20070705
JP 2007529199
T
20071025
IN 2006DN02967
A
20070831
US 20090123472
EP 2083089
A1
20090514
A1
20090729
TW 2005038553
A
20051201
EP 2267154
A1
20101229
AU 2004283294
B2
20110317
US 20110071073
WO 2005035588
A1
20110324
A1
20050421
WO 2005035588 A1 UPAB: 20100101
LILLY&CO ELI
EP 1664127
A1
20060607
BLACKBURN N T
KR 2006057015
A
20060525
NOVELTY: A linear, non-crosslinked,
immunomodulatory polymeric compound (C1), is
new.
DETAILED DESCRIPTION: A linear, noncrosslinked, immunomodulatory polymeric
compound (C1) of formula (I) or its salt, where the
linear polymer is not a homopolymer of the
formula called IV, where n is 75 to 375 or a
homopolymer comprising a monomeric unit of the
following formula V. [CONT.]
BLASZCZAK L C
AU 2004280329
A1
20050421
CLEVELAND J A
US 20070041986
A1
20070222
COHEN C E
CN 1867589
A
20061122
KRAFT A R
JP 2007505905
T
20070315
TAYLOR K A
KR 810770
B1
20080307
CN 100554279
C
20091028
AU 2004280329
B2
20110324
WO 2005028496
EP 1670507
A2
20050331
WO 2005028496 A2 UPAB: 20051221
A2
20060621
NOVELTY: A composition comprising different
antigenic peptides, each comprising one or more
HLA-binding epitopes of a different herpesvirus
peptide selected from among herpesvirus
peptides differing in amino acid sequence, the
amino acid sequence of each herpesvirus peptide
selected from any of the 49 sequences of 35
amino acids (SEQ ID Nos. 1-49), given in the
specification, is new. [CONT.]
KASHI R S
AU 2004274430
A1
20050331
LECLAIR K P
JP 2007505147
T
20070308
EP 2289547
US 20110059041
A1
20110302
A1
20110310
WO 2005027981
A1
20050331
LILLY & CO ELI
ANTIGENICS INC
405 New composition comprising different
antigenic peptides, each comprising one or
CHUANLIANG L
more HLA-binding epitopes of a different
herpesvirus peptide, useful for treating or
preventing infection, e.g. herpes simplex virus
1 or 2 infection
LEVEY D L
MO X
US 20070154467
US 20090123472
US 20110071073
US 20070041986
N
n = monomeric units of formula Ym in the polymer,
and is a single integer in the range from 2-375;
[CONT.]
US 20110059041
N
US 20050100506
N
TRUNEH A
406 Composition for imaging a pancreas,
comprises antidiabetic agent, a chelator and
chelated metal ion
UNIV TEXAS
WO 2005027981 A1 UPAB: 20100712
Composition (I) is useful for treating a pancreatic
disease, which involves administering (I) to a
subject in need of the treatment, where (I)
comprises an antidiabetic agent, chelator and
Composition (I) enables early diagnosis and
monitoring of response of pancreatic disease
during treatment.
PHARMACEUTICALS - Preferred Composition: In An INDEPENDENT CLAIM is also included for
(I), the metal ion is effective for contrast enhanced treating a pancreatic disease, which comprises
imaging when (I) is administered to a mammal
the administration of a composition as above.
during use. The chelator is diethylenetriamine
WO 2005027981
406 Composition for imaging a pancreas,
comprises antidiabetic agent, a chelator and
chelated metal ion
UNIV TEXAS SYSTEM
US 20050100506
A1
20050512
AZHDARINIA A
NO 2006001645
A
20060411
BRYANT J
EP 1675625
A1
20060705
KOHANIM S
BR 2004014512
A
20061107
OH C
AU 2004273911
A1
20050331
YANG D J
CN 1867363
A
20061122
YU D
JP 2007505915
T
20070315
KR 2006104984
A
20061009
IN 2006CN00948
A
20070615
US 7611693
B2
20091103
IN 237857
B
20100122
AU 2004273911
B2
20100415
CN 1867363
B
20100512
US 20100278731
A1
20101104
JP 2011052016
A
20110317
WO 2005025594
US 20050107300
A1
20050324
A1
20050519
EP 1663280
A1
20060607
AU 2004272055
A1
20050324
JP 2007505128
T
20070308
US 7196060
US 20070190025
US 20080267913
EP 1663280
B2
20070327
A1
20070816
A1
20081030
B1
20090805
DE 602004022427
E
20090917
US 20110064691
WO 2005018630
EP 1656130
A1
20110317
A1
20050303
WO 2005018630 A1 UPAB: 20050708
A1
20060517
NOVELTY: Restoring a more nearly normal joint
function in a dog having osteoarthritis; or
deceasing the likelihood of a dog developing
osteoarthritis, comprises feeding to the dog a
composition (I) comprising eicosapentaenoic acid
(EPA) at a concentration of at least 0.2 wt.%.
[CONT.]
MX 2005013757
A1
20060301
AU 2004266601
A1
20050303
BR 2004013287
A
20061010
CN 1835745
A
20060920
JP 2007502276
T
20070208
S-CELL BIOSCIENCES INC
407 Stimulating production of red blood cells,
granulocytes or platelets in subject diagnosed BEARDSLEY T R
as having less than desirable level of cells, by
administering to subject T-4 immune
stimulating factor, or compound that
stimulates CD4+ cells
MAIDA A E
408 Restoring nearly normal joint function in a dog HILLS PET NUTRITION INC
having osteoarthritis or deceasing the
HILL'S PET NUTRITION INC
likelihood of a dog developing osteoarthritis,
comprises feeding composition comprising
eicosapentaenoic acid
EP 1656130
B1
20080730
DE 602004015472
E
20080911
ES 2310757
T3
20090116
MX 265052
B
20090312
CN 100558352
C
20091111
CN 101653436
A
20100224
NOVELTY: A composition (I) for imaging a
pancreas, comprises an antidiabetic agent, a
chelator and a chelated metal ion.
DETAILED DESCRIPTION: An INDEPENDENT
CLAIM is also included for treating a pancreatic
disease, which comprises the administration of a
composition as above.
Composition (I) is useful for treating a pancreatic
disease, which involves administering (I) to a
subject in need of the treatment, where (I)
comprises an antidiabetic agent, chelator and
chelated metal ion, where the metal ion is a beta
emitter. The pancreatic disease is diabetes,
pancreatitis, hyperinsulinemia or insulinoma.
[CONT.]
Composition (I) enables early diagnosis and
monitoring of response of pancreatic disease
during treatment.
PHARMACEUTICALS - Preferred Composition: In An INDEPENDENT CLAIM is also included for
(I), the metal ion is effective for contrast enhanced treating a pancreatic disease, which comprises
imaging when (I) is administered to a mammal
the administration of a composition as above.
during use. The chelator is diethylenetriamine
pentaacetic acid (DTPA), EDTA, cyclohexyl 1,2diamine tetra-acetic acid (CDTA), ethyleneglycol0,0'bis(2-aminoethyl)-N,N,N',N'-tetra-acetic acid
(EGTA), N,N-bis(hydroxybenzyl)-ethylenediamineN,N'-diacetic acid [CONT.]
WO 2005027981
US 7611693
US 20100278731
ACTIVITY: Antidiabetic; Antiinflammatory;
Cytostatic. No biological data is given. [CONT.]
WO 2005025594 A1 UPAB: 20060122
(M1) is useful for stimulating the production of red
NOVELTY: Stimulating (M1) the production of red blood cells, granulocytes or platelets in a subject
blood cells, granulocytes or platelets in a subject, diagnosed as having a less than desirable level of
where the subject has been diagnosed as having red blood cells, granulocytes or platelets, where
the need of elevation of red blood cell count is
a less than desirable level of red blood cells,
granulocytes or platelets, involves administering to attributable to anemia (claimed).
the subject T-4 immune stimulating factor (TISF),
or a compound that stimulates CD4+ cells
effective to elevate the red blood cell,
granulocytes or platelet count. [CONT.]
BIOTECHNOLOGY - Preferred Method: In (M1),
the compound that stimulates CD4+ cells is
chosen from interleukin-1 (IL-1), IL-2, IL-3, IL-4, IL6, IL-7, IL-12, gamma-interferon, tumor necrosis
factor (TNF)-alpha, anti-CD3 antibody, CD28, and
superantigens.
An INDEPENDENT CLAIM is also included for a WO 2005025594
therapeutic protocol that comprises diagnosing a
subject as having a less than desirable level of red
blood cells, granulocytes or platelets, followed by
administering to the subject TISF effective to
elevate red blood cell, granulocyte or platelet
count in the subject.
US 20050107300
US 7196060
US 20070190025
US 20080267913
US 20110064691
(I) or (II) is useful to restore a more nearly normal
joint function in a dog having osteoarthritis; or to
decease the likelihood of a dog developing
osteoarthritis (claimed). The omega-3 fatty acid is
useful for the treatment of canine ostheoarthritis
as well as other forms of arthritis including
rheumatoid arthritis; particularly EPA is useful in
managing osteoarthritic diseases and symptoms
of such diseases in mammals (especially in dogs)
[CONT.]
PHARMACEUTICALS - Preferred Composition: (I)
is selected on the basis of the composition
comprising a fatty acid component comprising
EPA. (II) comprises a diet comprising EPA in an
amount of at least about 0.2 wt.% (preferably at
least about 0.3 wt.%). (II) comprises a ratio of
omega-6 fatty acids to omega-3 fatty acids of
about 0.2-1.1. (II) comprises a ratio of omega-6
fatty acids to EPA of about 1-12 [CONT.]
An INDEPENDENT CLAIM is also included for the WO 2005018630
use of EPA in the preparation of a
medicament/nutriment (II) for restoring a more
nearly normal joint function in a dog having
osteoarthritis; or for deceasing the likelihood of a
dog developing osteoarthritis, where (II) provides
to the animal an amount of EPA of at least about
27.5 mg/kg body weight.
N
AU 2004266601
B2
20110324
WO 2005016946
A2
20050224
WO 2005023824
A2
20050317
US 20050074502
A1
20050407
PALMER J W
US 20050080131
A1
20050414
STANKO J A
EP 1664070
A2
20060607
TURKSON J
EP 1675864
A2
20060705
YU H
AU 2004264421
A1
20050224
AU 2004270655
A1
20050317
JP 2007502301
T
20070208
JP 2007502777
T
20070215
US 7238372
US 20080187992
EP 1664070
B2
20070703
A1
20080807
B1
20080813
DE 602004015811
E
20080925
US 7566798
US 20090285884
EP 1675864
B2
20090728
A1
20091119
B1
20091230
DE 602004024909
E
20100211
US 7759510
US 7763585
US 20100310645
US 20100316704
B2
20100720
B2
20100727
A1
20101209
A1
20101216
AU 2004264421
B2
20110224
AU 2004270655
B2
20110324
WO 2005012493
A2
20050210
US 20050070693
A1
20050331
EP 1648512
A2
20060426
US 7109304
B2
20060919
US 20060257398
A1
20061116
JP 2007528209
T
20071011
US 7462352
US 20100068136
EP 2216342
US 20110052489
US 7902338
WO 2005012508
B2
20081209
A1
20100318
A1
20100811
A1
20110303
B2
20110308
A1
20050210
409 New platinum complexes are signal transducer UNIV SOUTH FLORIDA
and activator of transcription inhibitors useful
JOVE R
for treating e.g. an inflammatory disorder, a
viral, bacterial or parasitic infection such as
KAY H
trypanosomiasis and malaria and cancers
410 Novel anti-CD19 monoclonal antibody that
binds CD19 antigen, useful for treating B-cell
disease such as lymphoma, leukemia, or
autoimmune disease such as myasthenia
gravis, lupus nephritis, rheumatic fever,
diabetes mellitus
IMMUNOMEDICS INC
UNIV QUEENSLAND
411 New mammalian cell culture medium for
propagating keratinocytes for use in skin
growth and regeneration comprises an insulin-
WO 2005016946 A2 UPAB: 20090806
(A) are useful for treating an inflammatory
(A) (by maintaining their correct oxidaitive
disorder, a viral, bacterial or parasitic infection in a conformation as platinum (IV)) are more effective
than the existing platinum (II) compounds.
NOVELTY: Platinum complexes (A) and their salts mammal (preferably a human, monkey,
chimpanzee, ape, dog, cat, horse, cow or pig).
are new.
DETAILED DESCRIPTION: Platinum complexes The parasitic infection is caused by an organism
(Leishmania, Toxoplasma, Schistosoma,
(A) of formulae (I-VI) and their salts are new.
Plasmodium, Trypanosoma, Entamoeba, Giardia,
Trichomonas, Ascaris, Trichuris, Enterobius,
In formula (I):
Necator, Ancylostoma, Strongyloides or
Trichinella) and the disease condition is
leishmania, toxoplasmosis, schistosomiasis,
trypanosomiasis, pneumocystis, malaria or
Either X, Y = halo, -NO2, -ONO, -OH, H2O, trichinosis [CONT.]
SO(CH3)2 or 2-(4-(3-methyl-butyl)-phenyl)propionic acid; or
X+Y = 2,3-dihydroxy benzene, 2-hydroxy benzoic
acid, 2-hydroperoxy-phenol, -NH-C(=O)-NH(OH)-,
2,4-dihydroxypyrimidin-1-yl or -NH-C(=O)-NH-O-;
[CONT.]
INORGANIC CHEMISTRY - Preparation
(claimed): Preparation of (A) comprises mixing
cisplatin in water and an organic solvent, mixing a
ligand capable of bonding to the platinum of
cisplatin into the obtained mixture to form the
platinum complex product, contacting the obtained
product with nitrogen dioxide gas and separating
the platinum complex product from the solvent.
[CONT.]
Platinum complexes (A) of formulae (I-VI) and
their salts are new.
In formula (I):
WO 2005016946
US 20050074502
N
US 20050080131
Either X, Y = halo, -NO2, -ONO, -OH, H2O, SO(CH3)2 or 2-(4-(3-methyl-butyl)-phenyl)propionic acid; or
X+Y = 2,3-dihydroxy benzene, 2-hydroxy benzoic
acid, 2-hydroperoxy-phenol, -NH-C(=O)-NH(OH)-,
2,4-dihydroxypyrimidin-1-yl or -NH-C(=O)-NH-O-;
US 7238372
R1 = NH2, NH, -NO2 or -ONO; [CONT.]
US 7566798
US 20080187992
US 20090285884
US 7759510
US 7763585
US 20100310645
US 20100316704
WO 2005012493 A2 UPAB: 20100318
(I) is useful for treating B-cell disease in a subject,
which involves administering (I) formulated in a
NOVELTY: A monoclonal antibody or its fragment pharmaceutically acceptable vehicle. The B-cell
disease is lymphoma, leukemia, or autoimmune
(I) that binds a CD19 antigen, where (I) is
disease such as acute idiopathic
chimeric, humanized or is fully human, is new.
thrombocytopenic purpura, chronic idiopathic
thrombocytopenic purpura, dermatomyositis,
Sydenham's chorea, myasthenia gravis, systemic
lupus erythematosus, lupus nephritis, [CONT.]
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are also included for the following:
(1) an antibody fusion protein or its fragment (II),
comprising at least two MAbs or their fragments,
where each of the MAbs independently is an antiCD19 MAb of (I), or (I) and a second MAb or its
fragment, where the second MAb or its fragment is
other than (I); [CONT.]
BIOTECHNOLOGY - Preferred Antibody: (I) is
humanized or fully human. (I) comprises at least
one complementarity-determining region (CDR) of
a murine anti-CD19 MAb and a framework (FR)
region of a human antibody, where the humanized
anti-CD19 MAb or its fragment retains
substantially the B-cell, and B-cell lymphoma cell
and leukemia cell targeting the murine anti-CD19
MAb. [CONT.]
INDEPENDENT CLAIMS are also included for the WO 2005012493
following:
(1) an antibody fusion protein or its fragment (II),
comprising at least two MAbs or their fragments,
where each of the MAbs independently is an antiCD19 MAb of (I), or (I) and a second MAb or its
fragment, where the second MAb or its fragment is
other than (I);
US 20050070693
(2) a nucleic acid (III) comprising a sequence
encoding (I) or (II); [CONT.]
US 20060257398
N
US 7109304
US 7462352
US 20100068136
US 20110052489
US 7902338
WO 2005012508 A1 UPAB: 20090509
The cell culture medium and system, composition
and methods are useful for propagating
keratinocytes for subsequent use in skin growth
BIOTECHNOLOGY - Preferred Culture Medium:
INDEPENDENT CLAIMS are also included for:
The serum is absent or present to a concentration
no more than 1%, 0.5% or preferably 0.1% (v/v).
WO 2005012508
US 20060233764
N
propagating keratinocytes for use in skin
growth and regeneration comprises an insulin- UNIV QUEENSLAND TECHNOLOGY
like growth factor (IGF) and vitronectin or
fibronectin, and optionally an IGF binding
protein
412 New antibodies capable of binding to mouse
and human vascular endothelial growth
factors, useful for diagnosing, preventing or
treating diseases associated with abnormal
angiogenesis, e.g. cancer, inflammation or
immune disorders
EP 1664280
A1
20060607
NOVELTY: A mammalian cell culture medium
comprising at least one insulin-like growth factor
(IGF) selected from IGF-I and IGF-II; and an
absence of serum or an amount of serum which in
the absence of the IGF would not support cell
growth, is new.
HARKIN D
AU 2004260815
A1
20050210
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are also included for:
LEAVESLEY D
US 20060233764
A1
20061019
(1) a mammalian cell system comprising a culture
vessel and the mammalian cell culture medium
cited above; [CONT.]
UPTON Z
KR 2006054380
A
20060522
CN 1829791
A
20060906
JP 2007500001
T
20070111
IN 2006DN00385
A
20070817
NZ 544703
A
20081031
JP 2010057513
A
20100318
JP 4543036
B2
20100915
IN 2009DN01128
A
20100820
EP 1664280
B1
20110119
DE 602004031130
E
20110303
WO 2005012359
A2
20050210
US 20050106667
A1
20050519
EP 1648939
A2
20060426
NO 2006001014
A
20060424
AU 2004262006
A1
BR 2004012637
GENENTECH INC
WO 2005012359 A2 UPAB: 20090307
and methods are useful for propagating
keratinocytes for subsequent use in skin growth
and regeneration. These may be used for treating
burns, wounds or ulcers or for improving or
enhancing skin quality or appearance.
The antibody is useful in diagnosing or treating a
disorder associated with pathological
angiogenesis in a mammal. The disorder is
NOVELTY: An antibody capable of binding to a
mouse vascular endothelial growth factor (VEGF) cancer, such as breast cancer, colorectal cancer,
and human VEGF with Kd values within 10-fold of non-small cell lung cancer, non-Hodgkin's
the other and capable of inhibiting the binding of lymphoma (NHL), renal cancer, prostate cancer,
liver cancer, head and neck cancer, melanoma,
VEGF to a VEGF receptor, is new.
ovarian cancer, mesothelioma or multiple
myeloma. [CONT.]
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are also included for the following:
(1) selecting an hVEGF antibody from a library of
synthetic antibodies; [CONT.]
The serum is absent or present to a concentration
no more than 1%, 0.5% or preferably 0.1% (v/v). (1) a mammalian cell system comprising a culture
Preferably, the serum is absent. The IGF is IGF-I vessel and the mammalian cell culture medium
or IGF-II. The mammalian cell culture medium
cited above;
further comprises an IGF binding protein (IGFBP)
selected from IGFBP1, IGFBP2, IGFBP3, IGFBP4,
IGFBP5 and IGFBP6. The culture medium further
comprises vitronectin (VN) or its fragment [CONT.]
(2) cell culture, comprising culturing the one or
more cells in the mammalian cell culture system
cited above;
(3) a pharmaceutical composition for aerosol
delivery of keratinocytes or keratinocyte progenitor
cells, comprising one or more keratinocytes
cultured according to the above method, together
with a pharmaceutical carrier, diluent or excipient;
and [CONT.]
BIOTECHNOLOGY - Preferred Antibody: The
antibody is capable of binding to a human VEGF
G88A mutant with a Kd value that is within 10-fold
of the Kd value of unmutated human VEGF. It is
capable of binding a human VEGF G88A mutant
with a Kd value that is 10 nM or less. The antibody
contacts no more than 80% of the surface area of
G88 of human VEGF. The receptor is a VEGF
receptor 2 (KDR) or a VEGF receptor 1 (Flt-1)
[CONT.]
INDEPENDENT CLAIMS are also included for the WO 2005012359
following:
(1) selecting an hVEGF antibody from a library of
synthetic antibodies;
US 20050106667
(2) an isolated nucleic acid encoding the antibody
cited above;
(3) a vector comprising the nucleic acid;
US 20070020267
20050210
(4) a host cell transformed with the vector; and
US 20090023602
A
20060926
(5) a process of producing an antibody.
KR 2006067950
A
20060620
MX 2006001319
A1
20060501
US 20060280747
A1
20061214
AU 2004262006
A2
20050210
US 20070020267
A1
20070125
US 7691977
US 7758859
US 20100189719
US 7811785
US 20110014198
US 20110020346
CN 1863818
A
20061115
US 20070141065
A1
20070621
JP 2007526756
T
20070920
IN 2006DN01101
A
20070810
SG 145725
A1
20080929
US 20090023602
A1
20090122
NZ 545135
A
20091030
IN 237795
B
20100115
US 7691977
US 7758859
B2
20100406
B2
20100720
IN 2009DN03571
A
20100416
US 20100189719
US 7811785
US 20110014198
US 20110020346
A1
20100729
B2
20101012
A1
20110120
A1
20110127
MX 281243
B
20101123
US 20060280747
US 20070141065
N
413 Treating hepatocellular carcinoma in a
mammal by administering a composition
comprising a zvegf3 antagonist comprising
e.g., anti-zvegf3 antibodies or inhibitory
polynucleotides and a delivery vehicle
414 Nucleic acid-lipid particle useful for treating
diseases e.g., hepatitis, comprises siRNA,
cationic lipid, non- cationic lipid and
conjugated lipid that inhibits aggregation of
particles
ZYMOGENETICS INC
PALMER T E
PROTIVA BIOTHERAPEUTICS INC
415 Identifying whether a candidate compound is a ARENA PHARM INC
modulator of a RUP40 G protein-coupled
receptor or cardiovascular disorder, useful for
treating e.g. congestive heart failure,
comprises contacting the compound with the
receptor
JP 2011046732
A
20110310
WO 2005011742
US 20050191304
A1
20050210
A1
20050901
EP 1660135
A1
20060531
JP 2006528663
T
20061221
US 20070054858
US 20090028865
EP 1660135
A1
20070308
A1
20090129
B1
20090603
DE 602004021395
E
20090716
ES 2326978
T3
20091022
US 20110052588
WO 2005007196
US 20050064595
A1
20110303
A2
20050127
WO 2005007196 A2 UPAB: 20090811
A1
20050324
EP 1648519
A2
20060426
AU 2004257373
A1
20050127
NOVELTY: A nucleic acid-lipid particle (I)
comprises a siRNA, cationic lipid, non- cationic
lipid and a conjugated lipid that inhibits
aggregation of particles.
ACTIVITY: Antiinflammatory; Hepatotropic;
Virucide; Antilipemic; Antidiabetic; Cytostatic;
Neuroprotective.
MECHANISM OF ACTION: Downregulates the
expression of diseases or disorders associated
nucleic acid (e [CONT.]
KR 2006028655
A
20060330
US 20060240093
A1
20061026
JP 2007528863
T
20071018
WO 2005011742 A1 UPAB: 20060121
The zvegf3 antagonist is useful in preparing a
NOVELTY: Treating hepatocellular carcinoma in a composition for treating hepatocellular carcinoma
in a mammal (claimed).
mammal comprises administering to a mammal
having a hepatocellular carcinoma a composition
comprising a zvegf3 antagonist and a delivery
vehicle, where the zvegf3 antagonist is anti-zvegf3
antibodies, mitogenically inactive receptor-binding
zvegf3 variant polypeptides or inhibitory
polynucleotides, in an amount sufficient to
produce a tumor response in the mammal.
[CONT.]
BIOTECHNOLOGY - Preferred Method: Treating An INDEPENDENT CLAIM is included for a
hepatocellular carcinoma in a mammal comprises method of reducing cancer cell proliferation.
administering to a mammal having a
hepatocellular carcinoma a composition
comprising a zvegf3 antagonist and a delivery
vehicle, where the zvegf3 antagonist is anti-zvegf3
antibodies, mitogenically inactive receptor-binding
zvegf3 variant polypeptides or inhibitory
polynucleotides, in an amount sufficient to
produce a tumor response in the mammal
[CONT.]
WO 2005011742
US 20050191304
US 20070054858
N
US 20090028865
US 20110052588
WO 2005007196
A3
20080103
CN 101291653
A
20081022
IN 2008KN04213
A
20090306
SG 154530
A1
20090828
NZ 544637
A
20100430
AU 2004257373
B2
20110324
WO 2005003786
A2
20050113
WO 2005003786 A2 UPAB: 20060121
EP 1636583
A2
20060322
NOVELTY: Identifying whether a candidate
compound is a modulator of a RUP40 G proteincoupled receptor (GPCR) or a cardiovascular
disorder comprises contacting the candidate
compound with the receptor and determining
whether the receptor functionality is modulated.
[CONT.]
AU 2004254591
A1
20050113
CN 1806174
A
20060719
JP 2007524382
T
20070830
US 20070231792
A1
20071004
CN 100523816
C
20090805
EP 1636583
B1
20110126
DE 602004031223
E
20110310
(I) is useful for introducing an siRNA into a cell,
which involves contacting the cell with (I), where
the presence of (I) in target cells is detectable at
least 48 hours after administration of the particle.
The presence of (I) is detectable at least 24 hours
after administration of the particle. The cell is in a
mammal, where more than 10% of such particles
are present in plasma of the mammal 24 hours
after administration [CONT.]
The modulator (with RUP40 GPCR) or the
pharmaceutical composition is useful for
preventing or treating a heart disease in an
individual such as congenital heart defect,
congestive heart failure or hypertrophic
cardiomyopathy resulting from post-myocardial
infarction remodeling, cardiac valve disease,
sustained cardiac afterload, myocarditis or familial
hypertrophic cardiomyopathy. [CONT.]
(I) is nontoxic to mammals, and efficiently delivers
siRNA molecule to the subject. (I) are highly
stable, serum-resistant nucleic acid containing
particles that do not interact with cells and other
components of the vascular system, and interact
readily with target cells at disease site to deliver
siRNA intracellularly.
BIOTECHNOLOGY - Preferred Particle: The
siRNA component of (I) is resistant in aqueous
solution to degradation by a nuclease. (I) has a
median diameter of less than 150 nm. The siRNA
comprises 15-60 nucleotides, and is transcribed
from a plasmid encapsulated in the particle.
[CONT.]
WO 2005007196
US 20050064595
US 20060240093
BIOTECHNOLOGY - Preferred Method: In
identifying a modulator, the modulator is an
agonist, partial agonist, inverse agonist and
antagonist, preferably inverse agonist and
antagonist. Modulating the activity of a RUP40
GPCR above comprises contacting the receptor
with the modulator. The contacting comprises
administration of the modulator to an individual
comprising the receptor, where the individual is in
need of prevention of or treatment for a heart
disease [CONT.]
Identifying whether a candidate compound is a
WO 2005003786
modulator of a RUP40 G protein-coupled receptor
(GPCR) or cardiovascular disorder, where the
receptor couples to a G protein, the receptor
comprising an amino acid sequence selected
from:
US 20070231792
(a) amino acids 1-1346, 1-990, 991-1346 or 954997 of a sequence comprising 1346 amino acids
(SEQ ID NO:2) fully defined in the specification;
[CONT.]
N
N
NOVO NORDISK AS
416 Producing an antibody, useful for treating
proliferative, infectious or immune disease, or
bacterial and protozoa infections, comprises
immunizing a non-human mammal with an
immunogen comprising a KIR2DL polypeptide FUYUAN GROUP US
WO 2005003168
A2
20050113
WO 2005003168 A2 UPAB: 20060121
EP 1673397
A2
20060628
NOVELTY: Producing an antibody which crossreacts with multiple KIR2DL gene products and
which neutralizes the inhibitory activity of such
killer Ig-like receptors (KIRs) comprises
immunizing a non-human mammal with an
immunogen comprising a KIR2DL polypeptide, is
new.
INNATE PHARMA
AU 2004253630
A1
20050113
DETAILED DESCRIPTION: Producing an antibody
which cross-reacts with multiple KIR2DL gene
products and which neutralizes the inhibitory
activity of such KIRs comprises: [CONT.]
INNATE PHARMA SAS
BR 2004012153
A
20060822
UNIV GENOA
KR 2006079180
A
20060705
INNATE PHARMA SA
CN 1269840
C
20060816
MX 2005014074
A1
20060801
A1
20061214
A
20061004
CN 1852924
A
20061025
JP 2007524612
T
20070830
IN 2005DN05990
A
20080509
TW 2006012986
A
20060501
US 20090191213
A9
20090730
C2
20091220
US 20100291110
EP 1673397
A1
20101118
B1
20101208
AU 2004253630
B2
20101125
DE 602004030464
E
20110120
EP 2287195
EP 2289939
A2
20110223
A2
20110302
IN 241876
B
20100806
US 20050008646
WO 2005018667
A1
20050113
US 20050008646 A1 UPAB: 20060121
A1
20050303
NOVELTY: Treating (M1) a patient suffering from
a cancerous disease, involves administering to the
patient an anti-cancer antibody or their fragments
produced in accordance with a method for the
production of anti-cancer antibodies which are
useful in treating a cancerous disease, where the
antibody or their fragments are cytotoxic against
cells of a cancerous tissue and are essentially
benign to non-cancerous cells. [CONT.]
FINDLAY H P
EP 1667716
A1
20060614
HAHN S E
AU 2004266045
A1
20050303
YOUNG D S F
JP 2007503377
T
20070222
CHIRON CORP
US 7189397
B2
20070313
CN 1901936
A
20070124
NZ 545477
A
20090925
AU 2011200789
A1
20110317
AU 2004266045
B2
20110317
WO 2005002619
A2
20050113
BIOTECHNOLOGY - Preferred Method: The
primate is a cynomolgus monkey.
Producing an antibody which cross-reacts with
multiple KIR2DL gene products and which
neutralizes the inhibitory activity of such KIRs
comprises:
(a) immunizing a non-human mammal with an
immunogen comprising a KIR2DL polypeptide;
WO 2005003168
(b) preparing antibodies from the immunized
mammal, where the antibodies bind the KIR2DL
polypeptide;
US 20060280740
N
US 20090191213
US 20100291110
(c) selecting antibodies of (b) that cross-react with
at least two different KIR2DL gene products;
[CONT.]
RU 2376315
ARIUS RES INC
417 Treating patient suffering from cancerous
disease by administering anti-cancer antibody HOFFMANN LA ROCHE&CO AG F
or their fragments, to patient
418 An immunogenic composition for preventing
or treating Chlamydia trachomatis infections
comprises a combination of C. trachomatis
antigens, such as PepA, LcrE, ArtJ, DnaK,
CT398, OmpH-like, L7/L12, OmcA, or AtoS
US 20060280740
CN 1842541
The method is useful for producing an antibody
which cross-reacts with multiple KIR2DL gene
products and which neutralizes the inhibitory
activity of such KIRs. The antibodies,
compositions, and methods are useful for treating
cancer or other proliferative disorder, an infectious
disease, an immune disease, bacterial and
protozoa infections or used in transplantation.
WO 2005002619 A2 UPAB: 20060121
(M1) is useful for treating cancer (claimed).
BIOTECHNOLOGY - Preferred Method: In (M1),
the antibody or their fragments is humanized. (M1)
further involves conjugating the antibody or their
fragments with a member chosen from toxins,
enzymes, radioactive compounds, and
hematogenous cells, and administering
conjugated antibodies or their fragments to the
patient, where the conjugated antibodies are
placed in admixture with an adjuvant and are
administered to mediate treatment of the
cancerous disease [CONT.]
Treating (M1) a patient suffering from a cancerous US 20050008646
disease, involves administering to the patient an
anti-cancer antibody or their fragments produced
in accordance with a method for the production of
anti-cancer antibodies which are useful in treating
a cancerous disease, where the antibody or their
fragments are cytotoxic against cells of a
cancerous tissue and are essentially benign to
non-cancerous [CONT.]
US 20050008646
US 7189397
The immunogenic composition or vaccine is useful
for preparing a medicament for the prevention or
treatment of a C. trachomatis infection (claimed).
BIOTECHNOLOGY - Preferred Composition: The INDEPENDENT CLAIMS are also included for the WO 2005002619
first antigen group preferably comprises LcrE. The following:
second antigen group preferably includes LcrE or
OmpH-like protein. The composition further
comprises one or more immunoregulatory agents.
The immunoregulatory agents include an adjuvant
selected from a TH1 adjuvant and a TH2 adjuvant,
or aluminum salts and oligonucleotides comprising
US 20060034871
N
N
or treating Chlamydia trachomatis infections
comprises a combination of C. trachomatis
antigens, such as PepA, LcrE, ArtJ, DnaK,
CT398, OmpH-like, L7/L12, OmcA, or AtoS
NOVARTIS VACCINES&DIAGNOSTICS SRL
US 20060034871
A1
20060216
BONCI A
EP 1635865
A2
20060322
FINCO O
BR 2004011857
A
20060523
GRANDI G
MX 2005013260
A1
20060301
RATTI G
CN 1812809
A
20060802
JP 2007535473
T
20071206
RU 2352356
C2
20090420
US 20100255002
US 20110070266
WO 2004112498
US 20050058691
A1
20101007
A1
20110324
A1
20041229
A1
20050317
FRIESEN K G
EP 1635651
A1
20060322
KIRK C
AU 2004249301
A1
20041229
NACHREINER R
MX 2005013007
A1
20060301
VANDEGIESSEN T
BR 2004011712
A
20060808
WEDEKIND K
CN 1809282
A
20060726
ZA 2005010290
A
20070530
JP 2007515927
T
20070621
RU 2352143
C2
20090420
CN 101416685
A
20090429
CN 100456950
C
20090204
MX 278963
B
20100913
JP 4586018
B2
20101124
JP 2011006423
A
20110113
AU 2004249301
B2
20110120
HILLS PET NUTRITION INC
419 Dietary composition useful for restoring
thyroid function to more nearly normal state in HILL'S PET NUTRITION INC
feline having hyperthyroidism comprises
specific quantity of iodine that restricts iodine
intake
for preparing a medicament for the prevention or
treatment of a C. trachomatis infection (claimed).
NOVELTY: An immunogenic composition
comprises a combination of Chlamydia
trachomatis antigens, the combination consisting
of 2, 3, 4 or all 5 C. trachomatis antigens of a first
antigen group, the first antigen group consisting of
PepA, LcrE, ArtJ, DnaK and CT398; and 2-13 C.
trachomatis antigens of a second antigen group,
the second antigen group consisting of PepA,
LcrE, ArtJ, DnaK, CT398, OmpH-like, L7/L12,
OmcA, AtoS, CT547, Enolase, HtrA and MurG.
[CONT.]
WO 2004112498 A1 UPAB: 20050707
For restoring thyroid function to a more nearly
NOVELTY: A reduced-iodine packaged feline diet normal state in a feline having hyperthyroidism
(claimed).
composition comprises iodine less than 1
(preferably not more than 0.6, especially greater
than 0.005) mg/kg of diet.
ACTIVITY: Endocrine-Gen.; Antithyroid.
A diet (test) containing (mg/kg): selenium (0.66)
and iodine (0.27) was fed to hyperthyroid cats for
9 weeks. A diet comprising (mg/kg): selenium
(0.73) and iodine (2 [CONT.]
EP 1635651
B1
20110202
E
20110317
WO 2004108069
A2
20041216
WO 2004108069 A2 UPAB: 20060121
AU 2003304173
A1
20050104
NOVELTY: Promoting neurite outgrowth
comprises contacting neural cells with a
composition comprising one or more compounds
selected from chondroitinase AC, chondroitinase
AC II, chondroitinase AC III, or chondroitinase B.
IACI J F
EP 1575548
A2
20050921
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are also included for the following:
KASPERBAUER S
AU 2003304173
A8
20070201
(1) treating a subject having an injury to the
central nervous system; and [CONT.]
ROY G
US 20070274979
EP 1575548
A1
20071129
B1
20110309
VECCHIONE A M
US 20100255002
(2) a method of neutralizing a C. trachomatis
infection in a mammal; and
(3) methods of raising an immune response in a
mammal against a C. trachomatis infection, or
raising C. trachomatis specific antibodies.
DE 602004031296
ACORDA THERAPEUTICS INC
420 Promoting neurite outgrowth for treating
nervous system disorders by contacting neural
GRUSKIN E A
cells with a composition comprising
chondroitinase AC, chondroitinase AC II,
chondroitinase AC III, or chondroitinase B
first antigen group preferably comprises LcrE. The
second antigen group preferably includes LcrE or (1) a vaccine comprising the immunogenic
OmpH-like protein. The composition further
composition cited above;
comprises one or more immunoregulatory agents.
The immunoregulatory agents include an adjuvant
selected from a TH1 adjuvant and a TH2 adjuvant,
or aluminum salts and oligonucleotides comprising
CpG motifs. [CONT.]
The methods are useful for promoting neurite
outgrowth and for treating a subject having an
injury to the central nervous system.
The composition improves thyroid function to a
more nearly normal state, thereby improves the
quality and quantity of the life of the animal.
US 20110070266
FOOD - Preferred Composition: The composition
comprises protein at a concentration of 10 - 50
(preferably 20 - 40)% on a dry matter basis. The
composition additionally comprises (%): fat (10 20) and carbohydrate (10 - 55). Preferred
Components: The protein comprises iodine (not
more than 0.6, preferably not more than 0.2
mg/kg), a vegetable protein, or an animal protein.
[CONT.]
WO 2004112498
US 20050058691
BIOTECHNOLOGY - Preferred Method: In
promoting neurite outgrowth, the compound is
chondroitinase AC or chondroitinase B. The
composition further comprises a pharmaceutical
carrier and a stabilizer. Contacting comprises
administering the composition directly to a site of
central nervous system injury. [CONT.]
INDEPENDENT CLAIMS are also included for the WO 2004108069
following:
(1) treating a subject having an injury to the
central nervous system; and
US 20070274979
(2) a composition useful in promoting neurite
outgrowth comprising chondroitinase AC,
chondroitinase B, or its mixture and a
pharmaceutical carrier.
N
421 Food composition for weight management in
overweight or obese companion animal e.g.
dog or cat comprises high protein, high fat,
low carbohydrate and non-fermentable fiber
HILLS PET NUTRITION
WO 2004107878
US 20050025857
A1
20041216
HILLS PET NUTRITION INC
A1
20050203
HILL'S PET NUTRITION
EP 1633202
A1
20060315
HILL'S PET NUTRITION INC
AU 2004245056
A1
20041216
CLARK H M
MX 2005012917
A1
20060201
COWLEY C R
BR 2004010884
A
20060704
FRIESEN K G
JP 2006526417
T
20061124
KIRK C
ZA 2005009753
A
20070328
SCHOENHERR W D
CN 101022735
A
20070822
EP 1633202
B1
20081126
DE 602004017989
E
20090108
ES 2318307
T3
20090501
RU 2358441
C2
20090620
MX 265952
B
20090414
AU 2004245056
B2
20110303
EP 1489092
A1
20041222
WO 2004113372
A1
20041229
INST PASTEUR
EP 1633776
A1
20060315
BAUCHE C
US 20060159697
A1
20060720
EL-IDRISSI M E
BR 2004011510
A
20060725
LADANT D
AU 2004249431
A1
20041229
LECLERC C
KR 2006034645
A
20060424
LOUCKA J
CN 1839152
A
20060927
OSICKA R
JP 2007527697
T
20071004
SEBO P
IN 2005DN05881
A
20080201
AU 2004249431
B2
20091105
IN 245837
B
20110211
US 7906123
WO 2004098618
B1
20110315
A2
AU 2004237438
A1
CENT NAT RECH SCI
422 Novel Bordetella adenylate cyclase having or
lacking modified CD11b/CD18 interaction
domain, and reacting with antisera recognizing CNRS CENT NAT RECH SCI
wild-type Bordetella adenylate cyclase, useful
for treating whooping cough and Bordetella
infection
NORDIC BONE AS
423 Use of a strontium-containing compound (1)
and one or more active substances for treating OSTEOLOGIX AS
or preventing cartilage and/or bone diseases
(e.g. osteopenia and Paget's disease) resulting
in a dysregulation of cartilage and/or bone
metabolism
WO 2004107878 A1 UPAB: 20050707
For weight management in overweight or obese
NOVELTY: A food composition comprises (wt.%): companion animals (e.g. dog or cat) having
temporary abnormal carbohydrate metabolism or
high protein (preferably 51 - 53), high fat
(preferably 21 - 23), low carbohydrate (preferably tendency to gain weight.
15 - 16) and non-fermentable fiber (0.75 - 20,
preferably 8 - 10).
USE: For weight management in overweight or
obese companion animals (e.g. dog or cat) having
temporary abnormal carbohydrate metabolism or
tendency to gain weight. [CONT.]
The addition of non-fermentable fiber to a feline or
canine food composition increases the rate of
weight change, and/or provides less lean tissue
loss and/or increases the rate of fat loss
compared to low carbohydrate food without added
non-fermentable fiber. The non-fermentable fiber
provides enhanced weight loss in addition to
enhanced satiety.
EP 1489092 A1 UPAB: 20091209
(I) (III) (IX) and (X) are useful for preparing a
medicament for preventing or treating disease
symptoms associated with whooping cough, in
NOVELTY: A protein (I) consisting of Bordetella
human or in an animal and/or for protecting a
adenylate cyclase which is modified in the
CD11b/CD18 interaction domain by one or more human or an animal against the disease
symptoms associated with Bordetella infection
amino acid deletion, substitution or insertion,
where protein is deficient for CD11b/CD18 binding (e.g., B.pertussis). (II) comprising an
immunoprotective and non-toxic quantity of the
and is specifically reactive with antisera
protein, useful as vaccine. [CONT.]
recognizing a wild-type Bordetella adenylate
cyclase, is new. [CONT.]
(III) is not toxic when administered in vivo to a
mammal (claimed).
20041118
WO 2004098618 A2 UPAB: 20100621
Administration of (1) and (2) leads to:
20041118
NOVELTY: Treatment and/or prophylaxis of a
cartilage and/or bone disease and/or conditions
resulting in a dysregulation of cartilage and/or
bone metabolism in a mammal (e.g. a human
female, male adult, adolescent or a child),
comprises administration of a strontium-containing
compound (1) and one or more active substances
(2) capable of reducing the incidence of bone
fracture, increasing bone density and/or improving
healing of fractured bone. [CONT.]
(1) along with (2) is useful in the treatment or
prevention of a cartilage and/or bone disease
and/or conditions resulting in a dysregulation of
cartilage and/or bone metabolism in a mammal
(e.g. a human female, male adult, adolescent or a
child). The disease or condition e.g. [CONT.]
(a) improvement of bioavailability (10% (preferably
80%) or more) and pharmacokinetic parameters
(absorption rate, time to reach peak concentration
(tmax), peak concentration (Cmax), concentration
vs. time curve, distribution volume or distribution
to specific tissues, rate of metabolism, elimination
rate and excretion rate);
WO 2004107878
US 20050025857
BIOTECHNOLOGY - Preferred Protein: In (I),
INDEPENDENT CLAIMS are also included for:
EP 1489092
Bordetella adenylate cyclase is modified by the
complete deletion of CD11b/CD18 interaction
(1) a pharmaceutical composition (II) comprising
domain. The CD11b/CD18 interaction domain is
(I) in combination with a vehicle;
modified by insertion of a peptide. Bordetella
adenylate cyclase is further modified by insertion,
deletion or substitution of one or more amino acid
in the N-terminal catalytic domain, where the
modified Bordetella adenylate cyclase has a
catalytic activity which is decreased as compared
to the wild-type Bordetella adenylate cyclase
activity [CONT.]
(2) a polypeptide (III) capable of binding to
CD11b/CD18, the polypeptide is either a fragment
of Bordetella adenylate cyclase having 30-500
amino acids, preferably 50-300, and more
preferably 50-150 amino acids, the fragment
comprising a wild type CD11b/CD18 interaction
[CONT.]
US 20060159697
PHARMACEUTICALS - Preferred Method: (1) and
(2) are administered simultaneously or
sequentially as a single or separate composition.
(1) is a strontium salt (water soluble salt having a
water solubility of at least 1 g/l (preferably at least
100 g/l) measured at 25degreesC and is in
hydrate, anhydrous, solvate, polymorphous,
amorphous, crystalline, microcrystalline or
polymeric form) of an organic [CONT.]
US 20060275503
US 20100143473
Treatment and/or prophylaxis of a cartilage and/or WO 2004098618
bone disease and/or conditions resulting in a
dysregulation of cartilage and/or bone metabolism
in a mammal (e.g. a human female, male adult,
adolescent or a child) comprises administering to
a subject a strontium-containing compound (1)
and one or more further active substances (2)
capable of reducing the incidence of bone fracture
and/or increasing bone density and/or improving
healing of fractured bone. INDEPENDENT
CLAIMS are also included: [CONT.]
N
US 7906123
N
EP 1622630
A2
20060208
JP 2006525242
T
20061109
US 20060275503
US 20100143473
EP 2266584
EP 2266584
A1
20061207
A1
20100610
A2
20101229
A3
20110126
AU 2004237438
B2
20110120
AU 2011200693
A1
20110310
WO 2004098625
A2
20041118
US 20050058635
A1
20050317
AU 2004237408
A1
20041118
HOFFMANN T
EP 1620082
A2
20060201
NIESTROJ A J
BR 2004010078
A
20060516
SCHILLING S
MX 2005011861
A1
20060201
424 Use of effectors of glutaminyl cyclase (QC) for PROBIODRUG AG
treating diseases and/or for modulating
DEMUTH H
physiological processes based on the action
of pGlu-containing peptides
HEISER U
LI MIN PHARM FACTORY LIVZON
425 Compositions containing Radix Codonopsis
pilosulae, Radix Astragali and Radix Hedysari,
for treating conditions such as ischemic
LI MIN PHARM FACTORY LIVZON PHARM
diseases and acute pulmonary damage
(b) reduction of frequency and/or magnitude of
side-effects; [CONT.]
WO 2004098625 A2 UPAB: 20090407
The effectors of QC are useful for preparing a
medicament for treating diseases in mammals that
NOVELTY: Use of effectors of glutaminyl cyclase can be treated by modulation of QC activity in vivo
and/or for modulating physiological processes
(QC) for the preparation of a medicament for
treating diseases in mammals that can be treated based on the action of pGlu-containing peptides
caused by modulation of QC activity. The effectors
by modulation of QC activity in vivo and/or
modulating physiological processes based on the of QC is useful for altering the conversion of Nterminal glutamic acid or glutamine residues to
action of pGlu-containing peptides caused by
pyroglutamic acid residues in at least one QCmodulation of QC activity, is new.
substrate, e [CONT.]
BIOTECHNOLOGY - Preferred Effectors of QC:
The effector of QC is administered in combination
with an inhibitor of DP IV or DP IV-like enzymes
and/or an aminopeptidase-inhibitor. The H-isoAspAla-OH generating activity of a DP IV-like enzyme
is blocked. The DP IV-like enzyme is DP II.
[CONT.]
INDEPENDENT CLAIMS are also included for:
WO 2004098625
(1) a pharmaceutical composition, for parenteral,
enteral or oral administration, containing at least
one effector of QC in combination with at least one
inhibitor of DP IV or DP IV-like enzymes and/or at
least one aminopeptidase-inhibitor, optionally in
combination with carriers and/or excipients;
[CONT.]
US 20050058635
N
US 20060189523
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are also included for: [CONT.]
US 7381537
US 7462599
US 20080286810
US 20090068699
US 20090149394
US 20060189523
A1
20060824
KR 2006009902
A
20060201
CN 1784220
A
20060607
IN 2005KN02107
A
20060922
JP 2006525276
T
20061109
JP 2006525278
T
20061109
CN 1867324
A
20061122
ZA 2005008439
A
20070328
IN 2006KN01237
A
20070427
US 7381537
EP 1961416
US 7462599
US 20080286810
US 20090068699
B2
20080603
A1
20080827
B2
20081209
A1
20081120
A1
20090312
NZ 543146
A
20080926
US 20090149394
A1
20090611
NZ 568459
A
20090626
NZ 572274
A
20090626
AU 2004237408
B2
20091001
IN 221142
B
20080620
MX 269167
B
20090810
AU 2009227925
A1
20091112
KR 2010038477
A
20100414
EP 1620082
B1
20100421
DE 602004026712
E
20100602
EP 2206496
EP 1620082
A1
20100714
B9
20100825
KR 2010106630
A
20101001
CN 101837127
A
20100922
EP 2289498
WO 2004096249
A1
20110302
A1
20041111
WO 2004096249 A1 UPAB: 20090723
CN 1546065
A
20041117
NOVELTY: Pharmaceutical compositions
containing mainly Radix Codonopsis Pilosulae,
Radix Astragali and Radix Hedysari as raw
material, are new.
The drug compositions are for producing agents to With such drug compositions, there is a reduction
regulate the immune system, and may be used in in side effects e.g. during cancer therapy.
combination with chemotherapeutics or
radiotherapy for treating cancer. The compositions
are useful in producing medicaments for the
treatment of ischemic (cardiac) diseases including
coronary heart disease, myocardial infarction,
myocarditis and other heart diseases due to
PHARMACEUTICALS - Preferred Compositions:
Weight ratio of Radix Codonopsis pilosulae to
Radix Astragali and/or Radix Hedysari is
particularly 0.5:1-1:0.5 especially 1:1. The raw
material may also contain Chinese medicines for
supplementing qi and blood, e.g. Angelica
sinensis, Rehmannia glutinosa, Polygonum
multiflorum, Astractylodes macrocephala, Chinese
An INDEPENDENT CLAIM is also included for a
method for producing such drug compositions
comprising:
(a) removing impurities from Radix Codonopsis
pilosulae, Radix Astragali and/or Radix Hedysari
then processing into slices for making drinks;
WO 2004096249
US 20060110473
N
US 20080206374
426 Extraction of lipid from mushrooms for
foodstuffs, pet food, livestock feed and
cosmetics, involves extracting residue
obtained by carrying out water extraction of
mushrooms with organic solvent
LIMING PHARM FACTORY LIZHU GROUP
CN 1552420
A
20041208
LIVZON GROUP LIMIN PHARM FACTORY
EP 1523988
A1
20050420
LIVZON PHARM GROUP LIMIN PHARM
FACTORY
TAO D
US 20060110473
A1
20060525
CN 1733060
A
20060215
XIE W
CN 1245172
C
20060315
ZHI C
JP 2006524639
T
20061102
XUE W
CN 1284547
C
20061115
EP 1523988
US 20080206374
US 20080206375
B1
20080723
A1
20080828
A1
20080828
DE 602004015219
E
20080904
NIPPON FLOUR MILLS CO LTD
coronary heart disease, myocardial infarction,
myocarditis and other heart diseases due to
DETAILED DESCRIPTION: An INDEPENDENT
CLAIM is also included for a method for producing myocardial ischemia and myocardial hypoxia
[CONT.]
such drug compositions comprising:
US 20090169660
A1
20090702
JP 2011052005
A
20110317
JP 2004300438
A
20041028
JP 2004300438 A UPAB: 20110315
JP 4648641
B2
20110309
NOVELTY: Extracting lipid from mushrooms
involves extracting the residue obtained by
carrying out water extraction of the mushrooms,
with an organic solvent.
DETAILED DESCRIPTION: An INDEPENDENT
CLAIM is included for a lipid-containing extract.
428 New hyperimmune serum reactive antigens
from Streptococcus pneumoniae, and
encoding nucleic acid molecules, useful for
diagnosing, preventing or treating S.
pneumoniae infections
INTERCELL AG
20041021
US 20080206375
(a) removing impurities from Radix Codonopsis
pilosulae, Radix Astragali and/or Radix Hedysari
then processing into slices for making drinks;
[CONT.]
US 20090169660
For use in foodstuffs, pet food, livestock feed and The liquid component of mushroom has reduced
cosmetics (claimed).
impurity and can be extracted efficiently.
USE: For use in foodstuffs, pet food, livestock
feed and cosmetics (claimed). [CONT.]
427 Water-absorbing resin composition for use in SUMITOMO SEIKA CHEM CO LTD
absorbent article e.g. paper diaper, contains
water-absorbing resin, antimicrobial agent
consisting of porous substance which holds
antimicrobial metal, and metal chelating agent
sinensis, Rehmannia glutinosa, Polygonum
multiflorum, Astractylodes macrocephala, Chinese (b) washing Radix Codonopsis pilosulae, Radix
yam Dioscorea opposita or their combination
Astragali and/or Radix Hedysari after combining in
[CONT.]
a specific ratio with deionized water; [CONT.]
WO 2004090044
A1
WO 2004090044 A1 UPAB: 20050707
For use in absorbent article such as paper diaper, The water-absorbing resin composition has
sanitary towel, incontinence pad, urine absorbing excellent antimicrobial effect and effectively
material for pets, etc., and also useful for
suppresses the generation of bad odor.
NOVELTY: Water-absorbing resin composition
agriculture, horticulture, foodstuffs freshnesscontains water-absorbing resin, antimicrobial
agent consisting of porous substance, which holds keeping materials, material for civil engineering,
the antimicrobial metal, and metal chelating agent. packing material, water retaining material for soil,
etc.
JP 2004346089
A
20041209
EP 1616911
A1
20060118
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are also included for the following:
BR 2004009259
A
20060328
(1) absorber which consists of water-absorbing
resin and hydrophilic fiber; and [CONT.]
US 20060189953
A1
20060824
KR 2006002960
A
20060109
CN 1771296
A
20060510
JP 3979959
B2
20070919
CN 100422267
C
20081001
TW 2005000406
A
20050101
EP 1616911
B1
20100929
KR 982839
B1
20100916
DE 602004029348
E
20101111
US 7868075
US 20110068300
WO 2004092209
B2
20110111
A1
20110324
A2
20041028
WO 2004092209 A2 UPAB: 20050707
EP 1615950
A2
20060118
NOVELTY: An isolated nucleic acid molecule
encoding a hyperimmune serum reactive antigen
or its fragment, is new.
The composition (including the nucleic acid
molecule, hyperimmune serum-reactive antigen or
antibody) is useful for manufacturing a
medicament or pharmaceutical preparation (e.g. a
vaccine) for treating or preventing S. pneumoniae
infections. The antigen or its fragment may also
be used for isolating, purifying and/or identifying
an interaction partner of the hyperimmune serum
reactive antigen or fragment [CONT.]
ORGANIC CHEMISTRY - Preferred Method: The An INDEPENDENT CLAIM is included for a lipidresidue is obtained by extracting the mushrooms containing extract.
with a mixture of water and organic solvent.
Preferred Materials: The organic solvent is
ethanol, acetone, ethyl acetate and/or hexane.
The mixture of water and organic solvent contains
50 vol% of organic solvent. Preferably, the organic
solvent is hydrated ethanol having ethanol content
of 70 vol% or more. [CONT.]
ORGANIC CHEMISTRY - Preferred Composition:
The water-absorbing resin composition contains
(in weight parts) antimicrobial agent (0.001-1) and
metal chelating agent (0.01-10) with respect to
water-absorbing resin (100), and antimicrobial
metal (0.1-15) with respect to porous substance
(100). [CONT.]
BIOTECHNOLOGY - Preferred Nucleic Acid: The
sequence identity of the nucleic acid molecule is
at least 80%, especially 100%. The nucleic acid is
DNA or RNA. The nucleic acid molecule is
isolated from a genomic DNA, especially from S.
pneumoniae genomic DNA. Preferred Vector: The
vector is adapted for recombinant expression of
the hyperimmune serum reactive antigens or
fragment encoded by the nucleic acid molecule
cited above [CONT.]
JP 2004300438
INDEPENDENT CLAIMS are also included for the WO 2004090044
following:
(1) absorber which consists of water-absorbing
resin and hydrophilic fiber; and
US 20060189953
(2) absorbent article which consists of liquid
permeable sheet, liquid impermeable sheet and
absorber.
US 20110068300
An isolated nucleic acid molecule encoding a
hyperimmune serum reactive antigen or its
fragment, is new.
The nucleic acid molecule comprises:
WO 2004092209
N
US 7868075
US 20060263846
N
US 7635487
AU 2004230244
A1
20041028
DETAILED DESCRIPTION: An isolated nucleic
acid molecule encoding a hyperimmune serum
reactive antigen or its fragment, is new.
CN 1774447
A
20060517
The nucleic acid molecule comprises:
US 20060263846
A1
20061123
(a) a nucleic acid molecule comprising any of the
12 nucleotide sequences (e.g. [CONT.]
JP 2007525157
T
20070906
WO 2004092209
US 7635487
US 20100260790
A9
20081127
B2
20091222
A1
20101014
JP 2011004753
A
20110113
EP 2298934
US 20040208821
A1
20110323
A1
20041021
WO 2004091668
A1
20041028
COCKBAIN J
EP 1617876
A1
20060125
LARSEN R H
AU 2004229218
A1
20041028
BRULAND O
NO 2005005390
A
20060116
LARSEN R
BR 2004009387
A
20060418
MX 2005010804
A1
20060301
KR 2006015507
A
20060217
ALGETA AS
429 Treating soft tissue disease such as
carcinomas in mammal e.g., human, by
administering soft tissue targeting complex of BRULAND O S
thorium-227 and complexing agent to subject,
without generating radium-223 to cause
unacceptable myelotoxicity
430 Use of a chicory root product to
reduce/prevent boar taint, to reduce skatole
content in pigs and to reduce/prevent
gastrointestinal tract parasitic infections in
animals e.g. hare, pig, horse and sheep
US 20040208821 A1 UPAB: 20050707
A1
20061012
T
20061019
CN 1805760
A
20060719
ZA 2005007983
A
20070328
IN 2005DN05164
A
20070831
AU 2004229218
B2
20090507
CN 100586484
C
20100203
NZ 543044
A
20100430
CA 2522148
C
20100713
KR 2011022743
A
20110307
DANMARKS JORDBRUGSFORSKNING DANISH
INST
UNIV AARHUS
WO 2004084644
A1
20041007
WO 2004084644 A1 UPAB: 20110310
EP 1610623
A1
20060104
UNIV DEN KONGELIGE VETERINAER-OG
LANDBOH
US 20060240077
A1
20061026
NOVELTY: Reduction of taint in animals
comprises feeding to an animal a chicory root
product (I) during at least one day prior to
slaughtering the animal.
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are also included for the following:
DEN KONGELIGE
VETERINAER&LANDBOHOJSKO
EP 2289348
A2
20110302
BYRNE D
EP 2289348
A3
20110323
MEJER H
ROEPSTORFF A
US 20100260790
(M1) enables to treat soft tissue disease in a
mammal without generating an amount of radium223 sufficient to cause unacceptable myelotoxicity
(claimed).
BIOTECHNOLOGY - Preferred Method: In (M1),
the non-myelotoxic quantity is less than 300 or
150 kBq of radium-223/kg bodyweight. The
complex comprises chelated thorium-227 linked to
a ligand chosen from antibodies, antibody
constructs, antibody fragments, constructs of
antibody fragments and its mixtures. [CONT.]
INDEPENDENT CLAIMS are also included for the US 20040208821
following:
(1) a pharmaceutical composition comprising a
soft tissue targeting complex of thorium-227 and a
complexing agent, together with a carrier or
excipient;
US 20040208821
N
US 20060228297
(2) a soft tissue targeting complex of thorium-227
and a complexing agent; and
(3) a kit (II) for use in (M1), comprising: [CONT.]
US 20060228297
JENSEN M T
pneumoniae genomic DNA. Preferred Vector: The
vector is adapted for recombinant expression of
(a) a nucleic acid molecule comprising any of the
the hyperimmune serum reactive antigens or
12 nucleotide sequences (e.g. 1248, 2157 or 837
fragment encoded by the nucleic acid molecule
bp) fully defined in the specification;
cited above [CONT.]
(b) a nucleic acid molecule having at least 70%
sequence identity to any of the 45 nucleotide
sequences (e.g. [CONT.]
(M1) is useful for treating soft tissue disease such
as malignant disease chosen from carcinomas,
NOVELTY: Treating (M1) soft tissue disease in a sarcomas, myelomas, leukemias, lymphomas and
mixed type cancers in a mammalian subject e.g.,
mammalian subject, involves administering a
specific quantity of a soft tissue targeting complex human or canine. (II) is useful in carrying out (M1)
(I) of thorium-227 and a complexing agent to the (claimed).
subject, where the quantity is such that an
acceptably non-myelotoxic quantity of radium-223
is generated in vivo by nuclear decay of the
administered thorium-227. [CONT.]
JP 2006523664
HANSEN L L
infections. The antigen or its fragment may also
be used for isolating, purifying and/or identifying
an interaction partner of the hyperimmune serum
reactive antigen or fragment [CONT.]
(1) a method for reducing the skatole content in
animals comprising feeding (I) to an animal for at
least one day, e.g. at least two days prior to
slaughtering; [CONT.]
(I) is useful for preparing a feed product for grown- (I) improves the quality of meat.
up pigs, for preventing boar taint, for reducing
skatole content in pigs, in particular in boar meat
and fat, for reducing androsterone in pigs, and for
reducing or preventing gastrointestinal tract
infections in pigs. The infections are parasitic and
the parasites are particularly worms. [CONT.]
AGRICULTURE - Preferred Animal: The animal is
a ruminant, such as cow, sheep, goat or buffalo.
The animal may also be a monogastric species,
such as horse, pig, poultry, dog or cat (preferably
an entire male pig). The pig is 25-300 kg
(preferably 55-160 kg). The monogastric animal
may be a furred animal, such as mink, fox, mouse,
cat, muskrat, rabbit, hare, wolf or dog. [CONT.]
INDEPENDENT CLAIMS are also included for the WO 2004084644
following:
(1) a method for reducing the skatole content in
animals comprising feeding (I) to an animal for at
least one day, e.g. at least two days prior to
slaughtering;
(2) a method for reducing the androsterone
content in meat and/or fat and/or blood comprising
feeding (I) to an animal for at least one day, e.g. at
least two days; [CONT.]
US 20060240077
N
THAMSBORG S M
431 Identifying nucleic acid molecule differentially BIONOMICS LTD
expressed in an in vitro model of a biological
system, useful for diagnosing or treating e.g.,
GONDA T J
cancer, comprises performing suppression
subtractive hybridization (SSH) on cDNA pools
KREMMIDIOTIS G
432 New benzothiazole derivatives, useful to treat
or detect amyloid deposits in the brain,
Alzheimer's disease, Down's syndrome or
homozygotes for apolipoprotein E4 allele, are
amyloid beta peptide ligands
UNIV PITTSBURGH
UNIV PITTSBURGH COMMONWEALTH SYSTEM
HIGH
A1
20041007
WO 2004085675 A1 UPAB: 20110323
EP 1608778
A1
20051228
NOVELTY: Identifying a nucleic acid molecule
differentially expressed in an in vitro model of a
biological system comprises performing a
suppression subtractive hybridization (SSH) on
the cDNA pools from each time point sequentially
so as to progressively amplify cDNAs derived from
nucleic acid molecules differentially expressed
from one time period to the next. [CONT.]
JP 2006524492
T
20061102
US 20060246452
A1
20061102
EP 1947199
EP 1947199
US 20110064730
WO 2004083195
A2
20080723
A3
20081022
A1
20110317
A1
20040930
WO 2004083195 A1 UPAB: 20090907
US 20050043523
A1
20050224
NOVELTY: Benzothiazole derivatives (I) are new.
CA 2438032
A1
20050222
AU 2004221897
A1
20040930
EP 1611115
A1
20060104
DETAILED DESCRIPTION: Benzothiazole
derivatives of formula (I) and their salts, hydrates,
solvates or prodrugs are new.
R1 = OH, NO2, CN, C(O)OR, OCH2OR, 1-6C
alkyl, 2-6C alkenyl, 2-6C alkynyl, 1-6C alkoxy or
halo (where one or more of the atoms of R1 may
be a radiolabeled atom);
R = 1-6C alkyl, optionally containing one or more
radiolabeled C; [CONT.]
NO 2005004674
A
20051213
AU 2004221897
A2
20040930
BR 2004008274
A
20060321
JP 2006522104
T
20060928
CN 1784392
A
20060607
AU 2004221897
A9
20090820
US 20100021388
A1
20100128
AU 2004221897
B2
20101118
AU 2011200667
A1
20110310
US 20040197328
WO 2005092376
A1
20041007
A1
20051006
FERRY A L
EP 1732602
A1
20061220
FINDLAY H P
AU 2005226798
A1
20051006
HAHN S E
CN 1960755
A
20070509
YOUNG D S F
JP 2007530457
T
20071101
US 7393531
B2
20080701
CN 101254303
A
20080903
EP 1732602
WO 2004078995
B1
20110309
A2
20040916
ARIUS RES INC
433 Treating patient suffering from cancerous
disease, involves administering to patient anti- HOFFMANN LA ROCHE&CO AG F
cancer antibody or its fragment capable of
binding to antigenic moiety expressed by the
cancerous tissue
434 Identifying an agent that modulates
intracellular calcium, useful for treating
WO 2004085675
NEUROGENETICS INC
The nucleic acid molecule is useful for identifying
and/or obtaining full-length human genes involved
in an angiogenic process and for screening of
candidate pharmaceutical compounds useful in
the treatment of angiogenesis-related disorders.
[CONT.]
BIOTECHNOLOGY - Preferred Method: In
identifying a nucleic acid molecule, the model
system is an in vitro model for angiogenesis.
Identifying a nucleic acid molecule up-regulated in
an in vitro model of a biological system comprises
steps (a)-(d) in the method defined above, and (e)
cloning the amplified cDNAs; (f) locating DNA from
each, clone on a microarray; [CONT.]
Identifying a nucleic acid molecule differentially
expressed in an in vitro model of a biological
system comprises:
(a) harvesting cells from the model system at
predetermined time points;
WO 2004085675
US 20060246452
N
US 20110064730
(b) obtaining total RNA from the cells harvested at
each time point;
(c) preparing cDNA from the total RNA from each
time point to provide pools of cDNA; and [CONT.]
(I) are useful to detect amyloid deposits in the
brain of a mammal suspected to have Alzheimer's
disease, familial Alzheimer's disease, Down's
syndrome or homozygotes for apolipoprotein E4
allele (claimed). (I) are also useful in treatment of
Alzheimer's disease, familial Alzheimer's disease,
Down's syndrome or homozygotes for
apolipoprotein E4 allele.
(I) are less toxic than prior art compounds and
avoid production of potentially carcinogenic
metabolites, pass the blood-brain barrier easily
and are specific for amyloid deposits over normal
brain tissue.
ORGANIC CHEMISTRY - Preparation:
Preparation of (I) comprises reaction of 5substituted 2-aminothiophenol derivatives of
formula (A) with polyphosphoric acid derivatives of
formula (B). . PHARMACEUTICALS - Preferred
Method: In vivo detection is effected by gamma
imaging (PET or SPECT), magnetic resonance
imaging or magnetic resonance spectroscopy. (I)
(0. [CONT.]
Benzothiazole derivatives of formula (I) and their
salts, hydrates, solvates or prodrugs are new.
WO 2004083195
US 20050043523
N
R1 = OH, NO2, CN, C(O)OR, OCH2OR, 1-6C
alkyl, 2-6C alkenyl, 2-6C alkynyl, 1-6C alkoxy or
halo (where one or more of the atoms of R1 may
be a radiolabeled atom);
R = 1-6C alkyl, optionally containing one or more
radiolabeled C;
US 20100021388
R2 = H or optionally radioactive halo;
R3 = H, 1-6C alkyl, 2-6C alkenyl or 2-6C alkynyl;
[CONT.]
US 20040197328 A1 UPAB: 20090222
(M1) is useful for treating a patient suffering from a
cancerous disease (claimed).
NOVELTY: Treating a patient suffering from a
cancerous disease, involves administering to
patient anti-cancer antibody (deposited with ATCC
as PTA-5643) or its fragment, the antibody is
cytotoxic against cells of cancerous tissue and is a
monoclonal antibody or its antigen binding
fragment which binds to an antigenic moiety
expressed by the cancerous tissue. [CONT.]
BIOTECHNOLOGY - Preferred Method: In (M1),
the isolated monoclonal antibody or its antigen
binding fragment is humanized or chimerized.
(M1) involves conjugating the antibody or its
antigen binding fragment with a member chosen
from toxins, enzymes, radioactive compounds,
and hematogenous cells, thereby forming an
antibody conjugate, and administering the
antibody conjugate or conjugated fragments
[CONT.]
Treating (M1) a patient suffering from a cancerous US 20040197328
disease, involves administering to the patient an
anti-cancer antibody or its fragment produced in
accordance with a method for the production of
anti-cancer antibodies which are useful in treating
a cancerous disease, the antibody or its fragment
is cytotoxic against cells of a cancerous tissue,
and being essentially benign to non-cancerous
cells, [CONT.]
US 20040197328
US 7393531
N
WO 2004078995 A2 UPAB: 20050531
BIOTECHNOLOGY - Preferred Methods:
Identifying an agent that modulates intracellular
Identifying an agent that modulates intracellular
calcium comprises: (a) contacting one or more
US 20070031814
N
The method is useful for identifying an agent that
modulates intracellular calcium. The method is
WO 2004078995
434 Identifying an agent that modulates
intracellular calcium, useful for treating
autoimmune disease, asthma, or arthritis,
comprises identifying a test agent that
modulates intracellular calcium if it has an
effect on intracellular calcium
CALCIMEDICA INC
US 20070031814
A1
20070208
DIGREGORIO P J
US 20090311720
US 7645588
US 7820397
US 20110070237
A1
20091217
B2
20100112
B2
20101026
A1
20110324
EP 1462521
A1
20040929
WO 2004085468
A2
20041007
EP 1606408
A2
20051221
US 20060062792
A1
20060323
US 7910704
WO 2004075824
B2
20110322
A2
20040910
AU 2004216458
A1
20040910
EP 1596863
US 20060147388
A2
20051123
A1
20060706
JP 2006519219
T
20060824
CN 1802158
A
20060712
IN 2005DN03496
A
20070713
IN 2008DN09902
A
20090327
IN 231485
B
20090327
AU 2004216458
B2
20100325
AU 2010202623
A1
20100715
EP 2258368
A2
20101208
OHLSEN K L
ROOS J
STAUDERMAN K A
The method is useful for identifying an agent that
modulates intracellular calcium. The method is
NOVELTY: Identifying an agent that modulates
useful for treating diseases or disorders including
intracellular calcium comprises identifying a test
agent that modulates intracellular calcium if it has autoimmune disease, an immunodeficiency,
glomerulonephritis, psoriasis, asthma, arthritis,
an effect on intracellular calcium. [CONT.]
exocrinopathy, Sjogren's syndrome, or
neuropathic pain. [CONT.]
BIOTECHNOLOGY - Preferred Methods:
Identifying an agent that modulates intracellular
calcium comprises: (a) contacting one or more
test cells or portion comprising a STIM protein or
portion; (b) assessing the effects of the test agent
on intracellular calcium; and (c) identifying a test
agent as an agent that modulates intracellular
calcium if it has an effect on intracellular calcium.
[CONT.]
Identifying an agent that modulates intracellular
WO 2004078995
calcium comprises: (a) contacting one or more
test cells or a portion comprising one or more
proteins with a test agent, where the one or more
proteins is/are (a) at least 45% homologous to the
protein encoded by Drosophila gene CG9126
and/or a stromal interacting molecule (STIM) or
STIM-like protein over at least 52% of the protein
or (b) a portion [CONT.]
EP 1462521 A1 UPAB: 20060203
BIOTECHNOLOGY - Preferred Variant: (VI)
comprises partial or entire deletion of exon 7, exon
8 and/or exon 9. Preferred Vector: In (IV), (I) is
operatively linked to regulatory element allowing
transcription and synthesis of an (m)RNA in
prokaryotic and/or eukaryotic host cells. Preferred
Host Cell: (V) is a mammalian cell, bacterial cell,
an insect cell or a yeast cell. (V) is preferably a
transgenic mammal [CONT.]
INDEPENDENT CLAIMS are also included for the EP 1462521
following:
(1) an antisense RNA sequence (II) that is
complementary to an mRNA transcribed from (I)
and can selectively bind to the mRNA or its part,
the sequence being capable of inhibiting the
synthesis of the protein encoded by (I);
PHARMACEUTICALS - Preferred Composition:
The freeze-dried blend is from 0.1 (preferably 1-50
wt%) in an amorphous state. The active material
(0.5-50 wt%) in amorphous state (preferably 0.525 wt% is in amorphous or crystalline form), 5099.5 wt% (preferably 75-99 wt%) of excipient is in
crystalline state and 0-5 wt% (preferably 0.5-5
wt%) of excipient is in amorphous state. (I)
contains 2. [CONT.]
An INDEPENDENT CLAIM is also included for a WO 2004075824
method of preparing a powdered pharmaceutical
formulation for nasal delivery comprising forming a
mixed solution of active material (0.5-50 wt%) and
excipient(s) (50-99.5 wt%) and freeze-drying the
solution so that at least 0.1 wt% of the freeze dried
blend is in an amorphous state.
US 20060147388
INDEPENDENT CLAIMS are also included for:
US 20040175463
US 20090311720
US 7645588
US 7820397
US 20110070237
VELICELEBI G
435 New nucleic acid encoding a p53 variant that
can transactivate p21- and 14-3-3 sigmapromoter but not e.g. the PIG3-promoter, for
obtaining complementary sequences capable
of inhibiting expression of p53 variant and
treating tumor
DEPPERT W W
DORNREITER I
BRITANNIA PHARM LTD
436 Nasal powdered formulation, useful to treat
migraine, Parkinson's disease and/or sexual
ADAMS G
dysfunction, comprises a freeze-dried blend of
an active material and excipients e.g.
saccharide or sugar alcohol
LAMBERT P A
MERKUS F W H
437 Confectionery piece used for water-based ink
for ink jet printing comprises ink-jetted image
comprised of individual dried ink droplets
(V) is useful for making (VI), which involves
culturing (V) under conditions such that (VI) is
NOVELTY: A nucleic acid molecule (I) encoding a expressed, and recovering (VI). (II), (III), (IV) or
(VII) is useful for the preparation of a
p53 variant capable of transactivating the p21and 14-3-3sigma-promoter but not the mdm2-, bax- pharmaceutical composition for the prevention or
treatment of a tumor. (P1) is useful for preparation
and PIG3-promoter, is new.
of a diagnostic composition for diagnosing a tumor
characterized by the presence of (VI) or a
predisposition to such a tumor or for evaluating
DETAILED DESCRIPTION: INDEPENDENT
whether the treatment of a tumor by radio- or
CLAIMS are also included for the following:
chemotherapy will have undesired effects (all
claimed) [CONT.]
WO 2004075824 A2 UPAB: 20060203
(I) as a medicament is useful to treat migraine
NOVELTY: Powdered pharmaceutical formulation and/or Parkinson's disease and/or sexual
(I), for nasal delivery, which is a freeze-dried blend dysfunction in human (preferred) or animal
(preferably mammal) body (all claimed).
of active material (0.5-50 wt%) and excipient(s)
(50-99.5 wt %) and in which at least 0.1 wt% of
the blend is in an amorphous state. [CONT.]
Administration of (I) via nasal route provides rapid
absorption of the drug into the blood supply
through the nasal tissue. Freeze dried (without the
use of milling) particles retain the free-flowing
properties on storage and are physically and
chemically stable and are readily soluble. The
nasal powder form of (I) does not require the
addition of preservatives e.g. bactericides or
fungicides). [CONT.]
The invention can be used to print high resolution IMAGING AND COMMUNICATION - Preferred
images directly on edible substrate using
Compositions: The ink droplets are dried from an
conventional technology.
ink composition containing 50-85 wt.% water; 7-35
wt.% ethanol, isopropyl alcohol, butanol, and/or
propylene glycol; 0.5-15 wt.% edible colorant; 2-40
wt.% edible binder system; and 0.1-15 wt.%
hydrolyzable polysaccharide adhesive.
POLYMERS - Preferred Compositions: The edible
binder system comprises 8-25 wt. [CONT.]
JP 2011052021
A
20110317
US 20040175463
A1
20040909
US 20040175463 A1 UPAB: 20060203
MARS INC
WO 2004081126
A2
20040923
NOVELTY: A confectionery piece comprises inkjetted image comprised of individual dried ink
droplets having a resolution greater than 100
dots/inch on its surface. The ink droplet(s) is
printed in a non-pigmented water-based edible ink
comprising edible colorant and hydrolyzable
polysaccharide adhesive agent to enhance
adhesion of image on surface. [CONT.]
AU 2004220103
A1
20040923
EP 1601728
A2
20051207
A
20060118
JP 2006523751
T
20061019
EP 1601728
B1
20080521
DE 602004013934
E
20080703
N
US 7910704
(2) a ribozyme (III) complementary to an mRNA
transcribed from (I) or and can selectively bind to
and cleave the mRNA or parts, thus inhibiting the
synthesis of the protein encoded by (I); [CONT.]
(1) an antisense RNA sequence (II) that is
complementary to an mRNA transcribed from (I)
and can selectively bind to the mRNA or its part,
the sequence being capable of inhibiting the
synthesis of the protein encoded by (I); [CONT.]
BPSI HOLDINGS INC
CN 1723251
US 20060062792
Used for water-based ink for ink jet printing
(claimed).
(1) a non-pigmented water-based ink-jetted edible
ink free of conductivity enhancing salts for printing
on hydrophobic edible substrate comprising water,
edible colorant, and hydrolyzable polysaccharide
adhesive agent for hydrophobic edible substrate;
[CONT.]
US 20040175463
US 7906167
N
438 New isolated nucleic acid molecules encoding INTERCELL AG
hyperimmune serum-reactive antigens from
Streptococcus pyogenes, useful for
diagnosing, preventing and treating S.
pyogenes infections
C2
20090110
CN 100532473
C
20090826
AU 2004220103
B2
20100624
US 7906167
WO 2004078907
B2
20110315
A2
20040916
WO 2004078907 A2 UPAB: 20060203
AU 2004218284
A1
20040916
NOVELTY: An isolated nucleic acid molecule
encoding a hyperimmune serum reactive antigen
or its fragment, is new.
EP 1601770
A2
20051207
CN 1756843
A
20060405
DETAILED DESCRIPTION: The nucleic acid
molecule comprises a nucleotide sequence
selected from:
(a) a nucleic acid molecule having at least 70%
sequence identity to any of the 230 nucleotide
sequences given in the specification; [CONT.]
US 20060194751
A1
20060831
JP 2006520202
T
20060907
EP 2053125
A1
20090429
AU 2004218284
B2
20090723
EP 1601770
B1
20090902
DE 602004022923
E
20091015
ES 2330334
T3
20091209
US 7638136
B2
20091229
AU 2009230772
A1
20091126
US 20100255034
A1
20101007
JP 2011015689
A
20110127
EP 2287311
EP 2287312
EP 2287313
EP 2287314
EP 2287315
EP 2290082
WO 2004076634
EP 1599213
A1
20110223
A1
20110223
A1
20110223
A1
20110223
A1
20110223
A1
20110302
A2
20040910
WO 2004076634 A2 UPAB: 20060203
A2
20051130
NOVELTY: Modulating cellular function in a
mammal comprising locally administering a
modulatorily effective amount of a regulated
SNARE (soluble N-ethylmaleimide-sensitive factor
attachment protein receptor) inhibitor and a
translocating agent to the mammal, where the
translocation of the regulated SNARE inhibitor is
facilitated, is new. [CONT.]
US 20060153876
US 20110054442
WO 2004074481
A1
20060713
A1
20110303
A1
20040902
NOVARTIS PHARMA GMBH
US 20040247601
A1
20041209
SCRIPPS RES INST
AU 2004213568
A1
20040902
HOOPER J D
EP 1597367
A1
20051123
QUIGLEY J P
BR 2004007680
A
20060301
TESTA J E
MX 2005008794
A1
20060301
CN 1761750
A
20060419
SANDERS I
439 Modulating cellular function in a mammal,
useful for treating pain, inflammation, migraine
headache, allergy, or cystic fibrosis, comprises
locally administering a regulated SNARE
inhibitor and a translocating agent to the
mammal
440 New glycoprotein antigen SIMA135, useful for
diagnosing and treating cancer, e.g. prostate,
colon, gastric, liver, breast, lung, or kidney
cancer
RU 2343174
NOVARTIS AG
WO 2004074481 A1 UPAB: 20090205
The nucleic acid molecule or hyperimmune serumreactive antigen or its fragment are useful for the
manufacture of a pharmaceutical preparation,
especially a vaccine, against S. pyogenes
infection. The antibody is also used for the
preparation of a medicament for treating or
preventing S. pyogenes infections. [CONT.]
The method and SNARE inhibitor are useful for
treating a disease or medical condition, e.g. pain,
inflammation, migraine headache, allergy, cystic
fibrosis, a disease related to adipose tissue, a viral
infection, cancer, fever, a disease related to
sweating, ecrine, and apocrine, a disease
associated with holocrine secretions, acne, a
disease related to mucous secretion, prostatic
hypertrophy, a disease treatable by gene therapy,
a disease of veins, venous stasis, varicose veins,
hemorrhoids or high blood pressure [CONT.]
The antibody is used in a diagnostic method of
cancer, to determine if a test sample contains
metastatic cells, a therapeutic treatment of the
NOVELTY: A protein comprising a sequence of
836 amino acids (SEQ ID NO: 1), or its fragment human and animal body, to determine the
or variant, that is glycosylated or non-glycosylated, metastasis modulating ability of an agent, and to
determine if a candidate agent modulates SIMAl35
where the fragment contains amino acid 525
and/or amino acid 827 and where the variant the production by a cell. The antibody is useful for
amino acid 525 is Arginine and/or amino acid 827 preparing a medicament to inhibit metastasis by a
cancer cell, e.g. [CONT.]
is Serine, is new.
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are also included for: [CONT.]
BIOTECHNOLOGY - Preferred Nucleic Acid: The
sequence identity is at least 80%, preferably at
least 95%, especially 100%. The nucleic acid is
DNA or RNA. The nucleic acid molecule is
isolated from a genomic DNA, especially from S.
pyogenes genomic DNA. Preferred Vector: The
vector is adapted for recombinant expression of
the hyperimmune serum reactive antigens or their
fragments encoded by the nucleic acid molecule
cited above [CONT.]
The nucleic acid molecule comprises a nucleotide WO 2004078907
sequence selected from:
(a) a nucleic acid molecule having at least 70%
sequence identity to any of the 230 nucleotide
sequences given in the specification;
US 20060194751
(b) a nucleic acid molecule which is
complementary to (a);
US 20100255034
US 7638136
(c) a nucleic acid molecule comprising at least 15
sequential bases of the nucleic acid molecule of
(a) or (b); [CONT.]
BIOTECHNOLOGY - Preferred Method: In
modulating a cellular function in a mammal, the
translocating agent is an acid, an acidic
environment, an encapsulating vector, or a
transduction domain. The regulated SNARE
inhibitor is administered in a pharmaceutical
formulation. The regulated SNARE inhibitor is a
bacterial neurotoxin, preferably a clostridial
neurotoxin. [CONT.]
BIOTECHNOLOGY - Preferred Antibody: The
antibody is a monoclonal or a polyclonal antibody.
The antibody for use in a diagnostic method of
cancer which comprises contacting the antibody of
(1) with a test sample obtained from the mammal,
and determining if the antibody binds to the test
sample to a greater extent than the antibody binds
to a control sample of non-cancerous tissue.
[CONT.]
N
INDEPENDENT CLAIMS are also included for:
WO 2004076634
US 20060153876
US 20110054442
WO 2004074481
US 20040247601
(1) an antibody that binds specifically to the
protein, or its fragment or variant, where the
antibody is not mAb 41-2;
US 7589173
(2) a pharmaceutical composition comprising the
antibody of (1) and a pharmaceutical carrier; and
US 20100158917
(3) a kit comprising the antibody of (1) and
packaging material.
N
N
441 Novel fructose responsive transcriptionregulatory cis-element, useful as target for
treating metabolic disorders such as obesity,
hyperinsulinemia, hypertension
442 New serine proteases of peptidase family S2A
and/or S1E, derived from Brachysporiella
gayana, exhibiting stability in presence of
copper, useful in animal feed and for
improving nutritional value of animal feed
IN 2005CN01945
A
20070330
JP 2007523836
T
20070823
AU 2008201545
A1
20080501
CN 100422328
C
20081001
IN 2008CN04794
A
20090313
US 7589173
US 20100158917
EP 1597367
B2
20090915
A1
20100624
B1
20100707
DE 602004027992
E
20100819
MX 276055
B
20100520
JP 2011046712
A
20110310
WO 2004074475
A1
20040902
TAKEDA PHARM CO LTD
JP 2005013215
A
20050120
KASHIWAGI A
EP 1600507
A1
20051130
MAEGAWA H
US 20070032643
A1
20070208
NISHIO Y
JP 4451158
B2
20100414
EP 1600507
B1
20110119
DE 602004031088
E
20110303
WO 2004072221
A2
20040826
AU 2004211446
A1
20040826
TAKEDA CHEM IND LTD
NOVOZYMES AS
WO 2004074475 A1 UPAB: 20060203
NOVELTY: Fructose responsive transcriptionregulatory cis-element (I) having sequence (S1)
which is same or substantially same as region of
fully defined sequence of 574 nucleotides (S1'), as
given in specification, where (S1) contains
guanine at position 112 (S1) in which one or more
bases are deleted, substituted, inserted or added,
where transcriptional regulatory factor binds to
guanine of (S1) and does not bind to base
adjacent to it, is new. [CONT.]
(II) is useful for preventing or treating metabolic
disorders. (II) is useful for manufacture of
preventive/therapeutic agent for metabolic
disorders. The metabolic disorder is saccharide or
lipid metabolic failure (claimed). [CONT.]
443 New targeting system having a transposon
devoid of a polynucleotide encoding a
functional transposase and a fusion protein,
useful for diagnosing or treating hemophilia,
cystic fibrosis, cancer and diabetes
DELBRUECK CENT MOLEKULARE MEDIZIN
MAX
A2
20051116
BR 2004007294
A
20060207
US 20060147499
A1
20060706
CN 1774504
A
20060517
EP 1594963
B1
20070725
DE 602004007766
E
20070906
ES 2291883
T3
20080301
DE 602004007766
T2
20080605
AU 2004211446
B2
20090528
US 7588926
US 20090238922
US 7906310
WO 2004069995
B2
20090915
A1
20090924
B2
20110315
A2
20040819
INDEPENDENT CLAIMS are also included for:
WO 2004074475
US 20070032643
N
(1) diagnosing genetic susceptibility of an animal
to metabolic disorder comprising detecting the
protein expressed by (S1) in sterol regulatory
factor binding protein-1 (SREBP-1c) promoter;
(2) screening (M2) a therapeutic or preventive
agent for metabolic disorders, involves using (I), a
protein (P1), its partial peptide or salt, containing a
sequence which is same or substantially same as
a fully defined sequence of 428 (S2) or 388 (S3)
amino acids, as given in the specification; [CONT.]
WO 2004072221 A2 UPAB: 20090819
(I) is useful in animal feed, in the preparation of a
NOVELTY: A protease (I) of peptidase family S2A composition for use in animal feed, for improving
the nutritional value of an animal feed, for
and/or S1E, having a residual activity of at least
increasing digestible and/or soluble protein in
0.80 after incubation for 164 hours, at pH 7 and
animal diets, for increasing the degree of
25degreesC, in assay buffer supplemented with
hydrolysis of proteins in animal diets, and/or for
0.1% K-Sorbate, and in the presence of 1 mM
the treatment of vegetable proteins (claimed).
Cu2+, the residual activity being measured
relative to the activity after 0 hours of incubation,
and/or a relative activity of at least 0 [CONT.]
EP 1594963
BIOTECHNOLOGY - Preferred Regulatory
Element: In (I), the guanine at position 112 is
substituted by another base which is adenine.
Preferred Method: In (M1), the metabolic disorder
is saccharide or lipid metabolic failure. In (M2), the
inhibition of protein and/or nucleic acid is detected
in the presence of candidate substance. In (M2),
the animal is administered with saccharide and
the expression of (I) in the presence and absence
of candidate substance is compared [CONT.]
(I) is at least 90% pure and is relatively stable in
the presence of copper and/or is inhibited by
copper only to a limited extent.
BIOTECHNOLOGY - Preparation (Claimed):
Producing (I), involves cultivating (V) to produce a
supernatant comprising the polypeptide and
recovering the polypeptide. Preferred Protease: (I)
comprises an amino acid sequence which, when
aligned in clusters of 10 residues according to a
multiple alignment (A1) of the mature peptide part
of proteases derived from Nocardiopsis sp.
[CONT.]
A protease (I) of peptidase family S2A and/or
peptidase family S1E, which (i) has a residual
activity of at least 0.80 after incubation for 164
hours, at pH 7 and 25degreesC, in assay buffer
supplemented with 0.1% K-Sorbate, and in the
presence of 1 mM Cu2+, the residual activity
being measured relative to the activity after 0
hours of incubation and/or (ii) has a relative
activity of at least 0. [CONT.]
WO 2004072221
US 20060147499
US 7588926
US 20090238922
US 7906310
WO 2004069995 A2 UPAB: 20060203
The methods and compositions of the present
invention are useful for the diagnosis and/or
treatment of hemophilia, muscular dystrophy,
hypercholesterolemia, cystic fibrosis, cancer,
severe combined immunodeficiency, diabetes,
hereditary tyrosinemia type 1 and junctional
epidermolysis bullosa.
BIOTECHNOLOGY - Preferred Targeting System:
The polynucleotide in the targeting system further
encodes at least one the peptides cited above.
The targeting system further comprises the
peptide comprising the domain specifically binding
to a transposase or its fragment or derivative
having transposase function, a cellular or
A targeting system comprising a transposon which WO 2004069995
is devoid of a polynucleotide encoding a functional
transposase having a polynucleotide of interest, a
fusion protein, a polynucleotide encoding the
fusion protein, a transposase or its fragment or
derivative having transposase function, or a
polynucleotide encoding the transposase or its
US 20060236413
N
devoid of a polynucleotide encoding a
functional transposase and a fusion protein,
useful for diagnosing or treating hemophilia,
cystic fibrosis, cancer and diabetes
444 New targeting system having a transposon
devoid of a polynucleotide encoding a
functional transposase and a fusion protein,
useful for diagnosing or treating hemophilia,
cystic fibrosis, cancer and diabetes
IVICS Z
EP 1594971
A2
20051116
IZSVAK Z
JP 2006517104
T
20060720
US 20060236413
EP 1594971
A1
20061019
B1
20110202
DE 602004031284
E
20110317
WO 2004069994
A2
20040819
WO 2004069994 A2 UPAB: 20060203
EP 1594972
A2
20051116
JP 2006518203
T
20060810
NOVELTY: A targeting system comprising a
transposon which is devoid of a polynucleotide
encoding a functional transposase having a
polynucleotide of interest, and a fusion protein, is
new.
DETAILED DESCRIPTION: A targeting system
comprising a transposon which is devoid of a
polynucleotide encoding a functional transposase
having a polynucleotide of interest, and a fusion
protein, is new [CONT.]
US 20080008687
EP 1594972
A1
20080110
B1
20110209
DE 602004031325
E
20110324
WO 2004067038
US 20040202666
A1
20040812
WO 2004067038 A1 UPAB: 20060323
A1
20041014
NOVELTY: A conjugate (C1) of an anthracycline
drug and an antibody linked via a linker
comprising a hydrazide and a maleimide is new.
AU 2004207494
A1
20040812
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are included for:
EP 1594548
US 20050271671
A1
20051116
(a) preparation of (C1);
A1
20051208
(b) treatment (T1) of a disease in a mammal
involving administration of at least two (C1) that
target different antigens or different epitopes of
the same antigen on the same diseased cells;
[CONT.]
BR 2004006574
A
20060117
MX 2005007851
A1
20051001
JP 2006515892
T
20060608
KR 2005104354
A
20051102
CN 1764478
A
20060426
IN 2005CN01997
A
20070406
RU 2349343
C2
20090320
AU 2004207494
B2
20090528
IN 229294
B
20090320
AU 2009212806
A1
20090917
JP 2011012083
A
20110120
EP 1594548
WO 2004066988
B1
20110309
KANEKA CORP
A1
20040812
KANEGAFUCHI CHEM IND CO LTD
AU 2004208588
A1
20040812
DELBRUECK CENT MOLECULAR MEDICINE
MAX
DELBRUECK CENT MOLEKULARE MEDIZIN
MAX
445 New conjugate of an anthracycline drug and an IMMUNOMEDICS INC
antibody linked via a linker comprising a
hydrazide and a maleimide useful for treating
cancer e.g. skin cancer, head-and-neck cancer,
lung cancer, breast cancer or prostate cancer
446 Agent useful in pharmaceuticals, food and
drinks for improving muscular fatigue in
animals, vertebrates, mammals and humans,
contains reduced-type coenzyme Q as active
ingredient
NOVELTY: A targeting system comprising a
transposon which is devoid of a polynucleotide
encoding a functional transposase having a
polynucleotide of interest, a fusion protein, a
polynucleotide encoding the fusion protein, a
transposase or its fragment or derivative having
transposase function, or a polynucleotide
encoding the transposase or its fragment or
derivative having transposase function, is new.
[CONT.]
WO 2004066988 A1 UPAB: 20060122
invention are useful for the diagnosis and/or
treatment of hemophilia, muscular dystrophy,
hypercholesterolemia, cystic fibrosis, cancer,
severe combined immunodeficiency, diabetes,
hereditary tyrosinemia type 1 and junctional
epidermolysis bullosa.
The polynucleotide in the targeting system further
encodes at least one the peptides cited above.
The targeting system further comprises the
peptide comprising the domain specifically binding
to a transposase or its fragment or derivative
having transposase function, a cellular or
engineered peptide that comprises the DNA
targeting domain, or at least one polynucleotide
encoding the peptide [CONT.]
is devoid of a polynucleotide encoding a functional
transposase having a polynucleotide of interest, a
fusion protein, a polynucleotide encoding the
fusion protein, a transposase or its fragment or
derivative having transposase function, or a
polynucleotide encoding the transposase or its
fragment or derivative having transposase
function, is new. [CONT.]
The methods and compositions of the present
invention are useful for the diagnosis and/or
treatment of hemophilia, muscular dystrophy,
hypercholesterolemia, cystic fibrosis, cancer,
severe combined immunodeficiency, diabetes,
hereditary tyrosinemia type 1 and junctional
epidermolysis bullosa.
BIOTECHNOLOGY - Preferred Targeting System:
The polynucleotide in the targeting system further
encodes the cellular or engineered peptide
comprising a DNA targeting domain. The targeting
system further comprises the cellular or
engineered peptide comprising a DNA targeting
domain, or a polynucleotide encoding the peptide.
The transposon and/or the polynucleotide are
comprised in at least one vector [CONT.]
A targeting system comprising a transposon which WO 2004069994
is devoid of a polynucleotide encoding a functional
transposase having a polynucleotide of interest,
and a fusion protein, is new. The fusion protein in
the targeting system comprising a transposon,
which is devoid of a polynucleotide encoding a
functional transposase having a polynucleotide of
interest comprises: [CONT.]
US 20080008687
For treating disease e.g. cancer (e.g. skin cancer, The conjugate targets specifically of
head-and-neck cancer, lung cancer, breast
chemotherapy drug to human cancer, which
cancer, prostate cancer, ovarian cancer,
improve the efficacy of the cancer therapy.
endometrial cancer, cervical cancer, stomach
cancer, colon cancer, rectal cancer, bladder
cancer, brain cancer, pancreatic cancer, lymphatic
system cancer, sarcoma, melanoma, B-or T-cell
cancer, non-Hodgkin's lymphoma, Hodgkin's
disease, lymphatic leukemia, myeloid [CONT.]
ORGANIC CHEMISTRY - Preparation (Claimed):
Preparation of (C1) involves conjugating the linker
first with the anthracycline drug to produce an
anthracycline drug-linker conjugate, followed by
conjugation to a thiol-reduced monoclonal
antibody or antibody fragment. The anthracycline
drug-linker conjugate is not purified prior to
conjugation to the thiol-reduced monoclonal
antibody or antibody fragment [CONT.]
INDEPENDENT CLAIMS are included for:
WO 2004067038
US 20040202666
US 20050271671
PHARMACEUTICALS - Preferred Composition:
The fatigue improving agent contains reducedtype coenzyme Q of formula (1) or (2) as active
ingredient. n = as defined above. The composition
preferably contains coenzyme Q10 and further
contains antioxidant and/or antioxidant enzyme,
nourishing tonic components, auxiliary nutritive
components and/or antiinflammatory components.
The fatigue improving agent contains reducedtype coenzyme Q of formula (I) as active
ingredient.
n = 1-12.
WO 2004066988
US 20060165672
In pharmaceuticals (spraying agent, ointment,
liniment, lotion, cream, poultices, plaster or tape),
food and drinks for improving fatigue, especially
muscular fatigue in animals, vertebrates,
NOVELTY: A fatigue improving agent contains
reduced-type coenzyme Q (I) as active ingredient. mammals and humans (all claimed).
The fatigue reducing agent effectively prevents
fatigue, enables quick recovery from fatigue and
maintains stamina of middle-aged and elderly
people for prolonged period. The agent has
excellent oral absorptivity and is highly safe.
(a) preparation of (C1);
N
N
(b) treatment (T1) of a disease in a mammal
involving administration of at least two (C1) that
target different antigens or different epitopes of
the same antigen on the same diseased cells;
[CONT.]
Y
US20060165672A1
NO 2005003051
A
20050831
DETAILED DESCRIPTION: The fatigue improving
agent contains reduced-type coenzyme Q of
formula (I) as active ingredient.
EP 1588703
A1
20051026
n = 1-12.
AU 2004208588
A2
20040812
An INDEPENDENT CLAIM is also included for
improvement of fatigue in animals, vertebrates,
mammals or humans, which involves using the
above-mentioned agent. [CONT.]
JP 2005504674
X
20060518
CN 1723015
A
20060118
KR 2005092128
A
20050920
US 20060165672
A1
20060727
RU 2304432
C2
20070820
KR 696924
B1
20070320
AU 2004208588
B2
20090507
TW 2005001936
A
20050116
JP 4644121
B2
20110302
WO 2004067570
A2
20040812
WO 2004067570 A2 UPAB: 20060122
EP 1587837
A2
20051026
NOVELTY: An isolated antibody, or its antigenbinding fragment, which binds to an antigen, is
new.
BERNARD N
US 20070036719
A1
20070215
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are also included for the following:
[CONT.]
CUELLO C
US 7811564
US 20110064654
B2
20101012
A1
20110317
US 20040142035
A1
20040722
US 20040142035 A1 UPAB: 20060122
WO 2004062577
A2
20040729
NOVELTY: Pharmaceutical composition (I),
comprises a core containing one or more
pharmaceutically active ingredients (A) (having a
pH-dependent release profile) and a coating layer
(B) (comprising a combination of two or more
enteric coating materials (C), at least two of which
will dissolve at different pHs) surrounding the core.
CHANG R
EP 1589951
A2
20051102
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are also included for [CONT.]
SHAH N
US 7910128
WO 2004058156
B2
20110322
A2
20040715
US 20040185091
A1
20040923
AU 2003297320
A1
20040722
PROSCAN RX PHARMA
447 New isolated antibodies that bind to an
antigen, useful for detecting, imaging, staging,
treating or monitoring prostate cancer and/or PROSCAN RX PHARMA INC
its metastasis
DU RUISSEAU P
contains antioxidant and/or antioxidant enzyme,
nourishing tonic components, auxiliary nutritive
An INDEPENDENT CLAIM is also included for
components and/or antiinflammatory components. improvement of fatigue in animals, vertebrates,
[CONT.]
mammals or humans, which involves using the
above-mentioned agent.
The composition, methods and kit are useful for
detecting, imaging, staging, treating or monitoring
prostate cancer and/or its metastasis. The method
is also used for indicating the location of prostate
cancer and/or its metastasis within the individual
and/or sample obtained from the individual
(claimed).
BIOTECHNOLOGY - Preferred Antibody: The
antibody is a monoclonal antibody or a polyclonal
antibody. The monoclonal antibody is selected
from F34-8H12, F42-3E11, F42-17G1, F42-29B4,
F42-30C1 and F47-20F2. The binding fragment is
a Fab fragment, an F(ab')2 fragment, or an Fv
fragment. Preferred Antigen: The PSMA is from a
mammal, particularly a human. Preferred Nucleic
Acid: The nucleic acid is DNA. [CONT.]
INDEPENDENT CLAIMS are also included for the WO 2004067570
following:
(1) an antigen comprising an epitope of the
extracellular region of prostate specific membrane
antigen (PSMA), ranging from amino acids 51-67,
85-102, 104-118, 161-173, 236-245, 278-288, 345354, 490-500, 531-545, 551-567, 608-619, 649660, 716-724, or 738-750, which comprises any of
the 14 sequences having 10-19 amino acids fully
defined in the specification (SEQ ID NOs: 1-14);
[CONT.]
US 20070036719
N
US 7811564
US 20110064654
GOLD P
MOFFET S
SARAGOVI U
SHIRE LAB INC
448 Pharmaceutical composition, useful to treat
microbial infections, comprises a core
SUPERNUS PHARM INC
containing active ingredients and a coating
layer comprising a combination of two or more
enteric coating materials
MEDIMMUNE VACCINES INC
449 Preparing stable particles having bioactive
material, by high pressure spraying bioactive
MED IMMUNE VACCINES INC
materials in aqueous solution, with viscosity
enhancing agents to form mist of droplets and
drying droplets to form powder particles
MEDIMMUNE LLC
WO 2004058156 A2 UPAB: 20060122
(I) are useful for the treatment of microbial
infection (claimed).
(M1) is useful for preparing stable particles
comprising a bioactive material having peptides,
NOVELTY: Preparing (M1) stable particles having polypeptides, proteins, viruses, bacteria,
bioactive material, involves preparing an aqueous antibodies (monoclonal antibodies), cells or
liposomes (claimed) that is useful in therapeutics,
suspension or solution having bioactive material
and one or more viscosity enhancing agents in a nutrients, vaccines, pharmaceuticals,
prophylactics, etc.
concentration providing 0.05 centipoise or more
increase in viscosity, spraying suspension or
solution through nozzle at high pressure, drying
droplets to form powder particles and recovering
particles. [CONT.]
(I) increases bioavailability.
In (M1), the high pressure spraying allows fine
spray droplets to be dried in a shorter time, at a
lower temperature, and with less concomitant
degradation of sensitive molecules. The bioactive
material incorporated in the powder particles can
be more readily reconstituted at higher
concentrations.
PHARMACEUTICALS - Preferred Method: The
release profile is at first sustained while (I) is in a
part of the small intestine of a first pH and then
accelerated when (I) is in a part of the small
intestine of a second pH, and where the first pH is
lower than the second pH. (I) may be in the form
of a tablet, a capsule, beads, beadlets or sachet
for oral dosage. [CONT.]
INDEPENDENT CLAIMS are also included for
US 20040142035
(1) preparation of (I) comprising obtaining a
membrane controlled or matrix-controlled oral
dosage form that contains (I) and coating the
dosage form with a mixture of two or more (C);
and [CONT.]
US 7910128
BIOTECHNOLOGY - Preferred Method: In (M1),
the bioactive material is present in the suspension
or solution at a concentration of 1-200 mg/ml. The
viscosity enhancing agents comprise a polyol or a
polymer. The polyol is chosen from the trehalose,
sucrose, sorbose, melezitose, glycerol, fructose,
mannose, maltose, lactose, arabinose, xylose,
ribose, rhamnose, galactose, glucose, mannitol,
xylitol, erythritol, threitol, sorbitol, and raffinose
[CONT.]
Preparing (M1) stable particles comprising a
WO 2004058156
bioactive material, involves:
(i) preparing an aqueous suspension or solution
(90) comprising the bioactive material and one or
more viscosity enhancing agents in a
concentration providing a 0.05 centipoise or more
increase in viscosity over the suspension or
solution without the one or more viscosity
enhancing agents, [CONT.]
US 20040185091
US 20040142035
US 7378110
US 20080254132
N
N
450 New deimmunized monoclonal antibody,
useful in preventing or treating HIV infection
and CD-mediated autoimmune disorders in
humans
EP 1581639
A2
20051005
JP 2006510717
T
20060330
KR 2005088175
A
20050902
CN 1745170
A
20060308
IN 2005CN01251
A
20070608
AU 2003297320
B2
20080124
US 7378110
B2
20080527
AU 2003297320
B8
20080221
AU 2008201720
A1
20080508
US 20080254132
A1
20081016
IN 219105
B
20080606
KR 2010107083
A
20101004
JP 2011006444
A
20110113
AU 2008201720
B2
20110303
US 20040137000
A1
20040715
US 20040137000 A1 UPAB: 20090403
UNITED BIOMEDICAL INC
WO 2004064724
A2
20040805
NOVELTY: A deimmunized monoclonal antibody
or antibody fragment, is new.
UNITED BIOMEDICAL INC ASIA
AU 2003295440
A1
20040813
UNITED BIOMEDICAL ASIA
EP 1583558
A2
20051012
DETAILED DESCRIPTION: A deimmunized
monoclonal antibody or antibody fragment
comprises:
(a) an Fv antibody heavy chain fragment
comprising a sequence of 118 amino acids (SEQ
ID NOS: 5-8) and an Fv antibody light chain
fragment comprising a sequence of 111 amino
acids (SEQ ID NOS: 9-11); or [CONT.]
LYNN S
TW 2004018879
A
20041001
WANG C Y
CN 1738646
A
20060222
IN 2005DN03224
A
20061229
CN 101255195
A
20080903
CN 101293930
A
20081029
CN 101294159
A
20081029
UNITED BIOMEDICAL ASIA INC
UNIV RICE WILLIAM MARSH
451 Fibrocyte suppression composition for
diagnosing, preventing or treating scleroderma
GOMER R
or other fibrosing diseases, such as asthma,
comprises serum amyloid P in a concentration
to inhibit fibrocyte formation in a target
location
PILLING D
US 7501494
B2
20090310
CA 2648056
A1
20040805
CN 100546652
C
20091007
TW 2009030728
A
20090716
AU 2003295440
B2
20100401
CA 2512040
C
20100601
EP 1583558
WO 2004058292
B1
20110309
A2
20040715
WO 2004058292 A2 UPAB: 20060203
AU 2003300266
A1
20040722
US 20050238620
A1
20051027
EP 1596880
A2
20051123
NOVELTY: A fibrocyte suppression composition
comprising serum amyloid P (SAP) in a
concentration to inhibit fibrocyte formation in a
target location, is new.
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are also included for the following:
(1) a method of suppressing fibrocyte formation;
US 20060002938
A1
20060105
JP 2006514654
T
20060511
US 20070065368
A1
20070322
AU 2003300266
A2
20040722
EP 2017617
A1
20090121
AU 2003300266
B2
20091008
(2) a method of detecting the ability of an agent to
suppress fibrocyte formation; and [CONT.]
The deimmunized monoclonal antibody or
antibody fragment, methods and composition are
useful in preventing or treating HIV infection and
CD-mediated autoimmune disorders in humans.
BIOTECHNOLOGY - Preferred Antibody:
Specifically, the antibody is a deimmunized
aglycosylated monoclonal antibody or antibody
fragment, where Asn297 has been mutated to
His297, but not limited to His. Preferred Host Cell:
Specifically, the recombinant host cell secretes
the human or humanized monoclonal antibody or
antibody fragment, or deimmunized aglycosylated
monoclonal antibody or antibody fragment
[CONT.]
A deimmunized monoclonal antibody or antibody
fragment comprises:
(a) an Fv antibody heavy chain fragment
comprising a sequence of 118 amino acids (SEQ
ID NOS: 5-8) and an Fv antibody light chain
fragment comprising a sequence of 111 amino
acids (SEQ ID NOS: 9-11); or [CONT.]
US 20040137000
The composition and methods are useful for
suppressing the differentiation of monocytes into
fibrocytes, or for diagnosing, preventing or treating
scleroderma or other fibrosing diseases, such as
asthma, keloid scarring, rheumatoid arthritis or
lupus. [CONT.]
BIOTECHNOLOGY - Preferred Composition: The
fibrocyte suppression composition further
comprises an additional composition selected
from IL-12, laminin-1, IgG aggregates, crosslinked IgG, and their combinations. It comprises
SAP at a concentration of at least about 0.5
microg/ml. Preferred Method: Suppressing
fibrocyte formation comprises administering SAP,
IL-12 or laminin-1 to monocytes in a target
location in an amount and for a time to suppress
differentiation of the monocytes into fibrocytes
[CONT.]
INDEPENDENT CLAIMS are also included for the WO 2004058292
following:
(1) a method of suppressing fibrocyte formation;
US 20050238620
(2) a method of detecting the ability of an agent to
suppress fibrocyte formation; and
(3) a method for detecting a fibrosing disease in a
patient.
US 20070065368
US 20040137000
N
US 7501494
US 20060002938
US 7666432
US 7763256
US 20100221208
N
US 7666432
US 7763256
US 20100221208
B2
20100223
B2
20100727
A1
20100902
JP 2011016824
A
20110127
EP 1596880
WO 2004058181
B1
20110309
A2
20040715
AU 2003299872
A1
20040722
EP 1572714
A2
20050914
AU 2003299872
A8
20051110
US 20060240035
A1
20061026
B2
20101207
A2
20110309
DELIATROPH PHARM INC
US 7847084
EP 2292762
WO 2004058147
A2
20040715
HALOZYME INC
AU 2003297199
A1
20040722
EP 1636248
A2
20060322
AU 2003297199
A8
20051117
US 20070148156
A1
20070628
B2
20090609
A1
20100121
A1
20100818
A1
20110323
NEKTAR THERAPEUTICS AL CORP
US 7544499
US 20100015698
EP 2218779
EP 2298874
WO 2004056852
A2
20040708
US DEPT HEALTH & HUMAN SERVICES
AU 2003301122
A1
20040714
US GOVERNMENT
A1
US NAT INST OF HEALTH
US 20040258706
EP 1620129
US SEC OF NAVY
452 New isolated nucleic acid molecules encoding UNIV TEXAS SYSTEM
Variable Major Protein-like polypeptides of
Borrelia, useful for diagnosing, preventing or NORRIS S J
treating Borrelia infections such as Lyme
disease or relapsing fever
453 New purified chondroitinase glycoprotein
(CHASEGP) comprising a CHASEGP
polypeptide and a N-linked sugar moiety,
useful in preparing a composition for treating
or preventing scarring
454 Novel antiviral polypeptide having sequence
identity to native cyanovirin-N and having
cysteine substitution or insertion or arginine
substitution, useful for treating or preventing
infection of influenza virus or measles virus
WO 2004058181 A2 UPAB: 20101213
The composition and methods are useful for
diagnosing, preventing or treating infections
NOVELTY: An isolated nucleic acid comprising a caused by Borrelia sp., such as Lyme disease,
nucleotide sequence that encodes a vls peptide of relapsing fever or related disorders.
Borrelia garinii or Borrelia afzelii, is new.
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are also included for the following:
(1) a recombinant host cell comprising the
heterologous nucleic acid cited above;
(2) a method of using the above isolated nucleic
acid; [CONT.]
WO 2004058147 A2 UPAB: 20050530
The chondroitinase glycoprotein (CHASEGP) is
useful in preparing a composition for treating an
animal suffering from an excess of CHASEGP
NOVELTY: A new substantially purified
substrate (claimed) for treating or preventing
chondroitinase glycoprotein (CHASEGP)
comprises a CHASEGP polypeptide and at least 1 scarring.
N-linked sugar moiety that is covalently attached
to an asparagine residue of the polypeptide.
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are also included for the following:
(1) a nucleic acid molecule comprising a
sequence of nucleotides that encodes the
polypeptide; [CONT.]
BIOTECHNOLOGY - Preferred Nucleic Acid: The
nucleic acid comprises a nucleotide sequence that
encodes a peptide comprising any of the 36 amino
acid sequences (e.g. 138, 137 or 142 amino
acids) given in the specification. Alternatively, it
comprises a nucleotide sequence that encodes at
least 16, 20, 35 or at least 50 contiguous amino
acids of any of the amino acid sequences
mentioned above. [CONT.]
INDEPENDENT CLAIMS are also included for the WO 2004058181
following:
(1) a recombinant host cell comprising the
heterologous nucleic acid cited above;
BIOTECHNOLOGY - Preferred Protein: The
substantially purified glycoprotein consists
essentially of the chondroitinase domain of
CHASEGP. It is a mutein. It has more than about
80% sequence identity with a polypeptide that
comprises the 481-amino acid sequence. The
CHASEGP is a human polypeptide encoding a
soluble polypeptide 423-amino acid sequence.
[CONT.]
INDEPENDENT CLAIMS are also included for the WO 2004058147
following:
(1) a nucleic acid molecule comprising a
sequence of nucleotides that encodes the
polypeptide;
US 20070148156
(2) a vector comprising the nucleic acid molecule;
US 20100015698
US 20060240035
(2) a method of using the above isolated nucleic
acid;
(3) an isolated polypeptide comprising a Vls
polypeptide of B. garinii or B. afzelii;
(4) a protein composition comprising an isolated
polypeptide which specifically binds with
antibodies raised against a Vls polypeptide of B
[CONT.]
(3) a cell comprising the vector;
(4) a recombinant non-human animal, where an
endogenous gene that encodes the polypeptide
has been deleted or inactivated by homologous
recombination or insertional mutagenesis of the
animal or its ancestor; [CONT.]
US 20040258706
20041223
(2) a polynucleotide (III) encoding (I);
A2
20060201
(3) a vector (IV) comprising (III);
US 20080015151
US 7547509
MX 2005006688
A1
20060201
(4) a host cell comprising (IV); [CONT.]
NEKTAR THERAPEUTICS
JP 2006517400
T
20060727
US DEPT HEALTH&HUMAN SERVICES
KR 2005084433
A
20050826
20070911
A1
20080117
OKEEFE B R
US 7267941
US 20080015151
EP 1620129
B2
B1
20090318
ROBERTS M J
DE 60326774
E
20090430
MORI T
N
US 7544499
INDEPENDENT CLAIMS are also included for the WO 2004056852
following:
(1) an antiviral polypeptide fragment (II)
comprising at least twenty contiguous amino acids
and spanning one or more of the substitutions or
insertions of (I);
BOYD M R
N
US 7847084
WO 2004056852 A2 UPAB: 20090401
(I) is useful for preparing an antiviral polypeptidepolymer conjugate, useful in treating infection
caused by high mannose envelope virus. C1 is
NOVELTY: An antiviral polypeptide (I) having at
least 70% sequence identity to native cyanovirin-N useful for treating, preventing or mitigating
infection by one or more high mannose envelope
having a fully defined sequence of 101 amino
virus, which involves administering C1 to a patient
acids (S1) as given in the specification, and
having cysteine substitution or insertion at one or who is in need of the treatment, where the
more position chosen from 5, 9-21, 25, 29-40, 45- envelope virus is chosen from immunodeficiency
49, 52, 57, 59-72, 79-91, 96-101, the C-terminus, virus, influenza virus, measles virus, herpes virus
and the N-terminus, or an arginine substitution at 6, marburg virus and ebola virus (claimed)
least four residues chosen from 3, 48, 74, 84 and [CONT.]
99, is new. [CONT.]
(I) enables preparation of an antiviral polypeptidepolymer conjugate (claimed), which is highly pure
and possesses significant antiviral activity, with
reduced toxicity and immunogenicity, and longer
circulation time in vivo relative to native CV-N.
BIOTECHNOLOGY - Preferred Polypeptide: (I)
corresponding to (S1), has a cysteine substitution
or insertion at positions 9-21, 29-40, 45-49, 57, 5972, 79-91 and 96-101, or at positions 10-20, 3139, 46-48, 60-71, 80-90 and 97-100 or preferably
at positions 11, 14, 16, 19, 20, 31, 32, 33, 38, 46,
61, 62, 67, 68, 82 and 83. (I) has one or two
cysteine substitutions or insertions. [CONT.]
US 7267941
N
SNELL M E
455 New polyvalent, primary HIV-1 glycoprotein
DNA vaccines, useful in treating AIDS and in
inducing an immune response
US 7547509
B2
20090616
MX 265551
B
20090401
AU 2003301122
B2
20091126
JP 2011050382
A
20110317
WO 2004050856
A2
20040617
ADVANCED BIOSCIENCE LAB INC
US 20040191269
A1
20040930
ADVANCED BIOSCIENCE LAB
AU 2003298912
A1
20040623
KALYANARAMAN V
EP 1578766
A2
20050928
KEEN T
JP 2006509039
T
20060316
US 7901690
B2
20110308
WO 2004046120
A2
20040603
WO 2004046120 A2 UPAB: 20090130
AU 2003294329
A1
20040615
US 20040214817
A1
20041028
NOVELTY: Composition (A) comprising
diaminotriazoles (I) and carrier, adjuvant or
vehicle.
DETAILED DESCRIPTION: Composition (A)
comprising diaminotriazoles of formula (I) and
carrier, adjuvant or vehicle.
BINCH H
EP 1562589
A2
20050817
R1 = H or Y-R';
DAVIES R J
NO 2005002888
A
20050610
Y = an optionally substituted 1-6C alkylidene
chain, where 1-2 methylene units are optionally
replaced with -O-, -S-, -NR-, -OCO-, -COO- or -CO; or [CONT.]
FORSTER C J
BR 2003016350
A
20050927
GALULLO V
TW 2004013334
A
20040801
GRAY R
JP 2006515313
T
20060525
GREY R
CN 1738615
A
20060222
HENKEL G
KR 2006013480
A
20060210
JAYARAJ A
IN 2005KN01154
A
20061103
LEDEBOER M
US 7279469
US 20080014189
B2
20071009
LEDFORD B
A1
20080117
MESSERSMITH D
NZ 540662
A
20080430
NANTHAKUMAR S
EP 1562589
B1
20090107
PIERCE A C
DE 60325761
E
20090226
SALITURO F G
RU 2350606
C2
20090327
TIAN S
ES 2318189
T3
20090501
WANG J
IN 227666
B
20090116
XU J
AU 2003294329
B2
20100429
MX 2005005223
A1
20100930
IL 168571
A
20101031
US 7902239
WO 2004043445
B2
20110308
A1
20040527
UNIV MASSACHUSETTS
LU S
WO 2004050856 A2 UPAB: 20100107
The nucleic acid and/or protein composition,
pharmaceutical composition, methods are useful
NOVELTY: A nucleic acid composition comprising in treating AIDS and in inducing an immune
sets of nucleic acid molecules, each nucleic acid response, i.e. a protective, a cell-mediated, and/or
molecule encoding a HIV envelope glycoprotein, a humoral immune response.
where each set of nucleic acid molecules encodes
a different type of HIV envelope glycoprotein, or
comprises a primary isolate sequence from a
distinct genetic clade, is new.
BIOTECHNOLOGY - Preferred Composition:
Specifically, the nucleic acid composition
comprises sets of nucleic acid molecules, where
the composition comprises two or more sets, i.e.
sets of nucleic acid molecules, each encoding a
HIV envelope glycoprotein of any of the clades A,
B, C, or E. The nucleic acids comprise DNA
plasmids. The HIV envelope glycoprotein is
gp140, gp160, or gp41, preferably gp120 [CONT.]
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are also included for: [CONT.]
INDEPENDENT CLAIMS are also included for:
WO 2004050856
(1) an isolated protein composition comprising one
or more sets of isolated HIV envelope glycoprotein
molecules, where each molecule in the set
comprises a different type of HIV envelope
glycoprotein, or comprises a primary isolate
sequence from a distinct genetic glade;
US 20040191269
N
US 7901690
(2) a pharmaceutical composition comprising the
nucleic acid or protein composition and a
pharmaceutical excipient; [CONT.]
MARKHAM P
NAIR B
PAL R
WANG S
WHITNEY S C
VERTEX PHARM INC
456 Composition, useful to treat or lessen the
severity of diseases e.g. allergic disorders,
proliferative disorders, autoimmune disorders,
inflammatory disorders and destructive bone AMOST M
disorders, comprises new and known
diaminotriazoles
ARNOST M
457 Micellar composition useful in the treatment of SCHERING-PLOUGH LTD
parasite-infested state e.g. liver fluke and
nematode infection comprises two agents like
WO 2004043445 A1 UPAB: 20090817
(I) are useful for inhibiting FLT-3, FMS, c-KIT,
PDGFR, JAK, AGC sub-family of protein kinases
(e.g., PKA, PDK, p70S6K-l and -2, and PKB),
CDK, GSK, SRC, ROCK, and/or SYK kinase
activity (preferably FLT-3, c-KIT, JAC-3 or PDK-1)
activity and also treating or lessening the severity
of a disease i.e. [CONT.]
PHARMACEUTICALS - Preferred Composition:
(A) further comprises an additional therapeutic
agent (a chemotherapeutic or anti-proliferative
agent, a treatment for Alzheimer's disease, a
treatment for Parkinson's disease, an agent for
treating multiple sclerosis (MS), a treatment for
asthma, an agent for treating schizophrenia, an
anti-inflammatory agent, an immunomodulatory or
immunosuppressive agent, [CONT.]
Composition (A) comprising diaminotriazoles of
formula (I) and carrier, adjuvant or vehicle.
WO 2004046120
US 20040214817
N
R1 = H or Y-R';
US 7279469
Y = an optionally substituted 1-6C alkylidene
chain, where 1-2 methylene units are optionally
replaced with -O-, -S-, -NR-, -OCO-, -COO- or -CO; or
R2 = -(T)nAr1 or -(T)nCy1; or
US 20080014189
US 7902239
NR1R2 = an optionally substituted 5-8 membered
monocyclic or 8-12 membered bicyclic optionally
saturated ring having 0-3 additional heteroatoms
(N, O or S) (optionally substituted with x
occurrences of Q-Rx); either [CONT.]
For the treatment and prevention of parasiteinfested state e.g. liver fluke and nematode
infection or infestation in mammals (e.g. cattle,
The formulation provides broad-spectrum
PHARMACEUTICALS - Preferred Formulation:
protection against endo- and ecto-parasites,
(C1) Comprises (g/l): benzimidazole (preferably
through efficient delivery of water-insoluble active triclabendazole) (120 - 300, preferably 180 - 240,
WO 2004043445
US 20060121072
N
457 Micellar composition useful in the treatment of
parasite-infested state e.g. liver fluke and
SCHERING-PLOUGH PTY LTD
nematode infection comprises two agents like
benzimidazole and macrocyclic lactone,
surfactant, water-miscible solvent and water
SHEPHERD S
A1
20040603
NOVELTY: An aqueous micellar formulation (C1)
comprises two active agents (A1 and A2), and
additionally (g/l): surfactant(s) (100 - 400,
preferably 100 - 300), water-miscible solvent(s)
(200 - 750, preferably 300 - 650) and water (50 350, preferably 150). (A1) Is water insoluble
benzimidazole, salicylanilide, their derivatives or
salts. (A2) Is macrocyclic lactone, its derivative or
salt. [CONT.]
EP 1560572
A1
20050810
BR 2003016187
A
20050927
TW 2004023871
A
20041116
JP 2006508108
T
20060309
MX 2005005046
A1
20051201
US 20060121072
A1
20060608
KR 2005090385
A
20050913
ZA 2005003758
A
20061129
JP 2007008963
A
20070118
IN 2005CN00865
A
20070629
NZ 540589
A
20080328
AU 2003275779
B2
20090205
IN 219662
B
20080704
TW 314848
B1
20090921
JP 4643990
B2
20110302
FR 2846559
WO 2004042063
A1
20040507
A1
20040521
AU 2003292310
A1
20040607
EP 1556489
US 20060116341
A1
20050727
A1
20060601
JP 2006520319
T
20060907
US 20090124592
EP 1556489
A1
20090514
B1
20110126
DE 60335892
E
20110310
MUSC FOUND RES DEV
WO 2004045520
A2
20040603
WO 2004045520 A2 UPAB: 20100408
UNIV COLORADO
AU 2003298650
A1
20040615
EP 1569685
A2
20050907
NOVELTY: A composition (C1) comprising a
construct, where the construct comprises
complement receptor 2 (CR2) and a modulator of
complement activity.
ACTIVITY: Cytostatic; Antiasthmatic;
Antiinflammatory; Dermatological;
Immunosuppressive; Antiarthritic; Antirheumatic;
Vasotropic; Antidiabetic; Neuroprotective;
Antiallergic; Gastrointestinal-Gen; Antiulcer;
Antiviral [CONT.]
JP 2006512325
T
20060413
CN 1756560
A
20060405
US 20080267980
A1
20081030
AU 2003298650
B2
20100311
CN 100594037
C
20100317
AU 2010202455
A1
20100701
JP 2011006478
A
20110113
EP 2292259
A2
20110309
458 Composition containing nucleic acid encoding CNRS CENT NAT RECH SCI
a 5-HT4 receptor, useful for treatment and
CENT NAT RECH SCI
prevention of obsessional behavior, e.g.
anorexia or drug dependence, also screening
for drugs for treating such behavior
459 Composition useful for treating cancer, viral
infection, bacterial infection, parasitic
infection, inflammatory conditions, comprises
construct having complement receptor 2 and
modulator of complement activity
AU 2003275779
For the treatment and prevention of parasiteinfested state e.g. liver fluke and nematode
infection or infestation in mammals (e.g. cattle,
sheep, goats, pigs and horses) (claimed).
FR 2846559 A1 UPAB: 20060121
The composition is used to treat and/or prevent
obsessive behavioral disorders, e.g. anorexia,
NOVELTY: A pharmaceutical composition
comprising a nucleic acid (I) that encodes a 5-HT4 bulimia and drug dependence, optionally where
receptor (II), or its equivalent, for treatment and/or associated with stress. Ligands (agonists, reverse
agonists or antagonists) of (II) are used similarly.
prevention of a disorder associated with
obsessional behavior, is new.
DETAILED DESCRIPTION: An INDEPENDENT
CLAIM is also included for a method of identifying
compounds (III) suitable for treating a disorder
associated with obsessional behavior. [CONT.]
(C1) is useful for treating a condition affected by
complement in a subject which involves
administering (C1) to the subject. The conditions
is cancer chosen from lymphomas (Hodgkins and
non-Hodgkins), B cell lymphoma, T cell
lymphoma, myeloid leukemia, leukemias, mycosis
fungoides, carcinomas, carcinomas of solid
tissues, squamous cell carcinomas,
adenocarcinomas, sarcomas, gliomas, blastomas,
[CONT.]
The formulation provides broad-spectrum
protection against endo- and ecto-parasites,
through efficient delivery of water-insoluble active
agents, by topical administration rather than oral
drenching. The formulation is stable and gives
beneficial effects even through single application.
PHARMACEUTICALS - Preferred Formulation:
(C1) Comprises (g/l): benzimidazole (preferably
triclabendazole) (120 - 300, preferably 180 - 240,
especially 240), macrocyclic lactone (preferably
ivermectin) (7.5 - 20, preferably 15),
polyoxyethylene (20) sorbitan monolaurate (150 250), diethylene glycol monobutyl ether (450 550), polyethylene glycol-200 (20 - 50), sodium
dodecyl sulfate (10 - 30) and water (100 - 200,
preferably 150) [CONT.]
PHARMACEUTICALS - Preferred Composition: (I)
encodes a mammalian, specifically human,
receptor and is present in a (non-)viral vector.
Specified vectors are type 2 adeno-associated
virus; lentiviruses of various pseudotypes, and
vectors based on feline immune deficiency virus of
'foamy virus'. (I) is under control of the promoter of
the gene that encodes the dopamine capture
transporter, and is expressed in the accumbent
nucleus, amygdala, hippocampus or
hypothalamus [CONT.]
BIOTECHNOLOGY - Preferred Composition: In
(C1), the construct is a fusion protein. The fusion
protein inhibits complement. The modulator of
complement activity comprises a complement
inhibitor which is a decay accelerating factor
(DAF) which comprises 518 or 495 amino acids
sequence fully defined in the specification. The
complement inhibitor is human CD59 which
comprises 330 or 334 amino acid sequence fully
defined in the specification [CONT.]
An INDEPENDENT CLAIM is also included for a
method of identifying compounds (III) suitable for
treating a disorder associated with obsessional
behavior.
WO 2004043445
US 20060121072
FR 2846559
US 20060116341
US 20090124592
N
WO 2004045520
US 20080267980
N
EP 2292259
WO 2004042360
US 20040115131
A3
20110323
A2
20040521
WO 2004042360 A2 UPAB: 20090401
A1
20040617
NOVELTY: Determining (M1) the metabolism of at (a) diagnosing and treating insulin resistance or
least one sugar or fatty acid involves:
diabetes mellitus, high-fat diet-induced obesity,
wasting disorders, hypoglycemia and glycogen
storage device in e.g. human, rodent, primate,
hamster, guinea pig, dog and pig;
AU 2003291731
A1
20040607
(a) administering at least one composition
comprising at least one 2H-labeled sugar or fatty
acid;
(b) for identifying the effect of a drug agent which
can be then manufactured for therapeutic use;
EP 1558293
A2
20050803
(c) for isolating deuterated water molecule
(2H2O); [CONT.]
JP 2006505777
T
20060216
US 7504233
B2
20090317
(b) obtaining at least one bodily tissues or fluids;
and
(c) detecting incorporation of 2H from the labeled
sugars and fatty acids into water.
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are included for: [CONT.]
SG 152922
A1
20090629
AU 2003291731
B2
20090910
US 20100041082
A1
20100218
JP 4611025
B2
20110112
US 7910323
WO 2004024097
B2
20110322
GENENTECH INC
A2
20040325
WO 2004024097 A2 UPAB: 20090629
CHIU H
AU 2003291625
A1
20040430
NOVELTY: An isolated PRO polypeptide having
80 % amino acid sequence identity to one of 241
amino acid sequences (I), e.g. of 360 or 531
amino acids, fully defined in the specification, is
new.
The PRO polypeptide, an agonist or antagonist of
the polypeptide, or an antibody that binds to the
polypeptide is useful for diagnosing and treating a
B cell related disorder, e.g. X-linked infantile
hypogammaglobulinemia, polysaccharide antigen
unresponsiveness, selective IgA deficiency,
selective IgM deficiency, selective deficiency of
IgG subclasses, immunodeficiency with hyper
IgM, transient [CONT.]
CLARK H
EP 1578364
A2
20050928
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are also included for the following:
[CONT.]
DENNIS K
JP 2006515165
T
20060525
FONG S
US 20070010434
US 20090155263
A1
20070111
SCHOENFELD J R
A1
20090618
WOOD W I
AU 2003291625
B2
20091008
460 Determining metabolism of sugar or fatty acids UNIV CALIFORNIA
for diagnosis of e.g. diabetes involves
administering a composition comprising
deuterium labeled sugar or fatty acid and
detecting their incorporation into bodily
tissues or fluids
461 New PRO polypeptide, useful for diagnosing
and treating a B cell related disorder, e.g.
Burkitt's lymphoma, rheumatoid arthritis,
autoimmune mediated hemolytic anemia,
myasthenia gravis or ankylosing spondylitis
WU T D
462 New optimized Fc variant antibody useful for
diagnosing or treating diseases (e.g. cancer,
inflammation or cardiovascular diseases), in
research and in agricultural or industrial
applications
XENCOR
XENCOR INC
The method is used for:
The metabolism determination facilitates clinical
management of patients, and subsequently
diagnosis of sugar and fats metabolism related
diseases. The method combines simplicity of oral
glucose tolerance test and fat tolerance test with
improved precision, accuracy and metabolic
specificity of deuterium tracing, at high throughput
in inexpensive manner.
PHARMACEUTICALS - Preferred Method: (M1)
Additionally involves: (a) partially purifying
(preferably isolating) the water; (b) measuring 2H
incorporation or incorporation ratio into at least
one chemical composition; (c) measuring
endogenous glucose production; (d) measuring
the proportion of labeled glucose stored in tissue
glycogen relative to the labeled sugar
administered; [CONT.]
INDEPENDENT CLAIMS are included for:
WO 2004042360
(a) a kit for determining the metabolism of a sugar
or fatty acid in an individual comprising at least
one labeled sugar and instructions for use of the
kit;
(b) an information storage device (including
computer disc such as compact disc, digital video
disc and magnetic disc or report printed on paper,
plastic and microfiche) comprising data obtained
by (M1); and [CONT.]
US 20040115131
US 7504233
N
US 20100041082
US 7910323
N
WO 2004024097
A9
20100121
AU 2010200063
A1
20100128
JP 2011050389
A
20110317
WO 2004029207
A2
20040408
WO 2004029207 A2 UPAB: 20060121
US 20040132101
A1
20040708
NOVELTY: An antibody comprising an Fc variant
portion having an amino acid modification in the
Fc region of the parent Fc polypeptide, where the
Fc variant modulates binding to an FcgammaR
compared to the parent Fc polypeptide, is new.
AU 2003279719
A1
20040419
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are also included for the following:
US 20050054832
A1
20050310
(1) a pharmaceutical composition comprising the
above antibody and a pharmaceutical carrier; and
[CONT.]
EP 1553975
A2
20050720
BR 2003014814
A
20050809
JP 2006512407
T
20060413
CN 1705491
A
20051207
IN 2005MN00309
A
20051007
US 20060160996
A9
20060720
BIOTECHNOLOGY - Preparation: The PRO
polypeptide is prepared by standard recombinant
methods. Preferred Vector: The vector is operably
linked to control sequences recognized by a host
cell transformed with the vector. Preferred Host
Cell: The host cell is a Chinese hamster ovary cell,
an Escherichia coli, or a yeast cell. Preferred
Chimeric Molecule: The heterologous amino acid
sequence is an epitope tag sequence or an Fc
region of an immunoglobulin [CONT.]
INDEPENDENT CLAIMS are also included for the WO 2004024097
following:
(1) an isolated nucleic acid having at least 80%
sequence identity to: (a) a nucleotide sequence
encoding any one of the polypeptide sequences of
(I); (b) any one of 265 nucleotide sequences (II),
e.g. 972 bp, fully defined in the specification; or (c)
any one of the full-length coding sequences of (II);
US 20070010434
US 20090155263
(2) a vector comprising the nucleic acid of (1);
[CONT.]
The composition and methods are useful for
diagnosing or treating a variety of conditions
including cancer, inflammation and cardiovascular
diseases. The antibody may also be used in
research and in agricultural or industrial
applications.
BIOTECHNOLOGY - Preferred Antibody: The
modulation is an increase in affinity of the
antibody to the FcgammaR. The Fc variant portion
comprises at least one substitution at a position
corresponding to a position of the human
sequence selected from 234, 235, 239, 240, 241,
243, 244, 245, 247, 262, 263, 264, 265, 266, 267,
269, 296, 297, 298, 299, 313, 325, 326, 327, 328,
329, 330, 332, 333 and 334. [CONT.]
INDEPENDENT CLAIMS are also included for the WO 2004029207
following:
(1) a pharmaceutical composition comprising the
above antibody and a pharmaceutical carrier; and
US 20040132101
(2) a method of treating a mammal in need of
treatment, comprising administering an antibody
cited above.
US 20060160996
US 20050054832
US 20070003546
US 20070053901
US 20070160597
US 20070202098
US 20070219133
US 20070224189
US 20070224192
N
VITAK BV
463 Use of vitamin K or its derivative optionally
together with vitamin D or its derivative for the
NATTOPHARMA ASA
treatment of e.g. hypertension, stroke
PRONOVA BIOCARE AS
464 Processing of mixture of fat or oil with
environmental pollutants e.g. cosmetics, by
PRONOVA BIOPHARMA NORGE AS
adding volatile working fluid of fatty acid ester,
fatty acid amide and, free fatty acid, and
stripping to separate pollutant from mixture
PRONOVA BIOPHARMA NORGE
KR 2005071523
A
20050707
US 20070003546
US 20070053901
US 20070160597
US 20070202098
US 20070219133
US 20070224189
US 20070224192
US 7317091
US 20080057056
A1
20070104
A1
20070308
A1
20070712
A1
20070830
A1
20070920
A1
20070927
A1
20070927
B2
20080108
A1
20080306
RU 2325186
C2
20080527
KR 2008106371
A
20081204
AU 2003279719
B8
20090108
AU 2009200518
A1
20090305
AU 2003279719
B2
20081211
US 7662925
B2
20100216
KR 960560
B1
20100603
IL 167685
A
20100517
KR 980065
B1
20100903
JP 4580340
B2
20101110
EP 2298805
WO 2004019923
A2
20110323
A1
20040311
AU 2003264150
A1
20040319
EP 1556025
A1
20050727
US 20050261257
A1
20051124
US 20060166948
EP 1728507
EP 1556025
EP 1728507
WO 2004007654
A1
20060727
A1
20061206
B1
20110223
B1
20110316
A1
20040122
WO 2004007654 A1 UPAB: 20091106
AU 2003242925
A1
20040202
NOVELTY: Processing of mixture (2) comprising
fat or oil containing environmental pollutant,
involves adding volatile working fluid containing
fatty acid ester, fatty acid amide, free fatty acid
and/or hydrocarbon to the mixture, and subjecting
to stripping process to separate pollutant from the
mixture together with the volatile working fluid.
[CONT.]
EP 1523541
A1
20050420
JP 2005532460
T
20051027
US 20050256326
A1
20051117
CN 1668728
A
20050914
JP 3905538
B2
20070418
AU 2003242925
B2
20070201
US 20080234375
A1
20080925
CN 100475939
C
20090408
CN 101554210
A
20091014
US 7317091
US 20080057056
US 7662925
WO 2004019923 A1 UPAB: 20060203
In the manufacture of a medicament or nutritional
formulation for treating or preventing age related
NOVELTY: In the manufacture of a medicament or stiffening of arteries resulting from calcification of
the tunica media; hypertension, left ventricular
nutritional formulation for the treatment of e.g.
hypertension, a composition comprising vitamin K hypertrophy, congestive heart failure, myocardial
or its derivative optionally together with vitamin D infarction, stroke, Monckeberg's sclerosis or
coronary heart disease; [CONT.]
or its derivative is used.
The composition prevents or treats a reduction in
elasticity and distensibility of the vasculature and
thus lowers blood pressure and prevents
cardiovascular disease.
PHARMACEUTICALS - Preferred Composition:
(c1) comprises: vitamin K (0.5 - 1.5 mg), vitamin D
(5 - 10 microg), calcium (450 - 550 mg), zinc (7 12 mg) and magnesium (100 - 200 mg); or vitamin
K1 (1 mg), vitamin D3 (8 microg), calcium (500
mg), zinc (10 mg) and magnesium (150 mg).
Preferred Components: Vitamin K is vitamin K1
(phylloquinone) or vitamin K2 (menaquinone)
(preferably phylloquinone). [CONT.]
INDEPENDENT CLAIMS are included for the
WO 2004019923
following:
(1) composition (c1) comprising vitamin K or its
derivative; at least one additional component
selected from polyphenol, vitamin C, vitamin E
(tocopherol and/or tocotrienol), L-arginine,
phytosterol, antihypertensive peptide, soluble fiber
(preferably guar and pectin), omega-3, omega-6
and/or omega-9 fatty acids, carnitine, taurine,
coenzyme Q10, creatine, folic acid, folate,
magnesium, potassium, vitamin B6 or vitamin
B12; and optionally vitamin D or its derivative; and
[CONT.]
US 20050261257
The volatile working fluid, easily and effectively
removes the environmental pollutants present in
the fat or oil mixture. The method enables to
decrease the amount of dioxin in the fish oil,
chlorinated organic pesticides, DDT, toxaphenes
and/or polychlorinated biphenyls. High quality oil
product is obtained using the working fluid.
ORGANIC CHEMISTRY - Preferred Components:
The volatile working fluid is equally or less volatile
than the environmental pollutants that are to be
separated from fat or oil mixture. The volatile
working fluid is constituted by free fatty acids
comprised in the fat or oil. The acid, ester or
amide of fatty acid and free fatty acids are
obtained from vegetable, microbial and animal fat
or oil, preferably marine oil [CONT.]
Processing of mixture (2) comprising fat or oil
WO 2004007654
containing environmental pollutant which is edible
or used in cosmetics to decrease amount of
environmental pollutants, involves adding volatile
working fluid containing fatty acid ester, fatty acid
amide, free fatty acid and/or hydrocarbon to the
mixture, and subjecting to stripping process to
separate pollutant from the mixture together with
the volatile working fluid. [CONT.]
US 20050256326
US 20080234375
Y
EP1728507B1
Y
EP2295529A2
US 20060166948
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are included for the following:
(1) composition (c1) comprising vitamin K or its
derivative; [CONT.]
For decreasing the amount of environmental
pollutants in a mixture comprising a fat or oil which
is edible or for use in cosmetics, health sublimate,
pharmaceutical, animal feed product such as fish
feed product, cosmetic product and marine oil
product (claimed).
US 20100104657
US 7718698
US 7732488
US 20100233281
US 20100267829
465 New purified molecule that binds specifically
to B7-DC polypeptides on a cell, useful for
manufacturing a medicament having a tumor
antigen for the treatment of a tumor in a
mammal
EP 1523541
B1
20091230
DE 60330778
E
20100211
EP 2169038
US 20100104657
US 7718698
US 7732488
US 20100233281
US 20100267829
A1
20100331
A1
20100429
B2
20100518
B2
20100608
A1
20100916
A1
20101021
NO 329023
B1
20100726
20110316
MAYO FOUND MEDICAL EDUCATION&RES
EP 2295529
WO 2004007679
A2
A2
20040122
WO 2004007679 A2 UPAB: 20091214
NGUYEN L T
US 20040014207
A1
20040122
NOVELTY: A purified molecule (I) that binds
specifically to B7-DC polypeptides on a cell,
wherein the binding results in cross-linking of a
plurality of the B7-DC polypeptides, and wherein
the molecule can potentiate an immune response
upon administration to a mammal, is new.
PEASE L R
AU 2003253897
A1
20040202
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are also included for the following:
[CONT.]
RADHAKRISHNAN S
EP 1543037
US 20050249737
US 7052694
A2
20050622
A1
20051110
B2
20060530
AU 2003253897
A8
20051103
US 7390888
US 20080193467
US 20100009438
US 20100015163
US 20110065178
WO 2004000351
B2
20080624
A1
20080814
A1
20100114
A1
20100121
A1
20110317
A1
20031231
US 20040005338
A1
20040108
AU 2003242742
A1
20040106
EP 1513552
A1
20050316
BR 2003011995
A
20050405
KR 2005020790
A
20050304
MX 2004011210
A1
20050301
CN 1662253
A
20050831
JP 2006502979
T
20060126
ZA 2004008709
A
20060125
IN 2004CN02868
A
20060217
NZ 537002
A
20060630
RU 2322257
C2
20080420
AU 2003242742
B2
20090430
MX 269289
B
20090818
EP 1513552
B1
20101201
JP 4598519
B2
20101215
DE 60335186
E
20110113
US 20110070267
A1
20110324
RODRIGUEZ M
URE D
CYTOS BIOTECHNOLOGY AG
466 New compositions comprising a virus-like
particle (VLP), an immunostimulatory
BACHMANN M F
substance bound to the VLP, and an antigen
mixed with the VLP, useful for enhancing
immune response or for treating e.g. tumors or
chronic viral diseases
RENNER W A
The methods and compositions of the present
invention are useful for the manufacture of a
medicament for treating a tumor in a mammal,
wherein the medicament comprises a tumor
antigen (claimed).
BIOTECHNOLOGY - Preferred Purified Molecule:
(I) is a polypeptide that is an antibody, preferably
an IgM antibody that has the epitope specificity of
sHIgM12 or is sHIgM12. The antibody is also a
cross-linked, multivalent IgG, IgA, IgD, or IgE
complex. The molecule is also a polypeptide
immobilized on a solid substrate, wherein the
immobilized polypeptide is PD-1. [CONT.]
INDEPENDENT CLAIMS are also included for the WO 2004007679
following:
(1) a purified molecule that binds specifically to B7DC polypeptides on a cell, wherein the binding
results in cross-linking of a plurality of the B7-DC
polypeptides, and wherein dendritic cells
contacted with the molecule exhibit at least one
characteristic selected from prolonged longevity,
increased NF-kB expression, increased NP-kB
[CONT.]
US 20040014207
N
US 20050249737
US 7052694
US 7390888
US 20080193467
US 20100009438
US 20100015163
US 20110065178
WO 2004000351 A1 UPAB: 20090817
The composition or the vaccine is useful in the
manufacture of a pharmaceutical for the treatment
of a disorder or disease such as allergies, tumors,
NOVELTY: A composition for enhancing an
immune response in an animal comprising a virus- chronic diseases and chronic viral diseases. The
composition is also useful for enhancing an
like particle, an immunostimulatory substance
immune response in an animal (all claimed). Mice
bound to the virus-like particle, and an antigen
were subcutaneously primed with 5 microg of bee
mixed with the virus-like particle.
venom either alone or mixed with 50 microg VLP
alone or loaded and packaged, with CpGDETAILED DESCRIPTION: INDEPENDENT
oligonucleotides, or 50 microg VLP mixed with 20
CLAIMS are also included for the following:
nm CpG-oligonucleotides [CONT.]
(1) a method for enhancing an immune response
in an animal by introducing into the animal a
composition defined above; [CONT.]
BIOTECHNOLOGY - Preferred Composition: The
immunostimulatory substance is a toll-like
receptor activating substance, or a cytokine
secretion inducing substance. The toll-like
receptor activating substance is selected from
immunostimulatory nucleic acids, peptidoglycans,
lipopolysaccharides, lipoteichoic acids,
imidazoquinoline compounds, flagellines,
lipoproteins, immunostimulatory organic
molecules, unmethylated CpG-containing
oligonucleotides, and a mixture of these [CONT.]
INDEPENDENT CLAIMS are also included for the WO 2004000351
following:
(1) a method for enhancing an immune response
in an animal by introducing into the animal a
composition defined above;
(2) a vaccine comprising a composition above
together with a pharmaceutical diluent, carrier or
excipient; and
(3) a method of immunizing or treating an animal
comprising administering to the animal the
vaccine of (2).
US 20040005338
US 20110070267
N
NOVARTIS AG
467 Composition useful for treatment of e.g.
diabetes and metabolic syndrome comprises
NOVARTIS NUTRITION AG
viscous soluble fiber and viscosity-lowering
proteins e.g. wheat protein, collagen or casein
468 Identifying a candidate Chk1 pathway
modulating agent for treating e.g., cancer,
comprises contacting an assay system
comprising a MCHK polypeptide or nucleic
acid with a test agent and detecting a test
agent-biased activity
WO 2003105882
A1
AU 2003242692
A1
20031231
NESTEC SA
EP 1515741
A1
20050323
AURIO N
JP 2005534667
T
20051117
BEER M
ZA 2004009528
A
20060125
US 20060099324
A1
20060511
AU 2003242692
B2
20070301
JP 2010254702
A
20101111
EP 1515741
WO 2004004785
B1
20110323
A1
20040115
WO 2004004785 A1 UPAB: 20050528
AU 2003251799
A1
20040123
US 20110059066
A1
20110310
NOVELTY: Identifying a candidate Chk1 pathway
modulating agent comprises:
(a) providing an assay system comprising a
MCHK polypeptide or nucleic acid;
EXELIXIS INC
20031224
WO 2003105882 A1 UPAB: 20060203
In the manufacture of medicament and nutritional
composition in prevention or treatment of
NOVELTY: A composition (C1) comprises at least metabolic syndrome, diabetes; and for lowering
blood cholesterol level (claimed). Also in treatment
one viscous soluble fiber and at least one
of hypercholesterolemia, obesity, hyperlipidemia,
viscosity-lowering protein.
coronary heart disease, arteriosclerosis, colon
diverticulum, colon cancer, hypertension, Crohn's
disease, irritable bowel syndrome and
inflammatory bowel [CONT.]
The composition has viscosity less than 500
mPa.s at room temperature. As the composition is
convenient to administer without increasing the
glucidic value, it can be self-administered or under
medical supervision. The composition is safe to
consume and be continued for a long period.
The method is useful for identifying a candidate
Chk1 pathway-modulating agent (claimed) for
preparing a composition for diagnosing or treating
e.g., cancer.
(c) detecting a test agent-biased activity, and a
difference between the test agent-biased activity
and the reference activity. [CONT.]
WO 2003106656 A2 UPAB: 20090311
THRASOS INC
WO 2003106656
A2
20031224
THRASOS THERAPEUTICS
AU 2003247551
A1
20031231
CARLSON W D
EP 1572950
A2
20050914
KECK P C
JP 2006507804
T
20060309
US 20060259996
US 7482329
A1
20061116
B2
20090127
AU 2003247551
B2
20100715
AU 2010202764
A1
20100722
US 20110055942
A1
20110303
JP 4654029
B2
20110316
WO 2003097647
A1
20031127
WO 2003097647 A1 UPAB: 20090407
AU 2003243226
A1
20031202
NOVELTY: A vitamin-mitomycin conjugate (I) is
new.
EP 1504010
A1
20050209
DETAILED DESCRIPTION: A vitamin-mitomycin
conjugate of formula B-L-X (I) is new.
ENDOCYTE INC
470 New vitamin-mitomycin conjugate useful for
eliminating population of pathogenic cells and
LEAMON C P
for treating cancer e.g. carcinoma, leukemia
and sarcoma
VLAHOV I R
INDEPENDENT CLAIMS are included for the
WO 2003105882
following:
(1) use of the protein to modulate viscosity of a
composition containing at least one viscous
soluble fiber(s), where the protein is at least one
of wheat protein, egg protein, collagen, whey
protein, casein, soy protein, pea protein, muscle
protein, gluten, fibrillar protein, silk protein or their
hydrolysates; and [CONT.]
US 20060099324
BIOTECHNOLOGY - Preferred Method: Identifying
a candidate Chk1 pathway modulating agent
further comprises: (1) administering the candidate
Chk1 pathway modulating agent to a model
system comprising cells defective in Chk1
function; and (2) detecting a phenotype change in
the model system that indicates that indicates the
Chk1 function is restored. The model system is a
mouse model with defective Chk1 function
[CONT.]
Identifying a candidate Chk1 pathway modulating WO 2004004785
agent comprises:
(a) providing an assay system comprising a
MCHK polypeptide or nucleic acid;
(b) contacting the assay system with a test agent,
where the system provides a reference activity
except in the presence of the test agent; and
US 20110059066
BIOTECHNOLOGY - Preparation: Preparing a
compound, involves culturing a cell containing (III)
under conditions that provide for expression of the
compound and recovering the expressed
compound (claimed). Preferred Compound: (I)
modulates signal transduction across a membrane
of a cell that expresses a tissue differentiation
factor receptor. Preferred Vector: (III) further
comprises a promoter operably linked to the
nucleic acid molecule [CONT.]
A tissue differentiation factor related peptides
WO 2003106656
(TDFRP) compound (I) comprising an amino acid
sequence chosen from 208 sequences (S1) such
as Cys-Phe-Arg-Asp-Leu-Gly-Trp-Gln-Asp-Trp- IleIle-Ala-Pro-Cys, Glu-Cys-Arg-Asp-Leu-Gly-Trp-GlnAsp-Trp-Cys, Cys-Arg-Asp-Leu-Gly-Trp-Gln-AspTrp-Ile-Ile-Ala-Pro-Cys, Cys-Leu-Asn-Ser-Tyr-MetAsn-Ala-Thr-Asn-His-Ala-Cys, Cys-Phe-Ile-AsnPro-Glu-Thr-Val-Pro-Lys-Cys, Cys-Tyr-Phe-AspAsp-Ser-Ser-Asn-Val-Ile-Cys-Lys-Lys, Cys-TyrPhe-Asp-Asp-Ser-Ser-Asn-Val-Ile-Cys-Lys, etc
[CONT.]
US 20060259996
US 7482329
ORGANIC CHEMISTRY - Preparation (Claimed):
Preparation of conjugate of formula B'-L1-X
involves: (a) forming a thiosulfonate intermediate
of formula B'-(L'1)nSSO2R or an intermediate of
formula X-(L')nSSO2R; and (b) reacting the
thiosulfonate intermediate with a compound of
formula X-(L')n'-SH or B'-(L'1)n'-SH respectively.
B' = vitamin or vitamin-receptor-binding analog or
its derivative; [CONT.]
A vitamin-mitomycin conjugate of formula B-L-X (I) WO 2003097647
is new.
B = vitamin or its analog or derivative that binds to
a surface accessible vitamin receptor which is
uniquely expressed, overexpressed or
preferentially expressed by a population of
pathogenic cells;
L = cleavable linker; and
US 20050165227
Y
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are included for the following:
(1) use of the protein to modulate viscosity of a
composition containing at least one viscous
soluble fiber(s), where the protein is at least one
of wheat protein, egg protein, collagen, whey
protein, casein, soy protein, pea protein, muscle
protein, gluten, fibrillar protein, silk protein or their
hydrolysates; and [CONT.]
(b) contacting the system with a test agent, where
the system provides a reference activity except in
the presence of the test agent; and
469 Tissue differentiation factor related peptides
(TDFRP), polynucleotides encoding TDFRP
and variants, analogs, homologs, or their
fragments, useful for treating renal disease,
stroke, regeneration of muscle, dendritic
tissue
PHARMACEUTICALS - Preferred Components:
The viscous soluble fiber (1 - 10 wt.%) is at least
one of gum, pectin, beta-glucan, mucilage or
carrageenan. The gum is selected from konjac
gum, locust bean gum, tara bean gum, gum
tragacanth, karaya gum, xanthan gum, arabic
gum, guar gum and gellan gum. The ratio of fiber
to protein is 0.01:1 - 20:1.
(I) is useful for manufacture of a medicament for
treatment of a tissue differentiation factorNOVELTY: A tissue differentiation factor related
peptides (TDFRP) compound, and polynucleotides associated disorder. (I) is useful for identifying a
encoding the compound and its variants, analogs, compound that binds to (I) which involves
contacting the compound with (I) and determining
homologs, or fragments, where (I) is useful for
whether the compound binds to (I). (I) is useful for
treating a tissue differentiation factor-associated
treating or preventing a tissue differentiation factor
disorder. [CONT.]
associated disorder which involves administering
(I) to a subject (human) in which such treatment or
prevention is desired [CONT.]
For selectively eliminating a population of
pathogenic cells in a host animal harboring the
population of cells (claimed); for killing or inhibiting
the proliferation of tumor cell types and other
types of pathogenic cells overexpressing vitamin
receptors; for treating cancer e.g. carcinoma,
sarcoma, lymphoma, Hodgkin's disease,
melanoma, Burkitt's lymphoma, nasopharyngeal
carcinoma, leukemia and myeloma [CONT.]
The conjugate exhibits high binding affinity to
receptors on cancer cells or other pathogenic
cells. The conjugates can bind to soluble vitamin
receptors in the serum resulting in prolonged
circulation of the conjugates relative to
unconjugated mitomycin.
N
(c) detecting a test agent-biased activity, where a
difference between the test agent-biased activity
and the reference activity identifies the test agent
as a candidate Chk1 pathway modulating agent.
[CONT.]
N
US 20110055942
US 7910594
N
EP1515741B1
471 New antisense oligonucleotides
complementary to a region of kinase
suppressor of Ras (KSR) RNA which inhibit
KSR expression, useful for treating or
inhibiting progression of cancer, e.g.
pancreatic, lung, skin, or bladder cancer
472 New composition comprising a nucleic acid,
an endosomolytic spermine that includes a
cholestorol or fatty acid, and a targeting
spermine, useful or treating, stabilizing or
preventing a disease or disorder in a mammal
KR 2004106547
A
20041217
US 20050165227
A1
20050728
JP 2005531564
T
20051020
B = vitamin or its analog or derivative that binds to
a surface accessible vitamin receptor which is
uniquely expressed, overexpressed or
preferentially expressed by a population of
pathogenic cells;
L = cleavable linker; and [CONT.]
EP 1504010
B1
20090325
DE 60326833
E
20090507
EP 2060272
EP 2060272
A2
20090520
A3
20090527
ES 2324708
T3
20090813
US 7910594
WO 2003101386
B2
20110322
SLOAN KETTERING INST CANCER RES
A2
20031211
KOLESNICK R N
AU 2003238804
A1
20031219
XING H R
US 20050037455
A1
20050217
EP 1513859
A2
20050316
JP 2005534295
T
20051117
AU 2003238804
A8
20051103
US 20060252037
US 7301017
US 20080096840
US 7528116
US 20090143320
EP 1513859
A1
20061109
B2
20071127
A1
20080424
B2
20090505
A1
20090604
B1
20100714
DE 60333365
E
20100826
JP 4646625
B2
20110309
NUCLEONICS INC
WO 2003093449
A2
20031113
WO 2003093449 A2 UPAB: 20090706
ALNYLAM PHARM INC
AU 2003266014
A1
20031117
SATISHCHANDRAN C
EP 1549352
A2
20050706
NOVELTY: A composition comprising a nucleic
acid, an endosomolytic spermine that includes a
cholestorol or fatty acid, and a targeting spermine
that includes a ligand for a cell surface molecule,
is new.
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are included for the following:
JP 2006508896
T
20060316
US 20060084617
US 20090163436
A1
20060420
A1
20090625
AU 2003266014
B2
20090514
JP 2010235618
A
20101021
EP 2298358
A1
20110323
X = a mitomycin compound or its analog or
derivative. [CONT.]
WO 2003101386 A2 UPAB: 20060203
Compounds which inhibit the expression of
mammalian KSR protein are useful for treating or
inhibiting progression of cancer, including
NOVELTY: An oligonucleotide (I) which is
pancreatic, lung, skin, urinary tract, bladder, liver,
substantially complementary to a region of KSR
RNA, and which inhibits the expression of KSR, is thyroid, colon, intestinal, breast, ovarian, stomach,
head and neck, esophageal or prostate cancer,
new.
leukemia, lymphoma, and neuroblastoma
(claimed). [CONT.]
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are also included for the following:
(1) an antisense oligonucleotide comprising: (a) a
sequence substantially complementary to the CA1
region of KSR, or to nucleotides 124-243 (SEQ ID
NO: 1) of the coding sequence of KSR, or its
portion; or (b) a sequence of SEQ ID NO: 6, 7 or 8
(not given in the given in the specification);
[CONT.]
BIOTECHNOLOGY - Preferred Sequences: (I) is
substantially complementary to a nucleic acid
encoding mammalian or human KSR. The
oligonucleotide may be substantially
complementary to a translation initiation site, 5'
untranslated region, coding region or 3'
untranslated region of mRNA encoding
mammalian KSR. The oligonucleotide is labeled
with a detectable label selected from enzymes,
ligands, chemicals which fluoresce and
radioactive elements [CONT.]
INDEPENDENT CLAIMS are also included for the WO 2003101386
following:
(1) an antisense oligonucleotide comprising: (a) a
sequence substantially complementary to the CA1
region of KSR, or to nucleotides 124-243 (SEQ ID
NO: 1) of the coding sequence of KSR, or its
portion; or (b) a sequence of SEQ ID NO: 6, 7 or 8
(not given in the given in the specification);
[CONT.]
US 20050037455
N
US 20060252037
US 7301017
US 20080096840
US 7528116
US 20090143320
(1) a pharmaceutical composition comprising the
novel composition and a carrier; [CONT.]
The composition and methods are useful or
treating, stabilizing or preventing a disease or
disorder in a mammal (claimed).
The invention provides compositions with minimal BIOTECHNOLOGY - Preferred Composition: The
toxicity.
novel composition comprises 0.5 and 1.5, as the
ratio of the positive to negative charge. The
endosomolytic spermine constitutes at least 20,
40-90 or 20-90 % inclusive, of the sperminecontaining molecule in the composition. The
targeting spermine constitutes at least 100, 10-60
or 20-90 % of the spermine-containing molecules
in the composition. [CONT.]
INDEPENDENT CLAIMS are included for the
following:
(1) a pharmaceutical composition comprising the
novel composition and a carrier;
(2) a composition comprising a nucleic acid
complexed with a cationic amphiphile in an oil-inwater emulsion in which at least 10 % of the
complex is in the oil phase of the emulsion;
(3) expressing an RNA or protein molecule of
interest in a cell; [CONT.]
WO 2003093449
US 20060084617
US 20090163436
N
473 Preventing or treating coeliac disease
comprises administering agent which are
wheat gliadin T cell epitope capable of being
recognized by T cell receptor
474 New binding composition that specifically
binds to insulin-like growth factor receptor 1,
useful for treating or preventing a medical
condition that is mediated by elevated
expression or activity of IGFR1
ISIS INNOVATION LTD
WO 2003104273
A2
20031218
ANDERSON R P
AU 2003244771
A1
20031222
HILL A V S
EP 1513873
A2
20050316
JEWELL D P
MX 2004012117
A1
20050501
JP 2006512893
T
20060420
US 20060178299
A1
20060810
ZA 2004009740
A
20060927
IN 2007DN01497
A
20070803
NZ 537226
A
20080627
IN 2005DN00032
A
20090130
AU 2003244771
B2
20100107
JP 2010229138
A
20101014
EP 2292649
WO 2003100008
A2
20110309
A2
20031204
BRAMS P
US 20040018191
A1
20040129
FEINGERSH D
AU 2003241590
A1
20031212
GREENBERG R
EP 1506286
A2
20050216
HAILEY J
NO 2004005645
A
20041223
PACHTER J A
KR 2004111685
A
20041231
PRESTA L
JP 2005527222
T
20050915
SRINIVASAN M
MX 2004011624
A1
20050301
WANG Y
CN 1671837
A
20050921
WILLIAMS D
ZA 2004009440
A
20060726
JP 2006265262
A
20061005
US 20070059241
US 20070059305
US 7217796
A1
20070315
A1
20070315
B2
20070515
AU 2003241590
B2
20070301
AU 2007200876
A1
20070322
IN 2004CN02617
A
20070907
US 20080014197
A1
20080117
CN 100422316
C
20081001
NZ 554740
A
20090130
CN 101401938
A
20090408
CN 101402685
A
20090408
CN 101402956
A
20090408
NZ 536475
A
20080627
SCHERING CORP
WO 2003104273 A2 UPAB: 20060120
(M1) is useful for preventing or treating coeliac
disease. An agent (A) is useful for preparation of a
medicament for treating or preventing coeliac
disease. (A) is useful for preparation of a
diagnostic means for use in diagnosing coeliac
disease, or susceptibility to coeliac disease, in an
individual, which involves determining whether T
NOVELTY: Preventing or treating (M1) coeliac
disease, comprising administering to an individual cells of the individual recognize the agent,
agent which are wheat gliadin T cell epitope and recognition by the T cells indicating that the
individual has, or is susceptible to, coeliac disease
which is capable of being recognized by a T cell
[CONT.]
receptor, is new.
BIOTECHNOLOGY - Preferred Polynucleotide:
(VI) additionally comprises one or more regulatory
sequences operably linked to the coding
sequence, the regulatory sequences are capable
of securing the expression of the coding sequence
in a cell. The regulatory sequence allow
expression of coding sequence in a prokaryotic or
mammalian cell. (VI) is a vector or in the form of
the vector. [CONT.]
DETAILED DESCRIPTION: Preventing or treating
coeliac disease, comprises administering to an
individual at least one agent (A) chosen from a
peptide (I) comprising at least one epitope
comprising a sequence (S1) chosen from: PhePro-Gln-Pro-Gln-Leu-Pro-Tyr-Pro, [CONT.]
Preventing or treating coeliac disease, comprises WO 2003104273
administering to an individual at least one agent
(A) chosen from a peptide (I) comprising at least
one epitope comprising a sequence (S1) chosen
from: Phe-Pro-Gln-Pro-Gln-Leu-Pro-Tyr-Pro,
US 20060178299
N
Phe-Pro-Gln-Pro-Gln-Gln-Pro-Phe-Pro,
Pro-Gln-Gln-Pro-Gln-Gln-Pro-Phe-Pro,
Leu-Gln-Pro-Gln-Asn-Pro-Ser-Gln-Gln-Gln-ProGln,
Leu-Gln-Pro-Glu-Asn-Pro-Ser-Gln-Glu-Gln-ProGlu, [CONT.]
WO 2003100008 A2 UPAB: 20060120
The compositions and methods are useful for
preventing or treating a medical condition selected
NOVELTY: A binding composition that specifically from acromegaly, bladder cancer, Wilm's cancer,
ovarian cancer, pancreatic cancer, benign
binds to insulin-like growth factor receptor 1
prostatic hyperplasia, breast cancer, prostate
(IGFR1) is new.
cancer, bone cancer, lung cancer, colorectal
DETAILED DESCRIPTION: INDEPENDENT
cancer, cervical cancer, synovial sarcoma,
CLAIMS are also included for the following:
(1) a pharmaceutical composition comprising the diarrhea associated with metastatic carcinoid,
vasoactive intestinal peptide [CONT.]
binding composition and a carrier;
(2) an isolated nucleic acid encoding the
polypeptide;
(3) a recombinant vector comprising the nucleic
acid; [CONT.]
BIOTECHNOLOGY - Preferred Composition: The
binding composition specifically binds to IGFR1
comprising a member selected from: a light chain
amino acid sequence, which comprises CDR-L1,
CDR-L2, and CDR-L3; and a heavy chain amino
acid sequence, which comprises CDR-H1, CDRH2 and CDR-H3. The IGFR1 comprises a variable
region selected from: (1) amino acids 20-128 of
any of the 5 sequences of 128 amino acids
[CONT.]
INDEPENDENT CLAIMS are also included for the WO 2003100008
following:
(1) a pharmaceutical composition comprising the
binding composition and a carrier;
US 20040018191
(2) an isolated nucleic acid encoding the
polypeptide;
(3) a recombinant vector comprising the nucleic
acid;
US 20070059305
(4) a host cell comprising the vector;
US 20080014197
(5) a method for producing a polypeptide;
US 7667021
(6) a method for treating or preventing a medical
condition in a subject [CONT.]
US 7847068
US 20070059241
US 7217796
US 7851181
US 20110060130
N
IN 229559
B
20090327
US 7667021
B2
20100223
JP 4563171
B2
20101013
JP 2010246567
A
20101104
AU 2010227116
A1
20101104
AU 2007200876
B2
20101104
US 7847068
US 7851181
US 20110060130
WO 2003097820
B2
20101207
B2
20101214
A1
20110310
A1
20031127
AU 2003235403
A1
20031202
MATSUTANI CHEM IND LTD
EP 1538200
A1
20050608
TEIKOKU SEIYAKU KK
AU 2003235403
A8
20031202
FUSHIMI PHARM CO LTD
HAYASHIBARA SEIBUTSU KAGAKU
475 Utilizing physiological activity of rare
saccharide e.g. D-allose or D-psicose in
HAYASHIBARA SEIBUTSU KAGAKU KK
compositions like functional foods, drugs and
cosmetics in treating e.g. cancer, ischemic
disease and diabetes
476 An immunogenic composition comprising an
immunogenic component or an antibody
recognizing a glucan, useful for preventing or
treating cancer or microbial infection caused
by e.g. Streptococcus pyogenes
WO 2003097820 A1 UPAB: 20060120
The saccharides can be used in compositions like
NOVELTY: A method for utilizing the physiological functional foods, drugs and cosmetics (all
claimed) in treating e.g. cancer, ischemic disease
activity of a rare saccharide is characterized in
and diabetes by acting on cells sensitive to cancer
that the physiological activity-sensitive cells are
cell proliferation-inhibitory activity, active oxygen
treated with such saccharide to modify their
production-inhibitory activity, chemokine secretionfunction.
inhibitory activity, microglia migration-inhibitory
DETAILED DESCRIPTION: An INDEPENDENT
activity and hypoglycemic activity.
CLAIM is also included for compositions
containing the rare saccharides as active
ingredient for incorporation into physiological
activity-sensitive cells to effect the modification of
modification of their function. [CONT.]
BIOLOGY - Preferred Methods: The cells are
particularly human cells. Such cells for use with Dallose are those sensitive to cancer cell
proliferation-inhibitory activity or active oxygen
production-inhibitory activity, while the cells for
use with D-psicose are those sensitive to
chemokine secretion-inhibitory activity, microglia
migration-inhibitory activity or hypoglycemic
activity. [CONT.]
An INDEPENDENT CLAIM is also included for
compositions containing the rare saccharides as
active ingredient for incorporation into
physiological activity-sensitive cells to effect the
modification of modification of their function.
BIOTECHNOLOGY - Preferred Composition: The
immunogenic composition is free of mannoprotein.
It further comprises an adjuvant and an antifungal. It also comprises a saccharide antigen
from serogroups A, C, W135 and/or Y of Neiseriia
meningitidis, an antigen from Helicobacter pylori,
a protein antigen from Neiseriia meningitidis
serogroup B, an outer-membrane vesicle
preparation from Neiseriia meningitidis serogroup
B, a saccharide antigen from Streptococcus
pneumoniae, an antigen from hepatitis A, B or C
virus, an antigen from N [CONT.]
An immunogenic composition comprises an
WO 2003097091
immunogenic component or an antibody
recognizing a glucan and a carrier. The
immunogenic component is a glucan, mimotope of
a glucan, peptidomimetic of a glucan mimotope or
a nucleic acid encoding a glucan mimotope. When
the composition is administered to the mammal, it
elicits protective anti-glucan antibodies but does
not elicit antibodies that inhibit the protective
efficacy of the anti-glucan antibodies. [CONT.]
JP 2004506478
X
20050915
FUSHIMI SEISAKUSHO KK
US 20050245459
A1
20051103
SHIKOKU RES INST INC
CN 1668735
A
20050914
SHIKOKU SOGO KENKYUSHO KK
KR 2006071825
A
20060627
UNIV JAPAN KAGAWA
KR 868529
B1
20081112
UNIV JAPAN KAGAWA MEDICAL
KR 2008053407
A
20080612
UNIV KAGAWA
KR 2009032147
A
20090331
UNIV KAGAWA MEDICAL
KR 908626
B1
20090721
HAYASHIBARA SEIBUTSU KAGAKU
KENKYUSHO KK
UNIV KAGAWA NAT CORP
JP 2010059200
A
20100318
KR 945825
B1
20100305
JP 4609845
B2
20110112
US 7906487
WO 2003097091
B2
20110315
CASSONE A
A2
20031127
WO 2003097091 A2 UPAB: 20090706
POLONELLI L
AU 2003241104
A1
20031202
EP 1506009
A2
20050216
NOVELTY: An immunogenic composition
comprises an immunogenic component or an
antibody recognizing a glucan and a carrier, is
new.
DETAILED DESCRIPTION: An immunogenic
composition comprises an immunogenic
component or an antibody recognizing a glucan
and a carrier. The immunogenic component is a
glucan, mimotope of a glucan, peptidomimetic of a
glucan mimotope or a nucleic acid encoding a
glucan mimotope [CONT.]
US 20050208079
A1
20050922
JP 2005535298
T
20051124
US 20070141088
EP 1891970
EP 1506009
A1
20070621
A1
20080227
B1
20080514
DE 60320979
E
20080626
ES 2306871
T3
20081116
JP 2010131017
A
20100617
US 7824688
EP 1891970
US 20110059120
B2
20101102
B1
20110209
A1
20110310
DE 60336027
E
20110324
The immunogenic composition is useful for
preventing or treating cancer or microbial infection
caused by e.g., Streptococcus pyogenes
(claimed).
WO 2003097820
US 20050245459
US 7906487
N
US 20050208079
US 20070141088
US 7824688
US 20110059120
N
477 Composition useful for administering nucleic
acid to a mammal in the treatment of e.g.
malignancies, autoimmune disorders,
comprises complexes of cationic chitosan
oligomers and a nucleic acid
478 Inhibiting RNA virus infection by increasing
the endogenous 2'-5' oligoadenylate
synthetase activity, useful for preventing or
treating RNA viral diseases, such as
respiratory syncytial virus, HIV, hepatitis and
measles infection
FMC BIOPOLYMER AS
WO 2003092739
A1
PHARMA CONCEPTS AB
NO 2002002148
A
20031104
STIFTELSEN BIOPOLYMER
AU 2003228156
A1
20031117
ARTURSSON P
NO 317653
B1
20041129
CHRISTENSEN B E
A1
20050202
KOEPING-HOEGGARD M
EP 1501550
US 20050170355
A1
20050804
KOPING-HOGGARD M
CN 1655825
A
20050817
VARUM K M
JP 2005533016
T
20051104
WO 2003092739 A1 UPAB: 20060203
For administering nucleic acid to a mammal; in the
manufacture of a medicament for prophylactic or
NOVELTY: A composition comprises complexes therapeutic treatment of a mammal (e.g. in gene
of cationic chitosan oligomers (A) derived from a therapy, antisense therapy and in genetic
vaccination for prophylactic or therapeutic
cationic polysaccharide chitosan and a nucleic
acid (B). (A) contains a weight fraction (%) of less treatment of malignancies, autoimmune disorders,
inherited disorders, pathogenic infections and
than 20% of oligomers with a degree of
other pathological disorders); [CONT.]
polymerization (DP) of less than 10 and greater
than 50.
POLYMERS - Preferred Components: (A) is
An INDEPENDENT CLAIM is included for
obtained from chitosan by chemical or enzymatic preparation of the composition involving:
methods. Preferred Composition: (A) further
(i) exposing (A) to an aqueous solvent,
contains a weight fraction (%) of oligomers with a
DP of less than 12 and DP of greater than 40; and
with a DP of less than 15 and DP of greater than
50. The fraction of N-acetylated units (FA) of (A) is
(less than 0.6, preferably less than 0.35,
especially less than 0 [CONT.]
WO 2003092739
US 20050170355
N
US 20070298048
(ii) mixing the aqueous solution of step (i) with (B)
in an aqueous solvent, and
US 7767456
(iii) reducing the volume of the product solution of
step (ii) to achieve a desired concentration of the
composition.
US 20070298048
A1
20071227
C
20080604
AU 2003228156
B2
20080703
IN 2004DN03599
A
20091009
US 7767456
B2
20100803
JP 4658592
B2
20110323
WO 2003092618
A2
20031113
BEHERA A K
US 20040009152
A1
20040115
MOHAPATRA S S
AU 2003225281
A1
20031117
EP 1579001
A2
20050928
AU 2003225281
A8
20051117
US 7354908
US 20080175832
US 20110052558
WO 2003083482
B2
20080408
A1
20080724
A1
20110303
A1
20031009
AU 2003229586
A1
20031013
HIPFEL R
EP 1490694
A1
20041229
POHLNER J
US 20060024305
A1
20060202
(I) is useful for producing a recombinant nonhuman animal comprising a non-native gene
NOVELTY: An isolated nucleic acid (I) encoding a sequence coding for hTARPP (human isoform of
protein comprising a fully defined sequence of 813 the cyclic adenosine monophosphate regulated
amino acids (S1), as given in the specification, is phosphoprotein ARPP-21), useful for screening,
testing or validating compounds, agents or
new.
modulators in the developing diagnostics or
DETAILED DESCRIPTION: INDEPENDENT
therapeutics for treating neurodegenerative
CLAIMS are also included for:
disease, particularly Alzheimer's disease. [CONT.]
(1) a vector comprising (I);
VON DER KAMMER H
EP 1490694
B1
20110309
(2) a cell transformed with(I); [CONT.]
NESTEC SA
EP 1344458
A1
20030917
EP 1344458 A1 UPAB: 20090205
UNIV SOUTH FLORIDA
The non-viral DNA-chitosan complexes are stable
and mediate a high in vivo gene expression of the
nucleic acids in selected tissues when introduced
into a host cell. The composition contains welldefined polycationic chitosans having a narrow
molecular weight distribution.
DETAILED DESCRIPTION: An INDEPENDENT
CLAIM is included for preparation of the
composition involving: [CONT.]
CN 100391543
EVOTEC NEUROSCIENCES GMBH
479 New nucleic acid useful for preparing a
composition for treating, preventing,
diagnosing, prognosticating or monitoring the HANES J
progression of a neurodegenerative disease,
e.g. Alzheimer's disease
480 Pellets used as delivery system for probiotics
in moist, semi-moist, or semi-dry food
products, have a specific volume
20031113
WO 2003092618 A2 UPAB: 20060120
The methods and compositions of the present
invention are useful for prevention and/or
treatment of RNA viral diseases, such as
NOVELTY: Inhibiting an RNA virus infection in a
patient, comprising increasing the endogenous 2'- respiratory syncytial virus, rhinovirus, vaccinia
virus, reovirus, HIV, EMCV, hepatitis B, hepatitis
5' oligoadenylate synthetase activity within the
C, bovine respiratory syncytial virus, measles
patient, where the RNA virus is a type that
transiently produces double-stranded RNA during virus, sendai virus, parainfluenza virus, mumps
virus, simian virus, Newcastle virus, coronavirus
intermediate replication, is new.
and West Nile virus [CONT.]
BIOTECHNOLOGY - Preferred Method: The
increasing comprises administering a nucleotide
sequence encoding a 2'-5' oligoadenylate
synthetase, or at least one catalytically active
fragment, to the patient, where the nucleotide
sequence is expressed in the patient, where the
fragment comprises a catalytically active subunit
of 2'-5' oligoadenylate synthetase from p40, p69
and p100. [CONT.]
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are also included for the following:
[CONT.]
INDEPENDENT CLAIMS are also included for the WO 2003092618
following:
(1) a pharmaceutical composition comprising a
nucleotide sequence encoding a 2'-5'
oligoadenylate synthetase, or at least one
catalytically active fragment, and a carrier;
US 20040009152
(2) a pharmaceutical composition comprising a 2'5' oligoadenylate synthetase, or at least one
catalytically active fragment, and a carrier;
[CONT.]
US 20080175832
N
US 7354908
US 20110052558
WO 2003083482 A1 UPAB: 20050905
As a delivery system for probiotics in a moist,
semi-moist, or semi-dry food product (claimed).
BIOTECHNOLOGY - Preferred Nucleic Acid: The INDEPENDENT CLAIMS are also included for:
nucleic acid comprises: (a) a cDNA molecule
comprising a fully defined sequence of 2442 or
(1) a vector comprising (I);
3212 base pairs, as given in the specification; or
(b) a DNA molecule capable of hybridizing with the
complement of (a) under stringent conditions.
Preferred Vector: The vector is a plasmid, virus or (2) a cell transformed with(I);
bacteriophage. [CONT.]
WO 2003083482
US 20060024305
(3) a protein molecule comprising (S1) for use as
a diagnostic target for detecting, or screening
target for reagents or compounds for preventing,
treating or ameliorating a neurodegenerative
disease, preferably Alzheimer's disease;
The pellets provide improvement of the stability of
probiotic micro-organisms applied in semi-dry
and/or humid particulate foodstuffs. Processing is
easy and straightforward. The pellets provide a
delivery vehicle for further functional ingredients,
particularly probiotic fibers, which in turn may
provide the physico-chemical characteristics of the
FOOD - Preferred Properties: The inner matrix,
before of shortly after the coating, has a water
activity of below 0.3. The inner matrix has an
envelope density of more than 0.8 g/cm3.
Preferred Composition: The pellet comprises 1051014 viable micro-organisms. Preferred
Components: The inner matrix further comprises
(4) an antibody specifically immunoreactive with
an immunogen, which is a protein comprising
(S1); [CONT.]
INDEPENDENT CLAIMS are also included for:
EP 1344458
US 20050153018
N
in moist, semi-moist, or semi-dry food
products, have a specific volume
481 New polypeptide comprising an antibody,
useful for preparing a composition for
diagnosing or treating cancer, e.g., colorectal
adenocarcinoma, ovarian cancer, squamous
cell lung carcinoma or lobular mammary
carcinoma
semi-moist, or semi-dry food product (claimed).
NESTLE SA
WO 2003075676
A1
20030918
NOVELTY: New pellets comprising a compacted
inner matrix and at least one coating. The inner
matrix comprises viable micro-organisms and the
coating comprises a moisture barrier. The pellet
has a volume of at least 0.02 cm3.
SOC PROD NESTLE SA
AU 2003218748
A1
20030922
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are also included for: [CONT.]
EP 1482811
A1
20041208
BR 2003008586
A
20050111
JP 2005519600
T
20050707
US 20050153018
A1
20050714
CN 1642437
A
20050720
ZA 2004008199
A
20051228
MX 2004008814
A1
20050901
EP 1482811
B1
20060830
DE 60307993
E
20061012
DE 60307993
T2
20070222
ES 2269993
T3
20070401
AU 2003218748
B2
20071101
CN 100334964
C
20070905
RU 2323586
C2
20080510
MX 251421
B
20071113
IN 2004DN03105
A
20091204
JP 2011055832
A
20110324
ONCOMAB GMBH
WO 2003076472
A2
20030918
PATRYS LTD
DE 10210427
A1
20031009
MUELLER-HERMELINK H K
AU 2003214537
A1
20030922
VOLLMERS H
EP 1485415
US 20050208056
A2
20041215
A1
20050922
AU 2003214537
B2
20100218
VOLLMERS H P
IMMUNOMEDICS INC
482 New humanized anti-CD20 monoclonal
antibody (MAb) that retains substantially the B- MCCALL J D
cell and B-cell lymphoma and leukemia cell
targeting of the murine anti-CD20 MAb, useful
for treating B-cell lymphoma, leukemia or an
autoimmune diseases
WO 2003076472 A2 UPAB: 20100309
probiotic micro-organisms applied in semi-dry
and/or humid particulate foodstuffs. Processing is
easy and straightforward. The pellets provide a
delivery vehicle for further functional ingredients,
particularly probiotic fibers, which in turn may
provide the physico-chemical characteristics of the
pellet.
before of shortly after the coating, has a water
activity of below 0.3. The inner matrix has an
envelope density of more than 0.8 g/cm3.
Preferred Composition: The pellet comprises 1051014 viable micro-organisms. Preferred
Components: The inner matrix further comprises
fillers, functional ingredients, lubricants,
plasticizers, and/or food-grade binders [CONT.]
(1) a process for obtaining pellets to supplement a
food product with viable micro-organisms,
comprises mixing a preparation of microorganisms and further components; drying the
mixture to an Aw below 0.3; compacting the
mixture under pressure to obtain pellets
comprising a volume of at least 0.02 cm cubed;
and coating the pellets with a moisture barrier;
and [CONT.]
The polypeptide is useful for preparing a
NOVELTY: A new purified polypeptide comprises composition for diagnosing or treating cancer,
an antibody or its functional fragment that induces e.g., colorectal adenocarcinoma, ovarian cancer,
apoptosis of a neoplastic cell to which it binds, but squamous cell lung carcinoma or lobular
mammary carcinoma (claimed).
does not induce apoptosis of a non-neoplastic
cell, or that inhibits cell proliferation when bound
to a neoplastic cell, but does not inhibit
proliferation of a non-neoplastic cell. [CONT.]
BIOTECHNOLOGY - Preferred Polypeptide: The
polypeptide comprises a sequence that is identical
to a fully defined sequence having 102 or 109
amino acids. It is a functional fragment consisting
of VL, VH FV, FC, Fab, Fab' or F(ab')2. The
antibody is a human or monoclonal antibody. It
specifically binds to a colorectal adenocarcinoma,
ovarian cancer, squamous cell lung carcinoma, or
lobular mammary carcinoma cell and not to a nonneoplastic cell [CONT.]
BIOTECHNOLOGY - Preferred Antibody: The
INDEPENDENT CLAIMS are included for:
humanized antibody or its fragment comprises a
(1) a humanized antibody or its fragment
variable region that is a light and/or a heavy chain comprising the hA20Vk and hA2VH1 or hA2VH2;
variable region. It further comprises light and
heavy chain constant regions of at least one
human antibody. The light chain variable region
comprises: (a) CDR1 comprising an amino acid
sequence selected from the group consisting of
(A1-A3); [CONT.]
EP 1485415
B1
20110105
DE 60335610
E
20110217
EP 2292666
WO 2003068821
US 20030219433
A2
20110309
A2
20030821
WO 2003068821 A2 UPAB: 20090629
A1
20031127
NOVELTY: A humanized anti-CD20 (hCD20)
monoclonal antibody (MAb) or its antigen-binding
fragment comprising the complementarity
determining regions (CDRs) of at least one murine
anti-CD20 MAb variable region and the framework
regions (FRs) of at least one human IVlAb variable
region, where humanized anti-CD20 MAb or its
fragment retains substantially the B-cell and B-cell
lymphoma and leukemia cell targeting of the
murine anti-CD20 MAb, is new. [CONT.]
The antibodies, fusion proteins and conjugates
are useful for diagnosing or preventing B-cell
lymphoma, leukemia or an autoimmune disease
(claimed), e.g. thrombocytopenia, lupus or
rheumatoid arthritis.
The new purified polypeptide comprises an
WO 2003076472
antibody or its functional fragment that induces
apoptosis of a neoplastic cell to which it binds, but
does not induce apoptosis of a non-neoplastic
cell, or that inhibits cell proliferation when bound
to a neoplastic cell, but does not inhibit
proliferation of a non-neoplastic cell, where the
antibody specifically binds to HT-29 (ATCC
Accession No. HTB-38; [CONT.]
WO 2003068821
US 20050208056
N
US 20030219433
US 7151164
N
WYETH
483 New safer vaccine composition comprising
inactivated West Nile virus, and an antigen and WYETH CORP
DNA derived from the virus, useful for
preventing or ameliorating West Nile
encephalitis in horses, humans, other
mammals or birds
WYETH LLC
AU 2003208415
A1
20030904
(2) a chimeric anti-CD20 (cCD20) monoclonal
antibody, (MAb) or its fragment comprising the
CDRs of at least one murine anti-CD20 MAb
variable region and the FRs of at least one murine
anti-CD 20 MAb variable region;
US 20070020259
KR 2004086383
A
20041008
(3) a human anti-CD20 (huD20)MAb; [CONT.]
US 7435803
EP 1519959
A2
20050406
JP 2006500904
T
20060112
CN 1662557
A
20050831
IN 2004CN02017
A
20060224
US 7151164
US 20070020259
B2
20061219
A1
20070125
IN 2007CN03444
A
20071116
IN 2007CN03585
A
20080627
US 7435803
US 20090155253
B2
20081014
A1
20090618
AU 2003208415
B2
20090528
AU 2009202613
A1
20090716
JP 2009291197
A
20091217
CN 100522999
C
20090805
US 20100040541
A1
20100218
JP 4498746
B2
20100707
CN 101914158
A
20101215
EP 2295468
US 20030091595
WO 2003061555
A1
20110316
A1
20030515
A2
20030731
AU 2002365244
A1
20030902
EP 1427444
A2
20040616
KR 2004028952
A
20040403
BR 2002011492
A
20040817
MX 2004000680
A1
20040401
HU 2004001606
A2
20041129
CN 1535157
A
20041006
JP 2005515236
T
20050526
ZA 2004001596
A
20050727
IN 2004KN00109
A
20051230
IN 2004KO00327
A
20060421
US 7153513
B2
20061226
CN 1273189
C
20060906
CN 1935258
A
20070328
AU 2002365244
B2
20071206
IN 2007KN01073
A
20080801
NZ 531265
A
20080829
NZ 553165
A
20080926
KR 2009053967
A
20090528
MX 260579
B
20080917
IN 219347
B
20080502
EP 2281572
EP 2283858
EP 2283858
A1
20110209
A2
20110216
A3
20110323
US 20090155253
US 20100040541
US 20030091595 A1 UPAB: 20090409
The vaccine is useful against West Nile virus,
NOVELTY: A vaccine composition, which is made particularly for preventing or ameliorating West
Nile encephalitis in horses (particularly pregnant
safe, comprising an immunizing amount of an
mares) or other equidae (claimed). The vaccine is
immunologically active component, which is an
inactivated whole or subunit of West Nile virus, an also useful for preventing or ameliorating West
antigen derived from the virus, DNA derived from Nile encephalitis in humans, other mammals and
birds.
the virus, or
a mixture of them, an immunologically stimulating
amount of a metabolizable oil, and a carrier, is
new. [CONT.]
PHARMACEUTICALS - Preferred Vaccine: The
immunologically active component is an
inactivated whole or subunit of West Nile virus. A
dosage unit of the vaccine comprises 1x10 to the
power 4 TCID50 -1x10 to the power 9 TCID50 of
the virus, preferably in a quantity that provides at
least 1x10 to the power 6 TCID50 per unit dose/
The metabolizable oil is SP oil. The oil is present
in 4-10, preferably 5 %, vol/vol [CONT.]
An INDEPENDENT CLAIM is also included for
preventing or ameliorating West Nile encephalitis
in equidae by administering the vaccine
composition.
US 20030091595
US 20030091595
US 7153513
N
484 New phytase variants useful as animal feed
additives and for treating plant material and
manure
485 Food composition for maintenance of bone
health and prevention, alleviation and/or
treatment of bone disorders in humans and
pets, comprises plant or plant extract
containing phytochemicals
NOVOZYMES AS
JP 2011057692
A
20110324
WO 2003066847
US 20030208788
A2
20030814
WO 2003066847 A2 UPAB: 20060120
A1
20031106
NOVELTY: Active phytase variants (I) with one or
more specific substitutions, are new.
AU 2003203147
A1
20030902
DETAILED DESCRIPTION: An active phytase
variant (I) comprises a substitution in at least one
position of the regions 20; 26; 28-31; 37-48; 5569; 73-83; 91-119; 123-126; 135-142; 152-163;
169-199; 204-222; 229-238; 248-266; 284-289;
300-308; 321-335; 343-350; 384-398; [CONT.]
EP 1474508
A2
20041110
(iii) treating vegetables or proteins; and
BR 2003007086
A
20041207
(iv) liberating phosphorous from a phytase
substrate (claimed).
JP 2005516619
T
20050609
CN 1630719
A
20050622
US 7238378
B2
20070703
CN 100366736
C
20080206
CN 101177675
A
20080514
US 20090029004
A1
20090129
AU 2003203147
B2
20080529
JP 2010017193
A
20100128
JP 4426307
B2
20100303
20110316
A1
20030703
WO 2003053167 A1 UPAB: 20090327
SOC PROD NESTLE SA
EP 2295553
WO 2003053167
EP 1325681
A1
A1
20030709
NOVELTY: A food composition intended for
prevention, alleviation and/or treatment of bone
disorders or maintenance of bone health in
humans and pets, comprises as an active
ingredient plant(s) or plant extract(s) containing
phytochemicals having the ability to induce bone
morphogenic protein expansion.
NESTEC SA
AU 2002366734
A1
20030709
ACTIVITY: Osteopathic; Antiarthritic; Vulnerary.
[CONT.]
COURTOIS D
BR 2002014838
A
20040831
FEDERICI E
EP 1455601
A1
20040915
LEMAURE B
KR 2004083466
A
20041002
OFFORD-CAVIN E
NO 2004002151
A
20040907
US 20050079232
A1
20050414
JP 2005513078
T
20050512
CN 1602159
A
20050330
MX 2004005583
A1
20050101
ZA 2004005454
A
20050928
IN 2004DN01973
A
20070511
RU 2314717
C2
20080120
IL 161659
A
20080708
AU 2008201726
A1
20080508
NESTLE SA
US 20090060883
A1
20090305
NO 327135
B1
20090504
AU 2002366734
B2
20081211
CN 100521972
C
20090805
EP 2135517
A1
20091223
JP 2010088441
A
20100422
JP 2010088442
A
20100422
AU 2010201150
A1
20100415
EP 1455601
B1
20100707
DE 60236961
E
20100819
AU 2008201726
B2
20100812
EP 2263480
A1
20101222
(I) are useful for:
Compared with the wild-type enzyme, (I) have
BIOTECHNOLOGY - Preferred Variants: The
better
thermostability
and/or
specific
activity.
They
specification lists (combinations of) substitutions
(i) improving the nutritional value of animal feed
may
also
have
reduced
allergenic
potential.
for 70 (I). Preparation: (I) is prepared by standard
compositions (e.g. to increase growth rate, weight
recombinant techniques. 3-D protein coordinate
gain and/or feed conversion);
data available. [CONT.]
(ii) reducing phytate levels in animal manure;
The composition is used for maintenance of bone
health or prevention, alleviation and/or treatment
of bone disorders, especially for treating and
preventing osteoarthritis, building cartilage
stimulating bone regeneration during fracture
healing, decreasing bone loss (especially that
associated with age), increasing bone formation,
increasing bone mineral density during growth and
optimizing peak [CONT.]
The composition provides a safe, efficient
nutritional way to promote bone growth and
prevent or alleviate the symptoms of bone/joint
disorders in mammals.
BIOLOGY - Preferred Components: The plant is
from any part of the plant source, i.e. leaves,
tubers, fruits, seeds, roots, grains, embryos, or
cell cultures. The plant or plant extract is from
aerial parts of Lindera benzoin, aerial parts of
Artemisia vulgaris, rhizome of Acorus calamus,
seed or flower of Carthamus tinctorius, fruits of
Amelanchier ovalis, fruits of Amelanchier alnifolia,
roots of Cichorium intybus, rhizome of Curcuma
longa, aerial part of Epimedium brevicornum,
aerial part of Eriogonum giganteum, leaves or
roots of T [CONT.]
An active phytase variant (I) comprises a
WO 2003066847
substitution in at least one position of the regions
20; 26; 28-31; 37-48; 55-69; 73-83; 91-119; 123126; 135-142; 152-163; 169-199; 204-222; 229238; 248-266; 284-289; 300-308; 321-335; 343350; 384-398; 407-412 and 419-430 of a 423
amino acid (aa) sequence (S1) fully defined in the
specification, and has at least 75% sequence
identity with S1 but is specifically not one of the
following variants of the Peniophora lycii CBS 686
[CONT.]
US 20030208788
US 7238378
WO 2003053167
US 20050079232
US 20090060883
US 20090029004
486 Phage isolate preparation with a broad host
range useful for treating e.g. gastroenteritis
and diarrhea
B
20101015
EP 2272382
EP 2286675
A1
20110112
A1
20110223
JP 4653951
B2
20110316
NESTLE SA
WO 2003054173
A1
20030703
SOC PROD NESTLE SA
AU 2002366854
A1
20030709
NESTEC SA
EP 1458856
A1
20040922
BRUESSOW H
US 20040223954
A1
20041111
BRUTTIN A
BR 2002014928
A
20041130
CHENNOUFI S
CN 1602353
A
20050330
SIDOTI J
ZA 2004005513
A
20050928
MX 2004005395
A1
20050401
US 7211426
B2
20070501
IN 2004DN02005
A
20070406
US 20070134207
A1
20070614
CN 100336902
C
20070912
MX 264846
B
20090303
US 20100015098
A1
20100121
IN 246410
B
20110304
WO 2003046580
A1
20030605
US 20030133875
A1
20030717
AU 2002343063
A1
20030610
EP 1448995
A1
20040825
JP 2005510733
T
20050421
AU 2002343063
B2
20080605
EP 1448995
B1
20110119
DE 60239009
E
20110303
WO 2003030833
A2
MEDAREX INC
OLINER J D
487 Selecting a candidate drug for the treatment of ROWETT RES INST
inflammatory disease due to cytokine
production comprises exposing the candidate
drug to intestinal cells, and analyzing the
effect of the candidate drug
488 New specific binding agents (i.e. antiAngiopoietin-2 antibodies), useful for
inhibiting undesired angiogenesis, or treating
e.g. cancers, obesity, hemangioma,
arteriosclerosis, atherosclerosis or
endometriosis
MX 280065
AMGEN INC
WO 2003054173 A1 UPAB: 20091026
In the preparation of food, pet food product,
NOVELTY: A phage isolate preparation exhibiting nutritional composition, supplement and
pharmaceutical composition for treating and
substantial lytic potential towards pathogenic
preventing infections caused by pathogenic
Enterobacteriaceae e.g. Escherichia Coli and/or
Enterobacteriaceae (e.g. Salmonella, E. coli
Salmonella stains, is new. The phage is virulent
strains), and traveler's diarrhea, pediatric
and non-toxic.
gastroenteritis and urinary infections in human
ACTIVITY: Gastrointestinal-Gen.; Antibacterial;
and animals (e.g. pets) (all claimed).
Antidiarrheic.
No biological data is given.
The bacteriophage preparations have a broad
host range on diarrhea causing Escherichia coli
strains; and are non-toxic hence used safely in
food compositions for effective prevention and
treatment of infections caused by the strains. The
phage isolates can be propagated on a nonpathogenic E. coli strain without altering its broad
host range. [CONT.]
BIOLOGY - Preferred Phage: The phage is
Myoviridae (preferably T4-like), Nestle culture
collection (NCC)-JS9, NCC-JS31, NCC-JS102.2,
NCC-JS150, NCC-JS1, NCC-JS10 (renamed NCCJS4) (CNCM I-2763), NCC-JS22, NCC-JS32, NCCJS114.1, NCC-JS140.1, NCC-JS146.1, NCCJS65.1, NCC-JS65.2', NCC-JS76.2', NCC-JS12,
NCC-JS152, NCC-JS66, NCC-JS102.1, NCCJS140.2, NCC-JS146.2, NCC-JS61.2, NCCJS61.3, NCC-JS114. [CONT.]
WO 2003054173
US 20040223954
US 7211426
US 20070134207
US 20100015098
MECHANISM OF ACTION: Bacterial growth
inhibitor. [CONT.]
WO 2003046580 A1 UPAB: 20110124
The method, agent and Bacteroides
thetaiotaomicron or its component are useful for
treating inflammatory diseases caused by the
inflammatory response of intestinal cells, or
NOVELTY: Selecting a candidate drug for the
treatment of inflammatory disease due to cytokine associated with the production of an inflammatory
cytokine. The inflammatory disease includes
production comprising exposing the candidate
drug to intestinal cells, and analyzing the effect of inflammatory bowel disease, Crohn's disease,
irritable bowel syndrome, rheumatoid arthritis,
the candidate drug, is new.
immunodeficiency syndrome, cachexia, multiple
DETAILED DESCRIPTION: Selecting a candidate sclerosis, proliferation of keratinocytes,
hyperproliferation and inflammatory disorders of
drug for the treatment of inflammatory disease
the skin, psoriasis or acne vulgaris [CONT.]
due to cytokine production comprising: [CONT.]
BIOTECHNOLOGY - Preferred Method: Selecting
a candidate drug for the treatment of inflammatory
disease due to cytokine production further
comprises selecting a candidate drug that
demonstrates at least one of the effect selected
from the increase of nuclear export or the
decrease of nuclear import of transcription factors
of the NF-kappa B family, the disruption of
transcriptional activity of [CONT.]
20030417
WO 2003030833 A2 UPAB: 20060119
US 20030124129
A1
20030703
AU 2002343498
A1
20030422
KR 2004051606
A
20040618
NOVELTY: A specific binding agent, which
comprises at least one peptide selected from any
of 62 peptides with 106-128 amino acids fully
defined in the specification, or its fragment, is
new.
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are also included for the following:
(1) a hybridoma that produces the binding agent,
which is a monoclonal antibody; [CONT.]
PHARMACEUTICALS - Preferred Binding Agent:
The specific binding agent is an antibody,
particularly a polyclonal, monoclonal, chimeric,
humanized, or fully human antibody. The antibody
is a single chain antibody. The specific binding
agent comprises CDR1, CDR2 or CDR3 of any of
the following peptides: 526 HC, 528 HC, 531 HC,
533 HC, 535 HC, 536 HC, 537 HC, 540 HC, 543
HC, 544 HC, 545 HC, 546 HC, 551 [CONT.]
EP 1495053
A2
20050112
(4) a vector comprising the nucleic acid molecule;
NO 2004001907
A
20040510
(5) a host cell containing the vector;
JP 2005506067
T
20050303
(6) making the specific binding agent; [CONT.]
MX 2004003345
A1
20040701
CN 1602317
A
20050330
The specific binding agent, particularly the
antibody, is useful for inhibiting undesired
angiogenesis, treating cancers, inhibiting
undesired angiogenesis, modulating or inhibiting
angiopoietin-2 activity, modulating vascular
permeability or plasma leakage, or treating a
disease (e.g. [CONT.]
Selecting a candidate drug for the treatment of
WO 2003046580
inflammatory disease due to cytokine production
comprising:
(a) exposing the candidate drug to intestinal cells;
and
US 20030133875
N
(b) analyzing the effect of the candidate drug,
where the effect is the variation of nuclear export
or import of transcription factors of the NF-kappa
B family, the disruption of the transcriptional
activity of transcription factors from [CONT.]
INDEPENDENT CLAIMS are also included for the WO 2003030833
following:
(1) a hybridoma that produces the binding agent,
which is a monoclonal antibody;
(2) conjugates comprising the specific binding
agent;
(3) nucleic acid molecules encoding the specific
binding agent;
US 20030124129
US 7521053
N
489 New protein or peptide, useful for modulating
T cell proliferation and raising therapeutic
antibodies, contains the C'-D loop of a CD28
protein or its analog or mimic
490 Production of biomass involves culturing
microorganism in aqueous liquid culture
medium such that oxygen introduction is
effected at rate such that average dissolved
oxygen content does not exceed specified
concentration
AU 2002343498
B2
20060413
NZ 531901
A
20061130
ZA 2004002392
A
20070131
AU 2006228095
A1
20061102
BR 2002013224
A
20070327
HU 2005000994
A2
20071128
US 7521053
B2
20090421
JP 2009225799
A
20091008
CN 101671393
A
20100317
CN 100595211
C
20100324
KR 2010049682
A
20100512
AU 2006228095
B2
20101104
EP 2272869
A2
20110112
JP 4637480
B2
20110223
AU 2011200824
A1
20110317
TEGENERO AG
WO 2003048194
A2
20030612
WO 2003048194 A2 UPAB: 20050530
(I) are used:
TEGENERO GMBH
DE 10160516
A1
20030612
NOVELTY: Protein or peptide (I) that contains:
(i) for therapeutic modulation of T cell proliferation;
HANKE T
US 20030166860
A1
20030904
(i) the C'-D loop of a member of the CD28 family;
(ii) to prepare monoclonal antibodies (MAb) which
modulate, superagonistically, proliferation of T
cells, of many (up to all) subtypes; and
HUNIG T
AU 2002357427
A1
20030617
(ii) a peptide analogous to (i); or
(iii) to screen for compounds with similar activity.
(3) hybridoma cell that produces monoclonal
antibodies (MAb) able to bind to (I); and
LUHDER F
EP 1451224
A2
20040901
(iii) a compound that mimics (i) but is not a CD28
family member, is new.
MAb that bind (I), or their mimics or compounds
identified by screening method (iii), are used:
[CONT.]
(4) MAb produced by the cells of (3).
LUEHDER F
AU 2002357427
A8
20051027
US 20070031407
A1
20070208
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are also included for the following:
(1) nucleic acid (II) that encodes a peptide (I), or a
protein containing this peptide, but does not
encode a CD28 protein; [CONT.]
A1
20110303
A1
20030227
STATOIL ASA
US 20110052587
WO 2003016460
EP 1419234
A1
20040519
COCKBAIN J
NORFERM DA
AU 2002355910
A1
20030303
ERIKSEN H
US 20040241790
A1
20041202
JORGENSEN L
NO 2004000693
A
20040514
STRAND K
CN 1561386
A
20050105
AU 2002355910
B2
20060727
AU 2006235784
A1
20061123
AU 2006235784
B2
20080131
CN 100445395
C
20081224
US 7579163
US 20090263877
EP 1419234
WO 2003015705
B2
20090825
A1
20091022
B1
20110302
A2
20030227
WILLIAMS HOSPITAL ROGER
491 Treating cancer in a patient, by arming
activated autologous T cells with bispecific
antibodies specific for a certain tumor antigen
and infusing autologous cells comprising the
activated, armed T cells into patient
Agents that bind to the C'-D loop have improved
stimulatory or inhibitory activity.
WO 2003016460 A1 UPAB: 20090707
M1 is useful for the production of biomass useful M1 is readily formulated to contain necessary
as a component or precursor in food products,
nutrients, is easily digested by the animals and is
NOVELTY: Production (M1) of biomass
particularly when used as a substitute for natural palatable to the animals.
comprising culturing a microorganism in an
plasma in animal feeds and in pet foods. It is used
aqueous liquid culture medium circulating in a
as a texturant in meat products, e.g. meat balls,
loop reactor, is new. Oxygen introduction is
effected at locations along a flow path through the as a replacement for plasma proteins used as
extenders in fresh meat to increase weight and
loop reactor at a rate such that the average
volume, as an emulsifier, e.g. [CONT.]
dissolved oxygen content of the liquid culture
medium does not exceed 25 ppm. [CONT.]
WO 2003015705 A2 UPAB: 20100810
(M1) is useful for treating prostate, breast, colon,
brain, lung, neck cancer and leukemia in an
immunosuppressed patient, in particular a
mammal or rodent. The patient is suffering from,
or susceptible to diseases which are characterized
by abnormal cell growth and proliferation. (C1) is
useful for treatment of a mammal suffering from or
susceptible to diseases characterized by
The method significantly increases the chances of
overcoming some of the major barriers for
successful adoptive immunotherapy, such as for
example, tumor escape. This approach, increases
the precursor frequency of CTL directed to specific
tumors and improves specific binding and
enrichment of effector cells at the tumor site, as
well as augmenting tumoricidal activity. [CONT.]
BIOLOGY - Preferred Materials: Each end of (I) is
bound to a substrate-binding site (SBS), arranged
spatially in accordance with the binding sites of
the C'-D loop. The C'-D loop, or analog, is fixed in
a three-dimensional configuration that conforms to
the loop and is freely accessible to antibodies.
The substrate is not a member of the CD28 family
with a C'-D loop, or analogous natural peptide of
the relevant family member [CONT.]
BIOTECHNOLOGY - Preferred Component: The
culture medium contains a methanotrophic
bacterium and where oxygen and methane are
introduced into the reactor and mixed with the
liquid culture medium. Preferred Method: The
biomass containing liquid culture is harvested
from the reactor, and a chemical compound
produced by the microorganism is separated.
[CONT.]
INDEPENDENT CLAIMS are also included for the WO 2003048194
following:
(1) nucleic acid (II) that encodes a peptide (I), or a
protein containing this peptide, but does not
encode a CD28 protein;
(2) plasmid containing (II);
Production of biomass comprises culturing a
WO 2003016460
microorganism in an aqueous liquid culture
medium circulating in a loop reactor having an
effluent gas removal zone where carbon dioxidecontaining effluent gas is removed from the
reactor and upstream a degassing zone in which a
driving gas is introduced to drive carbon dioxide in
the liquid phase into a separable effluent gas
phase and having upstream of the degassing
zone a nutrient gas introduction zone in which
oxygen is introduced into the reactor and mixed
with the liquid culture medium [CONT.]
BIOTECHNOLOGY - Preferred Method: (M1)
Treating (M1) a patient suffering from cancer,
further comprises co-infusing intravenously or co- comprising:
injecting into a tumor arterial supply or tumor site
a composition of autologous dendritic cells, and
the activated T cells armed with BiAb, where the
autologous dendritic cells are cultured in IL-4 and
granulocyte macrophage-colony stimulating factor
(GM-CSF) for 7 days, with or without tumor
WO 2003015705
US 20030166860
N
US 20070031407
US 20110052587
US 20040241790
US 7579163
Y
US 20090263877
US 20030185823
N
EP1419234B1
activated autologous T cells with bispecific
antibodies specific for a certain tumor antigen WILLIAMS MEDICAL CENT ROGER
and infusing autologous cells comprising the
activated, armed T cells into patient
US 20030185823
A1
20031002
AU 2002323236
A1
20030303
EP 1450828
A2
20040901
JP 2004538331
T
20041224
AU 2002323236
A8
20051027
20100727
A1
20110317
UNIV KEIO
US 7763243
US 20110064689
WO 2003011337
B2
A1
20030213
GH KEIO GIJUKU
AU 2002318609
A1
20030217
AISO S
JP 2003516567
X
20041118
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are also included for
ASOU H
US 20050175998
A1
20050811
(1) detecting oligodendroglia and their precursor
cells capable of forming myelin, using as an
indicator the expression of Fc receptor gamma
chain in the precursor cells; [CONT.]
ELFENBEIN G
LUM L G
492 Drug compositions containing Fc receptor
gamma chain activator for treatment and
prevention of neurodegenerative disorders
including multiple sclerosis
NAKAHARA J
NOVELTY: Treating (M1) a patient suffering from
cancer, comprising isolating peripheral blood
mononuclear cells from the patient, activating T
cells, arming of activated T cells with bispecific
antibodies (BiAb) capable of binding to the T cell
receptor complex of a T cell and to tumorassociated antigens on tumor cells, and reinfusing
autologous cells comprising the activated T cells
armed with BiAb into a patient, is new. [CONT.]
overcoming some of the major barriers for
successful adoptive immunotherapy, such as for
example, tumor escape. This approach, increases
the precursor frequency of CTL directed to specific
tumors and improves specific binding and
enrichment of effector cells at the tumor site, as
well as augmenting tumoricidal activity. [CONT.]
further comprises co-infusing intravenously or coinjecting into a tumor arterial supply or tumor site
a composition of autologous dendritic cells, and
the activated T cells armed with BiAb, where the
autologous dendritic cells are cultured in IL-4 and
granulocyte macrophage-colony stimulating factor
(GM-CSF) for 7 days, with or without tumor
necrosis factor alpha (TNFalpha) for an additional
2 days [CONT.]
(a) isolating peripheral blood mononuclear cells
from a patient suffering from cancer, activating T
cells by ex vivo stimulation with soluble anti-CD3
monoclonal antibody, and growth of the activated
T cells in the presence of 100-500 IU/ml of
interleukin (IL)-2, arming of activated T cells with
BiAbs capable of binding to the T cell receptor
complex of a T cell, and to tumor-associated
antigens on a tumor cell, under conditions, where:
[CONT.]
US 7763243
US 20110064689
WO 2003011337 A1 UPAB: 20090307
Treatment and prevention of neurodegenerative
diseases, and disorders of myelin formation, such
NOVELTY: Drug composition containing as active as multiple sclerosis, Krabbe's disease,
adrenoleukodystrophy and metachromic
component a substance which activates Fc
leukodystrophy.
receptor gamma chain, is new.
US 20070178083
A1
20070802
JP 4214249
B2
20090128
US 7901678
WO 2003001876
B2
20110308
A2
20030109
WO 2003001876 A2 UPAB: 20090403
US 20030054448
A1
20030320
NOVELTY: Receptor comprising at least one
T1R1 and/or T1R3 or T1R2 and/or T1R3
polypeptide or its variant, fragment or chimera,
specifically binds to and/or is activated by umami
or sweet taste stimuli, is new.
ADLER J E
US 20030220479
A1
20031127
ECHEVERRI F
US 20030232407
A1
20031218
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are also included for:
(1) a composition containing the receptor;
LI X
EP 1412750
A2
20040428
(2) a cell that expresses the receptor; [CONT.]
STASZEWSKI L
AU 2002326315
A1
XU H
US 20040175792
SENOMYX INC
493 New receptor that comprises T1R1 and/or
T1R3 or T1R2 and/or T1R3 polypeptide and
that specifically binds to and/or is activated by SENUMYX INC
umami or sweet taste stimuli, useful for
identifying compounds that modulate taste
perception
brain, lung, neck cancer and leukemia in an
immunosuppressed patient, in particular a
mammal or rodent. The patient is suffering from,
or susceptible to diseases which are characterized
by abnormal cell growth and proliferation. (C1) is
useful for treatment of a mammal suffering from or
susceptible to diseases characterized by
abnormal cell growth and proliferation [CONT.]
The receptor is useful for identifying compounds
that modulate taste perception or for modifying
taste sensation in an animal.
BIOTECHNOLOGY - Preferred Activator: The
substance activating Fc receptor gamma chain is
a ligand for the gamma chain, and promotes
differentiation of oligodendroglia precursor cells,
activates Fyn tyrosine kinase and/or promotes
expression of myelin basic protein. It may be a
ligand to type I or type III Fc receptor gamma
chain, and is preferably an anti-Fc receptor
gamma chain IgG antibody of a sub-group such
as IgG2b or IgG3 [CONT.]
INDEPENDENT CLAIMS are also included for
WO 2003011337
US 20050175998
(1) detecting oligodendroglia and their precursor
cells capable of forming myelin, using as an
indicator the expression of Fc receptor gamma
chain in the precursor cells;
US 20070178083
(2) investigation of the expression of Fc receptor
gamma chain in animal brain tissue by immune
typing, cytochemical analysis, gene amplification
or Western blotting; [CONT.]
US 7901678
BIOTECHNOLOGY - Preferred Receptor: The
INDEPENDENT CLAIMS are also included for:
receptor contains a fragment, variant or chimera
of a native hT1R1 or hT1R3 polypeptide. hT1R1
(1) a composition containing the receptor;
and hT1R3 are derived from the same or different
species, comprising mammal, fish, reptile,
amphibian or bird. The receptor is bound to a solid
phase. It is in a solution or lipid bilayer or vesicle.
It is expressed in a cell. Its expression is under the
control of a regulated promoter [CONT.]
(2) a cell that expresses the receptor;
WO 2003001876
US 20030054448
US 20030220479
US 20030232407
(3) identifying compounds that modulate taste
perception;
(4) modifying taste sensation in an animal;
US 20040175792
20030303
(5) quantifying the taste of individual compounds
or food or beverage compositions;
US 20040185469
A1
20040909
(6) a cell line that inducibly expresses the human
T1R1/T1R3 umami taste receptor or the
T1R2/T1R3 sweet taste receptor; [CONT.]
US 20040191862
US 20040175793
US 20040185469
US 20040191862
A1
20040909
A1
20040923
A1
20040930
CN 1520516
A
20040811
JP 2005500318
T
20050106
US 20050084932
A1
20050421
MX 2003011410
A1
20040701
NO 2003005761
A
20040220
US 20040175793
US 20050084932
US 6955887
US 20050287517
US 20060014208
US 20060127977
US 20060160176
US 7208290
US 7241880
N
494 Treating a mammal afflicted with psoriasis or ZYMOGENETICS INC
psoriatic arthritis, comprises administering an FOLEY K P
antagonist to an interleukin-17 polypeptide
US 6955887
US 20050287517
US 20060014208
US 20060127977
US 20060160176
US 7208290
US 7241880
US 7294474
US 7297543
US 7297772
US 7301009
B2
20051018
A1
20051229
A1
20060119
A1
20060615
A1
20060720
B2
20070424
B2
20070710
B2
20071113
B2
20071120
B2
20071120
B2
20071127
AU 2002326315
B2
20070705
US 7303886
US 7309577
B2
20071204
B2
20071218
AU 2007203680
A1
20070823
US 20080020424
US 20080050778
US 7344859
US 7364903
US 7368285
US 7419791
US 20080244762
US 20080248996
US 20080248997
US 20080262087
US 20090061458
US 20090209731
US 20090215174
US 20090221000
US 20090221001
US 20090221002
US 20090221067
US 20090221709
US 20090221796
US 20090221797
US 20090221798
US 7588916
US 7601513
A9
20080124
A1
20080228
B2
20080318
B2
20080429
B2
20080506
B2
20080902
A1
20081002
A1
20081009
A1
20081009
A1
20081023
A1
20090305
A1
20090820
A1
20090827
A1
20090903
A1
20090903
A1
20090903
A1
20090903
A1
20090903
A1
20090903
A1
20090903
A1
20090903
B2
20090915
B2
20091013
CN 100489102
C
20090520
AU 2007203680
B2
20100603
AU 2007203680
B8
20100708
US 7294474
US 7297543
US 7297772
US 7301009
US 7303886
US 7309577
US 20080020424
US 20080050778
US 7344859
US 7364903
US 7368285
US 7419791
US 20080244762
US 20080248996
US 20080248997 [CONT.]
US 7786263
B2
20100831
JP 2010189391
A
20100902
CN 101891821
A
20101124
US 7892765
EP 2293067
US 7906328
US 7910322
WO 2002102411
EP 1359938
B2
20110222
A2
20110309
B2
20110315
B2
20110322
A2
20021227
WO 2002102411 A2 UPAB: 20050528
A2
20031112
NOVELTY: Treating a mammal afflicted with
psoriasis comprising administering an antagonist
to a 202, 187, 186, 185, 209, 187, 205 or 183
residue amino acid sequence (P1-P8), given in
the specification.
The antagonist is useful in the production of a
medicament for the treatment of psoriasis or
psoriatic arthritis (claimed).
BIOTECHNOLOGY - Preferred Method: The
antagonist is an antibody, an antibody fragment,
or a single-chain antibody. The antagonist is a
950, 929, 19 or 20 residue amino acid sequence,
given in the specification, or their subsequence.
An INDEPENDENT CLAIM is also included for a WO 2002102411
method for down-regulating a polypeptide selected
from P1-P8 by administering a 19 or 20 residue
amino acid sequence, given in the specification.
US 20040115191
US 20070048318
N
MADDEN K L
US 20040115191
A1
20040617
MOORE E E
AU 2002326285
A1
20030102
PRESNELL S R
AU 2002326285
A8
20051020
US 20070048318
US 20070280936
EP 1359938
WO 2002096350
US 20030068325
A1
20070301
A1
20071206
B1
20110316
A2
20021205
A1
20030410
AU 2002303211
A1
20021209
US 20040247612
EP 1497313
A1
20041209
A2
20050119
JP 2005506311
T
20050303
YAO Y
495 Novel peptide immunogen comprising a helper UNITED BIOMEDICAL INC
T cell epitope, an N-terminal fragment of
WANG C Y
amyloid beta peptide linked to the epitope, and
optionally a spacer, useful for preventing or
treating Alzheimer's disease
496 Novel variant of an immunointeractive
molecule, especially a murine-derived
monoclonal antibody having specificity for
cross-linked fibrin derivatives, useful for
detecting blood clots in vivo and clot
dissolution
US 6906169
B2
20050614
MX 2003010631
A1
20041101
ZA 2003008767
A
20050928
BR 2002010010
A
20051025
CN 1568329
A
20050119
TW 252233
B1
20060401
IN 2003DN01894
A
20070316
AU 2002303211
B2
20080228
AU 2008202270
A1
20080612
IN 2008DN07233
A
20080926
CN 101372511
A
20090225
CA 2665748
A1
20021205
JP 2009221213
A
20091001
JP 2009227683
A
20091008
IN 223212
B
20081031
EP 2123671
A1
20091125
JP 4440544
B2
20100324
AU 2008202270
B2
20100617
EP 1497313
B1
20100714
DE 60237044
E
20100826
EP 2123671
B1
20110126
DE 60239093
E
20110310
20110324
AGEN BIOMEDICAL LTD
US 20110070255
WO 2003000736
A1
A1
20030103
CARR F J
US 20030124056
A1
20030703
DETAILED DESCRIPTION: An INDEPENDENT
CLAIM is also included for a method for downregulating a polypeptide selected from P1-P8 by
administering a 19 or 20 residue amino acid
sequence, given in the specification. [CONT.]
WO 2002096350 A2 UPAB: 20090130
(II) is useful for preventing or treating Alzheimer's
NOVELTY: A peptide immunogen (I) of about 20- disease in a mammal, or for producing antibodies
100 amino acids, comprising a helper T cell (Th) to A beta(1-42) peptide that is cross-reactive to
soluble A beta peptides and brain tissue plaques
epitope, an N-terminal fragment of amyloid
formed from it, by administering (II) (claimed). (I)
peptide (P) consisting of 10-28 amino acids,
where the fragment comprises amino acid 1 of (P) is useful for eliciting a site-directed mutagenesis
or an immunologically functional analog of the N- against the main functional/regulatory site of the A
beta peptide and for generating antibodies, which
terminal fragment, and optionally a spacer
are highly cross-reactive to the soluble A beta(1consisting of at least an amino acid to separate
42) peptide and the amyloid plaques formed in the
the immunogenic domains, is new. [CONT.]
brain of Alzheimer's disease patients [CONT.]
WO 2003000736 A1 UPAB: 20090428
(I) further comprising a clot dissolution or clot
growth prevention agent fused, bound or attached
to it is useful for the dissolution or removal of a
NOVELTY: A variant (I) of an immunointeractive
molecule, comprising a portion having specificity blood clot in a human and in the manufacture of a
for cross-linked fibrin derivatives (which is derived medicament for the dissolution of a blood clot in a
human (claimed). [CONT.]
from an immunointeractive molecule obtainable
from one animal or avian creature), where the
variant exhibits reduced immunogenicity in
another animal or avian creature from the same or
different species, is new. [CONT.]
US 20070280936
(I) is stable, and no elaborate downstream
processing or elaborate manufacturing facility is
needed. The immune response elicited by (I) is
site-specific and is focused on the A beta target
and not the carrier. Thus, undesirable responses
such as epitopic suppression are avoided.
BIOTECHNOLOGY - Preferred Immunogen: In (I),
the spacer is chosen from G-G, (alpha,epsilon-N)K, and PP-Xaa-P-Xaa-P. The N-terminal fragment
of A beta(1-42) peptide is chosen from
DAEFRHDSGYEVHHQKLVFFAEDVGSNK,
DAEFRHDSGYEVHH, DAEFRHDSGYEV and
DAEFRHDSGY or its immunologically functional
analog. [CONT.]
A peptide immunogen (I) of about 20-100 amino
WO 2002096350
acids long, comprises a helper T cell (Th) epitope
having a sequence (S) selected from 64
sequences given in the specification such as
FFLLTRILTIPQSLD , an N-terminal fragment of A
beta(1-42) peptide having a sequence of
DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGL
MVGGVVIA consisting of 10-28 amino acid
residues where the fragment comprises amino
acid residue 1 of the A beta(1-42) peptide or an
immunologically functional analog of the Nterminal fragment, and optionally a spacer
consisting of at least an amino acid to separate
the immunogenic domains. [CONT.]
BIOTECHNOLOGY - Preferred Variant: The
INDEPENDENT CLAIMS are also included for:
immunointeractive molecule is an antibody,
preferably a monoclonal antibody from a murine
(1) a deimmunized form of monoclonal antibody
animal which is deimmunized with respect to
3B6, which is non-immunogenic in humans;
another murine animal or a non-murine species of
animal, especially human. The murine monoclonal
antibody is raised in a murine animal to nondenatured D-dimer of human origin. [CONT.]
WO 2003000736
US 20030068325
US 20040247612
N
US 6906169
US 20110070255
US 20030124056
US 7087724
N
HAMILTON A A
497 New polymorphic variants of the gene
encoding Cytochrome P450 polypeptide 2C8
(CYP2C8), useful for diagnosing or treating a
disease, e.g. arachidonic acid metabolism,
cancer or cardiovascular diseases
EP 1412388
A1
20040428
AU 2002318960
A1
20030108
BR 2002010648
A
20041005
CN 1531554
A
20040922
JP 2005502610
T
20050127
MX 2003012030
A1
20050701
US 7087724
US 20060239912
B2
20060808
A1
20061026
NZ 530122
A
20080328
AU 2002318960
B2
20080515
US 7459143
US 20090092546
B2
20081202
A1
20090409
JP 2009149686
A
20090709
20101111
B1
20110316
A2
20021212
WO 2002099099 A2 UPAB: 20050528
PGXHEALTH LLC
US 20100286375
EP 1412388
WO 2002099099
EP 1397486
A1
A2
20040317
NOVELTY: A new polynucleotide comprises a
polynucleotide: (a) having any of 101 nucleic acid
sequences with 18-19 bp fully defined in the
specification; (b) encoding any of seven
polypeptides having 7 amino acids, or a
polypeptide with 3 amino acids; (c) capable of
hybridizing to a Cytochrome P450 polypeptide
2C8 (CYP2C8) gene; (d) encoding a molecular
CYP2C8 variant polypeptide or its fragment.
[CONT.]
BRINKMANN U
AU 2002344369
A1
20021216
PENGER A
AU 2002344369
A8
20051020
US 20060172291
EP 1397486
A1
20060803
B1
20100728
DE 60237154
E
20100909
US 7871767
EP 2290055
WO 2002080954
B2
20110118
A2
20110302
A1
20021017
WO 2002080954 A1 UPAB: 20050528
SE 2001003754
A
20021006
NOVELTY: New fragment (I) of apo-lipoprotein B
(apoB) intended:
CEDARS SINAI MEDICAL CENT
US 20030105003
A1
20030605
(i) for immunization against, or therapy of,
ischemic cardiovascular disease (ICD) and/or
NILSSON J
EP 1383526
A1
20040128
SHAH P K
BR 2002008685
A
20040330
(ii) for diagnosing the presence/absence of
antibodies (Ab) that are associated with
increased/decreased risk of developing ICD.
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are also included for: [CONT.]
AU 2002246484
A1
20021021
JP 2004529143
T
20040924
CN 1505525
A
20040616
IN 2003CN01730
A
20090814
US 20070098725
A1
20070503
RU 2296582
C2
20070410
EPIDAUROS BIOTECHNOLOGIE AG
SPRENGER R
498 New fragments of apo-lipoprotein B, useful for FORSKARPATENT I SYD
treatment, prevention and diagnosis of
FORSKARPATENT I SYD AB
ischemic cardiovascular disease and
atherosclerosis
(2) generating a deimmunized monoclonal
antibody having specificity for antigenic
determinants on human D-dimer or other crosslinked fibrin derivatives, by obtaining a crosslinked fibrin derivative or extract containing same
from a human, generating an antibody in a nonhuman animal specific to the cross-linked fibrin
derivative but which does not cross-react with
fragment D, and subjecting the non-human
derived antibody to deimmunization methods;
[CONT.]
US 20060239912
US 7459143
US 20090092546
US 20100286375
The polynucleotide, gene, vector, polypeptide or
antibody is useful for diagnosing or treating a
disease, for preparing a diagnostic composition for
diagnosing a disease, or for preparing a
pharmaceutical composition for treating a disease.
This disease includes arachidonic acid
metabolism, cancer or cardiovascular diseases
(all claimed).
BIOTECHNOLOGY - Preferred Polynucleotide:
The polynucleotide: (a) has any of 101 nucleic
acid sequences with 18-19 bp fully defined in the
specification, e.g.: gatgtgatgt gtgaaaat; attttcaca
catcacatc; ggaaataaca gtactggtc; gaccagtact
gttatttcc; aaaacaatat aagcagcca; tggctgctta
tattgtttt; agtgctgaaa aactttcac; gtgaaagttt
ttcagcact; aacaacttta acttgtgag; ctcacaagtt
aaagttgtt; ttcacttgta aggtgatgc; [CONT.]
The new polynucleotide comprises a
WO 2002099099
polynucleotide: (a) having any of 101 nucleic acid
sequences with 18-19 bp fully defined in the
specification, e.g.: accccaatga gtatcagaa;
gtatttatgt tattatgt; (b) encoding any of seven
polypeptides having 7 amino acids, or a
polypeptide with 3 amino acids, e.g.: (b.1) Met-GluGln; or (b.2) Gln-Asp-Arg-Ile-His-Met-Pro; (c)
capable of hybridizing to a CYP2C8 gene;
[CONT.]
US 20060172291
US 7871767
(I) are useful for immunization or therapeutic
treatment of mammals, including humans, against
ischemic cardiovascular diseases, and for
diagnosing the presence or absence of antibodies
related to increased or decreased risk of
developing cardiovascular diseases (claimed). (I)
is useful for immunizing against or treating
particularly myocardial infarction and unstable
atherosclerotic plaques in which oxidized lowdensity lipoprotein may contribute to inflammation,
cell toxicity and risk of plaque rupture [CONT.]
BIOLOGY - Preferred Peptide: (I) are in native or
oxidized form, have been prepared using copper,
is present in combination with phospholipid
liposomes and is in the form of aldehyde,
specifically malondialdehyde (MDA) or
hydroxynonenal derivatives. Preferred Vaccine:
The vaccine comprises one or more
fragments/peptides, optionally in combination with
an adjuvant, or a therapeutically effective amount
of purified or recombinantly produced antibodies
against one or more of the native and/or MDA
modified sequences [CONT.]
INDEPENDENT CLAIMS are also included for:
US 20030105003
WO 2002080954
(1) A pharmaceutical preparation comprising a
therapeutically effective amount of one or more of
the fragments/peptides, and optionally one or
more fillers and/or adjuvants;
US 20070098725
(2) Vaccine for immunization of animals, including
humans, against ischemic cardiovascular
diseases; and
(3) Prophylactic or therapeutic treatment of an
animal.
US 20080317837
US 20080274170
US 20080268029
US 20090117137
US 20090117178
US 7527795
US 7528225
US 7537758
US 7544360
N
AU 2002246484
B2
20070419
AU 2002246484
B8
20070614
CA 2606839
A1
20021017
EP 1918300
A2
20080507
JP 2008169215
A
20080724
IN 2007CN05428
A
20080627
CN 101284874
A
20081015
US 20080317837
EP 2006301
US 20080274170
EP 1383526
A1
20081225
A1
20081224
A1
20081106
B1
20081126
DE 60230029
E
20090108
US 20080268029
US 20090117137
US 20090117178
US 7527795
US 7528225
US 7537758
US 7544360
EP 1918300
A1
20081030
A1
20090507
A1
20090507
B2
20090505
B2
20090505
B2
20090526
B2
20090609
A3
20090617
ES 2317999
T3
20090501
US 7556811
B2
20090707
CN 101486766
A
20090722
US 20090202523
US 20090202555
A1
20090813
A1
20090813
JP 2009191078
A
20090827
US 20090226454
US 20090226475
US 20090280126
A1
20090910
A1
20090910
A1
20091112
IN 237076
B
20091211
US 20100004430
A1
20100107
IL 158285
A
20091224
EP 2147680
EP 2147928
EP 2147929
EP 2147930
EP 2147680
EP 2147928
EP 2147929
EP 2147930
US 7704499
US 20100183706
US 7785589
EP 2289912
EP 2289913
EP 2289914
EP 2289915
EP 2289916
EP 2289917
EP 2289918
EP 2289919
EP 2289920
EP 2289921
EP 2289922
EP 2289923
EP 2289924
A2
20100127
A2
20100127
A2
20100127
A2
20100127
A3
20100414
A3
20100414
A3
20100414
A3
20100414
B2
20100427
A1
20100722
B2
20100831
A1
20110302
A1
20110302
A1
20110302
A1
20110302
A1
20110302
A1
20110302
A1
20110302
A1
20110302
A1
20110302
A1
20110302
A1
20110302
A1
20110302
A1
20110302
US 7556811
US 20090202523
US 20090202555
US 20090226454
US 20090226475
US 20090280126
US 20100004430
US 7704499
US 20100183706
US 7785589
EP 2289925
EP 2289926
EP 2289927
EP 2289928
EP 2289929
EP 2289930
EP 2289931
EP 2289932
EP 2289933
EP 2289934
EP 2289935
A1
20110302
A1
20110302
A1
20110302
A1
20110302
A1
20110302
A1
20110302
A1
20110302
A1
20110302
A1
20110302
A1
20110302
A1
20110302
IN 245267
B
20110114
EP 2295457
EP 2295458
EP 2295459
EP 2295460
EP 2295461
EP 2295462
EP 2295463
EP 2295464
WO 2002091994
A1
20110316
A1
20110316
A1
20110316
A1
20110316
A1
20110316
A1
20110316
A1
20110316
A1
20110316
A2
20021121
WO 2002091994 A2 UPAB: 20090706
US 20020197714
A1
20021226
NOVELTY: A cell culture (I) comprising at least
one lentivirus-infected host cell and a growth
promoting amount of an antibiotic consisting
essentially of neomycin or its biologically
compatible salt or derivative, is new.
WYETH INC
NO 2003004961
A
20031201
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are also included for the following:
[CONT.]
WYETH LLC
EP 1385540
A2
20040204
CZ 2003003046
A3
20040317
AU 2002342568
A1
20021125
KR 2004029981
A
20040408
CN 1514734
A
20040721
MX 2003010208
A1
20040301
ZA 2003009556
A
20050223
JP 2005508139
T
20050331
NZ 529326
A
20060929
BR 2002009482
A
20070102
499 New cell culture having at least one lentivirus- AMERICAN HOME PROD CORP
infected host cell and a growth promoting
WYETH
antibiotic, useful for maximizing growth and
density, and minimizing the presence of
harmful organisms such as bacteria
SYMBIONTICS INC
500 New targeted therapeutic that is active in a
mammalian lysosome binds an extracellular
ZYSTOR THERAPEUTICS INC
domain of human cation-independent
mannose-6-phosphate receptor, useful for
treating metabolic diseases such as lysosomal
storage disease
US 7160721
B2
20070109
HU 2004000283
A1
20070828
CN 1326992
C
20070718
AU 2002342568
B2
20071101
MX 250498
B
20071018
JP 4283544
B2
20090624
EP 2298343
WO 2002087510
A1
20110323
A2
20021107
US 20030082176
A1
20030501
WO 2002087510 A2 UPAB: 20090213
The methods and compositions of the present
invention of culturing cells useful for research and
study which are capable of harboring lentivirus,
maximizing growth and density, and minimizing
the presence of harmful organisms such as
bacteria.
The targeted therapeutic, nucleic acid, cell and
methods are useful for treating metabolic diseases
such as lysosomal storage disease (claimed), e.g.
NOVELTY: A targeted therapeutic comprising a
Gaucher's disease, Pompe's disease, Niemanntherapeutic agent that is active in a mammalian
Pick's disease, Hurler's syndrome, mannosidosis,
lysosome, and a means for binding an
extracellular domain of human cation-independent fucosidosis, Schindler's disease, mucolipidosis,
mannose-6-phosphate receptor in a mannose-6- cystinosis, Batten's disease, prosaposin, or
infantile neuronal ceroid lipofiscinosis.
phosphate independent manner, is new.
As compared to prior art, the invention provides a
simpler, more efficient and more cost-effective
methods for targeting therapeutic agents to a
cellular compartment.
BIOTECHNOLOGY - Preferred Cell Culture: The
neomycin in any of the cell cultures, is present in
an amount of up to 60 micro-g/ml of the culture.
The host cell is infected with at least one lentivirus
that is equine infectious anemia virus, Maedi-visna
virus, progressive pneumonia virus, caprine
arthritis-encephalitis virus, feline
immunodeficiency virus (FIV), simian
immunodeficiency virus or human
immunodeficiency virus (HIV) Types I and II,
preferably FIV, simian and HIV Types I and II
[CONT.]
INDEPENDENT CLAIMS are also included for the WO 2002091994
following:
(1) a cell culture comprising at least one lentivirusinfected host cell and neomycin, where the
neomycin is present substantially without another
antibiotic in an amount effective at inhibiting
bacterial growth and increasing the density of the
cell culture; [CONT.]
US 20020197714
BIOTECHNOLOGY - Preferred Targeted
Therapeutic: The means for binding of the
targeted therapeutic comprises retinoic acid
and/or its derivative, a protein having a sequence
that is at least 70 % identical to a domain of
urokinase-type plasminogen activator receptor,
insulin-like growth factor (IGF)-II or an antibody
variable domain. The association of the
therapeutic agent with the means of binding is
destabilized by a pH change from 7 [CONT.]
INDEPENDENT CLAIMS are also included for the WO 2002087510
following:
(1) a therapeutic fusion protein comprising a
therapeutic domain and a sub-cellular targeting
domain that binds to an extracellular domain of a
receptor on an exterior surface of a cell, and upon
internalization of the receptor, permits localization
of the therapeutic domain to a sub-cellular
compartment where the therapeutic domain is
therapeutically active; [CONT.]
US 20030082176
US 7160721
US 7396811
N
A1
20021111
EP 1436316
A2
20040714
JP 2004535791
T
20041202
EP 1436316
B1
20080123
DE 60224816
E
20080313
ES 2300439
T3
20080616
US 7396811
EP 1974752
B2
20080708
A1
20081001
AU 2002256423
B2
20080724
DE 60224816
T2
20090122
AU 2008230016
A1
20081113
DETAILED DESCRIPTION: INDEPENDENT
CLAIMS are also included for the following:
[CONT.]
US 20090203575
A1
20090813
IL 158623
A
20090922
JP 2010043103
A
20100225
JP 4641705
B2
20110302
WO 2002089597
US 20030125526
A1
20021114
WO 2002089597 A1 UPAB: 20060118
A1
20030703
NOVELTY: Oil seed meal is extracted at
5degreesC to form an aqueous protein solution
which is separated from residual oil seed meal.
Protein concentration is increased to provide a
concentrated solution which is diluted with chilled
water at below 15degreesC to form protein
micelles. The micelles are settled to form an
amorphous sticky, gelatinous, gluten-like micellar
mass [CONT.]
MARTENS R W
EP 1389920
A1
20040225
MURRAY E D
JP 2004519255
T
20040702
KR 2004026651
A
20040331
AU 2002308322
A1
20021118
CN 1523961
A
20040825
US 20040254353
A1
20041216
BR 2002009314
A
20050118
NZ 529509
A
20050128
ZA 2003008850
A
20050126
BURCON NUTRASCIENCE MB CORP
501 Preparation of protein isolate for use in
foodstuff, comprises extracting oil seed meal, BARKER L D
increasing protein concentration, diluting with
chilled water to form protein micelles and
recovering micelles mass from supernatant
502 Reducing level of beta-amyloid polypeptide in
cell/mammal for treating Alzheimer's disease,
by contacting the cell or administering to
mammal, a Cimicifuga extract and monitoring
level of beta-amyloid polypeptide
AU 2002256423
US 20050165220
A1
20050728
MX 2003010060
A1
20050101
JP 3756153
B2
20060315
CN 1288994
C
20061213
AU 2002308322
B2
20070913
RU 2316223
C2
20080210
US 20090275733
A1
20091105
KR 934200
B1
20091229
B2
20100330
B2
20100914
B1
20110302
MAYO FOUND MEDICAL EDUCATION RES
US 7687087
US 7794762
EP 1389920
US 20020127290
A1
20020912
MAYO FOUND MEDICAL EDUCATION&RES
WO 2002072125
A1
20020919
US 20090203575
For manufacturing canola protein isolate (claimed) The canola protein isolate has a high protein yield FOOD - Preferred Materials: The oil seed meal is
used as nutritional supplements in pets foods,
and high purity protein content.
canola oil seed meal, rapeseed meal and mustard
animal feed and in industrial and cosmetic
seed meal.
applications and in personal care products.
An oil seed meal is extracted at 5degreesC to
WO 2002089597
solubilize the protein in the meal and to form an
aqueous protein solution having a protein content
of 5-30 g/L (pH 5-6.8). The protein solution is
separated from residual oil seed meal. The protein
concentration of protein solution is increased to at
least 200 g/L while maintaining the ionic strength
substantially constant by using a selective
membrane technique to provide a concentrated
protein solution [CONT.]
US 20030125526
US 20040254353
US 20050165220
US 20090275733
US 7687087
US 7794762
US 20020127290 A1 UPAB: 20060118
M1 is useful for reducing the level of (I) in or
secreted from a cell, or in a mammal such as
rodent e.g. Tg2576 mouse expressing amyloid
NOVELTY: Reducing (M1) the level of a betaamyloid (Abeta) polypeptide (I) in or secreted from precursor protein (APP) carrying a Swedish
mutation. M2 is useful for treating a mammal
a cell, or in a mammal, involves contacting with
having Alzheimer's disease (AD) or at risk to
the cell or administering to the mammal, an
amount of Cimicifuga extract or its active fraction develop AD (claimed).
effective for reducing the level of (I) in the cell or
mammal and monitoring the level of (I) in or
secreted from the cell or in the mammal. [CONT.]
BIOTECHNOLOGY - Preferred Method: The
Cimicifuga extract or its active fraction is from
C.racemosa which is obtained from the root or
rhizome of the plant. C.racemosa extract is an
ethanolic extract or an aqueous extract. The active
component in the active fraction is soluble in a
solvent selected from methylene dichloride, ethyl
acetate and n-butanol. The active component is
lipophilic and having a molecular weight of less
than 10 kD [CONT.]
INDEPENDENT CLAIMS are included for the
following:
(1) treating (M2) a mammal having Alzheimer's
disease (AD) or at risk to develop AD, by
administering an amount of Cimicifuga extract or
its active fraction to the mammal, effective for
treating or preventing AD in the mammal;
US 20020127290
US 20020127290
US 6649196
503 New facially amphiphilic polymers, useful for
inhibiting the growth of microorganisms
504 Evaluating cell-mediated immunity, in
particular cytotoxic T lymphocyte responses,
by implanting vascular cells, useful for
treatment and research models for directly
targeting tumor neovasculature
ECKMAN C B
US 6649196
B2
20031118
FAUQ A
EP 1372684
A1
20040102
HAUGABOOK S
AU 2002254189
A1
20020924
YAGER D
EP 2298329
WO 2002072007
A1
20110323
A2
20020919
WO 2002072007 A2 UPAB: 20090720
DEGRADO W F
EP 1372674
A2
20040102
NOVELTY: Facially amphiphilic polymers (I) are
new.
KLEIN M L
AU 2002254133
A1
20020924
TEW G N
KR 2004011471
A
20040205
DETAILED DESCRIPTION: Facially amphiphilic
polymers of formula R1-(-A-G-B-)m-R2 (I) are
new.
A, B = ortho-, meta- or para-phenylene or
heteroarylene (both optionally substituted); or
KR 2004011472
A
20040205
CN 1505646
A
20040616
R1 = halo; and
UNIV PENNSYLVANIA
(2) producing (M3) an